# James_2020_Cognitive behavioural therapy for anxiety disorders in children and adolescents.

Cochrane
Library

Cochrane Database of Systematic Reviews

Cognitive behavioural therapy for anxiety disorders in children and
adolescents (Review)

James AC, Reardon T, Soler A, James G, Creswell C

James AC, Reardon T, Soler A, James G, Creswell C. 
Cognitive behavioural therapy for anxiety disorders in children and adolescents. 
Cochrane Database of Systematic Reviews 2020, Issue 11. Art. No.: CD013162. 
DOI: 10.1002/14651858.CD013162.pub2.

www.cochranelibrary.com

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

T A B L E   O F   C O N T E N T S

ABSTRACT.....................................................................................................................................................................................................
PLAIN LANGUAGE SUMMARY.......................................................................................................................................................................
SUMMARY OF FINDINGS..............................................................................................................................................................................
BACKGROUND..............................................................................................................................................................................................
OBJECTIVES..................................................................................................................................................................................................
METHODS.....................................................................................................................................................................................................
RESULTS........................................................................................................................................................................................................
Figure 1..................................................................................................................................................................................................
Figure 2..................................................................................................................................................................................................
Figure 3..................................................................................................................................................................................................
Figure 4..................................................................................................................................................................................................
Figure 5..................................................................................................................................................................................................
Figure 6..................................................................................................................................................................................................
Figure 7..................................................................................................................................................................................................
Figure 8..................................................................................................................................................................................................
DISCUSSION..................................................................................................................................................................................................
AUTHORS' CONCLUSIONS...........................................................................................................................................................................
ACKNOWLEDGEMENTS................................................................................................................................................................................
REFERENCES................................................................................................................................................................................................
CHARACTERISTICS OF STUDIES..................................................................................................................................................................
DATA AND ANALYSES....................................................................................................................................................................................
Analysis  1.1.  Comparison  1:  CBT  versus  waitlist/no  treatment,  Outcome  1:  Remission  of  primary  anxiety  diagnosis  post-
treatment (ITT)......................................................................................................................................................................................
Analysis 1.2. Comparison 1: CBT versus waitlist/no treatment, Outcome 2: Subgroup analysis: remission of primary anxiety
diagnosis post-treatment (ITT) (individual vs group).........................................................................................................................
Analysis 1.3. Comparison 1: CBT versus waitlist/no treatment, Outcome 3: Subgroup analysis: remission of primary anxiety
diagnosis post-treatment (ITT) (amount of therapist contact time).................................................................................................
Analysis 1.4. Comparison 1: CBT versus waitlist/no treatment, Outcome 4: Subgroup analysis: remission of primary anxiety
diagnosis post-treatment (ITT) (age)...................................................................................................................................................
Analysis 1.5. Comparison 1: CBT versus waitlist/no treatment, Outcome 5: Subgroup analysis: remission of primary anxiety
diagnosis post-treatment (ITT) (ASD vs non-ASD)..............................................................................................................................
Analysis  1.6.  Comparison  1:  CBT  versus  waitlist/no  treatment,  Outcome  6:  Remission  of  primary  anxiety  diagnosis  post-
treatment (completers).........................................................................................................................................................................
Analysis 1.7. Comparison 1: CBT versus waitlist/no treatment, Outcome 7: Acceptability (number of participants lost to post-
treatment assessment).........................................................................................................................................................................
Analysis 1.8. Comparison 1: CBT versus waitlist/no treatment, Outcome 8: Remission of all anxiety diagnoses post-treatment
(ITT)........................................................................................................................................................................................................
Analysis 1.9. Comparison 1: CBT versus waitlist/no treatment, Outcome 9: Subgroup analysis: remission of all anxiety diagnoses
post-treatment (ITT) (individual vs group)..........................................................................................................................................
Analysis  1.10.  Comparison  1:  CBT  versus  waitlist/no  treatment,  Outcome  10:  Subgroup  analysis:  remission  of  all  anxiety
diagnoses post-treatment (ITT) (amount of therapist contact time)................................................................................................
Analysis  1.11.  Comparison  1:  CBT  versus  waitlist/no  treatment,  Outcome  11:  Subgroup  analysis:  remission  of  all  anxiety
diagnoses post-treatment (ITT) (age)..................................................................................................................................................
Analysis 1.12. Comparison 1: CBT versus waitlist/no treatment, Outcome 12: Remission of all anxiety diagnoses post-treatment
(completers)...........................................................................................................................................................................................
Analysis 1.13. Comparison 1: CBT versus waitlist/no treatment, Outcome 13: Reduction in anxiety symptoms (child report) post-
treatment...............................................................................................................................................................................................
Analysis 1.14. Comparison 1: CBT versus waitlist/no treatment, Outcome 14: Sensitivity analysis: reduction in anxiety symptoms
(child report) post-treatment (broad anxiety measures)...................................................................................................................
Analysis 1.15. Comparison 1: CBT versus waitlist/no treatment, Outcome 15: Subgroup analysis: reduction in anxiety symptoms
(child report) post-treatment (individual vs group)...........................................................................................................................
Analysis 1.16. Comparison 1: CBT versus waitlist/no treatment, Outcome 16: Subgroup analysis: reduction in anxiety symptoms
(child report) post-treatment (amount of therapist contact time)....................................................................................................

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1
2
4
12
14
14
19
21
25
27
29
32
34
39
40
40
43
45
46
62
203
209

211

213

215

217

219

220

222

223

224

225

226

227

228

229

230

i

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.17. Comparison 1: CBT versus waitlist/no treatment, Outcome 17: Subgroup analysis: reduction in anxiety symptoms
(child report) post-treatment (age)......................................................................................................................................................
Analysis 1.18. Comparison 1: CBT versus waitlist/no treatment, Outcome 18: Subgroup analysis: reduction in anxiety symptoms
(child report) post-treatment (ASD vs non-ASD).................................................................................................................................
Analysis 1.19. Comparison 1: CBT versus waitlist/no treatment, Outcome 19: Reduction in anxiety symptoms (parent report)
post-treatment......................................................................................................................................................................................
Analysis 1.20. Comparison 1: CBT versus waitlist/no treatment, Outcome 20: Sensitivity analysis: reduction in anxiety symptoms
(parent report) post-treatment (broad anxiety measures only)........................................................................................................
Analysis 1.21. Comparison 1: CBT versus waitlist/no treatment, Outcome 21: Subgroup analysis: reduction in anxiety symptoms
(parent report) post-treatment (individual vs group).........................................................................................................................
Analysis 1.22. Comparison 1: CBT versus waitlist/no treatment, Outcome 22: Subgroup analysis: reduction in anxiety symptoms
(parent report) post-treatment (amount of therapist contact time).................................................................................................
Analysis 1.23. Comparison 1: CBT versus waitlist/no treatment, Outcome 23: Subgroup analysis: reduction in anxiety symptoms
(parent report) post-treatment (age)...................................................................................................................................................
Analysis 1.24. Comparison 1: CBT versus waitlist/no treatment, Outcome 24: Subgroup analysis: reduction in anxiety symptoms
(parent report) post-treatment (ASD vs non-ASD)..............................................................................................................................
Analysis  1.25.  Comparison  1:  CBT  versus  waitlist/no  treatment,  Outcome  25:  Reduction  in  depressive  symptoms  post-
treatment...............................................................................................................................................................................................
Analysis  1.26.  Comparison  1:  CBT  versus  waitlist/no  treatment,  Outcome  26:  Improvement  in  global  functioning  post-
treatment...............................................................................................................................................................................................
Analysis 1.27. Comparison 1: CBT versus waitlist/no treatment, Outcome 27: Remission of primary anxiety diagnosis at follow-
up (ITT)..................................................................................................................................................................................................
Analysis 1.28. Comparison 1: CBT versus waitlist/no treatment, Outcome 28: Remission of primary anxiety diagnosis at follow-
up (completers).....................................................................................................................................................................................
Analysis 1.29. Comparison 1: CBT versus waitlist/no treatment, Outcome 29: Remission of all anxiety diagnoses at follow-up
(ITT)........................................................................................................................................................................................................
Analysis 1.30. Comparison 1: CBT versus waitlist/no treatment, Outcome 30: Remission of all anxiety diagnoses at follow-up
(completers)...........................................................................................................................................................................................
Analysis 1.31. Comparison 1: CBT versus waitlist/no treatment, Outcome 31: Reduction in anxiety symptoms (child report) at
follow-up................................................................................................................................................................................................
Analysis 1.32. Comparison 1: CBT versus waitlist/no treatment, Outcome 32: Sensitivity analysis: remission of primary anxiety
diagnosis post-treatment (ITT) (only studies where sequence generation is clear).........................................................................
Analysis 1.33. Comparison 1: CBT versus waitlist/no treatment, Outcome 33: Sensitivity analysis: remission of primary anxiety
diagnosis post-treatment (ITT) (only studies where blind assessors used)......................................................................................
Analysis 2.1. Comparison 2: CBT versus treatment as usual, Outcome 1: Remission of primary anxiety diagnosis post-treatment
(ITT)........................................................................................................................................................................................................
Analysis  2.2.  Comparison  2:  CBT  versus  treatment  as  usual,  Outcome  2:  Subgroup  analysis:  remission  of  primary  anxiety
diagnosis post-treatment (ITT) (ASD vs non-ASD)..............................................................................................................................
Analysis 2.3. Comparison 2: CBT versus treatment as usual, Outcome 3: Remission of primary anxiety diagnosis post-treatment
(completers)...........................................................................................................................................................................................
Analysis  2.4.  Comparison  2:  CBT  versus  treatment  as  usual,  Outcome  4:  Acceptability  (number  of  participants  lost  to  post-
treatment assessment).........................................................................................................................................................................
Analysis  2.5.  Comparison  2:  CBT  versus  treatment  as  usual,  Outcome  5:  Remission  of  all  anxiety  diagnoses  post-treatment
(ITT)........................................................................................................................................................................................................
Analysis  2.6.  Comparison  2:  CBT  versus  treatment  as  usual,  Outcome  6:  Remission  of  all  anxiety  diagnoses  post-treatment
(completers)...........................................................................................................................................................................................
Analysis 2.7. Comparison 2: CBT versus treatment as usual, Outcome 7: Reduction in anxiety symptoms (child report) post-
treatment...............................................................................................................................................................................................
Analysis 2.8. Comparison 2: CBT versus treatment as usual, Outcome 8: Sensitivity analysis: reduction in anxiety symptoms
(child report) post-treatment (broad anxiety measures only)...........................................................................................................
Analysis 2.9. Comparison 2: CBT versus treatment as usual, Outcome 9: Reduction in anxiety symptoms (parent report) post-
treatment...............................................................................................................................................................................................
Analysis 2.10. Comparison 2: CBT versus treatment as usual, Outcome 10: Sensitivity analysis: reduction in anxiety symptoms
(parent report) post-treatment (broad anxiety measures only)........................................................................................................
Analysis 3.1. Comparison 3: CBT versus attention control, Outcome 1: Remission of primary anxiety diagnosis post-treatment
(ITT)........................................................................................................................................................................................................

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

231

232

233

234

235

236

237

238

239

239

240

240

241

242

242

243

244

246

247

247

248

248

249

249

249

250

250

252

ii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.2. Comparison 3: CBT versus attention control, Outcome 2: Subgroup analysis: remission of primary anxiety diagnosis
post-treatment (ITT) (individual vs group)..........................................................................................................................................
Analysis 3.3. Comparison 3: CBT versus attention control, Outcome 3: Remission of primary anxiety diagnosis post-treatment
(completers)...........................................................................................................................................................................................
Analysis  3.4.  Comparison  3:  CBT  versus  attention  control,  Outcome  4:  Acceptability  (number  of  participants  lost  to  post-
treatment assessment).........................................................................................................................................................................
Analysis 3.5. Comparison 3: CBT versus attention control, Outcome 5: Remission of all anxiety diagnoses post-treatment (ITT)....
Analysis  3.6.  Comparison  3:  CBT  versus  attention  control,  Outcome  6:  Remission  of  all  anxiety  diagnoses  post-treatment
(completers)...........................................................................................................................................................................................
Analysis  3.7.  Comparison  3:  CBT  versus  attention  control,  Outcome  7:  Reduction  in  anxiety  symptoms  (child  report)  post-
treatment...............................................................................................................................................................................................
Analysis 3.8. Comparison 3: CBT versus attention control, Outcome 8: Sensitivity analysis: reduction in anxiety symptoms (child
report) post-treatment (broad anxiety measures only)......................................................................................................................
Analysis 3.9. Comparison 3: CBT versus attention control, Outcome 9: Reduction in anxiety symptoms (parent report) post-
treatment...............................................................................................................................................................................................
Analysis 3.10. Comparison 3: CBT versus attention control, Outcome 10: Sensitivity analysis: reduction in anxiety symptoms
(parent report) post-treatment (broad anxiety measures only)........................................................................................................
Analysis 3.11. Comparison 3: CBT versus attention control, Outcome 11: Reduction in depressive symptoms post-treatment.....
Analysis 3.12. Comparison 3: CBT versus attention control, Outcome 12: Remission of primary anxiety diagnosis at follow-up
(ITT)........................................................................................................................................................................................................
Analysis 3.13. Comparison 3: CBT versus attention control, Outcome 13: Remission of primary anxiety diagnosis at follow-up
(completers)...........................................................................................................................................................................................
Analysis 3.14. Comparison 3: CBT versus attention control, Outcome 14: Remission of all anxiety diagnoses at follow-up (ITT)....
Analysis  3.15.  Comparison  3:  CBT  versus  attention  control,  Outcome  15:  Remission  of  all  anxiety  diagnoses  at  follow-up
(completers)...........................................................................................................................................................................................
Analysis 3.16. Comparison 3: CBT versus attention control, Outcome 16: Reduction in anxiety symptoms (child report) at follow-
up...........................................................................................................................................................................................................
Analysis  3.17.  Comparison  3:  CBT  versus  attention  control,  Outcome  17:  Reduction  in  anxiety  symptoms  (parent  report)  at
follow-up................................................................................................................................................................................................
Analysis 4.1. Comparison 4: CBT versus alternative treatment, Outcome 1: Acceptability (number of participants lost to post-
treatment assessment).........................................................................................................................................................................
Analysis 4.2. Comparison 4: CBT versus alternative treatment, Outcome 2: Remission of all anxiety diagnoses post-treatment
(ITT)........................................................................................................................................................................................................
Analysis 4.3. Comparison 4: CBT versus alternative treatment, Outcome 3: Remission of all anxiety diagnoses post-treatment
(completers)...........................................................................................................................................................................................
Analysis 4.4. Comparison 4: CBT versus alternative treatment, Outcome 4: Reduction in anxiety symptoms (child report) post-
treatment...............................................................................................................................................................................................
Analysis 4.5. Comparison 4: CBT versus alternative treatment, Outcome 5: Sensitivity analysis: reduction in anxiety symptoms
(child report) post-treatment (broad anxiety measures only)...........................................................................................................
Analysis 4.6. Comparison 4: CBT versus alternative treatment, Outcome 6: Reduction in anxiety symptoms (parent report) post-
treatment...............................................................................................................................................................................................
ADDITIONAL TABLES....................................................................................................................................................................................
APPENDICES.................................................................................................................................................................................................
WHAT'S NEW.................................................................................................................................................................................................
HISTORY........................................................................................................................................................................................................
CONTRIBUTIONS OF AUTHORS...................................................................................................................................................................
DECLARATIONS OF INTEREST.....................................................................................................................................................................
SOURCES OF SUPPORT...............................................................................................................................................................................
DIFFERENCES BETWEEN PROTOCOL AND REVIEW....................................................................................................................................
INDEX TERMS...............................................................................................................................................................................................

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

253

254

254

255
255

256

256

257

257

257
258

258

259
259

260

260

261

261

262

262

262

263

264
273
281
281
281
281
282
282
283

iii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

[Intervention Review]

Cochrane Database of Systematic Reviews

Cognitive behavioural therapy for anxiety disorders in children and
adolescents

Anthony C James1,2, Tessa Reardon1,3,4, Angela Soler2, Georgina James5, Cathy Creswell1,3,4

1Department of Psychiatry, University of Oxford, Oxford, UK. 2Highfield Unit, Warneford Hospital, Oxford, UK. 3Department of
Experimental Psychology, University of Oxford, Oxford, UK. 4School of Psychology & Clinical Language Sciences, University of Reading,
Reading, UK. 5Sunderland Royal Hospital, Sunderland, UK

Contact: Tessa Reardon, tessa.reardon@psy.ox.ac.uk.

Editorial group: Cochrane Common Mental Disorders Group.
Publication status and date: New, published in Issue 11, 2020.

Citation: James AC, Reardon T, Soler A, James G, Creswell C. Cognitive behavioural therapy for anxiety disorders in children and
adolescents. Cochrane Database of Systematic Reviews 2020, Issue 11. Art. No.: CD013162. DOI: 10.1002/14651858.CD013162.pub2.

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Background

A B S T R A C T

Previous  Cochrane  Reviews  have  shown  that  cognitive  behavioural  therapy  (CBT)  is  effective  in  treating  childhood  anxiety  disorders.
However, questions remain regarding the following: up-to-date evidence of the relative efficacy and acceptability of CBT compared to
waiting lists/no treatment, treatment as usual, attention controls, and alternative treatments; benefits across a range of outcomes; longer-
term  effects;  outcomes  for  different  delivery  formats;  and  amongst  children  with  autism  spectrum  disorders  (ASD)  and  children  with
intellectual impairments.

Objectives

To examine the effect of CBT for childhood anxiety disorders, in comparison with waitlist/no treatment, treatment as usual (TAU), attention
control, alternative treatment, and medication.

Search methods

We  searched  the  Cochrane  Common  Mental  Disorders  Controlled  Trials  Register  (all  years  to  2016),  the  Cochrane  Central  Register  of
Controlled Trials (CENTRAL), MEDLINE, Embase, and PsycINFO (each to October 2019), international trial registries, and conducted grey
literature searches.

Selection criteria

We  included  randomised  controlled  trials  of  CBT  that  involved  direct  contact  with  the  child,  parent,  or  both,  and  included  non-
CBT  comparators  (waitlist/no  treatment,  treatment  as  usual,  attention  control,  alternative  treatment,  medication).  Participants  were
younger  than  age  19,  and  met  diagnostic  criteria  for  an  anxiety  disorder  diagnosis.  Primary  outcomes  were  remission  of  primary
anxiety diagnosis post-treatment, and acceptability (number of participants lost to post-treatment assessment), and secondary outcomes
included remission of all anxiety diagnoses, reduction in anxiety symptoms, reduction in depressive symptoms, improvement in global
functioning, adverse effects, and longer-term effects.

Data collection and analysis

We used standard methodological procedures as recommended by Cochrane. We used GRADE to assess the quality of the evidence.

Main results

We included 87 studies and 5964 participants in quantitative analyses.

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Compared  with  waitlist/no  treatment,  CBT  probably  increases  post-treatment  remission  of  primary  anxiety  diagnoses  (CBT:  49.4%,
waitlist/no treatment: 17.8%; OR 5.45, 95% confidence interval (CI) 3.90 to 7.60; n = 2697, 39 studies, moderate quality); NNTB 3 (95% CI
2.25 to 3.57) and all anxiety diagnoses (OR 4.43, 95% CI 2.89 to 6.78; n = 2075, 28 studies, moderate quality).

Low-quality evidence did not show a difference between CBT and TAU in post-treatment primary anxiety disorder remission (OR 3.19, 95%
CI 0.90 to 11.29; n = 487, 8 studies), but did suggest CBT may increase remission from all anxiety disorders compared to TAU (OR 2.74, 95%
CI 1.16 to 6.46; n = 203, 5 studies).

Compared with attention control, CBT may increase post-treatment remission of primary anxiety disorders (OR 2.28, 95% CI 1.33 to 3.89;
n = 822, 10 studies, low quality) and all anxiety disorders (OR 2.75, 95% CI 1.22 to 6.17; n = 378, 5 studies, low quality).

There was insufficient available data to compare CBT to alternative treatments on post-treatment remission of primary anxiety disorders,
and low-quality evidence showed there may be little to no difference between these groups on post-treatment remission of all anxiety
disorders (OR 0.89, 95% CI 0.35 to 2.23; n = 401, 4 studies)

Low-quality evidence did not show a difference for acceptability between CBT and waitlist/no treatment (OR 1.09, 95% CI 0.85 to 1.41;
n=3158, 45 studies), treatment as usual (OR 1.37, 95% CI 0.73 to 2.56; n = 441, 8 studies), attention control (OR 1.00, 95% CI 0.68 to 1.49; n
= 797, 12 studies) and alternative treatment (OR 1.58, 95% CI 0.61 to 4.13; n=515, 7 studies).

No adverse effects were reported across all studies; however, in the small number of studies where any reference was made to adverse
effects, it was not clear that these were systematically monitored.

Results from the anxiety symptom outcomes, broader outcomes, longer-term outcomes and subgroup analyses are provided in the text.

We  did  not  find  evidence  of  consistent  differences  in  outcomes  according  to  delivery  formats  (e.g.  individual  versus  group;  amount
of  therapist  contact  time)  or  amongst  samples  with  and  without  ASD,  and  no  studies  included  samples  of  children  with  intellectual
impairments.

Authors' conclusions

CBT is probably more effective in the short-term than waiting lists/no treatment, and may be more effective than attention control. We
found little to no evidence across outcomes that CBT is superior to usual care or alternative treatments, but our confidence in these findings
are limited due to concerns about the amount and quality of available evidence, and we still know little about how best to efficiently
improve outcomes.

P L A I N   L A N G U A G E   S U M M A R Y

Cognitive behavioural therapy for anxiety in children and young people

Why is this review important?

Many children and young people experience problems with anxiety. Children and young people with anxiety disorders are more likely than
their peers to have difficulty with friendships, family life, and school, and to develop mental health problems later in life. Therapies such
as cognitive behavioural therapy (CBT) can help children and young people to overcome difficulties with anxiety by using new ways of
thinking and facing their fears.

Who will be interested in this review?

Parents, children, and young people; people working in education and mental health services for children and young people; and general
practitioners.

What questions does this review aim to answer?

This review updates and replaces previous Cochrane Reviews from 2005 and 2015, which showed that CBT is an effective treatment for
children and young people with anxiety disorders.

This review aimed to answer the following questions:

• Is CBT more effective than a waiting list or no treatment?

• Is CBT more effective than other treatments and medication?

• Does CBT help to reduce anxiety for children and young people in the longer term?

• Are some types of CBT more effective than others? (e.g. individual versus group therapy)

• Is CBT effective for specific groups? (e.g. children with autism)

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

2

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Which studies were included in the review?

Cochrane Database of Systematic Reviews

We searched the databases to find all studies of CBT for anxiety disorders in children and young people published up to October 2019. In
order to be included in the review, studies had to be randomised controlled trials (a type of study in which participants are assigned to one
of two or more treatment groups using a random method) and had to include young people under 19 years of age with an anxiety disorder
diagnosis. We included 87 studies with a total of 5964 participants in the analysis.

What does the evidence from the review tell us?

We rated the overall quality of the evidence as 'moderate’ or 'low'. There is evidence that CBT is more effective than a waiting list or no
treatment in reducing anxiety in children and young people, although the findings did vary across studies. There is no clear evidence that
CBT is more effective than other treatments. A small number of studies looked at outcomes six months after CBT was given and showed
that reductions in anxiety continued. We found no clear evidence that one way of providing CBT is more effective than another (e.g. in a
group, longer treatments, with parents) or that CBT is more or less effective for any specific group of children (e.g. children with autism
spectrum disorders).

What should happen next?

Future research should compare CBT to alternative treatments and medication; identify who does and does not benefit from CBT and what
those who do not benefit need; establish how to make CBT more accessible; and give far more consideration to neglected populations,
including children and young people from low- and middle-income countries.

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

3

 
 
C
o
p
y
r
i
g
h
t

©
2
0
2
0
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

C
o
g
n
i
t
i
v
e
b
e
h
a
v
i
o
u
r
a
l

t
h
e
r
a
p
y
f
o
r
a
n
x
i
e
t
y
d
i
s
o
r
d
e
r
s
i

n
c
h
i
l

d
r
e
n
a
n
d
a
d
o
l
e
s
c
e
n
t
s
(
R
e
v
i
e
w

)

S U M M A R Y   O F   F I N D I N G S

Summary of findings 1.   CBT compared with waitlist for children and adolescents with anxiety disorders

CBT compared with waitlist for children and adolescents with anxiety disorders

Patient or population: children and adolescents with anxiety disorders

Settings: outpatient clinics/schools

Intervention: CBT

Comparison: waitlist/no treatment

Outcomes

Illustrative comparative risks*
(95% CI)

Relative effect
(95% CI)

No. of partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

Assumed risk

Corresponding
risk

Waitlist1

CBT

Remission of pri-
mary anxiety
diagnosis post-
treatment (ITT)

178 per 1000

541 per 1000
(458 to 622)

OR 5.45 (3.90 to
7.60)

2697
(39 studies)

⊕⊕⊕⊝
moderate 2

Subgroup analyses:

• Difference in outcomes for different delivery formats
(child-focused, child and parent, parent only) (Chi2 =
8.57, df = 2, P = 0.01, I2 = 76.7%)

• No  difference  in  outcomes  for  individual  versus
group formats (Chi2 = 0.90, df = 1, P = 0.34; I2 = 0%)
• No difference in outcomes for interventions with dif-
ferent amounts of therapist contact (Chi2 = 0.52, df =
2, P = 0.77; I2 = 0%)

• No difference in outcomes for participants with and
without ASD (Chi2 = 2.25, df = 1, P = 0.13; I2 = 55.5%)

Acceptability
(number of par-
ticipants lost to
post-treatment
assessment)

Remission of
all anxiety di-
agnoses post-
treatment (ITT)

4

104 per 1000

112 per 1000
(90 to 141)

OR 1.09 (0.85 to
1.41)

3158
(45 studies)

⊕⊕⊝⊝
low 3

191 per 1000

512 per 1000
(406 to 616)

OR 4.43 (2.89 to
6.78)

2075

(28 studies)

⊕⊕⊕⊝
moderate 2

Subgroup analyses:

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
2
0
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

C
o
g
n
i
t
i
v
e
b
e
h
a
v
i
o
u
r
a
l

t
h
e
r
a
p
y
f
o
r
a
n
x
i
e
t
y
d
i
s
o
r
d
e
r
s
i

n
c
h
i
l

d
r
e
n
a
n
d
a
d
o
l
e
s
c
e
n
t
s
(
R
e
v
i
e
w

)

5

Reduction in
anxiety symp-
toms (child re-
port) post-treat-
ment

The mean anxiety symptoms (child
report) in the CBT groups was 0.67
standard deviations lower (0.88 to
0.47 lower).

Moderate effect
size

2831
(45 studies)

⊕⊕⊝⊝
low 4

Reduction in
anxiety symp-
toms (parent re-
port) post-treat-
ment

The mean anxiety symptoms (par-
ent report) in the CBT groups was
0.70 standard deviations lower
(0.90 to 0.51 lower).

Moderate effect
size

2137
(35 studies)

⊕⊕⊝⊝
low 4

Reduction in de-
pressive symp-
toms post-treat-
ment

The mean depressive symptoms in
the CBT groups was 0.34 standard
deviations lower (0.51 to 0.17 low-
er).

Small effect size

1157

(17 studies)

Improvement in
global function-

The mean global functioning in the
CBT groups was 1.03 standard de-

Large effect size

557

(11 studies)

⊕⊕⊕⊝
moderate 2

⊕⊕⊝⊝
low 5

• Difference in outcomes for different delivery formats
(child-focused, child and parent, parent only) (Chi2 =
8.14, df = 2, P = 0.02, I2 = 75.4%)

• No  difference  in  outcomes  for  individual  versus
group formats (Chi2 = 0.35, df = 1, P = 0.56; I2 = 0%)
• Difference in outcomes for interventions with differ-
ent amounts of therapist contact (Chi2 = 10.75, df =
2, P= 0.005; I2 = 81.4%)

• Insufficient  studies  for  subgroup  analyses  examin-
ing outcomes for participants with and without ASD

Subgroup analyses:

• Difference in outcomes for different delivery formats
(child-focused, child and parent, parent only) (Chi2 =
14.67,df = 2, P < 0.001, I2 = 86.4%)

• Difference in outcomes for individual versus group

formats (Chi2 =6.47, df = 1, P = 0.01; I2 = 84.5%)

• No difference in outcomes for interventions with dif-
ferent amounts of therapist contact (Chi2 = 3.33, df =
2, P = 0.19; I2 = 39.9%)

• No difference in outcomes for participants with and
without ASD (Chi2 = 0.02, df = 1, P = 0.88; I2 = 0%)

Subgroup analyses:

• No difference in outcomes for different delivery for-
mats (child-focused, child and parent, parent only)
(Chi2 = 3.43, df = 2, P = 0.18, I2 = 41.8%)

• Difference in outcomes for individual versus group
formats (Chi2 = 6.79,df = 1, P = 0.009, I2 = 85.3%)
• No difference in outcomes for interventions with dif-
ferent amounts of therapist contact (Chi2 = 3.77, df =
2, P = 0.15; I2 = 46.9%)

• No difference in outcomes for participants with and
without ASD (Chi2 = 1.42, df = 1, P = 0.23; I2 = 29.8%)

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
ing post-treat-
ment

viations higher (0.68 to 1.38 high-
er).

Adverse events
(randomisation
to post-treat-
ment)

See comment

See comment

Not estimable

-

See comment

No study reported adverse events in both CBT and
waitlist/no treatment groups

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The
corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and
the relative effect of the intervention (and its 95% CI).
CBT: cognitive behavioural therapy; CI: confidence interval; ITT: intention-to-treat; OR: odds ratio

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of ef-
fect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of ef-
fect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1Control group risk estimates come from pooled estimates of waitlist groups.
2Downgraded one level due to moderate heterogeneity (inconsistency).
3Downgraded two levels due large variation in treatment effects across studies (inconsistency) and wide confidence intervals (imprecision).
4Downgraded two levels due to substantial heterogeneity (inconsistency).
5Downgraded two levels due to substantial heterogeneity (inconsistency) and assessed and reported in small number of eligible studies (study limitations).

Summary of findings 2.   CBT compared with treatment as usual for anxiety disorders in children and adolescents

CBT compared with treatment as usual for anxiety disorders in children and adolescents

Patient or population: children and adolescents with anxiety disorders

Settings: outpatient clinics/schools

Intervention: CBT

Comparison: treatment as usual

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk1

Corresponding risk

Relative effect
(95% CI)

No. of partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

C
o
p
y
r
i
g
h
t

©
2
0
2
0
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

C
o
g
n
i
t
i
v
e
b
e
h
a
v
i
o
u
r
a
l

t
h
e
r
a
p
y
f
o
r
a
n
x
i
e
t
y
d
i
s
o
r
d
e
r
s
i

n
c
h
i
l

d
r
e
n
a
n
d
a
d
o
l
e
s
c
e
n
t
s
(
R
e
v
i
e
w

)

6

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
2
0
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

C
o
g
n
i
t
i
v
e
b
e
h
a
v
i
o
u
r
a
l

t
h
e
r
a
p
y
f
o
r
a
n
x
i
e
t
y
d
i
s
o
r
d
e
r
s
i

n
c
h
i
l

d
r
e
n
a
n
d
a
d
o
l
e
s
c
e
n
t
s
(
R
e
v
i
e
w

)

Treatment as usu-
al

CBT

Remission of primary anxiety
diagnosis post-treatment (ITT)

408 per 1000

687 per 1000
(383 to 886)

OR 3.19 (0.90 to
11.29)

487

(8 studies)

⊕⊕⊝⊝
low 2

Acceptability (number of par-
ticipants lost to post-treatment
assessment)

93 per 1000

124 per 1000
(70 to 209)

OR 1.37 (0.73 to
2.56)

Remission of all anxiety diag-
noses post-treatment (ITT)

414 per 1000

660 per 1000
(451 to 820)

OR 2.74 (1.16 to
6.46)

441

(8 studies)

203

(5 studies)

Reduction in anxiety symptoms
(child report) post-treatment

The mean anxiety symptoms (child report)
in the CBT groups was 0.15 standard devi-
ations lower (0.78 lower to 0.48 higher).

Cross 0

214

(6 studies)

Reduction in anxiety symptoms
(parent report) post-treatment

The mean anxiety symptoms (parent re-
port) in the CBT groups was 0.32 standard
deviations lower (0.70 lower to 0.06 high-
er).

Cross 0

228

(7 studies)

⊕⊕⊝⊝
low 3

⊕⊕⊝⊝
low 3

⊕⊕⊝⊝
low 2

⊕⊕⊝⊝
low 2

Subgroup analyses:

• Difference in outcomes for
different  delivery  formats
(child-focused versus child
and parent) (Chi2 = 10.90, df
= 1, P < 0.001, I2 = 90.8%)
• Insufficient studies for sub-
group  analyses  examin-
in  out-
ing  differences 
comes  for  individual  ver-
sus  group  formats  and  in-
terventions  with  varying-
amount  of  therapist  con-
tact time

• Difference in outcomes for
participants with and with-
out ASD (Chi2 = 5.71, df = 1,
P = 0.02; I2 = 82.5%)

Reduction in depressive symp-
toms post-treatment

See comment

Improvement in global func-
tioning post-treatment

See comment

7

Not estimable

Not estimable

-

-

See comment

Insufficient evidence to esti-
mate effect

See comment

Insufficient evidence to esti-
mate effect

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
2
0
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

C
o
g
n
i
t
i
v
e
b
e
h
a
v
i
o
u
r
a
l

t
h
e
r
a
p
y
f
o
r
a
n
x
i
e
t
y
d
i
s
o
r
d
e
r
s
i

n
c
h
i
l

d
r
e
n
a
n
d
a
d
o
l
e
s
c
e
n
t
s
(
R
e
v
i
e
w

)

8

Adverse events (randomisation
to post-treatment)

See comment

See comment

Not estimable

-

See comment

No study reported adverse
events in both CBT and Treat-
ment as Usual groups

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and
its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95%
CI).
CBT: cognitive behavioural therapy; CI: confidence interval; ITT: intention-to-treat; OR: odds ratio

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the
estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change
the estimate.
Very low quality: We are very uncertain about the estimate.

1Control group risk estimates come from pooled estimates of treatment as usual groups.
2Downgraded two levels due to at least moderate heterogeneity (inconsistency) and wide confidence intervals and small number of events or participants (imprecision).
3Downgraded two levels due to large variation in treatment effects across studies (inconsistency) and wide confidence intervals and small number of events (imprecision).

Summary of findings 3.   CBT compared with attention control for anxiety disorders in children and adolescents

CBT compared with attention control for anxiety disorders in children and adolescents

Patient or population: children and adolescents with anxiety disorders

Settings: outpatient clinics/schools

Intervention: CBT

Comparison: attention control

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

Attention control1

CBT

Relative effect
(95% CI)

No. of partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

Remission of primary anxiety
diagnosis post-treatment (ITT)

293 per 1000

486 per 1000
(355 to 617)

OR 2.28 (1.33 to
3.89)

822
(10 studies)

⊕⊕⊝⊝
low 2,

Subgroup analyses:

• Difference  in  outcomes
for  different  delivery
formats  (child-focused

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
2
0
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

C
o
g
n
i
t
i
v
e
b
e
h
a
v
i
o
u
r
a
l

t
h
e
r
a
p
y
f
o
r
a
n
x
i
e
t
y
d
i
s
o
r
d
e
r
s
i

n
c
h
i
l

d
r
e
n
a
n
d
a
d
o
l
e
s
c
e
n
t
s
(
R
e
v
i
e
w

)

9

versus child and parent)
(Chi2  =  7.65,  df  =  1,  P  =
0.006; I2 = 86.9%)

• No  difference  in  out-
comes 
individual
for 
versus  group  formats
(Chi2  =  1.22,  df  =  1,  P  =
0.27; I2 = 17.7%)

• Insufficient  studies  for
subgroup  analyses  ex-
amining  outcomes  for
interventions with vary-
ing  amounts  of  thera-
pist contact, and partic-
ipants with and without
ASD

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

Acceptability (number of par-
ticipants lost to post-treatment
assessment)

201 per 1000

201 per 1000
(146 to 272)

OR 1.00 (0.68 to
1.49)

797
(12 studies)

Remission of all anxiety diag-
noses post-treatment (ITT)

185 per 1000

385 per 1000
(217 to 584)

OR 2.75 (1.22 to
6.17)

378
(5 studies)

⊕⊕⊝⊝
low 3

⊕⊕⊝⊝
low 2

Reduction in anxiety symptoms
(child report) post-treatment

The mean anxiety symptoms (child report) in
the CBT groups was 0.31 standard deviations
lower (0.51 to 0.11 lower).

Small effect size

978
(15 studies)

⊕⊕⊕⊝
moderate 4

Reduction in anxiety symptoms
(parent report) post-treatment

The mean anxiety symptoms (parent report) in
the CBT groups was 0.25 standard deviations
lower (0.61 lower to 0.11 higher).

Reduction in depressive symp-
toms post-treatment

The mean depressive symptoms in the CBT
groups was 0.18 standard deviations lower
(0.45 lower to 0.09 higher).

Improvement in global func-
tioning post-treatment

See comment

Cross 0

Cross 0

Not estimable

Adverse events (randomisation
to post-treatment)

See comment

See comment

Not estimable

638
(8 studies)

613
(10 studies)

⊕⊕⊝⊝
low 5

⊕⊕⊝⊝
low 5

-

-

See comment

Insufficient evidence to
estimate effect

See comment

No study reported adverse
events in both CBT and at-
tention control groups

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its
95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
CBT: cognitive behavioural therapy; CI: confidence interval; ITT: intention-to-treat; OR: odds ratio

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the esti-
mate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the
estimate.
Very low quality: We are very uncertain about the estimate.

1Control group risk estimates come from pooled estimates of attention control groups.
2Downgraded two levels due to at least moderate heterogeneity and large variation in treatment effects (inconsistency) and small number of events (imprecision).
3Downgraded two levels due to large variation in treatment effects across studies (inconsistency) and wide confidence intervals and small number of events (imprecision).
4Downgraded one level due to moderate heterogeneity (inconsistency).
5Downgraded two levels due to at least moderate heterogeneity (inconsistency) and wide confidence intervals (imprecision).

Summary of findings 4.   CBT compared with alternative treatment for anxiety disorders in children and adolescents

CBT compared with alternative treatment for anxiety disorders in children and adolescents

Patient or population: children and adolescents with anxiety disorders

Settings: outpatient clinics/schools

Intervention: CBT

Comparison: alternative treatment

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

Alternative treat-
ment1

CBT

Relative effect
(95% CI)

No. of partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

Remission of primary anxiety diagno-
sis post-treatment (ITT)

See comment

See comment

Not estimable

-

See comment

Insufficient ev-
idence to esti-
mate effect or
conduct sub-
group analyses

Acceptability (number of participants
lost to post-treatment assessment)

115 per 1000

171 per 1000
(74 to 350)

OR 1.58 (0.61 to
4.13)

515
(7 studies)

⊕⊕⊝⊝

C
o
p
y
r
i
g
h
t

©
2
0
2
0
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

C
o
g
n
i
t
i
v
e
b
e
h
a
v
i
o
u
r
a
l

t
h
e
r
a
p
y
f
o
r
a
n
x
i
e
t
y
d
i
s
o
r
d
e
r
s
i

n
c
h
i
l

d
r
e
n
a
n
d
a
d
o
l
e
s
c
e
n
t
s
(
R
e
v
i
e
w

)

1
0

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Remission of all anxiety diagnoses
post-treatment (ITT)

607 per 1000

579 per 1000
(351 to 775)

OR 0.89 (0.35 to
2.23)

401
(4 studies)

Reduction in anxiety symptoms (child
report) post-treatment

The mean anxiety symptoms (child report) in the
CBT groups was 0.09 standard deviations lower
(0.40 lower to 0.21 higher).

Reduction in anxiety symptoms (par-
ent report) post-treatment

The mean anxiety symptoms (child report) in the
CBT groups was 0.13 standard deviations lower
(0.33 lower to 0.06 higher).

Cross 0

Cross 0

399
(6 studies)

423
(6 studies)

Reduction in depressive symptoms
post-treatment

Not estimable

Improvement in global functioning
post-treatment

Not estimable

Not estimable

Not estimable

Adverse events (randomisation to
post-treatment)

See comment

See comment

Not estimable

-

-

-

low 2

⊕⊕⊝⊝

low 2

⊕⊕⊝⊝
low 3

⊕⊕⊝⊝
low 4

See comment

See comment

See comment

Insufficient ev-
idence to esti-
mate effect

No evidence
available to es-
timate effect

No study re-
ported adverse
events in both
CBT and Treat-
ment as Usual
groups

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confi-
dence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CBT: cognitive behavioural therapy; CI: confidence interval; ITT: intention-to-treat; OR: odds ratio

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1Control group risk estimates come from pooled estimates of alternative treatment groups.
2Downgraded two levels due to at least moderate heterogeneity (inconsistency) and wide confidence intervals and small number of events (imprecision).
3Downgraded two levels due to moderate heterogeneity (inconsistency) and wide confidence intervals (imprecision).
4Downgraded two levels due to large variation in treatment effects across studies (inconsistency) and wide confidence intervals (imprecision).

C
o
p
y
r
i
g
h
t

©
2
0
2
0
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

C
o
g
n
i
t
i
v
e
b
e
h
a
v
i
o
u
r
a
l

t
h
e
r
a
p
y
f
o
r
a
n
x
i
e
t
y
d
i
s
o
r
d
e
r
s
i

n
c
h
i
l

d
r
e
n
a
n
d
a
d
o
l
e
s
c
e
n
t
s
(
R
e
v
i
e
w

)

1
1

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

B A C K G R O U N D

Description of the condition

Anxiety  disorders  are  amongst  the  most  common  psychiatric
disorders,  occurring  in  6.5%  of  all  children  and  adolescents
(Polanczyk  2015).  One  of  the  diagnostic  challenges  in  children
and adolescents involves distinguishing normal, developmentally
appropriate  worries,  fears,  and  shyness  from  anxiety  disorders.
For example, primary school-age children commonly have worries
about  injury  and  natural  events,  whereas  older  children  and
adolescents  typically  have  worries  and  fears  related  to  school
performance, social competence, and health issues (Beesdo 2009).
Distinguishing  features  of  pathological  anxiety  include  severity,
persistence, and associated impairment.

The International Classification of Diseases (ICD), WHO 1992, and
Diagnostic  and  Statistical  Manual  of  Mental  Disorders  (DSM-5),
APA 2013, diagnostic systems distinguish various types of anxiety
disorders,  including  generalised  anxiety  disorder,  panic  disorder,
social anxiety disorder, separation anxiety disorder, agoraphobia,
specific  phobias,  and  selective  mutism.  These  anxiety  disorders
are  often  associated  with  significant  impairment  in  personal,
social,  and  academic  functioning  (Pine  2009).  Comorbidities  are
common, in particular with other anxiety disorders in children and
adolescents  (Leyfer  2013),  and  depression  in  adolescents  (Essau
2003).

The presentation of anxiety disorders varies with age. Separation
anxiety  disorders  are  more  common  in  younger  children  than
in  adolescents,  and  difficulties  with  social  anxiety  are  typically
associated  with  greater  disturbance  in  adolescence  (Waite  2014).
Anxiety  disorders  with  an  onset  in  childhood  often  persist  into
adolescence  and  early  adulthood  (Copeland  2014),  and  are  also
associated with adverse academic, health, and social functioning
in adulthood (Copeland 2014; Essau 2014). Yet these often remain
untreated,  with  an  average  delay  of  9  to  23  years  before  anxiety
disorders  are  first  treated  (Wang  2005).  It  is  clear  that  anxiety
disorders in this age group present serious ongoing health issues,
therefore effective and readily accessible treatments are needed.

Description of the intervention

Current treatments for anxiety disorders in this age group include
behavioural  therapy,  cognitive  behavioural  therapy  (CBT),  or
medication,  or  a  combination  of  some  or  all  these.  National
Institute  for  Health  and  Care  Excellence  (NICE)  guidelines  are
available  for  the  treatment  of  social  anxiety  disorder,  which
recommend CBT that is specifically focused on social anxiety (NICE
2013). Given the prevalence of these disorders, the age of onset, and
public views on the acceptability of pharmacological treatments,
psychological  treatments  are  often  preferred  as  first-line  therapy
(Brown  2007;  Young  2006).  CBT  is  a  collaborative  psychological
treatment that can be delivered in various formats, individually or
in groups, and with varying levels of parent or family involvement.

One  of  the  first  manualised  CBT  programmes  was  Coping  Cat
(Kendall 1994), which consists of psycho-education, modification
of  negative  cognitions,  exposure,  social  competence  training,
coping  behaviour,  and  self-reinforcement  sessions.  Others  have
followed,  including  the  Cool  Kids  programme  (Hudson  2009;
Rapee  2006),  the  Coping  Koala  programme  (Barrett  1996),  Skills
for  Academic  and  Social  Success  (SASS)  (Masia-Warner  2005),

Cochrane Database of Systematic Reviews

ACTION (Waters 2009), Intervention With Adolescents With Social
Phobia  (IAFS)  (Sanchez-Garcia  2009),  the  TAPS  (Warner  2011),
and  Building  Confidence  programme  (Galla  2012).  Alternative
programmes  involve  providing  direct  support  to  parents  alone,
guiding them to implement CBT strategies with their child (Guided
Parent-Delivered  CBT  (GPD-CBT)  (Lyneham  2006;  Thirlwall  2013;
Waters  2009).  CBT  programmes  have  typically  adopted  a  generic
approach  and  target  a  range  of  anxiety  disorders  (e.g.  Coping
Cat), but some are disorder-specific, targeting, for example, social
anxiety disorder (e.g. SASS). CBT programmes have been modified
in  various  ways  to  make  them  appropriate  for  children  with
autism  spectrum  disorders  (ASD),  such  as  by  including  social
stories,  social  coaching,  visual  aids,  and  structured  worksheets
(Ung 2015). Such programmes include the Multimodal Anxiety and
Social  Skills  Intervention  (MASSI)  programme  (White  2013),  TAFF
(Schneider 2011), Behavioural Interventions for Anxiety in Children
with  Autism  (BIACA)  (Wood  2009),  and  Facing  Your  Fears  (FYF)
(Reaven 2012).

How the intervention might work

CBT  for  anxiety  disorders  in  children  and  adolescents  typically
involves  helping  the  child  to  recognise  anxious  feelings  and
bodily  or  somatic  reactions  to  anxiety,  identify  thoughts  or
cognitions  in  anxiety-provoking  situations  (e.g.  unrealistic  or
negative  attributions  and  expectations),  and  modifying  these
anxiety-provoking  cognitions  (e.g.  testing  out  predictions  based
on  anxious  thoughts,  modifying  anxious  self-talk  into  coping
self-talk).  A  key  CBT  procedure  is  exposure  (Creswell  2020b),
which  typically  involves  testing  out  and  ‘facing’  fears,  often  in  a
gradually increasing hierarchy. Behavioural training strategies such
as modelling and role playing are often applied as opportunities for
developing  coping  skills  (e.g.  problem-solving  skills,  social  skills,
relaxation training).

CBT  for  anxiety  disorders  in  children  and  adolescents  has
traditionally  begun  with  six  to  nine  face-to-face  sessions  of
anxiety management strategies (emotion identification, relaxation
training, cognitive strategies), followed by exposure work (Barrett
1996;  Kendall  2006).  In  one  meta-analysis  (Reynolds  2012),  this
traditional  format  of  anxiety  management  sessions  followed  by
exposure  was  observed  in  93%  of  studies.  However,  Ale  2015
found  that  treatment  outcomes  in  CBT  treatment  trials  for  child
and  adolescent  anxiety  disorders  were  not  related  to  the  use
of  relaxation  strategies  or  the  timing  of  exposure  work,  and
therefore suggested that relaxation training may not be an essential
ingredient  of  CBT,  and  that  it  may  not  be  necessary  to  delay
exposure until after anxiety management sessions. Moreover, there
is also some preliminary evidence that introducing exposure early
in  treatment,  without  any  prior  anxiety  management  sessions,
could  improve  outcomes  whilst  requiring  fewer  appointments
(Whiteside 2015).

Indeed, questions remain about the mechanism of change within
CBT.  Cognitive  restructuring  and  exposure  tasks  have  each  been
found to make substantial contributions to improvement in child
and adolescent anxiety in line with CBT theory (Peris 2015). More
time  devoted  to  exposure  has  been  linked  to  better  outcomes,
and greater time spent on more difficult exposure tasks has been
shown to predict better outcomes (Peris 2017). Change in coping
efficacy,  but  not  anxious  self-talk,  has  been  found  to  mediate
change  in  anxiety  symptoms  associated  with  CBT,  medication
(sertraline),  and  their  combination,  compared  to  placebo  control

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

12

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

(Kendall 2016). Furthermore, therapists’ ratings of child compliance
and mastery also predict better outcomes (Peris 2017). Cognitive
development  also  plays  an  important  role,  and  whilst  targeting
behavioural  avoidance  appears  to  be  crucial  for  both  children
and adolescents, treatment that directly addresses interpretation
biases may be particularly beneficial for adolescents, but less so for
younger children (Waite 2015).

CBT has been adapted to include family and parents in treatment
sessions;  however,  parents/family  members  have  been  included
in  a  wide  variety  of  ways,  including,  for  example,  providing
education  and  information  on  the  child-focused  CBT,  and/or
modifying  parents’  beliefs  and  behaviours,  and/or  addressing
parental anxiety. These different approaches are based on different
conceptualisations  of  the  mechanisms  of  change  in  child  anxiety
through  parental  involvement.  It  is  important  to  note,  however,
that  changes  in  parent  and  child  responses  are  likely  to  be
bidirectional.  For  example,  one  study  found  that  child-focused
anxiety  treatments  resulted  in  improvements  in  non-targeted
parent  symptoms  and  family  functioning,  particularly  when
children responded successfully to treatment (Keeton 2013).

It is generally assumed that CBT can be applied only after the child
has reached a certain level of cognitive development. Kendall 1993
argued that the ability to measure a thought or belief against the
notion  of  a  rational  standard  and  the  ability  to  understand  that
a  thought  or  belief  can  cause  a  person  to  behave  and  feel  in  a
certain way were central to its proper use. The question arises: at
what age does a child have the cognitive capacities to undertake
these cognitive operations? One study reported positive effects of
CBT  in  children  younger  than  six  years  of  age  (Hirshfeld-Becker
2010);  however,  it  is  not  clear  whether  children  this  age  are  able
to use the cognitive strategies that are included in traditional CBT
protocols. In line with this, research suggests that young children
may  be  more  responsive  to  the  behavioural  than  the  cognitive
elements  of  this  approach  (Essau  2004).  With  younger  children,
parental involvement appears particularly important. Indeed, the
treatment of anxiety disorders in young children can be effective
by applying CBT principles through working directly with parents
alone  (Cartwright-Hatton  2011),  although  there  are  inconsistent
findings  in  relation  to  whether  child-parent  delivery  format  is
superior to parent-only or not (Monga 2015; Waters 2009).

Why it is important to do this review

Anxiety  disorders 
in  children  and  adolescents  represent  a
considerable  source  of  morbidity  and  are  associated  with  later
adult  psychopathology  and  greater  cost  than  any  other  mental
health disorder (Fineberg 2013). However, despite high prevalence
and  substantial  morbidity,  anxiety  disorders  in  childhood  and
adolescence  can  be  difficult  to  diagnose,  and  may  be  under-
recognised (NICE 2013), and therefore undertreated (Pine 2009). It
is widely reported that only a minority of children and adolescents
with  mental  health  problems  receive  treatment  (Green  2004;
Merikangas 2011); a recent UK survey reported that fewer than 40%
of children with anxiety disorders receive any professional support,
and  less  than  3%  receive  CBT  (Reardon  2020).  Limited  service
provision  represents  a  key  barrier  to  treatment  access  (Reardon
2017), highlighting the importance of maximising the efficiency of
treatment delivery to help ensure that effective treatment is more
readily available to children and young people when they need it.

Cochrane Database of Systematic Reviews

The evidence base for the treatment of anxiety disorders in children
and  adolescents  is  growing.  Initial  trials  of  CBT  were  positive
(Barrett 1996; Kendall 1994; Kendall 1997), and further randomised
controlled  trials  and  reviews  followed.  Several  reviews  suggest
that  CBT  for  anxiety  disorders  in  this  age  group  is  effective  (Ale
2015;  Crowe  2017;  James  2015;  Reynolds  2012;  Silverman  2008),
including an overview of systematic reviews and a network meta-
analysis (Bennett 2016; Zhou 2019). Overall there was a moderate
response rate (e.g. 59%; James 2015), and a recent review indicated
that  benefits  extend  to  broader  outcomes,  including  depressive
symptoms  and  general  functioning  (Kreuze  2018).  However,  CBT
has not been shown to be superior to active controls or treatment
as  usual  (James  2015;  Southam-Gerow  2010).  In  some  previous
studies, the effect sizes associated with CBT for childhood anxiety
disorders did not differentiate it from attention placebo, although
CBT has been found to be more effective than waiting list control
(Ale 2015). It remains unclear whether CBT is superior to alternative
treatment approaches.

This  review  updates  and  replaces  previous  Cochrane  Reviews  of
CBT for anxiety disorders in children and adolescents (James 2005;
James  2015).  The  current  review  aims  to  provide  comprehensive
and up-to-date evidence on the efficacy and acceptability of CBT in
the treatment of anxiety disorders in children and adolescents, with
varying  amounts  of  therapist  contact  time  and  differing  delivery
formats,  including  individual,  group,  with/without  family/parent
involvement, and parent-led. Furthermore, we planned to examine
the efficacy of CBT relative to treatment as usual, attention control,
and  alternative  treatments.  The  question  of  the  comparative
efficacy of medication versus CBT and the combination of CBT and
medication was also to be addressed.

A  recent  development  is  the  issue  of  the  reporting  of  remission
of all anxiety diagnoses, as well as the primary anxiety diagnosis
(Warwick 2016). Given the high level of comorbid anxiety disorders,
this  is  an  important  issue,  but  surprisingly  has  been  previously
overlooked. Indeed, focusing solely on recovery from the primary
anxiety  diagnosis  means  that  children  with  comorbid  anxiety
disorders that are present following treatment are often still classed
as  ‘recovered’.  As  such,  this  review  distinguishes  between  and
examines  outcomes  based  on  both  the  absence  of  the  ‘primary
anxiety  disorder’  and  the  absence  of  all  anxiety  disorders.  As
well  as  providing  evidence  on  anxiety  outcomes  (diagnoses  and
symptoms),  we  also  planned  to  examine  benefits  in  relation  to
broader  outcomes,  including  depressive  symptoms  and  global
functioning.

We  also  aimed  to  assess  whether  treatment  effects  of  CBT  are
maintained beyond post-treatment and at longer-term follow-up.
Whilst  it  would  not  be  possible  to  determine  the  youngest  age
at  which  a  child  can  benefit  from  CBT  without  individual  patient
data,  we  would  identify  the  age  of  the  youngest  participants
in  trials  of  CBT  for  child  and  adolescent  anxiety  disorders.  It  is
recognised that children and adolescents with ASDs have high rates
of anxiety disorders (van Steensel 2013); however, studies of CBT
for  anxiety  disorders  in  ASD  have  had  mixed  outcomes  (Murphy
2017; Ung 2015). Furthermore, it is unclear how anxiety disorders
are  recognised  or,  indeed,  treated  in  those  with  intellectual
impairments, indicating a pressing need for work in this area. We
planned to examine the efficacy of CBT in children and adolescents
with ASD and those with intellectual impairments.

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

13

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Previous Cochrane Reviews used a cutoff of nine sessions of CBT,
based on the practice and thinking at the time (James 2005; James
2015). However, since the last Cochrane Review (James 2015), there
have been several developments in the delivery of CBT for anxiety
disorders. These include briefer or shorter interventions, in terms
of not only the number of sessions, but also the total duration of
treatment. As such, we would not set a threshold for the minimum
number of sessions, and would explore how treatment effects differ
with treatment duration. It is important to note that one potentially
efficient means to deliver CBT is online or via digital devices (e.g.
computerised  CBT).  But  as  online  and  digital  CBT  interventions
for  child  anxiety  disorders  have  been  reviewed  elsewhere  (e.g.
Pennant 2015), this review focused on face-to-face delivery models
that include direct contact with either the child or parent alone, or
the child and parent together.

Diagnosis

We  included  participants  meeting  diagnostic  criteria  of  the  DSM
(DSM III, III-R, IV, IV-TR, 5), APA 1980; APA 1987; APA 1994; APA 2000;
APA  2013,  or  the  ICD-9  and  ICD-10,  WHO  1978;  WHO  1992,  for  an
anxiety disorder.

Diagnoses  had  to  be  made  by  reliable  and  valid  structured
interviews for DSM or ICD child and adolescent anxiety disorders.
Disorders  classified  as  anxiety  disorders  vary  across  different
versions  of  the  DSM,  and  we  included  participants  meeting
diagnostic  criteria  for  one  or  more  of  the  following  disorders:
generalised  anxiety  disorder  or  overanxious  disorder,  separation
anxiety  disorder,  social  phobia  or  social  anxiety  disorder,  panic
disorder,  agoraphobia,  simple  or  specific  phobias,  or  selective
mutism.

O B J E C T I V E S

Comorbidity

• To carry out a meta-analysis of identified studies to determine
whether  CBT  leads  to  remission  of  1)  the  primary  child/
adolescent anxiety disorder and 2) all anxiety diagnoses, and/
or  3)  a  clinically  significant  reduction  in  anxiety  symptoms  in
comparison with waiting list/no treatment, treatment as usual,
attention control, alternative treatment, or medication.

• To  determine  the  comparative  efficacy  of  CBT  alone,  and  the
combination of CBT and medication, versus drug placebo.
• To  determine  if  CBT  is  an  acceptable  treatment,  relative  to
waiting list/no treatment, treatment as usual, attention control,
alternative treatment, and medication.

• To  determine  whether  CBT 

to  a
clinically significant reduction in depressive symptoms and/or
improvements in global functioning.

for  anxiety 

leads 

• To identify any adverse effects associated with CBT, relative to
waiting list/no treatment, treatment as usual, attention control,
alternative treatment, and medication.

We included all comorbidities allowable for anxiety disorders under
the  rules  of  DSM  or  ICD,  such  as  ASD,  intellectual  impairment,
depressive disorders, and physical disorders.

Settings

We  included  all  settings,  such  as  research  settings  (i.e.  university
outpatient  clinics,  inpatient  services,  community  clinics,  and
schools).

Exclusion criteria

We  excluded  studies  that  only  included  participants  with  post-
traumatic  stress  disorder  or  obsessive  compulsive  disorder,  or
both,  as  they  are  covered  by  separate  Cochrane  Reviews  (Gillies
2016;  O'Kearney  2006),  and  are  no  longer  classified  as  ‘anxiety
disorders’ in the DSM-5 (APA 2013).

Types of interventions

• To  determine  whether  post-treatment  gains  of  CBT  are

Experimental intervention

maintained at longer-term follow-up.

• To describe the age range of participants included in CBT trials
in order to determine the age of the youngest participants.
• To  carry  out  subgroup  analyses  of  different  types  of  CBT
according to 1) amount of therapist contact time; and 2) delivery
format (individual and group; child-focused, child and parent/
family, and parent-only).

• To  carry  out  a  subgroup  analysis  of  CBT  for  children  and
adolescents  with  ASD  and  for  children  and  adolescents  with
intellectual impairments.

M E T H O D S

Criteria for considering studies for this review

Types of studies

We included randomised controlled trials (RCTs), cross-over trials,
and cluster-randomised trials.

Types of participants

Participant characteristics

Children and adolescents younger than 19 years.

The  intervention  had  to  be  manualised  CBT,  or  modular  CBT,
alone or in combination with medication, following a documented,
written protocol and provided by trained therapists. Since the last
review (James 2015), where the number of sessions was arbitrarily
fixed at nine, there are now several studies indicating that shorter
treatment, in terms of number of sessions or duration of sessions,
or both, may be effective. We therefore did not include a minimum
number of sessions or duration of sessions as a requirement.

CBT  had  to  be  administered  according  to  standard  principles  as
a  psychological  model  of  treatment  involving  helping  the  child
to  recognise  anxious  feelings  and  somatic  reactions  to  anxiety;
identify  cognitions  in  anxiety-provoking  situations;  modify  these
anxiety-provoking cognitions; and respond to behavioural training
strategies with exposure in vivo or by imagination.

CBT could be delivered to children (child-focused), to children and
parents/family  members  (child  and  parent),  or  to  parents  alone
(parent-only).  In  child-focused  CBT,  the  child  had  direct  face-to-
face contact with a therapist, and the intervention was delivered
to  children  only,  with  minimal  or  no  parental  involvement.
CBT  with  direct  parent/family  involvement  (child  and  parent)
included  face-to-face  child  sessions  and  conjoint  or  separate
sessions  with  parents/family  that  included  providing  psycho-
education  for  parents  or  teaching  parents  to  be  co-therapists.

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

14

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Parent-delivered  CBT  (parent-only)  only  involved  direct  face-to-
face  contact  with  parents,  and  provided  support  for  parents  to
help  them  to  implement  CBT  strategies  in  their  child’s  day-to-
day  life.  Child-focused,  child  and  parent,  and  parent-only  CBT
could  be  delivered  individually  or  in  a  group  format.  We  did  not
include  CBT  interventions  delivered  online  or  via  digital  devices
(e.g. computerised CBT).

Where studies included medication for the treatment of anxiety (in
combination with CBT or alone), no concurrent medication for the
treatment of anxiety was to be administered naturalistically. Where
studies  did  not  include  medication  for  the  treatment  of  anxiety,
any medications administered naturalistically needed to be stable
before and during the study.

Comparator interventions

Where CBT was delivered alone

• Waitlist and no treatment for anxiety during that period
• Treatment as usual (usual treatment or care; where usual care

includes therapy, it does not include elements of CBT)

• Attention control (attention only, e.g. support or education, but

with no elements of CBT)

• Alternative 

treatment 

(one  specific  non-pharmacological
intervention  for  the  treatment  of  anxiety  that  followed  a
documented protocol and did not include CBT elements)

• Medication for the treatment of anxiety
• Drug placebo

Where CBT was delivered in combination with medication for the
treatment of anxiety

• Drug placebo

Types of outcome measures

We  included  studies  that  met  the  above  inclusion  criteria  and
reported  or  provided  data  on  at  least  one  of  the  following
outcomes.

Primary outcomes

• Remission: the absence of the primary diagnosis of an anxiety
disorder post-treatment, made by reliable and valid structured
interviews  for  DSM  or  ICD  child  and  adolescent  anxiety
disorders, such as:
◦ Anxiety Disorder Interview Schedule for Children – Child and

Parent (ADIS-C/P) (Silverman 1987);

◦ Anxiety  Disorder  Interview  Schedule  for  Children  –  Child

(ADIS-C) (Silverman 1987);

◦ Anxiety  Disorder  Interview  Schedule  for  Children  –  Parent

(ADIS-P) (Silverman 1987);

◦ Diagnostic Interview Schedule for Children, Adolescents and

Parents (DISCAP) (Holland 1995).

• Acceptability: loss of participants to post-treatment assessment

Secondary outcomes

• Remission:  defined  as  the  absence  of  all  diagnoses  of  an
anxiety  disorder  post-treatment,  made  by  reliable  and  valid
structured  interviews  for  DSM  or  ICD  child  and  adolescent
anxiety disorders.

Cochrane Database of Systematic Reviews

• Reduction in anxiety symptoms post-treatment: measured using
psychometrically  robust  measures  of  anxiety  symptoms  that
yield symptom scores on continuous scales (Myers 2002), such
as:
◦ Screen  for  Child  Anxiety  Related  Emotional  Disorders

(SCARED) (Birmaher 1999);

◦ Spence Children’s Anxiety Scale (SCAS) (Spence 1997);
◦ Revised  Children’s  Anxiety  and  Depression  Scale  (RCADS)  –

Anxiety Scale (Chorpita 2000);

◦ Revised Children’s Manifest Anxiety Scale (RCMAS) (Reynolds

1985);

◦ Multidimensional  Anxiety  Scale  for  Children  (MASC)  (March

1997);

◦ State-Trait  Anxiety 
(Spielberger 1973);

Inventory 

for  Children 

(STAI-C)

◦ Social  Phobia  and  Anxiety  Inventory  for  Children  (SPAI-C)

(Beidel 1995);

◦ Social Anxiety Scale for Adolescents (SAS-A) (La Greca 1998).

These  scales  could  be  self-report  or  completed  by  a  parent  or
an  independent  rater.  Multiple  reporters  are  often  used,  but
the  reliability  of  each  reporter  is  likely  to  vary  with  the  child’s
age  (Evans  2017).  We  therefore  determined  reduction  in  anxiety
symptoms  separately  for  1)  self-reported  and  2)  parent-reported
or  independent  rater,  or  both.  Multiple  measures  are  also  often
reported, and we included the most validated, best recognised, or
most frequently used measures in the analysis.

A  crucial  issue  is  how  well  these  measures  discriminate  between
clinical and non-clinical levels of anxiety. We prioritised symptom
measures  that  were  closely  aligned  with  diagnostic  categories,
with strong discriminant validity (e.g. RCADS, SCAS, SCARED). We
also  prioritised  broad  measures  of  anxiety  symptoms  (e.g.  SCAS,
SCARED, MASC), rather than disorder-specific symptom measures
(e.g. SPAI-C, SAS-A). (See Appendix 1)

• Reduction  in  depressive  symptoms  post-treatment:  measured
using  psychometrically 
robust  measures  of  depressive
symptoms that yielded symptom scores on continuous scales,
such as:
◦ Children’s Depression Inventory (Kovacs 1989);
◦ Beck Depression Inventory (Beck 1996);
◦ Revised  Children’s  Anxiety  and  Depression  Scale  (RCADS)  –

Depression Scale (Chorpita 2000);

◦ Mood and Feelings Questionnaire (Angold 1995).

If multiple depressive symptom measures/reporters were used, we
included the most validated, best recognised, or most frequently
used measures in the analysis.

• Improvement  in  global  functioning  post-treatment:  measured
using  psychometrically  robust  measures  of  global  functioning
that yield symptom scores on continuous scales, such as:
◦ Children’s Global Assessment Scale (CGAS) (Shaffer 1983).

If  multiple  global  functioning  measures/reporters  were  used,  we
included the most validated, best recognised, or most frequently
used measures in the analysis.

• Adverse  events:  we  determined  adverse  events  outcomes  by
the  number  and  type  of  reported  adverse  events  during  the

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

15

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

trial  from  randomisation  to  post-treatment  assessment  (e.g.
deterioration  in  anxiety  symptoms,  deterioration  in  global
functioning, rates of self-harm, suicide attempts).

• Remission  defined  by  the  absence  of  the  primary  anxiety
disorder  diagnosis  at  a  series  of  follow-up  time  points  (≤  6
months  post-treatment,  >  6  months  post-treatment  but  ≤  12
months post-treatment, and > 12 months post-treatment).
• Remission defined as the absence of all diagnoses of an anxiety
disorder at a series of follow-up time points (≤ 6 months post-
treatment,  >  6  months  post-treatment  but  ≤  12  months  post-
treatment, and >12 months post-treatment).

• Reduction  in  anxiety  symptoms  at  a  series  of  follow-up  time
points (≤ 6 months post-treatment, > 6 months post-treatment
but  ≤  12  months  post-treatment,  and  >  12  months  post-
treatment).

• Proquest Dissertations & Theses Global (search.proquest.com/

pqdtglobal/dissertations/)

Reference lists

We checked the reference lists of all included studies and relevant
systematic reviews to identify additional studies missed from the
original electronic searches (e.g. unpublished or in-press citations).

Correspondence

We  contacted  study  authors  and  subject  experts  for  information
on  unpublished  or  ongoing  studies,  or  to  request  additional
data. Where studies included some eligible participants (i.e. some
participants were younger than 19 years, or some participants met
the  diagnostic  criteria  for  an  anxiety  disorder),  we  contacted  the
authors to request data on eligible participants.

Search methods for identification of studies

Data collection and analysis

We  identified  eligible  studies  (RCTs)  of  CBT  for  anxiety  disorders
in  children  and  adolescents  from  the  Cochrane  Common  Mental
Disorders  Controlled  Trials  Register  (CCMDCTR;  all  years  to  2016)
(Appendix 2).

Electronic searches

We  also  ran  searches  on  the  following  databases  using  relevant
keywords, subject headings (controlled vocabularies), and search
syntax, appropriate to each resource (Appendix 3). Searches were
initially conducted on 21 November 2018 and updated 10 October
2019.

• Cochrane Central Register of Controlled Trials (CENTRAL; Issue

10 of 12, 2019) in the Cochrane Library
• Ovid MEDLINE (2016 to 10 October 2019)
• Ovid Embase (2016 to 2019 Week 40)
• Ovid PsycINFO (all years to October Week 40 2019)

We applied no restriction on language or publication status to the
searches.

We  also  searched  the  international  trial  registries  (10  October
2019)  (including  US  National 
Institutes  of  Health  Ongoing
Trials  Register  ClinicalTrials.gov  (clinicaltrials.gov)  and  the  World
Health Organization International Clinical Trials Registry Platform
(apps.who.int/trialsearch/))  to  identify  additional  ongoing  and
unpublished studies.

Searching other resources

Grey literature

We  searched  the  grey  literature  for  dissertations  and  theses  (all
years to 14 October 2019) (Appendix 4), as follows.

• Electronic  Theses  Online  Service  (EThOS)  -  British  Library

(ethos.bl.uk/Home.do)

• DART  -  Europe  e-theses  Portal  (www.dart-europe.eu/basic-

search.php)

• Networked Digital Library of Theses and Dissertations (NDLTD)

(search.ndltd.org/)

• PQDT  Open 

-  open  access  dissertations  and 

theses

(pqdtopen.proquest.com/search.html)

Selection of studies

Two review authors (AJ, TR) independently screened the titles and
abstracts of all studies identified as a result of the search, coding
them  as  ‘retrieve'  (eligible  or  potentially  eligible/unclear)  or  ‘do
not retrieve'. We retrieved the full-text study reports/publications,
and  two  review  authors  (AJ,  TR)  independently  screened  the  full
texts to identify studies for inclusion, and identified and recorded
reasons for exclusion of the ineligible studies. Any disagreements
were resolved through discussion or by consulting a third review
author (GJ, AS, CC) if required. We identified and excluded duplicate
records and collated multiple reports that related to the same study
so that each study, rather than each report, was the unit of interest
in  the  review.  We  recorded  the  selection  process  in  sufficient
detail to complete a PRISMA flow diagram and ‘Characteristics of
excluded studies' table (Moher 2015). We used Covidence software
for the screening process (Covidence).

Data extraction and management

We  used  a  data  collection  form  created  in  Covidence  to  extract
study characteristics and outcome data that we had piloted on two
studies in the review. Two review authors (AJ, TR) extracted study
characteristics  and  outcome  data  from  the  included  studies.  We
extracted the following study characteristics.

• Methods:  study  design,  total  duration  of  study,  details  of  any
‘run-in'  period,  number  of  study  centres  and  location,  study
setting, withdrawals, and date of study

• Participants: number, mean age, age range, gender, severity of
condition,  diagnostic  criteria,  comorbid  conditions,  inclusion
criteria, and exclusion criteria

• Interventions: 

concomitant
medications, excluded medications, delivery format, therapist
contact time, who delivers intervention

intervention, 

comparison, 

• Outcomes:  primary  and  secondary  outcomes  specified  and

collected, and time points reported

• Notes:  funding  for  study,  and  notable  conflicts  of  interest  of

study authors

We  noted  in  the  ‘Characteristics  of  included  studies'  table
if  outcome  data  were  not  reported  in  a  useable  way.  Any
disagreements were resolved by consensus or by involving a third
review author (GJ, AS, CC). One review author (TR) transferred data
into the Review Manager 5 file (Review Manager 2014). We double-

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

16

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

checked  that  data  were  entered  correctly  by  comparing  the  data
presented in the systematic review with the study reports. A second
review author (AJ) spot-checked study characteristics for accuracy
against the study report.

trials  with  high  or  unclear  risk  of  bias  for  blinding  of  outcome
assessment if appropriate. We reported the remainder of the ‘Risk
of bias' assessments for these trials, and included discussion of this
assessment in the Results and Discussion sections.

Main comparisons

Measures of treatment effect

• CBT compared with waiting list and no treatment controls
• CBT compared with treatment as usual
• CBT compared with attention control
• CBT compared with alternative treatments
• CBT compared with medication or drug placebo
• CBT and medication combination compared with drug placebo

Assessment of risk of bias in included studies

Two  review  authors  (AJ,  TR)  independently  assessed  risk  of
bias  for  each  study  using  the  criteria  outlined  in  the  Cochrane
Handbook  for  Systematic  Reviews  of  Interventions  (Higgins  2017).
Any  disagreements  were  resolved  by  discussion  or  by  involving
another review author (GJ, CC). We assessed risk of bias according
to the following domains.

• Random sequence generation
• Allocation concealment
• Blinding of participants and personnel
• Blinding of outcome assessment
• Incomplete outcome data
• Selective outcome reporting
• Other bias, including therapy integrity

In order to assess post-treatment outcomes, we used dichotomous
data  on  remission  of  primary  anxiety  diagnosis  and  all  anxiety
diagnoses, and continuous data on anxiety symptoms, depressive
symptoms,  and  global  functioning,  with  the  use  of  standardised
measures.  We  used  data  from  the  assessment  administered
immediately after treatment (or the assessment closest to the end
of  treatment)  to  assess  post-treatment  outcomes.  We  also  used
these measures to evaluate the maintenance of treatment effects
at  a  series  of  follow-up  time  points  (≤  6  months  post-treatment,
> 6 months post-treatment but ≤ 12 months post-treatment, and
>  12  months  post-treatment).  Where  studies  reported  follow-up
data at multiple time points within one category (e.g. one-month
and three-month follow-up), we used data from the longer follow-
up  period.  To  assess  acceptability,  we  used  frequency  data  on
the  numbers  of  participants  who  were  lost  to  post-treatment
assessment. Adverse events were determined by the number and
type of adverse events during the trial, from randomisation to the
post-treatment assessment.

Dichotomous data

We  analysed  dichotomous  data  as  odds  ratios  (OR)  and  95%
confidence intervals (CI).

Continuous data

We judged each potential source of bias as low, high, or unclear and
provided  a  supporting  quotation  from  the  study  report  together
with a justification for our judgement in the ‘Risk of bias' table. We
summarised the 'Risk of bias' judgements across different studies
for each of the domains listed.

We  analysed  continuous  data  as  mean  difference  (MD)  or
standardised mean difference (SMD). We entered data presented as
a scale with a consistent direction of effect.

We  narratively  described  skewed  data  reported  as  medians  and
interquartile ranges.

Selection  bias:  we  assessed  the  adequacy  of  the  randomisation
process  in  terms  of  the  description  of  adequacy  of  sequence
generation and the concealment of treatment group allocation.

Unit of analysis issues

Cluster-randomised trials

Performance bias: given the nature of psychological interventions,
blinding  of  either  participants  or  personnel  delivering  the
treatments could only be possible in studies involving CBT versus
treatment  as  usual,  attention  control,  or  alternative  treatment,
therefore we were only able to assess attempts at blinding in those
studies.

Detection  bias:  we  evaluated  whether  study  personnel  carrying
out outcome assessments were blinded to the treatment status of
participants.

Attrition  bias:  we  determined  whether  studies  provided  a
description of withdrawals and dropouts.

Other bias: we also assessed therapy integrity, including therapist
competence and adherence to treatment protocol, for all included
studies.

We  did  not  exclude  studies  from  meta-analysis  on  the  basis  of
the  ‘Risk  of  bias’  assessment.  We  conducted  sensitivity  analyses
for  the  primary  outcome,  excluding  trials  with  high  or  unclear
risk  of  bias  ratings  for  allocation  concealment,  and  excluding

We included cluster-randomised controlled trials based in schools.
Cluster-randomised  trials  can,  in  principle,  be  combined  with
individually  randomised  trials  in  the  same  meta-analysis  (Deeks
2017).  We  did  not  anticipate  that  there  would  be  many  cluster-
randomised  trials,  therefore  we 
identified  cluster-
randomised  trials  in  the  meta-analyses  and  sensitivity  analyses
that we planned to undertake to investigate the robustness of any
conclusions drawn. To correct the influence of any cluster trials, we
used  an  average  intraclass  correlation  coefficient  of  0.02  (Health
Services Research Unit 2004).

included 

The effective sample size of a single intervention group in a cluster-
randomised trial is its original sample size divided by the ‘design
effect’. The design effect is 1 + (M − 1) ICC, where M is the average
cluster size and ICC is the intracluster correlation coefficient (Rao
1992).  For  dichotomous  data,  we  divided  both  the  number  of
participants and the number experiencing the event by the same
design  effect.  For  continuous  data,  only  the  sample  size  was
reduced; we did not alter means and standard deviations (SDs).

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

17

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cross-over trials

We did not anticipate that there would be many cross-over trials,
and  the  data  required  to  include  a  paired  analysis  in  a  meta-
analysis is often not reported (Higgins 2011). We therefore planned
to include any identified cross-over trials in the meta-analysis, but
only data from the first trial period (i.e. prior to the ‘cross-over').

Studies with multiple treatment groups

Where  multiple  trial  arms  were  reported  in  a  single  trial,  we
included  only  the  relevant  arms.  Studies  with  more  than  two
intervention arms can pose analytical problems in pair-wise meta-
analysis. Where studies had two or more relevant active treatment
arms to be compared against controls, we managed data as follows.

Continuous data

We divided the control group equally into two or more groups to
compare the means and SDs of these groups against the means and
SDs of the two treatment arms.

Dichotomous data

For  trials  with  two  or  more  active  treatment  arms  and  a  control
group,  we  split  participants  in  the  control  arm  group  equally
between the active treatment arms.

Dealing with missing data

We  contacted  investigators  or  study  sponsors  in  order  to  verify
key study characteristics and to obtain missing numerical outcome
data  where  possible  (e.g.  when  we 
identified  a  study  as
abstract only, when a study included a post-treatment diagnostic
assessment  but  did  not  report  the  required  remission  outcomes,
or  when  a  study  did  not  report  standard  errors  or  SDs).  We
documented all correspondence with study authors and reported
which study authors responded to our queries.

Missing statistics

In  the  first  instance,  we  attempted  to  contact  the  original
researchers  for  any  missing  data.  If  the  study  only  reported
standard errors, we calculated SDs.

Missing participants

We  undertook  intention-to-treat  (ITT)  analyses.  When  analysing
dichotomous  data,  we  assumed  that  all  non-completers  in  the
CBT  group  were  treatment  failures,  and  non-completers  in  the
control group were treatment successes, thereby yielding the most
conservative treatment estimate.

For dichotomous outcomes, we also undertook completer analysis,
using only data from participants who completed post-treatment
assessments.

We did not use any statistical or other methods to impute missing
data  for  continuous  outcomes,  as  we  did  not  have  access  to  raw
data.

Assessment of heterogeneity

We  assessed  clinical  heterogeneity  by  comparing  differences  in
the  distribution  of  important  participant  factors  between  studies
(e.g.  age,  gender,  specific  diagnosis,  duration  and  severity  of
disorder, associated comorbidities). We assessed methodological
(randomisation,
heterogeneity  by  comparing 

factors 

trial 

Cochrane Database of Systematic Reviews

concealment,  blinding  of  outcome  assessment,  losses  to  follow-
up). We used the Chi2 test, Deeks 2017, and the I2 statistic, Higgins
2003,  to  assess  heterogeneity.  We  set  significance  at  P  <  0.1.
The  Cochrane  Handbook  for  Systematic  Reviews  of  Interventions
recommends  using  a  range  for  the  I2  statistic  and  a  guide
to  interpretation  (Deeks  2017).  If  we  found  either  moderate
heterogeneity  (I2  in  the  range  of  30%  to  60%)  or  substantial
heterogeneity  (I2  in  the  range  of  60%  to  90%),  we  performed
subgroup and sensitivity analyses where possible.

Assessment of reporting biases

Where  a  minimum  of  10  studies  were  included,  we  investigated
publication  bias  using  funnel  plots,  Sterne  2017,  and  subjected
any asymmetry found to statistical investigation using Egger’s test
(Stata 2012).

Data synthesis

We  undertook  meta-analyses  only  where  this  was  meaningful,
that is if the treatments, participants, and the underlying clinical
question  were  similar  enough  for  pooling  to  make  sense.  We
undertook ITT and completer analyses.

We planned to carry out separate analyses to identify whether CBT
was more effective post-treatment than waiting list/no treatment;
treatment  as  usual,  attention  controls,  alternative  treatments,
medication;  and  drug  placebo;  and  also  to  identify  whether  CBT
in  combination  with  medication  was  more  effective  than  drug
placebo.

We used follow-up data for each comparison to assess maintenance
of  treatment  gains.  If  it  was  meaningful  to  do  so,  we  pooled
data  separately  for  each  follow-up  time  point  (≤  6  months  post-
treatment,  >  6  months  post-treatment  but  ≤  12  months  post-
treatment,  and  >  12  months  post-treatment).  Where  studies
reported follow-up data at multiple time points within one category
(e.g. 9-month and 12-month follow-up), we included data from the
longer follow-up period.

Dichotomous data

We used ORs and 95% CIs based on the random-effects model, with
pooling of data via the inverse variance method of weighting. We
set  significance  at  P  <  0.05.  Where  available,  we  used  combined
data from an interview with the child or adolescent and the parent;
otherwise  we  used  data  from  one  interview  (child/adolescent  or
parent  interview).  We  calculated  the  number  needed  to  treat  for
an additional beneficial outcome (NNTB) with 95% CIs (Stata 2012).
We  calculated  a  summary  statistic  of  all  those  responding  to
treatment as a percentage of the total number of participants for
each comparison.

Continuous data

We conducted analysis of continuous data based on the random-
effects model, with pooling of data via the inverse variance method
of weighting. We used the SMD to pool continuous data measured
in  different  ways  across  studies  but  conceptually  the  same  (i.e.
measuring anxiety or depressive symptoms or global functioning).
For  continuous  data  measuring  anxiety  symptoms,  we  pooled
child/adolescent report and parental/clinician reports separately.
Where both endpoint and change data were available for the same
outcome,  we  presented  the  endpoint.  We  set  significance  at  P  <
0.05.

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

18

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Tables and figures

We  transferred  data  into  Review  Manager  5  (Review  Manager
2014),  and  presented  them  graphically,  so  that  the  area  to  the
left  of  the  line  of  no  effect  (or  right  for  remission  outcomes)
indicated a favourable outcome for CBT. We used tables to display
characteristics  of  the  included  studies.  We  presented  a  brief  list
of excluded studies in a table with their reasons for exclusion. We
summarised  risk  of  bias  in  the  included  studies  in  a  figure,  and
included a PRISMA flow chart (Moher 2015).

Subgroup analysis and investigation of heterogeneity

The  critical  need  to  improve  access  to  treatment  for  child
anxiety  disorders  means  that  it  is  particularly  important  to
explore  the  efficacy  of  approaches  that  may  help  maximise
treatment  efficiency,  including  alternative  delivery  formats  and
briefer  interventions  that  involve  less  therapist  contact  time
than  traditional  approaches.  As  outlined  above,  there  are  also
unanswered  questions  in  relation  to  the  benefits  of  CBT  for
children and adolescents with ASD and intellectual impairments.
We  therefore  set  out  to  explore  the  efficacy  of  different  delivery
formats and of briefer and shorter interventions, and to examine
treatment  effects  amongst  children  and  adolescents  with  ASD
and those with intellectual impairment, using subgroup analyses.
Specifically,  where  it  was  possible  and  meaningful  to  do  so,  we
undertook subgroup analyses to examine differences between:

• delivery  formats  (child-focused,  child  and  parent,  and  parent-

only; individual and group);

• interventions with a varying amount of therapist contact time (<

10 hours, ≥ 10 hours and < 20 hours, ≥ 20 hours);
• children and adolescents with and without ASDs;
• children  and  adolescents  with  and  without 

intellectual

impairments.

To  examine  differences  between  age  groups,  we  also  undertook
post  hoc  subgroup  analyses  evaluating  the  differences  between
studies where all participants were age 12 or younger (≤ 12 years);
all participants were age 12 or older (≥ 12 years); and studies that
included participants under and over age 12 (< 12 years and ≥ 12
years).

We  undertook  subgroup  analyses  for  the  primary  outcome
(remission of primary anxiety disorder) across comparisons. For the
main comparison with the largest number of studies (CBT versus
waitlist/no  treatment),  we  also  undertook  subgroup  analyses  for
the  most  frequently  reported  secondary  outcomes  (remission
of  all  anxiety  diagnoses  post-treatment  and  reduction  in  child-
and parent-reported anxiety symptoms post-treatment). To ensure
subgroup  analyses  were  meaningful,  we  only  undertook  these
analyses where there were data from at least three studies for each
subgroup.

We assessed statistical heterogeneity for all analyses and between
groups with the Chi2 test and the I2 statistic, and set significance at
P < 0.1.

Sensitivity analysis

Sensitivity  analysis  is  the  study  of  how  the  uncertainty  in  the
output  of  an  analysis  can  be  apportioned  to  different  sources
of  uncertainty  in  its  inputs.  Sensitivity  analyses  can  therefore
be  carried  out  to  test  the  robustness  of  decisions  made  in  the

Cochrane Database of Systematic Reviews

review process. We carried out sensitivity analyses where there was
evidence of the following:

• significant  heterogeneity:  we 

inspected  forest  plots  and
examined  each  study  in  turn  to  determine  the  source  of  any
significant heterogeneity;

• selection bias: we excluded those studies judged to be at high

risk of selection bias from the main analysis;

• allocation concealment: we excluded those studies judged to be
at  high  risk  of  bias  for  allocation  concealment  from  the  main
analysis.

Where  appropriate,  we  undertook  all  of  the  above  sensitivity
analyses for the ITT and completer analyses.

Where meta-analyses examining anxiety symptoms included broad
measures  of  anxiety  symptoms  and  disorder-specific  symptom
measures, we also undertook sensitivity analyses excluding studies
that only reported disorder-specific symptom measures.

GRADE and ‘Summary of findings' table

We created a ‘Summary of findings' table including the following
primary outcomes:

• remission of primary anxiety diagnosis post-treatment;
• acceptability  in  terms  of  dropouts  from  randomisation  to  the

post-treatment assessment;

and the following secondary outcomes:

• remission of all anxiety diagnoses post-treatment;
• reduction  in  anxiety  symptoms  (self-reported  and  parent-

reported) post-treatment;

• reduction in depressive symptoms post-treatment;
• improvement in global functioning post-treatment;
• adverse  events  from  randomisation  to  the  post-treatment

assessment.

We  used  the  five  GRADE  considerations  (study 
limitations,
consistency  of  effect,  imprecision,  indirectness,  and  publication
bias)  to  assess  the  quality  of  a  body  of  evidence  as  it  relates
to  the  studies  that  contribute  data  to  the  meta-analyses  for  the
prespecified primary and secondary outcomes. Two review authors
(AJ,  TR)  independently  assessed  risk  of  bias,  and  in  case  of
disagreement sought consensus between four review authors (AJ,
TR, GJ, CC). We used the methods and recommendations described
in  Section  8.5,  Higgins  2017,  and  Chapter  12,  Schünemann  2017,
of the Cochrane Handbook for Systematic Reviews of Interventions,
employing GRADEpro GDT software (GRADEpro GDT). We justified
all decisions to downgrade or upgrade the quality of studies using
footnotes, and made comments to aid the reader's understanding
of the review where necessary. We considered whether there was
any additional outcome information that could not be incorporated
into the meta-analyses, noting this in the comments and stating if it
supported or contradicted the information from the meta-analyses.

R E S U L T S

Description of studies

See Characteristics of included studies and Table 1.

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

19

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Results of the search

The  initial  database  search  (21  November  2018)  identified  6354
records,  and  an  updated  database  search  (10  October  2019)
identified  a  further  2081  records.  A  search  of  the  grey  literature
identified a further 473 records, and an additional 38 records were

identified from searching reference lists and correspondence with
study authors and experts in the field.

After  removing  duplicates,  we  screened  a  total  of  5488  titles/
abstracts, and excluded 4746 records. We then assessed 742 full-
texts  for  eligibility  for  inclusion  in  the  review,  and  identified  88
eligible studies (130 articles) (Figure 1).

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

20

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 1.   Study flow diagram.

Cochrane Database of Systematic Reviews

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

21

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 1.   (Continued)

Cochrane Database of Systematic Reviews

We contacted 58 study authors for clarification or additional data,
or both, and 16 study authors provided relevant outcome data for
20 of the included studies.

Included studies

Eighty-eight studies met the criteria for inclusion in the review, and
87 studies were included in meta-analyses.

Design

All  included  studies  were  RCTs.  Two  studies  used  a  cluster-
randomised  design,  where  schools,  Dadds  1997,  and  school-
based  clinicians,  Ginsburg  2019a,  were  randomised,  rather  than
individual  participants.  No  included  studies  used  a  cross-over
design.

Amongst  the  studies  included  in  meta-analyses,  20  studies  had
two  CBT  arms  (Afshari  2014;  Barrett  1996;  Barrett  1998;  Cheung
2016; Flannery Schroeder 2000; Hancock 2018; Herbert 2009; Ingul
2013;  Kendall  2008;  Masia  Warner  2016;  Olivares  2014;  Olivares
2019;  Ost  2001;  Salum  2018;  Simon  2011;  Spence  2000;  Thirlwall
2013;  Villabo  2018;  Waters  2009;  Wergeland  2014),  including  one
factorial design (Salum 2018), and another three studies included
multiple  comparison  arms  (Cheung  2016;  Ollendick  2009;  Rosa
Alcazar 2009).

Fifty-seven  studies  were  included  in  CBT  versus  waitlist/no
treatment  comparisons  (Afshari  2014;  Arendt  2016;  Barrett  1996;
Barrett  1998;  Berge  2017;  Cartwright  Hatton  2011;  Chalfant  2007;
Cheung  2016;  Chiu  2013;  Cobham  2017;  Cornacchio  2019;  Dadds
1997;  Flannery  Schroeder  2000;  Gallagher  2004;  Hancock  2018;
Hirshfeld Becker 2010; Holmes 2014; Ishikawa 2019; Kendall 1994;
Kendall  1997;  Kennedy  2009;  Kidd  2018;  Lau  2010;  Lau  2017;
Leutgeb 2012; Masia Warner 2005; Masia Warner 2011; McConachie
2014;  McNally  Keehn  2013;  Melfsen  2011;  Olivares  2005;  Olivares
2014; Olivares 2019; Ollendick 2009; Ost 2001; Perrin 2019; Rapee
2005; Rapee 2006; Rosa Alcazar 2009; Salari 2018; Sanchez Garcia

2009; Santucci 2013; Schneider 2011; Shortt 2001; Silverman 1999b;
Simon 2011; Smith 2014; Spence 2000; Spence 2006; Spence 2011;
Thirlwall 2013; Villabo 2018; Waters 2009; Wergeland 2014; White
2013; Wood 2009; Wood 2015). With the exception of three studies
(Dadds  1997;  Rapee  2005;  Simon  2011),  participants  assigned  to
the  control  arm  were  offered  CBT  after  a  waitlist  period.  Seven
studies included eligible follow-ups that included CBT and waitlist/
no treatment participants. Follow-up assessments were conducted
between 3 and 24 months post-treatment.

Twelve  studies  compared  CBT  to  treatment  as  usual  (TAU)
(Barrington  2005;  Fujii  2013;  Ginsburg  2012;  Ginsburg  2019a;
O'Brien  2007;  Reaven  2012;  Sciberras  2018;  Shahnavaz  2016;
Sharma  2017;  Southam  Gerow  2010;  Storch  2013;  Storch  2015).
TAU varied considerably across studies, ranging from eclectic non-
CBT  therapeutic  approaches  or  strategies  that  were  offered  as
part  of  routine  care  (Barrington  2005;  Ginsburg  2012;  Ginsburg
2019a; Southam Gerow 2010), to allowing participants to continue
and seek any psychosocial or pharmacological interventions (Fujii
2013;  Reaven  2012;  Storch  2013;  Storch  2015).  Four  CBT  versus
TAU studies included 6-month, 12-month, or both 6- and 12-month
follow-ups.

Fifteen  studies  compared  CBT  to  an  attention  control  (Ginsburg
2002; Herbert 2009; Hudson 2009; Ingul 2013; Kendall 2008; Khanna
2010;  Last  1998;  Masia  Warner  2007;  Masia  Warner  2016;  Muris
2002; Ollendick 2009; Pincus 2010; Rosa Alcazar 2009; Salum 2018;
Silverman  1999a),  which  was  designed  to  act  as  an  attention
condition, and often included a psychoeducation component. Six
CBT versus attention control studies included follow-ups up to 12
months.

Seven  studies  included  a  CBT  versus  an  alternative  treatment
comparison (Cheung 2016; Creswell 2017; Lebowitz 2019; Reigada
2015;  Salum  2018;  Silk  2018).  Alternative  treatments  designed
to target children's anxiety difficulties included: solution-focused

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

22

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

therapy (Creswell 2017), the parent intervention SPACE (Supportive
Parenting for Anxious Childhood Emotions) (Lebowitz 2019), child-
centred  therapy  (Silk  2018),  counselling  (Murphy  2017),  non-
directive supportive therapy (Reigada 2015), and ABMT (Attention
Bias Modification Treatment) (Cheung 2016; Salum 2018). Four CBT
versus alternative treatment studies included follow-ups up to 12
months post-treatment.

Only  one  study  compared  CBT  to  medication,  and  CBT  in
combination  with  medication  to  drug  placebo  (Walkup  2008),
therefore  it  was  not  possible  to  conduct  meta-analyses  for  these
comparisons.

Sample size

The 87 studies included in meta-analyses involved a total of 3492
CBT participants and 2472 controls (waitlist/no treatment controls,
N  =  1537;  TAU,  N  =  260;  attention  control,  N  =  441;  alternative
treatment, N = 234).

Study  sample  sizes  ranged  from  12  participants,  Ginsburg  2002;
Sciberras 2018, to 206 participants (corrected sample size; Ginsburg
2019a).

Setting

Two-thirds  of  the  included  studies  were  conducted  in  either  the
USA or Australia. The remaining studies were conducted in the UK,
Spain,  Norway,  the  Netherlands,  Germany,  Sweden,  Iran,  Brazil,
Hong Kong, India, Japan, Denmark, and Ireland.

Most studies were conducted in clinical settings, either university
research clinics (specified in 41 studies), community mental health
clinics  (specified  in  12  studies),  or  dental  clinics  (Berge  2017;
Shahnavaz  2016).  Sixteen  studies  recruited  participants  through
schools  (Chiu  2013;  Dadds  1997;  Ginsburg  2002;  Ginsburg  2012;
Ginsburg  2019a;  Ingul  2013;  Masia  Warner  2005;  Masia  Warner
2007; Masia Warner 2016; Muris 2002; Olivares 2005; Olivares 2014;
Olivares  2019;  Rosa  Alcazar  2009;  Sanchez  Garcia  2009;  Simon
2011),  and  two  through  preschools  (Lau  2017;  Rapee  2005).  No
studies were conducted in inpatient settings.

Participants

The included studies involved participants of varied ages. Sixteen
studies  focused  on  adolescents  and  only  included  participants
aged  12  years  or  over  (Ginsburg  2002;  Herbert  2009;  Ingul  2013;
Kidd 2018; Masia Warner 2005; Masia Warner 2007; Masia Warner
2016;  Murphy  2017;  Olivares  2005;  Olivares  2014;  Olivares  2019;
Pincus  2010;  Rosa  Alcazar  2009;  Spence  2011;  White  2013;  Wood
2015). Twenty-five studies included participants up to age 12 years
(Cartwright  Hatton  2011;  Cheung  2016;  Chiu  2013;  Cornacchio
2019;  Creswell  2017;  Fujii  2013;  Gallagher  2004;  Hirshfeld  Becker
2010; Holmes 2014; Kennedy 2009; Lau 2010; Lau 2017; Lebowitz
2019;  Muris  2002;  Rapee  2005;  Rapee  2006;  Salari  2018;  Salum
2018; Santucci 2013; Schneider 2011; Sciberras 2018; Shortt 2001;
Storch  2013;  Thirlwall  2013;  Waters  2009),  including  5  studies
where participants were all under 8 years of age (Hirshfeld Becker
2010; Kennedy 2009; Lau 2017; Rapee 2005; Schneider 2011). The
youngest  participants  in  the  included  studies  were  two  to  three
years  of  age  (Cartwright  Hatton  2011;  Kennedy  2009;  Lau  2017;
Rapee  2005).  The  remaining  studies  included  participants  both
under and over 12 years.

Cochrane Database of Systematic Reviews

All participants met the diagnostic criteria for at least one anxiety
disorder.  In  most  studies,  any  anxiety  disorder,  or  a  subset  of
anxiety  disorders  (e.g.  generalised  anxiety  disorder  (GAD),  social
anxiety disorder, or separation anxiety disorder) was required for
inclusion.  In  five  studies  (Cartwright  Hatton  2011;  Creswell  2017;
Dadds  1997;  Rapee  2005;  Simon  2011),  not  all  study  participants
met the diagnostic criteria for an anxiety disorder, but only those
who did were included in this review.

Twenty-four studies focused on a specific anxiety disorder where
participants  all  met  the  diagnostic  criteria  for  the  target  anxiety
disorder. Disorder-specific studies included participants with social
anxiety disorder (Gallagher 2004; Herbert 2009; Ingul 2013; Masia
Warner  2005;  Masia  Warner  2007;  Masia  Warner  2016;  Melfsen
2011;  Olivares  2005;  Olivares  2014;  Olivares  2019;  Rosa  Alcazar
2009;  Sanchez  Garcia  2009;  Spence  2000),  specific  phobia  (Berge
2017;  Leutgeb  2012;  Ollendick  2009;  Ost  2001;  Shahnavaz  2016),
separation  anxiety  disorder  (Santucci  2013;  Schneider  2011),
GAD  (Holmes  2014;  Perrin  2019),  panic  disorder  with/without
agoraphobia  (Pincus  2010),  and  selective  mutism  (Cornacchio
2019).

In some studies comorbid conditions were required for inclusion.
Twelve studies included participants with an ASD (Chalfant 2007;
Fujii  2013;  Kidd  2018;  McConachie  2014;  McNally  Keehn  2013;
Murphy  2017;  Reaven  2012;  Storch  2013;  Storch  2015;  White
2013;  Wood  2009;  Wood  2015).  Other  comorbidities  required
for  inclusion  in  individual  studies  included  attention-deficit/
hyperactivity disorder (ADHD) (Sciberras 2018), school refusal (Last
1998),  headaches  (Sharma  2017),  functional  physical  complaints
(Masia  Warner  2011),  and  inflammatory  bowel  disease  (IBD)
(Reigada  2015).  No  studies  included  samples  of  children  with
intellectual impairments.

Intervention

The  most  commonly  used  or  adapted  treatment  manuals  were
Coping  Cat  (Kendall  1994),  and  Cool  Kids  (Hudson  2009;  Rapee
2006).  Studies  targeting  specific  anxiety  disorders  used  disorder-
specific  interventions  (e.g.  OST  (One-Session  Treatment)  for
specific  phobias,  IAFS  (Intervention  in  Adolescents  with  Social
Phobia) for social anxiety disorder), and studies targeting children
with  ASD  (or  another  comorbidity)  used  adapted  interventions
developed  specifically  for  the  target  population  (e.g.  BIACA
(Behavioral Interventions for Anxiety in Children with Autism), TAPS
(Treatment of Anxiety and Physical Symptoms)).

Delivery formats varied across the included studies, including child-
focused interventions (45 studies), interventions delivered to both
children and parents (40 studies), and interventions delivered only
to parents (10 studies). Approximately half of the CBT interventions
involved  a  group  format,  including  child-focused  interventions
(e.g. Gallagher 2004; Ginsburg 2002; Olivares 2005), interventions
delivered to children and parents (e.g. Hudson 2009; McConachie
2014; Waters 2009), and parent-only interventions (e.g. Cartwright
Hatton 2011; Cobham 2017; Rapee 2005).

The amount of therapist contact time also varied considerably in
the included studies, ranging from under 10 hours (interventions
in 16 studies, e.g. Creswell 2017; Ishikawa 2019; Ollendick 2009) to
more than 20 hours (interventions in 23 studies, e.g. Herbert 2009;
Sharma 2017; Storch 2015). The remaining interventions involved
between 10 and 20 hours of therapist contact time.

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

23

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Measures

The  majority  of  included  studies  (70  out  of  87)  included  in
meta-analyses used a post-treatment diagnostic assessment, and
reported (or provided) data on remission from primary and/or all
anxiety  disorders.  In  most  cases,  the  Anxiety  Disorder  Interview
Schedule  for  Children  (ADIS-C)  was  used,  although  there  was
variation  in  how  it  was  administered,  including  either  separate
child  and  parent  interviews  (e.g.  Spence  2011;  Thirlwall  2013;
Wergeland  2014),  joint  child  and  parent  interviews  (Barrington
2005;  Ishikawa  2019;  Khanna  2010),  only  child  interviews  (e.g.
Ginsburg 2002; Olivares 2005; Sanchez Garcia 2009), or only parent
interviews  (e.g.  Lau  2017;  McNally  Keehn  2013;  Waters  2009).
Alternative  post-treatment  diagnostic  assessments  included:  the
Kinder-DIPS  (Melfsen  2011;  Schneider  2011),  Kiddie  Schedule  for
Affective Disorders and Schizophrenia (K-SADS) (Hirshfeld Becker
2010; Last 1998; Lau 2010; Silk 2018), Diagnostic Interview Schedule
for  Children,  Adolescents  and  Parents  (DISCAP)  (Shortt  2001),
Diagnostic Interview Schedule for Children (Southam Gerow 2010),
an adapted version of the Development and Well-Being Assessment
(DAWBA) (Shahnavaz 2016), and the Mini-KID (Sharma 2017).

Anxiety symptoms were assessed using a range of child- and parent-
reported  questionnaire  measures  of  child  anxiety  symptoms,
including  the  Spence  Children's  Anxiety  Scale  (SCAS-C/P)  (or  the
parent-reported  Preschool  Anxiety  Scale  for  younger  children),
Multidimensional Anxiety Scale for Children (MASC-C/P), the Screen
for  Children  Anxiety  Related  Emotional  Disorders  (SCARED-C/
P),  State  Trait  Anxiety  Inventory-Trait  Scale  (STAIC-T),  the  child-
reported  Revised  Children’s  Manifest  Anxiety  Scale  (RCMAS),
the  child-reported  Revised  Child  Anxiety  and  Depression  Scale-
Anxiety  Scale  (RCADS-A),  the  parent-reported  Child  Behavior
Checklist-Anxiety  Scale  (CBCL-A),  and  the  parent-reported  Child
and  Adolescent  Symptom  Inventory-4  ASD  Anxiety  Scale.  Where
broad  measures  of  anxiety  symptoms  were  not  reported,  the
following disorder-specific symptom questionnaire measures were
used  in  the  main  analyses:  Social  Anxiety  Scale  for  Adolescents
(SAS-A)  (Herbert  2009;  Masia  Warner  2005;  Masia  Warner  2007;
Olivares  2014;  Rosa  Alcazar  2009),  Social  Phobia  and  Anxiety
Inventory  for  Children  (SPAI)  (Herbert  2009;  Masia  Warner  2005;
Masia  Warner  2007;  Masia  Warner  2016;  Melfsen  2011;  Olivares
2005; Rosa Alcazar 2009; Sanchez Garcia 2009), IBD-Specific Anxiety
Scale (IBD-SAS) (Reigada 2015), Intra Oral Injection Fear Scale (IOIF-
s) (Berge 2017), and Child Survey Fear Schedule: Dental Subscale
(Shahnavaz 2016).

Depressive  symptoms  were  most  frequently  assessed  using  self-
reported  questionnaires,  and  where  parent-report  was  used,
it  was  always  used  alongside  self-report,  so  only  self-report
depressive  symptom  measures  were  used  in  the  analyses.  The
most  frequently  used  measure  of  depressive  symptoms  was  the
Children's  Depression  Inventory;  other  measures  included  the

Cochrane Database of Systematic Reviews

Short  Mood  and  Feelings  Questionnaire  (Arendt  2016;  Kidd  2018;
Thirlwall 2013; Wergeland 2014), Mood and Feelings Questionnaire
(Perrin  2019),  Revised  Child  Anxiety  and  Depression  Scale-
Depression  scale  (RCADS-D)  (Muris  2002),  and  Beck  Depression
Inventory-II (BDII) (Masia Warner 2007).

included  studies  that  assessed  post-treatment  global
The 
functioning  all  used 
the  clinician-rated  Children’s  Global
Assessment  Scale  (CGAS)  or  adapted,  White  2013,  or  translated
versions of the CGAS (Melfsen 2011).

Excluded studies

We  excluded  593  full-text  articles;  the  reasons  for  exclusion  are
detailed in Characteristics of excluded studies.

We  excluded  studies  if  participants  were  not  fully  randomised  to
conditions (Bodden 2008a; Cobham 2012; Hayward 2000; Kujawa
2019;  Mendlowitz  1999;  Nauta  2003),  or  if  the  study  did  not  use
a  standardised  structured  interview  to  determine  the  presence
of  baseline  anxiety  disorders  (e.g.  Gil  Bernal  2009;  Jansen  2012;
Kerns 2016; Sevi Tok 2016; Sung 2011). We excluded studies where
only  some  participants  were  under  19  years  of  age  (e.g.  Salzer
2018),  or  only  some  participants  met  the  diagnostic  criteria  for
anxiety disorder (e.g. Bernstein 2005; Ginsburg 2019b; Pereira 2014;
Weisz 2012), if the study authors did not provide data on eligible
participants. We also excluded studies if the intervention did not
include both cognitive and behavioural elements (e.g. Beidel 2000;
Beidel  2007;  Bergman  2013;  Cotton  2019;  Ebrahiminejad  2016;
Oerbeck 2014; Ollendick 2018; Ost 2015; Ozyurt 2018; Rudy 2017;
Storch 2019); there were no face-to-face CBT sessions (e.g. Lyneham
2006); or where the control intervention included elements of CBT
(e.g. Clementi 2019).

We excluded five studies because useable data were not provided
for any relevant outcomes (Asbrand; Asbrand 2019; Baer 2005; Flatt
2010; NCT00576719).

Ongoing studies

We identified five ongoing studies that meet our inclusion criteria
(see Characteristics of ongoing studies).

Studies awaiting classification

We  identified  trial  registrations  for  13  studies  where  insufficient
information  was  available  to  determine  eligibility,  and  either  the
trial  was  ongoing/not  started  or  the  trial  data  were  not  available
(see Characteristics of studies awaiting classification).

Risk of bias in included studies

A summary of the risk of bias in the included studies is provided in
Figure 2 and Figure 3.

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

24

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

s
e
m
o
c
t
u
o

l
l

A

:
)
s
a
i
b

e
c
n
a
m
r
o
f
r
e
p
(

l
e
n
n
o
s
r
e
p

d
n
a

s
t
n
a
p
i
c
i
t
r
a
p
f
o

g
n
i
d
n
i
l

B

s
e
m
o
c
t
u
o

l
l

A

:
)
s
a
i
b

n
o
i
t
c
e
t
e
d
(

t
n
e
m
s
s
e
s
s
a

e
m
o
c
t
u
o
f
o

g
n
i
d
n
i
l

B

s
e
m
o
c
t
u
o

l
l

A

:
)
s
a
i
b

n
o
i
t
i
r
t
t
a
(

a
t
a
d

e
m
o
c
t
u
o
e
t
e
l
p
m
o
c
n
I

)
s
a
i
b

n
o
i
t
c
e
l
e
s
(

n
o
i
t
a
r
e
n
e
g

e
c
n
e
u
q
e
s
m
o
d
n
a
R

)
s
a
i
b

n
o
i
t
c
e
l
e
s
(

t
n
e
m
l
a
e
c
n
o
c

n
o
i
t
a
c
o
l
l

A

y
t
i
r
g
e
t
n
i

y
p
a
r
e
h
T
-

s
a
i
b
f
o

e
c
r
u
o
s

r
e
h
t
O

)
s
a
i
b

g
n
i
t
r
o
p
e
r
(

g
n
i
t
r
o
p
e
r

e
v
i
t
c
e
l
e
S

s
a
i
b

r
e
h
t
O

Afshari 2014
Arendt 2016
Barrett 1996
Barrett 1998
Barrington 2005
Berge 2017
Cartwright Hatton 2011
Chalfant 2007
Cheung 2016
Chiu 2013
Cobham 2017
Cornacchio 2019
Creswell 2017
Dadds 1997
Flannery Schroeder 2000
Fujii 2013
Gallagher 2004
Ginsburg 2002
Ginsburg 2012
Ginsburg 2019a
Hancock 2018
Herbert 2009
Hirshfeld Becker 2010

? ? + + - + ? ?
+ + + + + + ? +
? ? + + ? + + +
? ? + + ? + + +
? ? ? + ? + + +
+ + + + + + ? +
+ + + + + + + ?
? ? + ? ? + ? +
? + ? + ? + ? +
? ? + + + + + +
+ + + + + + + +
? ? + + + + + +
+ + + + + + + +
? ? + + + + + +
? ? + ? + + + -
? ? + + + + + -
? ? + + ? + + +
+ ? ? + + + + +
+ + ? + + + ? +
? + ? + + + + +
+ + + + + + + +
+ ? ? + + + + +
+ + + + + + ? +

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

25

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 2.   (Continued)

Cochrane Database of Systematic Reviews

Herbert 2009
Hirshfeld Becker 2010
Holmes 2014
Hudson 2009
Ingul 2013
Ishikawa 2019
Kendall 1994
Kendall 1997
Kendall 2008
Kennedy 2009
Khanna 2010
Kidd 2018
Last 1998
Lau 2010
Lau 2017
Lebowitz 2019
Leutgeb 2012
Masia Warner 2005
Masia Warner 2007
Masia Warner 2011
Masia Warner 2016
McConachie 2014
McNally Keehn 2013
Melfsen 2011
Muris 2002
Murphy 2017
O'Brien 2007
Olivares 2005
Olivares 2014
Olivares 2019
Ollendick 2009
Ost 2001
Perrin 2019
Pincus 2010
Rapee 2005
Rapee 2006
Reaven 2012
Reigada 2015
Rosa Alcazar 2009
Salari 2018
Salum 2018
Sanchez Garcia 2009
Santucci 2013
Schneider 2011
Sciberras 2018
Shahnavaz 2016
Sharma 2017

+ ? ? + + + + +
+ + + + + + ? +
+ + + + + + + +
+ ? + ? + + + +
+ ? ? + ? + ? +
+ + + + + + + -
? ? + ? ? + + -
? ? + ? ? + + -
+ + ? + + + ? +
+ ? + ? + + ? +
+ + ? + + + + +
+ + + + + + + +
- + + +
? ? ? ?
? ? + + + + + +
+ + + + + + ? +
+ + + + + + + +
? ? + + + + ? +
? ? + + + + ? +
? ? ? + + + + +
-
+ ? + + + + ?
+ + ? + + + + ?
+ + + + + + + +
+ ? + + + + + +
+ + + + + + + +
? ? ? + + + ? +
+ + ? + + + + +
? ? + + + ? + +
? ? + + + + ? +
? ? + ? ? + + +
? ? + + ? + ? +
+ + ? + + + + +
? ? + + + + ? +
+ + + + + + + +
? ? + ? ? + + -
? ? + + + + ? +
+ + + + + + ? +
+ + + + + + + +
+ ? ? + + + + +
? ? ? ? + + ? +
? ? + + + + ? +
+ + + + - + + +
? ? + ? ? + ? ?
? ? + + + + ? +
+ + + + + + + +
+ + + + + + ? +
+ + + + + + + +
+ + + ? + + ? +

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

26

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 2.   (Continued)

Cochrane Database of Systematic Reviews

Shahnavaz 2016
Sharma 2017
Shortt 2001
Silk 2018
Silverman 1999a
Silverman 1999b
Simon 2011
Smith 2014
Southam Gerow 2010
Spence 2000
Spence 2006
Spence 2011
Storch 2013
Storch 2015
Thirlwall 2013
Villabo 2018
Walkup 2008
Waters 2009
Wergeland 2014
White 2013
Wood 2009
Wood 2015

+ + + + + + + +
+ + + ? + + ? +
? ? + + + + + +
? ? ? + + + + +
? ? ? ? ? + + +
? ? + + ? + + +
? ? + ? + + + +
? ? + + ? + + +
+ ? ? + + + + +
? ? + + + + ? +
+ ? + ? + + + +
+ + + + + + + +
+ + + + + + + +
+ + + + + + + +
+ + + + + + + +
+ + + + + + + +
+ + + + + + + +
? ? + + + ? + +
? ? + ? + + + +
+ + + + + + + +
+ + + + + + + +
+ + + + + + + +

Figure 3.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.

Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias): All outcomes
Blinding of outcome assessment (detection bias): All outcomes
Incomplete outcome data (attrition bias): All outcomes
Selective reporting (reporting bias)
Other source of bias - Therapy integrity
Other bias

Low risk of bias

Unclear risk of bias

High risk of bias

0%

25%

50%

75% 100%

Allocation

Over  half  of  the  included  studies  (47  out  of  88)  clearly  described
an adequate process of sequence generation, and just under half
(39 out of 88) clearly described an adequate process of allocation
concealment. In remaining studies, insufficient or no information
about the sequence generation process was provided.

We  performed  a  sensitivity  analysis  for  the  primary  outcome
(remission  of  primary  anxiety  disorder  post-treatment)  amongst
CBT versus waitlist controls, using only those studies that clearly

described sequence generation, and found similar findings to the
main  analysis  (odds  ratio  (OR)  4.84,  95%  confidence  interval  (CI)
3.03 to 7.73, Z = 6.61, P < 0.001) (Analysis 1.32).

Blinding

The  vast  majority  of  studies  (72  out  of  88)  either  clearly  detailed
using  blind  assessors  to  administer  post-treatment  diagnostic
interviews,  or  only  used  a  parent/child  report  questionnaire,
therefore we judged the risk of bias from not blinding to be low.

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

27

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

We performed a sensitivity analysis examining remission of primary
anxiety  disorder  diagnosis  amongst  CBT  versus  waitlist  controls,
where  studies  that  did  not  specify  using  blind  assessors  were
removed. The findings were similar to the main analysis (OR 5.54,
95% CI 3.76 to 8.18, Z = 8.63, P < 0.001) (Analysis 1.33).

Blinding of participants and personnel was only possible in some
CBT  versus  TAU,  active  control,  or  alternative  treatment  studies.
These  studies  described  measures  to  ensure  comparability  of
interventions (e.g. amount of contact time); however, few studies
specifically  detailed  attempts  to  conceal  'test'  versus  'control'
intervention from participants.

Incomplete outcome data

Most  studies  described  information  on  dropouts  and  missing
outcome  data.  The  amount  of  missing  data  was  small,  with
a  description  of  appropriate  methods  to  manage  missing  data
provided.  Sixteen  studies  provided  insufficient  information  on
missing data, and in three studies missing data were not balanced
across groups, with more missing data in the CBT group than in the
control group (Afshari 2014; Last 1998; Salum 2018).

Selective reporting

With  the  exception  of  two  studies  where  post-treatment  anxiety
symptoms  outcomes  were  not  reported  for  CBT  and  controls
(O'Brien 2007; Waters 2009), the study reports included expected
outcomes relevant to this review.

Notably, however, six studies included a post-treatment diagnostic
assessment  and  reported  outcomes  from  this  assessment  (e.g.
remission of a subset of anxiety disorders, reduction in the number
of  anxiety  disorders),  but  did  not  report  or  provide  data  on
remission  of  primary  anxiety  disorder  or  remission  of  all  anxiety
disorders  (Ginsburg  2012;  Hancock  2018;  Murphy  2017;  Pincus
2010; Walkup 2008; Wood 2009), so these studies were not included
in our analyses of diagnostic outcomes.

Other potential sources of bias

Therapy integrity, including therapist competence and adherence,
was assessed across all studies. In the majority of studies (61 out
of 88), trained and supervised therapists were used, and adherence
was measured and reported. In the remaining studies insufficient
information was provided on competence or adherence, or both.

Cochrane Database of Systematic Reviews

The  most  frequently  identified  other  potential  source  of  bias
related  to  the  timing  of  the  post-treatment  assessment.  In  seven
studies  (Flannery  Schroeder  2000;  Fujii  2013;  Ishikawa  2019;
Kendall 1994; Kendall 1997; Masia Warner 2011; Pincus 2010), the
timing of the post-treatment assessment varied across groups, with
a shorter waitlist or control period than treatment period.

Effects of interventions

See:  Summary  of  findings  1  CBT  compared  with  waitlist  for
children  and  adolescents  with  anxiety  disorders;  Summary  of
findings  2  CBT  compared  with  treatment  as  usual  for  anxiety
disorders  in  children  and  adolescents;  Summary  of  findings  3
CBT  compared  with  attention  control  for  anxiety  disorders  in
children and adolescents; Summary of findings 4 CBT compared
with  alternative  treatment  for  anxiety  disorders  in  children  and
adolescents

Comparison 1: CBT versus waitlist/no treatment

See Summary of findings 1.

Primary outcomes

1.1 Remission of primary anxiety diagnosis post-treatment

We  included  39  studies  in  the  analyses  examining  remission  of
primary  anxiety  disorder  diagnosis  post-treatment  (Arendt  2016;
Cartwright  Hatton  2011;  Cobham  2017;  Cornacchio  2019;  Dadds
1997;  Flannery  Schroeder  2000;  Gallagher  2004;  Hirshfeld  Becker
2010;  Holmes  2014;  Ishikawa  2019;  Kendall  1994;  Kendall  1997;
Kidd  2018;  Lau  2010;  Masia  Warner  2005;  Masia  Warner  2011;
McConachie  2014;  McNally  Keehn  2013;  Melfsen  2011;  Olivares
2005;  Olivares  2014;  Olivares  2019;  Ollendick  2009;  Ost  2001;
Perrin 2019; Rapee 2006; Rosa Alcazar 2009; Sanchez Garcia 2009;
Santucci  2013;  Schneider  2011;  Silverman  1999b;  Spence  2000;
Spence  2006;  Spence  2011;  Thirlwall  2013;  Villabo  2018;  Waters
2009; Wergeland 2014; Wood 2015).

Moderate-quality evidence from ITT analysis revealed a response
rate for remission of primary anxiety diagnosis of 49.4% (802 out of
1623) for CBT versus 17.8% (191 out of 1074) for controls (OR 5.45,
95% CI 3.90 to 7.60, Z = 9.96, P < 0.001) (Analysis 1.1). Over half of
the studies (59%; 23 out of 39) and comparisons (52%; 25 out of 48)
showed a clear benefit for CBT (95% CI does not cross 1) (Figure 4),
with evidence of moderate heterogeneity (Chi2 = 97.73, df = 47, P <
0.001; I2 = 52%).

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

28

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 4.   Forest plot of comparison: 1 CBT vs waitlist/no treatment, outcome: 1.1 Remission of primary anxiety
diagnosis post-treatment (ITT).

Study or Subgroup

Events

Total

CBT

Wait list / no treatment
Events

Total

Weight

Odds Ratio
IV, Random, 95% CI

Odds Ratio
IV, Random, 95% CI

1.1.1 Child focused
Dadds 1997
Flannery Schroeder 2000
Flannery Schroeder 2000
Gallagher 2004
Kendall 1994
Kendall 1997
Lau 2010
Masia Warner 2005
Masia Warner 2011
McNally Keehn 2013
Olivares 2005
Olivares 2014
Olivares 2014
Olivares 2019
Olivares 2019
Ollendick 2009
Ost 2001
Perrin 2019
Rosa Alcazar 2009
Sanchez Garcia 2009
Spence 2000
Villabo 2018
Villabo 2018
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.85; Chi² = 43.41, df = 22 (P = 0.004); I² = 49%
Test for overall effect: Z = 7.94 (P < 0.00001)

23
18
13
12
40
69
21
21
20
12
17
39
39
36
36
85
21
20
20
28
19
55
55
719

21
9
6
5
17
32
14
12
9
7
10
11
20
8
13
47
18
16
12
21
11
29
36

28
2
1
0
1
17
0
5
1
0
0
2
2
0
0
1
0
0
0
0
1
4
4

384

69

1.1.2 Child and parent
Arendt 2016
Cornacchio 2019
Hirshfeld Becker 2010
Holmes 2014
Ishikawa 2019
Kidd 2018
McConachie 2014
Melfsen 2011
Ost 2001
Rapee 2006
Santucci 2013
Schneider 2011
Silverman 1999b
Spence 2000
Spence 2006
Spence 2011
Waters 2009
Wergeland 2014
Wergeland 2014
Wood 2015
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.28; Chi² = 29.75, df = 19 (P = 0.06); I² = 36%
Test for overall effect: Z = 6.79 (P < 0.00001)

56
14
34
20
23
26
17
21
20
90
15
21
37
17
22
44
31
67
77
19
671

37
1
22
9
10
18
0
7
12
44
7
16
16
14
13
13
17
24
27
6

6
1
13
3
4
10
1
2
0
17
1
4
5
1
3
4
1
3
3
6

313

88

33
7
7
11
20
49
17
21
20
10
17
19
20
18
18
41
10
20
20
25
7
27
28
465

53
15
30
22
24
23
15
23
9
87
14
22
19
8
23
27
5
19
19
14
471

2.1%
1.9%
1.4%
1.0%
1.6%
3.8%
1.0%
2.7%
1.6%
1.0%
1.0%
2.2%
2.3%
1.0%
1.0%
1.7%
1.0%
1.0%
1.0%
1.0%
1.5%
3.0%
2.9%
38.7%

3.3%
1.1%
3.3%
2.4%
2.7%
3.0%
0.9%
2.1%
1.0%
4.0%
1.5%
2.5%
2.9%
1.3%
2.5%
2.9%
1.5%
2.7%
2.7%
2.5%
46.6%

1.88 [0.33 , 10.63]
2.50 [0.38 , 16.42]
5.14 [0.48 , 55.64]
16.87 [0.81 , 351.79]
14.04 [1.71 , 115.41]
1.63 [0.77 , 3.46]
67.67 [3.56 , 1287.81]
4.27 [1.13 , 16.05]
15.55 [1.73 , 139.65]
28.64 [1.37 , 600.41]
49.00 [2.53 , 948.62]
3.34 [0.66 , 16.92]
9.47 [1.93 , 46.46]
11.04 [0.60 , 202.89]
21.26 [1.18 , 381.56]
49.47 [6.50 , 376.64]
111.00 [5.21 , 2363.64]
150.33 [7.54 , 2997.83]
60.29 [3.20 , 1137.79]
146.20 [7.89 , 2709.82]
8.25 [0.82 , 82.67]
6.41 [1.96 , 21.01]
11.37 [3.44 , 37.58]
10.42 [5.84 , 18.58]

15.25 [5.53 , 42.05]
1.08 [0.06 , 19.05]
2.40 [0.87 , 6.57]
5.18 [1.15 , 23.29]
3.85 [0.99 , 14.89]
2.92 [0.91 , 9.44]
0.28 [0.01 , 7.31]
5.25 [0.95 , 29.05]
27.94 [1.43 , 546.98]
3.94 [2.01 , 7.71]
11.38 [1.17 , 110.42]
14.40 [3.29 , 63.08]
2.13 [0.64 , 7.16]
32.67 [2.85 , 374.13]
9.63 [2.19 , 42.37]
2.41 [0.70 , 8.36]
4.86 [0.49 , 48.57]
2.98 [0.79 , 11.26]
2.88 [0.77 , 10.77]
0.62 [0.15 , 2.58]
4.08 [2.72 , 6.11]

1.1.3 Parent only
Cartwright Hatton 2011
Cobham 2017

21
20

37
33

5
6

33
30

3.0%
3.1%

7.35 [2.32 , 23.27]
6.15 [1.98 , 19.14]

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

29

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 4.   (Continued)

21
20
18
25
21

Cartwright Hatton 2011
Cobham 2017
Thirlwall 2013
Thirlwall 2013
Waters 2009
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.74; Chi² = 13.17, df = 4 (P = 0.01); I² = 70%
Test for overall effect: Z = 2.20 (P = 0.03)

37
33
61
64
38
233

5
6
11
11
1

105

34

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.61; Chi² = 97.73, df = 47 (P < 0.0001); I² = 52%
Test for overall effect: Z = 9.96 (P < 0.00001)
Test for subgroup differences: Chi² = 8.57, df = 2 (P = 0.01), I² = 76.7%

1623

802

191

Cochrane Database of Systematic Reviews

33
30
34
35
6
138

3.0%
3.1%
3.5%
3.6%
1.5%
14.7%

7.35 [2.32 , 23.27]
6.15 [1.98 , 19.14]
0.88 [0.35 , 2.16]
1.40 [0.58 , 3.35]
6.18 [0.66 , 58.03]
2.83 [1.12 , 7.16]

1074

100.0%

5.45 [3.90 , 7.60]

0.1
0.001
Favours Wait list / no treatment

1

10

1000

Favours CBT

Subgroup analyses

1.2 Acceptability: loss of participants to post-treatment assessment

We  found  a  difference  in  outcomes  for  the  different  delivery
formats  (child-focused,  child  and  parent,  parent  only)  (Chi2  =
8.57,  df  =  2,  P  =  0.01),  with  substantial  subgroup  heterogeneity
(I2  =  76.7%)  (Analysis  1.1).  Inspection  of  the  forest  plot  and  the
summary  statistics  suggest  that  studies  evaluating  child-focused
CBT produced greater remission of primary anxiety diagnosis in the
CBT arms (OR 10.42, 95% CI 5.84 to 18.58) compared to waitlist/no
treatment controls than studies evaluating CBT delivered to both
children and parents (OR 4.08, 95% CI 2.72 to 6.11) or parents only
(OR  2.83,  95%  CI  1.12  to  7.16).  Notably,  however,  there  was  also
evidence  of  moderate  heterogeneity  amongst  studies  evaluating
child-focused CBT (Chi2 = 43.41, df = 22, P = 0.004; I2 = 49%).

We found no differences in remission of primary anxiety diagnosis
outcomes for individual- versus group-delivered CBT (Chi2 = 0.90,
df = 1, P = 0.34; I2 = 0%); interventions with different amounts of
therapist contact time (< 10 hours, ≥ 10 and < 20 hours, ≥ 20 hours)
(Chi2 = 0.52, df = 2, P = 0.77; I2 = 0%); or studies with participants
in different age groups (≤ 12 years, ≥ 12 years, < 12 years and ≥12
years) (Chi2 = 1.59, df = 2, P = 0.45; I2 = 0%) (Analysis 1.2; Analysis
1.3; Analysis 1.4).

Subgroup analyses revealed no significant difference in outcomes
between studies including participants with and without ASD (Chi2
= 2.25, df = 1, P = 0.13; I2 = 55.5%) (Analysis 1.5); however, only four
studies  included  children/adolescents  with  ASD,  compared  to  35
studies with participants without ASD. The four studies of children/
adolescents  with  ASD  revealed  no  significant  difference  between
CBT  and  waitlist/no  treatment  controls  in  rates  of  remission  of
primary anxiety disorder diagnosis (OR 1.79, 95% CI 0.39 to 8.16, Z
= 0.76, P = 0.45, n = 136, I2 = 59%).

Low-quality  evidence  showed  no  difference  between  CBT  and
waitlist/no  treatment  controls  in  the  rate  of  those  lost  to  post-
treatment assessment (Analysis 1.7), indicating a similar degree of
acceptability.  The  rate  of  loss  to  post-treatment  assessment  was
13.5% (260 out of 1919) in the CBT group versus 10.4% (129 out of
1239) in the control group (OR 1.09, 95% CI 0.85 to 1.41, Z = 0.69, P
= 0.49, n = 3158, k = 45, I2 = 4%).

Secondary outcomes

1.3 Remission for all anxiety disorders post-treatment

We included 28 studies in the analyses examining post-treatment
remission  of  all  anxiety  disorder  diagnoses  (Arendt  2016;  Barrett
1996;  Barrett  1998;  Cartwright  Hatton  2011;  Chalfant  2007;  Chiu
2013; Cobham 2017; Dadds 1997; Hirshfeld Becker 2010; Ishikawa
2019;  Kennedy  2009;  Lau  2017;  McConachie  2014;  Melfsen  2011;
Olivares 2005; Perrin 2019; Rapee 2005; Rapee 2006; Rosa Alcazar
2009; Sanchez Garcia 2009; Shortt 2001; Simon 2011; Spence 2000;
Spence  2006;  Spence  2011;  Thirlwall  2013;  Villabo  2018;  Waters
2009).

The ITT analysis included 1213 CBT participants and 862 controls,
with a response rate for remission of all anxiety disorder diagnoses
of  46.8%  for  CBT  versus  19.1%  for  waitlist/no  treatment  controls
(OR 4.43, 95% CI 2.89 to 6.78, Z = 6.85, P < 0.001) (Analysis 1.8). Sixty
per cent of included studies (17 out of 28) and 51% of comparisons
(18 out of 35) reported findings showing a clear benefit for CBT (95%
CI does not cross 1). There was evidence of moderate heterogeneity
(Chi2  =  84.49,  df  =  34,  P  <  0.001;  I2  =  60%),  and  thus  moderate-
quality evidence overall for the benefit of CBT compared to waitlist/
no treatment controls for remission of all anxiety disorders.

Completer analysis

Subgroup analyses

The  completer  analysis  included  1422  CBT  participants  and  984
controls,  with  a  response  rate  for  remission  of  primary  anxiety
diagnosis of 56.4% for CBT versus 11.7% for controls (OR 11.55, 95%
CI  8.41  to  15.86,  Z  =  15.11,  P  <  0.001)  (Analysis  1.6).  Most  of  the
studies  (89%,  34  out  of  38)  and  comparisons  (81%;  38  out  of  47)
showed a clear benefit for CBT (95% CI does not cross 1). There was
no heterogeneity across studies (Chi2 = 61.53, df = 46, P = 0.06; I2 =
25%).

We  found  a  difference  in  outcomes  for  different  delivery  formats
(child-focused,  child  and  parent,  parent-only)  (Chi2  =  8.14,  df
=  2,  P  =  0.02),  with  substantial  subgroup  heterogeneity  (I2  =
75.4%). There was evidence of substantial heterogeneity amongst
studies  evaluating  child-focused  CBT  (I2  =  70%),  but  we  found
that  overall  these  studies  produced  greater  remission  of  all
anxiety disorder diagnoses following CBT compared to waitlist/no
treatment  controls  (OR  8.52,  95%  CI  2.97  to  24.39),  than  studies
evaluating child-and-parent delivered CBT (OR 5.19, 95% CI 3.26 to

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

30

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

8.27), or studies evaluating parent-delivered CBT (OR 1.89, 95% CI
crosses 1).

We  found  no  differences  in  remission  of  all  anxiety  disorder
diagnoses  outcomes  for  individual-  versus  group-delivered  CBT
(Chi2  =  0.35,  df  =  1,  P  =  0.56;  I2  =  0%)  (Analysis  1.9);  however,
there was variation in these outcomes amongst interventions with
differing  amounts  of  therapist  contact  time  (Chi2  =  10.75,  df  =  2,
P  =  0.005;  I2  =  81.4%)  (Analysis  1.10).  Only  five  studies  evaluated
interventions involving < 10 hours therapist contact time (Cobham
2017;  Ishikawa  2019;  Rapee  2005;  Simon  2011;  Thirlwall  2013),
and  did  not  indicate  a  benefit  for  CBT  compared  to  waitlist/no
treatment control groups for remission of all anxiety disorders (OR
1.42, 95% CI 0.68 to 2.96, Z = 0.93, P = 0.35), whilst interventions
with 10 to 20 hours or ≥ 20 hours contact time both showed a clear
benefit for CBT (OR 6.59, 95% CI 3.62 to 12.01 and OR 5.03, 95% CI
2.55 to 9.93, respectively).

Subgroup  analyses  did  not  show  differences  in  remission  of
all  anxiety  disorder  diagnoses  outcomes  amongst  studies  with
participants in different age groups (Chi2 = 0.80, df = 2, P = 0.67; I2
= 0%) (Analysis 1.11), and as only two studies included participants
with ASD, meaningful subgroup analyses comparing studies with
and without participants with ASD was not possible.

Completer analysis

The  completer  analysis  included  1074  CBT  participants  and  797
controls, with a response rate for remission of any anxiety disorder

Cochrane Database of Systematic Reviews

diagnosis of 52.9% for CBT versus 14.2% for controls (OR 9.13, 95%
CI 5.78 to 14.41, Z = 9.49, P < 0.001) (Analysis 1.12). More than three-
quarters of included studies (21 out of 27) and 65% of comparisons
(22 out of 34) reported findings showing a clear benefit for CBT (95%
CI does not cross 1). There was evidence of moderate heterogeneity
(Chi2 = 68.75, df = 33, P < 0.001; I2 = 52%).

1.4 Reduction in anxiety symptoms (child report) post-treatment

We included 45 studies in the analyses examining post-treatment
child-reported  anxiety  symptoms  (Afshari  2014;  Arendt  2016;
Barrett 1996; Berge 2017; Chalfant 2007; Cheung 2016; Chiu 2013;
Cobham  2017;  Dadds  1997;  Flannery  Schroeder  2000;  Gallagher
2004;  Hancock  2018;  Holmes  2014;  Ishikawa  2019;  Kendall  1994;
Kendall  1997;  Kidd  2018;  Lau  2010;  Leutgeb  2012;  Masia  Warner
2005;  McConachie  2014;  McNally  Keehn  2013;  Melfsen  2011;
Olivares 2005; Olivares 2014; Ollendick 2009; Ost 2001; Perrin 2019;
Rapee 2006; Rosa Alcazar 2009; Salari 2018; Sanchez Garcia 2009;
Santucci  2013;  Schneider  2011;  Shortt  2001;  Silverman  1999b;
Simon 2011; Smith 2014; Spence 2000; Spence 2006; Spence 2011;
Thirlwall  2013;  Villabo  2018;  Wergeland  2014;  Wood  2009).  The
standardised  mean  difference  (SMD)  between  CBT  groups  and
waitlist/no  treatment  controls  was  −0.67  (95%  CI  −0.88  to  −0.47,
Z = 6.36, P < 0.001, n = 2831) (Analysis 1.13; Figure 5). Substantial
heterogeneity (Chi2 = 352.54, df = 56, P < 0.001; I2 = 84%) reduced our
confidence in this result, and we rated this evidence as low-quality.

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

31

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 5.   Forest plot of comparison: 1 CBT vs waitlist/no treatment, outcome: 1.13 Reduction in anxiety symptoms
(child report) post-treatment.

Study or Subgroup

Mean

CBT
SD

Total

Mean

Wait list / no treatment
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.13.1 Child focused
Afshari 2014
Afshari 2014
Barrett 1996
Berge 2017
Cheung 2016
Chiu 2013
Dadds 1997
Flannery Schroeder 2000
Flannery Schroeder 2000
Gallagher 2004
Kendall 1994
Kendall 1997
Lau 2010
Leutgeb 2012
Masia Warner 2005
McNally Keehn 2013
Olivares 2005
Olivares 2014
Olivares 2014
Ollendick 2009
Ollendick 2009
Ost 2001
Perrin 2019
Rosa Alcazar 2009
Sanchez Garcia 2009
Simon 2011
Spence 2000
Villabo 2018
Villabo 2018
Subtotal (95% CI)
Heterogeneity: Tau² = 0.89; Chi² = 231.01, df = 28 (P < 0.00001); I² = 88%
Test for overall effect: Z = 5.48 (P < 0.00001)

4.6
7.8
6.8
5.1
19.39
17.91
7.36
11.24
5.71
5.8
10.9
11.89
9.26
6.7
6.3
20.79
28.7
7.53
8.13
11.34
9.57
6
12.5
23.38
7.77
23.86
4.68
12.236727503707838
10.975973760901576

31.5
36.7
9
18.6
54.82
47.83
11.44
38.4
43.8
9.75
41.43
43.05
24.86
32.1
16.3
26.75
64.29
41.63
44.54
44.43
48.78
7
15.2
67.99
15.45
26.59
10.31
48.8
48.61

1.13.2 Child and parent
Arendt 2016
Barrett 1996
Chalfant 2007
Hancock 2018
Hancock 2018
Holmes 2014
Ishikawa 2019
Kidd 2018
McConachie 2014
Melfsen 2011
Ost 2001
Rapee 2006
Santucci 2013
Schneider 2011
Shortt 2001
Silverman 1999b
Spence 2000
Spence 2006
Spence 2011
Wergeland 2014
Wergeland 2014
Wood 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.18; Chi² = 67.99, df = 21 (P < 0.00001); I² = 69%
Test for overall effect: Z = 3.99 (P < 0.0001)

14.42
4.6
10.96
13.33
11.56
20.25
17.75
19
18.1
9.13
4.5
16.7
16.67
0.2
0.97
6.19
5.78
11.72
16.649456447584107
13.37
16.27
14.76

21.57
6.6
13.79
54.56
49.46
34.88
28.28
27.2
31.47
12.3
5.65
25.6
29.67
0.23
8.62
8.87
10.06
22.25
31.54
27.49
26.12
49.93

1.13.3 Parent only
Cobham 2017
Salari 2018
Simon 2011
Smith 2014
Thirlwall 2013
Thirlwall 2013
Subtotal (95% CI)
Heterogeneity: Tau² = 0.18; Chi² = 15.59, df = 5 (P = 0.008); I² = 68%
Test for overall effect: Z = 0.19 (P = 0.85)

13.9
4.4
17.68
20.48
20
12.6

34.4
16.3
29.08
52.21
28.47
30

51.8
51.8
11.6
38.7
51.65
52.5
12.65
53.83
53.83
14.73
51.94
49.67
41.12
35
21.5
36.11
126
68.29
68.29
41.86
46.3
6.74
46.3
125.93
30.8
31.59
13.36
51.95
51.95

32.55
11.6
41.37
61.23
61.23
40.84
35.95
29.85
32.33
18.41
6.74
25.5
34.41
0.29
9.82
12.79
13.36
25.83
26.52
29.61
29.61
46.5

42.1
11.23
31.59
51.11
29.4
29.4

10
10
28
29
18
22
23
12
13
12
27
60
21
16
18
12
17
38
37
44
41
21
20
20
28
17
19
55
55
743

56
25
28
68
63
17
25
25
17
21
20
90
14
13
53
25
17
20
44
56
57
14
768

31
20
25
14
47
40
177

13.8
13.8
6
9.3
27.99
15.29
7.71
16.52
16.52
7.66
13.5
10.16
11.77
8.2
10.6
16.46
18.3
5.36
5.36
12.89
8.9
4.4
15.9
17.05
5.75
16.67
8.69
11.865917579353056
11.865917579353056

15.64
6
9.09
11.67
11.67
19.93
19.44894855769845
3.24
27.05
8.53
4.4
15.9
13.15
0.22
2
7.53
8.69
14.02
16.523764704207082
16.23
16.23
15.83

11.5
4.9
16.67
23.63
16.28
16.28

5
5
12
27
18
18
33
6
6
11
20
34
17
14
17
10
17
18
17
21
20
10
20
20
25
13
7
27
28
496

53
11
19
31
31
19
24
19
15
23
9
87
14
21
12
16
7
23
27
17
17
22
517

29
22
14
8
28
29
130

1.1%
1.2%
1.8%
1.7%
1.8%
1.8%
1.9%
1.4%
1.4%
1.6%
1.8%
2.0%
1.7%
1.7%
1.8%
1.6%
1.5%
1.5%
1.6%
1.9%
1.9%
1.7%
1.7%
1.6%
1.8%
1.7%
1.6%
2.0%
2.0%
48.8%

2.0%
1.7%
1.6%
2.0%
2.0%
1.8%
1.9%
1.8%
1.8%
1.8%
1.7%
2.1%
1.7%
1.8%
1.8%
1.8%
1.6%
1.8%
2.0%
1.9%
1.9%
1.8%
40.2%

1.9%
1.8%
1.8%
1.6%
2.0%
2.0%
11.0%

-2.23 [-3.65 , -0.81]
-1.42 [-2.64 , -0.19]
-0.39 [-1.07 , 0.29]
-2.67 [-3.40 , -1.94]
0.13 [-0.53 , 0.78]
-0.27 [-0.90 , 0.35]
-0.16 [-0.69 , 0.38]
-1.12 [-2.18 , -0.06]
-0.94 [-1.97 , 0.08]
-0.71 [-1.56 , 0.14]
-0.86 [-1.46 , -0.25]
-0.58 [-1.01 , -0.15]
-1.52 [-2.26 , -0.79]
-0.38 [-1.10 , 0.35]
-0.59 [-1.27 , 0.09]
-0.47 [-1.33 , 0.38]
-2.50 [-3.43 , -1.58]
-3.80 [-4.72 , -2.88]
-3.17 [-4.01 , -2.32]
0.21 [-0.31 , 0.74]
0.26 [-0.28 , 0.80]
0.05 [-0.71 , 0.80]
-2.13 [-2.92 , -1.34]
-2.78 [-3.67 , -1.88]
-2.19 [-2.89 , -1.50]
-0.23 [-0.96 , 0.49]
-0.50 [-1.38 , 0.38]
-0.26 [-0.72 , 0.20]
-0.29 [-0.75 , 0.16]
-1.04 [-1.41 , -0.67]

-0.73 [-1.11 , -0.34]
-0.97 [-1.72 , -0.22]
-2.64 [-3.45 , -1.84]
-0.52 [-0.95 , -0.08]
-1.01 [-1.46 , -0.55]
-0.29 [-0.95 , 0.37]
-0.41 [-0.97 , 0.16]
-0.18 [-0.78 , 0.42]
-0.04 [-0.73 , 0.66]
-0.68 [-1.29 , -0.07]
-0.24 [-1.03 , 0.55]
0.01 [-0.29 , 0.30]
-0.31 [-1.05 , 0.44]
-0.28 [-0.97 , 0.42]
-0.98 [-1.63 , -0.33]
-0.57 [-1.21 , 0.07]
-0.48 [-1.37 , 0.42]
-0.27 [-0.87 , 0.33]
0.30 [-0.18 , 0.78]
-0.15 [-0.69 , 0.39]
-0.21 [-0.76 , 0.33]
0.22 [-0.45 , 0.89]
-0.45 [-0.67 , -0.23]

-0.59 [-1.11 , -0.08]
1.07 [0.41 , 1.72]
-0.14 [-0.80 , 0.51]
0.05 [-0.82 , 0.92]
-0.05 [-0.52 , 0.42]
0.04 [-0.44 , 0.52]
0.04 [-0.38 , 0.46]

Total (95% CI)
Heterogeneity: Tau² = 0.52; Chi² = 352.54, df = 56 (P < 0.00001); I² = 84%
Test for overall effect: Z = 6.36 (P < 0.00001)
Test for subgroup differences: Chi² = 14.67, df = 2 (P = 0.0007), I² = 86.4%

1688

1143

100.0%

-0.67 [-0.88 , -0.47]

-4

-2
Favours CBT

0

2

4
Favours Wait list / no treatment

Indeed, including only studies that used a broad measure of child-
reported anxiety symptoms (38 studies, 2459 participants), the SMD

between  CBT  groups  and  waitlist  controls  was  reduced  to  −0.41
(95% CI −0.57 to −0.25, Z = 5.13, P < 0.001, I2 = 68%) (Analysis 1.14).

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

32

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Subgroup analyses

We found a significant difference between child-focused, child-and-
parent, and parent-only CBT (Chi2 = 14.67, df = 2, P < 0.001) on child-
reported anxiety symptom outcomes, with considerable subgroup
heterogeneity  (I2  =  86.4%).  There  was  no  significant  difference
between  CBT  and  waitlist/no  treatment  control  groups  in  post-
treatment  child-reported  anxiety  symptoms  for  parent-delivered
CBT (SMD 0.04, 95% CI −0.38 to 0.46, Z = 0.19, P = 0.85, 5 studies). The
forest plot and summary statistics indicated that child-focused CBT
produced a greater reduction on child-reported anxiety symptoms
amongst  CBT  groups  compared  to  waitlist/no  treatment  controls
(SMD −1.04, 95% CI −1.41 to −0.67, Z = 5.48, P < 0.001, 24 studies)
than  child-and-parent  delivered  CBT  (SMD  −0.45,  95%  CI  −0.67
to  −0.23,  Z  =  3.99,  P  <  0.001,  20  studies),  but  with  substantial
heterogeneity within each of these subgroups (child-focused: I2 =
88%; child-and-parent: I2 = 69%).

Subgroup analyses also revealed a significance difference between
individual- and group-focused CBT (Chi2 = 6.47, df = 1, P = 0.01; I2
= 84.5%) (Analysis 1.15). The SMD in post-treatment child-reported
anxiety symptoms between CBT and waitlist/no treatment control
groups  was  −0.91  (95%  CI  −1.22  to  −0.60)  in  studies  evaluating
group-focused  CBT  compared  to  −0.39  (95%  CI  −0.64  to  −0.15)  in
studies evaluating individual-focused CBT.

We  found  no  differences  between  interventions  with  different
amounts of therapist contact time (< 10 hours, ≥ 10 and < 20 hours,
≥  20  hours)  (Chi2  =  3.33,  df  =  2,  P  =  0.19;  I2  =  39.9%)  (Analysis
1.16),  but  child-reported  anxiety  symptoms  outcomes  did  vary

amongst  different  age  groups  (Chi2  =  8.27,  df  =  2,  P  =  0.02),  with
substantial  subgroup  heterogeneity  (I2  =  75.8%)  (Analysis  1.17).
Amongst studies of children aged ≥ 12 years, the SMD between CBT
and waitlist/no treatment controls was −1.78 (95% CI −3.01 to −0.56)
compared to −0.62 (95% CI −0.83 to −0.41) where studies included
participants over and under 12 years of age, and −0.23 (95% CI cross
0) amongst studies of children ≤ 12 years, but with variation within
each of these age groups (I2 = 71% to 95%).

We did not find differences between studies including participants
with  and  without  ASD  on  post-treatment  child-reported  anxiety
symptoms outcomes (Chi2 = 0.02, df = 1, P = 0.88; I2 = 0%) (Analysis
1.18).

1.5 Reduction in anxiety symptoms (parent report) post-treatment

We  included  35  studies  in  analyses  examining  post-treatment
parent-reported  anxiety  symptoms  (Afshari  2014;  Arendt  2016;
Chalfant  2007;  Cheung  2016;  Chiu  2013;  Cobham  2017;  Flannery
Schroeder 2000; Holmes 2014; Ishikawa 2019; Kendall 1994; Kendall
1997; Kennedy 2009; Kidd 2018; Lau 2010; Lau 2017; Masia Warner
2005; McConachie 2014; McNally Keehn 2013; Olivares 2014; Perrin
2019; Rapee 2005; Rapee 2006; Rosa Alcazar 2009; Santucci 2013;
Schneider  2011;  Silverman  1999b;  Smith  2014;  Spence  2006;
Spence 2011; Thirlwall 2013; Villabo 2018; Wergeland 2014; White
2013; Wood 2009; Wood 2015). The SMD between CBT and waitlist/
no  treatment  control  groups  was  −0.70  (95%  CI  −0.90  to  −0.51,  Z
= 7.01, P < 0.001, n = 2137, low-quality evidence), with substantial
heterogeneity (Chi2 = 171.97, df = 40, P < 0.001; I2 = 77%) (Analysis
1.19; Figure 6.

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

33

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 6.   Forest plot of comparison: 1 CBT vs waitlist/no treatment, outcome: 1.19 Reduction in anxiety symptoms
(parent report) post-treatment.

Study or Subgroup

Mean

CBT
SD

Total

Mean

Wait list / no treatment
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.19.1 Child focused
Afshari 2014
Afshari 2014
Cheung 2016
Chiu 2013
Flannery Schroeder 2000
Flannery Schroeder 2000
Kendall 1994
Kendall 1997
Lau 2010
Masia Warner 2005
McNally Keehn 2013
Olivares 2014
Olivares 2014
Perrin 2019
Rosa Alcazar 2009
Villabo 2018
Villabo 2018
Subtotal (95% CI)
Heterogeneity: Tau² = 0.37; Chi² = 67.98, df = 16 (P < 0.00001); I² = 76%
Test for overall effect: Z = 4.98 (P < 0.00001)

11.7
10.9
18.93
12.64
10.37
10.31
9.55
4.66
10.49
2.6
11.34
10.93
8.27
12.4
17.42
19.133792096706802
18.243848278255324

26.8
29.5
62.71
43.38
38.46
41.08
59
8.21
29.71
9.4
20.08
47.95
51.63
18.9
45.9
47.25
49.72

1.19.2 Child and parent
Arendt 2016
Chalfant 2007
Holmes 2014
Ishikawa 2019
Kidd 2018
Lau 2017
McConachie 2014
Rapee 2006
Santucci 2013
Schneider 2011
Silverman 1999b
Spence 2006
Spence 2011
Wergeland 2014
Wergeland 2014
White 2013
Wood 2009
Wood 2015
Subtotal (95% CI)
Heterogeneity: Tau² = 0.30; Chi² = 78.59, df = 17 (P < 0.00001); I² = 78%
Test for overall effect: Z = 4.57 (P < 0.00001)

12.59
5.11
12.7
12.85
7.7
16.74
16.23
13.6
9.56
0.19
4.61
7.91
11.873516749472332
10.76
15.01
5.67
14.72
12.71

22.25
13.96
29.94
25.42
24.64
44.74
38.35
23.7
28.93
0.23
12.96
19.53
26.78
26.32
28.76
13.6
58.48
50.21

1.19.3 Parent only
Cobham 2017
Kennedy 2009
Rapee 2005
Smith 2014
Thirlwall 2013
Thirlwall 2013
Subtotal (95% CI)
Heterogeneity: Tau² = 0.18; Chi² = 17.42, df = 5 (P = 0.004); I² = 71%
Test for overall effect: Z = 1.77 (P = 0.08)

4.9
18.39
15.09
17.14
12.93
11.52

20.1
50.6
31.24
54.32
24.16
20.45

37.9
37.9
54.59
52.37
52.58
52.58
63.55
10.91
39.29
11.5
31.7
66.37
66.37
38.2
81
50.86
50.86

37.04
44.16
31.47
27.57
29.92
63.28
42
27.7
35.39
0.46
16.94
26.04
25.22
30.53
30.53
16.4
76.57
58.44

32.3
61.04
31.81
52.98
24.15
24.15

11.5
11.5
22.7
18.01
11.07
11.07
12.61
3.99
10.07
3.1
13.36
8.74
8.74
14.9
5.98
18.169686293384366
18.169686293384366

16.95
9.04
8.79
12.835326252183863
8.98
20.85
19.53
13.8
8.21
0.21
5.31
7.69
11.79526599954405
12.36
12.36
8.87
14.65
9.01

11.9
20.79
15.08
14.08
11.36
11.36

10
10
18
22
13
12
27
60
21
18
12
37
38
20
20
55
55
448

56
28
17
25
25
39
17
90
14
14
25
20
44
57
60
15
14
19
579

31
32
59
14
38
42
216

5
5
18
18
6
6
20
34
17
17
10
18
17
20
20
28
27
286

53
19
19
24
19
33
15
87
14
19
16
23
27
16
17
15
22
14
452

29
31
42
8
23
23
156

1.6%
1.6%
2.4%
2.5%
1.7%
1.7%
2.6%
2.9%
2.4%
2.4%
2.0%
2.4%
2.4%
2.4%
2.0%
2.9%
2.9%
38.9%

3.0%
1.7%
2.5%
2.7%
2.5%
2.8%
2.4%
3.1%
2.2%
2.3%
2.5%
2.5%
2.8%
2.7%
2.7%
2.3%
2.3%
2.3%
45.2%

2.6%
2.8%
3.0%
2.0%
2.7%
2.8%
15.9%

-0.90 [-2.03 , 0.24]
-0.71 [-1.83 , 0.40]
0.38 [-0.28 , 1.04]
-0.58 [-1.21 , 0.06]
-1.27 [-2.34 , -0.21]
-1.04 [-2.09 , 0.01]
-0.41 [-0.99 , 0.18]
-0.60 [-1.03 , -0.17]
-0.91 [-1.59 , -0.24]
-0.72 [-1.41 , -0.03]
-0.91 [-1.80 , -0.02]
-1.77 [-2.43 , -1.11]
-1.73 [-2.39 , -1.06]
-1.38 [-2.08 , -0.68]
-2.64 [-3.51 , -1.77]
-0.19 [-0.65 , 0.27]
-0.06 [-0.52 , 0.40]
-0.87 [-1.21 , -0.53]

-0.99 [-1.39 , -0.59]
-4.27 [-5.34 , -3.20]
-0.14 [-0.79 , 0.52]
-0.16 [-0.73 , 0.40]
-0.63 [-1.24 , -0.01]
-0.98 [-1.47 , -0.49]
-0.20 [-0.90 , 0.50]
-0.29 [-0.59 , 0.01]
-0.70 [-1.47 , 0.06]
-1.11 [-1.86 , -0.36]
-0.80 [-1.45 , -0.14]
-0.82 [-1.45 , -0.19]
0.13 [-0.35 , 0.61]
-0.37 [-0.93 , 0.18]
-0.12 [-0.66 , 0.42]
-0.37 [-1.09 , 0.36]
-1.21 [-1.94 , -0.47]
-0.71 [-1.42 , 0.00]
-0.69 [-0.98 , -0.39]

-1.34 [-1.90 , -0.78]
-0.53 [-1.03 , -0.02]
-0.04 [-0.43 , 0.36]
0.08 [-0.79 , 0.95]
0.00 [-0.52 , 0.52]
-0.32 [-0.83 , 0.19]
-0.37 [-0.77 , 0.04]

Total (95% CI)
Heterogeneity: Tau² = 0.30; Chi² = 171.97, df = 40 (P < 0.00001); I² = 77%
Test for overall effect: Z = 7.01 (P < 0.00001)
Test for subgroup differences: Chi² = 3.43, df = 2 (P = 0.18), I² = 41.8%

1243

894

100.0%

-0.70 [-0.90 , -0.51]

-4

-2
Favours CBT

0

2

4
Favours Wait list / no treatment

Including  only  studies  that  used  a  broad  measure  of  parent-
reported anxiety symptoms (32 studies, 1952 participants), the SMD
between  CBT  and  waitlist  groups  was  reduced  to  −0.59  (95%  CI
−0.77 to −0.41, Z = 6.33, P < 0.001, I2 = 71%) (Analysis 1.20).

no  treatment  post-treatment  parent-reported  anxiety  symptoms
was  −0.92  (95%  CI  −1.21  to  −0.62)  amongst  group  interventions,
individual
compared  to  −0.43  (95%  CI  −0.65  to  −0.21)  for 
interventions.

Subgroup analyses

Subgroup  analyses  revealed  no  significant  differences  between
child-focused,  child  and  parent,  and  parent-only  on  parent-
reported  anxiety  symptom  outcomes  (Chi2  =  3.43,  df  =  2,  P  =
0.18) (Analysis 1.19). However, there was evidence of a difference
amongst individual compared to group interventions (Chi2 = 6.79,
df  =  1,  P  =  0.009),  with  substantial  subgroup  heterogeneity  (I2
=  85.3%)  (Analysis  1.21).  The  SMD  between  CBT  and  waitlist/

We  did  not  find  differences  in  parent-reported  anxiety  symptom
outcomes  across  interventions  involving  varying  amount  of
therapist contact time (Chi2 = 3.77, df = 2, P = 0.15; Analysis 1.22).
On  the  other  hand,  there  was  evidence  of  a  difference  in  these
outcomes amongst different age groups (Chi2 = 5.87, df = 2, P = 0.05),
with  substantial  subgroup  heterogeneity  (I2  =  65.9%)  (Analysis
1.23). Amongst studies that included participants aged ≥ 12 years,
the SMD between CBT and waitlist/no treatment groups was −1.07
(95% CI −1.78 to −0.37), compared to −0.76 (95% CI −1.04 to −0.49)

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

34

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

in  studies  that  included  participants  under  and  over  12  years  of
age, and −0.40 (95% CI −0.63 to −0.17) where participants were ≤ 12
years.

2011). Neither ITT analyses (Analysis 1.29) nor completer analyses
(Analysis  1.30)  showed  a  significant  difference  between  CBT  and
waitlist/no treatment at any of these follow-up time points.

We  found  no  significant  differences  in  parent-reported  anxiety
symptom outcomes amongst samples with and without ASD (Chi2
= 1.42, df = 1, P = 0.23; Analysis 1.24).

1.6 Reduction in depressive symptoms post-treatment

Seventeen studies reported post-treatment depressive symptoms
(Arendt  2016;  Barrett  1996;  Flannery  Schroeder  2000;  Gallagher
2004; Ishikawa 2019; Kendall 1994; Kendall 1997; Kidd 2018; Masia
Warner 2005; Melfsen 2011; Ollendick 2009; Ost 2001; Perrin 2019;
Salari 2018; Silverman 1999b; Thirlwall 2013; Wergeland 2014). The
SMD  between  CBT  and  waitlist/no  treatment  control  groups  was
−0.34 (95% CI −0.51 to −0.17, Z = 3.96, P < 0.001, n = 1157, moderate-
quality evidence), with moderate heterogeneity (Chi2 = 39.62, df =
22, P = 0.01; I2 = 44%) (Analysis 1.25).

1.7 Improvement in global functioning post-treatment

Data pooled from 11 studies that reported post-treatment global
functioning  produced  an  SMD  between  CBT  and  waitlist/no
treatment  control  groups  of  1.03  (95%  CI  0.68  to  1.38,  Z  =
5.83,  P  <  0.001,  n  =  557,  low-quality  evidence),  with  substantial
heterogeneity (Chi2 = 37.41, df = 11, P < 0.001; I2 = 71%) (Analysis
1.26)  (Cornacchio  2019;  Holmes  2014;  Masia  Warner  2005;  Masia
Warner 2011; Melfsen 2011; Perrin 2019; Salari 2018; Santucci 2013;
Spence 2011; Villabo 2018; White 2013).

1.8 Adverse events

No  included  study  reported  adverse  events  in  both  CBT  and
waitlist/no treatment groups, so meta-analysis was not possible.

Remission of primary anxiety disorder diagnosis at follow-up

Four  studies  reported  remission  of  primary  anxiety  disorder  at
follow-up  assessments  ≤  6  months  post-treatment  (Dadds  1997;
Gallagher 2004; Olivares 2005; Rosa Alcazar 2009), with ITT analysis
showing a rate for remission of primary anxiety diagnosis of 66.7%
(48  out  of  72)  for  CBT  groups  versus  34.6%  (28  out  of  81)  for
waitlist/no  treatment  controls  (OR  10.94,  95%  CI  2.33  to  51.41,
Z  =  3.03,  P  =  0.002,  I2  =  40%)  (Analysis  1.27).  Only  3  studies
(166 participants) reported remission of primary anxiety disorder
12  months  post-treatment  (Cartwright  Hatton  2011;  Dadds  1997;
Rosa Alcazar 2009); pooled data did not suggest a benefit for CBT
compared  to  waitlist/no  treatment  control  groups  (OR  2.80,  95%
0.24 to 33.19, Z = 0.82, P = 0.41, I2 = 83%).

Only one study reported remission of primary anxiety disorder > 12
months post-treatment, so meta-analysis was not possible.

Completer  analyses  produced  similar  findings,  with  evidence  of
an intervention effect at follow-up assessments ≤ 6 months post-
treatment but not at 12-month follow-up (Analysis 1.28)

Remission of all anxiety disorder diagnoses at follow-up

Five  studies  reported  data  on  remission  of  all  anxiety  disorders
at  follow-up  assessments  (Cartwright  Hatton  2011;  Dadds  1997;
Olivares 2005; Rosa Alcazar 2009; Simon 2011), including ≤ 6 months
post-treatment (Dadds 1997; Olivares 2005; Rosa Alcazar 2009), 12
months post-treatment (Cartwright Hatton 2011; Dadds 1997; Rosa
Alcazar 2009), and 24 months post-treatment (Dadds 1997; Simon

Reduction in anxiety symptoms at follow-up

Six  studies  reported  data  on  child-reported  anxiety  symptoms  at
follow-up  assessments  (Analysis  1.31)  (Afshari  2014;  Dadds  1997;
Gallagher  2004;  Olivares  2005;  Rosa  Alcazar  2009;  Simon  2011).
Child-reported  anxiety  symptoms  at  ≤  6  months  post-treatment
produced an SMD of −1.92 (95% CI −2.95 to −0.89, Z = 3.65, P < 0.001,
n  =  179)  between  CBT  and  waitlist/no  treatment  groups  (Afshari
2014;  Dadds  1997;  Gallagher  2004;  Olivares  2005;  Rosa  Alcazar
2009), with substantial heterogeneity across studies (Chi2 = 35.35,
df = 5, P < 0.001; I2 = 86%). Only two studies reported corresponding
outcomes at 12-month follow-up (Dadds 1997; Rosa Alcazar 2009),
and only one study at 24-month follow-up (Simon 2011), so meta-
analyses were not possible for these time points.

As  only  two  studies  reported  data  on  parent-reported  anxiety
symptoms at 6 months post-treatment (Afshari 2014; Rosa Alcazar
2009),  and  one  with  corresponding  data  at  12  months  post-
treatment (Rosa Alcazar 2009), meta-analyses were not performed
using these data.

Comparison 2: CBT versus treatment as usual

See Summary of findings 2.

Primary outcomes

2.1 Remission of primary anxiety diagnosis post-treatment

Eight  studies  provided  uncertain  evidence  on  post-treatment
remission of primary anxiety disorder diagnosis for CBT versus TAU
(Fujii 2013; Ginsburg 2019a; Reaven 2012; Shahnavaz 2016; Sharma
2017; Southam Gerow 2010; Storch 2013; Storch 2015).

The  ITT  analysis  included  281  CBT  participants  and  206  TAU
participants, with no evidence of a significant difference in the rate
of  remission  of  primary  anxiety  diagnosis  post-treatment  (44.1%
and 40.8% respectively; OR 3.19, 95% CI 0.90 to 11.29, Z = 1.80, P
= 0.07, low-quality evidence) (Analysis 2.1). There was evidence of
substantial heterogeneity (Chi2 = 28.93, df = 7, P < 0.001; I2 = 76%).

Subgroup analyses

There was a significant difference in remission of primary anxiety
disorder outcomes amongst studies evaluating child-focused CBT
compared to child-and-parent delivered CBT (Chi2 = 10.90, df = 1, P
< 0.001; I2 = 90.8%). Data pooled from five studies (172 participants)
that  evaluated  a  child-and-parent  delivered  intervention  showed
a clear benefit for CBT compared to TAU (OR 8.56, 95% CI 3.10 to
23.66,  Z  =  4.14,  P  <  0.001),  whereas  data  from  three  studies  (315
participants)  evaluating  child-focused  interventions  did  not  (OR
0.61, 95% CI cross 1). None of the studies that compared CBT to TAU
evaluated a parent-only intervention.

Planned  subgroup  analyses  comparing  individual  versus  group
interventions,  interventions  with  varying  amount  of  therapist
contact time, and different age groups were not possible due to an
insufficient number of studies. Only two studies evaluated group
CBT; only one study used an intervention with < 10 hours therapist
contact time; and five (out of eight) studies included pre-adolescent
and adolescent participants.

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

35

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Subgroup  analyses  also  indicated  a  difference  in  remission
outcomes  in  studies  with  participants  with  ASD  compared  to
studies with participants without ASD (Chi2 = 5.71, df = 1, P = 0.02; I2
= 82.5%) (Analysis 2.2). Pooled data from four ASD samples showed
a higher rate of remission of primary anxiety disorder amongst CBT
groups compared to TAU groups (OR 11.25, 95% CI 3.11 to 40.79, Z
= 3.68, P < 0.001, n = 142, I2 = 0%), but corresponding data from four
samples  without  ASD  showed  no  significant  difference  between
CBT and TAU groups (OR 1.14, 95% CI 0.29 to 4.47, Z = 0.18, P = 0.85,
n = 345, I2 = 75%).

Completer analysis

The completer analysis included 248 CBT participants and 192 TAU
participants, with a response rate for remission of primary anxiety
diagnosis of 50.4% for CBT versus 36.5% for controls (OR 4.87, 95%
CI  1.51  to  15.72,  Z  =  2.65,  P  =  0.008)  (Analysis  2.3).  Similar  to  the
ITT analysis, there was substantial heterogeneity across the eight
studies (Chi2 = 21.30, df = 7, P = 0.003; I2 = 67%).

2.2 Acceptability: loss of participants to post-treatment assessment

We  found  no  evidence  of  a  difference  between  CBT  and  TAU  in
rate  of  those  lost  to  post-treatment  assessment,  illustrating  a
comparable degree of acceptability (OR 1.37, 95% CI 0.73 to 2.56, Z
= 0.98, P = 0.33, I2 = 0%, k = 8, n = 441, low-quality evidence) (Analysis
2.4).

Secondary outcomes

2.3 Remission of all anxiety disorders post-treatment

Five studies provided uncertain evidence on remission of all anxiety
disorder diagnoses post-treatment for CBT versus TAU (Barrington
2005; Sciberras 2018; Sharma 2017; Storch 2013; Storch 2015).

The ITT analyses showed a rate of remission of all anxiety diagnoses
of 55.8% for CBT versus 41.4% for TAU (OR 2.74, 95% CI 1.16 to 6.46,
Z = 2.30, P = 0.02, k = 5, n = 203, low-quality evidence) (Analysis 2.5).
There was no evidence of significant heterogeneity (Chi2 = 3.92, df
= 4, P = 0.42; I2 = 0%).

Completer  analyses  showed  a  similar  benefit  for  CBT  versus  TAU
(OR 2.78, 95% CI 1.18 to 6.55, Z = 2.33, P = 0.02, k = 5, n = 201, I2 =
0%) (Analysis 2.6).

2.4 Reduction in anxiety symptoms (child-report) post-treatment

We included six studies in the analyses examining post-treatment
child-reported anxiety symptoms (Barrington 2005; Ginsburg 2012;
Sciberras  2018;  Shahnavaz  2016;  Sharma  2017;  Southam  Gerow
2010).  We  found  no  difference  between  CBT  and  TAU  in  child-
reported  anxiety  symptoms  post-treatment  (SMD  −0.15,  95%  CI
−0.78  to  0.48,  Z  =  0.46,  P  =  0.64,  n  =  214,  low-quality  evidence),
although there was substantial heterogeneity (Chi2 = 23.55, df = 5,
P < 0.001; I2 = 79%) (Analysis 2.7). This finding was replicated after
removal of the one study that used a disorder-specific symptoms
measure (SMD 0.07, 95% CI −0.54 to 0.68, Z = 0.22, P = 0.83, n = 187,
I2 = 74%) (Analysis 2.8).

2.5 Reduction in anxiety symptoms (parent-report) post-treatment

Pooled  data  from  seven  studies  showed  no  difference  between
CBT and TAU in post-treatment parent-reported anxiety symptoms
(SMD −0.32, 95% CI −0.70 to 0.06, Z = 1.64, P = 0.10, n = 228, low-
quality evidence) (Barrington 2005; Ginsburg 2002; Sciberras 2018;
Shahnavaz 2016; Southam Gerow 2010; Storch 2013; Storch 2015),

Cochrane Database of Systematic Reviews

with moderate heterogeneity across studies (Chi2 = 11.66, df = 6, P
= 0.07; I2 = 49%) (Analysis 2.9). Removal of one study that used a
disorder-specific measure did not change this finding (SMD −0.16,
95% CI −0.44 to 0.11, Z = 1.16, P = 0.25, n = 202, I2 = 0%) (Analysis
2.10).

2.6 Reduction in depressive symptoms post-treatment

Only one study reported depressive symptoms post-treatment for
CBT versus TAU (O'Brien 2007), so meta-analysis was not possible.

2.7 Improvement in global functioning post-treatment

Only one study reported post-treatment global functioning for CBT
versus TAU (Sharma 2017), so meta-analysis was not possible.

2.8 Adverse events

No  included  study  reported  adverse  events  in  both  CBT  and  TAU
groups, so meta-analysis was not possible.

2.9 Follow-up outcomes

There  was  an 
insufficient  number  of  studies  to  conduct
meta-analyses  examining  longer-term  diagnostic  or  symptom
outcomes.  Only  two  studies  reported  remission  from  primary
anxiety  disorders  at  12  months  post-treatment  (Ginsburg  2019a;
Shahnavaz  2016),  and  one  study  reported  remission  from
all  anxiety  disorders  at  6  and  12  months  (Barrington  2005).
Similarly,  only  three  studies  reported  child-reported  and  parent-
reported anxiety symptoms at 6-month and/or 12-month follow-up
(Barrington 2005; Ginsburg 2012; Shahnavaz 2016).

Comparison 3: CBT versus attention control

See Summary of findings 3.

Primary outcomes

3.1 Remission of primary anxiety diagnosis post-treatment

Ten studies evaluating CBT versus attention control provided data
on post-treatment remission of primary anxiety disorder diagnosis
(Ginsburg  2002;  Hudson  2009;  Kendall  2008;  Khanna  2010;  Last
1998; Masia Warner 2007; Masia Warner 2016; Ollendick 2009; Rosa
Alcazar 2009; Silverman 1999a).

The  ITT  analysis  (484  CBT  participants;  338  control  participants)
provided  uncertain  evidence  for  a  greater  rate  of  remission  of
primary  anxiety  diagnosis  post-treatment  for  CBT  compared  to
attention  controls  (48.3%  versus  29.3%;  OR  2.28,  95%  CI  1.33  to
3.89,  Z  =  3.00,  P  =  0.003,  low-quality  evidence),  with  moderate
heterogeneity across studies (Chi2 = 28.77, df = 12, P = 0.004; I2 =
58%) (Analysis 3.1).

Subgroup analyses

None of the studies that evaluated CBT versus attention controls
used  a  parent-only  intervention,  but  there  was  a  difference  in
the  pattern  of  results  for  remission  of  primary  anxiety  disorder
outcomes amongst studies evaluating child-focused CBT and child-
and-parent  delivered  CBT  when  each  was  compared  to  attention
controls  (Chi2  =  7.65,  df  =  1,  P  =  0.006;  I2  =  86.9%)  (Analysis
3.1). Summary statistics indicated a benefit for CBT compared to
attention  controls  amongst  child-focused  interventions  (OR  3.58,
95% CI 1.92 to 6.65, k = 7, n = 509), but not amongst child-and-parent
delivered interventions (OR 1.12, 95% CI cross 1, k = 4, n = 313).

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

36

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Subgroup analyses revealed no significant difference in remission
of  primary  anxiety  disorder  outcomes  in  studies  evaluating
individual CBT versus group CBT (Chi2 = 1.22, df = 1, P = 0.27; I2 =
17.7%) (Chi2 = 0.48, df = 1, P = 0.49; I2 = 0%) (Analysis 3.2).

heterogeneity across studies (Chi2 = 47.61, df = 11, P < 0.001; I2 =
77%) (Analysis 3.9). Removal of studies that used disorder-specific
measures did not change this finding (SMD −0.04, 95% CI −0.26 to
0.18, Z = 0.36, P = 0.72, n = 345, k = 4, I2 = 0%) (Analysis 3.10).

Further subgroup analyses were not possible because there were
fewer  than  three  studies  in  at  least  one  group  for  each  planned
subgroup analysis.

Completer analysis

In the completer analysis, 53.1% of CBT participants compared to
23.2% of attention control participants were free of their primary
anxiety  disorder  diagnosis  post-treatment,  with  a  significant
intervention effect (OR 3.88, 95% CI 2.52 to 5.97, Z = 6.17, P < 0.001,
k = 10, n = 752, I2 = 21%) (Analysis 3.3).

3.2 Acceptability: loss of participants to post-treatment assessment

Low-quality  evidence 
indicated  no  difference  between  CBT
and  attention  controls  in  rate  of  those  lost  to  post-treatment
assessment, suggesting a similar degree of acceptability (OR 1.00,
95% CI cross 1, Z = 0.01, P = 0.99, n = 797, k = 12, I2 = 0%) (Analysis
3.4).

Secondary outcomes

3.6 Reduction in depressive symptoms post-treatment

Ten studies reported post-treatment depressive symptoms for CBT
versus attention controls (Ingul 2013; Kendall 2008; Khanna 2010;
Last 1998; Masia Warner 2007; Muris 2002; Ollendick 2009; Pincus
2010;  Salum  2018;  Silverman  1999a),  finding  no  between-group
difference (SMD −0.18, 95% CI −0.45 to 0.09, Z = 1.32, P = 0.19, n =
613,  low-quality  evidence)  (Analysis  3.11).  There  was  evidence  of
moderate  heterogeneity  across  studies  (Chi2  =  29.19,  df  =  12,  P  =
0.004; I2 = 59%).

3.7 Improvement in global functioning post-treatment

Only  two  studies  reported  post-treatment  global  functioning  for
CBT versus attention controls (Khanna 2010; Masia Warner 2007),
so meta-analysis was not possible.

3.8 Adverse events

No study reported adverse events in both CBT and attention control
groups, so meta-analysis was not possible.

3.3 Remission of all anxiety disorders post-treatment

Remission of primary anxiety disorder diagnoses at follow-up

We  included  five  studies  in  analyses  comparing  CBT  versus
attention  controls  for  remission  of  all  anxiety  disorder  diagnoses
post-treatment (Ginsburg 2002; Hudson 2009; Kendall 2008; Masia
Warner 2007; Rosa Alcazar 2009).

Both ITT analyses and completer analyses indicated a benefit for
CBT compared to attention control conditions (ITT: OR 2.75, 95% CI
1.22 to 6.17, Z = 2.45, P = 0.01, n = 378, I2 = 49%, low-quality evidence;
completers: OR 3.88, 95% CI 1.58 to 9.51, Z = 2.96, P = 0.003, n = 359,
I2 = 48%) (Analysis 3.5; Analysis 3.6).

3.4 Reduction in anxiety symptoms (child-report) post-treatment

Fifteen  studies  provided  moderate-quality  evidence  for  post-
treatment child-reported anxiety symptoms for CBT and attention
control groups (Ginsburg 2002; Herbert 2009; Hudson 2009; Ingul
2013;  Kendall  2008;  Khanna  2010;  Last  1998;  Masia  Warner  2007;
Masia Warner 2016; Muris 2002; Ollendick 2009; Pincus 2010; Rosa
Alcazar 2009; Salum 2018; Silverman 1999a). The SMD between CBT
and  attention  controls  for  child-reported  anxiety  symptoms  was
−0.31 (95% CI −0.51 to −0.11, Z = 3.09, P = 0.002, n = 978) (Analysis
3.7). There was evidence of moderate heterogeneity across studies
(Chi2 = 40.95, df = 20, P = 0.004; I2 = 51%).

After  removal  of  studies  that  used  a  disorder-specific  symptom
measure, the SMD between CBT and attention controls was reduced
to −0.18 (95% CI −0.34 to −0.02, Z = 2.26, P = 0.02, n = 685, k = 11, I2
= 0%) (Analysis 3.8).

3.5 Reduction in anxiety symptoms (parent-report) post-treatment

Eight  studies  provided  data  on  post-treatment  parent-reported
anxiety  symptoms  for  CBT  and  attention  control  groups  (Herbert
2009;  Hudson  2009;  Kendall  2008;  Masia  Warner  2007;  Masia
Warner  2016;  Rosa  Alcazar  2009;  Salum  2018;  Silverman  1999a).
The analyses indicated no significant differences between CBT and
attention  controls  (SMD  −0.25,  95%  CI  −0.61  to  0.11,  Z  =  1.37,
P  =  0.17,  n  =  638,  low-quality  evidence),  but  with  substantial

Four  studies  provided  data  on  remission  of  primary  anxiety
disorder at ≤ 6 months follow-up (Hudson 2009; Masia Warner 2007;
Masia  Warner  2016;  Rosa  Alcazar  2009).  ITT  analyses  showed  a
greater  rate  of  remission  for  CBT  groups  compared  to  attention
controls (OR 3.06, 95% CI 1.22 to 7.65, Z = 2.39, P = 0.02, n = 341), but
with substantial heterogeneity across studies (Chi2 = 12.62, df = 5, P
= 0.02; I2 = 60%) (Analysis 3.12).

The  intervention  effect  increased  in  the  completer  analysis  (OR
6.52, 95% CI 2.58 to 16.43, Z = 3.97, P < 0.001, k = 4, n = 302, I2 = 44%)
(Analysis 3.13).

Only one study reported remission of primary anxiety disorder at
12-month follow-up, so meta-analysis was not possible for this time
point.

Remission of all anxiety disorder diagnoses at follow-up

Three  studies  reported  remission  from  all  anxiety  disorder
diagnoses  at  ≤  6  months  post-treatment  (Hudson  2009;  Masia
Warner  2007;  Rosa  Alcazar  2009).  ITT  analyses  and  completer
analyses  indicated  a  greater  rate  of  remission  of  all  anxiety
disorders for CBT groups compared to attention controls (ITT: OR
5.44,  95%  CI  1.00  to  29.60,  Z  =  1.96,  P  =  0.05,  n  =  205;  completer
analysis: OR 11.19, 95% CI 1.94 to 64.51, Z = 2.70, P = 0.007, n = 182),
but  with  substantial  heterogeneity  across  studies  (ITT:  I2  =  72%,
completer analysis: I2 = 62%) (Analysis 3.14; Analysis 3.15).

Only one study reported remission of all anxiety disorder diagnoses
at 12 months (Rosa Alcazar 2009), so meta-analysis was not possible
for this time point.

Reduction in anxiety symptoms at follow-up

Six studies reported child-reported anxiety symptoms at ≤ 6 months
post-treatment  (Herbert  2009;  Hudson  2009;  Masia  Warner  2007;
Masia  Warner  2016;  Rosa  Alcazar  2009;  Silverman  1999a).  Pooled
data  from  these  studies  indicated  a  benefit  for  CBT  compared  to

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

37

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

attention  controls  (SMD  −0.44,  95%  CI  −0.79  to  −0.08,  Z  =  2.40,  P
=  0.02,  n  =  434),  but  there  was  substantial  heterogeneity  across
studies (Chi2 = 23.08, df = 8, P = 0.003; I2 = 65%) (Analysis 3.16).

The same six studies provided parent-reported anxiety symptoms
at  ≤  6  months  post-treatment;  analyses  showed  no  significant
difference between CBT and attention controls (SMD −0.63, 95% CI
cross 0, n = 434, I2 = 90%) (Analysis 3.17).

Only  two  studies  reported  child-reported  anxiety  symptoms  and
parent-reported anxiety symptoms at 12 months follow-up (Rosa
Alcazar  2009;  Silverman  1999a),  so  meta-analyses  for  these
outcomes were not possible for this time point.

Comparison 4: CBT versus alternative treatment

See Summary of findings 4.

Primary outcomes

4.1 Remission of primary anxiety diagnosis post-treatment

Only  two  studies  that  compared  CBT  to  an  alternative  treatment
reported  post-treatment  remission  of  primary  anxiety  disorder
(Creswell 2017; Reigada 2015), therefore data were insufficient to
conduct meaningful meta-analysis or planned subgroup analyses
for this outcome.

anxiety symptoms (SMD −0.09, 95% CI crosses 0, Z = 0.58, P = 0.56, k
= 6, n = 399, I2 = 51%) (Analysis 4.4). Removal of one study that used
a disorder-specific symptom measure did not change this finding
(Analysis 4.5).

4.5 Reduction in anxiety symptoms (parent-report) post-treatment

We  also  found  no  significant  differences  between  CBT  and
alternative  treatment  groups  in  post-treatment  parent-reported
anxiety  symptoms  (SMD  −0.13,  95%  CI  −0.33  to  0.06,  Z  =  1.31,  P
=  0.19,  k  =  6,  n  =  423,  6  studies,  I2  =  0%,  low-quality  evidence)
(Analysis 4.6). The studies all used a broad-based anxiety measure,
so planned sensitivity analysis was not required.

4.6 Reduction in depressive symptoms post-treatment

Only  only  study  reported  post-treatment  depressive  symptoms
(Salum 2018), so meta analysis was not possible.

4.7 Improvement in global functioning post-treatment

No  studies  reported  post-treatment  global  functioning  for  CBT
versus alternative treatments.

4.8 Adverse events

No  included  study  reported  adverse  events  in  both  CBT  and
alternative treatment groups, so meta-analysis was not possible.

4.2 Acceptability: loss of participants to post-treatment assessment

4.9 Follow-up outcomes

Low-quality  evidence  showed  no  difference  between  CBT  and
alternative  treatments  in  rate  of  those  lost  to  post-treatment
assessment (OR 1.58, 95% CI crosses 1, Z = 0.94, P = 0.35, k = 7, n
= 515, I2 = 53%), suggesting no difference in degree of acceptability
(Analysis 4.1).

Secondary outcomes

4.3 Remission of all anxiety disorders post-treatment

Pooled data from four studies that reported remission of all anxiety
disorder diagnoses post-treatment showed no difference between
CBT  and  alternative  treatment  groups  in  either  ITT  analyses  (OR
0.89, 95% CI crosses 1, Z = 0.25, P = 0.80, n = 401, I2 = 73%, low-quality
evidence) or completer analyses (OR 1.52, 95% CI crosses 1, Z = 1.06,
P = 0.29, n = 348, I2 = 57%) (Analysis 4.2; Analysis 4.3) (Creswell 2017;
Lebowitz 2019; Reigada 2015; Silk 2018).

4.4 Reduction in anxiety symptoms (child-report) post-treatment

Low-quality  evidence  showed  no  differences  between  CBT  and
alternative  treatment  groups  in  post-treatment  child-reported

For  each  of  the  longer-term  outcomes,  data  were  only  available
from  a  maximum  of  two  studies,  so  meta-analyses  were  not
possible.

Publication bias

We  investigated  publication  bias  in  relation  to  remission  of  the
primary  anxiety  disorder  post-treatment  for  CBT  versus  waitlist
controls, and CBT versus attention controls.

CBT versus waitlist/no treatment

There was clear evidence of publication bias from inspection of the
funnel plot (Figure 7), which was asymmetric, and the Egger’s test,
which  was  highly  significant  (t  =  5.52,  P  <  0.000).  Furthermore,  a
contour funnel plot (not included here) indicated that the missing
studies were in the areas of low significance, more compatible with
publication bias than other explanations of funnel plot asymmetry
such as variable study design (Peters 2008).

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

38

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 7.   Funnel plot of comparison: 1 CBT vs waitlist/no treatment, outcome: 1.1 Remission of primary anxiety
diagnosis post-treatment (ITT).

0

SE(log[OR])

0.5

1

1.5

2
0.001

0.1

1

10

OR

1000

CBT versus attention control

There  was  no  evidence  of  publication  bias  with  a  symmetrical
funnel plot (Figure 8) and non-significant Egger’s test (t = 1.99, P =
0.072).

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

39

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 8.   Funnel plot of comparison: 3 CBT vs attention control, outcome: 3.1 Remission of primary anxiety
diagnosis post-treatment (ITT).

0

SE(log[OR])

0.5

1

1.5

2
0.01

Subgroups
Child focused

D I S C U S S I O N

Summary of main results

0.1

1

10

Child and parent

OR

100

Since  the  last  Cochrane  Review,  James  2015,  there  has  been  a
considerable increase in the number of studies available for review,
from  41  to  88,  with  more  than  three  times  the  total  number  of
participants. We found moderate-quality evidence that CBT leads
to  greater  remission  of  primary  and  all  anxiety  disorders  than
waitlist/no  treatment  in  the  short  term.  Using  conservative  ITT
criteria, we found a remission rate of 49% for the primary anxiety
disorder  for  CBT  versus  18%  for  waitlist/no  treatment  controls
(OR  5.45,  95%  CI  3.90  to  7.60).  Although  this  indicates  a  slight
attenuation  in  effects  from  the  last  Cochrane  Review,  this  is  not
uncommon as studies accumulate over time. Consistent with the
last review, the number needed to treat for an additional beneficial
outcome (NNTB) using these conservative ITT data was 3 (95% CI
2.25 to 3.57). Notably, the benefit of CBT compared to waitlist/no
treatment controls was shown across all post-treatment outcomes,
albeit  with  uncertain  evidence  due  to  variation  in  reductions
in  child-  and  parent-reported  anxiety  symptoms,  and  depressive
symptoms, and limited data related to global functioning.

Unfortunately,  despite  the  general  increase  in  studies,  there
remains  a  relatively  small  number  of  studies  comparing  CBT
to  'active'  controls,  and  where  this  has  been  done  the  control
arms  included  a  broad  range  of  interventions  (from  undefined
and  variable  ‘treatment  as  usual’  to  attention  controls,  and  in
a  small  number  of  cases  treatments  that  might  credibly  be
delivered  in  practice).  Due  to  insufficient  data,  there  was  low-
quality  evidence  for  each  of  these  comparisons  across  most
outcomes. Encouragingly, the available data did indicate that CBT
may be associated with a higher rate of remission of the primary
anxiety disorder and all anxiety disorders and a greater reduction in
child-reported anxiety symptoms, compared to attention controls.
However,  the  limited  data  did  not  reveal  an  advantage  of  CBT
compared to treatment as usual across most outcomes, or indicate
a  benefit  of  CBT  compared  to  specified  alternative  treatments.
Furthermore, we were unable to compare CBT to medication or CBT
in combination with medication to drug placebo due to a lack of
available studies.

Unsurprisingly given the high frequency of waitlist control designs,
there also continues to be only a very small number of studies that
have controlled outcomes at longer-term follow-up points. Where
outcomes  beyond  post-treatment  were  available,  the  studies

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

40

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

had  mixed  results,  but  in  terms  of  remission  of  the  primary
anxiety  disorder,  the  current  findings  support  an  advantage  of
CBT compared to waitlist/no treatment and attention controls six
months after treatment. However, there is as yet no evidence that
this advantage of CBT continues at later time points, and there were
insufficient  data  to  determine  whether  any  longer-term  benefits
hold up against treatment as usual or alternative treatments.

Previous Cochrane Reviews on this topic have only included studies
that  involved  children  older  than  four  years  of  age;  however,  in
the current review we removed this restriction in order to identify
the  age  of  the  youngest  participants  in  RCTs  of  CBT  for  child
anxiety disorders, and to explore relative outcomes for different age
groups.  We  identified  studies  that  included  children  as  young  as
two years of age. Notably, studies with younger children typically
took a parent-led approach in which parents were supported by a
clinician to implement CBT principles in their child’s day-to-day life
(e.g. Cartwright Hatton 2011).

Given the low number of children with anxiety disorders who access
evidence-based  treatments  for  anxiety  disorders  (e.g.  Reardon
2020), we specifically looked at outcomes for subgroups of studies
categorised  by  the  amount  of  therapist  contact  time.  Relatively
few  studies  involved  less  than  10  hours  of  therapist  contact
time,  limiting  the  amount  of  data  available.  However,  primary
anxiety disorder and anxiety symptom outcomes for CBT compared
to  waitlist/no  treatment  did  not  differ  from  the  more  lengthy
treatments.  The  currently  available  data  therefore  suggests  that
services could provide CBT programmes that involve relatively low
levels of therapist contact time without a negative impact on post-
treatment outcomes.

The  wide  variation  across  trials  in  relation  to  a  range  of
study  and  sample  characteristics  limits  our  ability  to  draw
clear  conclusions  about  particular  treatment  formats  or  age
groups.  Amongst  waitlist/no  treatment  comparisons,  we  found
stronger  effects  for  child-focused  CBT  than  child-and-parent  and
parent-only  interventions.  However,  parent  involvement  in  trials
is  related  to  potentially  confounding  factors  (e.g.  child's  age,
study  setting),  and  even  within  the  child-focused  CBT  studies
there  was  considerable  heterogeneity  in  outcomes  and  variation
across  study  characteristics.  Indeed,  although  we  also  found
variation  in  outcomes  amongst  different  age  groups  for  CBT
versus wait list/no treatment comparisons, this differed according
to  outcome  and  may  indicate  age-related  measurement  issues,
rather  than  differences  in  true  effects.  We  found  stronger  effects
amongst  samples  of  adolescents  than  samples  of  children  or
mixed  child/adolescent  samples  on  child-  and  parent-reported
anxiety  symptoms,  but  not  in  terms  of  remission  of  primary  or
all  anxiety  disorders.  We  found  a  similar  picture  when  looking  at
subgroups of studies on the basis of whether they delivered CBT
with  individuals  or  groups.  For  example,  there  was  no  evidence
of  different  results  on  diagnostic  outcomes,  but  outcomes  for
group formats were stronger than individual formats when parent-
and  child-reported  symptoms  were  assessed  (in  the  waitlist/no
treatment  comparison).  Again,  various  potential  confounders  are
likely to have influenced these outcomes, including, for example,
participant  age,  study  setting  (e.g.  school  versus  clinic),  and
target disorders. Consequently, on the basis of findings relating to
treatment format, the currently available literature does not give
clear  and  consistent  evidence  that  one  format  is  better  or  worse
than any other.

Cochrane Database of Systematic Reviews

Finally, we also set out to assess outcomes specifically for children
with autism spectrum disorders (ASD) and intellectual disabilities.
Twelve studies evaluated CBT for the treatment of anxiety disorders
in  children  with  ASD,  with  mixed  findings  across  comparisons
and  outcomes.  Notably,  the  four  studies  that  compared  CBT
to  treatment  as  usual  for  children  with  ASD  (where  'treatment
as  usual'  typically  meant  participants  could  continue  to  seek
alternative interventions only) did find a consistent advantage of
CBT in relation to remission of primary anxiety disorder. However,
amongst waitlist/no treatment control comparisons, we only found
evidence of a benefit for CBT in parent-reported anxiety symptoms,
not  child-reported  symptoms  or  diagnostic  outcomes.  No  RCTs
evaluated the effectiveness of CBT for anxiety disorders amongst
children with intellectual disabilities.

Overall completeness and applicability of evidence

As  in  the  previous  Cochrane  Review,  almost  all  included  studies
involved participants of both sexes. Whilst a number of countries
are represented in this review, it is notable that they were almost
exclusively high-income countries (with two-thirds of the included
studies having been conducted either in the USA or Australia).

Although the overall age of participants ranged from 2 to 18 years,
less than 30% of studies focused specifically on children up to age
12 (with less than 6% focusing on children under 8 years of age), and
less than 20% focused specifically on adolescents, with the majority
including children and adolescents across broad age ranges. This
made it difficult to draw conclusions on the basis of specific child
ages.

We 
included  participants  with  comorbid  disorders  such  as
depression, other anxiety disorders, ADHD, and conduct disorders,
permitting generalised conclusions that appear to be applicable to
clinical practice. However, the majority of studies were conducted
in  outpatient  settings,  with  41  studies  conducted  in  university-
based  research  settings.  We  considered  other  settings,  including
primary  care  and  schools;  notably,  however,  no  studies  were
conducted  with  the  most  severe  cases  who  receive  treatment
as  day-  or  inpatients,  which  is  perhaps  a  reflection  of  the
challenges associated with running trials in these settings. Despite
the  continued  growth  in  studies  evaluating  CBT  for  anxiety
disorders in general, there were few additional studies that targeted
children  with  ASD  since  the  last  Cochrane  Review,  and  the  lack
of  evaluation  of  CBT  for  anxiety  disorders,  including  parent-only
approaches, amongst children with intellectual disabilities remains
a considerable limitation.

It  is  important  to  note  that  we  conducted  separate  analyses  for
different diagnostic and child/parent report measures; this meant
that  given  the  high  levels  of  inconsistency  in  measures  used  and
how  they  were  reported,  only  a  subset  of  studies  were  included
in  any  one  analysis.  The  most  consistent  diagnostic  outcome
measure was remission of the primary diagnosis (included in about
two-thirds of the CBT versus waitlist/no treatment comparisons),
whereas  less  than  half  of  the  studies  reported  remission  of  all
anxiety disorder diagnoses. Some studies did not report remission
of anxiety disorders in either of these ways, instead, for example,
reporting  remission  from  particular  groups  of  diagnoses,  or
changes  in  the  total  number  of  different  diagnoses.  As  a  result,
these  studies  were  not  included  in  our  analyses  of  diagnostic
outcomes. Similarly, relevant studies were identified that did not

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

41

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

provide data on any of the target outcomes and were therefore not
included in the review (e.g. Baer 2005; Flatt 2010; NCT00576719).

Encouragingly,  the  evidence  of  the  acceptability  of  CBT  was
consistent across comparisons, with no difference in the number
of  CBT  participants  retained  to  post-treatment  assessments
compared to each of the control groups. However, it is important to
acknowledge that rates of attrition may in part reflect acceptability
of the research process, and alternative measures of acceptability
(e.g. participant perceptions of the intervention) were not assessed
in this review.

As in previous Cochrane Reviews of CBT for child anxiety disorders,
the number of follow-up studies remains very limited (four studies
reported  on  our  primary  outcome  at  follow-up  assessments),
making it difficult to draw conclusions about the medium- to long-
term benefits of CBT. The available findings from controlled studies
suggest  that  there  is  evidence  that  CBT  provides  an  advantage
over waitlist/no treatment six months after treatment, but there is
currently  no  evidence  to  support  longer-term  benefits.  However,
the  recent  Child/Adolescent  Anxiety  Multimodal  Study  (CAMS)
highlights  the  importance  of  controlled  outcome  data  at  longer-
term  follow-up,  based  on  their  findings  that  over  two-thirds  of
patients  that  showed  initial  treatment  gains  relapsed  over  the
following four years (Ginsburg 2018).

A  major  weakness  found  across  studies  was  the  absence  of
systematic  reporting  of  adverse  effects.  No  adverse  effects  were
reported across all studies; however, in the small number of studies
where any reference was made to adverse effects, it was not clear
that these were systematically monitored. This issue is not limited
to trials of CBT for child anxiety disorders; for example, Duggan 2014
reported that none of the 72 trials of psychological interventions
considered  in  their  systematic  review  mentioned  the  occurrence
of adverse events in their final report, despite the recognition that
psychological treatments can introduce a range of negative effects
(Barlow 2010).

Given the limited data for treatment as usual, attention control, and
alternative treatment comparisons, not all analyses were possible
across all comparisons, and many of our subgroup analyses were
limited to waitlist/no treatment comparisons.

Quality of the evidence

This review included 87 studies in the quantitative synthesis, with
a  reasonably  large  number  of  study  participants  (n=  5964).  As
noted  above,  we  distinguished  between  baseline  and  outcome
measures using tight criteria in order to ensure we were comparing
like  with  like  as  far  as  possible.  For  example,  we  distinguished
between remission in the primary anxiety disorder and remission
of all anxiety disorders, and selected symptom measures that were
most consistently reported, prioritising measures of broad anxiety
symptoms where possible.

We rated evidence as moderate or low quality across comparisons
and  outcomes.  There  was  consistent  evidence  for  the  benefit  of
CBT compared to waitlist/no treatment controls, but with moderate
to  substantial  heterogeneity  across  outcomes,  reducing  certainty
in  the  results.  We  assessed  the  evidence  for  CBT  compared  to
treatment as usual, attention controls, and alternative treatments
mostly  as  low  quality,  primarily  due  to  the  limited  amount  of
available data.

Cochrane Database of Systematic Reviews

We noted methodological shortcomings in some studies, although
this typically reflected inadequate reporting, rather than evidence
of  high  risk  of  bias,  and  was  more  common  amongst  older
studies.  Participant  blinding  is  not  possible  in  research  on
psychological interventions, which is an obvious potential source
of bias; however, the evaluations were typically carried out blind.
Nonetheless, we found similar outcomes when we removed studies
with weaknesses related to allocation and blinding, supporting the
robustness of the results.

Given  the  increase  in  number  of  studies  available  since  previous
reviews,  we  took  the  opportunity  for  a  stricter  approach  to
our  inclusion  criteria.  We  only  included  studies  with  robust
randomisation procedures, and excluded studies included in other
reviews  where,  for  example,  children  who  might  be  considered
at  risk  were  automatically  enrolled  in  the  intervention  arm  (e.g.
Nauta  2003).  However,  we  did  include  studies  where  assessment
points differed between treatment arms, and, in some cases, the
period between randomisation and assessment was twice as long
in the intervention arm compared to the control arm (e.g. Fujii 2013;
Kendall 1994; Kendall 1997), which clearly introduces the potential
for substantial bias. The timing of the post-treatment assessment
(the  assessment  closest  to  the  end  of  the  treatment)  also  varied
across trials.

There  was  evidence  of  publication  bias  (asymmetric  funnel  plot,
significant  Egger’s  test  and  contour  funnel  plot),  with  a  marked
absence of non-significant studies for both CBT versus waitlist/no
treatment controls. This is an area that has been richly debated, and
remains a significant area of concern when interpreting the results
of  meta-analyses,  as  it  is  likely  that,  with  the  lack  of  published
negative trials, any estimate of the effectiveness of an intervention
(CBT in this case) is likely to be inflated. We welcome the call for
journals to publish negative trials, and for chief investigators of all
registered trials to publish findings, especially negative ones, online
within a set time of the trial end date.

Potential biases in the review process

We  were  able  to  obtain  all  the  referenced  papers;  we  searched
grey literature and reference lists; and made contact with leading
researchers  in  the  field.  We  also  included  studies  that  were  not
in  the  English  language.  However,  meta-analyses  are  limited  by
the  robustness  of  any  search  method.  The  electronic  search  was
thorough  and  large  in  scale  with  broad  parameters.  Of  note,  we
broadened certain parameters since the last Cochrane Review on
this  topic,  for  example  removing  a  restriction  on  the  minimum
number  of  sessions,  minimum  child  age,  and  including  CBT
delivered via parents. Nonetheless, there are some limitations to
the  review.  For  example,  whilst  we  set  a  fairly  broad  definition
of  ‘cognitive  behaviour  therapy’,  some  studies  were  excluded
where  the  description  of  the  intervention  did  not  include  all  the
core stated components of CBT despite the treatments appearing
similar in many ways (e.g. social effectiveness therapy; Beidel 2000;
Beidel  2007;  behaviour  therapy;  Rudy  2017;  Storch  2019),  and  it
is  possible  that  the  brief  descriptions  of  treatments  provided  in
papers may not fully reflect how the treatment is being delivered
in  practice.  We  also  required  some  in-person  treatment  delivery,
and  therefore  did  not  include  CBT  interventions  delivered  online
or  purely  over  the  telephone,  despite  these  interventions  often
being very similar in content. Indeed there is evidence supporting
the  effectiveness  of  these  remotely  delivered  approaches  (e.g.
Lyneham 2006; Pennant 2015).

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

42

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

The analysis of studies with three arms - CBT in two formats versus
waiting  list  controls  or  active  controls  -  is  problematic  in  that
double counting of any group is wrong. We chose a conservative
approach  to  managing  this  by  splitting  the  control  samples  into
two  equal  halves  between  the  CBT  groups;  however,  this  means
that  in  these  cases  the  odds  ratios  and  confidence  intervals
appear  smaller  despite  recovery  rates  that  are  similar  to  those
found  in  other  studies  (e.g.  Flannery  Schroeder  2000;  Thirlwall
2013). We also prioritised ITT analyses and adopted a conservative
approach  in  which  drop  out  in  the  treatment  group  was  treated
as  if  the  participant  did  not  recover,  but  drop  out  in  the  control
group  was  treated  as  recovery.  This  conservative  approach  may
have underestimated treatment effects; unsurprisingly, treatment
effects  were  larger  in  the  follow-up  completer  analyses.  Whilst
we  took  a  strict  approach  to  measures  that  were  included  (only
using specific measures of anxiety symptoms and not, for example,
combined  measures  of  emotional  and  behavioural  symptoms),
and  prioritised  broad measures of anxiety symptoms to promote
consistency, this may have come at a disadvantage for studies that
focused on treating specific disorders, where only a subset of the
items on a broad measure might apply to the target of treatment.

Agreements and disagreements with other studies or
reviews

Two  previous  Cochrane  Reviews  have  been  conducted  on  this
topic.  The  first  review  identified  18  studies  with  498  participants
and 311 controls, and found a response rate for remission of any
measure of anxiety diagnosis using an ITT analysis of 56% for CBT
versus 28.2% for controls with the NNTB of 3.0 (95% CI 2.5 to 4.5)
(James  2005).  The  second  review  identified  41  studies  with  1806
participants,  with  a  rate  of  remission  of  any  measure  of  anxiety
disorder  of  58.9%  for  CBT  versus  16%  for  the  waitlist  (James
2015).  In  the  current  review,  we  identified  a  further  substantial
increase in studies, including 81 studies with 5964 participants. We
made a number of changes, most notably distinguishing between
remission  of  the  primary  anxiety  disorder  and  remission  of  all
anxiety  disorders;  however,  the  findings  were  fairly  consistent,
with  49.4%  of  participants  being  free  of  their  primary  anxiety
disorder  following  CBT  (versus  17.8%  for  waitlist  controls),  and
46.8% being free of all anxiety disorders (versus 19.1% for waitlist
controls). It is important to note that studies presenting remission
based on primary diagnosis and all anxiety diagnoses only partly
overlapped, so these outcomes should not be compared directly.
Despite  the  differences  in  outcome  measures,  and  our  broader
inclusion criteria for CBT formats, length, and participant ages, the
NNTB has been consistent at NNTB = 3 across all three Cochrane
Reviews.  These  effects  are  consistent  with  other  meta-analyses
of  CBT  for  anxiety  disorders  in  children  and  young  people  (e.g.
Cartwright-Hatton 2004; Compton 2004; Reynolds 2012; Seligman
2011; Silverman 2008; Wang 2017; Warwick 2016).

Our findings are also consistent with previous reviews in terms of
the limited available data for comparisons with treatment as usual/
alternative  treatments  (e.g.  Wang  2017).  Indeed,  like  others,  we
have  concluded  that  there  is  no  clear  evidence  of  an  advantage
of CBT over treatment as usual or treatments that might credibly
be used within mental health settings. However, we did find more
consistent evidence of an advantage of CBT over attention controls,
although the available data are still limited.

However, our conclusions differed from those of a recent network
meta-analysis of psychotherapies for anxiety disorders in children

Cochrane Database of Systematic Reviews

and  young  people,  which  concluded  that  group  CBT  was  more
effective  that  other  forms  of  psychotherapy  (including  other
CBT  formats  included  in  this  review)  (Zhou  2019).  Notably,  this
network  meta-analysis  considered  outcomes  based  on  symptom
questionnaires  (prioritising  child  self-report).  Indeed,  when  we
consider  our  subgroup  analyses,  amongst  waitlist/no  treatment
comparisons,  we  also  found  stronger  effects  of  group  CBT  than
individual  CBT  on  child-  and  parent-reported  anxiety  symptoms;
however  we  did  not  find  significant  differences  between  these
subgroups  based  on  our  primary  outcome  (remission  of  primary
anxiety  diagnosis)  or  on  our  other  diagnostic  outcome  (free
of  all  anxiety  diagnoses).  Furthermore,  studies  that  differed  in
terms  of  treatment  delivery  format  also  differed  on  a  number
of  other  characteristics  that  would  likely  be  associated  with
outcome  (including  differences  in  the  study  setting,  population,
and  nature  of  outcome  measures).  For  example,  most  (5  out  of
7) studies that only reported disorder-specific symptom measures
were  studies  that  evaluated  treatments  delivered  in  groups,  so
differences between group versus individual formats may reflect a
measurement issue rather than a true difference in effect sizes. As
such, we do not feel that the evidence provides clear and consistent
support  for  group  CBT  having  an  advantage  over  other  delivery
formats.

The same conclusion applies to treatment delivery with children,
children and parents, or parents alone. Like previous reviews (e.g.
Breinholst 2012; Reynolds 2012; Silverman 2008), we did not find
clear  evidence  of  an  advantage  of  any  of  these  delivery  formats.
Although  we  found  the  strongest  effects  for  child-focused  CBT
among waitlist/no treatment comparisons, there was considerable
variation  in  findings  amongst  child-focused  CBT  studies,  and  the
treatment delivery subgroups also often differed on other key study
and  sample  characteristics  (e.g.  child  age,  setting,  comorbidities,
treatment duration). Notably, there were relatively few studies that
delivered treatment through parents only, and these tended to be
more  recent  studies  and  included  children  of  younger  ages  than
studies that took a child-only or child-and-parent approach.

Where  there  were  sufficient  studies,  we  generally  found  fairly
consistent  findings  regardless  of  whether  children  in  the  studies
had  ASD  or  not,  supporting  the  evidence  from  previous  meta-
analyses  suggesting  that  CBT  can  be  an  effective  treatment  of
anxiety for children with ASD (e.g. Perihan 2019; Ung 2015). Notably,
recent  reviews  have  suggested  that  parental  involvement  may
be particularly important for treating childhood anxiety disorders
in  the  context  of  ASD,  and  that  longer-term  interventions  were
associated with larger effects (Perihan 2019). These questions are
beyond the scope of the current review; however, it is noteworthy
that neither of these sets of findings were replicated in our broader
sample, highlighting the need to consider the specific conditions
that  are  needed  to  optimise  CBT  approaches  amongst  particular
subgroups of children and young people with anxiety disorders.

A U T H O R S '   C O N C L U S I O N S

Implications for practice

This  review  reinforces  conclusions  from  previous  reviews  finding
moderate-quality  evidence  that  cognitive  behavioural  therapy
(CBT)  is  more  effective  in  improving  diagnostic  outcomes  in  the
short  term  than  a  waiting  list  or  no  treatment.  The  advantage  of
CBT  compared  to  waitlist/no  treatment  is  evident  across  a  range
of  other  short-term  outcomes,  although  variation  in  findings  or

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

43

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

limited available data, or both, reduces certainty in these results.
Clear and consistent evidence of differences between the formats
of individual, group, and parent/family CBT continues to be lacking.
Available, low-quality evidence supports a benefit of CBT compared
to  attention  control,  but  the  evidence  base  remains  small,  and
there continues to be insufficient and inclusive evidence that CBT
is superior to either treatment as usual or alternative treatments.

Pharmacological interventions are typically not recommended as
a first-line treatment due to patient preference (e.g. Brown 2007),
relative high rates of attrition, and concerns about potential side
effects  (Wang  2017).  However,  we  know  very  little  about  the
comparative  efficacy  of  pharmacological  interventions  and  CBT,
with  evidence  still  limited  to  one,  albeit  large,  multicentre  study
(Walkup  2008).  Clearly  further  work  is  needed  to  guide  practice
about  the  circumstances  in  which  pharmacological  approaches
might be most acceptable and effective for the treatment of anxiety
disorders in children and young people.

A  major  challenge  for  clinical  practice  is  the  very  limited  access
that  children  with  anxiety  disorders  have  to  evidence-based
psychological  interventions,  such  as  CBT.  In  a  recent  study,  only
2% of children with anxiety disorders identified in the community
in  England  had  received  CBT  (Reardon  2020).  These  findings  are
consistent  with  previous  studies  indicating  low  rates  of  service
use  in  the  UK,  Australia,  and  the  USA  (Green  2004;  Lawrence
2015;  Merikangas  2011).  Of  importance  to  this  clinical  challenge
is our finding that there is currently no evidence of differences in
outcome on the basis of therapist contact time, with similar effects
being  achieved  when  therapists  provided  less  than  10  hours  of
clinical  contact  compared  to  higher  amounts  of  clinical  contact
in  terms  of  remission  of  the  primary  anxiety  disorder  and  child-
and parent-reported anxiety symptoms. Notably, results were less
strong  in  terms  of  remission  of  all  anxiety  disorders;  however,
there is evidence to suggest that benefits might generalise to other
disorders beyond the end of (brief) treatment (e.g. Ollendick 2010).
These findings indicate that access could be improved through the
provision  of  stepped-care  models  of  treatment  delivery  in  which
relatively  brief  interventions  are  offered  as  a  first-line  approach,
and  more  intensive  interventions  are  saved  for  those  who  need
them (Bower 2005). A recent systematic evaluation of stepped-care
treatment for child anxiety disorders provided promising evidence
for a benefit of a stepped-care approach in terms of clinical time
saved and reduced societal costs (Chatterton 2019).

Implications for research

There is now sufficient evidence to conclude that CBT is an effective
treatment for anxiety disorders in children and young people when
compared to waiting lists/no treatment.

A  number  of  reviews  have  concluded  that  overall  about  50%  of
children  and  young  people  recover  from  their  primary  anxiety
disorder  following  a  course  of  CBT,  but  still  very  little  is  known
about how these outcomes can be improved and what the other
50%  of  patients  need.  A  better  understanding  of  what  the  core
mechanisms  of  effective  interventions  are  and  how  this  varies
according  to  individual  characteristics  or  contexts  is  needed.  For
example,  currently  very  little  is  known  about  how  treatments
should best be delivered according to child age and developmental
status, the presence of comorbid conditions, or the nature of the
anxiety disorders experienced. Almost three-quarters of the studies
in  this  review  included  children  with  a  broad  range  of  anxiety

Cochrane Database of Systematic Reviews

disorders, and those that focused on specific disorders were spread
across  studies  of,  for  example,  social  anxiety  disorder,  selective
mutism, panic disorder, generalised anxiety disorder, and specific
phobia, thereby limiting our ability to draw firm conclusions about
any particular approach for any particular disorder, let alone how
that might vary according to, for example, child age. Larger studies
that are sufficiently powered to examine predictors, mediators, and
moderators of treatment outcomes are now needed to identify how
to  improve  treatment  outcomes  and  develop  more  personalised
models of care.

Individual  patient  data  meta-analyses  may  be  useful  to  help  us
better  understand  the  extensive  heterogeneity  between  study
outcomes; however, meaningful conclusions will rely on clear and
consistent  reporting  across  studies  so  that  data  can  be  linked
in  sensible  ways.  In  this  review  we  focused  on  remission  of  the
primary and all anxiety diagnoses, but a number of studies were
excluded from these analyses as they reported other kinds of data
from diagnostic assessments. This issue was highlighted in a recent
position  paper  which  set  out  a  number  of  recommendations  for
reporting  and  terminology  to  promote  greater  consistency  going
forwards  (Creswell  2020a).  It  is  important  to  note  a  number  of
other  areas  where  the  field  would  benefit  from  greater  clarity
and  consistency  in  reporting  by  researchers.  For  example,  in
treatment as usual studies, it was not always clear what 'treatment
as  usual'  actually  consisted  of  and  to  what  extent  it  differed
from  the  index  treatment  or  a  no  treatment  control.  Indeed,
categorising  the  format  of  any  treatment  typically  relied  on  only
a brief description, which may have led to faulty conclusions. We
encourage researchers to make good use of online supplementary
materials to ensure clear descriptions of the content and format of
interventions, using consistent terminology (Creswell 2020a).

There  continues  to  be  a  lack  of  evidence  that  CBT  is  superior
to  other  credible  alternative  treatments,  so  it  will  be  essential
to  identify  what  the  core  components  of  effective  treatments
are, for example through experimental and treatment dismantling
studies (e.g. Whiteside 2015), so that outcomes can be optimised
and  treatments  can  be  targeted  to  maximise  their  efficiency.
Head-to-head  comparisons  of  different  active  (and  credible)
interventions  will  be  required,  but  these  will  inevitably  require
larger  sample  sizes,  as  they  will  need  to  be  set  up  to  detect
smaller  effects  than  those  found  with  waitlist/no  treatment
comparisons;  however,  these  designs  will  also  enable  studies
to  compare  longer-term  outcomes  between  groups.  Given  the
risks for longer-term adjustment of anxiety disorders in childhood
and  adolescence,  controlled  studies  with  longer-term  outcomes
are  essential  to  ensure  that  children’s  life  trajectories  are  being
optimally supported through early intervention.

As  noted  above,  increasing  access  to  effective  treatments  is
an  urgent  challenge  for  our  field,  and  it  will  be  essential  that
studies  consider  accessibility  of  treatment  and  cost-effectiveness
going  forwards.  We  did  not  consider  outcomes  in  terms  of  cost-
effectiveness  in  this  review;  however,  it  is  clear  that  to  date
very few studies have taken cost-effectiveness into account when
evaluating  CBT  for  child  anxiety  disorders.  We  anticipate  that
cost-effectiveness  data  will  have  a  marked  impact  on  the  clinical
implications  that  can  be  drawn  from  the  available  evidence,
particularly  given  our  finding  that  clinician  contact  time  did  not
seem  to  be  related  to  treatment  outcome.  Equally,  it  is  often
assumed  that  group  treatments  may  be  cost-effective;  however,

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

44

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

this has not been supported when evaluated in other contexts (e.g.
Mavranezouli 2015), and some of the group treatments identified in
this review involved very high levels of therapist involvement and
supported activities. Future studies would benefit from including a
cost-effectiveness analysis, and considering the costs and benefits
to  both  the  health  service  and  broader  society  including  costs
related  to  the  child  themselves  and  family  members,  whose
work  and  home  lives  are  often  heavily  impacted  by  child  anxiety
problems (e.g. Bodden 2008b).

Finally,  it  was  disappointing  to  see  that,  whilst  the  number  of
trials evaluating CBT for childhood anxiety disorders has increased
substantially,  these  have  not  extended  to  children  in  low-  or
middle-income countries, children with intellectual disabilities or
physical health conditions, the most severely affected children in
inpatient  settings,  and  there  are  still  very  few  studies  that  have
focused specifically on either young children or (strikingly given the
prevalence of anxiety disorders) adolescents.

the  University  of  Reading,  and  the  University  of  Oxford  provided
support to the review authors to complete this review.

We  are  extremely  grateful  to  the  Cochrane  Common  Mental
Disorders  Group  (CCMD)  for  their  guidance,  and  in  particular  to
Sarah Dawson (CCMD Information Specialist) for her input.

The authors and the Cochrane Common Mental Disorders Editorial
Team  are  grateful  to  the  protocol  peer  reviewers  and  Copy  Edit
Support  for  their  time  and  comments.  Peer  reviewers  included:
Georgina Cox, Lina Gega, David Marshall, Ruth Simmonds, and Gill
Worthy.

Cochrane review group funding acknowledgement: the NIHR is the
largest single funder of Cochrane Common Mental Disorders.

Disclaimer: the views expressed are those of the author(s) and not
necessarily those of the NHS, the NIHR, or the Department of Health
and Social Care.

A C K N O W L E D G E M E N T S

Oxford  Health  Foundation  NHS  Trust,  Guy’s  and  St  Thomas’  NHS
Foundation  Trust,  National  Institute  for  Health  Research  (NIHR),

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

45

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

R E F E R E N C E S

References to studies included in this review

Afshari 2014 {published data only (unpublished sought but not
used)}

Afshari A, Neshat-Doost HT, Maracy M, Ahmady MK, Amiri S.
The effective comparison between emotion-focused cognitive
behavioral group therapy and cognitive behavioral group
therapy in children with separation anxiety disorder. Journal of
Research in Medical Sciences 2014;19(3):221-7.

Arendt 2016 {published data only (unpublished sought but not
used)}

Arendt K, Thastum M, Hougaard E. Efficacy of a Danish version
of the Cool Kids program: a randomized wait-list controlled
trial. Acta Psychiatrica Scandinavica 2016;133(2):109-21. [DOI:
10.1111/acps.12448]

Barrett 1996 {published data only (unpublished sought but not
used)}

Barrett PM, Dadds MR, Rapee RM. Family treatment of
childhood anxiety: a controlled trial. Journal of Consulting and
Clinical Psychology 1996;64(2):333-42.

Barrett 1998 {published data only (unpublished sought but not
used)}

Barrett PM. Evaluation of cognitive-behavioral group
treatments for childhood anxiety disorders. Journal of
Clinical Child Psychology 1998;27(4):459-68. [DOI: 10.1207/
s15374424jccp2704_10]

Barrington 2005 {published data only (unpublished sought but not
used)}

Barrington J, Prior M, Richardson M, Allen K. Effectiveness
of CBT versus standard treatment for childhood anxiety
disorders in a community clinic setting. Behaviour Change
2005;22(1):29-43. [DOI: 10.1375/bech.22.1.29.66786]

Berge 2017 {published data only}

* 
ZZZ <label> ZZZ*
Berge KG, Agdal ML, Vika M, Skeie MS. Treatment of intra-
oral injection phobia: a randomized delayed intervention
controlled trial among Norwegian 10- to 16-year-olds.
Acta Odontologica Scandinavica 2017;75(4):294-301. [DOI:
10.1080/00016357.2017.1297849]

NCT02083432. Cognitive behavioural treatment of intra-oral
Injection-phobia in 10-16 year old children and adolescents.
clinicaltrials.gov/show/nct02083432 (first received 11 March
2014).

Cartwright Hatton 2011 {published data only (unpublished sought
but not used)}

Cartwright-Hatton S, McNally D, Field AP, Rust S, Laskey B,
Dixon B, et al. A new parenting-based group intervention for
young anxious children: results of a randomized controlled
trial. Journal of the American Academy of Child and Adolescent
Psychiatry 2011;50(3):242-51. [10.1016/j.jaac.2010.12.015 ]

Chalfant 2007 {published data only (unpublished sought but not
used)}

Chalfant AM, Rapee R, Carroll L. Treating anxiety disorders in
children with high functioning autism spectrum disorders: a
controlled trial. Journal of Autism and Developmental Disorders
2007;37(10):1842-57. [DOI: 10.1007/s10803-006-0318-4]

Cheung 2016 {published data only}

Cheung MC. Effectiveness of Attention Bias Modification
Treatment for Children With Social Anxiety Problem [Thesis].
Pokfulam, Hong Kong: The University of Hong Kong, 2016.
[hub.hku.hk/handle/10722/239961]

Chiu 2013 {published data only (unpublished sought but not used)}

* 
ZZZ <label> ZZZ*
Chiu AW, Langer DA, McLeod BD, Har K, Drahota A, Galla BM, et
al. Effectiveness of modular CBT for child anxiety in elementary
schools. School Psychology Quarterly 2013;28(2):141-53. [DOI:
10.1037/spq0000017]

NCT00569829. Modular cognitive behavioral therapy for the
treatment of child anxiety disorders in elementary school
settings. clinicaltrials.gov/show/nct00569829 (first received 7
December 2007).

Cobham 2017 {published data only}

Cobham VE, Filus A, Sanders MR. Working with parents to
treat anxiety-disordered children: a proof of concept RCT
evaluating Fear-less Triple P. Behaviour Research and Therapy
2017;95:128-38. [DOI: 10.1016/j.brat.2017.06.004]

Cornacchio 2019 {published data only (unpublished sought but not
used)}

* 
ZZZ <label> ZZZ*
Cornacchio D, Furr JM, Sanchez AL, Hong N, Feinberg LK,
Tenenbaum R, et al. Intensive group behavioral treatment
(IGBT) for children with selective mutism: a preliminary
randomized clinical trial. Journal of Consulting and Clinical
Psychology 2019;87(8):720-33. [DOI: 10.1037/ccp0000422]

NCT03612102. Evaluating intensive group behavioral treatment
for children with selective mutism. clinicaltrials.gov/show/
nct03612102 (first received 2 August 2018).

Creswell 2017 {published and unpublished data}

* 
ZZZ <label> ZZZ*
Creswell C, Violato M, Fairbanks H, White E, Parkinson M,
Abitabile G, et al. Clinical outcomes and cost-effectiveness
of brief guided parent-delivered cognitive behavioural
therapy and solution-focused brief therapy for treatment
of childhood anxiety disorders: a randomised controlled
trial. Lancet Psychiatry 2017;4(7):529-39. [DOI: 10.1016/
S2215-0366(17)30149-9]

ISRCTN07627865. Guided self-help for childhood anxiety
problems: a comparison with usual care. www.isrctn.com/
ISRCTN07627865 (first received 13 March 2012).

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

46

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Dadds 1997 {published and unpublished data}

Dadds MR, Holland DE, Laurens KR, Mullins M, Barrett PM,
Spence SH. Early intervention and prevention of anxiety
disorders in children: results at 2-year follow-up. Journal of
Consulting and Clinical Psychology 1999;67(1):145-50.

* 
ZZZ <label> ZZZ*
Dadds MR, Spence SH, Holland DE, Barrett PM, Laurens KR.
Prevention and early intervention for anxiety disorders: a
controlled trial. Journal of Consulting and Clinical Psychology
1997;65(4):627-35.

Flannery Schroeder 2000 {published data only (unpublished
sought but not used)}

* 
ZZZ <label> ZZZ*
Flannery-Schroeder EC, Kendall PC. Group and individual
cognitive-behavioral treatments for youth with anxiety
disorders: a randomized clinical trial. Cognitive Therapy and
Research 2000;24(3):251-78. [DOI: 10.1023/A:1005500219286]

Fujii 2013 {published data only (unpublished sought but not used)}

Fujii C, Renno P, McLeod BD, Lin CE, Decker K, Zielinski K, et al.
Intensive cognitive behavioral therapy for anxiety disorders in
school-aged children with autism: a preliminary comparison
with treatment-as-usual. School Mental Health 2013;5(1):25-37.
[DOI: 10.1007/s12310-012-9090-0]

Gallagher 2004 {published data only (unpublished sought but not
used)}

* 
ZZZ <label> ZZZ*
Gallagher HM, Rabian BA, McCloskey MS. A brief group
cognitive-behavioral intervention for social phobia in
childhood. Journal of Anxiety Disorders 2004;18(4):459-79. [DOI:
10.1016/S0887-6185(03)00027-6]

Ginsburg 2002 {published data only}

Ginsburg GS, Drake KL. School-based treatment for anxious
African-American adolescents: a controlled pilot study. Journal
of the American Academy of Child and Adolescent Psychiatry
2002;41(7):768-75. [DOI: 10.1097/00004583-200207000-00007]

Ginsburg 2012 {published data only (unpublished sought but not
used)}

* 
ZZZ <label> ZZZ*
Ginsburg GS, Becker KD, Drazdowski TK, Tein J. Treating anxiety
disorders in inner city schools: results from a pilot randomized
controlled trial comparing CBT and usual care. Child and Youth
Care Forum 2012;41(1):1-19. [DOI: 10.1007/s10566-011-9156-4 ]

NCT00536094. School-based treatment for anxious children.
clinicaltrials.gov/show/nct00536094 (first received 27
September 2007).

Ginsburg 2019a {published data only (unpublished sought but not
used)}

* 
ZZZ <label> ZZZ*

Cochrane Database of Systematic Reviews

Ginsburg GS, Pella JE, Pikulski PJ, Tein JY, Drake KL. School-
Based Treatment for Anxiety Research Study (STARS):
a randomized controlled effectiveness trial. Journal of
Abnormal Child Psychology 2019;48(3):407-17. [10.1007/
s10802-019-00596-5 ]

NCT01761396. School-based Treatment of Anxiety Research
Study (STARS). clinicaltrials.gov/show/nct01761396 (first
received 4 January 2013).

Hancock 2018 {published data only (unpublished sought but not
used)}

ACTRN12611001280998. Efficacy of acceptance-
mindfulness therapy in children with anxiety: a
controlled trial. www.who.int/trialsearch/Trial2.aspx?
TrialID=ACTRN12611001280998 (first received 13 December
2011).

* 
ZZZ <label> ZZZ*
Hancock KM, Swain J, Hainsworth CJ, Dixon AL, Koo S,
Munro K. Acceptance and commitment therapy versus
cognitive behavior therapy for children with anxiety:
outcomes of a randomized controlled trial. Journal of Clinical
Child and Adolescent Psychology 2018;47(2):296-311. [DOI:
10.1080/15374416.2015.1110822]

Swain J, Hancock K, Dixon A, Koo S, Bowman J. Acceptance and
commitment therapy for anxious children and adolescents:
study protocol for a randomized controlled trial. Trials
2013;14:140. [DOI: 10.1186/1745-6215-14-140]

Swain J, Hancock K, Hainsworth C, Bowman J. Mechanisms of
change: exploratory outcomes from a randomised controlled
trial of acceptance and commitment therapy for anxious
adolescents. Journal of Contextual Behavioral Science
2015;4(1):56-67. [DOI: 10.1016/j.jcbs.2014.09.001]

Herbert 2009 {published data only (unpublished sought but not
used)}

Herbert JD, Gaudiano BA, Rheingold AA, Moitra E, Myers VH,
Dalrymple KL, et al. Cognitive behavior therapy for generalized
social anxiety disorder in adolescents: a randomized controlled
trial. Journal of Anxiety Disorders 2009;23(2):167-77. [DOI:
10.1016/j.janxdis.2008.06.004]

Hirshfeld Becker 2010 {published and unpublished data}

* 
ZZZ <label> ZZZ*
Hirshfeld-Becker DR, Masek B, Henin A, Blakely LR, Pollock-
Wurman RA, McQuade J, et al. Cognitive behavioural therapy for
4- to 7-year old children with anxiety disorders: a randomized
clinical trial. Journal of Consulting and Clinical Psychology
2010;78(4):498-510. [DOI: 10.1037/a0019055]

NCT00865306. Early intervention for children at risk for anxiety.
clinicaltrials.gov/show/nct00865306 (first received 19 March
2009).

Holmes 2014 {published data only (unpublished sought but not
used)}

Holmes MC, Donovan CL, Farrell LJ, March S. The efficacy
of a group-based, disorder-specific treatment program for

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

47

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

childhood GAD - a randomized controlled trial. Behaviour
Research and Therapy 2014;61:122-35. [DOI: 10.1016/
j.brat.2014.08.002]

and temperament. Journal of the American Academy of Child
and Adolescent Psychiatry 2009;48(6):602-9. [DOI: 10.1097/
CHI.0b013e31819f6fa9]

Hudson 2009 {published data only}

Hudson JL, Rapee RM, Deveney C, Schniering CA, Lyneham HJ,
Bovopoulos N. Cognitive-behavioral treatment versus an active
control for children and adolescents with anxiety disorders:
a randomized trial. Journal of the American Academy of Child
and Adolescent Psychiatry 2009;48(5):533-44. [DOI: 10.1097/
CHI.0b013e31819c2401]

Ingul 2013 {published data only}

Ingul JM, Aune T, Nordahl HM. A randomized controlled trial
of individual cognitive therapy, group cognitive behaviour
therapy and attentional placebo for adolescent social phobia.
Psychotherapy and Psychosomatics 2013;83(1):54-61. [DOI:
10.1159/000354672]

Ishikawa 2019 {published data only}

Ishikawa S, Kikuta K, Sakai M, Mitamura T, Motomura N,
Hudson JL. A randomized controlled trial of a bidirectional
cultural adaptation of cognitive behavior therapy for children
and adolescents with anxiety disorders. Behaviour Research and
Therapy 2019;120:103432. [DOI: 10.1016/j.brat.2019.103432]

Kendall 1994 {published and unpublished data}

Kendall PC. Treating anxiety disorders in youth: results of a
randomized clinical trial. Journal of Consulting and Clinical
Psychology 1994;62(1):100-10.

Kendall 1997 {published data only (unpublished sought but not
used)}

Kendall PC, Flannery-Schroeder E, Panichelli-Mindel SM,
Southam-Gerow M, Henin A, Warman M. Therapy for youths
with anxiety disorders: a second randomized clinical trial.
Journal of Consulting and Clinical Psychology 1997;65(3):366-80.

Kendall 2008 {published and unpublished data}

* 
ZZZ <label> ZZZ*
Kendall PC, Hudson JL, Gosch E, Flannery-Schroeder E,
Suveg C. Cognitive-behavioral therapy for anxiety disordered
youth: a randomized clinical trial evaluating child and family
modalities. Journal of Consulting and Clinical Psychology
2008;76(2):282-97. [DOI: 10.1037/0022-006X.76.2.282]

NCT00081406. Individual and family therapy for children with
anxiety disorders. clinicaltrials.gov/show/nct00081406 (first
received 12 April 2004).

Suveg CH, Hudson JL, Brewer G, Flannery-Schroeder E, Gosch E,
Kendall PC. Cognitive-behavioral therapy for anxiety-disordered
youth: secondary outcomes from a randomized clinical trial
evaluating child and family modalities. Journal of Anxiety
Disorders 2009;23(3):341-9. [DOI: 10.1016/j.janxdis.2009.01.003]

Kennedy 2009 {published data only (unpublished sought but not
used)}

Kennedy SJ, Rapee RM, Edwards SL. A selective intervention
program for inhibited preschool-aged children of parents
with an anxiety disorder: effects on current anxiety disorders

Khanna 2010 {published data only (unpublished sought but not
used)}

Khanna MS, Kendall PC. Computer-assisted cognitive behavioral
therapy for child anxiety: results of a randomized clinical trial.
Journal of Consulting and Clinical Psychology 2010;78(5):737-45.
[DOI: 10.1037/a0019739]

Kidd 2018 {published data only}

ACTRN12610001014044. Assessing the efficacy and social
validity of a manualised, family-based group Cognitive
Behavioural Therapy for adolescents with high-functioning
autism and comorbid anxiety disorder. www.who.int/
trialsearch/Trial2.aspx?TrialID=ACTRN12610001014044 (first
received 19 November 2010).

* 
ZZZ <label> ZZZ*
Kidd TC. Treating Anxiety in Adolescents With Autism
Spectrum Disorder Using Group Cognitive Behaviour
Therapy: A Randomised Controlled Trial [Doctoral
thesis]. Perth, Western Australia: Curtin University, 2018.
[hdl.handle.net/20.500.11937/73526]

Last 1998 {published data only}

Last CG, Hansen C, Franco N. Cognitive-behavioral treatment
of school phobia. Journal of the American Academy of
Child and Adolescent Psychiatry 1998;37(4):404-11. [DOI:
10.1097/00004583-199804000-00018]

Lau 2010 {published and unpublished data}

Lau WY, Chan CK, Li JC, Au TK. Effectiveness of group cognitive-
behavioral treatment for childhood anxiety in community
clinics. Behaviour Research and Therapy 2010;48(11):1067-77.
[DOI: 10.1016/j.brat.2010.07.007]

Lau 2017 {published data only (unpublished sought but not used)}

Lau EX, Rapee RM, Coplan RJ. Combining child social skills
training with a parent early intervention program for inhibited
preschool children. Journal of Anxiety Disorders 2017;51:32-8.
[DOI: 10.1016/j.janxdis.2017.08.007]

Lebowitz 2019 {published data only (unpublished sought but not
used)}

* 
ZZZ <label> ZZZ*
Lebowitz ER, Marin C, Martino A, Shimshoni Y, Silverman WK.
Parent-based treatment as efficacious as cognitive-behavioral
therapy for childhood anxiety: a randomized noninferiority
study of supportive parenting for anxious childhood emotions.
Journal of the American Academy of Child and Adolescent
Psychiatry 2019 Mar 7 [Epub ahead of print]. [DOI: 10.1016/
j.jaac.2019.02.014]

Lebowitz ER, Marin C, Martino A, Shimshoni Y, Silverman WK.
Parent-based treatment as efficacious as cognitive-behavioral
therapy for childhood anxiety: a randomized noninferiority
study of supportive parenting for anxious childhood emotions.

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

48

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Journal of the American Academy of Child and Adolescent
Psychiatry 2020;59(3):362-72. [DOI: 10.1016/j.jaac.2019.02.014]

McNally Keehn 2013 {published data only (unpublished sought but
not used)}

NCT02310152. Explanatory clinical trial of a novel parent
intervention for childhood anxiety (SPACE). clinicaltrials.gov/
show/nct02310152 (first received 5 December 2014).

Leutgeb 2012 {published data only}

Leutgeb V, Schienle A. Changes in facial electromyographic
activity in spider-phobic girls after psychotherapy. Journal
of Psychiatric Research 2012;46(6):805-10. [DOI: 10.1016/
j.jpsychires.2012.02.017]

Masia Warner 2005 {published data only (unpublished sought but
not used)}

Masia Warner C, Klein RG, Dent HC, Fisher PH, Alvir J,
Albano AM, et al. School-based intervention for adolescents
with social anxiety disorder: results of a controlled study.
Journal of Abnormal Child Psychology 2005;33(6):707-22. [DOI:
10.1007/s10802-005-7649-z]

Masia Warner 2007 {published data only}

Masia Warner C, Fisher PH, Shrout PE, Rathor S, Klein RG.
Treating adolescents with social anxiety disorder in school:
an attention control trial. Journal of Child Psychology and
Psychiatry and Allied Disciplines 2007;48(7):676-86. [DOI:
10.1111/j.1469-7610.2007.01737.x]

Masia Warner 2011 {published data only (unpublished sought but
not used)}

Masia Warner C, Colognori D, Kim RE, Reigada LC, Klein RG,
Browner-Elhanan KJ, et al. Cognitive-behavioral treatment
of persistent functional somatic complaints and pediatric
anxiety: an initial controlled trial. Depression and Anxiety
2011;28(7):551-9. [DOI: 10.1002/da.20821]

Masia Warner 2016 {published data only (unpublished sought but
not used)}

* 
ZZZ <label> ZZZ*
Masia Warner C, Colognori D, Brice C, Herzig K, Mufson L,
Lynch C, et al. Can school counselors deliver cognitive-
behavioral treatment for social anxiety effectively? A
randomized controlled trial. Journal of Child Psychology and
Psychiatry and Allied Disciplines 2016;57(11):1229-38. [DOI:
10.1111/jcpp.12550]

NCT01320800. CBT for social anxiety disorder delivered by
school counselors. clinicaltrials.gov/show/nct01320800 (first
received 22 March 2011).

McConachie 2014 {published data only}

ISRCTN11219568. Effective therapy for anxiety in young
people with autism spectrum disorder. www.isrctn.com/
ISRCTN11219568 (first received 12 May 2010).

McNally Keehn RH, Lincoln AJ, Brown MZ, Chavira DA. The
Coping Cat program for children with anxiety and autism
spectrum disorder: a pilot randomized controlled trial. Journal
of Autism and Developmental Disorders 2013;43(1):57-67. [DOI:
10.1007/s10803-012-1541-9]

Melfsen 2011 {published and unpublished data}

Melfsen S, Kuhnemund M, Schwieger J, Warnke A, Stadler C,
Poustka F, et al. Cognitive behavioral therapy of socially phobic
children focusing on cognition: a randomised wait-list control
study. Child and Adolescent Psychiatry and Mental Health
2011;5:ArtID2. [DOI: 10.1186/1753-2000-5-5]

Muris 2002 {published data only}

Muris P, Meesters C, van Melick M. Treatment of childhood
anxiety disorders: a preliminary comparison between cognitive-
behavioral group therapy and a psychological placebo
intervention. Journal of Behavior Therapy and Experimental
Psychiatry 2002;33(3-4):143-58.

Murphy 2017 {published data only (unpublished sought but not
used)}

Murphy SM, Chowdhury U, White SW, Reynolds L, Donald L,
Gahan H, et al. Cognitive behaviour therapy versus a
counselling intervention for anxiety in young people with high-
functioning autism spectrum disorders: a pilot randomised
controlled trial. Journal of Autism and Developmental Disorders
2017;47(11):3446-57. [DOI: 10.1007/s10803-017-3252-8]

O'Brien 2007 {published data only (unpublished sought but not
used)}

O'Brien F, Olden N, Migone M, Dooley B, Atkins L, Ganter K, et al.
Group cognitive behavioural therapy for children with anxiety
disorder - an evaluation of the 'Friends for Youth' programme.
Irish Journal of Psychological Medicine 2007;24(1):5-12.

Olivares 2005 {published and unpublished data}

Olivares J, Rosa-Alcazar AI, Piqueras JA. Early detection and
treatment of adolescents with generalized social phobia.
Psicothema 2005;17(1):1-8.

Olivares 2014 {published data only}

Olivares J, Olivares-Olivares PJ, Rosa-Alcazar AI, Montesinos L,
Macia D. The contribution of the therapist's competence in
the treatment of adolescents with generalized social phobia.
Psicothema 2014;26(4):483-9.

Olivares 2019 {published data only}

Olivares-Olivares PJ, Ortiz-González PF, Olivares J. Role
of social skills training in adolescents with social anxiety
disorder. International Journal of Clinical and Health Psychology
2019;19(1):41-8.

* 
ZZZ <label> ZZZ*
McConachie H, McLaughlin E, Grahame V, Taylor H, Honey E,
Tavernor L, et al. Group therapy for anxiety in children with
autism spectrum disorder. Autism 2014;18(6):723-32. [DOI:
10.1177/1362361313488839]

Ollendick 2009 {published data only}

Ollendick TH, Ost LG, Reuterskiold L, Costa N, Cederlund R,
Sirbu C, et al. One-session treatment of specific phobias
in youth: a randomized clinical trial in the United States
and Sweden. Journal of Consulting and Clinical Psychology
2009;77(3):504-16. [DOI: 10.1037/a0015158]

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

49

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ost 2001 {published and unpublished data}

Ost LG, Svensson L, Hellstrom K, Lindwall R. One-session
treatment of specific phobias in youths: a randomized
clinical trial. Journal of Consulting and Clinical Psychology
2001;69(5):814-24. [DOI: 10.1037/0022-006X.69.5.814]

Perrin 2019 {published data only}

ISRCTN50951795. Cognitive therapy for generalised anxiety in
youth. www.isrctn.com/ISRCTN50951795 (first received 30 June
2010).

* 
ZZZ <label> ZZZ*
Perrin S, Bevan D, Payne S, Bolton D. GAD-specific cognitive
behavioral treatment for children and adolescents: a pilot
randomized controlled trial. Cognitive Therapy and Research
2019;43(6):1051-64. [DOI: 10.1007/s10608-019-10020-3]

Pincus 2010 {published data only (unpublished sought but not
used)}

NCT00705380. Effectiveness of cognitive behavioral therapy
with panic control treatment for adolescents with panic
disorder. clinicaltrials.gov/show/nct00705380 (first received 25
June 2008).

* 
ZZZ <label> ZZZ*
Pincus DB, May JE, Whitton SW, Mattis SG, Barlow DH.
Cognitive-behavioral treatment of panic disorder in
adolescence. Journal of Clinical Child and Adolescent Psychology
2010;39(5):638-49. [DOI: 10.1080/15374416.2010.501288]

Rapee 2005 {published and unpublished data}

* 
ZZZ <label> ZZZ*
Rapee RM, Kennedy S, Ingram M, Edwards S, Sweeney L.
Prevention and early intervention of anxiety disorders
in inhibited preschool children. Journal of Consulting
and Clinical Psychology 2005;73(3):488-97. [DOI:
10.1037/0022-006X.73.3.488]

Rapee RM, Kennedy SJ, Ingram M, Edwards SL, Sweeney L.
Altering the trajectory of anxiety in at-risk young children.
American Journal of Psychiatry 2010;167(12):1518-25. [DOI:
10.1176/appi.ajp.2010.09111619]

Rapee RM. The preventative effects of a brief, early intervention
for preschool-aged children at risk for internalising: follow-
up into middle adolescence. Journal of Child Psychology &
Psychiatry 2013;54(7):780-8. [DOI: 10.1111/jcpp.12048]

Rapee 2006 {published and unpublished data}

Rapee RM, Abbott MJ, Lyneham HJ. Bibliotherapy for
children with anxiety disorders using written materials
for parents: a randomized controlled trial. Journal of
Consulting and Clinical Psychology 2006;74(3):436-44. [DOI:
10.1037/0022-006X.74.3.436]

Reaven 2012 {published data only}

Reaven J, Blakeley-Smith A, Culhane-Shelburne K, Hepburn S.
Group cognitive behavior therapy for children with high-
functioning autism spectrum disorders and anxiety: a

Cochrane Database of Systematic Reviews

randomized trial. Journal of Child Psychology and Psychiatry and
Allied Disciplines 2012;53(4):410-9.

Reigada 2015 {published and unpublished data}

Reigada LC, Polokowski AR, Walder DJ, Szigethy EM, Benkov KJ,
Bruzzese JM, et al. Treatment for comorbid pediatric
gastrointestinal and anxiety disorders: a pilot study of a flexible
health sensitive cognitive-behavioral therapy program. Clinical
Practice in Pediatric Psychology 2015;3(4):314-26. [DOI: 10.1037/
cpp0000116]

Rosa Alcazar 2009 {published and unpublished data}

Rosa-Alcazar AI, Olivares-Olivares PJ, Olivares J. The role of non-
specific effects in the psychological treatment of adolescents
with social phobia. Anuario de Psicologia 2009;40(1):43-61.

Salari 2018 {published and unpublished data}

NCT01513915. A parent-only group cognitive behavioral
intervention for children with anxiety disorders: a control group
study. clinicaltrials.gov/show/nct01513915 (first received 20
January 2012).

* 
ZZZ <label> ZZZ*
Salari E, Shahrivar Z, Mahmoudi-Gharaei J, Shirazi E, Sepasi M.
Parent-only group cognitive behavioral intervention for
children with anxiety disorders: a control group study. Journal
of the Canadian Academy of Child and Adolescent Psychiatry
2018;27(2):130-6.

Salum 2018 {published data only}

NCT01687764. Combination of active or placebo Attentional
Bias Modification Treatment (ABMT) to either Cognitive
Behavioral Group Therapy (CBGT) or Psychoeducational
Control Intervention (PCI) for anxiety disorders in children: a
randomized clinical trial. https://www.clinicaltrials.gov/ct2/
show/NCT01687764 19 September 2012.

* 
ZZZ <label> ZZZ*
Salum GA, Petersen CS, Jarros RB, Toazza R, DeSousa D,
Borba LN, et al. Group cognitive behavioral therapy and
attention bias modification for childhood anxiety disorders:
a factorial randomized trial of efficacy. Journal of Child and
Adolescent Psychopharmacology 2018;28(9):620-30. [DOI:
10.1089/cap.2018.0022]

Sanchez Garcia 2009 {published and unpublished data}

Sanchez-Garcia R, Olivares J. Effectiveness of a program
for early detection/intervention in children/adolescents
with generalized social phobia. Anales de Psicologia
2009;25(2):241-9.

Santucci 2013 {published data only (unpublished sought but not
used)}

Santucci LC, Ehrenreich-May J. A randomized controlled trial
of the child anxiety multi-day program (CAMP) for separation
anxiety disorder. Child Psychiatry and Human Development
2013;44(3):439-51. [DOI: 10.1007/s10578-012-0338-6]

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

50

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Schneider 2011 {published data only (unpublished sought but not
used)}

disorders. Journal of Clinical Child and Adolescent Psychology
2018;47(4):542-54. [DOI: 10.1080/15374416.2016.1138408]

Schneider S, Blatter-Meunier J, Herren C, Adornetto C, In-
Albon T, Lavallee K. Disorder-specific cognitive-behavioral
therapy for separation anxiety disorder in young children: a
randomized waiting-list-controlled trial. Psychotherapy and
Psychosomatics 2011;80(4):206-15. [DOI: 10.1159/000323444]

Sciberras 2018 {published data only (unpublished sought but not
used)}

ISRCTN33930984. Does the identification and treatment
of comorbid anxiety disorders in children with attention
deficit hyperactivity disorder (ADHD) improve outcomes?
www.isrctn.com/ISRCTN33930984 (first received 2 October
2013).

* 
ZZZ <label> ZZZ*
Sciberras E, Mulraney M, Anderson V, Rapee RM, Nicholson JM,
Efron D, et al. Managing anxiety in children with ADHD using
cognitive-behavioral therapy: a pilot randomized controlled
trial. Journal of Attention Disorders 2018;22(5):515-20. [DOI:
10.1177/1087054715584054]

Shahnavaz 2016 {published data only}

NCT01798355. Children and adolescents with dental anxiety -
randomized controlled study of cognitive behavioral therapy.
clinicaltrials.gov/show/nct01798355 (first received 25 February
2013).

* 
ZZZ <label> ZZZ*
Shahnavaz S, Hedman E, Grindefjord M, Reuterskiold L,
Dahllof G. Cognitive behavioral therapy for children
with dental anxiety: a randomized controlled trial. JDR
Clinical and Translational Research 2016;1(3):234-43. [DOI:
10.1177/2380084416661473]

Sharma 2017 {published and unpublished data}

Sharma P, Mehta M, Sagar R. Efficacy of transdiagnostic
cognitive-behavioral group therapy for anxiety disorders
and headache in adolescents. Journal of Anxiety Disorders
2017;46:78-84. [DOI: 10.1016/j.janxdis.2016.11.001]

Shortt 2001 {published data only}

Shortt AL, Barrett PM, Fox TL. Evaluating the FRIENDS
program: a cognitive-behavioral group treatment for anxious
children and their parents. Journal of Clinical Child and
Adolescent Psychology 2001;30(4):525-35. [DOI: 10.1207/
S15374424JCCP3004_09]

Silk 2018 {published and unpublished data}

NCT00774150. Transdisciplinary studies of CBT for anxiety in
youth: child anxiety treatment study. clinicaltrials.gov/show/
nct00774150 (first received 17 October 2008).

* 
ZZZ <label> ZZZ*
Silk JS, Tan PZ, Ladouceur CD, Meller S, Siegle GJ, McMakin DL,
et al. A randomized clinical trial comparing individual cognitive
behavioral therapy and child-centered therapy for child anxiety

Silverman 1999a {published data only (unpublished sought but
not used)}

Silverman WK, Kurtines WM, Ginsburg GS, Weems CF, Rabian B,
Serafini LT. Contingency management, self-control, and
education support in the treatment of childhood phobic
disorders: a randomized clinical trial. Journal of Consulting and
Clinical Psychology 1999;67(5):675-87.

Silverman 1999b {published data only (unpublished sought but
not used)}

Silverman WK, Kurtines WM, Ginsburg GS, Weems CF,
Lumpkin PW, Carmichael DH. Treating anxiety disorders in
children with group cognitive-behavioral therapy: a randomized
clinical trial. Journal of Consulting and Clinical Psychology
1999;67(6):995-1003.

Simon 2011 {published and unpublished data}

NTR1143. Prevention of childhood anxiety disorders via the
parent or via the child? www.who.int/trialsearch/Trial2.aspx?
TrialID=NTR1143 (first received 27 November 2007).

* 
ZZZ <label> ZZZ*
Simon E, Bogels SM, Voncken JM. Efficacy of child-focused
and parent-focused interventions in a child anxiety prevention
study. Journal of Clinical Child and Adolescent Psychology
2011;40(2):204-19. [DOI: 10.1080/15374416.2011.546039]

Smith 2014 {published data only (unpublished sought but not
used)}

* 
ZZZ <label> ZZZ*
Smith AM, Flannery-Schroeder EC, Gorman KS, Cook N.
Parent cognitive-behavioral intervention for the treatment of
childhood anxiety disorders: a pilot study. Behaviour Research
and Therapy 2014;61:156-61.

Smith AM. Cognitive-behavioral treatment of childhood
anxiety: examining a parent consultation model. Dissertation
Abstracts International: Section B: The Sciences and Engineering
2014;74:8-B(E).

Southam Gerow 2010 {published data only (unpublished sought
but not used)}

Southam-Gerow MA, Weisz JR, Chu BC, McLeod BD, Gordis EB,
Connor-Smith JK. Does cognitive behavioral therapy for youth
anxiety outperform usual care in community clinics? An initial
effectiveness test. Journal of the American Academy of Child
and Adolescent Psychiatry 2010;49(10):1043-52. [DOI: 10.1016/
j.jaac.2010.06.009]

Spence 2000 {published and unpublished data}

Spence SH, Donovan C, Brechman-Toussaint M. The treatment
of childhood social phobia: the effectiveness of a social skills
training-based, cognitive-behavioural intervention, with and
without parental involvement. Journal of Child Psychology and
Psychiatry and Allied Disciplines 2000;41(6):713-26.

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

51

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Spence 2006 {published data only}

Spence SH, Holmes JM, March S, Lipp OV. The feasibility
and outcome of clinic plus internet delivery of cognitive-
behavior therapy for childhood anxiety. Journal of
Consulting and Clinical Psychology 2006;74(3):614-21. [DOI:
10.1037/0022-006X.74.3.614]

Spence 2011 {published data only}

Spence SH, Donovan CL, March S, Gamble A, Anderson RE,
Prosser S, et al. A randomized controlled trial of online versus
clinic-based CBT for adolescent anxiety. Journal of Consulting
and Clinical Psychology 2011;79(5):629-42. [DOI: 10.1037/
a0024512]

Storch 2013 {published data only}

NCT01178385. Cognitive-behavioral treatment for anxiety
disorders in children with autism spectrum disorders.
clinicaltrials.gov/show/nct01178385 (first received 10 August
2010).

* 
ZZZ <label> ZZZ*
Storch EA, Arnold EB, Lewin AB, Nadeau JM, Jones AM, De
Nadai AS, et al. The effect of cognitive-behavioral therapy
versus treatment as usual for anxiety in children with autism
spectrum disorders: a randomized, controlled trial. Journal
of the American Academy of Child and Adolescent Psychiatry
2013;52(2):132-42.e2. [DOI: 10.1016/j.jaac.2012.11.007]

Storch 2015 {published data only}

NCT01563003. Cognitive behavioral therapy for anxiety
disorders in adolescents with autism. clinicaltrials.gov/show/
nct01563003 (first received 26 March 2012).

* 
ZZZ <label> ZZZ*
Storch EA, Lewin AB, Collier AB, Arnold E, De Nadai AS, Dane BF,
et al. A randomized controlled trial of cognitive-behavioral
therapy versus treatment as usual for adolescents with autism
spectrum disorders and comorbid anxiety. Depression and
Anxiety 2015;32(3):174-81. [DOI: 10.1002/da.22332]

Thirlwall 2013 {published data only}

Thirlwall K, Cooper PJ, Karalus J, Voysey M, Willetts L,
Creswell C. Treatment of child anxiety disorders via guided
parent-delivered cognitive-behavioural therapy: randomised
controlled trial. British Journal of Psychiatry 2013;203(6):436-44.
[DOI: 10.1192/bjp.bp.113.126698]

Villabo 2018 {published data only}

NCT00735995. Effectiveness of cognitive behavioral therapy
(CBT) for child anxiety disorders in community clinics in
Norway. clinicaltrials.gov/show/nct00735995 (first received 15
August 2008).

* 
ZZZ <label> ZZZ*
Villabo MA, Narayanan M, Compton SN, Kendall PC, Neumer SP.
Cognitive-behavioral therapy for youth anxiety: an effectiveness
evaluation in community practice. Journal of Consulting
and Clinical Psychology 2018;86(9):751-64. [DOI: 10.1037/
ccp0000326]

Cochrane Database of Systematic Reviews

Walkup 2008 {published data only (unpublished sought but not
used)}

Albano AM, Comer JS, Compton SN, Piacentini J, Kendall PC,
Birmaher B, et al. Secondary outcomes from the Child/
Adolescent Anxiety Multimodal Study: implications for clinical
practice. Evidence-Based Practice in Child and Adolescent Mental
Health 2018;3(1):30-41. [DOI: 10.1080/23794925.2017.1399485]

Compton SN, Walkup JT, Albano AM, Piacentini JC, Birmaher B,
Sherrill JT, et al. Child/Adolescent Anxiety Multimodal
Study (CAMS): rationale, design, and methods. Child and
Adolescent Psychiatry and Mental Health 2010;4:1. [DOI:
10.1186/1753-2000-4-1]

Ginsburg GS, Becker EM, Keeton CP, Sakolsky D, Piacentini J,
Albano AM, et al. Naturalistic follow-up of youths treated for
pediatric anxiety disorders. JAMA Psychiatry 2014;71(3):310-8.
[DOI: 10.1001/jamapsychiatry.2013.4186]

Ginsburg GS, Becker-Haimes EM, Keeton C, Kendall PC,
Lyengar S, Sakolsky D, et al. Results from the Child/Adolescent
Anxiety Multimodal Extended Long-Term Study (CAMELS):
primary anxiety outcomes. Journal of the American Academy
of Child and Adolescent Psychiatry 2018;57(7):471-80. [DOI:
10.1016/j.jaac.2018.03.017]

Ginsburg GS, Kendall PC, Sakolsky D, Compton SN, Piacentini J,
Albano AM, et al. Remission after acute treatment in children
and adolescents with anxiety disorders: findings from the CAMS.
Journal of Consulting and Clinical Psychology 2011;79(6):806-13.
[DOI: 10.1037/a0025933]

NCT00052078. Child and Adolescent Anxiety Disorders (CAMS).
clinicaltrials.gov/ct2/show/NCT00052078 (first received 23
January 2003).

Piacentini J, Bennett S, Compton SN, Kendall PC, Birmaher B,
Albano AM, et al. 24- and 36-week outcomes for the Child/
Adolescent Anxiety Multimodal Study (CAMS). Journal of
the American Academy of Child and Adolescent Psychiatry
2014;53(3):297-310. [DOI: 10.1016/j.jaac.2013.11.010]

Rynn MA, Walkup JT, Compton SN, Sakolsky DJ, Sherrill JT,
Shen S, et al. Child/Adolescent Anxiety Multimodal Study:
evaluating safety. Journal of the American Academy of Child
and Adolescent Psychiatry 2015;54(3):180-90. [DOI: 10.1016/
j.jaac.2014.12.015]

* 
ZZZ <label> ZZZ*
Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN,
Sherrill JT, et al. Cognitive behavioural therapy, sertraline or
a combination in childhood anxiety. New England Journal of
Medicine 2008;359(26):2753-66. [DOI: 10.1056/NEJMoa0804633]

Waters 2009 {published data only}

Waters AM, Ford LA, Wharton TA, Cobham VE. Cognitive-
behavioural therapy for young children with anxiety disorders:
comparison of a child + parent condition versus a parent only
condition. Behaviour Research and Therapy 2009;47(8):654-62.
[DOI: 10.1016/j.brat.2009.04.008]

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

52

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Wergeland 2014 {published and unpublished data}

NCT00586586. Effectiveness study of CBT for anxiety in children.
clinicaltrials.gov/show/nct00586586 (first received 4 January
2008).

* 
ZZZ <label> ZZZ*
Wergeland GJ, Fjermestad KW, Marin CE, Haugland BS,
Bjaastad JF, Oeding K, et al. An effectiveness study of individual
vs. group cognitive behavioral therapy for anxiety disorders
in youth. Behaviour Research and Therapy 2014;57:1-12. [DOI:
10.1016/j.brat.2014.03.007]

White 2013 {published data only}

NCT00926471. Social skills and anxiety reduction treatment
for children and adolescents with autism spectrum disorders.
clinicaltrials.gov/show/nct00926471 (first received 23 June
2009).

* 
ZZZ <label> ZZZ*
White SW, Ollendick T, Albano AM, Oswald D, Johnson C,
Southam-Gerow MA, et al. Randomized controlled trial:
Multimodal Anxiety and Social Skill Intervention for adolescents
with autism spectrum disorder. Journal of Autism and
Developmental Disorders 2013;43(2):382-94. [DOI: 10.1007/
s10803-012-1577-x]

Wood 2009 {published data only (unpublished sought but not
used)}

Wood JJ, Drahota A, Sze K, Har K, Chiu A, Langer DA. Cognitive
behavioral therapy for anxiety in children with autism
spectrum disorders: a randomized, controlled trial. Journal
of Child Psychology and Psychiatry and Allied Disciplines
2009;50(3):224-34. [DOI: 10.1111/j.1469-7610.2008.01948.x]

Wood 2015 {published data only (unpublished sought but not
used)}

NCT01177969. CBT for anxiety disorders in autism: adapting
treatment for adolescents. clinicaltrials.gov/ct2/show/
nct01177969 (first received 9 August 2010).

* 
ZZZ <label> ZZZ*
Wood JJ, Ehrenreich-May J, Alessandri M, Fujii C, Renno P,
Laugeson E, et al. Cognitive behavioral therapy for early
adolescents with autism spectrum disorders and clinical
anxiety: a randomized, controlled trial. Behavior Therapy
2015;46(1):7-19. [DOI: 10.1016/j.beth.2014.01.002]

Cochrane Database of Systematic Reviews

stress response in child social anxiety disorder but this
effect can be prevented with CBT. Psychoneuroendocrinology
2019;109:104352. [DOI: 10.1016/j.psyneuen.2019.06.003]

Asbrand J, Heinrichs N, Schmidtendorf S, Nitschke K, Tuschen-
Caffier B. Experience versus report: where are changes
seen after exposure-based cognitive-behavioral therapy? A
randomized controlled group treatment of childhood social
anxiety disorder. Child Psychiatry and Human Development
2020;51(3):427-41. [DOI: 10.1007/s10578-019-00954-w]

* 
ZZZ <label> ZZZ*
Asbrand J, Schmitz J, Kramer M, Nitschke K, Heinrichs N,
Tuschen-Caffier B. Effects of group-based CBT on post-
event processing in children with social anxiety disorder
following an experimental social stressor. Journal of Abnormal
Child Psychology 2019;47(12):1945-56. [DOI: 10.1007/
s10802-019-00558-x]

Baer 2005 {published data only}

Baer S, Garland EJ. Pilot study of community-based
cognitive behavioral group therapy for adolescents
with social phobia. Journal of the American Academy of
Child and Adolescent Psychiatry 2005;44(3):258-64. [DOI:
10.1097/00004583-200503000-00010]

Beidel 2000 {published data only}

Beidel DC, Turner SM, Morris TL. Behavioral treatment of
childhood social phobia. Journal of Consulting and Clinical
Psychology 2000;68(6):1072-80.

Beidel DC, Turner SM, Young B, Paulson A. Social effectiveness
therapy for children: three-year follow-up. Journal of Consulting
and Clinical Psychology 2005;73(4):721-5.

Beidel DC, Turner SM, Young BJ. Social effectiveness therapy for
children: five years later. Behavior Therapy 2006;37(4):416-25.

Beidel 2007 {published data only}

* 
ZZZ <label> ZZZ*
Beidel DC, Turner SM, Sallee FR, Ammerman RT, Crosby LA,
Pathak S. SET-C versus fluoxetine in the treatment of childhood
social phobia. Journal of the American Academy of Child and
Adolescent Psychiatry 2007;46(12):1622-32. [DOI: 10.1097/
chi.0b013e318154bb57]

NCT00043537. Treatment of childhood social phobia.
clinicaltrials.gov/ct2/show/NCT00043537 (first received 12
August 2002).

References to studies excluded from this review

Bergman 2013 {published data only}

Asbrand {unpublished data only}

Asbrand J. Exposure-based cognitive behavior therapy for
children and adolescents with social anxiety disorder: a
randomized controlled group treatment trial. Manuscript
provided by author (on 21 May 2019).

Asbrand 2019 {published data only}

Asbrand J, Heinrichs N, Nitschke K, Wolf OT, Schmidtendorf S,
Tuschen-Caffier B. Repeated stress leads to enhanced cortisol

Bergman RL, Gonzalez A, Piacentini J, Keller ML. Integrated
Behavior Therapy for Selective Mutism: a randomized
controlled pilot study. Behaviour Research and Therapy
2013;51(10):680-9. [DOI: 10.1016/j.brat.2013.07.003]

NCT00458198. Integrated behavioral therapy for treating
children with selective mutism. clinicaltrials.gov/ct2/show/
NCT00458198 (first received 9 April 2007).

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

53

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Bernstein 2005 {published data only (unpublished sought but not
used)}

Bernstein GA, Bernat DH, Victor AM, Layne AE. School-based
interventions for anxious children: 3-, 6-, and 12-month
follow-ups. Journal of the American Academy of Child and
Adolescent Psychiatry 2008;47(9):1039-47. [DOI: 10.1097/
CHI.ob013e31817eecco]

Bernstein GA, Layne AE, Egan EA, Tennison DM.
School-based interventions for anxious children.
Journal of the American Academy of Child and
Adolescent Psychiatry 2005;44(11):1118-27. [DOI:
10.1097/01.chi.0000177323.40005.a1]

Lee SS, Victor AM, James MG, Roach LE, Bernstein GA. School-
based interventions for anxious children: long-term follow-up.
Child Psychiatry and Human Development 2016;47(2):183-93.
[DOI: 10.1007/s10578-015-0555-x]

Bodden 2008a {published data only}

Bodden DH, Bogels SM, Nauta MH, De Haan E, Ringrose J,
Appelboom C, et al. Child versus family cognitive-behavioral
therapy in clinically anxious youth: an efficacy and partial
effectiveness study. Journal of the American Academy of Child
and Adolescent Psychiatry 2008;47(12):1384-94. [DOI: 10.1097/
CHI.0b013e318189148e]

Bodden DHM, Dirksen CD, Bogels SM, Nauta MH, De Haan E,
Ringrose J, et al. Costs and cost-effectiveness of family CBT
versus individual CBT in clinically anxious children. Clinical
Child Psychology and Psychiatry 2008;13(4):543-64. [DOI:
10.1177/1359104508090602]

Clementi 2019 {published data only}

Clementi MA. Efficacy of an integrated sleep and anxiety
intervention for anxious children: a pilot randomized controlled
trial. Dissertation Abstracts International: Section B: The Sciences
and Engineering 2019;80:7-B(E).

Cobham 2012 {published data only}

Cobham V. Do anxiety-disordered children need to come into
the clinic for efficacious treatment? Journal of Consulting and
Clinical Psychology 2012;80(3):465-76.

Cotton 2019 {published data only}

Cotton S, Kraemer KM, Sears RW, Strawn JR, Wasson RS,
McCune N, et al. Mindfulness-based cognitive therapy for
children and adolescents with anxiety disorders at-risk for
bipolar disorder: a psychoeducation waitlist controlled pilot
trial. Early Intervention in Psychiatry 2019;14(2):211-9.

Ebrahiminejad 2016 {published data only}

Ebrahiminejad S, Poursharifi H, Bakhshiour Roodsari A,
Zeinodini Z, Noorbakhsh S. The effectiveness of mindfulness-
based cognitive therapy on Iranian female adolescents suffering
from social anxiety. Iranian Red Crescent Medical Journal
2016;18(11):e25116. [DOI: 10.5812/ircmj.25116]

Flatt 2010 {published data only}

Flatt N, King N. Brief psycho-social interventions in the
treatment of specific childhood phobias: a controlled trial and a
1-year follow-up. Behaviour Change 2010;27(3):130-53.

Gil Bernal 2009 {published data only}

Gil-Bernal F, Hernandez-Guzman L. Cognitive-behavioural
treatment in Mexican children with social phobia. Anuario de
Psicologia 2009;40(1):89-104.

Ginsburg 2019b {published data only (unpublished sought but not
used)}

Ginsburg GS, Drake KL, Muggeo MA, Stewart CE, Pikulski PJ,
Zheng D, et al. A pilot RCT of a school nurse delivered
intervention to reduce student anxiety. Journal of Clinical Child
and Adolescent Psychology 2019 Aug 2 [Epub ahead of print].
[DOI: 10.1080/15374416.2019.1630833]

Hayward 2000 {published data only}

Hayward C, Varady S, Albano AM, Thienemann M, Henderson L,
Schatzberg AF. Cognitive-behavioral group therapy for social
phobia in female adolescents: results of a pilot study. Journal
of the American Academy of Child and Adolescent Psychiatry
2000;39(6):721-6. [DOI: 10.1097/00004583-200006000-00010]

Jansen 2012 {published data only}

Jansen M, van Doorn MM, Lichtwarck-Aschoff A, Kuijpers RC,
Theunissen H, Korte M, et al. Effectiveness of a cognitive-
behavioral therapy (CBT) manualized program for
clinically anxious children: study protocol of a randomized
controlled trial. BMC Psychiatry 2012;12(1):16. [DOI:
10.1186/1471-244X-12-16]

Kerns 2016 {published data only}

* 
ZZZ <label> ZZZ*
Kerns CM, Wood JJ, Kendall PC, Renno P, Crawford EA,
Mercado RJ, et al. The Treatment of Anxiety in Autism Spectrum
Disorder (TAASD) study: rationale, design and methods. Journal
of Child and Family Studies 2016;25(6):1889-902. [DOI: 10.1007/
s10826-016-0372-2]

NCT02028247. Psychotherapy for Anxiety in Children With
Autism Spectrum Disorder (TAASD). clinicaltrials.gov/show/
NCT02111395 (first received 7 January 2014).

Kujawa 2019 {published data only}

Kujawa A, Burkhouse KL, Karich SR, Fitzgerald KD, Monk CS,
Phan KL. Reduced reward responsiveness predicts change in
depressive symptoms in anxious children and adolescents
following treatment. Journal of Child and Adolescent
Psychopharmacology 2019;29(5):378-85.

Lyneham 2006 {published data only}

Lyneham HJ, Rapee RM. Evaluation of therapist-supported
parent-implemented CBT for anxiety disorders in rural children.
Behaviour Research and Therapy 2006;44(9):1287-300. [DOI:
10.1016/j.brat.2005.09.009]

Mendlowitz 1999 {published data only}

Mendlowitz SL, Manassis K, Bradley S, Scapillato D, Miezitis S,
Shaw BF. Cognitive-behavioral group treatments in childhood
anxiety disorders: the role of parental involvement. Journal
of the American Academy of Child and Adolescent Psychiatry
1999;38(10):1223-9.

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

54

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Nauta 2003 {published data only}

Nauta MH, Scholing A, Emmelkamp PM, Minderaa RB.
Cognitive-behavioral therapy for children with anxiety
disorders in a clinical setting: no additional effect of a
cognitive parent training. Journal of the American Academy
of Child and Adolescent Psychiatry 2003;42(11):1270-8. [DOI:
10.1097/01.chi.0000085752.71002.93]

NCT00576719 {published data only}

Elkins RM, Gallo KP, Pincus DB, Comer JS. Moderators of
intensive cognitive behavioral therapy for adolescent panic
disorder: the roles of fear and avoidance. Child and Adolescent
Mental Health 2016;21(1):30-6. [DOI: 10.1111/camh.12122]

Gallo KP, Chan PT, Buzzella BA, Whitton SW, Pincus DB. The
impact of an 8-day intensive treatment for adolescent panic
disorder and agoraphobia on comorbid diagnoses. Behavior
Therapy 2012;43(1):153-9. [DOI: 10.1016/j.beth.2011.05.002]

Gallo KP, Cooper-Vince CE, Hardway CL, Pincus DB, Comer JS.
Trajectories of change across outcomes in intensive treatment
for adolescent panic disorder and agoraphobia. Journal of
Clinical Child and Adolescent Psychology 2014;43(5):742-50.

Hardway CL, Pincus DB, Gallo KP, Comer JS. Parental
involvement in intensive treatment for adolescent panic
disorder and its impact on depression. Journal of Child
and Family Studies 2015;24(11):3306-17. [DOI: 10.1007/
s10826-015-0133-7]

* 
ZZZ <label> ZZZ*
NCT00576719. Effectiveness of intensive cognitive behavioral
therapy in treating adolescent panic disorder and agoraphobia.
clinicaltrials.gov/show/nct00576719 (first received 19 December
2007).

Pincus DB, Whitton SW, Gallo KP, Weiner CL, Chow C,
Hardway C. Intensive treatment of adolescent panic disorder:
results of a randomized controlled trial with short-term
maintenance. Citation.

Oerbeck 2014 {published data only}

Oerbeck B, Overgaard KR, Stein MB, Pripp AH, Kristensen H.
Treatment of selective mutism: a 5-year follow-up study.
European Child & Adolescent Psychiatry 2018;27(8):997-1009.
[DOI: 10.1007/s00787-018-1110-7]

Oerbeck B, Stein MB, Pripp AH, Kristensen H. Selective mutism:
follow-up study 1 year after end of treatment. European Child
& Adolescent Psychiatry 2015;24(7):757-66. [DOI: 10.1007/
s00787-014-0620-1]

Oerbeck B, Stein MB, Wentzel-Larsen T, Langsrud O,
Kristensen H. A randomized controlled trial of a home and
school-based intervention for selective mutism - defocused
communication and behavioural techniques. Child and
Adolescent Mental Health 2014;19(3):192-8. [DOI: 10.1111/
camh.12045]

Cochrane Database of Systematic Reviews

for adolescents with social anxiety disorder. Behavior Therapy
2018;50(1):126-39. [DOI: 10.1016/j.beth.2018.04.002]

Ost 2015 {published data only}

Öst LG, Cederlund R, Reuterskiöld L. Behavioral treatment of
social phobia in youth: does parent education training improve
the outcome? Behaviour Research and Therapy 2015;67:19-29.
[DOI: 10.1016/j.brat.2015.02.001]

Ozyurt 2018 {published data only}

Ozyurt G, Gencer O, Ozturk Y, Ozbek A. Is Triple P effective in
childhood anxiety disorder? A randomized controlled study.
Psychiatry and Clinical Psychopharmacology 2019;29(4):570-8.
[DOI: 10.1080/24750573.2018.1483790]

Pereira 2014 {published data only (unpublished sought but not
used)}

Pereira AI, Marques T, Russo V, Barros L, Barrett P. Effectiveness
of the friends for life program in Portuguese schools: study with
a sample of highly anxious children. Psychology in the Schools
2014;51(6):647-57. [DOI: 10.1002/pits.21767]

Rudy 2017 {published data only}

NCT02051192. A brief behavioral treatment for anxiety in
young children. clinicaltrials.gov/ct2/show/NCT02051192 (first
received 31 January 2014).

Rudy BM, Zavrou S, Johnco C, Storch EA, Lewin AB. Parent-led
exposure therapy: a pilot study of a brief behavioral treatment
for anxiety in young children. Journal of Child and Family Studies
2017;26(9):2475-84. [DOI: 10.1007/s10826-017-0772-y]

Salzer 2018 {published data only (unpublished sought but not
used)}

Dams J, Kronmüller KT, Leibing E, Steil R, Henningsen P,
Leichsenring F, et al. Direct costs of social phobia in adolescents
and cost-effectiveness of psychotherapy. Psychiatrische Praxis
2019;46(3):148-55. [DOI: 10.1055/a-0733-4999]

ISRCTN22752528. Cognitive therapy (CT-A) versus short-term
psychodynamic psychotherapy (STPP-A) for social phobia (SP)
in adolescents. www.isrctn.com/ISRCTN22752528 (first received
17 February 2011).

* 
ZZZ <label> ZZZ*
Salzer S, Stefini A, Kronmuller KT, Leibing E, Leichsenring F,
Henningsen P, et al. Cognitive-behavioral and psychodynamic
therapy in adolescents with social anxiety disorder: a
multicenter randomized controlled trial. Psychotherapy and
Psychosomatics 2018;87(4):223-33. [DOI: 10.1159/000488990]

Sevi Tok 2016 {published data only}

Sevi Tok ES, Arkar H, Bildik T. The effectiveness of cognitive
behavioral therapy, medication, or combined treatment for
childhood anxiety disorders. Turk Psikiyatri Dergisi [Turkish
Journal of Psychiatry] 2016;27(2):1-8.

Storch 2019 {published data only}

Ollendick 2018 {published data only}

Ollendick TH, White SW, Richey J, Kim-Spoon J, Ryan SM,
Wieckowski AT, et al. Attention bias modification treatment

NCT01919970. Exposure-focused family-based CBT for youth
with ASD and comorbid anxiety. clinicaltrials.gov/ct2/show/
NCT01919970 (first received 9 August 2013).

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

55

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

* 
ZZZ <label> ZZZ*
Storch EA, Schneider SC, De Nadai AS, Selles RR, McBride NM,
Grebe SC, et al. A pilot study of family-based exposure-focused
Treatment for Youth with Autism Spectrum Disorder and
Anxiety. Child Psychiatry & Human Development 2019 Sep 6
[Epub ahead of print]. [DOI: 10.1007/s10578-019-00923-3]

Sung 2011 {published data only}

NCT01031511. Effect of cognitive behavioural therapy (CBT)
for children with autistic spectrum disorders. clinicaltrials.gov/
show/nct01031511 (first received 14 December 2009).

* 
ZZZ <label> ZZZ*
Sung M, Ooi YP, Goh TJ, Pathy P, Fung DS, Ang RP, et al. Effects
of cognitive-behavioral therapy on anxiety in children with
autism spectrum disorders: a randomized controlled trial. Child
Psychiatry and Human Development 2011;42(6):634-49. [DOI:
10.1007/s10578-011-0238-1]

Weisz 2012 {published data only}

Chorpita BF, Weisz JR, Daleiden EL, Schoenwald SK, Palinkas LA,
Miranda J, et al. Long-term outcomes for the Child STEPs
randomized effectiveness trial: a comparison of modular
and standard treatment designs with usual care. Journal of
Consulting and Clinical Psychology 2013;81(6):999-1009. [DOI:
10.1037/a0034200]

NCT01178554. The Clinic Treatment Project (CTP).
clinicaltrials.gov/ct2/show/nct01178554 (first received 10
August 2010).

* 
ZZZ <label> ZZZ*
Weisz JR, Chorpita BF, Palinkas LA, Schoenwald SK, Miranda J,
Bearman SK, et al. Testing standard and modular designs
for psychotherapy treating depression, anxiety, and conduct
problems in youth: a randomized effectiveness trial. Archives
of General Psychiatry 2012;69(3):274-82. [DOI: 10.1001/
archgenpsychiatry.2011.147]

References to studies awaiting assessment

ACTRN12613000217707 {unpublished data only}

ACTRN12613000217707. A multi-centre randomised controlled
trial of cognitive behavioural therapy for managing anxiety
in adolescents with acquired brain injury. www.who.int/
trialsearch/Trial2.aspx?TrialID=ACTRN12613000217707 (first
received 25 February 2013).

ACTRN12615000730505 {unpublished data only}

ACTRN12615000730505. Cognitive behaviour therapy
for comorbid anxiety and sleep disorders: a randomized
controlled trial. www.who.int/trialsearch/Trial2.aspx?
TrialID=ACTRN12615000730505 (first received 15 July 2015).

ACTRN12619000619145 {unpublished data only}

ACTRN12619000619145. SCAN Study - Self Compassion
& Cognitive Behavioural Therapy (CBT): Early family
intervention for children with Type 1 diabetes experiencing

Cochrane Database of Systematic Reviews

anxiety. www.who.int/trialsearch/Trial2.aspx?
TrialID=ACTRN12619000619145 (first received 26 April 2019).

DRKS00012823 {unpublished data only}

DRKS00012823. Short-term, long-term and cost-effectiveness
of treating depression and anxiety disorders in children and
adolescents a randomized controlled trial. www.who.int/
trialsearch/Trial2.aspx?TrialID=DRKS00012823 (first received 27
September 2017).

IRCT20181006041250N {unpublished data only}

IRCT20181006041250N1. Effectiveness of coping cat-based
cognitive-behavioral therapy (CBT) in group format on
treatment of anxiety in children. www.who.int/trialsearch/
Trial2.aspx?TrialID=IRCT20181006041250N1 (first received 18
October 2018).

ISRCTN59518816 {unpublished data only}

ISRCTN59518816. Does the treatment of anxiety in children with
ADHD improve outcomes? www.who.int/trialsearch/Trial2.aspx?
TrialID=ISRCTN59518816 (first received 29 September 2015).

JPRN-UMIN000008724 {unpublished data only}

JPRN-UMIN000008724. Japanese Anxiety Children/Adolescents
CBT study. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-
UMIN000008724 (first received 27 August 2012).

JPRN-UMIN000032275 {unpublished data only}

JPRN-UMIN000032275. Transdiagnostic intervention for anxiety
and depression in children and adolescents. www.who.int/
trialsearch/Trial2.aspx?TrialID=JPRN-UMIN000032275 (first
received 19 April 2018).

JPRN-UMIN000033218 {unpublished data only}

JPRN-UMIN000033218. The efficacy of group CBT for
children with autism spectrum disorder to reduce anxiety
symptoms. www.who.int/trialsearch/Trial2.aspx?TrialID=JPRN-
UMIN000033218 (first received 1 July 2018).

NCT02810171 {unpublished data only}

NCT02810171. Dimensional brain behavior predictors of
CBT outcomes in pediatric anxiety. clinicaltrials.gov/show/
nct02810171 (first received 20 June 2016).

NCT02977962 {unpublished data only}

NCT02977962. Treatment of anxiety in late adolescents with
autism. clinicaltrials.gov/show/nct02977962 (first received 28
November 2016).

NCT03412227 {unpublished data only}

NCT03412227. Transdiagnostic individual behavioral activation
and exposure therapy. clinicaltrials.gov/show/nct03412227 (first
received 15 October 2017).

NCT03899948 {unpublished data only}

NCT03899948. Teacher anxiety program for elementary
students. clinicaltrials.gov/show/NCT03899948 (first received 28
March 2019).

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

56

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

References to ongoing studies

APA 1994

ACTRN12616001552471 {published data only}

ACTRN12616001552471. Effectiveness of school group-based
acceptance and commitment therapy for children with anxiety:
a randomised controlled trial. www.who.int/trialsearch/
Trial2.aspx?TrialID=ACTRN12616001552471 (first received 10
November 2016).

NCT02725619 {published data only}

NCT02725619. CBT for anxiety in children with autism.
clinicaltrials.gov/show/nct02725619 (first received 1 April 2016).

NCT02908321 {published data only}

Kilburn TR, Sorensen MJ, Thastum M, Rapee RM, Rask CU,
Arendt KB, et al. Rationale and design for cognitive behavioral
therapy for anxiety disorders in children with autism spectrum
disorder: a study protocol of a randomized controlled trial.
Trials 2018;19:210. [DOI: 10.1186/s13063-018-2591-x]

* 
ZZZ <label> ZZZ*
NCT02908321. CBT for anxiety disorder in children with co-
morbid ASD. clinicaltrials.gov/show/nct02908321 (first received
20 September 2016).

NCT03279471 {published data only}

NCT03279471. Specifying and treating anxiety in autism
research. clinicaltrials.gov/show/nct03279471 (first received 12
September 2017).

NCT03585010 {published data only}

NCT03585010. Brain response associated with parent-based
treatment for childhood anxiety disorders. clinicaltrials.gov/ct2/
show/NCT03585010 (first received 12 July 2018).

Additional references

Ale 2015

Ale CM, McCarthy DM, Rothschild LM, Whiteside SP.
Components of cognitive behavioral therapy related to
outcome in childhood anxiety disorders. Clinical Child and
Family Psychology Review 2015;18(3):240-51.

Angold 1995

Angold A, Costello EJ, Messer SC, Pickles A, Winder F,
Silver D. The development of a short questionnaire for use
in epidemiological studies of depression in children and
adolescents. International Journal of Methods in Psychiatric
Research 1995;5:237-49.

APA 1980

American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders (DSM-III). 3rd edition. Washington,
DC: American Psychiatric Association, 1980.

APA 1987

American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders (DSM-III-R). 3rd revised edition.
Washington, DC: American Psychiatric Association, 1987.

American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV). 4th edition. Washington,
DC: American Psychiatric Association, 1994.

APA 2000

American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV-TR). 4th text revision
edition. Washington, DC: American Psychiatric Association,
2000.

APA 2013

American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders. 5th edition. Washington, DC:
American Psychiatric Association, 2013.

Barlow 2010

Barlow DH. Negative effects from psychological treatments:
a perspective. American Psychologist 2010;65(1):13-20. [DOI:
10.1037/a0015643]

Beck 1996

Beck A, Steer RA, Brown GK. Beck Depression Inventory Section
Edition Manual. San Antonio: The Psychological Corporation,
1996.

Beesdo 2009

Beesdo K, Knappe S, Pine DS. Anxiety and anxiety disorders
in children and adolescents: developmental issues and
implications for DSM-V. Psychiatric Clinics 2009;32(3):483-524.

Beidel 1995

Beidel DC, Turner SM, Morris TL. A new instrument to assess
childhood social anxiety and phobia: the Social Phobia and
Anxiety Inventory for Children. Psychological Assessment
1995;10:73-9.

Bennett 2016

Bennett K, Manassis K, Duda S, Bagnell A, Bernstein GA,
Garland EJ, et al. Treating child and adolescent anxiety
effectively: overview of systematic reviews. Clinical Psychology
Review 2016;50:80-94.

Birmaher 1999

Birmaher B. Screen for Child Anxiety Related Emotional
Disorders (SCARED). Pittsburgh, PA: Western Psychiatric
Institute and Clinic, 1999.

Bodden 2008b

Bodden DH, Dirksen CD, Bögels SM. Societal burden of clinically
anxious youth referred for treatment: a cost-of-illness study.
Journal of Abnormal Child Psychology 2008;36(4):487-97.

Bower 2005

Bower P, Gilbody S. Stepped care in psychological therapies:
access, effectiveness and efficiency – narrative literature review.
British Journal of Psychiatry 2005;186:11-7.

Breinholst 2012

Breinholst S, Esbjorn BH, Reinholdt-Dunne ML, Stallard P. CBT
for the treatment of child anxiety disorders: a review of why

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

57

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

parental involvement has not enhanced outcomes. Journal of
Anxiety Disorders 2012;26(3):416–24.

Brown 2007

Brown AM, Deacon BJ, Abramowitz JS, Dammann J,
Whiteside SP. Parents' perceptions of pharmacological
and cognitive-behavioral treatments for childhood anxiety
disorders. Behaviour Research and Therapy 2007;45(4):819-28.

Cartwright-Hatton 2004

Cartwright-Hatton S, Roberts C, Chitsabesan P, Fothergill C,
Harrington R. Systematic review of the efficacy of cognitive-
behaviour therapies for childhood and adolescent anxiety
disorders. British Journal of Clinical Psychology 2004;43:421-36.

Cartwright-Hatton 2011

Cartwright-Hatton S, McNally D, Field AP, Rust S, Laskey B,
Dixon C, et al. A new parenting-based group intervention for
young anxious children: results of a randomized controlled
trial. Journal of the American Academy of Child and Adolescent
Psychiatry 2011;50(3):242-51.e6.

Chatterton 2019

Chatterton ML, Rapee RM, Catchpool M, Lyneham HJ,
Wuthrich V, Hudson JL, et al. Economic evaluation of stepped
care for the management of childhood anxiety disorders: results
from a randomised trial. Australian and New Zealand Journal of
Psychiatry 2019;53:673-82.

Chorpita 2000

Chorpita BF, Yim L, Moffitt C, Umemoto LA, Francis SE.
Assessment of symptoms of DSM-IV anxiety and depression
in children: a revised child anxiety and depression scale.
Behaviour Research and Therapy 2000;38(8):835-55.

Compton 2004

Compton SN, March JS, Brent D, Albano AM, Weering R, Curry J.
Cognitive-behavioral psychotherapy for anxiety and depressive
disorders in children and adolescents: an evidence-based
medicine review. Journal of the American Academy Child and
Adolescent Psychiatry 2004;43:930–59.

Copeland 2014

Copeland WE, Angold A, Shanahan L, Costello EJ. Longitudinal
patterns of anxiety from childhood to adulthood: the Great
Smoky Mountains Study. Journal of the American Academy of
Child and Adolescent Psychiatry 2014;53(1):21-33.

Covidence [Computer program]

Covidence. Version Accessed 3 December 2018. Melbourne,
Australia: Veritas Health Innovation. Available at covidence.org.

Creswell 2020a

Creswell C, Nauta M, Hudson J, March S, Reardon T, Arendt K, et
al. Recommendations for reporting on treatment trials for child
and adolescent anxiety disorders: an international consensus
statement. Journal of Child Psychology and Psychiatry 2020 Jul
19 [Epub ahead of print]. [DOI: 10.1111/jcpp.13283]

Creswell 2020b

Creswell C, Waite P, Hudson J. Practitioner Review: Anxiety
disorders in children and young people – assessment and
treatment. Journal of Child Psychology and Psychiatry
2020;61(6):628-43. [DOI: 10.1111/jcpp.13186]

Crowe 2017

Crowe K, McKay D. Efficacy of cognitive-behavioral therapy for
childhood anxiety and depression. Journal of Anxiety Disorders
2017;49:76-87.

Deeks 2017

Deeks JJ, Higgins JP, Altman DG, editor(s) on behalf of the
Cochrane Statistical Methods Group. Chapter 9: Analysing
data and undertaking meta-analyses. In: Higgins JPT,
Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane
Handbook for Systematic Reviews of Interventions version
5.2.0 (updated June 2017). Cochrane, 2017. Available from
www.training.cochrane.org/handbook.

Duggan 2014

Duggan C, Parry G, McMurran M, Davidson K, Dennis J. The
recording of adverse events from psychological treatments in
clinical trials: evidence from a review of NIHR-funded trials.
Trials 2014;15:335.

Essau 2003

Essau CA. Comorbidity of anxiety disorders in adolescents.
Depression and Anxiety 2003;18(1):1-6. [DOI: 10.1002/da.10107]

Essau 2004

Essau CA, Conradt J, Ederer EM. Anxiety prevention among
school children. Versicherungsmedizin 2004;56:123-30.

Essau 2014

Essau CA, Lewinsohn PM, Olaya B, Seeley JR. Anxiety disorders
in adolescents and psychosocial outcomes at age 30. Journal of
Affective Disorders 2014;163:125-32.

Evans 2017

Evans R, Thirlwall K, Cooper P, Creswell C. Using symptom
and interference questionnaires to identify recovery among
children with anxiety disorders. Psychological Assessment
2017;29(7):835-43.

Fineberg 2013

Fineberg NA, Haddad PM, Carpenter L, Gannon B, Sharpe R,
Young AH, et al. The size, burden and cost of disorders of
the brain in the UK. Journal of Psychopharmacology (Oxford,
England) 2013;27(9):761-70.

Galla 2012

Galla BM, Wood JJ, Chiu AW, Langer DA, Jacobs J,
Ifekwunigwe M, et al. One year follow-up to modular cognitive
behavioral therapy for the treatment of pediatric anxiety
disorders in an elementary school setting. Child Psychiatry and
Human Development 2012;43(2):219-26.

Gillies 2016

Gillies D, Maiocchi L, Bhandari AP, Taylor F, Gray C, O'Brien L.
Psychological therapies for children and adolescents exposed

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

58

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

to trauma. Cochrane Database of Systematic Reviews 2016, Issue
10. Art. No: CD012371. [DOI: 10.1002/14651858.CD012371]

for parents and family functioning. Depression and Anxiety
2013;30(9):865-72.

Ginsburg 2018

Kendall 1993

Ginsburg GS, Becker-Haimes EM, Keeton C, Kendall PC,
Lyengar S, Sakolsky D, et al. Results from the Child/Adolescent
Anxiety Multimodal Extended Long-Term Study (CAMELS):
primary anxiety outcomes. Journal of the American Academy
of Child and Adolescent Psychiatry 2018;57(7):471-80. [DOI:
10.1016/j.jaac.2018.03.017]

GRADEpro GDT [Computer program]

GRADEpro GDT. Version (accessed 4 October 2018). Hamilton
(ON): McMaster University (developed by Evidence Prime).
Available at gradepro.org.

Green 2004

Green H, McGinnity A, Meltzer H, Ford T, Goodman R. Mental
health of children and young people in Great Britain, 2004.
no-pa.uk/wp-content/uploads/2015/02/Mental-health-of-
children.pdf (accessed 4 October 2018).

Health Services Research Unit 2004

Health Services Research Unit. Database of ICCs: spreadsheet
(empirical estimates of ICCs from changing professional
practice studies). https://www.abdn.ac.uk/hsru/what-we-do/
tools/index.php (accessed 1 September 2020).

Higgins 2003

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring
inconsistency in meta-analyses. BMJ 2003;327:557-60.

Higgins 2011

Higgins JP, Deeks JJ, Altman DG, editor(s). Chapter 16: Special
topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane
Handbook for Systematic Reviews of Interventions Version
5.1.0 (updated March 2011). The Cochrane Collaboration, 2011.
Available from handbook.cochrane.org.

Higgins 2017

Higgins JP, Altman DG, Sterne JA, editor(s). Chapter 8:
Assessing risk of bias in included studies. In: Higgins JPT,
Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane
Handbook for Systematic Reviews of Interventions version
5.2.0 (updated June 2017). Cochrane, 2017. Available from
www.training.cochrane.org/handbook.

Hirshfeld-Becker 2010

Hirshfeld-Becker DR, Masek B, Henin A, Blakely LR, Pollock-
Wurman RA, McQuade J, et al. Cognitive behavioral therapy for
4- to 7-year-old children with anxiety disorders: a randomized
clinical trial. Journal of Consulting and Clinical Psychology
2010;78(4):498-510.

Holland 1995

Kendall PC. Cognitive-behavioral therapies with youth: guiding
theory, current status, and emerging developments. Journal of
Consulting and Clinical Psychology 1993;61(2):235-47.

Kendall 2006

Kendall PC, Hedtke KA. Cognitive-Behavioral Therapy for
Anxious Children: Therapist Manual. 1st edition. Ardmore, PA:
Workbook Publishing, 2006.

Kendall 2016

Kendall PC, Cummings CM, Villabo MA, Narayanan MK,
Treadwell K, Birmaher B, et al. Mediators of change in the Child/
Adolescent Anxiety Multimodal Treatment Study. Journal of
Consulting and Clinical Psychology 2016;84(1):1-14.

Kovacs 1989

Kovacs M, Gatsonis C, Paulauskas S, Richards C. Depressive
disorders in childhood. IV. A longitudinal study of comorbidity
with and the risk for anxiety disorders. Archives of General
Psychiatry 1989;46:776-82.

Kreuze 2018

Kreuze LJ, Pijnenborg GHM, de Jonge YB, Nauta MH. Cognitive-
behavior therapy for children and adolescents with anxiety
disorders: a meta-analysis of secondary outcomes. Journal of
Anxiety Disorders 2018;60:43-57.

La Greca 1998

La Greca A. Manual for Social Anxiety Scales for Children and
Adolescents. Coral Gables, FL: University of Miami, 1998.

Lawrence 2015

Lawrence D, Johnson S, Hafekost J, de Haan KB,
Sawyer M, Ainley J, et al. The Mental Health of Children
and Adolescents. Report on the Second Australian Child
and Adolescent Survey of Mental Health and Wellbeing.
www1.health.gov.au/internet/main/publishing.nsf/
Content/9DA8CA21306FE6EDCA257E2700016945/$File/
child2.pdf (accessed 4 October 2020).

Leyfer 2013

Leyfer O, Gallo K, Cooper-Vince C, Pincus DB. Patterns and
predictors of comorbidity of DSM-IV anxiety disorders in a
clinical sample of children and adolescents. Journal of Anxiety
Disorders 2013;27(3):306-11.

March 1997

March JS, Parker JD, Sullivan K, Stallings P, Conners CK. The
Multidimensional Anxiety Scale for Children (MASC): factor
structure, reliability, and validity. Journal of the American
Academy of Child and Adolescent Psychiatry 1997;36(4):554-65.

Holland D, Dadds M. Diagnostic Interview Schedule for Children,
Adolescents and Parents. Brisbane: Griffith University, 1995.

Masia-Warner 2005

Keeton 2013

Keeton CP, Ginsburg GS, Drake KL, Sakolsky D, Kendall PC,
Birmaher B, et al. Benefits of child-focused anxiety treatments

Masia-Warner C, Klein RG, Dent HC, Fisher PH, Alvir J,
Albano AM, et al. School-based intervention for adolescents
with social anxiety disorder: results of a controlled study.
Journal of Abnormal Child Psychology 2005;33(6):707-22.

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

59

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Mavranezouli 2015

Perihan 2019

Mavranezouli I, Mayo-Wilson E, Dias S, Kew K, Clark DM,
Ades AE, et al. The cost effectiveness of psychological
and pharmacological interventions for social anxiety
disorder: a model-based economic analysis. PLOS ONE
2015;10(10):e0140704. [DOI: 10.1371/journal.pone.0140704]

Merikangas 2011

Merikangas KR, He JP, Burstein M, Swendsen J, Avenevoli S,
Case B, et al. Service utilization for lifetime mental disorders in
U.S. adolescents: results of the National Comorbidity Survey-
Adolescent Supplement (NCS-A). Journal of the American
Academy of Child and Adolescent Psychiatry 2011;50(1):32-45.

Perihan C, Burke M, Bowman-Perrott L, Bicer A, Gallup J,
Thompson J, et al. Effects of cognitive behavioral therapy
for reducing anxiety in children with high functioning ASD:
a systematic review and meta-analysis. Journal of Autism
and Developmental Disorders 2019;27:1-5. [DOI: 10.1007/
s10803-019-03949-7]

Peris 2015

Peris TS, Compton SN, Kendall PC, Birmaher B, Sherrill J,
March J, et al. Trajectories of change in youth anxiety during
cognitive-behavior therapy. Journal of Consulting and Clinical
Psychology 2015;83(2):239-52.

Moher 2015

Peris 2017

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A,
Petticrew M, et al, PRISMA-P Group. Preferred reporting
items for systematic review and meta-analysis protocols
(PRISMA-P) 2015 statement. Systematic Review 2015;4:1. [DOI:
10.1186/2046-4053-4-1]

Peris TS, Caporino NE, O'Rourke S, Kendall PC, Walkup JT,
Albano AM, et al. Therapist-reported features of exposure
tasks that predict differential treatment outcomes for youth
with anxiety. Journal of the American Academy of Child and
Adolescent Psychiatry 2017;56(12):1043-52.

Monga 2015

Peters 2008

Monga S, Rosenbloom BN, Tanha A, Owens M, Young A.
Comparison of child-parent and parent-only cognitive-
behavioral therapy programs for anxious children aged 5 to 7
years: short- and long-term outcomes. Journal of the American
Academy of Child and Adolescent Psychiatry 2015;54(2):138-46.

Myers 2002

Myers K, Winters NC. Ten year review of rating scales II: scales
for internalising disorders. Journal of the American Academy of
Child and Adolescent Psychiatry 2002;41:634-59.

Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L.
Contour-enhanced meta-analysis funnel plots help distinguish
publication bias from other causes of asymmetry. Journal of
Clinical Epidemiology 2008;61(10):991-6.

Pine 2009

Pine DS, Helfinstein SM, Bar-Haim Y, Nelson E, Fox NA.
Challenges in developing novel treatments for
childhood disorders: lessons from research on anxiety.
Neuropsychopharmacology 2009;34(1):213-28.

NICE 2013

Polanczyk 2015

National Institute for Health and Care Excellence. Social anxiety
disorder: recognition, assessment and treatment: Clinical
guideline [CG159]. www.nice.org.uk/guidance/cg159 (accessed
4 October 2020).

O'Kearney 2006

O'Kearney RT, Anstey KJ, von Sanden C. Behavioural and
cognitive behavioural therapy for obsessive compulsive
disorder in children and adolescents. Cochrane Database of
Systematic Reviews 2006, Issue 4. Art. No: CD004856. [DOI:
10.1002/14651858.CD004856.pub2]

Ollendick 2010

Ollendick TH, Öst LG, Reuterskiöld L, Costa N. Comorbidity
in youth with specific phobias: impact of comorbidity on
treatment outcome and the impact of treatment on comorbid
disorders. Behaviour Research and Therapy 2010;48(9):827-31.

Polanczyk GV, Salum GA, Sugaya LS, Caye A, Rohde LA. Annual
research review: a meta-analysis of the worldwide prevalence
of mental disorders in children and adolescents. Journal
of Child Psychology and Psychiatry and Allied Disciplines
2015;56(3):345-65.

Rao 1992

Rao JN, Scott AJ. A simple method for the analysis of clustered
binary data. Biometrics 1992;48(2):577-85.

Reardon 2017

Reardon T, Harvey K, Baranowska M, O'Brien D, Smith L,
Creswell C. What do parents perceive are the barriers and
facilitators to accessing psychological treatment for mental
health problems in children and adolescents? A systematic
review of qualitative and quantitative studies. European Child &
Adolescent Psychiatry 2017;26(6):623-47.

Pennant 2015

Reardon 2020

Pennant ME, Loucas CE, Whittington C, Creswell C, Fonagy P,
Fuggle P, et al. Computerised therapies for anxiety and
depression in children and young people: a systematic
review and meta-analysis. Behaviour Research and Therapy
2015;67:1-18.

Reardon T, Harvey K, Creswell C. Seeking and accessing
professional support for child anxiety in a community sample.
European Child and Adolescent Psychiatry 2020;29:649-64. [DOI:
10.1007/s00787-019-01388-4]

Review Manager 2014 [Computer program]

Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic
Cochrane Centre, The Cochrane Collaboration, 2014.

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

60

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Reynolds 1985

Spence 1997

Reynolds CR, Richmond BO. Revised Children's Manifest Anxiety
Scale (RCAMS) Manual. Los Angeles: Western Psychological
Services, 1985.

Spence S. Stucture of anxiety symptoms amongst children:
a confirmatory factor-analytic study. Journal of Abnormal
Psychology 1997;106:280-97.

Reynolds 2012

Spielberger 1973

Reynolds S, Wilson C, Austin J, Hooper L. Effects of
psychotherapy for anxiety in children and adolescents: a meta-
analytic review. Clinical Psychology Review 2012;32(4):251-62.

Spielberger C, Edwards C, Montuori J, Lushene R. State-Trait
Anxiety Inventory for Children. Palto Alto, CA: Consulting
Psychologist Press, 1973.

Sanchez-Garcia 2009

Stata 2012 [Computer program]

Sanchez-Garcia R, Olivares J. Effectiveness of a program for
early detection/intervention in children/adolescents with
generalized social phobia. Anales de Psicologia 2009;25:241-9.

Schünemann 2017

Schünemann HJ, Oxman AD, Vist GE, Higgins JP, Deeks JJ,
Glasziou P, et al, on behalf of the Cochrane Applicability
and Recommendations Methods Group. Chapter 12:
Interpreting results and drawing conclusions. In: Higgins JPT,
Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane
Handbook for Systematic Reviews of Interventions version
5.2.0 (updated June 2017). Cochrane, 2017. Available from
www.training.cochrane.org/handbook.

Seligman 2011

Seligman L, Ollendick T. Cognitive behavioral therapy for
anxiety disorders in youth. Child & Adolescent Psychiatric Clinics
of North America 2011;20(2):217-38.

Shaffer 1983

Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, et al.
A children's global assessment scale (CGAS). Archives of General
Psychiatry 1983;40(11):1228-31.

Silverman 1987

Silverman WK. Anxiety Disorder Interview for Children (ADIC).
New York, NY: Graywind Publications, 1987.

Silverman 2008

Silverman WK, Pina AA, Viswesvaran C. Evidence-
based psychosocial treatments for phobic and anxiety
disorders in children and adolescents. Journal of
Clinical Child and Adolescent Psychology 2008;37:105-30.

Stata. Version Stata/IC 12.1. College Station, TX: StataCorp,
2012. Available at www.stata.com.

Sterne 2017

Sterne JA, Egger M, Moher D, Boutron I, editor(s). Chapter
10: Addressing reporting biases. In: Higgins JPT, Churchill
R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook
for Systematic Reviews of Interventions version 5.2.0
(updated June 2017). Cochrane, 2017. Available from
www.training.cochrane.org/handbook.

Suveg 2006

Suveg C, Kendall PC, Comer JS, Robin J. Emotion-focused
cognitive-behavioral therapy for anxious youth: a multiple-
baseline evaluation. Journal of Contemporary Psychotherapy
2006;36(2):77-85.

Ung 2015

Ung D, Selles R, Small BJ, Storch EA. A systematic review and
meta-analysis of cognitive-behavioral therapy for anxiety in
youth with high-functioning autism spectrum disorders. Child
Psychiatry and Human Development 2015;46(4):533-47.

van Steensel 2013

van Steensel F, Bogels S, Perrin S. Anxiety disorders in
children and adolescents with autistic spectrum disorders:
a meta-analysis. Clinical Child and Family Psychology Review
2011;14:302-17.

Waite 2014

Waite P, Creswell C. Children and adolescents referred
for treatment of anxiety disorders: differences in clinical
characteristics. Journal of Affective Disorders 2014;167:326-32.

Silverman 2009

Waite 2015

Silverman WK, Kurtines WM, Jaccard J, Pina AA. Directionality of
change in youth anxiety treatment involving parents: an initial
examination. Journal of Consulting and Clinical Psychology
2009;77:474-85.

Waite P, Codd J, Creswell C. Interpretation of ambiguity:
differences between children and adolescents with and
without an anxiety disorder. Journal of Affective Disorders
2015;188:194-201.

Southam-Gerow 2010

Wang 2005

Southam-Gerow MA, Weisz JR, Chu BC, McLeod BD, Gordis EB,
Connor-Smith JK. Does cognitive behavioral therapy for youth
anxiety outperform usual care in community clinics? An initial
effectiveness test. Journal of the American Academy of Child and
Adolescent Psychiatry 2010;49(10):1043-52.

Wang PS, Berglund P, Olfson M, Pincus HA, Wells KB, Kessler RC.
Failure and delay in initial treatment contact after first onset
of mental disorders in the National Comorbidity Survey
Replication. Archives of General Psychiatry 2005;62(6):603-13.

Wang 2017

Wang Z, Whiteside S, Sim L, Farah W, Morrow AS, Alsawas M, et
al. Comparative effectiveness and safety of cognitive behavioral
therapy and pharmacotherapy for childhood anxiety disorders:

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

61

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

a systematic review and meta-analysis. JAMA Pediatrics
2017;171(11):1049-56. [DOI: 10.1001/jamapediatrics.2017.3036]

phobia: parental concerns about medication. Journal of Anxiety
Disorders 2006;20(8):1133-47.

Warner 2011

Zhou 2019

Zhou X, Zhang Y, Furukawa TA, Cuijpers P, Pu J, Weisz JR, et
al. Different types and acceptability of psychotherapies for
acute anxiety disorders in children and adolescents: a network
meta-analysis. JAMA Psychiatry 2019;76(1):41-50. [DOI: 10.1001/
jamapsychiatry.2018.3070]

References to other published versions of this review

James 2005

James AA, Soler A, Weatherall RR. Cognitive behavioural
therapy for anxiety disorders in children and adolescents.
Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No:
CD004690. [DOI: 10.1002/14651858.CD004690]

James 2015

James AC, James G, Cowdrey FA, Soler A, Choke A.
Cognitive behavioural therapy for anxiety disorders
in children and adolescents. Cochrane Database of
Systematic Reviews 2015, Issue 2. Art. No: CD004690. [DOI:
10.1002/14651858.CD004690.pub4]

James 2018

James AC, Reardon T, Soler A, James G, Creswell C. Cognitive
behavioural therapy for anxiety disorders in children and
adolescents. Cochrane Database of Systematic Reviews 2018,
Issue 10. Art. No: CD013162. [DOI: 10.1002/14651858.CD013162]

* Indicates the major publication for the study

Warner CM, Colognori D, Kim RE, Reigada LC, Klein RG, Browner-
Elhanan KJ, et al. Cognitive-behavioral treatment of persistent
functional somatic complaints and pediatric anxiety: an initial
controlled trial. Depression and Anxiety 2011;28(7):551-9.

Warwick 2016

Warwick H, Reardon T, Cooper P, Murayama K, Reynolds S,
Wilson C, et al. Complete recovery from anxiety disorders
following cognitive behavior therapy in children and
adolescents: a meta-analysis. Clinical Psychology Review
2016;52:77-91.

Whiteside 2015

Whiteside SP, Ale CM, Young B, Dammann JE, Tiede MS,
Biggs BK. The feasibility of improving CBT for childhood anxiety
disorders through a dismantling study. Behaviour Research and
Therapy 2015;73:83-9.

WHO 1978

World Health Organization. The ICD-9 Classification of Mental
and Behavioural Disorders: Clinical Description and Diagnostic
Guidelines. Geneva: World Health Organization, 1978.

WHO 1992

World Health Organization. The ICD-10 Classification of Mental
and Behavioural Disorders: Clinical Description and Diagnostic
Guidelines. Geneva: World Health Organization, 1992.

Young 2006

Young BJ, Beidel DC, Turner SM, Ammerman RT, McGraw K,
Coaston SC. Pretreatment attrition and childhood social

C H A R A C T E R I S T I C S   O F   S T U D I E S

Characteristics of included studies [ordered by study ID]

Afshari 2014 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 10- to 12-week treatment, 3-month follow-up

Number of study centres and location: 1, Iran

Study setting: private clinic

Date of study: October 2011 to August 2012

Participants

N = 34 (CBT: N = 12; CBT (emotion-focused): N = 12; no treatment control: N = 10)

Mean age (SD): 10.57 (2.27)

Age range: 9 to 13 years

Inclusion criteria: separation anxiety disorder diagnosis (based on the ADIS-C/P), not receiving med-
ication or stopped using drugs for at least 1 month before pretest

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

62

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Afshari 2014  (Continued)

Cochrane Database of Systematic Reviews

Exclusion criteria: IQ < 80, learning disorders, psychosis, serious mental or physical problems, low in-
terest in continuing the study

Interventions

CBT

Intervention: Coping Cat

Concomitant/excluded medications: no medication or stopped for at least 1 month before pretest

Delivery format: child-only sessions, does not specify if parent sessions included; group format

Therapist contact time: 10 hours (10 x 1 hour)

Who delivers the intervention: advanced PhD students in psychology

CBT (emotion-focused)

Intervention: emotion-focused CBT (ECBT) (Suveg 2006)

Concomitant/excluded medications: no medication or stopped for at least 1 month before pretest

Delivery format: child-only sessions, and 2 parent sessions; group format

Therapist contact time: 12 hours (child: 10 x 1; parent: 2 x 1)

Who delivers the intervention: advanced PhD students in psychology

Wait list/no treatment

Intervention: no treatment

Concomitant/excluded medications: no medication or stopped for at least 1 month before pretest

Outcomes

Reduction in anxiety symptoms (child report) post-treatment and 3-month follow-up: SCARED-C

Reduction in anxiety symptoms (parent report) post-treatment and 3-month follow-up: SCARED-P

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Judgement Comment: No detail given

Unclear risk

Judgement Comment: No detail given

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Judgement Comment: No detail given but child/parent report questionnaires
only

Judgement Comment: Reason for missing outcome data (low interest in at-
tending sessions) likely to be related to outcome

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

63

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Afshari 2014  (Continued)

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes for each measure reported

Other source of bias -
Therapy integrity

Unclear risk

Judgement Comment: Therapists PhD students. No detail on any attempt to
maintain or measure therapy integrity

Other bias

Unclear risk

Judgement Comment: Timings for post-treatment assessment not detailed.
Treatment period different for 2 treatment groups

Arendt 2016 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: non-controlled 3-month and 12-month follow-up

Number of study centres and location: 1, in Denmark

Study setting: university research clinic

Date of study: October 2011 to August 2012

Participants

N = 109 (CBT: N = 56; waitlist: N = 53)

Mean age (SD): 11.78 (2.74)

Age range: 7 to 16

Gender: 62 (57%) female

Inclusion criteria: primary anxiety disorder diagnosis (based on the ADIS-C/P)

Exclusion criteria: psychosis, untreated attention deficit hyperactivity disorder (ADHD), intellectual
disability, and severe behaviour disorders

Notes: funded by TrygFonden (grant ID n10691). Authors declare no competing interests

Interventions

CBT

Intervention: Cool Kids

Concomitant/excluded medications: encouraged not to change medication during treatment period

Delivery format: child and parent sessions; group

Therapist contact time: 20 hours (10 x 2 hours), plus 1-hour booster

Who delivers the intervention: psychologists, plus graduate psychologists as assistants

Waitlist/no treatment

Intervention: 3-month waitlist

Concomitant/excluded medications: encouraged not to change medication during treatment period

Outcomes

Remission of primary anxiety diagnosis post-treatment: ADIS-C/P

Remission of all anxiety disorder diagnoses post-treatment: ADIS-C/P

Reduction in anxiety symptoms (child report) post-treatment: SCAS-C

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

64

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Arendt 2016  (Continued)

Cochrane Database of Systematic Reviews

Reduction in anxiety symptoms (parent report) post-treatment: SCAS-P (mother report)

Reduction in depressive symptoms post-treatment: SMFQ-C

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Judgement Comment: Block randomisation, computer-generated list. Good
detail

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Low risk

Judgement Comment: Sequence list and allocation concealed from re-
searchers and therapists until start of treatment

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: ADIS assessors blind to group and prior diagnosis

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Missing data reported in consort and have been imput-
ed using appropriate methods. Small amount of missing data

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes for planned measures all reported, and
where collected and not reported acknowledged

Other source of bias -
Therapy integrity

Unclear risk

Judgement Comment: Therapists trained and supervised. No assessment of
adherence

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Barrett 1996 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: non-controlled 6-month, 12-month, and 6-year follow-up

Number of study centres and location: 1, in Australia

Study setting: university research clinic

Participants

N = 85 (CBT-child: N = 31; CBT-family: N = 27; waitlist: N = 27)

Mean age (SD): CBT-child: 9.7 (2.5); CBT-family: 10.1 (1.9); waitlist: 8.2 (1.9)

Age range: 7 to 14

Gender: 34 (43%) female

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

65

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Barrett 1996  (Continued)

Cochrane Database of Systematic Reviews

Inclusion criteria: principal diagnosis of overanxious disorder, separation anxiety disorder, or social
phobia (based on ADIS-C/P)

Exclusion criteria: intellectual or physical disabilities, anti-anxiety or depression medication, parents
involved in acute marital breakdown

Interventions

CBT- child

Intervention: Coping Koala (adaptation of Coping Cat)

Concomitant/excluded medications: anti-anxiety and depression medication excluded

Delivery format: child-only sessions; individual

Therapist contact time: 12 to 16 hours (12 x 60 to 80 minutes)

Who delivers the intervention: registered clinical psychologists

CBT- family

Intervention: Coping Koala (adaptation of Coping Cat), plus Family Anxiety Management (FAM)

Concomitant/excluded medications: anti-anxiety and depression medication excluded

Delivery format: child-only sessions, and parent and child sessions (FAM); individual

Therapist contact time: 12 to 16 hours (12 x 60 to 80 minutes)

Who delivers the intervention: registered clinical psychologists

Waitlist/no treatment

Intervention: 12-week waitlist

Concomitant/excluded medications: anti-anxiety and depression medication excluded

Outcomes

Remission of all anxiety disorder diagnoses post-treatment: ADIS-C/P

Reduction in anxiety symptoms (child report) post-treatment: RCMAS

Reduction in depressive symptoms post-treatment: CDI

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Judgement Comment: Lacks details; randomisation to treatment groups/ther-
apists unclear and refers to "alternating"

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

Judgement Comment: No detail given

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Blinded assessors

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

66

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Barrett 1996  (Continued)

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

Judgement Comment: Dropouts reported, but number randomised vs com-
pleters not clear and not reported for individual measures

Low risk

Judgement Comment: Outcomes for all measures reported

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Protocol adherence assessed and confirmed for 60%
sessions by blind clinician

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Barrett 1998 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: non-controlled 12-month follow-up

Number of study centres and location: 1, in Australia

Study setting: clinic

Participants

N = 60 (CBT-child: N = 23; CBT-family: N = 17; waitlist: N = 20)

Age range: 7 to 14

Gender: 28 (46.7%) female

Inclusion criteria: principal diagnosis of overanxious disorder, separation anxiety disorder, or social
phobia (based on ADIS-C/P)

Exclusion criteria: principal diagnosis of simple phobia, intellectual or physical disabilities, currently
taking anti-anxiety or depression medication, parents involved in acute marital breakdown

Interventions

CBT- child

Intervention: Coping Koala (adaptation of Coping Cat)

Concomitant/excluded medications: anti-anxiety and depression medication excluded

Delivery format: child-only sessions; group

Therapist contact time: 24 hours (12 x 2 hours)

Who delivers the intervention: registered clinical psychologists

CBT- family

Intervention: Coping Koala (adaptation of Coping Cat) and Group Family Anxiety Management

Concomitant/excluded medications: anti-anxiety and depression medication excluded

Delivery format: child and parent sessions; group

Therapist contact time: 24 hours (12 x 2 hours)

Who delivers the intervention: registered clinical psychologists

Waitlist/no treatment

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

67

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Barrett 1998  (Continued)

Intervention: 12-week waitlist

Cochrane Database of Systematic Reviews

Concomitant/excluded medications: anti-anxiety and depression medication excluded

Outcomes

Remission of all anxiety disorder diagnoses post-treatment: ADIS-C/P

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Judgement Comment: No detail given. Refers to matching across conditions
but does not detail procedure

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

Judgement Comment: No detail given

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Blind assessors

Unclear risk

Judgement Comment: Insufficient detail on completers vs number ran-
domised for each measure or how missing data were managed

Low risk

Judgement Comment: Reported outcomes for all measures

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Blind clinician assessed therapy integrity of random
sessions; trained therapists delivered treatment

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Barrington 2005 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 12-month follow-up

Number of study centres and location: Australia

Study setting: clinic

Participants

N = 54 (CBT: N = 28; TAU: N = 26)

Mean age (SD): CBT: 9.8 (2.29); TAU: 10.2 (1.75)

Age range: 7 to 14

Gender: 35 (64.8%) female

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

68

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Barrington 2005  (Continued)

Cochrane Database of Systematic Reviews

Inclusion criteria: referrals with predominantly anxiety-related problems (100% primary anxiety disor-
der diagnosis, based on ADIS-C/P, parent and child interviewed together)

Exclusion criteria: predominant high levels of aggressive behaviour, intellectual disability, focus of
court procedures, exposed to recent trauma

Interventions

CBT

Intervention: based on CBT guidelines and CBT toolkit

Delivery format: child-only sessions and parent-only/child and parent together sessions; individual

Therapist contact time: 12 hours (approximate)

Who delivers the intervention: experienced therapists, masters/doctoral level, CBT trained

TAU

Intervention: variety of treatment modalities, including family therapy, play therapy, supportive psy-
chotherapy, psychodynamic psychotherapy, non-CBT eclectic approaches

Delivery format: child-only sessions and parent-only/child and parent together sessions; individual

Therapist contact time: 12 hours (approximate)

Who delivers the intervention: experienced therapists, masters/doctoral level, CBT trained

Outcomes

Remission of all anxiety disorder diagnoses post-treatment, 6-month follow-up and 12-month fol-
low-up: ADIS-C/P (child and parent interviewed together)

Reduction in anxiety symptoms (child report) post-treatment, 6-month follow-up and 12-month
follow-up: RCMAS

Reduction in anxiety symptoms (parent report) post-treatment, 6-month follow-up and 12-month
follow-up: SCAS-P

Number randomised not clear in paper. Report SCAS-C z score, so prioritise RCMAS

Authors' judgement

Support for judgement

Unclear risk

Judgement Comment: No detail given

Unclear risk

Judgement Comment: No detail given

Unclear risk

Judgement Comment: No detail given about whether participants were blind-
ed to condition

Low risk

Judgement Comment: Assessor blind to treatment condition and therapist

Unclear risk

Judgement Comment: Missing data for questionnaires detailed, but number
randomised vs completers not clear

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

69

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Barrington 2005  (Continued)

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Outcomes reported for all measures

Low risk

Judgement Comment: Adherence monitored and independently assessed

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Berge 2017 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: non-controlled 12-month follow-up

Number of study centres and location: 1, in Norway

Study setting: odontophobia clinic

Date of study: 2013 to 2016

Participants

N = 67 (CBT: N = 34; waitlist: N = 33)

Mean age (SD): 12.2 (2.0)

Age range: 10 to 16

Gender: 39 (58.2%) female

Inclusion criteria: 10 to 16 years, primary diagnosis of intra-oral injection phobia (I-OIP) (DSM-5 crite-
ria, using modified ADIS), other phobias as either secondary diagnoses or co-primary diagnoses with I-
OIP allowed, willingness to try exposure treatment; willingness to participate in the study for a period
of 1 year

Exclusion criteria: primary depression, drug or alcohol abuse, intellectual disabilities, psychotic symp-
toms

Interventions

CBT

Intervention: One Session Treatment (OST), modified for 5 sessions

Concomitant/excluded medications: no detail given

Delivery format: child only; individual

Therapist contact time: 5 hours (5 x 1 hour)

Who delivers the intervention: dentists, trained and accredited in OST

Waitlist/no treatment

Intervention: 5-week waitlist

Concomitant/excluded medications: no detail given

Outcomes

Reduction in anxiety symptoms (child report) post-treatment: Intra Oral Injection Fear Scale (IOIF-
s)

Notes

Anxiety symptoms measure - measure of intra-oral injection fears

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

70

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Berge 2017  (Continued)

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Computer-generated random number

Low risk

Low risk

Judgement Comment: Opaque and sealed envelopes were put in order ac-
cording to the randomisation

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Outcome assessment questionnaires only

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Dropouts detailed, and where reasons known this infor-
mation was provided; missing data for each measure reported

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes for all measures reported

Other source of bias -
Therapy integrity

Unclear risk

Judgement Comment: Dentists trained and accredited in the OST delivered in-
tervention, but no detail provided on adherence

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Cartwright Hatton 2011 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 12-month follow-up

Number of study centres and location: 1, in the UK

Study setting: research hospital

Date of study: recruitment January 2006 to January 2008

Withdrawals: 1 family randomised to treatment group withdrawn

Participants

N = 74 randomised (CBT: N = 38; waitlist: N = 36); NB: N = 70 met diagnostic criteria for an anxiety disor-
der and included here

Mean age: 6.6 years (n = 74)

Age range: 2.7 to 9 years (n = 74)

Gender: 42 (56.8%) (n = 74)

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

71

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cartwright Hatton 2011  (Continued)

Cochrane Database of Systematic Reviews

Inclusion criteria: ≥ cut-off on CBCL Internalising Scale or Preschool Behaviour Checklist Internalising
Scale and likely to have an anxiety disorder (NB: only those who met diagnostic criteria for an anxiety
disorder based on ADIS-P are included here)

Exclusion criteria: parent/child had moderate-to-severe learning difficulties; child had moderate-to-
severe autistic spectrum disorder

Interventions

CBT

Intervention: Timid Tiger

Concomitant/excluded medications:

Delivery format: parent only; group

Therapist contact time: 20 hours (10 x 2 hours)

Who delivers the intervention: clinical psychologist

Waitlist/no treatment

Intervention: 10-week waitlist

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment and 12-month follow-up: ADIS-P

Notes

Risk of bias

Bias

Remission of all anxiety disorder diagnoses post-treatment and 12-month follow-up: ADIS-P

Symptom measures - data not available for those who met diagnostic criteria for an anxiety disorder at
baseline (N = 70)

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Judgement Comment: Minimisation with random element using 3 factors;
planned 1:1 ratio

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Low risk

Low risk

Judgement Comment: Telephone, with concealed allocation by independent
agency

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Assessors blind to group allocation

Low risk

Low risk

Low risk

Judgement Comment: Missing outcome data balanced in numbers across in-
tervention groups, and where possible imputed with appropriate method

Judgement Comment: Outcomes for all measures reported (with the excep-
tion of teacher reports, which is justified)

Judgement Comment: Therapist qualifications evidenced, and therapy adher-
ence detailed

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

72

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cartwright Hatton 2011  (Continued)

Other bias

Unclear risk

Cochrane Database of Systematic Reviews

Judgement Comment: Long-term follow-up data: 38% controls reported to
have received additional intervention vs 7% in the CBT group

Chalfant 2007 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: treatment period 5.5 months

Number of study centres and location: 1, in Australia

Study setting: clinic

Participants

N = 51 (CBT: N = 32; waitlist: N = 19)

Mean age: 10.8 (1.35) (n = 47)

Age range: 8 to 13

Gender: 12 (25.5%) (n = 47)

Inclusion criteria: documentation of diagnosis of high functioning autistic disorder or Asperger's dis-
order. Received primary anxiety disorder diagnosis (based on ADIS-C/P)

Exclusion criteria: intellectual delay, physical disability, currently taking anti-anxiety or anti-depres-
sant medication, presented with marked externalising difficulties (e.g. conduct disorder or opposition-
al defiant disorder), parents experiencing acute marital breakdown

Interventions

CBT

Intervention: adaptation of Cool Kids

Concomitant/excluded medications: currently taking anti-anxiety and anti-depressant medication
excluded

Delivery format: child and parent concurrent sessions; group

Therapist contact time: 24 hours (12 x 2 hours)

Who delivers the intervention: clinical psychologist

Waitlist/no treatment

Intervention: waitlist, approximately 5.5 months

Concomitant/excluded medications: currently taking anti-anxiety and anti-depressant medication
excluded

Outcomes

Remission of all anxiety disorder diagnoses post-treatment: ADIS-C/P

Reduction in anxiety symptoms (child report) post-treatment: SCAS-C

Reduction in anxiety symptoms (parent report) post-treatment: SCAS-P

Notes

Total N randomised not clear.
Author confirmed not able to provide additional diagnostic outcome data.

Sample with ASD

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

73

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Chalfant 2007  (Continued)

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Authors' judgement

Support for judgement

Unclear risk

Judgement Comment: No detail on sequence generation given

Unclear risk

Judgement Comment: No detail on allocation given

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Unclear risk

Judgement Comment: Clinicians who collected post-treatment data not blind
to study aims. Not specified if blind to intervention group

Unclear risk

Judgement Comment: Detailed number of dropouts, but not clear if dropouts
included in analyses. Did not provide n for individual measures or any detail
on how missing data were managed

Low risk

Judgement Comment: Data reported for all outcome measures

Other source of bias -
Therapy integrity

Unclear risk

Judgement Comment: Therapy delivered by clinical psychologists, no other
detail on training/supervision or adherence

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Cheung 2016 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: non-controlled 6-month follow-up

Number of study centres and location: 1, in Hong Kong

Study setting: Clinic-Child Assessment Service

Date of study: 2014 to 2015

Participants

N = 81 (CBT: 22; active control (Attention Bias Modification Training (ABM)): 20; CBT + ABM: 20; waitlist:
19)

Mean age: 7.37

Age range: 6 to 12

Gender: 48 (64%) (n = 75)

Inclusion criteria: diagnostic criteria for social anxiety disorder (based on ADIS-P)

Exclusion criteria: sensory impairments or other physical disabilities, ASD, received psychotherapy
(such as CBT) or medication for anxiety or mood problems within the previous 6 months

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

74

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cheung 2016  (Continued)

Interventions

CBT

Cochrane Database of Systematic Reviews

Intervention: adapted version of Coping Cat

Delivery format: child-only sessions, parent join some sessions

Therapist contact time: 18 hours (9 x 2 hours)

Who delivers the intervention: clinical psychologist

Active control (ABM)

Intervention: Attention Bias Modification Training (8 sessions computerised ABM training)

CBT (CBT + ABM)

Intervention: adapted version of Coping Cat and ABM (8 sessions computerised ABM training)

Delivery format: child-only sessions, parent join some sessions

Therapist contact time: 18 hours (9 x 2 hours)

Who delivers the intervention: clinical psychologist

Waitlist/no treatment

Intervention: 2-month waitlist

Outcomes

Reduction in anxiety symptoms (child report) post-treatment: SCAS-C

Reduction in anxiety symptoms (parent report) post-treatment: SCAS-P

Notes

Comparisons: CBT vs waitlist; CBT + ABM vs active control (ABM)

Active control (ABM) = alternative treatment

Used post-treatment diagnostic assessment but did not report remission outcomes

Thesis

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Judgement Comment: Computerised random number generator, but unclear
allocation of additional children recruited after dropouts from CBT group

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Computer based, so unlikely to foresee assignment

Unclear risk

Judgement Comment: No detail

Low risk

Judgement Comment: Blind assessors

Unclear risk

Judgement Comment: No ITT analyses reported

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

75

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Cheung 2016  (Continued)

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Outcomes for relevant measures reported

Unclear risk

Judgement Comment: No detail

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Chiu 2013 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: treatment period 3 months. Non-controlled 1-year follow-up

Number of study centres and location: 2 schools in the USA

Study setting: elementary schools

Date of study: recruitment January 2005 to April 2008

Participants

N = 40 (CBT: N = 22; waitlist: N = 18)

Mean age: 8.51 (1.74)

Age range: 5 to 12

Gender: 18 (45%) female

Inclusion criteria: primary diagnosis of separation anxiety disorder, social phobia, or generalised anx-
iety disorder (DSM–IV) (based on ADIS-C/P); no psychiatric medication use or stable use of psychiatric
medication for at least 1 month and agree to maintain that dose throughout the study

Exclusion criteria: child was currently in psychotherapy

Interventions

CBT

Intervention: Building Confidence

Concomitant/excluded medications: no psychiatric medication use or stable use

Delivery format: child only, or if parent opted to attend session divided into child only, parent alone,
parent and child together; individual

Therapist contact time: up to 16 hours (up to 16 x 1 hour)

Who delivers the intervention: clinical/educational psychology doctoral students

Waitlist/no treatment

Intervention: 3-month waitlist

Concomitant/excluded medications: no psychiatric medication use or stable use

Outcomes

Remission of all anxiety disorder diagnoses post-treatment: ADIS-C/P

Reduction in anxiety symptoms (child report) post-treatment: MASC-Child report

Reduction in anxiety symptoms (parent report) post-treatment: MASC-Parent report

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

76

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Chiu 2013  (Continued)

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Judgement Comment: Did not detail sequence generation, description of
stratification method unclear

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

Judgement Comment: No detail given

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Assessors blind to treatment condition

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Described method for managing missing data. Small
amount of missing data, only 1 dropout

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Data for each measure reported

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Trained clinicians, regular supervision. Blind assessors
rated random-selection therapy sessions for fidelity

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Cobham 2017 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: non-controlled 12-month follow-up

Number of study centres and location: 1, in Australia

Study setting: university clinic

Participants

N = 63 (CBT: N = 33; waitlist: N = 30)

Mean age: 9.3 (2.0) (n = 60)

Age range: 7 to 14

Gender: 30 (49.2%) female

Inclusion criteria: child aged 7 to 14 years; child meets diagnostic criteria for a primary DSM-IV anxiety
diagnosis (based on ADIS-C/P); parent able to attend treatment

Exclusion criteria: child currently in psychotherapy

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

77

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cobham 2017  (Continued)

Interventions

CBT

Cochrane Database of Systematic Reviews

Intervention: Fear-less Triple P

Concomitant/excluded medications: medication for anxiety excluded

Delivery format: parent only; group

Therapist contact time: 9 hours (6 x 1.5 hours)

Who delivers the intervention: postgraduate clinical psychology interns

Waitlist/no treatment

Intervention: 6-week waitlist

Concomitant/excluded medications: medication for anxiety excluded

Outcomes

Remission of primary anxiety disorder diagnoses post-treatment: ADIS-C/P

Remission of all anxiety disorder diagnoses post-treatment: ADIS-C/P

Reduction in anxiety symptoms (child report) post-treatment: SCAS-C

Reduction in anxiety symptoms (parent report) post-treatment: SCAS-P

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Computer-generated, block randomisation

Low risk

Judgement Comment: Computer generated, so unlikely to foresee assignment

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Assessors blind to treatment condition

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Attrition/withdrawals detailed, with reasons provided.
Few dropouts. Detail related to missing data provided, with evidence missing
at random and appropriate imputation methods used

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes reported for all measures

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Intervention delivered by trained therapists, weekly su-
pervision. Treatment integrity assessed and confirmed by blind researcher

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

78

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Cornacchio 2019 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: non-controlled school year follow-up

Number of study centres and location: 1, in the USA

Study setting: selective mutism treatment centre

Participants

N = 29 (CBT: N = 14; waitlist: N = 15)

Mean age: 6.6 (1.3)

Age range: 5 to 9

Gender: 22 (75.9%) female

Inclusion criteria: age 5 to 9, meet DSM–5 criteria for selective mutism (based on ADIS-P)

Exclusion criteria: identified as having any mental health condition more impairing than selective
mutism; or they were non-verbal with both of their parents

Interventions

CBT

Intervention: intensive group CBT programme centred around graded exposure to verbal communica-
tion that draws on parent-child interaction therapy

Concomitant/excluded medications: medication for anxiety excluded

Delivery format: child-only and parent-only sessions; group

Therapist contact time: 30 to 40 hours (5 x 6 to 8 hours, 5 consecutive days)

Who delivers the intervention: counsellor and masters-level therapist

Waitlist/no treatment

Intervention: 4-week waitlist, 1-page psychoeducation information brochure on selective mutism

Concomitant/excluded medications: medication for anxiety excluded

Outcomes

Remission of primary anxiety disorder diagnoses post-treatment: ADIS-P

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)

Improvement in global functioning post-treatment: CGAS

Report CBCL-Anxiety t score

Authors' judgement

Support for judgement

Unclear risk

Judgement Comment: Not detailed

Unclear risk

Judgement Comment: Not detailed

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

79

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Cornacchio 2019  (Continued)

All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Judgement Comment: Masked assessors

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Retention detailed, and procedure for managing miss-
ing data appropriate

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Outcomes reported for relevant measures

Low risk

Judgement Comment: Trained staff, and fidelity assessed and reported

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Creswell 2017 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 6-month follow-up

Number of study centres and location: 4, in the UK

Study setting: CAMHS

Date of study: recruitment March 2012 to March 2014

Participants

N = 136 randomised (CBT: N = 68; active control: N = 68) NB: N = 122 met diagnostic criteria for an anxi-
ety disorder and were included here (based on ADIS-C/P)

Age range: 5 to 12

Gender: 63 (51.6%) female (n = 122)

Inclusion criteria: child aged 5 to 12 years with anxiety associated with clinical impairment as the pri-
mary presenting problem. NB: we only included those who met diagnostic criteria (90% original sam-
ple)

Exclusion criteria: children prescribed psychotropic medication, and parents or children with little un-
derstanding of English or with physical or intellectual impairment (including autism spectrum disorder)
that would interfere with their ability to participate in assessments or treatment

Interventions

CBT

Intervention: parent-guided CBT

Concomitant/excluded medications: not allowed

Delivery format: parent only; individual

Therapist contact time: 5 hours (5 x 1 hour) (face-to-face and telephone sessions)

Who delivers the intervention: primary mental health workers

Active control

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

80

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Creswell 2017  (Continued)

Cochrane Database of Systematic Reviews

Intervention: Solution Focused Therapy

Concomitant/excluded medications: not allowed

Delivery format: child only, and 1 session parent and child; individual

Therapist contact time: 5 hours (5 x 1 hour)

Who delivers the intervention: primary mental health workers

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment and 6-month follow-up: ADIS-C/P

Remission of all anxiety disorder diagnoses post-treatment and 6-month follow-up: ADIS-C/P

Reduction in anxiety symptoms (child report) post-treatment and 6-month follow-up: SCAS-C

Reduction in anxiety symptoms (parent report) post-treatment and 6-month follow-up: SCAS-P

Notes

Risk of bias

Bias

Active control = alternative treatment

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Judgement Comment: Secure online minimisation tool

Allocation concealment
(selection bias)

Low risk

Judgement Comment: Allocation sequence was retained on the secure online
minimisation program, only accessible to the principal investigator and the
clinical supervisor who allocated participants to clinicians

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Low risk

Low risk

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Judgement Comment: Research staff who obtained outcome measurements
were masked to group allocation

Judgement Comment: Dropouts detailed, and appropriate methods used to
manage missing data

Low risk

Judgement Comment: Outcomes reported/provided for all measures

Low risk

Judgement Comment: Trained, supervised and adherence measured

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Dadds 1997 

Study characteristics

Methods

Study design: cluster-randomised controlled trial

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

81

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Dadds 1997  (Continued)

Cochrane Database of Systematic Reviews

Total duration of study: 6-, 12-, and 24-month follow-up

Number of study centres and location: 8 primary schools in Australia

Study setting: primary schools

Participants

N = 128 randomised (CBT: N = 61; active control: N = 68) (NB: N = 64 met diagnostic criteria for an anxi-
ety disorder and were included here (based on ADIS-P))

Age range: 7 to 14 years

Inclusion criteria: children met diagnostic criteria for anxiety disorder or features of anxiety disorder.
We only included those who met diagnostic criteria (based on ADIS-P, CSR = 4+)

Exclusion criteria: Clinical Severity Rating 6 to 8

Interventions

CBT

Intervention: Coping Koala (Australian modification of Coping Cat)

Concomitant/excluded medications:

Delivery format: child only, parent only; group

Therapist contact time: 10 to 23 hours (10 x 1 to 2 hours, plus 3 parent sessions)

Who delivers the intervention: clinical psychologists

Waitlist/no treatment

Intervention: monitoring, no intervention

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment and 6-, 12-, and 24-month fol-
low-up: ADIS-P

Remission of all anxiety disorder diagnoses post-treatment and 6-, 12-, and 24-month follow-up:
ADIS-P

Reduction in anxiety symptoms (child report) post-treatment and 6-, 12-, and 24-month fol-
low-up: RCMAS

Notes

Author provided data on outcomes for participants who met diagnostic criteria for an anxiety disorder
(CSR 4+) at baseline.

Cluster trial - adjustments for analysis as per protocol

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Judgement Comment: Schools matched for size, sociodemographics, and
were randomly allocated to condition. No further detail

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)

Unclear risk

Judgement Comment: No detail

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Blind assessors

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

82

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Dadds 1997  (Continued)

All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Author provided data

Low risk

Judgement Comment: Outcomes reported/provided

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Regular supervision, integrity monitored, and no signif-
icant departures from protocol reported

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Flannery Schroeder 2000 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: non-controlled 3-month and 1-year follow-up

Number of study centres and location: 1, in the USA

Study setting: university clinic

Participants

N = 45 (CBT-individual: N = 18; CBT-group: N = 13; waitlist: N = 14)

Age range: 8 to 14 years

Inclusion criteria: DSM-IV diagnostic criteria for a childhood anxiety disorder (generalised anxiety dis-
order, separation anxious disorder, social phobia) (based on ADIS-C/P)

Exclusion criteria: a disabling physical condition, psychotic symptoms or current use of anti-anxiety
or anti-depressant medication; primary diagnosis of simple phobia

Interventions

CBT-individual

Intervention: Coping Cat

Concomitant/excluded medications: current use of anti-anxiety or anti-depressant medication ex-
cluded

Delivery format: child-only sessions, with additional parent meetings; individual

Therapist contact time: 15 to 18 hours (18 x 50 to 60 minutes)

Who delivers the intervention: trained therapists, doctoral candidates

CBT-group

Intervention: Adapted Coping Cat for groups

Concomitant/excluded medications: current use of anti-anxiety or anti-depressant medication ex-
cluded

Delivery format: child-only sessions, with additional parent meetings; group

Therapist contact time: 27 hours (18 x 90 minutes)

Who delivers the intervention: trained therapists, doctoral candidates

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

83

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Flannery Schroeder 2000  (Continued)

Waitlist/no treatment

Intervention: 9-week waitlist

Cochrane Database of Systematic Reviews

Concomitant/excluded medications: current use of anti-anxiety or anti-depressant medication ex-
cluded

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-C/P

Reduction in anxiety symptoms (child report) post-treatment: RCMAS

Reduction in anxiety symptoms (parent report) post-treatment: STAIC-trait (mother report)

Reduction in depressive symptoms post-treatment: CDI

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Judgement Comment: Block randomisation used to assign to group CBT. No
detail on sequence generation

Allocation concealment
(selection bias)

Unclear risk

Judgement Comment: No detail given (only detail on teachers blind to condi-
tion)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Unclear risk

Judgement Comment: No detail given regarding whether or not diagnostic as-
sessments were administered by blind assessors

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Detail on dropouts. Reported ITT similar pattern as
completers on continuous measures

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Measures reported

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Therapy adherence assessed by independent rater.
Therapists trained

Other bias

High risk

Judgement Comment: Waitlist duration shorter than treatment

Fujii 2013 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 32-week treatment period

Number of study centres and location: 1, in the USA

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

84

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Fujii 2013  (Continued)

Study setting: clinic

Participants

N = 16 (CBT: N = 10; TAU: N = 6)

Mean age (SD): 8.80 (1.60), n = 12

Age range: 7 to 11

Gender: 3 (25%) female (n = 12)

Cochrane Database of Systematic Reviews

Inclusion criteria: research criteria for ASD and at least 1 anxiety disorder, CSR 5+ (based on ADIS-C/P)

Exclusion criteria: verbal IQ < 70, primary diagnosis other than anxiety

Interventions

CBT

Intervention: Building Confidence CBT Program

Concomitant/excluded medications: psychiatric medication, if used, was maintained at a stable dose
for at least 1 month prior to intake and throughout the duration of the trial

Delivery format: child and parent (part of each session individually, and part together); individual

Therapist contact time: 48 hours (32 x 90 minutes)

Who delivers the intervention: graduate/postdocs in psychology or psychiatry

TAU

Intervention: free to seek any kind of treatment for period of 16 weeks

Concomitant/excluded medications: psychiatric medication, if used, was maintained at a stable dose
for at least 1 month prior to intake. Allowed to alter medication during TAU period, as long as stable for
at least 1 month prior to post-assessment

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-C/P

Notes

Risk of bias

Bias

Sample with ASD

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Judgement Comment: Blocked randomised by sex and age. No detail on se-
quence generation

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Unclear risk

Judgement Comment: No detail given

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Judgement Comment: All assessments were conducted by independent evalu-
ators blind

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Attrition detailed, data reported

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

85

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Fujii 2013  (Continued)

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Low risk

Low risk

Cochrane Database of Systematic Reviews

Judgement Comment: Reported diagnostic outcomes. No mention of other
measures (but reasonable given small sample, population)

Judgement Comment: Trained and supervisors therapists. Adherence as-
sessed and reported

Other bias

High risk

Judgement Comment: TAU period shorter than treatment period

Gallagher 2004 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 3-week follow-up (3 weeks after end of treatment)

Number of study centres and location: 1 in the USA

Study setting: clinic

Participants

N = 23 (CBT: N = 12; waitlist: N = 11)

Age range: 8 to 11

Gender: 12 (52.2%) female

Inclusion criteria: meet diagnostic criteria for social phobia (based on ADIS-C/P)

Exclusion criteria: Attention Deficit Hyperactivity Disorder, conduct disorder, Oppositional Defiant
Disorder, bipolar, suicidal ideation, mental retardation

Interventions

CBT

Intervention: brief group intervention for preadolescents with social phobia

Delivery format: child only (plus initial child + parent session); group

Therapist contact time: 9 hours (3 x 180 minutes)

Who delivers the intervention: primary investigator and graduate students

Waitlist/no treatment

Intervention: 6-week waitlist

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-P

Reduction in anxiety symptoms (child report) post-treatment: RCMAS

Reduction in depressive symptoms post-treatment: CDI

Report parent and child ADIS data separately; given age of sample, use ADIS-P data here

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Unclear risk

Judgement Comment: No detail given on sequence generation

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

86

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Gallagher 2004  (Continued)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Unclear risk

Low risk

Judgement Comment: Separation of therapists from initial screening, but allo-
cation concealment not detailed

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Judgement Comment: Procedure somewhat unclear, but sufficient detail to
determine post-treatment assessments carried out by blind assessors

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

Judgement Comment: N given for diagnostic outcomes, but attrition not spec-
ified. Refer to missing parent data, but not detailed by group

Low risk

Judgement Comment: Report outcomes for measures

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Treatment administered by doctoral students and au-
thor of manual. Adherence assessed and reported

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Ginsburg 2002 

Study characteristics

Methods

Study design: randomised controlled trial

Number of study centres and location: 1, in the USA

Study setting: urban high school

Participants

N = 12 (CBT: N = 6; active control: N = 6)

Mean age (SD): 15.6

Age range: 14 to 17

Inclusion criteria: DSM-IV criteria for a primary (i.e. most severe) anxiety diagnosis (excluding Obses-
sive Compulsive Disorder and Post Traumatic Stress Disorder), with CSR ≥ 4 (based on ADIS-C); not cur-
rently participating in psychiatric or psychosocial treatment aimed at reducing anxiety symptoms

Exclusion criteria: psychiatric condition contradicting study treatment (e.g. suicidal intent) or needed
more immediate or alternative treatment

Interventions

CBT

Intervention: modified version of group CBT manual (Silverman 1999b)

Concomitant/excluded medications: currently participating in any psychiatric treatment excluded

Delivery format: child only; group

Therapist contact time: 7.5 hours (10 x 45 minutes)

Who delivers the intervention: 2 advanced graduate students trained in CBT

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

87

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ginsburg 2002  (Continued)

Active control

Cochrane Database of Systematic Reviews

Intervention: attention-support control. Sharing and discussing experiences related to anxiety. Avoid-
ed components of CBT

Concomitant/excluded medications: currently participating in any psychiatric treatment excluded

Delivery format: child only; group

Therapist contact time: 7.5 hours (10 x 45 minutes)

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-C

Remission of all anxiety disorder diagnoses post-treatment: ADIS-C

Reduction in anxiety symptoms (child report) post-treatment: SCARED-C

Active control = attention control

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Used random number table

Unclear risk

Judgement Comment: No detail given

Unclear risk

Judgement Comment: No detail given about blinding participants

Low risk

Judgement Comment: ADIS assessors unaware of treatment condition

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Attrition reported and similar across groups, and rea-
son reported where available ("no longer need group")

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes reported for all relevant included measures

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Therapists trained and adherence monitored and ap-
proach justified

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Ginsburg 2012 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 1-month follow-up

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

88

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ginsburg 2012  (Continued)

Number of study centres and location: 14 schools in the USA

Study setting: school-based mental health clinics

Participants

N = 32 (CBT: N = 17; TAU: N = 15)

Mean age (SD): CBT: 11.12 (2.75); TAU: 9.33 (2.06)

Age range: 7 to 17

Gender: CBT: 12 (70.6%) female; TAU: 8 (53.3%) female

Inclusion criteria: age 7 to 17, presence of GAD, social anxiety disorder, separation anxiety disorder,
specific phobia, or anxiety disorder not otherwise stated (based on ADIS-C/P), no medical or psychiatric
conditions contraindicating study intervention, not currently receiving anxiety treatment

Exclusion criteria: failed a previous trial of CBT for anxiety

Interventions

CBT

Intervention: modular CBT adapted from CBT manuals

Concomitant/excluded medications: stable medication for another psychiatric disorder allowed

Delivery format: child only, encouraged to involve parents in at least 3 sessions; individual

Therapist contact time: 6 hours (8 x 45 minutes over 12 weeks)

Who delivers the intervention: novice CBT school-based clinicians

TAU

Intervention: therapeutic intervention that did not include CBT strategies. Therapy represented usual
care for that therapist (e.g. art, play, or supportive therapy), and provided with attention control manu-
al to use if they desired

Concomitant/excluded medications: stable medication for another psychiatric disorder allowed

Delivery format: child only, encouraged to involve parents in at least 3 sessions; individual

Therapist contact time: 6 hours (8 x 45 minutes over 12 weeks)

Who delivers the intervention: novice CBT school-based clinician

Outcomes

Reduction in anxiety symptoms (child report) post-treatment and follow-up (≤ 6 months):
SCARED-C

Notes

Risk of bias

Bias

Reduction in anxiety symptoms (parent report) post-treatment and follow-up (≤ 6 months):
SCARED-P

Post-treatment diagnostic assessment included, but did not report required remission outcomes.

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Judgement Comment: Sequence online and separate for each clinician

Allocation concealment
(selection bias)

Low risk

Judgement Comment: Use website to generate number, so unlikely to foresee
assignment

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

89

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Ginsburg 2012  (Continued)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

Judgement Comment: No detail given

Low risk

Low risk

Judgement Comment: Independent assessors, scores reviewed by senior clini-
cian blind to condition

Judgement Comment: Attrition detailed, appropriate imputation for dealing
with missing data. 11% outcome data missing

Low risk

Judgement Comment: Outcomes reported

Other source of bias -
Therapy integrity

Unclear risk

Judgement Comment: Adherence assessed and reported; there was some evi-
dence that TAU participants received elements of CBT, which could potentially
have influenced outcomes

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Ginsburg 2019a 

Study characteristics

Methods

Study design: cluster-randomised controlled trial

Total duration of study: 1-year follow-up

Number of study centres and location: USA

Study setting: schools

Date of study: 2012 to 2017

Participants

N = 216 (CBT: 148; TAU: 68)

Mean age (SD): 10.87 (3.27)

Age range: 6 to 18

Gender: 48.6% female

Inclusion criteria: age 6 to 18, met DSM-IV diagnostic criteria for primary anxiety disorder (based on
ADIS-C/P)

Excluded criteria: medical or psychiatric condition contraindicating study treatment (e.g. suicidali-
ty) and needed immediate or alternative treatment, were receiving psychosocial treatment for anxiety
and/or were in the custody of state social services

Interventions

CBT

Intervention: modular CBT. Adapted from empirically supported manuals. Included: psychoeducation,
exposure, rewards, cognitive restructuring, problem solving, somatic/relaxation skills, relapse preven-
tion, optional parental psychoeducation module

Concomitant/excluded medications: stable dose allowed

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

90

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ginsburg 2019a  (Continued)

Cochrane Database of Systematic Reviews

Delivery format: child only, optional parent; individual

Therapist contact time: 6 to 8 hours (12 x 30 to 40 minutes)

Who delivers the intervention: school-based clinicians

TAU

Intervention: therapeutic strategies clinicians would typically provide (e.g. supportive therapy)

Concomitant/excluded medications: stable dose allowed

Delivery format: child only; individual

Therapist contact time: 6 to 8 hours (12 x 30 to 40 minutes)

Who delivers the intervention: school-based clinicians

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment and 12-month follow-up: ADIS-C/
P

Notes

SCARED-C, SCARED-P, CGAS reported but no SDs

Cluster trial - reported data adjusted as per protocol

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Judgement Comment: Web-based randomisation plan generator, but change
in randomisation ratios post onset

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Judgement Comment: Web based, so unlikely to foresee assignment

Unclear risk

Judgement Comment: Not specified

Low risk

Judgement Comment: Blind assessors

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Attrition reported and appropriate method for manag-
ing missing data

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Outcomes reported

Low risk

Judgement Comment: Adherence measured

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

91

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Hancock 2018 

Study characteristics

Cochrane Database of Systematic Reviews

Methods

Study design: randomised controlled trial

Total duration of study: 3-month follow-up for treatment groups only

Number of study centres and location: 1 in Australia

Study setting: university hospital

Participants

N = 193 (CBT (Acceptance and Commitment Therapy): N = 68; CBT: N = 63; waitlist: N = 62)

Mean age (SD): 11.2 (2.76)

Age range: 7 to 17

Gender: 111 (58%) female

Inclusion criteria: DSM-IV anxiety disorder (based on ADIS-C/P), age 7 to 17

Exclusion criteria: non-English speaker, complex mental health problems (e.g. psychotic symptoms,
major depression primary disorder) or medical conditions, attention deficit disorder with hyperactivi-
ty that was not well controlled, taking psychotropic medication for less than 2 months, post-traumat-
ic stress disorder (due to specialised treatment required), or academically more than 1 grade behind
peers

Interventions

CBT (ACT)

Intervention: ACT programme. Included mindfulness, psychoeducation, cognitive defusion, exposure,
cognitive coping, problem solving, social skills

Concomitant/excluded medications: medication-free or stabilised on anti-depressants for at least 2
months

Delivery format: child and parent; group

Therapist contact time: 15 hours (10 x 90 minutes)

Who delivers the intervention: clinical psychologists

CBT (Cool Kids/Chilled)

Intervention: Cool Kids/Chilled programme for children and adolescents

Concomitant/excluded medications: medication-free or stabilised on anti-depressants for at least 2
months

Delivery format: child and parent; group

Therapist contact time: 15 hours (10 x 90 minutes)

Who delivers the intervention: clinical psychologists

Waitlist

Intervention: 10 weeks waitlist

Concomitant/excluded medications: medication-free or stabilised on anti-depressants for at least 2
months

Outcomes

Reduction in anxiety symptoms (child report) post-treatment: MASC-C

Notes

Use post-treatment diagnostic assessment, but did not report remission outcomes

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

92

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Hancock 2018  (Continued)

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Clear details of sequence allocation

Allocation concealment
(selection bias)

Low risk

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Low risk

Low risk

Low risk

Low risk

Low risk

Judgement Comment: Participants’ enrolment into the study was conducted
by an intake officer. They were subsequently assessed by researchers masked
to the treatment condition, with both parties informed of the group allocation
after assessment.

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Judgement Comment: Blind assessors and subset interviews rated by clini-
cians blind to original diagnosis and group

Judgement Comment: Attrition detailed and reasons provided. Some of rea-
sons for attrition were potentially related to group allocation, but appropriate
imputation methods were used to manage missing data (ITT analyses under-
taken).

Judgement Comment: Outcomes for planned relevant measures reported.
Some measures reported elsewhere.

Judgement Comment: Therapist competence and adherence assessed and re-
ported

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Herbert 2009 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 6-month follow-up

Number of study centres and location: 1 in the USA

Study setting: university clinic

Participants

N = 73 (CBT-group: N = 23; CBT-individual: N = 24; control: N = 26)

Mean age (SD): CBT-group: 14.6 (2.8); CBT-individual: 14.3 (2.1); control: 15.1 (1.4)

Age range: 12 to 17

Gender: 42 (57.5%) female

Inclusion criteria: primary social anxiety disorder, generalised subtype (based on ADIS-C); aged 12 to
17; literacy in English

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

93

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Herbert 2009  (Continued)

Cochrane Database of Systematic Reviews

Excluded criteria: history of mental retardation, pervasive developmental disorder, organic mental
disorder, bipolar disorder, a psychotic disorder, or borderline or schizotypal personality disorder, im-
minent suicidal risk, substance abuse or dependence within the past year, or a previous trial of behav-
iour or CBT for social anxiety disorder

Interventions

CBT (group)

Intervention: psychoeducation, breathing retraining, cognitive restructuring, simulated and in vivo ex-
posure to phobic stimuli, and social skills training

Concomitant/excluded medications: stabilised (at least 3 months with no change in medication or
dosage) allowed

Delivery format: child only; group

Therapist contact time: 24 hours (12 x 2 hours)

Who delivers the intervention: advanced doctoral candidates in clinical psychology

CBT (individual)

Intervention: same content as group CBT

Concomitant/excluded medications: stabilised (at least 3 months with no change in medication or
dosage) allowed

Delivery format: child only; individual

Therapist contact time: 12 hours (12 x 1 hour)

Who delivers the intervention: advanced doctoral candidates in clinical psychology

Active control

Intervention: psychoeducational supportive therapy. Discussions around various topics relevant to
social anxiety disorder. Therapists offered support but did not provide specific advice, teach skills,
problem-solve, or assign exposure exercises.

Concomitant/excluded medications: stabilised (at least 3 months with no change in medication or
dosage) allowed

Delivery format: child only; group

Therapist contact time: 24 hours (12 x 2 hours)

Who delivers the intervention: advanced doctoral candidates in clinical psychology

Outcomes

Reduction in anxiety symptoms (child report) post-treatment and follow-up (6 months): SPAI-C

Reduction in anxiety symptoms (parent report) post-treatment and follow-up (6 months): SAS-P

Notes

Post-treatment diagnostic assessment used but required remission outcomes not reported.

Active control = attention control

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Judgement Comment: Block randomisation

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

94

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Herbert 2009  (Continued)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

Judgement Comment: No detail

Unclear risk

Judgement Comment: No detail

Low risk

Judgement Comment: Blind outcome assessment

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Attrition detailed, differences between completers and
dropouts examined and reported; details for managing missing data reported

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes for planned measures reported

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Trained therapists, regular supervisor to monitor ad-
herence, measures of fidelity given

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Hirshfeld Becker 2010 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 1-year non-controlled follow-up

Number of study centres and location: 1 in the USA

Study setting: research clinic

Date of study: February 2001 to January 2004

Participants

N = 64 (CBT: N = 34; waitlist: N = 30)

Mean age (SD): 5.4 (1.0)

Age range: 4 to 7

Gender: 34 (53%) female

Inclusion criteria: current DSM-IV anxiety disorder (based on K-SADS)

Exclusion criteria: active psychosis, suicidality, or substance abuse in a parent; mental retardation
in the child; current psychiatric treatment or past CBT; if a consensus of 2 senior clinicians judged the
child to be too unco-operative or distractible to take part in the trial or too severely symptomatic to
wait 6 months to receive treatment, based on suicidal ideation, serious impairment in eating or sleep-
ing habits, severe social isolation, severe impairment in school function or attendance, or severe OCD

Interventions

CBT

Intervention: Being Brave: A Program for Coping with Anxiety for Young Children and Their Parents.
Loosely modelled after the manualised Coping Cat programme

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

95

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Hirshfeld Becker 2010  (Continued)

Concomitant/excluded medications:

Delivery format: parent only, and child and parent sessions; individual

Therapist contact time: up to 20 sessions over 6 months

Who delivers the intervention: psychologists and postdoctoral fellow

Waitlist/no treatment

Intervention: 6-month waitlist

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: K-SADS-E

Remission of all anxiety disorder diagnoses post-treatment: K-SADS-E

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Judgement Comment: Block randomisation; the allocation sequences were
generated in advance for the 2 cells (presence or absence of parental anxiety
disorders) by the study co-ordinator

Allocation concealment
(selection bias)

Low risk

Judgement Comment: Concealed in a computer file from all other staff (in-
cluding the clinicians who enrolled the participants, the assessors and clini-
cians who conducted the assessments, and the clinicians who determined the
eligibility of each child)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Blind assessors

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Attrition fully reported, and for all measures. Quite high
level of missing data for CBCL-I, which is potentially related to outcome but
not used here

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes reported for all measures

Other source of bias -
Therapy integrity

Unclear risk

Judgement Comment: Intervention delivered by psychologists/postdoctoral
fellow, but no detail given on assessment of adherence and competence

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Holmes 2014 

Study characteristics

Methods

Study design: randomised controlled trial

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

96

 
 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Holmes 2014  (Continued)

Total duration of study: non-controlled 3-month follow-up

Number of study centres and location: 1 in Australia

Participants

N = 42 (CBT: N = 20; waitlist: N = 22)

Mean age (SD): 9.64 (1.41)

Age range: 7 to 12

Gender: 28 (66.7%) female

Inclusion criteria: aged 7 to 12, primary diagnosis GAD (based on ADIS-C/P)

Exclusion criteria: pervasive developmental disorder, intellectual handicap or learning disability, be-
havioural problems more impairing than anxiety, substance abuse, self-harm or suicidal ideation; cur-
rently receiving psychological assistance or medical treatment

Interventions

CBT

Intervention: No Worries - target intolerance of uncertainty, negative beliefs about worry, negative
problem orientation, cognitive avoidance

Delivery format: child and parent; group

Therapist contact time: 15 hours (10 x 90 minutes)

Who delivers the intervention: postgraduate students receiving advanced clinical training, super-
vised

Waitlist/no treatment

Intervention: 12-week waitlist

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-C/P

Reduction in anxiety symptoms (child report) post-treatment: SCAS-C

Reduction in anxiety symptoms (parent report) post-treatment: SCAS-P

Improvement in global functioning post-treatment: CGAS

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Computer-generated, blocked randomisation list

Low risk

Judgement Comment: Computer generated, so unlikely to foresee assignment

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Judgement Comment: Assessors blind to both experimental condition and
client history

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

97

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Holmes 2014  (Continued)

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Dropouts and reasons for them detailed and clear.
Completer analysis reported, and compared to ITT.

Low risk

Judgement Comment: Outcomes for all measures reported.

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Adherence rated and reported; delivered by provision-
ally registered psychologists, with regular supervision

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Hudson 2009 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 3-month follow-up

Number of study centres and location: 1 in Australia

Study setting: research clinic

Participants

N = 112 (CBT: N = 60; active control: N = 52)

Mean age (SD): CBT: 10.2 (2.4) (n = 51); active control: 0.2 (2.7) (n = 44)

Age range: 7 to 16

Gender: CBT: 37.3% female (n = 51); active control: 52.3% female (n = 44)

Inclusion criteria: primary anxiety disorder (based on ADIS-C/P)

Exclusion criteria: mental retardation, psychoses, and concurrent psychological treatment

Interventions

CBT

Intervention: Cool Kids

Concomitant/excluded medications: allowed if stable

Delivery format: child and parent; group

Therapist contact time: 20 hours (10 x 2 hours)

Who delivers the intervention: clinical psychologists or postgraduate students

Active control

Intervention: group support and attention. Aim to provide supportive environment, activities to help
express and understand emotions and build relationships between and within families. Therapists in-
structed not to provide CBT interpretations or strategies.

Concomitant/excluded medications: allowed if stable

Delivery format: child and parent; group

Therapist contact time: 20 hours (10 x 2 hours)

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

98

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Hudson 2009  (Continued)

Who delivers the intervention: clinical psychologists or postgraduate students

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment and 3-month follow-up: ADIS-C/P

Remission of all anxiety disorder diagnoses post-treatment and 3-month follow-up: ADIS-C/P

Reduction in anxiety symptoms (child report) post-treatment and 3-month follow-up: SCAS-C

Reduction in anxiety symptoms (parent report-mother) post-treatment and 3-month follow-up:
SCAS-P

Notes

Risk of bias

Bias

Active control = attention control

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Judgement Comment: Used a schedule from a random number generator to
assign each group

Allocation concealment
(selection bias)

Unclear risk

Judgement Comment: Performed by principal investigator. No detail on at-
tempt to conceal allocation

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Judgement Comment: Appropriate methods to conceal differences between
control and CBT; participants told 1 treatment new to the clinic, once assign-
ment informed about their condition

Unclear risk

Judgement Comment: Reliability of ADIS outcomes assessed, but no detail on
blinding of assessors/double raters

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Attrition detailed. Appropriate methods for handling
missing data. Completer analyses reported, and ITT also performed for com-
parison.

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes for all measures reported

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Therapists qualified and supervised. Therapy adher-
ence assessed and reported. Detailed procedure for managing 1 instance of
protocol breach

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Ingul 2013 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: non-controlled 12-month follow-up

Number of study centres and location: Norway

Study setting: recruitment through school screening

Participants

N = 128 (CBT-individual: N = 36; CBT-group: N = 58; active control: N = 34)

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

99

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ingul 2013  (Continued)

Mean age (SD): 14.5 (1.01) (n = 57)

Age range: 13 to 16

Gender: 32 (56.1%) female (n = 57)

Cochrane Database of Systematic Reviews

Inclusion criteria: primary problem social phobia diagnosis (based on ADIS-C)

Exclusion criteria: mental retardation or psychosis; being treated elsewhere for mental health condi-
tions

Interventions

CBT-individual

Intervention: Clark and Wells manual, adapted for adolescents

Delivery format: child only; individual

Therapist contact time: 10 hours (12 x 50 minutes)

Who delivers the intervention: clinical psychologist and co-therapists

CBT-group

Intervention: based on CAT Project Manual for CBT of Anxious Adolescents, with some play elements
from SET-C

Delivery format: child only; group

Therapist contact time: 15 hours (10 x 90 minutes)

Who delivers the intervention: clinical psychologist and co-therapists

Active control

Intervention: attentional placebo. No active components in CBT. Social activity, social interaction, and
social support

Delivery format: child only; group

Therapist contact time: 15 hours (10 x 90 minutes)

Who delivers the intervention: experienced milieu therapists

Outcomes

Reduction in anxiety symptoms (child report) post-treatment: SCARED-C

Reduction in depressive symptoms post-treatment: CDI

Notes

Active control = attention control

Follow-up diagnostic assessment, but only CBT groups

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Pre-assigned random schedule

Unclear risk

Judgement Comment: State performed at each site, but no further detail

Unclear risk

Judgement Comment: No detail given

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

100

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Ingul 2013  (Continued)

All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Assessors blind

Unclear risk

Judgement Comment: High dropout rate and large amount of missing data
and related to treatment group, although ITT analysis reported to confirm
completer analysis

Low risk

Judgement Comment: Outcomes for measures reported

Other source of bias -
Therapy integrity

Unclear risk

Judgement Comment: Therapists appropriately qualified. Adherence and
competence assessed and reported in 2 CBT groups, but not the control.

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Ishikawa 2019 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: non-controlled 3- and 6-month follow-up

Number of study centres and location: Japan

Study setting: clinic

Date of study: recruitment 2012 to 2015; follow-up complete 2017

Participants

N = 51 (CBT: N = 26; waitlist: N = 25)

Mean age (SD): 10.9 (2.0)

Age range: 8 to 15

Gender: 29 (56.9%) female

Inclusion criteria: (a) age 7 to 15, (b) attend the programme with their parents, (c) have an anxiety dis-
order (based on ADIS), (d) did not fulfil criteria for PTSD, disruptive behavioural disorders, substance
abuse, mental retardation, pervasive developmental disorder, or a psychotic disorder, and (e) agree to
discontinue other forms of therapy for the duration of the study

Interventions

CBT

Intervention: Japanese Anxiety Children/Adolescents Cognitve Behaviour Therapy Program

Concomitant/excluded medications: none currently taking medication

Delivery format: child and parent together; individual

Therapist contact time: 8 hours (8 x 1 hour)

Who delivers the intervention: clinical psychologist

Waitlist/no treatment

Intervention: 2-month waitlist

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

101

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Ishikawa 2019  (Continued)

Concomitant/excluded medications: none currently taking medication

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-C/P (parent and child inter-
viewed together)

Remission of all anxiety disorder diagnoses post-treatment: ADIS-C/P (parent and child interviewed
together)

Reduction in anxiety symptoms (child report) post-treatment: SCAS-C

Reduction in anxiety symptoms (parent report) post-treatment: SCAS-P

Reduction in depressive symptoms post-treatment: CDI

4 participants met diagnostic criteria for an anxiety disorder, but primary disorder was a depressive
disorder. Included in all analyses apart from remission of primary anxiety disorder diagnosis

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Random number generator

Low risk

Judgement Comment: Independent person

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Blind assessors

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Report ITT and completer analyses. Only 1 dropout in
each condition

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Outcomes for measures reported

Low risk

Judgement Comment: Trained therapists. Adherence assessed and reported.

Other bias

High risk

Judgement Comment: Difference in timing for post-assessment for CBT vs
waitlist - shorter time period for waitlist (70 days vs 122). Included children
with depressive disorders as primary diagnoses

Kendall 1994 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: non-controlled long-term follow-up

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

102

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kendall 1994  (Continued)

Number of study centres and location: 1 in the USA

Study setting: university clinic

Participants

N = 60 (CBT: N = 30; waitlist: N = 30)

Age range: 9 to 13

Gender: 40% female (n = 47)

Cochrane Database of Systematic Reviews

Inclusion criteria: primary anxiety disorder diagnosis (i.e. over-anxious disorder, separation anxiety
disorder, avoidant disorder) based on ADIS-C/P

Exclusion criteria: primary diagnosis of specific phobia, IQ below 80, disabling physical condition, dis-
played psychotic symptoms, currently using anti-anxiety medications

Interventions

CBT

Intervention: Coping Cat

Concomitant/excluded medications: anti-anxiety medication excluded

Delivery format: child only; individual

Therapist contact time: 13 to 20 hours (16 to 20 x 50- to 60-minute sessions over 16 weeks)

Who delivers the intervention: doctoral students

Waitlist/no treatment

Intervention: 8-week waitlist

Concomitant/excluded medications: anti-anxiety medication excluded

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-P

Reduction in anxiety symptoms (child report) post-treatment: RCMAS

Reduction in anxiety symptoms (parent report) post-treatment: STAIC-trait-parent

Reduction in depressive symptoms post-treatment: CDI

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Judgement Comment: No detail given

Unclear risk

Judgement Comment: No detail given

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Unclear risk

Judgement Comment: Specify observational data rated by blind assessors,
but no detail about diagnostic assessments

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

103

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Kendall 1994  (Continued)

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

Judgement Comment: Number of dropouts detailed, and dropouts vs remain-
ers compared, but analyses only include completers; insufficient detail on how
missing data were managed or comparison with ITT

Low risk

Judgement Comment: Outcomes for measures reported

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Therapists appropriately qualified, integrity assessed
and reported

Other bias

High risk

Judgement Comment: Endpoint different for waitlist (8 weeks) and CBT group
(16 weeks)

Kendall 1997 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: non-controlled long-term follow-up

Number of study centres and location: 1 in the USA

Study setting: university clinic

Participants

N = 118 (CBT: N = 69; waitlist: N = 49)

Age range: 9 to 13

Gender: 38% female (n = 94)

Inclusion criteria: age 9 to 13; primary anxiety disorder (overanxious disorder, separation anxiety dis-
order, avoidant disorder) based on ADIS, NB: diagnosis based on parent report when discrepancy with
child report

Exclusion criteria: primary specific phobia diagnosis, psychotic symptoms, taking anti-anxiety med-
ication

Interventions

CBT

Intervention: Coping Cat

Concomitant/excluded medications: anti-anxiety medication excluded

Delivery format: child-only sessions and parent meeting; individual

Therapist contact time: 18 hours (18 x 1 hour)

Who delivers the intervention: doctoral students

Waitlist/no treatment

Intervention: 8-week waitlist

Concomitant/excluded medications: anti-anxiety medication excluded

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-P

Reduction in anxiety symptoms (child report) post-treatment: RCMAS

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

104

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kendall 1997  (Continued)

Cochrane Database of Systematic Reviews

Reduction in anxiety symptoms (parent report) post-treatment: CBCL-Anxiety scale (mother)

Reduction in depressive symptoms post-treatment: CDI

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Authors' judgement

Support for judgement

Unclear risk

Judgement Comment: No detail given

Unclear risk

Judgement Comment: No detail given

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Unclear risk

Judgement Comment: No detail given

Unclear risk

Judgement Comment: Dropout numbers given and reported that no there was
no difference between dropouts and completers on pretreatment characteris-
tics, but reasons for dropouts not reported. No detail on missing data for indi-
vidual measures or how missing data for questionnaires were managed

Low risk

Judgement Comment: Outcomes reported for all measures

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Therapists appropriately qualified. Integrity indepen-
dently assessed.

Other bias

High risk

Judgement Comment: Time of endpoint (post-assessment) differed between
waitlist and treatment group

Kendall 2008 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: non-controlled long-term follow-up

Number of study centres and location: 1 in the USA

Study setting: university clinic

Date of study: referred 2000 to 2006

Participants

N = 161 (CBT-individual: N = 55; CBT-family: N = 56; active control: N = 50)

Age range: 7 to 14

Gender: 71 (44%) female

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

105

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kendall 2008  (Continued)

Cochrane Database of Systematic Reviews

Inclusion criteria: age 7 to 14; primary anxiety disorder (based on ADIS-C/P), at least 1 parent speaks
English

Exclusion criteria: psychotic symptoms, mental retardation, a disabling medical condition, the child’s
participation in concurrent treatment, or the child’s taking anti-anxiety or anti-depressant medications

Interventions

CBT

Intervention: Coping Cat

Concomitant/excluded medications: anti-anxiety medication excluded

Delivery format: child (14 sessions), parent (2 sessions); individual

Therapist contact time: 16 hours (16 x 1 hour)

Who delivers the intervention: master’s level therapists with 2 to 3 years of experience at the clinic
and doctoral-level psychologist

CBT

Intervention: family CBT for anxious children manual (Howard, Chu, Krain, Marrs-Garcia, & Kendall,
2000) and used the Coping Cat Workbook

Concomitant/excluded medications: anti-anxiety medication excluded

Delivery format: child and parent together, 2 sessions child and parent separate; individual

Therapist contact time: 16 hours (16 x 1 hour)

Who delivers the intervention: master’s level therapists with 2 to 3 years of experience at the CAADC
and doctoral-level psychologist

Active control

Intervention: manual for family education, support, and attention for anxious children and used a
workbook to add child interest/involvement

Concomitant/excluded medications: anti-anxiety medication excluded

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-C/P

Remission of all anxiety disorder diagnoses post-treatment: ADIS-C/P

Reduction in anxiety symptoms (child report) post-treatment: MASC-C

Reduction in anxiety symptoms (parent report) post-treatment: CBCL-Anxiety scale (mother)

Reduction in depressive symptoms post-treatment: CDI

Include 1-year follow-up, but control group who still met criteria offered treatment after post-treat-
ment, so did not include follow-up here
Active control = attention control

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

Judgement Comment: The co-ordinator used a predetermined schedule (ran-
dom number generated)

Allocation concealment
(selection bias)

Low risk

Judgement Comment: Key to blind held by co-ordinator, not primary investi-
gator or therapist, but no further detail given

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

106

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Kendall 2008  (Continued)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

Judgement Comment: No detail given regarding blinding of participants

Low risk

Low risk

Judgement Comment: Independent assessors and families asked not to dis-
cuss treatment

Judgement Comment: Attrition detailed, and reasons for dropouts given. ITT
analysis. Missing data for measures handled appropriately (last observation
carried forward).

Low risk

Judgement Comment: Outcomes reported for all measures

Other source of bias -
Therapy integrity

Unclear risk

Judgement Comment: Therapists trained and supervised, and integrity as-
sessed. Evidence of CBT bleeding in control group could have influenced out-
comes.

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Kennedy 2009 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 6 months (post-treatment assessment)

Number of study centres and location: Australia

Study setting: university

Participants

N = 71 (CBT: N = 35; waitlist: N = 36)

Mean age (SD): 47.07 months (7.05 months)

Age range: 36 to 58 months

Gender: CBT: 58% female; waitlist: 51% female

Inclusion criteria: child aged 36 to 58 months, high on a laboratory measure of behavioural inhibition
(BI), at least 1 parent met DSM-IV criteria for diagnosis of an anxiety disorder (NB: not inclusion criteria,
but all children meet diagnostic criteria for anxiety disorder based on ADIS-P)

Exclusion criteria: diagnosed developmental disorder or a severe language delay in the child, or par-
ents who were unable to complete questionnaires in English

Interventions

CBT

Intervention: parent intervention - modified Cool Kids Program

Delivery format: parent only; group

Therapist contact time: 12 hours (8 x 90 minutes)

Who delivers the intervention: clinical psychologist

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

107

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kennedy 2009  (Continued)

Waitlist/no treatment

Intervention: 6-month waitlist

Cochrane Database of Systematic Reviews

Outcomes

Remission of all anxiety disorder diagnoses post-treatment: ADIS-P

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Reduction in anxiety symptoms (parent report) post-treatment: PAS-R (mother report)

Post-treatment assessment point is 6 months.

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Toss of coin

Unclear risk

Judgement Comment: No detail given

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Unclear risk

Judgement Comment: ADIS assessors trained, and reliability assessed, but no
detail as to whether blind or not

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Attrition detailed, and although reasons not given,
small numbers and across both groups

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes reported for all measures

Other source of bias -
Therapy integrity

Unclear risk

Judgement Comment: Therapy delivered by qualified and experienced thera-
pist, but integrity not assessed/reported

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Khanna 2010 

Study characteristics

Methods

Study design: randomised controlled trial

Study setting: university

Date of study: 2006 to 2008

Participants

N = 49 randomised (CBT: N = 17; computerised CBT: 16; active control: N = 16) (NB: N = 33 included
here)

Age range: 7 to 13

Inclusion criteria: primary anxiety disorder (separation anxiety, social phobia, GAD, specific phobia, or
panic disorder) (based on ADIS-parent and child interviewed together)

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

108

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Khanna 2010  (Continued)

Cochrane Database of Systematic Reviews

Exclusion criteria: IQ < 80, psychotic symptoms, use of anti-anxiety or depression medication or ongo-
ing psychotherapy

Interventions

CBT

Intervention: individual CBT - Coping Cat

Concomitant/excluded medications: use of anti-anxiety or depression medication not allowed

Delivery format: child only, with parent included in 2 sessions; individual

Therapist contact time: 10 hours (12 x 50 minutes)

Who delivers the intervention: school psychologists, psychology doctoral candidates, clinical psy-
chologist

Active control

Intervention: computer-assisted education support & attention. Education, support, and attention
manual (as in Kendal and colleagues, 2008) and child use of computer age-appropriate games

Concomitant/excluded medications: use of anti-anxiety or depression medication not allowed

Delivery format: child only; individual

Therapist contact time: 10 hours (12 x 30 minutes of support, 20 minutes child use computer)

Who delivers the intervention: school psychologists, psychology doctoral candidates, clinical psy-
chologist

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS (parent and child inter-
viewed together)

Reduction in anxiety symptoms (child report) post-treatment: MASC-C

Reduction in depressive symptoms post-treatment: CDI

Improvement in global functioning post-treatment: CGAS

Notes

Did not include "Camp Cope-A lot" arm (computer-assisted CBT)

Active control = attention control

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Random number-generating program

Low risk

Judgement Comment: Computer generated, so unlikely to foresee assignment

Unclear risk

Judgement Comment: No evidence of blinding participants in individual CBT
vs control, but as control computer program potentially not feasible

Low risk

Judgement Comment: Assessors blind to treatment condition

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

109

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Khanna 2010  (Continued)

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Attrition detailed and ITT analysis reported, with ap-
propriate imputation for missing data. 2 participants in control group with-
drawn due to worsening of symptoms.

Low risk

Judgement Comment: Outcomes reported

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Therapist trained and supervised. Adherence assessed
and reported.

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Kidd 2018 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: non-controlled 6-month follow-up

Number of study centres and location: 1 in Australia

Study setting: university clinic

Participants

N = 49 (CBT: N = 26; waitlist: N = 23)

Mean age (SD): 14.23 (1.76)

Age range: 12 to 18

Gender: 9 (18.4%) female

Inclusion criteria: meet diagnostic criteria for an anxiety disorder, with CSR 4+ (based on ADIS-P); able
to demonstrate a clinical diagnosis of ASD, Asperger’s disorder, or pervasive developmental disorder
– not otherwise specified (PDD-NOS); aged 12 to 18; verbal IQ above 70; ability to read English; not tak-
ing any psychotropic medication or taking a stable dose of psychiatric medication and, if taking med-
ication, agreement for this to be maintained throughout the study

Exclusion criteria: participated in psychotherapy, social skills training, or behavioural intervention
over the course of the study; the family were attending child-related health professional services or
parenting classes; taking psychiatric medication or changed his or her dosage during the intervention
period; family was not able to participate in the intervention program

Interventions

CBT

Intervention: Cool Kids, ASD adaptation

Concomitant/excluded medications: stable dose, and maintain stable dose during study allowed

Delivery format: combination of child alone, parent alone, and child and parent together; group

Therapist contact time: 24 hours (12 x 2 hours)

Who delivers the intervention: psychology graduate trainee Master's or PhD students

Waitlist/no treatment

Intervention: 4.5-month waitlist

Concomitant/excluded medications: stable dose, and maintain stable dose during study allowed

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

110

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kidd 2018  (Continued)

Cochrane Database of Systematic Reviews

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-P

Reduction in anxiety symptoms (child report) post-treatment: SCAS-C

Reduction in anxiety symptoms (parent report) post-treatment: SCAS-P

Reduction in depressive symptoms post-treatment: SMFQ-C

Sample with ASD

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Randomisation software

Low risk

Judgement Comment: Computer generated, so unlikely to foresee assignment

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Blind assessors

Low risk

Judgement Comment:Missing data detailed and managed appropriately

Low risk

Judgement Comment:Outcomes reported for all measures

Low risk

Judgement Comment: Independent integrity assessment

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Last 1998 

Study characteristics

Methods

Study design: randomised controlled trial

Study setting: university clinic

Date of study: September 1993 through April 1995

Participants

N = 56 (CBT: N = 32; active control: N = 24)

Mean age (SD): CBT: 11.67 (3.00); active control: 12.40 (2.79)

Age range: 6 to 17

Gender: CBT: 13 (56%) female; active control: 15 (62%) female

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

111

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Last 1998  (Continued)

Cochrane Database of Systematic Reviews

Inclusion criteria: (1) anxiety-based school refusal; (2) current enrolment in elementary, middle, or
high school; (3) current DSM-lll-R anxiety disorder diagnosis (based on K-SADS-P); (4) at least 10% ab-
senteeism from classes for at least 1 month before intake; (5) no current diagnosis of major depression;
and (6) no current use of psychiatric medication

Interventions

CBT

Intervention: modified adult treatment for treatment of anxiety-based school refusal. In vivo exposure
and coping self statements

Concomitant/excluded medications: psychiatric medication excluded

Delivery format: child and parent; individual

Therapist contact time: 12 hours (12 x 1 hour)

Who delivers the intervention: Therapist. Involvement of school-based contact

Active control

Intervention: educational support therapy - modification of control therapy used previously: educa-
tional presentations and supportive psychotherapy

Concomitant/excluded medications: psychiatric medication excluded

Delivery format: child only?; individual

Therapist contact time: 12 hours (12 x 1 hour)

Who delivers the intervention: Therapist. Involvement of school-based contact

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: K-SADS (parent and child, abbre-
viated form)

Reduction in anxiety symptoms (child report) post-treatment: STAIC-modified

Reduction in depressive symptoms post-treatment: CDI

Active control = attention control

Authors' judgement

Support for judgement

Unclear risk

Judgement Comment: No detail given

Unclear risk

Judgement Comment: No detail given

Unclear risk

Judgement Comment: No detail given

Unclear risk

Judgement Comment: Assessor blind to initial diagnosis, but no detail given
regarding whether blind to condition

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Judgement Comment: Attrition reported, but relatively high dropout rate and
greater in CBT group, with only completer analysis reported

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

112

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Last 1998  (Continued)

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes reported

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Treatment fidelity assessed and reported as highly
credible

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Lau 2010 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: non-controlled 3- and 6-month follow-up

Number of study centres and location: 1 in Hong Kong

Study setting: community clinic

Participants

N = 45 randomised (NB: we only include those who met diagnostic criteria for an anxiety disorder at
baseline: N = 38; CBT: N = 21; waitlist: N = 17)

Age range: 6 to 11

Inclusion criteria: diagnosed with anxiety problems/disorders (we only include participants that meet
diagnostic criteria based on K-SADS)

Exclusion criteria: only specific phobia, severe hyperactivity symptoms

Interventions

CBT

Intervention: Anxiety Group treatment programme - adaptation of Coping Cat

Delivery format: child, with parents invited to observe and meet with co-therapists at the beginning of
some sessions; group

Therapist contact time: 18 hours (9 x 2 hours)

Waitlist/no treatment

Intervention: 13-week waitlist

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: K-SADS

Reduction in anxiety symptoms (child report) post-treatment: SCAS-C (modified, only 4 subscales)

Reduction in anxiety symptoms (parent report) post-treatment: SCAS-P (modified, only 4 sub-
scales)

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Judgement Comment: No detail given

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

113

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Lau 2010  (Continued)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Unclear risk

Judgement Comment: No detail given

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Judgement Comment: Independent coder blind to treatment condition rated
subset of interviews

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Low risk

Judgement Comment:No missing data

Low risk

Judgement Comment: Report outcomes for all measures

Low risk

Judgement Comment: Trained therapists, adherence assessed and reported

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Lau 2017 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 6 months (post-treatment assessment); non-controlled 12-month follow-up

Number of study centres and location: 1 in Australia

Study setting: recruited through child care centres and preschools; intervention delivery in university
setting

Participants

N = 72 (CBT: N = 39; waitlist: N = 33)

Mean age (SD): 52.1 months

Age range: 36 to 65 months

Gender: 34 (47.2%) female

Inclusion criteria: (1) age 36 to 66 months at the time of recruitment; (2) minimum of 30 (1.15 SD
above the norm) on the child's score of social approach on the Short Temperament Scale for Children;
(3) a minimum of 30 on at least 1 parent’s self-reported scores on the Depression Anxiety Stress Scales;
(4) no known diagnosis of any severe developmental disorders; and (5) parents who were able to com-
plete questionnaires in English (NB: all children met diagnostic criteria for an anxiety disorder (based
on ADIS-P), but this was not an inclusion criterion)

Interventions

CBT

Intervention: parent and child intervention. Parent: Cool Little Kids. Child: Social Skills Facilitated Play
programme

Delivery format: parent sessions and child sessions; group

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

114

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Lau 2017  (Continued)

Cochrane Database of Systematic Reviews

Therapist contact time: 18 hours total (6 x 90 minutes - parent; 6 x 90 minutes - child)

Who delivers the intervention: clinical psychologist (parent), graduate or final-year students (child)

Waitlist/no treatment

Intervention: 6-month waitlist

Outcomes

Remission of all anxiety disorder diagnoses post-treatment: ADIS-P

Reduction in anxiety symptoms (parent report-mother) post-treatment: Preschool Anxiety Scale-
Revised (PAS-R) - mother report

Post-treatment assessment point 6 months

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Coin toss

Low risk

Low risk

Judgement Comment: A coin toss by a research assistant who was blind to
baseline assessment details was used to allocate families to the 2 conditions

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Interviewers blind to treatment condition

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Dropouts and missing questionnaire data detailed.
Only 1 dropout. Used appropriate imputation to manage missing item data.
Mother report low rate missing data

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Report all outcomes

Other source of bias -
Therapy integrity

Unclear risk

Judgement Comment: Therapist qualifications detailed, but no further detail
given on assessing/monitoring competence/adherence

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Lebowitz 2019 

Study characteristics

Methods

Study design: randomised controlled trial

Number of study centres and location: 1 in the USA

Study setting: clinic

Participants

N = 124 (CBT: N = 60; control: N = 64)

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

115

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Lebowitz 2019  (Continued)

Mean age (SD): 9.4 (2.41)

Age range: 7 to 12

Gender: 66 (53%) female

Cochrane Database of Systematic Reviews

Inclusion criteria: primary DSM-5 anxiety disorder diagnosis (based on ADIS-C/P); aged 7 to 14 years;
residing with mother at least 50% of the time; fluent in English; medication-free or on a stable dose of
anti-depressant or stimulant when child and parent agreed to refrain from changes during the study
period; parental informed permission and consent; child assent

Exclusion criteria: drug or alcohol abuse; psychotic symptoms; autism spectrum disorder; any comor-
bid disorder more impairing than the most severe anxiety disorder; concurrent psychotherapy or med-
ication, apart from stable dose of anti-depressant or stimulant; serious suicidal intent or risk

Interventions

CBT

Intervention: manual used in Silverman 2009. Psychoeducation, exposure hierarchy, cognitive restruc-
turing

Concomitant/excluded medications: stable dose of anti-depressant or stimulant allowed

Delivery format: child only (NB: therapist met with parent to provide information on child's therapy);
individual

Therapist contact time: 12 hours total (12 x 1 hour)

Who delivers the intervention: doctoral- and postdoctoral-level psychology students

Active control

Intervention: SPACE (Supportive Parenting for Anxious Childhood Emotions) manual. Family modifica-
tions mapped out and target accommodation selected for modification, modules for problem-solving
difficulties related to child's responses to reduced accommodation

Concomitant/excluded medications: stable dose of anti-depressant or stimulant allowed

Delivery format: parent only; individual

Therapist contact time: 12 hours total (12 x 1 hour)

Who delivers the intervention: doctoral- and postdoctoral-level psychology students

Outcomes

Remission of all anxiety disorder diagnoses post-treatment: ADIS-C/P

Reduction in anxiety symptoms (child report) post-treatment: SCARED-C

Reduction in anxiety symptoms (parent report) post-treatment: SCARED-P

Active control = alternative treatment

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Computerised randomisation algorithm

Low risk

Judgement Comment: Computer generated, so unlikely to foresee assignment

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

116

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Lebowitz 2019  (Continued)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Low risk

Low risk

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Judgement Comment: Independent evaluators masked to treatment assign-
ment

Judgement Comment: Focus on completer analysis justified. Report remission
rates, comparison between completers and non-completers and missing data
bias

Low risk

Judgement Comment: Outcomes reported for all measures

Low risk

Judgement Comment: Trained therapists, regular supervision, fidelity checks

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Leutgeb 2012 

Study characteristics

Methods

Study design: randomised controlled trial

Number of study centres and location: 1 in Austria

Study setting: university

Participants

N = 30 (CBT: N = 16; waitlist: N = 14)

Mean age (SD): CBT: 137.3 (15) months; waitlist: 138.5 (21.0) months

Age range: 8 to 14

Gender: 100% female

Inclusion criteria: aged 8 to 14, spider phobia (based on DIPS-K), non-medicated, right-handed, fe-
male

Exclusion criteria: any other mental disorder

Interventions

CBT

Intervention: Single Session CBT (OST)

Concomitant/excluded medications: not allowed

Delivery format: child only; individual

Therapist contact time: 4 hours total

Waitlist/no treatment

Intervention: 1-week waitlist

Concomitant/excluded medications: not allowed

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

117

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Leutgeb 2012  (Continued)

Cochrane Database of Systematic Reviews

Outcomes

Reduction in anxiety symptoms (child report) post-treatment: STAIC-C (trait)

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Judgement Comment: Not detailed

Unclear risk

Judgement Comment: Not detailed

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Judgement Comment: Not detailed, but no post-treatment diagnostic assess-
ment used

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: No missing data

Low risk

Judgement Comment: Relevant outcomes reported

Unclear risk

Judgement Comment: No detail given

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Masia Warner 2005 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: non-controlled 9-month follow-up

Number of study centres and location: 2 schools in the USA

Study setting: schools

Participants

N = 42 (CBT: N = 21; waitlist: N = 21)

Mean age (SD): 14.8 (.81) (n = 35)

Age range: 13 to 17 (n = 35)

Gender: 26 (74.3%) female (n = 35)

Inclusion criteria: met diagnostic criteria for DSM-IV social anxiety disorder (based on ADIS-C/P)

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

118

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Masia Warner 2005  (Continued)

Cochrane Database of Systematic Reviews

Exclusion criteria: diagnosis of substance use disorder, oppositional defiant disorder, conduct disor-
der, or major depression that was of greater severity than social phobia; experiencing psychotic symp-
toms or current suicidal or homicidal thoughts; or had a current major life event requiring immediate
attention (e.g. a parent dying)

Interventions

CBT

Intervention: SASS (Skills for Social and Academic Success)

Concomitant/excluded medications: current pharmacological treatment excluded

Delivery format: child sessions, plus parent meetings; group plus individual meetings

Therapist contact time: 17.5 hours total (12 x 40 min - group, 2 x 15 min - individual, 4 x 90 min - group
social events, 2 x 45 min - parent, 2 x 45 min - teachers)

Who delivers the intervention: clinical psychologist and clinical psychology graduate student

Waitlist/no treatment

Intervention: waitlist

Concomitant/excluded medications: current pharmacological treatment excluded

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-C/P

Reduction in anxiety symptoms (child report) post-treatment: SPAI-C (child)

Reduction in anxiety symptoms (parent report) post-treatment: SAS-A (parent)

Reduction in depressive symptoms post-treatment: CDI

Improvement in global functioning post-treatment: CGAS

Anxiety symptom measures are social anxiety symptom measures.

Authors' judgement

Support for judgement

Unclear risk

Judgement Comment: No detail given

Unclear risk

Judgement Comment: No detail given

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Independent blind assessors

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Dropouts detailed. Report running completer and ITT
analyses, and no differences in results

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes reported for all measures

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

119

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Masia Warner 2005  (Continued)

Cochrane Database of Systematic Reviews

Other source of bias -
Therapy integrity

Unclear risk

Judgement Comment: Qualified therapists, but no detail provided on assess-
ment of competence or adherence

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Masia Warner 2007 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 6-month follow-up

Number of study centres and location: 2 schools in the USA

Study setting: schools

Withdrawals: 1 participant died after allocation and is not included in number randomised

Participants

N = 36 (CBT: N = 19; active control: N = 17)

Mean age (SD): 15.1 (0.6)

Age range: 14 to 16

Gender: 30 (83.3%) female

Inclusion criteria: primary social anxiety disorder (based on ADIS-C/P)

Excluded criteria: 1) current psychological or psychopharmacological treatment, 2) current diagnosis
of substance use or conduct disorder, 3) concurrent mental disorder of greater severity than social pho-
bia, and 4) psychotic symptoms or current suicidal or homicidal ideation

Interventions

CBT

Intervention: Skills for Academic and Social Success (SASS)

Concomitant/excluded medications: current psychopharmacological treatment excluded

Delivery format: child-only sessions, plus parent sessions; group, plus 4 individual

Therapist contact time: 17.5 hours total (12 x 40 min - group, 2 x 15 min - individual, 4 x 90 min - group
social events, 2 x 45 min - parent, 2 x 45 min teachers)

Who delivers the intervention: clinical psychologists and clinical psychology graduate

Active control

Intervention: identical professional attention and format as SASS. Psychoeducation or general relax-
ation techniques, support targeting social anxiety symptoms

Concomitant/excluded medications: current psychopharmacological treatment excluded

Delivery format: child-only sessions, plus parent sessions; group, plus 4 individual

Therapist contact time: 17.5 hours total (12 x 40 min - group, 2 x 15 min - individual, 4 x 90 min - group
social events, 2 x 45 min - parent, 2 x 45 min - teachers)

Who delivers the intervention: clinical psychologists and clinical psychology graduates

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment and 6-month follow-up: ADIS-C/P

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

120

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Masia Warner 2007  (Continued)

Cochrane Database of Systematic Reviews

Remission of all anxiety disorder diagnoses post-treatment and 6-month follow-up: ADIS-C/P

Reduction in anxiety symptoms (child report) post-treatment and 6-month follow-up: SPAI-C

Reduction in anxiety symptoms (parent report) post-treatment and 6-month follow-up: SAS-A

Reduction in depressive symptoms post-treatment: BDI-II

Improvement in global functioning post-treatment: CGAS

Notes

Remission data reported in Warwick 2016.

Anxiety symptom measures are social anxiety symptom measures.

Active control = attention control

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Judgement Comment: No detail given

Unclear risk

Judgement Comment: No detail given

Unclear risk

Judgement Comment: Students did not know students in other condition to
prevent contamination, but no detail provided regarding whether participants
were blind to receiving 'intervention' or 'control'

Low risk

Judgement Comment: Independent blind assessors

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Dropouts detailed, completer and ITT analyses report-
ed, with appropriate imputation

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes reported for all measures

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Qualified therapists. Measures to ensure treatment in-
tegrity

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Masia Warner 2011 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: non-controlled 3-month follow-up

Number of study centres and location: USA

Study setting: paediatric primary care and speciality physicians

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

121

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Masia Warner 2011  (Continued)

Participants

N = 40 (CBT: N = 20; waitlist: N = 20)

Mean age (SD): 12.4 (2.6)

Age range: 8 to 16

Gender: 26 (65%) female

Inclusion criteria: age 8 to 16 with functional physical complaints (primarily gastrointestinal symp-
toms) and a principal anxiety disorder (based on ADIS-C/P), psychiatric medication allowed if receiving
for 6 months and stable during intervention phase

Interventions

CBT

Intervention: TAPS (Treatment of Anxiety and Physical Symptoms). Jointly addresses anxiety and
physical symptoms through identifying contexts where symptoms occur and interact

Concomitant/excluded medications: children receiving psychiatric medication for more than 6
months and stable medication during intervention phase allowed

Delivery format: child-only sessions, and parent meetings; individual

Therapist contact time: 11 to 14 hours (12 x 45 to 60 minutes (child), 3 x 45 minutes (parent))

Who delivers the intervention: PhD level clinical psychologists trained in CBT

Waitlist/no treatment

Intervention: 8-week waitlist

Concomitant/excluded medications: children receiving psychiatric medication for more than 6
months and stable medication during intervention phase allowed

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-C/P

Improvement in global functioning post-treatment: CGAS

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Table of random numbers

Unclear risk

Judgement Comment: Predetermined, but no further detail given

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Blind assessors

Low risk

Judgement Comment: 1 dropout in control group. n reported for outcomes.

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

122

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Masia Warner 2011  (Continued)

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes reported for all measures

Other source of bias -
Therapy integrity

Unclear risk

Judgement Comment: Therapist clinical psychologist with training in CBT, no
detail given regarding supervision or adherence

Other bias

High risk

Judgement Comment: Timing post-treatment assessment differs across
groups

Masia Warner 2016 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: recruitment over 3 academic years. 5 months follow-up

Number of study centres and location: 3 schools in the USA

Study setting: schools

Withdrawals: 2 removed (in P-SASS) - irregular school attendance, medical emergency (NB: relate to
inclusion criteria, so not included in number randomised)

Participants

N = 136 (CBT (C-SASS): N = 46; CBT (P-SASS): N = 47; active control: N = 43)

Mean age (SD): 15.42 (0.81)

Age range: 13 to 17

Gender: 92 (67.7%) female

Inclusion criteria: diagnosis of social anxiety disorder (based on ADIS-C/P); if other disorders present,
SAD had to be of equal or greater severity

Exclusion criteria: require immediate care, unreliable school attendance, receiving CBT

Interventions

CBT (C-SASS)

Intervention: Skills for Academic and Social Success delivered by school counsellors (C-SASS)

Concomitant/excluded medications: anxiety medication allowed if stable

Delivery format: child-only sessions, plus 2 parent sessions; group, plus 2 brief individual

Therapist contact time: 16 hours - 12 x 40 minutes (group), 2 x 15 minutes (individual), 2 x 45 minutes
(parent), 4 x 90 minutes social activities

Who delivers the intervention: Master's-level school counsellors

CBT (P-SASS)

Intervention: Skills for Academic and Social Success delivered by psychologists (P-SASS)

Concomitant/excluded medications: anxiety medication allowed if stable

Delivery format: child-only sessions, plus 2 parent sessions; group, plus 2 brief individual

Therapist contact time: 16 hours - 12 x 40 minutes (group), 2 x 15 minutes (individual), 2 x 45 minutes
(parent), 4 x 90 minutes social activities

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

123

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Masia Warner 2016  (Continued)

Who delivers the intervention: doctoral-level clinical psychologists

Active control

Intervention: Skills for Life - non-specific counselling programme

Concomitant/excluded medications: anxiety medication allowed if stable

Delivery format: child-only sessions, plus 1 parent session; group, plus 1 brief individual

Therapist contact time: 9 hours (12 x 40 minutes (group), 1 x 15 minutes (individual), 1 x 45 minutes
(parent))

Who delivers the intervention: Master's-level counsellors

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment and 5-month follow-up: ADIS-C/P

Reduction in anxiety symptoms (child report) post-treatment and 5-month follow-up: SPAI-C

Reduction in anxiety symptoms (parent report) post-treatment and 5-month follow-up: SPAI-P

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Active control = attention control
Social anxiety symptom measures

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Independent randomisation

Low risk

Judgement Comment: Independent

Unclear risk

Judgement Comment: No detail given

Low risk

Judgement Comment: Blinded independent assessors

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Dropouts detailed across groups, and examined differ-
ences between dropouts and completers, and completer analysis vs ITT

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes reported for all measures

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Therapist qualifications detailed, and treatment adher-
ence assessed and reported (NB: contamination in 42% of control sessions,
but with 1 exception was mild, so assume low risk of bias)

Other bias

Unclear risk

Judgement Comment: Amount of therapist contact time and social events not
equal across conditions

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

124

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

McConachie 2014 

Study characteristics

Cochrane Database of Systematic Reviews

Methods

Study design: randomised controlled trial

Total duration of study: assessed 3 months (post-treatment), 6 months, and 9 months

Number of study centres and location: the UK

Study setting: referrals from CAMHS teams in England

Participants

N = 32 (CBT: N = 17; waitlist: N = 15)

Mean age (SD): CBT: 11.7 (1.4); waitlist: 11.8 (1.3)

Age range: 9 to 13

Gender: CBT: 2 (11.8%); waitlist: 2 (13.3)

Inclusion criteria: child had a confirmed diagnosis of ASD, met criteria for at least 1 anxiety disorder
(based on ADIS-P), aged 9 years to 13 years 11 months with intellectual ability in the average range (full
scale IQ > 69). Parent(s) also had to be willing to attend group therapy in parallel with their child.

Exclusion criteria: children with untreated ADHD or oppositional behaviour that was considered likely
to disrupt a small-group setting

Interventions

CBT

Intervention: Exploring Feelings, with minor adjustments for UK setting

Concomitant/excluded medications: clinician asked to avoid alteration in medication

Delivery format: child and parent separate sessions; group

Therapist contact time: 28 hours total (7 x 2 hours - child; 7 x 2 hours - parent), parent and child ses-
sions run same time

Who delivers the intervention: trainee psychologists, no prior CBT qualification

Waitlist/no treatment

Intervention: delayed treatment, 9 months wait (assessment 3 months, 6 months, 9 months)

Concomitant/excluded medications: clinician asked to avoid alteration in medication

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-P

Remission of all anxiety disorder diagnoses post-treatment: ADIS-P

Reduction in anxiety symptoms (child report) post-treatment: SCAS-C

Reduction in anxiety symptoms (parent report) post-treatment: SCAS-P

6- and 9-month follow-up anxiety symptoms outcomes reported, but only change scores.
Sample with ASD

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

Judgement Comment: Random permuted blocks of variable length (www.ran-
domization.com)

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

125

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

McConachie 2014  (Continued)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Judgement Comment: Measures to ensure concealed allocation

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Blind assessors

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Attrition detailed. Only 1 dropout. Use last observation
carried forward for this case for questionnaires

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes reported for all measures

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Therapists trained and supervised, and fidelity as-
sessed and reported

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

McNally Keehn 2013 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: non-controlled 2-month follow-up

Number of study centres and location: 1 in the USA

Study setting: university clinic

Date of study: June to September 2009; post- and follow-up assessments completed by April 2010

Participants

N = 22 (CBT: N = 12; waitlist: N = 10)

Mean age (SD): 11.26 (1.53)

Age range: 8 to 14

Gender: 1 (4.5%) female

Inclusion criteria: a) diagnosis of ASD based on the Autism Diagnostic Observation Schedule (ADOS),
Autism Diagnostic Interview-Revised (ADI-R), and expert clinical judgement based on DSM-IV criteria,
(b) diagnosis of separation anxiety disorder, social phobia, or GAD (based on ADIS-P), c) IQ > 70, d) age 7
to 14, and e) English as the primary language

Interventions

CBT

Intervention: Modified Coping Cat to accommodate learning styles of ASD

Concomitant/excluded medications: usual medication allowed

Delivery format: child sessions, plus 2 parent sessions; individual

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

126

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

McNally Keehn 2013  (Continued)

Cochrane Database of Systematic Reviews

Therapist contact time: 16 to 24 hours (16 x 60 to 90 minutes)

Who delivers the intervention: lead author

Waitlist/no treatment

Intervention: 16-week waitlist

Concomitant/excluded medications: usual medication allowed

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-P

Reduction in anxiety symptoms (child report) post-treatment: SCAS-C

Reduction in anxiety symptoms (parent report) post-treatment: SCAS-P

Notes

Author provided data on remission for separation anxiety disorder, social phobia, and GAD, not able to
use.

Sample with ASD

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Block randomised, stratified

Unclear risk

Judgement Comment: No detail given

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Blind assessors

Low risk

Judgement Comment: Detailed no dropouts to post-treatment

Low risk

Judgement Comment: Outcomes reported for all measures

Low risk

Judgement Comment: Adherence rated and reported

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Melfsen 2011 

Study characteristics

Methods

Study design: randomised controlled trial

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

127

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Melfsen 2011  (Continued)

Total duration of study: 10-month follow-up for treatment group (6 months post-treatment)

Number of study centres and location: 1 in Germany

Study setting: clinic

Date of study: recruitment 2004 to 2006

Participants

N = 44 (CBT: N = 21; waitlist: N = 23)

Mean age (SD): CBT: 10.60 (1.64); waitlist: 10.76 (1.90)

Age range: 8 to 14

Gender: 21 (47.8%) female

Inclusion criteria: a) DSM-IV criteria for social phobia (based on DIPS-K), (b) child experienced social
phobia for at least 6 months, (c) social phobia was considered to be the child’s main current problem,
(d) child age 8 to 13 years, (e) child and parent agreed not to start any additional treatment during the
trial

Exclusion criteria: psychotic symptoms, current suicidal or self-harming behaviour, or current involve-
ment in other psychosocial or psychopharmacological treatment for phobia and anxiety problems

Interventions

CBT

Intervention: psychoeducation, cognitive restructuring, behavioural experiments, relapse

Concomitant/excluded medications: psychopharmacological treatment not allowed

Delivery format: child and parent sessions; individual

Therapist contact time: 20 hours (20 x 50 minutes, 4 x parent sessions)

Who delivers the intervention: advanced doctoral-level graduate students

Waitlist/no treatment

Intervention: 4-month waitlist

Concomitant/excluded medications: psychopharmacological treatment not allowed

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: DIPS-K

Remission of all anxiety disorder diagnoses post-treatment: DIPS-K

Reduction in anxiety symptoms (child report) post-treatment: SPAIK-C

Reduction in depressive symptoms post-treatment: CDI

Improvement in global functioning post-treatment: K-GAS

Refer to follow-up but do not report follow-up data

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

Judgement Comment: Web-based computerised randomisation plan genera-
tor

Allocation concealment
(selection bias)

Low risk

Judgement Comment: Independent research assistant placed participants on
randomisation list in next available slot

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

128

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Melfsen 2011  (Continued)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Low risk

Low risk

Selective reporting (re-
porting bias)

Low risk

Cochrane Database of Systematic Reviews

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Judgement Comment: Assessor not blind, but video recordings of assessments
viewed and rated by blind expert

Judgement Comment: Attrition detailed and use appropriate imputation, and
report ITT

Judgement Comment: Relevant outcomes reported. Not report follow up data
for intervention group, but the follow-up h as no comparison group so would
not be eligible for inclusion here

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Therapy delivered by advanced doctoral graduates, ad-
herence assessed

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Muris 2002 

Study characteristics

Methods

Study design: randomised controlled trial

Number of study centres and location: 2 primary schools in the Netherlands

Study setting: primary schools

Participants

N = 20 (CBT: N = 10; control: N = 10) (NB: study also includes 10 participants (not randomly) assigned to
no treatment control, not included here)

Mean age (SD): 10 (0.8)

Age range: 9 to 12

Gender: 13 (65%) female

Inclusion criteria: elevated RCADS score; generalised anxiety disorder, separation anxiety disorder, or
social phobia diagnosis (based on DISC)

Interventions

CBT

Intervention: Coping Koala

Delivery format: child only; group

Therapist contact time: 6 hours (12 x 30 minutes)

Who delivers the intervention: clinical psychology student

Active control

Intervention: Emotional Disclosure

Delivery format: child only; group

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

129

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Muris 2002  (Continued)

Therapist contact time: 6 hours (12 x 30 minutes)

Who delivers the intervention: clinical psychology student

Cochrane Database of Systematic Reviews

Outcomes

Reduction in anxiety symptoms (child report) post-treatment: RCADS-C Anxiety Scale

Reduction in depressive symptoms post-treatment: RCADS-C-Depression Scale

Notes

Participants randomised to CBT vs active control. Study also includes no treatment control, but non-
randomised allocation so not included here.

Active control = attention control

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Judgement Comment: No detail given

Unclear risk

Judgement Comment: No detail given

Unclear risk

Judgement Comment: No detail given

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Judgement Comment: Questionnaires administered by psychologist not in-
volved in treatment

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Reports no dropouts

Low risk

Judgement Comment: Outcomes reported for measures

Other source of bias -
Therapy integrity

Unclear risk

Judgement Comment: Therapist supervised, but no detail given on maintain-
ing adherence

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Murphy 2017 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 12-week follow-up

Number of study centres and location: 3 CAMHS clinics in the UK

Study setting: clinics

Date of study: recruitment April 2011 to April 2013

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

130

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Murphy 2017  (Continued)

Participants

N = 36 (CBT: N = 17; active control: N = 19)

Mean age (SD): CBT: 14.94 (1.63); active control: 15.56 (1.91)

Age range: 12 to 18

Gender: 14 (38.9%) female

Inclusion criteria: ASD and anxiety disorder diagnoses (separation anxiety, social anxiety, specific
phobia, and/or generalised anxiety) based on ADOS, ADI-R, ADIS-C/P); attend mainstream school

Exclusion criteria: primary diagnosis OCD, agoraphobia with/without panic disorder, PTSD, psychosis,
depression, substance abuse; receipt of current psychological therapy from another source

Interventions

CBT

Intervention: Multimodal Anxiety and Social Skill Intervention for adolescents with ASD (MASSI). CBT
for anxiety, plus strategies targeting social skills deficits

Concomitant/excluded medications: not alter medication doses during intervention

Delivery format: child only, parents included at end of all sessions; individual and group

Therapist contact time: 10 hours (plus group sessions) (12 x 50 minutes individual sessions)

Who delivers the intervention: NHS clinicians

Active control

Intervention: counselling offered in the NHS dealt with anxiety as and when the client raised it, in a
supportive manner, but with no focus on physical symptoms or cognitions

Concomitant/excluded medications: not alter medication doses during intervention

Delivery format: child only, parents included at end of all sessions; individual and group

Therapist contact time: 10 hours (plus group sessions) (12 x 50 minutes individual sessions)

Who delivers the intervention: NHS clinicians

Outcomes

Reduction in anxiety symptoms (parent report) post-treatment and follow-up (< 6 months): CASI-
ASD Anxiety Scale

Notes

Diagnostic assessment post-treatment but not required remission data

Sample with ASD

Active control = alternative treatment (counselling)

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Judgement Comment: Predetermined random sequence by an independent
statistician

Allocation concealment
(selection bias)

Low risk

Judgement Comment: Randomisation was managed by a statistician uncon-
nected with the study who prepared sequentially numbered envelopes con-
taining allocation status

Blinding of participants
and personnel (perfor-
mance bias)

Unclear risk

Judgement Comment: No detail given regarding blinding of participants

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

131

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Murphy 2017  (Continued)

All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Judgement Comment: Blind assessors

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Attrition detailed. ITT analyses reported, and method
for managing missing data.

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Outcomes reported

Low risk

Judgement Comment: Qualified therapists. Fidelity assessed and reported.

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

O'Brien 2007 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 10 weeks; end of 10 weeks TAU group offered CBT

Number of study centres and location: 1 in Ireland

Study setting: clinic

Participants

N = 14 (CBT: N = 7; TAU: N = 7)

Mean age (SD): CBT: 13.8 (0.5); TAU: 12.5 (1.0)

Age range: 7 to 15

Gender: 7 (50%) female

Inclusion criteria: diagnosis of DSM-IV-R anxiety disorder (based on ADIS)

Exclusion criteria: children with intellectual disabilities, pervasive developmental disorder, or recent
history of psychotic symptoms

Interventions

CBT

Intervention: group CBT: Friends for Youth

Concomitant/excluded medications: stable dose allowed

Delivery format: child sessions and parent sessions; group

Therapist contact time: 19.5 hours (10 x 90 minutes - child; 3 x 90 minutes - parent)

Who delivers the intervention: mental health professionals, and supervised by main author

TAU

Intervention: 10 weeks TAU. Received maximum of 4 reviews with primary clinician - review of
progress, medication, and supportive approach

Concomitant/excluded medications: stable dose allowed

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

132

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

O'Brien 2007  (Continued)

Delivery format: individual

Therapist contact time: maximum of 4 sessions

Who delivers the intervention: primary clinician

Outcomes

Reduction in depressive symptoms post-treatment: CDI

Cochrane Database of Systematic Reviews

Notes

Risk of bias

Bias

Anxiety symptoms outcomes only reported after both groups received CBT intervention.

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Judgement Comment: Sequence generation lacks detail, and unclear how age
managed in the process

Allocation concealment
(selection bias)

Unclear risk

Judgement Comment: Refers to person doing randomisation being blind, but
further detail is lacking

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Judgement Comment: Not detailed, but no post-treatment diagnostic assess-
ment

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Data reported

Selective reporting (re-
porting bias)

Unclear risk

Judgement Comment: Did not report outcomes for all measures at post-as-
sessment separately for 2 groups

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Experienced supervisors. Sessions recorded to moni-
tor and ensure adherence, although lacking detail on how adherence was as-
sessed

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Olivares 2005 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 6-month follow-up

Number of study centres and location: Spain

Study setting: schools (screening)

Participants

N = 34 (CBT: N = 17; waitlist: N = 17)

Mean age (SD): 15.03 (0.86)

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

133

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Olivares 2005  (Continued)

Age range: 14 to 17

Gender: 60% female

Cochrane Database of Systematic Reviews

Inclusion criteria: diagnosis of social phobia (based on ADIS-C)

Interventions

CBT

Intervention: IAFS (multicomponent programme: Intervention in Adolescents with Social Phobia)

Delivery format: child only; group

Therapist contact time: 18 hours (12 x 90 minutes)

Waitlist/no treatment

Intervention: waitlist

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment and 6-month follow-up: ADIS-C

Remission of all anxiety disorder diagnoses post-treatment and 6-month follow-up: ADIS-C

Reduction in anxiety symptoms (child report) post-treatment and 6-month follow-up: SPAI-C

Anxiety symptoms measure - social anxiety symptoms

Authors' judgement

Support for judgement

Unclear risk

Judgement Comment: No detail given

Unclear risk

Judgement Comment: No detail given

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Judgement Comment: Independent assessor carried out diagnostic interview
and evaluation

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: No missing data

Low risk

Judgement Comment: Outcomes reported for all measures

Unclear risk

Judgement Comment: Lacks detail

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

134

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Olivares 2014 

Study characteristics

Cochrane Database of Systematic Reviews

Methods

Study design: randomised controlled trial

Number of study centres and location: 9 high schools in Spain

Study setting: schools

Participants

N = 117 (CBT (expert): N = 39; CBT (inexperienced): N = 39; waitlist: N = 39)

Mean age (SD): 15.42 (0.97)

Age range: 14 to 17

Gender: 61.8% female

Inclusion criteria: generalised social phobia (based on ADIS-C)

Exclusion criteria: depression, borderline personality disorder, narcissistic disorder, paranoid disor-
der, long history of substance abuse, aggressive behaviour, missing 3 consecutive treatment sessions,
and have not previously received psychological treatment

Interventions

CBT (expert)

Intervention: IAFS (multicomponent programme: Intervention in Adolescents with Social Phobia)

Delivery format: child only; group

Therapist contact time: 18 hours (12 x 90 minutes)

Who delivers the intervention: clinical psychologists (degree in psychology) with more than 2 years'
experience treating individual cases and applying psychological treatment to groups with social anxi-
ety

CBT (inexperienced)

Intervention: IAFS (multicomponent programme: Intervention in Adolescents with Social Phobia)

Delivery format: child only; group

Therapist contact time: 18 hours (12 x 90 minutes)

Who delivers the intervention: psychologists (degree in psychology) with no experience in applying
psychological treatment

Waitlist/no treatment

Intervention: waitlist

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-C

Reduction in anxiety symptoms (child report) post-treatment: SAS-A

Reduction in anxiety symptoms (parent report) post-treatment: SAS-P

Anxiety symptoms measures - social anxiety symptoms

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Unclear risk

Judgement Comment: No detail given

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

135

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Olivares 2014  (Continued)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Unclear risk

Judgement Comment: No detail given

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Unclear risk

Judgement Comment: Evaluators trained, and therapist competence masked,
but does not specify if blind to waitlist vs treatment

Unclear risk

Judgement Comment: Attrition given, but only reports completer analyses. No
mention of how missing item data were managed

Low risk

Judgement Comment: Outcomes reported for all measures

Low risk

Judgement Comment: Fidelity measured

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Olivares 2019 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: non-controlled follow-up

Number of study centres and location: 7 schools in Spain

Study setting: high schools

Participants

N = 108 randomised (CBT-IAFS: N = 36; CBT-IAFS without social skills training: N = 36; waitlist: N = 36)

Mean age: 15.4 (1.11)

Age range: 14 to 17

Gender: 63% female

Inclusion criteria: met diagnostic criteria for generalised social phobia (based on ADIS-C)

Exclusion criteria: no written parental consent, met diagnostic criteria for severe psychopathology
(e.g. depression or narcissistic disorder), long history of substance abuse, aggressive behaviour, miss-
ing 3 consecutive treatment sessions, and have not previously received psychological or psychiatric
treatment

Interventions

CBT

Intervention: IAFS (Intervention in Adolescents with Social Phobia)

Delivery format: child only; group

Therapist contact time: 18 hours (12 x 90 minutes)

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

136

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Olivares 2019  (Continued)

Who delivers the intervention: psychology graduates

CBT

Intervention: IAFS without social skills training

Delivery format: child only; group

Therapist contact time: 18 hours (12 x 90 minutes)

Who delivers the intervention: psychology graduates

Waitlist/no treatment

Intervention: waitlist

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-C

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Symptom measures only reported pre-post change.

Authors' judgement

Support for judgement

Unclear risk

Judgement Comment: No detail

Unclear risk

Judgement Comment: No detail

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Independent assessors

Unclear risk

Judgement Comment: High number of dropouts in 1 CBT group

Low risk

Judgement Comment: Outcomes reported for relevant measure

Unclear risk

Judgement Comment: Experienced therapists, no further detail

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Ollendick 2009 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 6-month follow-up

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

137

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Ollendick 2009  (Continued)

Number of study centres and location: 2; Sweden and the USA

Study setting: clinics

Date of study: 2001 to 2006

Participants

N = 196 (CBT: N = 85; active control: N = 70; waitlist: N = 41)

Mean age (SD): Virginia site: 10.9 (1.7); Stockholm site: 11.1 (1.9)

Age range: 7 to 16

Gender: 106 (43.3%)

Inclusion criteria: age 7 to 16; specific phobia diagnosis, present for 6 months with CSR 4+ (based on
ADIS-C/P); discontinue other psychotherapy or anti-anxiety medication for duration of study

Exclusion criteria: primary major depression, pervasive developmental disorder, drug or alcohol
abuse, psychotic symptoms

Interventions

CBT

Intervention: One Session Treatment (OST) (follow Ost, but flexibly implemented)

Concomitant/excluded medications: anti-anxiety treatment not allowed

Delivery format: child only; individual

Therapist contact time: 3 hours 45 minutes (pretreatment interview 45 minutes, treatment 3 hours)

Who delivers the intervention: clinicians with at minimum a Master's degree, trained

Active control

Intervention: education support therapy

Concomitant/excluded medications: anti-anxiety treatment not allowed

Delivery format: child only; individual

Therapist contact time: 3 hours

Who delivers the intervention: clinicians with at minimum a Master's degree, trained

Waitlist/no treatment

Intervention: 4-week waitlist

Concomitant/excluded medications: anti-anxiety treatment not allowed

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-C/P (mini version to assess
pretreatment diagnoses)

Reduction in anxiety symptoms (child report) post-treatment: MASC-C

Reduction in depressive symptoms post-treatment: CDI

Notes

Author confirmed diagnosis free = free from primary disorder

Reported no adverse events during treatment

Active control = attention control

Symptom measures reported for each site separately.

Follow-up includes waitlist participants re-randomised to OST vs active control

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

138

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Ollendick 2009  (Continued)

Risk of bias

Bias

CBT vs waitlist and CBT vs active control (did not divide CBT group as included in separate compar-
isons)

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Judgement Comment: Computerised randomisation procedures or random
number generators

Allocation concealment
(selection bias)

Low risk

Judgement Comment: Randomisation assignments were kept in opaque en-
velopes that remained unopened until the time of assignment

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Unclear risk

Judgement Comment: Did not specify whether participants were blind to 'ac-
tive' vs 'control' treatment

Low risk

Judgement Comment: Blind assessors

Low risk

Judgement Comment: No dropouts

Low risk

Judgement Comment: Outcomes reported for all measures

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Therapists trained, supervised, and adherence and
competence monitored

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Ost 2001 

Study characteristics

Methods

Study design: randomised controlled trial

Number of study centres and location: Sweden

Study setting: referrals from child psychiatric services and school services

Participants

N = 60 (CBT (child): N = 21; CBT (child + parent) N = 20; waitlist: N = 19)

Mean age (SD): 11.7 (2.8)

Age range: 7 to 17

Gender: 37 (61%) female

Inclusion criteria: aged 7 to 17, primary specific phobia, with CSR 4+ and present for minimum of 1
year (based on ADIS-C/P), be motivated for treatment

Exclusion criteria: primary depression, drug or substance abuse, developmental disorder, psychotic
symptoms

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

139

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Ost 2001  (Continued)

Interventions

CBT (child)

Cochrane Database of Systematic Reviews

Intervention: One Session Treatment (OST), adjusted to developmental age

Delivery format: child only; individual

Therapist contact time: 3 hours 45 minutes (pretreatment interview - 45 minutes, treatment - 3 hours)

Who delivers the intervention: experienced clinical psychologist, experienced in treating specific pho-
bias with CBT

CBT (child + parent)

Intervention: One Session Treatment (OST), adjusted to developmental age. Same as child condition,
only parent present too

Delivery format: child and parent; individual

Therapist contact time: 3 hours 45 minutes (pretreatment interview - 45 minutes, treatment - 3 hours)

Who delivers the intervention: experienced clinical psychologist, experienced in treating specific pho-
bias with CBT

Waitlist/no treatment

Intervention: 4-week waitlist

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-C/P (mini version to assess
pretreatment diagnoses)

Reduction in anxiety symptoms (child report) post-treatment: RCMAS

Reduction in depressive symptoms post-treatment: CDI

Author provided remission of all diagnoses for those with pretreatment diagnoses only.

Authors' judgement

Support for judgement

Unclear risk

Judgement Comment: No detail given

Unclear risk

Judgement Comment: No detail given

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Assessors blind to condition

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Not clear if there were dropouts/missing data/ap-
proach to managing missing data, but author provided data

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes reported for measures

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

140

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Ost 2001  (Continued)

Other source of bias -
Therapy integrity

Unclear risk

Judgement Comment: Experienced therapists, but no detail given on assess-
ing adherence

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Perrin 2019 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 10-week treatment period; 3-month non-controlled follow-up

Number of study centres and location: referrals from 11 sites in 1 NHS Trust in the UK

Study setting: referral from CAMHS services and specialist anxiety clinician at NHS Trust

Participants

N = 40 (CBT: N = 20; waitlist: N = 20)

Mean age (SD): CBT: 13.2 (2.4); waitlist: 13.6 (2.8)

Age range: 10 to 18

Gender: 25 (62.5%) female

Inclusion criteria: (1) aged 10 to 18 years; (2) referred for treatment of anxiety; (3) a current, prima-
ry diagnosis of DSM-IV GAD (Based on ADIS-C/P); (4) no other psychiatric problems in need of more ur-
gent treatment (including self-injurious thoughts/behaviours or substance use/abuse); (5) no concur-
rent psychological or pharmacological treatment for any disorder; and (6) the absence of moderate to
severe learning difficulties as evidenced in the medical or school records or as reported by the refer-
rer/parent at the pretrial screening

Interventions

CBT

Intervention: child-friendly adaptation of CBT for GAD approach

Concomitant/excluded medications: concurrent pharmacological treatment for any disorder not al-
lowed

Delivery format: child only, parent invited to join for 1 session and to join end of sessions; individual

Therapist contact time: 10 sessions

Who delivers the intervention: doctoral-level clinical psychologists

Waitlist

Intervention: 10-week waitlist

Concomitant/excluded medications: concurrent pharmacological treatment for any disorder not al-
lowed

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-C/P

Remission of all anxiety disorder diagnoses post-treatment: ADIS-C/P

Reduction in anxiety symptoms (child report) post-treatment: SCARED-C

Reduction in anxiety symptoms (parent report) post-treatment: SCARED-P

Reduction in depressive symptoms post-treatment: MFQ-C

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

141

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Perrin 2019  (Continued)

Improvement in global functioning post-treatment: CGAS

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Online random allocation program

Low risk

Low risk

Judgement Comment: Online random allocation program created by CTU, al-
location after initial assessment

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Independent blind assessors

Low risk

Judgement Comment: Attrition low and detailed. Report ITT

Low risk

Judgement Comment: Outcomes reported for all measures

Low risk

Judgement Comment: Trained and supervisor therapist. Adherence assessed

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Pincus 2010 

Study characteristics

Methods

Study design: randomised controlled trial

Number of study centres and location: 1 in the USA

Study setting: university research clinic

Participants

N = 26 (CBT: N = 13; active control: N = 13)

Mean age (SD): 15.75 (1.10)

Age range: 14 to 17

Gender: 19 (73.1%) female

Inclusion criteria: panic disorder diagnosis, with or without agoraphobia, CSR 4+ (based on ADIS-C/P)

Interventions

CBT

Intervention: Panic Treatment Programme (PCT-A) downward extension of Panic Control Treatment

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

142

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Pincus 2010  (Continued)

Cochrane Database of Systematic Reviews

Concomitant/excluded medications: stabilisation period prior to assessment required

Delivery format: child sessions, with parent included in some sessions; individual

Therapist contact time: 9 hours (11 x 50 minutes)

Active control

Intervention: attention control. 8-week self-monitoring, meet with therapist every other week to dis-
cuss self-monitoring panic and anxiety

Concomitant/excluded medications: stabilisation period prior to assessment required

Delivery format: child only; individual

Therapist contact time: 2 hours (4 x 30 minutes)

Outcomes

Reduction in anxiety symptoms (child report) post-treatment: MASC-C

Reduction in depressive symptoms post-treatment: CDI

Notes

Use mini-ADIS post-treatment. Remission outcomes not reported/provided.

Active control = attention control

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Authors' judgement

Support for judgement

Unclear risk

Judgement Comment: No detail given

Unclear risk

Judgement Comment: No detail given

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Unclear risk

Judgement Comment: Not specified

Unclear risk

Judgement Comment: Attrition and how missing data managed detailed, but
high rate of missing data (24% for questionnaires)

Low risk

Judgement Comment: Outcomes reported

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Adherence assessed by independent raters and report-
ed

Other bias

High risk

Judgement Comment: Time point for post-treatment assessment varies across
conditions

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

143

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Rapee 2005 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 11-year follow-up

Number of study centres and location: Australia

Study setting: screening in 95 preschools

Cochrane Database of Systematic Reviews

Participants

N = 146 randomised (NB: we included N = 111 who met diagnostic criteria for an anxiety disorder at
baseline. CBT: N = 60; no intervention: N = 51)

Mean age (SD): CBT: 47.23 (5.08); no intervention: 45.71 (4.15)

Age range: 36 to 62 months

Gender: 64 (57.7%) female

Inclusion criteria: inhibited children (score > 1.5 SD above mean) and met for behavioural inhibition
on the lab assessment. We only included children who met diagnostic criteria in the review.

Interventions

CBT

Intervention: parent education. Nature of anxiety, parent management, exposure, cognitive restruc-
turing for parent, apply cognitive principles with child

Delivery format: parent only, group

Therapist contact time: 9 hours (6 x 90 minutes)

Who delivers the intervention: clinical psychologist

No treatment

Intervention: monitor condition. No intervention

Outcomes

Remission of all anxiety disorder diagnoses post-treatment: ADIS-P

Reduction in anxiety symptoms (parent report) post-treatment: Preschool Anxiety Scale

We only included children who met diagnostic criteria for an anxiety disorder at baseline.

Authors' judgement

Support for judgement

Unclear risk

Judgement Comment: No detail given

Unclear risk

Judgement Comment: No detail given

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Blind assessors

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

144

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Rapee 2005  (Continued)

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Author provided data

Low risk

Judgement Comment: Outcomes reported/provided

Other source of bias -
Therapy integrity

Unclear risk

Judgement Comment: Experienced therapist delivered intervention. No fur-
ther detail

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Rapee 2006 

Study characteristics

Methods

Study design: randomised controlled trial

Number of study centres and location: 1 in Australia

Study setting: university clinic

Date of study: recruitment 1999 to 2002

Participants

N = 267 randomised (NB: we included N = 177, randomised to CBT: N = 90; waitlist: N = 87)

Mean age (SD): CBT: 113.7 months (20.4); waitlist: 114.1 months (19.1)

Age range: 6 to 12

Gender: CBT: 52.3% female; waitlist: 29.9% female

Inclusion criteria: year 1 to 6 at school (age 6 to 12), primary anxiety disorder (based on ADIS-C/P), par-
ent able to read standard English newspaper

Interventions

CBT

Intervention: Cool Kids

Concomitant/excluded medications: stable dose for month before allowed

Delivery format: child and parent sessions, group

Therapist contact time: 18 hours (9 x 2 hours)

Who delivers the intervention: graduate students in clinical psychology

Waitlist/no treatment

Intervention: 3-month waitlist

Concomitant/excluded medications: stable dose for month before allowed

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-C/P

Remission of all anxiety disorder diagnoses post-treatment: ADIS-C/P

Reduction in anxiety symptoms (child report) post-treatment: SCAS-C

Reduction in anxiety symptoms (parent report) post-treatment: SCAS-P

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

145

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Rapee 2006  (Continued)

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Trial included "bibliotherapy" arm (parent-only condition with no face-to-face contact, so not includ-
ed).

Report no adverse events during treatment

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Block randomisation, random number schedule

Low risk

Low risk

Judgement Comment: Random number schedule known only to study co-ordi-
nator

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Blind to treatment condition

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Dropouts detailed. ITT and completer analysis provid-
ed, including appropriate method for imputing missing data.

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Outcomes reported for all measures

Unclear risk

Judgement Comment: Experienced therapist. No detail on adherence

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Reaven 2012 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 4-month intervention period

Number of study centres and location: 1 in the USA

Study setting: research clinic

Participants

N = 50 (CBT: N = 24; TAU: N = 26)

Mean age (SD): CBT: 125.75 months (21.47); TAU: 125.00 months (20.45)

Age range: 7 to 14

Gender: 48 (96%) female

Inclusion criteria: age 7 to 14; diagnosis of an ASD (determined by expert clinical psychologists based
upon review of a recent ADOS and the Social Communication Questionnaire); speaking in full, com-

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

146

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Reaven 2012  (Continued)

Cochrane Database of Systematic Reviews

plex sentences, and as reflected in recent standardised cognitive assessment, and clinically significant
symptoms of anxiety (NB: include ADIS-P and participants met diagnostic criteria)

Excluded criteria: primary psychiatric symptoms reflective of another condition such as depression or
psychosis; child does not demonstrate “group readiness” in the first 3 sessions of Facing Your Fears; 1
parent could not commit to attending 80% of sessions

Interventions

CBT

Intervention: Facing Your Fears. Adapted CBT programme for children with ASD

Concomitant/excluded medications: medications allowed

Delivery format: child and parent together, group

Therapist contact time: 18 hours (12 x 90 minutes)

Who delivers the intervention: clinical psychologist and co-therapists

TAU

Intervention: maintained current interventions and allowed to pursue new interventions for 4 months

Concomitant/excluded medications: medications allowed

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-P

Remission of all anxiety disorder diagnoses post-treatment: ADIS-P

Notes

Use data published in Warwick 2016 review

Sample with ASD

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Computer generated

Low risk

Judgement Comment: Computer generated, so unlikely to foresee assignment

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Blind assessors

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Attrition detailed, report ITT. Diagnostic outcomes only
relevant outcome

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes reported/available for relevant measure

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Trained therapists, regular supervision, adherence as-
sessed and reported

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

147

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Reaven 2012  (Continued)

Cochrane Database of Systematic Reviews

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Reigada 2015 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 3-month follow-up

Number of study centres and location: 1 in the USA

Study setting: university clinic

Participants

N = 22 (CBT: N = 11; active control: N = 11)

Mean age (SD): 13.2 (2.1)

Age range: 9 to 17

Gender: 13 (59.1%) female

Inclusion criteria: confirmed inflammatory bowel disease (IBD) diagnosis and met diagnostic criteria
for a DSM-IV anxiety disorder (based on ADIS-C/P)

Exclusion criteria: current suicidal thoughts requiring immediate clinical attention; current use of a
psychotropic medication prescribed within the last 2 months; current substance use disorder, conduct
disorder, or pervasive developmental disorder; schizophrenia or other psychosis; a history of or current
bipolar disorder; or a principal diagnosis of post-traumatic stress disorder

Interventions

CBT

Intervention: Treatment of Anxiety and Physical symptoms related to IBD (TAPS + IBD)

Concomitant/excluded medications: current use of a psychotropic medication prescribed within the
last 2 months excluded

Delivery format: child sessions and 3 parent sessions; individual

Therapist contact time: 16 hours (13 x 1 hour; 3 x 1-hour parent sessions)

Who delivers the intervention: clinical psychology doctoral students

Active control

Intervention: non-directive supportive therapy. Offered social and emotional support through the use
of non-directive techniques (e.g. reflection, summarisation), empathetic communication, and support-
ive statements

Concomitant/excluded medications: current use of a psychotropic medication prescribed within the
last 2 months excluded

Delivery format: child sessions and parent sessions; individual

Therapist contact time: 16 hours (13 x 1 hour; 3 x 1-hour parent sessions)

Who delivers the intervention: clinical psychology doctoral students

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment and 3-month follow-up: ADIS-C/P

Remission of all anxiety disorder diagnoses post-treatment and 3-month follow-up: ADIS-C/P

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

148

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Reigada 2015  (Continued)

Cochrane Database of Systematic Reviews

Reduction in anxiety symptoms (child report) post-treatment and 3-month follow-up: IBD-Specific
Anxiety Scale

Notes

Anxiety symptom measure measure of anxiety related to IBD symptoms

Active control = alternative treatment

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Random number charts

Unclear risk

Judgement Comment: No detail given

Unclear risk

Judgement Comment: No detail on participant blinding

Low risk

Judgement Comment: Blind independent evaluators

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Attrition and missing data detailed. Detailed method of
managing missing data to report ITT analyses

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes reported for all measures

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Therapists trained and supervised. Adherence and con-
tamination in control assessed and reported

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Rosa Alcazar 2009 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 6- and 12-month follow-up

Number of study centres and location: Spain

Study setting: schools (screening)

Participants

N = 77 (CBT: N = 20; active control (psychoeducation): N = 19; active control: N = 18; waitlist: N = 20)

Mean age (SD): 14.87 (0.80)

Age range: 14 to 17

Gender: 75% female

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

149

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Rosa Alcazar 2009  (Continued)

Inclusion criteria: generalised social phobia diagnosis (based on ADIS-C), parental consent

Interventions

CBT

Intervention: IAFS (Intervención en Adolescentes con Fobia Social)

Delivery format: child only; group

Therapist contact time: 18 hours (12 x 90 minutes)

Who delivers the intervention: therapists

Active control

Intervention: psychoeducation

Delivery format: child only; group

Therapist contact time: 18 hours (12 x 90 minutes)

Who delivers the intervention: therapists

Active control

Intervention: health education

Concomitant/excluded medications:

Delivery format: child only; group

Therapist contact time: 18 hours (12 x 90 minutes)

Who delivers the intervention: therapists

Waitlist/no treatment

Intervention: waitlist

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment, 6-month and 12-month fol-
low-up: ADIS-C

Remission of all anxiety disorder diagnoses post-treatment, 6-month and 12-month follow-up:
ADIS-C

Reduction in anxiety symptoms (child report) post-treatment, 6-month and 12-month follow-up:
SPAIC

Reduction in anxiety symptoms (parent report) post-treatment, 6-month and 12-month fol-
low-up: SAS-P

Notes

Active controls = attention controls

Comparisons: CBT (split CBT group) vs active control, CBT (split CBT group) vs active control, CBT (total
CBT group) vs waitlist

Anxiety symptoms measures social anxiety symptom measures

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Unclear risk

Judgement Comment: Lack of detail

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

150

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Rosa Alcazar 2009  (Continued)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Unclear risk

Judgement Comment: No detail

Unclear risk

Judgement Comment: No detail

Unclear risk

Judgement Comment: Lack of detail

Low risk

Judgement Comment: Author provided data

Low risk

Judgement Comment: Outcomes reported/provided for all relevant measures

Unclear risk

Judgement Comment: Lack of detail

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Salari 2018 

Study characteristics

Methods

Study design: randomised controlled trial

Number of study centres and location: 1 in Iran

Study setting: university-affiliated outpatient clinic

Participants

N = 42 (CBT: N = 20; waitlist: N = 22)

Mean age (SD): CBT: 8.5 (2.5); waitlist: 8.1 (1.9)

Age range: 6 to 12

Gender: CBT: 47.4% female; waitlist: 21.4% female

Inclusion criteria: DSM-IV criteria for primary diagnosis of GAD, separation anxiety disorder, social
phobia, or specific phobia (based on K-SADS), 1 SSRI (Selective Serotonin Reuptake Inhibitor) medicine
at a stable dose for at least 8 weeks before baseline

Excluded criteria: 1) diagnosed as major psychiatric/neurologic disorders; 2) change in medication
during the study; 3) parents missed more than 2 of 6 sessions of treatment

Interventions

CBT

Intervention: parent training - group CBT "Friends for life" (parent-training element, translated ver-
sion)

Concomitant/excluded medications: a stable dose of SSRI for at least 8 weeks before baseline al-
lowed

Delivery format: parent only; group

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

151

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Salari 2018  (Continued)

Therapist contact time: 12 hours (6 x 2 hours)

Who delivers the intervention child psychiatrist and co-led by a fellow of child psychiatry

Waitlist/no treatment

Intervention: 6-week waitlist

Concomitant/excluded medications: a stable dose of SSRI for at least 8 weeks before baseline

Outcomes

Reduction in anxiety symptoms (child report) post-treatment: RCMAS

Reduction in depressive symptoms post-treatment: CDI

Improvement in global functioning post-treatment: CGAS

Author confirmed no diagnostic assessment post-treatment.

Authors' judgement

Support for judgement

Unclear risk

Judgement Comment: No information provided

Unclear risk

Judgement Comment: No information provided

Low risk

Low risk

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Judgement Comment: No information provided, but no post-treatment diag-
nostic assessment used

Judgement Comment: Did not include participants who missed more than 2
sessions, which is a potential source of bias. 25% dropout in CBT group, but
author provided data

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Did not report diagnostic outcomes, but author con-
firmed no diagnostic assessment post-treatment

Other source of bias -
Therapy integrity

Unclear risk

Judgement Comment: Treatment delivery by psychiatrist. Refer to adherence
ratings, but no further detail reported

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Salum 2018 

Study characteristics

Methods

Study design: factorial randomised controlled trial

Number of study centres and location: Brazil

Date of study: recruitment from July 2011 to September 2012

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

152

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Salum 2018  (Continued)

Cochrane Database of Systematic Reviews

Withdrawals: N = 96 originally randomised, but 17 withdrew before first session and were not aware of
allocation - not included

Participants

N = 79 (CBT + Attention Bias Modification N = 21; CBT + Attention Control Training: N = 21; active control
therapy + Attention Bias Modification: N = 17; active control therapy + Attention Control Training: N =
20)

Age range: 7 to 11

Inclusion criteria: primary diagnosis of generalised anxiety disorder, separation anxiety disorder, or
social anxiety disorder (based on K-SADS)

Exclusion criteria: (i) other psychiatric disorder judged by the clinician to cause more impairment
or distress than GAD, separation anxiety disorder, or social anxiety disorder; (ii) any history of mental
health treatment; (iii) IQ lower than 70

Interventions

CBT (CBT + Attention Bias Modification)

Intervention: Friends for Life (group CBT) + Attention Bias Modification (160 trials)

Delivery format: child and parent sessions; group

Therapist contact time: 15 hours (10 x 90 minutes)

Who delivers the intervention: trained psychologists

CBT (CBT + Attention Control Training)

Intervention: Friends for Life (group CBT) + Attention Control Training (160 trials)

Delivery format: child and parent sessions; group

Therapist contact time: 15 hours (10 x 90 minutes)

Who delivers the intervention: trained psychologists

Active control (control therapy + Attention Bias Modification)

Intervention: control therapy - educational tasks and psychoeducation + Attention Bias Modification
(160 trials)

Delivery format: child and parent sessions; group

Therapist contact time: 15 hours (10 x 90 minutes)

Who delivers the intervention: trained psychologists

Active control (control therapy + Attention Control Training)

Intervention: control therapy - educational tasks and psychoeducation + Attention Control Training
(160 trials)

Delivery format: child and parent sessions; group

Therapist contact time: 15 hours (10 x 90 minutes)

Who delivers the intervention: trained psychologists

Outcomes

Reduction in anxiety symptoms (child report) post-treatment: SCAS-C

Reduction in anxiety symptoms (parent report) post-treatment: SCAS-P

Reduction in depressive symptoms post-treatment: CDI

Notes

Comparisons:

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

153

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Salum 2018  (Continued)

Cochrane Database of Systematic Reviews

• CBT + Attention Bias Modification vs active control therapy + Attention Bias Modification
• CBT + Attention Control Training vs active control therapy + Attention Control Training

Active control therapy + Attention Bias Modification = alternative treatment

Active control therapy + Attention Control Training = attention control

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Judgement Comment: Computer-generated numbers used to allocate partici-
pants to each group

Allocation concealment
(selection bias)

Low risk

Quote: "Allocation to groups was concealed, so therapists did not know the
participant’s group allocation until the delivery of the ﬁrst therapy session."

Judgement Comment: Independent

Low risk

Judgement Comment: Participants and investigators were blind

Low risk

Judgement Comment: Independent assessors

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

High risk

Judgement Comment: Attrition detailed, and ITT reported. However, there
was a large number of dropouts (23/79), and dropouts were related to CBT +
Attention Bias Modification.

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Outcomes reported

Low risk

Judgement Comment: Trained therapists. Fidelity monitored in supervision.

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Sanchez Garcia 2009 

Study characteristics

Methods

Study design: randomised controlled trial

Number of study centres and location: screening in 17 schools in Spain

Study setting: schools

Withdrawals: 7 excluded because they failed to attend 3 consecutive sessions (NB: group not reported)

Participants

N = 82 (included here: N = 53, randomised to: CBT: N = 28; waitlist: N = 25)

Age range: 10 to 14

Inclusion criteria: generalised social phobia diagnosis (based on ADIS-C)

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

154

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Sanchez Garcia 2009  (Continued)

Exclusion criteria: failed to attend 3 consecutive treatment sessions

Interventions

CBT

Intervention: Intervention in Adolescents with Social Phobia (IAFS), version for 10- to 14-year-olds. Ed-
ucation, training in social skills, exposure, cognitive restructuring

Delivery format: child only; group

Therapist contact time: 18 hours (12 x 90 minutes)

Waitlist/no treatment

Intervention: waitlist

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-C

Remission of all anxiety disorder diagnoses post-treatment: ADIS-C

Reduction in anxiety symptoms (child report) post-treatment: SPAI -C

Notes

Study includes third arm (IAFS without cognitive restructuring) not used in the review.

Anxiety symptoms measure = social anxiety symptoms measure

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Authors' judgement

Support for judgement

Unclear risk

Judgement Comment: No information given

Unclear risk

Judgement Comment: No information given

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Unclear risk

Judgement Comment: No information given

Unclear risk

Judgement Comment: Dropouts (beyond those excluded) and missing data
not detailed

Low risk

Judgement Comment: Author provided diagnostic outcomes data

Unclear risk

Judgement Comment: No information given

Other bias

Unclear risk

Judgement Comment: Participants who missed treatment sessions were ex-
cluded

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

155

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Santucci 2013 

Study characteristics

Cochrane Database of Systematic Reviews

Methods

Study design: randomised controlled trial

Number of study centres and location: USA

Study setting: university research clinic (conducted over 3 consecutive summers)

Participants

N = 29 (CBT: N = 15; waitlist: N = 14)

Mean age (SD): 9.18 (1.58)

Age range: 7 to 12

Gender: 100% female

Inclusion criteria: diagnosis of separation anxiety disorder (based on ADIS-C/P); female

Exclusion criteria: bipolar or psychotic disorder; anxiety or mood symptoms were primarily due to a
medical/physical condition

Interventions

CBT

Intervention: Child Anxiety Multi-Day Program (CMAP) for SAD. Psychoeducation, somatic anxiety
management, cognitive restructuring, problem solving, graduated exposure. Conducted over 7 days,
cumulating in sleepover. Parent sessions incorporate "Building confidence"

Concomitant/excluded medications: consistent dose of psychotropic medication allowed

Delivery format: child sessions and parent sessions; parent present in some of child sessions; group

Therapist contact time: 38 hours (4 x 5 hours; 1 x 3 hours; 1 x 15 hours (sleepover))

Who delivers the intervention: treatment developers and doctoral/PhD candidate assistants

Waitlist/no treatment

Intervention: 8-week waitlist

Concomitant/excluded medications: consistent dose of psychotropic medication allowed

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-C/P

Reduction in anxiety symptoms (child report) post-treatment: SCAS-C

Reduction in anxiety symptoms (parent report) post-treatment: SCAS-P

Improvement in global functioning post-treatment: CGAS

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Authors' judgement

Support for judgement

Unclear risk

Judgement Comment: No information given

Unclear risk

Judgement Comment: No information given

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

156

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Santucci 2013  (Continued)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Independent assessors

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Attrition detailed. Small amount of missing data, and
method for imputing data for missing values detailed and appropriate

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes reported

Other source of bias -
Therapy integrity

Unclear risk

Judgement Comment: Therapists trained, and supervision used to monitor/re-
view protocol, but no specific detail on adherence

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Schneider 2011 

Study characteristics

Methods

Study design: randomised controlled trial

Number of study centres and location: 1 in Germany

Study setting: university clinic

Date of study: 2004 to 2009

Participants

N = 43 (CBT: N = 21; waitlist: N = 22)

Mean age (SD): CBT: 6.29 (1.01); waitlist: 6.18 (0.73)

Age range: 5 to 7

Gender: 25 (58.1%) female

Inclusion criteria: primary diagnosis of separation anxiety disorder according to the DSM-IV-TR (based
on Kinder-DIPS); knowledge of the local language; age 5 to 7 years; written parental informed consent
and verbal child assent

Exclusion criteria: taking psychotropic medication

Interventions

CBT

Intervention: Separation Anxiety Family Therapy (TAFF) - disorder-specific CBT

Concomitant/excluded medications: psychotropic medication excluded

Delivery format: child-only sessions, parent-only sessions, and family sessions; individual

Therapist contact time: 13 hours, 20 min (4 x 50 min - child, 4 x 50 min - parent, 8 x 50 min - family/par-
ent) over 12 weeks

Who delivers the intervention: child psychiatrist and co-led by a fellow of child psychiatry

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

157

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Schneider 2011  (Continued)

Waitlist/no treatment

Intervention: 12-week waitlist

Cochrane Database of Systematic Reviews

Concomitant/excluded medications: psychotropic medication excluded

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-C/P

Reduction in anxiety symptoms (child report) post-treatment: RCMAS-C

Reduction in anxiety symptoms (parent-mother report) post-treatment: RCMAS-P

Diagnostic post-treatment assessment = 4-week follow-up assessment

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

Judgement Comment: Randomisation conducted by statistician using a com-
puterised permuted block design

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Low risk

Judgement Comment: Assignments concealed until the time of group assign-
ment

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Blind assessors

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Attrition detailed and clear. Appropriate methods used
for managing missing data.

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes reported

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Therapists trained and supervised. Adherence assessed
and reported.

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Sciberras 2018 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 5 months

Number of study centres and location: 1 in Australia

Study setting: Attention Deficit Hyperactivity Disorder (ADHD) assessment clinic

Participants

N = 12 (CBT: N = 6; usual care: N = 6)

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

158

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Sciberras 2018  (Continued)

Mean age (SD): CBT: 10.4 (1.3); usual care: 11.6 (0.6)

Age range: 8 to 12

Gender: 1 (8.3%) female

Inclusion criteria: meet criteria for ADHD and generalised, social, or separation anxiety disorder
(based on ADIS-P); 8 to 12 years of age

Exclusion criteria: receiving specialist help to manage anxiety

Interventions

CBT

Intervention: Cool Kids CBT; adaptations to make acceptable for children with ADHD

Concomitant/excluded medications: medication for anxiety allowed if stable dose for 6 weeks prior
to enrolment

Delivery format: child and parent together and child and parent alone; individual

Therapist contact time: 10 hours (8 x 1 hour, 2 x 1 hour)

Who delivers the intervention: trained facilitators

TAU

Intervention: continued to receive treatment as usual for ADHD

Concomitant/excluded medications: medication for anxiety allowed if stable dose for 6 weeks prior
to enrolment

Outcomes

Remission of all anxiety disorder diagnoses post-treatment: ADIS-P

Reduction in anxiety symptoms (child report) post-treatment: SCAS-C

Reduction in anxiety symptoms (parent report) post-treatment: SCAS-P

Notes

Risk of bias

Bias

Post-treatment assessment = 5 months postrandomisation, approximately 6 weeks post-treatment

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Low risk

Judgement Comment: An independent statistician generated a randomisation
schedule using a computerised random number sequence

Allocation concealment
(selection bias)

Low risk

Judgement Comment: Independent statistician. Allocation was concealed
from families and researchers using sealed, opaque envelopes until parent
consent was obtained.

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Blind assessors

Low risk

Judgement Comment: No dropouts

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

159

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Sciberras 2018  (Continued)

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes reported for all measures

Other source of bias -
Therapy integrity

Unclear risk

Judgement Comment: Trained facilitators delivered treatment. No further de-
tails

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Shahnavaz 2016 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 1-year follow-up

Number of study centres and location: 2 in Sweden

Study setting: dental clinics

Date of study: recruitment January 2013 to March 2014

Participants

N = 30 (CBT: N = 13; TAU: N = 17)

Mean age (SD): 10 (3.1)

Age range: 7 to 18

Gender: 22 (73.3%) female

Inclusion criteria: 1) patient and all primary caregivers agreed to participate; 2) patient had a princi-
pal diagnosis of specific phobia (dental anxiety or intraoral injection phobia) according to the DSM-IV-
TR (adapted DAWBA); 3) no other psychiatric or developmentally related diagnoses considered to be
the primary diagnosis, 4) patient was not receiving concurrent psychological treatments and did not
have appointments for psychological examination elsewhere; and 5) patient needed dental care but
not emergency care; and practical requirements

Interventions

CBT

Intervention: manual developed by research team. Behavioural analyses, psychoeducation, parent
education, exposure to dental procedures both in vivo and in films, relaxation techniques, procedural
pain management information, and cognitive restructuring

Delivery format: child and parent; individual

Therapist contact time: 10 hours (10 x 1 hour)

Who delivers the intervention: psychologists, CBT training

TAU

Intervention: tell-show-do, distraction, premedication with midazolam, nitrous oxide sedation, gener-
al anaesthesia

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment and 12-month follow-up: adapt-
ed DAWBA

Reduction in anxiety symptoms (child report) post-treatment and 12-month follow-up: Child Sur-
vey Fear Schedule: Dental Subscale

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

160

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Shahnavaz 2016  (Continued)

Cochrane Database of Systematic Reviews

Reduction in anxiety symptoms (parent report) post-treatment and 12-month follow-up: Child
Survey Fear Schedule: Dental Subscale

Notes

Anxiety symptoms measure dental phobia symptoms measure

No adverse events reported in CBT group.

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Judgement Comment: True randomisation list, generated at www.random.org

Low risk

Low risk

Judgement Comment: External person. Allocation after eligibility assessed,
agreed to be included

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Blind assessors

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Attrition detailed and reasons provided for small num-
ber of dropouts. Outcomes reported for completers

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes reported

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Trained therapists with regular supervision where ad-
herence and competence monitored

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Sharma 2017 

Study characteristics

Methods

Study design: randomised controlled trial

Number of study centres and location: 1 in India

Study setting: university clinic

Participants

N = 63 randomised (NB: N = 61 aged 10 to 18 included here: CBT: N = 30; TAU: N = 31)

Age range: 10 to 18

Inclusion criteria: aged 10 to 19 (NB: 19-year-olds not included in analysis in review); current ICD di-
agnosis of anxiety disorder (mini-KID); current International Headache Society diagnosis of primary
headaches; basic reading and writing; no significant medication change in last 4 weeks; no history of
organic disorder; willingness to be randomised

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

161

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Sharma 2017  (Continued)

Exclusion criteria: depression excluded on basis CDI

Interventions

CBT

Intervention: transdiagnostic CBT

Delivery format: child only; group

Therapist contact time: 24 hours (12 x 2 hours)

TAU

Intervention: continued receiving TAU - pharmacotherapy, visit psychiatrist for medication review

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: mini-KID

Remission of all anxiety disorder diagnoses post-treatment: mini-KID

Reduction in anxiety symptoms (child report) post-treatment: STAIC-trait

Improvement in global functioning post-treatment: CGAS

Author provided data on under 19s.

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Computer-generated list

Low risk

Judgement Comment: Computer generated, so unlikely to foresee assignment

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Unclear risk

Judgement Comment: Not detailed

Low risk

Judgement Comment: Data presented

Low risk

Judgement Comment: Outcomes reported/provided

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Unclear risk

Judgement Comment: Review of treatment content by committee, but no fur-
ther detail

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Shortt 2001 

Study characteristics

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

162

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Shortt 2001  (Continued)

Methods

Study design: randomised controlled trial

Total duration of study: non-controlled 12-month follow-up

Number of study centres and location: 1 in Australia

Study setting: university clinic

Participants

N = 71 (CBT: N = 54; waitlist: N = 17)

Mean age (SD): CBT: 7.83 (1.33); waitlist: 7.88 (1.32)

Age range: 6 to 10

Gender: CBT: 57% female; waitlist: 65% female

Inclusion criteria: a principal diagnosis of Generalised Anxiety Disorder, Separation Anxiety Disorder,
or Social Phobia (determined using the DISCAP)

Exclusion criteria: all children with intellectual or severe physical impairment, or who were currently
involved in psychosocial or psychopharmacological interventions

Interventions

CBT

Intervention: FRIENDS. Children work through workbook, parents booklet with parent strategies

Concomitant/excluded medications: medications not allowed

Delivery format: child-only and parent-only sessions, with parent and child together for some ses-
sions; group

Therapist contact time: 15 hours (10 x 1 hour (child sessions), 10 x 30 min (parent sessions))

Who delivers the intervention: clinical doctoral candidates

Waitlist/no treatment

Intervention: 10-week waitlist

Concomitant/excluded medications: medications not allowed

Outcomes

Remission of all anxiety disorder diagnoses post-treatment: DISCAP

Reduction in anxiety symptoms (child report) post-treatment: RCMAS

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Judgement Comment: 3:1 ratio, but no further detail

Unclear risk

Judgement Comment: No detail

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

163

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Shortt 2001  (Continued)

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Judgement Comment: Blind assessors

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Attrition reported. Completer and ITT analyses for diag-
nostic outcomes. Missing data managed appropriately.

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Outcomes for relevant measures reported

Low risk

Judgement Comment: Integrity assessed and reported

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Silk 2018 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 12-month follow-up

Number of study centres and location: 1 in the USA

Participants

N = 133 (CBT: N = 90; active control: N = 43)

Mean age (SD): CBT: 10.943 (1.395); waitlist: 10.981 (1.633)

Age range: 9 to 14

Gender: CBT: 50 (55.6%) female; active control: 24 (55.8%) female

Inclusion criteria: meet criteria for current Generalised Anxiety Disorder, Separation Anxiety Disorder,
and/or Social Anxiety Disorder (Based on K-SADS)

Exclusion criteria: IQ below 70, psychoactive medications; acute suicidality or risk for harm to self or
others; presence of metal objects in the body; current primary diagnosis of major depressive disorder,
OCD, PTSD, conduct disorder, substance abuse or dependence, or ADHD. Anxious youth were also ex-
cluded if they had evidence of an autism spectrum disorder or a lifetime diagnosis of bipolar disorder,
psychotic depression, schizophrenia, or schizoaffective disorder.

Interventions

CBT

Intervention: Coping Cat. Anxiety management sessions; exposure sessions

Concomitant/excluded medications: psychoactive medication not allowed

Delivery format: child only; 2 parent sessions; individual

Therapist contact time: 16 sessions

Who delivers the intervention: Master's and doctoral-level therapists

Active control

Intervention: Child Centred Therapy (CCT). Manualised non-directive, supportive psychotherapy
based on humanistic principles such as unconditional positive regard, empathy, and therapist genuine-
ness

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

164

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Silk 2018  (Continued)

Cochrane Database of Systematic Reviews

Concomitant/excluded medications: psychoactive medication not allowed

Delivery format: child only; 2 parent sessions; individual

Therapist contact time: 16 sessions

Who delivers the intervention: Master's and doctoral-level therapists

Outcomes

Remission of all anxiety disorder diagnoses post-treatment and 12-month follow-up: K-SADS

Reduction in anxiety symptoms (child report) post-treatment and 12-month follow-up: SCARED-C

Reduction in anxiety symptoms (parent report) post-treatment and 12-month follow-up: SCARED-
P

Active control = alternative treatment

Authors' judgement

Support for judgement

Unclear risk

Judgement Comment: No detail

Unclear risk

Judgement Comment: No detail

Unclear risk

Judgement Comment: No detail blinding of participants

Low risk

Judgement Comment: Independent evaluators

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Attrition detailed, and missing data managed appropri-
ately

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Outcomes reported for all measures

Low risk

Judgement Comment: Trained therapists, and integrity assessed and reported

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Silverman 1999a 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 12-month follow-up

Number of study centres and location: 1 in the USA

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

165

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Silverman 1999a  (Continued)

Study setting: university clinic

Cochrane Database of Systematic Reviews

Participants

N = 104 randomised (NB: N = 64 included here, randomised to: CBT: N = 41; active control: N = 23)

Mean age (SD): CBT: 10.3 (2.6); active control: 9.7 (2.9)

Age range: 6 to 16

Gender: CBT: 20 (48.8%) female; active control: 14 (60.9%) female

Inclusion criteria: primary phobic disorder (simple phobia-majority; social phobia or agoraphobia)
(ADIS-C/P)

Exclusion criteria: pervasive developmental disorders, psychotic symptoms, current involvement in
psychosocial or psychopharmacological treatment

Interventions

CBT

Intervention: exposure + self control. Faciliate graded exposure, using cognitive self-control proce-
dures. Taught cognitive strategies and devised fear hierarchy, perform in- and out-of-session exposure

Concomitant/excluded medications: psychopharmacological treatment not allowed

Delivery format: child sessions and parent sessions, and part of session together; individual

Therapist contact time: 13 hours 20 min (10 x 80 min)

Who delivers the intervention: postdoctoral fellows

Active control

Intervention: educational support. Education about phobias and treatment. No information on thera-
peutic strategies or implementing these

Concomitant/excluded medications: psychopharmacological treatment not allowed

Delivery format: child sessions and parent sessions, and part of session together; individual

Therapist contact time: 13 hours 20 min (10 x 80 min)

Who delivers the intervention: postdoctoral fellows

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-C/P

Reduction in anxiety symptoms (child report) post-treatment and 6-month and 12-month fol-
low-up: RCMAS-C

Reduction in anxiety symptoms (parent report) post-treatment and 6-month and 12-month fol-
low-up: RCMAS-P

Reduction in depressive symptoms post-treatment: CDI

Study includes Contingency Management condition - behavioural intervention not included here.
Active control = attention control

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Unclear risk

Judgement Comment: Not detailed

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

166

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Silverman 1999a  (Continued)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Unclear risk

Judgement Comment: Not detailed

Unclear risk

Judgement Comment: Not detailed

Unclear risk

Judgement Comment: Not detailed

Unclear risk

Judgement Comment: Overall attrition detailed. Missing data for measures
and procedure for managing missing data not detailed. It appears that com-
pleter analysis was reported only.

Low risk

Judgement Comment: Outcomes reported

Low risk

Judgement Comment: Therapists trained and supervised. Integrity assessed.

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Silverman 1999b 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: non-controlled 12-month follow-up

Number of study centres and location: 1 in the USA

Study setting: university clinic

Participants

N = 56 (CBT: N = 37; waitlist: N = 19)

Mean age (SD): 9.96

Age range: 6 to 16

Gender: CBT: 17 (46%) female; waitlist 5 (26%) female

Inclusion criteria: primary diagnosis of social phobia, overanxious disorder, or GAD (based on ADIS-C/
P)

Exclusion criteria: pervasive developmental disorder, psychotic symptoms, current psychological or
psychopharmacological treatment

Interventions

CBT

Intervention: group CBT - parent and child. Contigency management, exposure, child self-talk

Concomitant/excluded medications: psychopharmacological treatment not allowed

Delivery format: child sessions and parent sessions, and parent joined child sessions; group

Therapist contact time: ? sessions 40 minutes each + 15 minutes together

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

167

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Silverman 1999b  (Continued)

Who delivers the intervention: psychologist and doctoral student

Waitlist/no treatment

Intervention: 8- to 10-week waitlist

Concomitant/excluded medications: psychopharmacological treatment not allowed

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-C/P

Reduction in anxiety symptoms (child report) post-treatment: RCMAS-C

Reduction in anxiety symptoms (parent report) post-treatment: RCMAS-P

Reduction in depressive symptoms post-treatment: CDI

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Judgement Comment: Not detailed

Unclear risk

Judgement Comment: Not detailed

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Judgement Comment: Subsample rated by independent evaluators, although
blinding of assessors not specified

Incomplete outcome data
(attrition bias)
All outcomes

Unclear risk

Judgement Comment: Attrition detailed. 27% dropout. Completers compared
to non-completers on baseline characteristics. It appears that only completer
analysis was reported, and does not specify comparison to ITT.

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Outcomes reported

Low risk

Judgement Comment: Integrity assessed and reported

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Simon 2011 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 24-month follow-up

Number of study centres and location: the Netherlands

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

168

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Simon 2011  (Continued)

Study setting: primary schools (screening)

Participants

N = 412 randomised (NB: N = 75 included here, CBT (parent): N = 27; CBT (child): N = 18; no treatment:
N = 30)

Mean age (SD): CBT (parent): 9.67 (1.04); CBT (child): 9.61 (1.15); no treatment: 10.10 (1.27)

Age range: 8 to 13

Gender: 33 (44% female)

Inclusion criteria: score top 15% on SCARED-71 in screening (NB: we only included those who met di-
agnostic criteria for an anxiety disorder based on ADIS-C/P in the review)

Interventions

CBT (parent)

Intervention: parent-focused CBT

Delivery format: parent only; group (and telephone)

Therapist contact time: 5 hours 45 minutes (3 x 90 minutes (group); 5 x 15 minutes (telephone))

Who delivers the intervention: psychology graduates

CBT (child)

Intervention: child-focused CBT

Delivery format: child only; group

Therapist contact time: 12 hours (8 x 90 minutes)

Who delivers the intervention: psychology graduates

Waitlist/no treatment

Intervention: no intervention

Outcomes

Remission of all anxiety disorder diagnoses post-treatment and 24-month follow-up: ADIS-C/P

Reduction in anxiety symptoms (child report) post-treatment and 24-month follow-up: SCARED-C

Notes

We only included participants who met diagnostic criteria for anxiety disorder at baseline.

Post-treament assessment = 12 months

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)

Authors' judgement

Support for judgement

Unclear risk

Judgement Comment: Not detailed

Unclear risk

Judgement Comment: Not detailed

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Unclear risk

Judgement Comment: Not detailed

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

169

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Simon 2011  (Continued)

All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Detail provided on missing data

Low risk

Judgement Comment: Data on outcomes provided by author

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Trained and supervised, integrity assessed and report-
ed

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Smith 2014 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: non-controlled 3-month follow-up

Number of study centres and location: 1 in the USA

Study setting: university clinic

Participants

N = 31 (CBT: N = 18; waitlist: N = 13)

Mean age (SD): 9.80 (1.78)

Age range: 7 to 13

Gender: 12 (38.7%)

Inclusion criteria: met DSM-IV diagnostic criteria for 1 or more of the following: separation anxiety dis-
order, social anxiety disorder, specific phobia, and/or generalised anxiety disorder

Exclusion criteria: comorbid pervasive developmental disorder, traumatic brain injury, organic brain
damage, psychotic symptoms, or engagement in concurrent psychotherapy for anxiety

Interventions

CBT

Intervention: individualised parent intervention. Includes psychoeducation and strategies for re-
sponding adaptively to child anxiety, and demonstrates CBT techniques for parents to teach their chil-
dren

Concomitant/excluded medications: concurrent pharmacological treatment for anxiety required sta-
ble dosages 1 month prior to and throughout participation

Delivery format: parent only; individual

Therapist contact time: 10 hours (10 x 1 hour)

Who delivers the intervention: advanced doctoral psychology student

Waitlist

Intervention: 10-week waitlist

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

170

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Smith 2014  (Continued)

Cochrane Database of Systematic Reviews

Concomitant/excluded medications: concurrent pharmacological treatment for anxiety required sta-
ble dosages 1 month prior to and throughout participation

Outcomes

Reduction in anxiety symptoms (child report) post-treatment: MASC-C

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Reduction in anxiety symptoms (parent report) post-treatment: MASC-P

Post-treatment diagnostic assessment used, but required outcomes not reported.

Authors' judgement

Support for judgement

Unclear risk

Judgement Comment: Not detailed

Unclear risk

Judgement Comment: Not detailed

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Blind assessors

Unclear risk

Judgement Comment: High rate of missing questionnaire data

Low risk

Judgement Comment: Outcomes for measures reported

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Trained therapists. Regular supervision, fidelity moni-
tored

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Southam Gerow 2010 

Study characteristics

Methods

Study design: randomised controlled trial

Number of study centres and location: USA

Study setting: recruited from 6 mental health clinics

Participants

N = 48 (CBT: N = 24; TAU: N = 24)

Mean age (SD): 10.9 (2.1)

Age range: 8 to 15

Gender: 56.2% female

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

171

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Southam Gerow 2010  (Continued)

Cochrane Database of Systematic Reviews

Inclusion criteria: primary diagnosis of GAD, separation anxiety disorder, social phobia, specific pho-
bia (based on DISC); anxiety the treatment priority

Exclusion criteria: a) pervasive developmental disorder, (b) a psychotic disorder, or (c) mental retar-
dation

Interventions

CBT

Intervention: Coping Cat

Concomitant/excluded medications: medication use was tracked during treatment

Delivery format: child only; individual

Therapist contact time: 16 to 20 sessions

Who delivers the intervention: social workers/doctoral-level psychologists/Master's-level psycholo-
gists/other (e.g. marriage and family therapists)

TAU

Intervention: usual care. Therapists used treatment procedures regularly used and believed to be ef-
fective in clinical practice.

Concomitant/excluded medications: medication use was tracked during treatment

Delivery format: child only; individual

Who delivers the intervention: social workers/doctoral-level psychologists/Master's-level psycholo-
gists/other (e.g. marriage and family therapists)

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: DISC

Reduction in anxiety symptoms (child report) post-treatment: STAIC-Trait

Reduction in anxiety symptoms (parent report) post-treatment: STAIC-Trait

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Block randomised

Unclear risk

Judgement Comment: No detail given

Unclear risk

Judgement Comment: No detail given

Low risk

Judgement Comment: Blind assessors

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Attrition fully described. Appropriate method used for
managing missing data - diagnostic outcomes report for completers and using
ITT, and explored if any differences between those with and without missing
data.

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

172

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Southam Gerow 2010  (Continued)

Cochrane Database of Systematic Reviews

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes for measures reported

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Therapists trained and supervised. Adherence as-
sessed.

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Spence 2000 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: non-controlled 6- and 12-month follow-up

Number of study centres and location: 1 in Australia

Study setting: university clinic

Participants

N = 51 (CBT (child + parent): N = 17; CBT (child only): N = 19; waitlist: N = 15)

Mean age (SD): CBT (child + parent): 10.94 (1.92), n = 17; CBT (child only): 11 (2.45), n = 19; waitlist: 9.93
(1.77), n = 14

Age range: 7 to 14

Gender: CBT (child + parent): 7 (41.2%) female, n = 17; CBT (child only): 9 (47.4%), n = 19; waitlist: 3
(21.4%) female, n = 14

Inclusion criteria: social phobia principal diagnosis (based on ADIS-C/P)

Exclusion criteria: not report any avoidance or worry related to any social situation on the SWQ-PU,
severe learning difficulty, medication for a psychological disorder

Interventions

CBT (child + parent)

Intervention: social skills training, relaxation techniques, social problem-solving, positive self-instruc-
tion, cognitive challenging and graded exposure. Parent observes child sessions and attends parent
training sessions.

Concomitant/excluded medications: medications excluded

Delivery format: child-only sessions (parent observes), plus parent-only sessions; group

Therapist contact time: 24 hours (child: 12 x 1 hour + 12 x 30 min; parents: 6 hours)

Who delivers the intervention: psychologists

CBT (child only)

Intervention: social skills training, relaxation techniques, social problem-solving, positive self-instruc-
tion, cognitive challenging and graded exposure

Concomitant/excluded medications: medications excluded

Delivery format: child only; group

Therapist contact time: 18 hours (12 x 1 hour + 12 x 30 min)

Who delivers the intervention: psychologists

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

173

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Spence 2000  (Continued)

Waitlist/no treatment

Intervention: 12-week waitlist

Cochrane Database of Systematic Reviews

Concomitant/excluded medications: medications excluded

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-C/P

Remission of all anxiety disorder diagnosis post-treatment: ADIS-C/P

Reduction in anxiety symptoms (child report) post-treatment: RCMAS

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Authors' judgement

Support for judgement

Unclear risk

Judgement Comment: No detail given

Unclear risk

Judgement Comment: No detail given

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Judgement Comment: Blind assessor not specified for post-treatment, but in-
dependent rater assessed subset of interviews

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Data provided by author

Low risk

Judgement Comment: Outcomes for all measures reported

Other source of bias -
Therapy integrity

Unclear risk

Judgement Comment: Qualified therapists, but no further detail on assess-
ing/monitoring adherence/competence

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Spence 2006 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 12-month non-controlled follow-up

Number of study centres and location: 1 in Australia

Study setting: university clinic

Participants

N = 72 randomised (NB: N = 45 included here, randomised to CBT: N = 22; waitlist: N = 23)

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

174

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Spence 2006  (Continued)

Cochrane Database of Systematic Reviews

Mean age (SD): CBT: 10.26 (2.05); waitlist: 9.70 (1.73)

Age range: 7 to 14

Gender: CBT: 40.90% female; waitlist: 43.50% female

Inclusion criteria: primary diagnosis of an anxiety disorder (based on ADIS-P), aged 7 to 14, ability to
read and write English, and access to internet at home

Exclusion criteria: no significant differences in demographic or clinical variables

Interventions

CBT

Intervention: clinic group. Components included identifying physiological symptoms of anxiety; pro-
gressive muscle relaxation, guided imagery, and deep breathing; coping self-talk and cognitive restruc-
turing; graded exposure; problem solving; and self-evaluation and reward. Parent component included
psychoeducation about (a) child anxiety, (b) contingency management, and (c) ways of assisting their
child with relaxation training, cognitive restructuring, graded exposure, and problem solving.

Concomitant/excluded medications: not allowed

Delivery format: child only and parent only; group

Therapist contact time: 16 hours (10 x 1 hour (child), 6 x 1 hour (parent))

Who delivers the intervention: psychologists

Waitlist/no treatment

Intervention: 10-week waitlist

Concomitant/excluded medications: not allowed

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-P

Remission of all anxiety disorder diagnosis post-treatment: ADIS-P

Reduction in anxiety symptoms (child report) post-treatment: SCAS-C

Reduction in anxiety symptoms (child report) post-treatment: SCAS-P

Study included "NET" condition (online delivery) which we did not include in the review.

Authors' judgement

Support for judgement

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Low risk

Judgement Comment: A coin was tossed

Allocation concealment
(selection bias)

Unclear risk

Judgement Comment: Assigned in advance, but no further detail provided,
e.g. if independent

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Unclear risk

Judgement Comment: Interrater reliability assessed, with rater blind to origi-
nal diagnoses, but does not specify if assessors were blind to condition

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

175

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Spence 2006  (Continued)

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Report ITT and completer analyses. Attrition detailed.

Low risk

Judgement Comment: Outcomes reported

Low risk

Judgement Comment: Independent assessment of integrity

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Spence 2011 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 12-month non-controlled follow-up

Number of study centres and location: 3 in Australia

Study setting: 3 university clinics

Participants

N = 115 randomised (NB: N = 71 included here: CBT: N = 44; waitlist: N = 27)

Age range: 12 to 18

Inclusion criteria: primary diagnosis of separation anxiety disorder, social phobia, GAD, or specific
phobia (ADIS-C/P); aged 12 to 18; access to computer and internet at home; able to read and write Eng-
lish at age-appropriate level

Exclusion criteria: primary diagnosis of panic disorder, OCD, PTSD, mood disorder with CSR 6+, per-
vasive developmental disorder, learning disorder, significant behavioural, substance abuse, suicidal
ideation or current self-harm

Interventions

CBT

Intervention: BRAVE CLINIC. Manualised individual CBT for adolescent anxiety, adapted from child ver-
sion (equivalent to online programme in content, number, and length sessions)

Delivery format: child only and parent only; individual

Therapist contact time: 15 hours (10 x 1 hour (child), 5 x 1 hour (parent))

Who delivers the intervention: psychologists

Waitlist/no treatment

Intervention: 12-week waitlist

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-P

Remission of all anxiety disorder diagnosis post-treatment: ADIS-P

Reduction in anxiety symptoms (child report) post-treatment: SCAS-C

Reduction in anxiety symptoms (child report) post-treatment: SCAS-P

Improvement in global functioning post-treatment: CGAS

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

176

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Spence 2011  (Continued)

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Study included "NET" condition (online CBT) which we did not include in the review.

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Computer-generated sequence

Low risk

Judgement Comment: In advance, implemented by independent researcher

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Blind assessors

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Attrition reported. Reported completer and ITT analy-
ses for diagnostic outcomes, and ITT for continuous. Examined and reported
impact of missing data

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes reported

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Trained therapists, regular supervision, fidelity as-
sessed and reported

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Storch 2013 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: non-controlled 3-month follow-up

Number of study centres and location: 1 in the USA

Study setting: university clinic

Participants

N = 45 (CBT: N = 24: TAU: N = 21)

Mean age (SD): 8.89 (13.4)

Age range: 7 to 11

Gender: 9 (20%) female

Inclusion criteria: diagnosis of autistic disorder, Asperger’s syndrome, or pervasive developmental
disorder–not otherwise specified; primary diagnosis of separation anxiety disorder, social phobia, gen-
eralised anxiety disorder, or obsessive-compulsive disorder (based on ADIS-C/P)

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

177

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Storch 2013  (Continued)

Cochrane Database of Systematic Reviews

Exclusion criteria: full-scale or verbal comprehension IQ less than 70 on a standardised test; concur-
rent participation in psychosocial interventions (excluding occupational/speech therapy, and social
skills training groups that did not include homework and were less than 90 minutes per week, given
that treatment efficacy for anxiety was limited, and parents are often reluctant to give up services); ac-
tive suicidality or engagement in suicidal behaviours within 6 months before enrolment; or bipolar or
psychotic disorder

Interventions

CBT

Intervention: Behavioral Interventions for Anxiety in Children with Autism (BIACA)

Concomitant/excluded medications: stable dose before screening allowed

Delivery format: child only and parent only; individual

Therapist contact time: 16 to 24 hours (16 x 60 to 90 minutes)

Who delivers the intervention: doctoral students or postdoctoral fellows in clinical or school psychol-
ogy

TAU

Intervention: free to begin, continue, change, or refrain from any psychosocial or pharmacological
treatment

Concomitant/excluded medications: any allowed

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-C/P

Remission of all anxiety disorder diagnosis post-treatment: ADIS-C/P

Reduction in anxiety symptoms (parent report) post-treatment: MASC-P

Notes

Sample with ASD

Remission for all anxiety diagnoses reported in Warwick 2016.

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Computer-generated algorithm

Low risk

Judgement Comment: Computer generated, so unlikely to foresee assignment

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Blind assessors

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Attrition and missing data detailed. Small amount of
missing data, and appropriate methods used to manage missing data

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

178

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Storch 2013  (Continued)

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Outcomes reported

Low risk

Judgement Comment: Therapists trained. Fidelity assessed and reported.

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Storch 2015 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 1-month non-controlled follow-up

Number of study centres and location: 1 in the USA

Study setting: university clinic

Participants

N = 31 (CBT: N = 16: TAU: N = 15)

Mean age (SD): 12.74 (1.34)

Age range: 12 to 16

Gender: 6 (19.4%) female

Inclusion criteria: met criteria for (1) a diagnosis of autism, Asperger’s syndrome, or Pervasive Devel-
opmental Disorder– Not Otherwise Specified

; (2) a co-occurring anxiety diagnosis of separation anxiety disorder, generalised anxiety disorder, Ob-
sessive Compulsive Disorder, or social phobia (based on ADIS-C/P); (3) a score of 13 on the Pediatric
Anxiety Rating Scale (PARS); and (4) an IQ 80 evaluated by the Wechsler Abbreviated Scale of Intelli-
gence or review of standardised testing occurring in the prior 2 years

Exclusion criteria: (1) initiation of new medications within 6 weeks (anti-psychotics, Attention Deficit
Hyperactivity Disorder medications) or 12 weeks (anti-depressants) before study enrolment; (2) concur-
rent participation in psychotherapy, social skills training over 90 min per week, or other programmatic
behavioural interventions (e.g. applied behavioural analysis); (3) active suicidality; (4) lifetime history
of mania, psychosis, or substance abuse

Interventions

CBT

Intervention: developmentally modified version of the Behavioral Interventions for Anxiety in Children
with Autism (BIACA) treatment manual. A minimum of 3 sessions were spent developing coping skills
(e.g. behavioural activation, cognitive restructuring) with at least 8 sessions of exposure therapy.

Concomitant/excluded medications: any stable medication allowed

Delivery format: child sessions, with parent included in most sessions; individual

Therapist contact time: 16 to 24 hours (16 x 60 to 90 minutes)

Who delivers the intervention: postdoctoral fellows or doctoral students in clinical or school psychol-
ogy with at least 1 year of experience in CBT for childhood anxiety

TAU

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

179

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Storch 2015  (Continued)

Cochrane Database of Systematic Reviews

Intervention: participants could seek any psychosocial or pharmacological treatment that they chose,
or not seek treatment, for 16 weeks

Concomitant/excluded medications: continued with pre-existing medications or therapy or were able
to initiate dosage changes or new medications with the prescribing provider

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-C/P

Remission of all anxiety disorder diagnoses post-treatment: ADIS-C/P

Reduction in anxiety symptoms (parent report) post-treatment: MASC-P

Notes

Remission from all anxiety disorders diagnoses provided in Warwick 2016.

Sample with ASD

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Computer generated

Low risk

Judgement Comment: Computer generated, so unlikely to foresee assignment

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Blind assessors

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: No dropouts to post-treatment assessment. Missing da-
ta managed appropriately.

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes reported/available

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Therapists trained and supervised, and adherence rat-
ed and reported

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Thirlwall 2013 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: non-controlled 6-month follow-up and 3- to 5-year follow-up

Number of study centres and location: 1 in the UK

Study setting: university and NHS clinic

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

180

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Thirlwall 2013  (Continued)

Date of study: recruitment April 2008 to December 2010

Participants

N = 194 (CBT (full): N = 64: CBT (brief): N = 61; waitlist: N = 69)

Age range: 7 to 12

Gender: CBT (full): 30 (46.9%) female; CBT (brief): 30 (49.2%) female; waitlist: 34 (49.3%) female

Inclusion criteria: age 7 to 12, primary diagnosis of GAD, social phobia, separation anxiety disorder,
panic disorder/agoraphobia, or specific phobia (based on ADIS-C/P), no significant physical or intellec-
tual impairment, if prescription of psychotropic medication, stable dose (parent and child), primary
carer not have current anxiety disorder or other serious mental health disorder, parent not have signifi-
cant intellectual impairment

Interventions

CBT (full)

Intervention: guided parent-delivered CBT treatment. Parents given self-help book and receive full
guidance, some face-to-face and some on phone.

Concomitant/excluded medications: stable dose allowed

Delivery format: parent only; individual

Therapist contact time: 5 hours 20 minutes

Who delivers the intervention: some clinical experience or novice (some experience delivering CBT or
working with clinical populations)

CBT (brief)

Intervention: guided parent-delivered CBT treatment. Parents given self-help book and receive brief
guidance, some face-to-face and some on phone.

Concomitant/excluded medications: stable dose allowed

Delivery format: parent only; individual

Therapist contact time: 2 hours 40 minutes

Who delivers the intervention: some clinical experience or novice (some experience delivering CBT or
working with clinical populations)

Waitlist/no treatment

Intervention: 12-week waitlist

Concomitant/excluded medications: stable dose allowed

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-C/P

Remission of all anxiety disorder diagnoses post-treatment: ADIS-C/P

Reduction in anxiety symptoms (child report) post-treatment: SCAS-C

Reduction in anxiety symptoms (parent report) post-treatment: SCAS-P

Reduction in depressive symptoms post treatment: SMFQ-child

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

181

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Thirlwall 2013  (Continued)

Cochrane Database of Systematic Reviews

Random sequence genera-
tion (selection bias)

Low risk

Judgement Comment: Centralised telephone randomisation service at the
Centre for Statistics in Medicine, University of Oxford

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Judgement Comment: Centralised

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Blind assessors

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Attrition and missing data detailed. Sensitivity analyses
used to examine impact of missing data.

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes reported for all measures

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Therapists attend training and regular supervision. Ad-
herence assessed and reported.

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Villabo 2018 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: 2-year non-controlled follow-up

Number of study centres and location: 5 clinics in Norway

Study setting: community clinics

Date of study: recruitment September 2008 through October 2011

Participants

N = 165 (CBT (individual CBT): N = 55: CBT ( group CBT): N = 55; waitlist: N = 55)

Mean age (SD): 10.46 (1.49)

Age range: 7 to 13

Gender: CBT (ICBT): 24 (43.6%) female; CBT (GCBT): 25 (45.5%) female; waitlist: 26 (47.3%) female

Inclusion criteria: age 7 to 13, primary diagnosis of SAD, GAD, or social anxiety disorder (based on
ADIS-C/P), significant functional impairment, IQ 70+, 1 parent + proficient in Norwegian

Exclusion criteria: (a) a mental health disorder with a higher treatment priority, (b) pervasive develop-
mental disorder(s), (c) psychosis, or (d) current use of anxiolytic medication

Interventions

CBT (individual CBT)

Intervention: Norwegian translation of Coping Cat

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

182

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Villabo 2018  (Continued)

Concomitant/excluded medications: current use of anxiolytic medication not allowed

Delivery format: child only, and 2 parent only; individual

Therapist contact time: 14 sessions

Who delivers the intervention: community therapists (psychologists, social workers, psychiatry resi-
dents)

CBT (group CBT)

Intervention: Norwegian translation of Coping Cat

Concomitant/excluded medications: current use of anxiolytic medication not allowed

Delivery format: child only, and 2 parent only; group

Therapist contact time: 14 sessions

Who delivers the intervention: community therapists (psychologists, social workers, psychiatry resi-
dents)

Waitlist/no treatment

Intervention: 12-week waitlist

Concomitant/excluded medications: current use of anxiolytic medication not allowed

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-C/P

Remission of all anxiety disorder diagnoses post-treatment: ADIS-C/P

Reduction in anxiety symptoms (child report) post-treatment: MASC-C

Reduction in anxiety symptoms (parent report) post-treatment: MASC-P

Improvement in global functioning post-treatment: CGAS

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Computer-generated permuted blocking procedure

Low risk

Judgement Comment: Computer generated, so unlikely to foresee assignment

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Blind assessors

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Attrition reported. Appropriate methods used to man-
age missing data.

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

183

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Villabo 2018  (Continued)

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes reported for all measures

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Therapists with a range of experience. Adherence as-
sessed and reported.

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Walkup 2008 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: long-term follow-up (6 years) to date

Number of study centres and location: 6 in the USA

Study setting: university clinics

Date of study: 2002 to 2007

Participants

N = 488 (CBT alone: N = 139: CBT + sertraline: N = 140; sertraline alone: N = 133; drug placebo: N = 76)

Mean age (SD): CBT alone: 10.5 (2.9); CBT + sertraline: 10.7 (2.8); sertraline alone: 10.8 (2.8); drug place-
bo: 10.6 (2.8)

Age range: 7 to 17

Gender: CBT alone: 72 (51.8%) female; CBT + sertraline: 72 (51.4%) female; sertraline alone: 61 (45.9%)
female; drug placebo: 37 (48.7%) female

Inclusion criteria: aged 7 to 17, primary diagnosis of separation or generalised or social phobia, sub-
stantial impairment (based on ADIS-C/P), IQ 80+

Exclusion criteria: unstable medical condition, were refusing to attend school because of anxiety, or
had tried but had no response to 2 adequate trials of SSRIs or an adequate trial of CBT. Girls who were
pregnant or sexually active and were not using an effective method of birth control were also exclud-
ed. Children who were receiving psychoactive medications other than stable doses of stimulants and
who had psychiatric diagnoses that made participation in the study clinically inappropriate (i.e. current
major depressive or substance use disorder; unmedicated ADHD, combined type; or a lifetime history
of bipolar, psychotic, or pervasive developmental disorders) or who presented an acute risk to them-
selves or others were also excluded.

Interventions

CBT alone

Intervention: based on Coping Cat

Concomitant/excluded medications: receiving psychoactive medications other than stable doses of
stimulants excluded

Delivery format: child only, parent check-in, and 2 parent only

Therapist contact time: 14 hours (14 x 1 hour)

Who delivers the intervention: experienced psychotherapists certified in the Coping Cat protocol

CBT + sertraline

Intervention: based on Coping Cat + sertraline (Zoloft)

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

184

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Walkup 2008  (Continued)

Cochrane Database of Systematic Reviews

Concomitant/excluded medications: receiving psychoactive medications other than stable doses of
stimulants excluded

Delivery format: child only, parent check-in, and 2 parent only

Therapist contact time: 18 to 22 hours: 14 hours (14 x 1 hour) + 4 to 8 hours (8 x 30 to 60 minutes)

Who delivers the intervention: experienced psychotherapists certified in the Coping Cat protocol.
Psychiatrists and nurse clinicians with experience in medicating children with anxiety disorders

Sertraline alone

Intervention: sertraline (Zoloft)

Concomitant/excluded medications: receiving psychoactive medications other than stable doses of
stimulants excluded

Therapist contact time: 4 to 8 hours (8 x 30 to 60 minutes)

Who delivers the intervention: psychiatrists and nurse clinicians with experience in medicating chil-
dren with anxiety disorders

Drug placebo

Intervention: drug placebo

Concomitant/excluded medications: receiving psychoactive medications other than stable doses of
stimulants excluded

Therapist contact time: 4 to 8 hours (8 x 30 to 60 minutes)

Who delivers the intervention: psychiatrists and nurse clinicians with experience in medicating chil-
dren with anxiety disorders

Outcomes

Reduction in anxiety symptoms (child report) post-treatment and 36-week follow-up: MASC-C

Reduction in anxiety symptoms (parent report) post-treatment and 36-week follow-up: MASC-P

Improvement in global functioning post-treatment: CGAS

Reduction in depressive symptoms post-treatment: MFQ-C

Notes

Adverse events reported.

Long-term remission outcomes reported elsewhere.

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Computer generated

Low risk

Judgement Comment: Managed central pharmacy

Low risk

Judgement Comment: Drug placebo kept secret from participants

Low risk

Judgement Comment: Independent blind assessors

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

185

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Walkup 2008  (Continued)

All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Cochrane Database of Systematic Reviews

Judgement Comment: Dropouts clear, and procedures for managing clear and
robust

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes reported for all measures

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Experienced therapists. Regular supervision. Fidelity
assessed.

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Waters 2009 

Study characteristics

Methods

Study design: randomised controlled trial

Number of study centres and location: 1 in Australia

Study setting: university clinic

Participants

N = 80 (CBT (parent + child): N = 31; CBT (parent only): 38; waitlist: N = 11)

Mean age (SD): CBT (parent + child): 6.89 (1.2); CBT (parent only): 6.68 (1.20); waitlist: 6.68 (1.20)

Age range: 4 to 8

Gender: CBT (parent + child): 17 (54.8%) female; CBT (parent only): 20 (64.5%) female; waitlist: 5
(45.5%) female

Inclusion criteria: specific phobia, social phobia, GAD, and/or separation anxiety disorder diagnosis
(based on ADIS-P)

Exclusion criteria: comorbid externalising disorder, pervasive developmental disorder, organic brain
damage, or psychosis. Children involved in psychological or pharmacological treatment for anxiety dis-
orders were excluded.

Interventions

CBT (parent + child)

Intervention: Take Action. Children: psychoeducation, training in relaxation, identifying anxious self-
talk, coping strategies, exposure, problem solving, social skills. Parent sessions: provided with child
workbook, cover: psychoeducation, parent strategies for managing anxiety, coverage of take action
steps children complete each week, positive parent coping, communication and problem-solving skills

Concomitant/excluded medications: not allowed

Delivery format: child sessions and parent sessions; group

Therapist contact time: 20 hours (10 x 1 hour (child); 10 x 1 hour (parent))

Who delivers the intervention: psychologists trained in CBT for child anxiety

CBT (parent only)

Intervention: same as parent sessions in parent + child above

Concomitant/excluded medications: not allowed

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

186

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Waters 2009  (Continued)

Cochrane Database of Systematic Reviews

Delivery format: parent sessions; group

Therapist contact time: 10 hours (10 x 1 hour (parent))

Who delivers the intervention: psychologists trained in CBT for child anxiety

Waitlist/no treatment

Intervention: approximately 10-week wait

Concomitant/excluded medications: not allowed

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-P

Remission of all anxiety disorder diagnoses post-treatment: ADIS-P

Anxiety symptoms measure not reported for waitlist, so not able to use in review.

Authors' judgement

Support for judgement

Unclear risk

Judgement Comment: No detail given

Unclear risk

Judgement Comment: No detail given

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Blind ADIS assessors

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Report dropouts. High number of dropouts, but report
completer analyses and ITT and same conclusions

Selective reporting (re-
porting bias)

Unclear risk

Judgement Comment: Did not report parent-reported child anxiety symptoms
for waitlist

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Trained therapists, regular supervision. Therapist
checklist used to maintain integrity.

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Wergeland 2014 

Study characteristics

Methods

Study design: randomised controlled trial

Total duration of study: non-controlled 1-year follow-up

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

187

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Wergeland 2014  (Continued)

Cochrane Database of Systematic Reviews

Number of study centres and location: 7 public child and adolescent mental health outpatient clinics
in Norway

Study setting: CAMHS clinics

Date of study: 2008 to 2010

Participants

N = 182 (CBT (iCBT): N = 77; CBT (GCBT): N = 67; waitlist: N = 38)

Mean age (SD): 11.5 (2.1)

Age range: 8 to 15

Gender: 96 (52.7%) female

Inclusion criteria: principal anxiety disorder SAD, SOP, GAD (based on ADIS-C/P)

Exclusion criteria: pervasive developmental disorder, psychotic disorder, and/or mental retardation

Interventions

CBT (iCBT)

Intervention: individual CBT - Friends

Concomitant/excluded medications: stable dose allowed

Delivery format: child only, child + parent for 2 sessions and part of 8 sessions; individual

Therapist contact time: 10 hours (10 x 1 hour)

Who delivers the intervention: clinical psychologists, clinical pedagogues, clinical social worker

CBT (GCBT)

Intervention: group CBT - Friends

Concomitant/excluded medications: stable dose allowed

Delivery format: child only, child + parent for 2 sessions and part of 8 sessions; group

Therapist contact time: 15 hours (10 x 90 minutes)

Who delivers the intervention: clinical psychologists, clinical pedagogues, clinical social worker

Waitlist/no treatment

Intervention: 10-week waitlist

Concomitant/excluded medications: stable dose allowed

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-C/P

Reduction in anxiety symptoms (child report) post-treatment: SCAS-C

Reduction in anxiety symptoms (parent report) post-treatment: SCAS-P

Reduction in depressive symptoms post-treatment: MFQ-child

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

188

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Wergeland 2014  (Continued)

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Unclear risk

Judgement Comment: Block randomisation, no further detail

Unclear risk

Judgement Comment: Block randomisation, no further detail

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Unclear risk

Judgement Comment: Assessor not blind to treatment approach

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Appropriate methods used for managing missing data.
Report ITT, and also conducted completer analyses

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Outcomes reported

Low risk

Judgement Comment: Adherence and competence assessed and reported

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

White 2013 

Study characteristics

Methods

Study design: randomised controlled trial

Number of study centres and location: 1 in the USA

Study setting: university clinic

Date of study: recruitment October 2008 to October 2010

Participants

N = 30 (CBT: N = 15; waitlist: N = 15)

Mean age (SD): 15 years

Age range: 12 to 17

Gender: 7 (23%) female

Inclusion criteria: age 12 to 17, ASD diagnosis supported by ADOS, meet criteria for social phobia GAD,
specific phobia, or separation anxiety disorder (based on ADIS-C/P)

Exclusion criteria: primary OCD, panic disorder, or panic disorder with agoraphobia or serious behav-
iour problems

Interventions

CBT

Intervention: Multimodal Anxiety and Social Skills Intervention (MASSI). Individual, group, and parent
education. Select appropriate modules from manual

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

189

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

White 2013  (Continued)

Cochrane Database of Systematic Reviews

Concomitant/excluded medications: concomitant psychiatric medication was permitted if the dose
was stable for at least 4 weeks with no planned changes for the duration of the randomised trial

Delivery format: child only, parent attend for part of session; individual and group

Therapist contact time: 21 to 23 hours (13 x 60 to 70 minutes (individual), 7 x 75 minutes (group))

Who delivers the intervention: principal investigator and doctoral students

Waitlist/no treatment

Intervention: 14-week waitlist

Concomitant/excluded medications: concomitant psychiatric medication was permitted if the dose
was stable for at least 4 weeks with no planned changes for the duration of the trial

Outcomes

Reduction in anxiety symptoms (parent report) post-treatment: CASI-Anxiety Scale

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Incomplete outcome data
(attrition bias)
All outcomes

Selective reporting (re-
porting bias)

Improvement in global functioning post-treatment: DD-CGAS

Sample with ASD

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Names drawn from a box

Low risk

Low risk

Judgement Comment: Done by person unaffiliated with study. Baseline mea-
sures complete prior to allocation

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Blind assessors for appropriate measures

Low risk

Judgement Comment: Use appropriate methods for managing missing data

Low risk

Judgement Comment: Outcomes reported

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Trained and supervised therapists. Sessions recorded
and reviewed. Fidelity assessed independently.

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Wood 2009 

Study characteristics

Methods

Study design: randomised controlled trial

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

190

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Wood 2009  (Continued)

Number of study centres and location: 1 in the USA

Participants

N = 40 (CBT: N = 17; waitlist: N = 23)

Mean age (SD): CBT: 9.18 (1.42); waitlist: 9.22 (1.57)

Gender: CBT: 5 (29%) female; waitlist: 8 (35%) female

Inclusion criteria: 1) autism/Asperger's or Pervasive Developmental Disorder – Not Otherwise Speci-
fied (PDD-NOA) diagnosis; 2) separation anxiety disorder, social phobia, or OCD (based on ADIS-C/P); 3)
no psychiatric medication or stable dose for at least 1 month and maintained throughout study

Exclusion criteria: GAD diagnosis only, IQ less than 70, current psychotherapy or social skills training,
family therapy, or parent coaching

Interventions

CBT

Intervention: Building confidence CBT

Concomitant/excluded medications: stable dose allowed

Delivery format: child only, and parent/family with child; individual

Therapist contact time: 24 hours (16 x 90 minutes)

Who delivers the intervention: doctoral students

Waitlist/no treatment

Intervention: 3-month waitlist

Concomitant/excluded medications: stable dose allowed

Outcomes

Reduction in anxiety symptoms (child report) post-treatment: MASC-C

Reduction in anxiety symptoms (parent report) post-treatment: MASC-P

Notes

Only report remission from 4 entry diagnoses

Sample with ASD

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Authors' judgement

Support for judgement

Low risk

Judgement Comment: Computer randomisation program

Low risk

Judgement Comment: Concealed from investigators

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Blinded assessors

Incomplete outcome data
(attrition bias)

Low risk

Judgement Comment: Dropouts reported. ITT and completer analyses report-
ed

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

191

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Wood 2009  (Continued)

All outcomes

Selective reporting (re-
porting bias)

Low risk

Judgement Comment: Outcomes for planned measures reported

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Therapists trained and supervised and adherence mea-
sures

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

Wood 2015 

Study characteristics

Methods

Study design: randomised controlled trial

Number of study centres and location: 2 in the USA

Study setting: 2 university clinics

Participants

N = 33 (CBT: N = 19; waitlist: N = 14)

Mean age (SD): CBT: 12.3 (1.14); waitlist: 12.2 (0.98)

Age range: 11 to 15

Gender: CBT: 6 (32%) female; waitlist: 4 (29%) female

Inclusion criteria: criteria for ASD and 1 anxiety disorder (based on ADIS-C/P)

Exclusion criteria: receiving CBT, social skills training with homework or applied behavioural analy-
sis, had initiated an anti-depressant or anti-psychotic within 12 or 6 weeks, respectively, prior to treat-
ment, suicide risk, bipolar, schizophrenia, or substance abuse

Interventions

CBT

Intervention: Behavioral Interventions for Anxiety in Children with Autism (BIACA)

Concomitant/excluded medications: stable dose allowed

Delivery format: child only, parent only, altogether; individual

Therapist contact time: 24 hours (16 x 90 minutes)

Who delivers the intervention: postdoctoral clinical fellow or doctoral students

Waitlist/no treatment

Intervention: 16-week waitlist

Concomitant/excluded medications: stable dose allowed

Outcomes

Remission of primary anxiety disorder diagnosis post-treatment: ADIS-C/P

Reduction in anxiety symptoms (parent report) post-treatment: MASC-P

Notes

Risk of bias

Sample with ASD

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

192

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Wood 2015  (Continued)

Bias

Authors' judgement

Support for judgement

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias)
All outcomes

Blinding of outcome as-
sessment (detection bias)
All outcomes

Low risk

Judgement Comment: Computer randomisation

Low risk

Judgement Comment: Concealed from investigators

Low risk

Judgement Comment: Even though blinding was not possible, we judged that
it was unlikely this led to a departure from the intended intervention

Low risk

Judgement Comment: Independent evaluators

Incomplete outcome data
(attrition bias)
All outcomes

Low risk

Judgement Comment: Dropouts detailed. Imputed missing data, but small
amount of missing data

Selective reporting (re-
porting bias)

Other source of bias -
Therapy integrity

Low risk

Judgement Comment: Outcomes reported for all measures

Low risk

Judgement Comment: Trained, supervised, adherence rated and reported

Other bias

Low risk

Judgement Comment: The study appears to be free of other sources of bias

ADI-R: Autism Diagnostic Interview-Revised
ADIS-C/P: Anxiety Disorder Interview Schedule for Children-Child and Parent interviews
ADOS: Autism Diagnostic Observation Schedule
ASD: Autism Spectrum Disorder
BDI-II: Beck Depression Inventory-II
CAMHS: Child and Adolescent Mental Health Services
CASI: Child and Adolescent Symptom Inventory
CBCL: Child Behaviour Checklist
CBT: cognitive behaviour therapy
CDI: Children's Depression Inventory
CGAS: Children's Global Assessment Scale
CSR: Clinical Severity Rating
CTU: Clinical Trials Unit
DAWBA: Development and Wellbeing Assessment
DD-CGAS: Developmental Disabled Children’s Global Assessment Scale
DIPS-K: Diagnostischen Interviews bei psychischen Störungen im Kindes- und Jugendalter
DISC: Diagnostic Interview Schedule for Children
DISCAP: Diagnostic Interview Schedule for Children, Adolescents, and Parents
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders-4th edition
DSM-5: Diagnostic and Statistical Manual of Mental Disorders-5th edition
ICD: International Classification of Disease
IQ: intelligence quotient
ITT: intention-to-treat
K-GAS: Children's Global Assessment Scale (German Version)
K-SADS: Kiddie Schedule for Affective Disorders and Schizophrenia
MASC-C/P: Multidimensional Anxiety Scale for Children-Child/Parent report
MFQ-C: Mood and Feelings Questionnaire-Child report
MINI-KID: Mini International Neuropsychiatric Interview for Children and Adolescents
PAS-R: Preschool Anxiety Scale-Revised

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

193

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

RCADS: Revised Children’s Anxiety and Depression Scale
RCMAS: Revised Children's Manifest Anxiety Scale
SAS-A: Social Anxiety Scale for Adolescents
SAS-C/P: Social Anxiety Scale for Children-Child/Parent report
SET-C: Social Effectiveness Therapy for Children
SCAS-C/P: Spence Children's Anxiety Scale-Child/Parent report
SCARED-C/P: Screen for Child Anxiety Related Emotional Disorders-Child/Parent report
SD: standard deviation
SMFQ-C: Short Mood and Feelings Questionnaire-Child report
SPAI-C: Social Phobia and Anxiety Inventory for Children
SPAIK-C: Social Phobia and Anxiety Inventory for Children (German Version)
STAIC: State-Trait Anxiety Inventory for Children
TAU: treatment as usual

Characteristics of excluded studies [ordered by study ID]

Study

Asbrand

Reason for exclusion

Data not analysable

Asbrand 2019

Data not analysable

Baer 2005

Beidel 2000

Beidel 2007

Data not analysable

Not manualised/modular CBT

Not manualised/modular CBT

Bergman 2013

Not manualised/modular CBT

Bernstein 2005

Participants did not all meet diagnostic criteria for an anxiety disorder.

Bodden 2008a

Not an RCT

Clementi 2019

No non-CBT control/comparator

Cobham 2012

Not an RCT

Cotton 2019

Not manualised/modular CBT

Ebrahiminejad 2016

Not manualised/modular CBT

Flatt 2010

Data not analysable

Gil Bernal 2009

No baseline structured diagnostic assessment/participants did not meet diagnostic criteria for anx-
iety disorder

Ginsburg 2019b

Participants did not all meet diagnostic criteria for an anxiety disorder.

Hayward 2000

Not an RCT

Jansen 2012

Kerns 2016

No baseline structured diagnostic assessment/participants did not meet diagnostic criteria for anx-
iety disorder

No baseline structured diagnostic assessment/participants did not meet diagnostic criteria for anx-
iety disorder

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

194

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study

Reason for exclusion

Kujawa 2019

Not an RCT

Lyneham 2006

No direct contact with parent/child/not face-to-face

Mendlowitz 1999

Not an RCT

Nauta 2003

Not an RCT

NCT00576719

Data not analysable

Oerbeck 2014

Not manualised/modular CBT

Ollendick 2018

Not manualised/modular CBT

Ost 2015

Ozyurt 2018

Pereira 2014

Rudy 2017

Salzer 2018

Sevi Tok 2016

Storch 2019

Sung 2011

Not manualised/modular CBT

Not manualised/modular CBT

Participants did not all meet diagnostic criteria for an anxiety disorder.

Not manualised/modular CBT

Adults (≥ 19 years) (includes 20-year-olds)

No baseline structured diagnostic assessment/participants did not meet diagnostic criteria for anx-
iety disorder

Not manualised/modular CBT

No baseline structured diagnostic assessment/participants did not meet diagnostic criteria for anx-
iety disorder

Weisz 2012

Participants did not all meet diagnostic criteria for an anxiety disorder.

CBT: cognitive behavioural therapy
RCT: randomised controlled trial

Characteristics of studies awaiting classification [ordered by study ID]

ACTRN12613000217707 

Methods

Participants

Interventions

Outcomes

Notes

RCT

Inclusion criteria: age 12 to 19, clinical levels of anxiety acquired brain injury

CBT

Primary: SCAS, SCARED, ADIS

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

195

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

ACTRN12615000730505 

Methods

RCT. CBT vs waitlist

Cochrane Database of Systematic Reviews

Participants

Inclusion criteria: anxiety disorder, sleep problems

Age: 13 to 17

Interventions

Cognitive behaviour therapy for adolescents with anxiety and sleep-related problems

Outcomes

Notes

Primary: ADIS (anxiety). Insomnia (Insomnia Severity Index)

Status: not yet recruiting

ACTRN12619000619145 

Methods

RCT

Participants

Target: N = 80

Inclusion criteria: age 10 to 14; diagnosed with diabetes, clinical or subclinical anxiety

Interventions

Outcomes

Notes

CBT

Waitlist

Primary: YAM-5

Not yet recruiting

DRKS00012823 

Methods

RCT

Participants

Target: N = 420

Inclusion criteria: depressive disorder or anxiety disorder; age 6 to 18

Interventions

CBT

Outcomes

Notes

IRCT20181006041250N 

Methods

Participants

Psychodynamic psychotherapy

Primary: number of psychiatric diagnoses

RCT

Inclusion criteria: female; age 8 to 12; anxiety symptoms (SCAS cut-off), mild to moderate anxiety
disorder not requiring drug therapy

Interventions

CBT: group, based on Coping Cat

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

196

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

IRCT20181006041250N  (Continued)

Control: group, storytelling

Outcomes

Notes

SCAS, SDQ, CDI

Complete

ISRCTN59518816 

Methods

RCT

Participants

Target: N = 228

Inclusion criteria: aged 8 to 12; Attention Deficit Hyperactivity Disorder; anxiety disorder (gener-
alised anxiety disorder, social anxiety disorder, separation anxiety disorder)

Interventions

CBT

Treatment As Usual

Outcomes

Notes

JPRN-UMIN000008724 

Methods

Participants

Remission of anxiety disorder (GAD, social anxiety disorder, separation anxiety disorder)

Complete

RCT

Inclusion criteria: age 7 to 18; anxiety disorder (based on ADIS); discontinue other psychotherapy
for the trial

Interventions

CBT

Outcomes

Notes

JPRN-UMIN000032275 

Methods

Participants

Control (no treatment)

Primary: ADIS

RCT

Inclusion criteria: age 9 to 15; clinical or subclinical diagnosis of anxiety disorder or depressive dis-
order

Interventions

CBT

Control: no treatment

Primary: ADIS

Outcomes

Notes

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

197

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

JPRN-UMIN000033218 

Methods

RCT

Participants

Target: N = 60

Inclusion criteria: age 10 to 16; IQ in average range; Autism Spectrum Disorder diagnosis; clinical
level of anxiety (semi-structured interview)

Interventions

CBT

Outcomes

Notes

Active control

Primary: anxiety symptoms

No longer recruiting

NCT02810171 

Methods

RCT

Participants

Target: N = 280

Inclusion: age 7 to 17; clinically significant anxiety as determined by structured clinical interview;
anxiety primary concern

Interventions

CBT

Relaxation Therapy

Outcomes

Primary: brain function/structure

Secondary: Pediatric Anxiety Rating Scale

Notes

Started December 2016

NCT02977962 

Methods

RCT

Participants

Target: N = 44

Inclusion criteria: age 16 to 21; ASD; diagnosis of 1 of the following anxiety disorders: separation
anxiety disorder, specific phobia, panic disorder, generalised anxiety disorder, social phobia, or ob-
sessive compulsive disorder, and minimum score of 14 on the Hamilton Anxiety Scale

Interventions

Outcomes

Notes

CBT

TAU

Primary: Hamilton Anxiety Scale (change from baseline)

Not all participants would be eligible.

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

198

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT03412227 

Methods

RCT

Participants

Target: N = 200

Inclusion criteria: age 9 to 17; primary DSM-5 anxiety disorder or depressive disorder

Interventions

Individual Behavioral Activation Therapy (IBAT)

The PASCET Program for Youth Depressive Disorders

Coping Cat (CBT)

Waitlist

Outcomes

Notes

Primary: Clinical Global Impression Severity (CGIS) scale (change)

NCT03899948 

Methods

RCT

Participants

Target N = 135

Inclusion criteria: attend elementary school, elevated anxiety symptoms and Clinical Severity Rat-
ing 3+ on ADIS

Interventions

Teacher Anxiety Program for Elementary Students (TAPES)

Outcomes

Notes

Teacher Anxiety Training (TAT)

Secondary: change on modified ADIS

Anxiety diagnosis not required.

ADIS: Anxiety Disorder Interview Schedule for Children
CBT: cognitive behavioural therapy
CDI: Children's Depression Inventory
IQ: intelligence quotient
RCT: randomised controlled trial
SCARED: Screen for Child Anxiety Related Emotional Disorders
SCAS: Spence Children's Anxiety Scale
SDQ: Strengths and Difficulties Questionnaire
YAM-5: Youth Anxiety Scale for DSM-5

Characteristics of ongoing studies [ordered by study ID]

ACTRN12616001552471 

Study name

Effectiveness of school group-based acceptance and commitment therapy for children with anxi-
ety: a randomised controlled trial

Methods

RCT

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

199

 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

ACTRN12616001552471  (Continued)

Participants

Target N = 130

Cochrane Database of Systematic Reviews

Inclusion criteria: 1. Aged between 7 and 17 years. 2. Meet criteria for a primary diagnosis of an anx-
iety disorder. 3. Available/able to attend The Children’s Hospital at Westmead for pretreatment,
immediate post-treatment, and 6-month post-treatment assessments as well as attending a min-
imum of 80% of therapy sessions. 4. Have a parent/caregiver who is willing to attend and partici-
pate in the assessment as well as 2 parent sessions

Interventions

Proactive (Acceptance and Commitment Therapy group-based manualised therapy programme
delivered by school counsellors) vs waitlist (10 weeks)

Outcomes

Primary outcomes:

Change in score on the Pediatric Anxiety Rating Scale (PARS) - clinician, child, and parent rated
(pre-, post-treatment and 6 months post-treatment)

Change in the Spence Anxiety Scale for Children (SCAS) - child and parent rated (pre-, post-treat-
ment and 6 months post-treatment)

Starting date

28 September 2016

Contact information

Dr Karen Hancock

SCHN, CHW Department of Psychological Medicine Locked Bag 4001 Westmead NSW 2145

Australia

karen.hancock@health.nsw.gov.au

Notes

www.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12616001552471

anzctr.org.au/ACTRN12616001552471.aspx

NCT02725619 

Study name

Neural mechanisms of CBT for anxiety in children with autism: randomized controlled trial

Methods

RCT

Participants

Target N = 150

Inclusion criteria: aged 8 to 14; diagnosis of autism spectrum disorder; diagnosis of anxiety disor-
der and clinically significant level of anxiety; full-scale IQ and verbal IQ > 70; unmedicated or on sta-
ble medication with no planned changes for duration of study; able to meet MRI safety (e.g. no met-
al medical implants) and data quality requirements (e.g. able to keep head still during scanning)

Interventions

CBT vs Psychoeducation and Supportive Therapy (PST)

Outcomes

Primary outcomes:

Pediatric Anxiety Rating Scale (PARS) (change from baseline - midpoint; change from baseline -
endpoint)

Clinical Global Impression-Improvement (CGI-I) scale (change from baseline - midpoint; change
from baseline - endpoint)

Blood oxygenation level dependent signal (BOLD) during down-regulation versus passive viewing
of affective images (change from baseline - midpoint; change from baseline - endpoint)

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

200

 
 
 
 
Cochrane Database of Systematic Reviews

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT02725619  (Continued)

Starting date

April 2016

Contact information

Denis Sukhodolsky

Yale Child Study Center
New Haven, Connecticut, USA

denis.sukhodolsky@yale.edu

Notes

clinicaltrials.gov/show/nct02725619

NCT02908321 

Study name

Cognitive behavioural therapy for anxiety disorder in children with co-morbid autism spectrum dis-
order

Methods

RCT

Participants

Target N = 50

Inclusion criteria: aged 7 to 14; diagnosed with Autism Spectrum Disorder and experiencing anxiety
symptoms impairing their quality of life

Exclusion criteria: IQ under 70; not meeting diagnostic criteria for primary anxiety diagnosis on
ADIS; active psychosis; untreated Attention Deficit Hyperactivity Disorder; families not able to fol-
low programme

Interventions

CBT (Cool Kids ASD) vs waitlist

Outcomes

Primary outcomes: ADIS (baseline, 14 weeks, 3 months)

Starting date

August 2016

Contact information

Tina R Kilburn

Centre for Child and Adolescent Psychiatry

Risskov, Region Of Midtjylland, Denmark, 8240

tinakilb@rm.dk

Notes

clinicaltrials.gov/show/nct02908321

NCT03279471 

Study name

Specifying and treating the anxiety phenotype in autism spectrum disorder

Methods

RCT

Participants

Target N = 132

Inclusion criteria: age 8 to 14; meets criteria for a diagnosis of ASD; clinically significant anxiety
symptoms (minimum score of 8 on the Pediatric Anxiety Rating Scale); clinically significant anxiety
symptoms as defined by qualifying for a diagnosis on 1 or more non-phobia items on the ADIS; full-
scale and verbal comprehension IQ greater than 50; anxiety symptoms are considered the prima-

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

201

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT03279471  (Continued)

Cochrane Database of Systematic Reviews

ry mental health problem (i.e. most impairing/distressing); stable medication, non-psychotherapy
and psychosocial regimen

Interventions

CBT vs drug (sertraline) vs pill placebo

Outcomes

Primary outcome: change in Pediatric Anxiety Rating Scale (pretreatment, post-treatment, 3-
month follow-up)

Starting date

1 November 2017

Contact information

Brianna Health, PhD

UC Davis MIND Institute

Sacramento, California, USA, 95817

bheath@ucdavis.edu

Notes

clinicaltrials.gov/ct2/show/nct03279471

NCT03585010 

Study name

Brain response associated with parent-based treatment for childhood anxiety disorders

Methods

RCT

Participants

Target N = 226

Inclusion criteria: prepubertal; clinical diagnosis of primary anxiety disorder; must not have anoth-
er mental illness more impairing than the most impairing anxiety disorder; IQ of at least 80

Interventions

Supportive Parenting for Anxious Child Emotions vs CBT vs parent educational support

Outcomes

Primary outcome: Pediatric Anxiety Rating Scale (PARS) (12 weeks)

Secondary outcome: Multidimensional Anxiety Scale for Children (MASC) parent and child report
(12 weeks)

Starting date

1 September 2018

Contact information

Eli R Lebowitz, PhD

Yale University Child Study Center

New Haven, Connecticut, USA, 06519

eli.lebowitz@yale.edu

Notes

clinicaltrials.gov/ct2/show/NCT03585010

ADIS: Anxiety Disorder Interview Schedule for Children
CBT: cognitive behavioural therapy
IQ: intelligence quotient
MRI: magnetic resonance imaging
RCT: randomised controlled trial

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

202

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

D A T A   A N D   A N A L Y S E S

Comparison 1.   CBT versus waitlist/no treatment

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.1 Remission of primary anxiety diag-
nosis post-treatment (ITT)

1.1.1 Child focused

1.1.2 Child and parent

1.1.3 Parent only

1.2 Subgroup analysis: remission of
primary anxiety diagnosis post-treat-
ment (ITT) (individual vs group)

1.2.1 Individual focused

1.2.2 Group focused

1.3 Subgroup analysis: remission of
primary anxiety diagnosis post-treat-
ment (ITT) (amount of therapist con-
tact time)

39

19

19

4

39

17

25

39

1.3.1 Therapist contact (< 10 hours)

6

1.3.2 Therapist contact (≥10 and < 20
hours)

1.3.3 Therapist contact (≥ 20 hours)

1.4 Subgroup analysis: remission of
primary anxiety diagnosis post-treat-
ment (ITT) (age)

1.4.1 ≤ 12 years

1.4.2 Mixed age range (< 12 and ≥ 12
years)

1.4.3 ≥ 12 years

23

13

39

11

21

7

2697

1184

1142

371

1165

1532

513

1622

562

789

1447

461

Odds Ratio (IV, Random, 95%
CI)

5.45 [3.90, 7.60]

Odds Ratio (IV, Random, 95%
CI)

10.42 [5.84,
18.58]

Odds Ratio (IV, Random, 95%
CI)

4.08 [2.72, 6.11]

Odds Ratio (IV, Random, 95%
CI)

2.83 [1.12, 7.16]

Odds Ratio (IV, Random, 95%
CI)

Subtotals only

Odds Ratio (IV, Random, 95%
CI)

4.53 [2.55, 8.03]

Odds Ratio (IV, Random, 95%
CI)

6.25 [4.45, 8.78]

Odds Ratio (IV, Random, 95%
CI)

Subtotals only

Odds Ratio (IV, Random, 95%
CI)

6.12 [2.08, 18.00]

Odds Ratio (IV, Random, 95%
CI)

5.85 [3.95, 8.64]

Odds Ratio (IV, Random, 95%
CI)

4.44 [2.26, 8.72]

Odds Ratio (IV, Random, 95%
CI)

Subtotals only

Odds Ratio (IV, Random, 95%
CI)

3.93 [2.20, 7.02]

Odds Ratio (IV, Random, 95%
CI)

6.43 [3.90, 10.58]

Odds Ratio (IV, Random, 95%
CI)

5.28 [2.83, 9.86]

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

203

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.5 Subgroup analysis: remission of
primary anxiety diagnosis post-treat-
ment (ITT) (ASD vs non-ASD)

1.5.1 Sample with ASD

1.5.2 Not sample with ASD

1.6 Remission of primary anxiety diag-
nosis post-treatment (completers)

1.7 Acceptability (number of partici-
pants lost to post-treatment assess-
ment)

1.8 Remission of all anxiety diagnoses
post-treatment (ITT)

1.8.1 Child focused

1.8.2 Child and parent

1.8.3 Parent only

1.9 Subgroup analysis: remission of all
anxiety diagnoses post-treatment (ITT)
(individual vs group)

1.9.1 Individual focused

1.9.2 Group focused

1.10 Subgroup analysis: remission of
all anxiety diagnoses post-treatment
(ITT) (amount of therapist contact
time)

39

4

35

38

45

28

11

15

7

28

9

20

28

1.10.1 Therapist contact (< 10 hours)

5

1.10.2 Therapist contact (≥ 10 and < 20
hours)

17

1.10.3 Therapist contact (≥ 20 hours)

9

Odds Ratio (IV, Random, 95%
CI)

Subtotals only

Odds Ratio (IV, Random, 95%
CI)

1.79 [0.39, 8.16]

Odds Ratio (IV, Random, 95%
CI)

5.88 [4.19, 8.24]

Odds Ratio (IV, Random, 95%
CI)

11.55 [8.41,
15.86]

Odds Ratio (IV, Random, 95%
CI)

1.09 [0.85, 1.41]

Odds Ratio (IV, Random, 95%
CI)

4.43 [2.89, 6.78]

Odds Ratio (IV, Random, 95%
CI)

8.52 [2.97, 24.39]

Odds Ratio (IV, Random, 95%
CI)

5.19 [3.26, 8.27]

Odds Ratio (IV, Random, 95%
CI)

1.89 [0.98, 3.65]

Odds Ratio (IV, Random, 95%
CI)

Subtotals only

Odds Ratio (IV, Random, 95%
CI)

3.72 [1.70, 8.12]

Odds Ratio (IV, Random, 95%
CI)

4.92 [2.95, 8.20]

Odds Ratio (IV, Random, 95%
CI)

Subtotals only

Odds Ratio (IV, Random, 95%
CI)

1.42 [0.68, 2.96]

Odds Ratio (IV, Random, 95%
CI)

6.59 [3.62, 12.01]

Odds Ratio (IV, Random, 95%
CI)

5.03 [2.55, 9.93]

136

2561

2406

3158

2075

564

916

595

671

1404

461

1123

491

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

204

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.11 Subgroup analysis: remission of
all anxiety diagnoses post-treatment
(ITT) (age)

1.11.1 ≤ 12 years

1.11.2 Mixed age range (< 12 years and
≥ 12 years)

1.11.3 ≥ 12 years

1.12 Remission of all anxiety diagnoses
post-treatment (completers)

1.13 Reduction in anxiety symptoms
(child report) post-treatment

1.13.1 Child focused

1.13.2 Child and parent

1.13.3 Parent only

1.14 Sensitivity analysis: reduction in
anxiety symptoms (child report) post-
treatment (broad anxiety measures)

1.15 Subgroup analysis: reduction in
anxiety symptoms (child report) post-
treatment (individual vs group)

1.15.1 Individual focused

1.15.2 Group focused

1.16 Subgroup analysis: reduction in
anxiety symptoms (child report) post-
treatment (amount of therapist con-
tact time)

28

10

15

3

27

45

24

20

5

38

45

21

27

45

1.16.1 Therapist contact (< 10 hours)

9

1.16.2 Therapist contact (≥ 10 and < 20
hours)

29

1.16.3 Therapist contact (≥ 20 hours)

10

Odds Ratio (IV, Random, 95%
CI)

Subtotals only

Odds Ratio (IV, Random, 95%
CI)

3.59 [1.97, 6.56]

Odds Ratio (IV, Random, 95%
CI)

4.87 [2.58, 9.21]

Odds Ratio (IV, Random, 95%
CI)

8.48 [0.79, 91.08]

Odds Ratio (IV, Random, 95%
CI)

9.13 [5.78, 14.41]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.67 [-0.88,
-0.47]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.04 [-1.41,
-0.67]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.45 [-0.67,
-0.23]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

0.04 [-0.38, 0.46]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.41 [-0.57,
-0.25]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.39 [-0.64,
-0.15]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.91 [-1.22,
-0.60]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.36 [-0.75, 0.03]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.81 [-1.09,
-0.52]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.62 [-1.06,
-0.18]

950

980

145

1871

2831

1239

1285

307

2459

1203

1628

587

1840

404

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

205

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.17 Subgroup analysis: reduction in
anxiety symptoms (child report) post-
treatment (age)

1.17.1 ≤ 12 years

1.17.2 Mixed age range (< 12 years and
≥ 12 years)

1.17.3 ≥ 12 years

1.18 Subgroup analysis: reduction in
anxiety symptoms (child report) post-
treatment (ASD vs non-ASD)

1.18.1 Sample with ASD

1.18.2 Not sample with ASD

1.19 Reduction in anxiety symptoms
(parent report) post-treatment

1.19.1 Child focused

1.19.2 Child and parent

1.19.3 Parent only

1.20 Sensitivity analysis: reduction
in anxiety symptoms (parent report)
post-treatment (broad anxiety mea-
sures only)

1.21 Subgroup analysis: reduction
in anxiety symptoms (parent report)
post-treatment (individual vs group)

1.21.1 Individual focused

1.21.2 Group focused

1.22 Subgroup analysis: reduction
in anxiety symptoms (parent report)
post-treatment (amount of therapist
contact time)

45

11

28

6

45

5

40

35

13

17

5

32

35

17

21

35

663

1834

334

181

2650

2137

734

1031

372

1952

858

1279

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.23 [-0.54, 0.08]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.62 [-0.83,
-0.41]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.78 [-3.01,
-0.56]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.61 [-1.54, 0.33]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.68 [-0.90,
-0.47]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.70 [-0.90,
-0.51]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.87 [-1.21,
-0.53]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.69 [-0.98,
-0.39]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.37 [-0.77, 0.04]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.59 [-0.77,
-0.41]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.43 [-0.65,
-0.21]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.92 [-1.21,
-0.62]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

206

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.22.1 Therapist contact (< 10 hours)

4

1.22.2 Therapist contact (≥ 10 and < 20
hours)

22

1.22.3 Therapist contact (≥ 20 hours)

10

1.23 Subgroup analysis: reduction
in anxiety symptoms (parent report)
post-treatment (age)

1.23.1 ≤ 12 years

1.23.2 Mixed age range (< 12 years and
≥ 12 years)

1.23.3 ≥ 12 years

1.24 Subgroup analysis: reduction
in anxiety symptoms (parent report)
post-treatment (ASD vs non-ASD)

1.24.1 Sample with ASD

1.24.2 Not sample with ASD

1.25 Reduction in depressive symp-
toms post-treatment

1.26 Improvement in global function-
ing post-treatment

1.27 Remission of primary anxiety di-
agnosis at follow-up (ITT)

1.27.1 Follow-up (≤ 6 months)

1.27.2 Follow-up (> 6 and ≤ 12 months)

1.28 Remission of primary anxiety di-
agnosis at follow-up (completers)

1.28.1 Follow-up (≤ 6 months)

1.28.2 Follow-up (> 6 and ≤ 12 months)

35

11

18

6

35

7

28

17

11

5

4

3

5

4

3

336

1402

399

750

1057

330

244

1893

1157

557

153

166

151

161

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.36 [-0.81, 0.10]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.66 [-0.89,
-0.43]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.03 [-1.55,
-0.52]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.40 [-0.63,
-0.17]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.76 [-1.04,
-0.49]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.07 [-1.78,
-0.37]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.12 [-1.91,
-0.34]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.63 [-0.82,
-0.44]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-0.34 [-0.51,
-0.17]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

1.03 [0.68, 1.38]

Odds Ratio (IV, Random, 95%
CI)

Subtotals only

Odds Ratio (IV, Random, 95%
CI)

10.94 [2.33,
51.41]

Odds Ratio (IV, Random, 95%
CI)

2.80 [0.24, 33.19]

Odds Ratio (IV, Random, 95%
CI)

Subtotals only

Odds Ratio (IV, Random, 95%
CI)

11.46 [2.40,
54.67]

Odds Ratio (IV, Random, 95%
CI)

4.04 [0.77, 21.20]

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

207

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1.29 Remission of all anxiety diagnoses
at follow-up (ITT)

1.29.1 Follow-up (≤ 6 months)

1.29.2 Follow-up (> 6 and ≤ 12 months)

1.29.3 Follow-up (> 12 months)

1.30 Remission of all anxiety diagnoses
at follow-up (completers)

1.30.1 Follow-up (≤ 6 months)

1.30.2 Follow-up (> 6 and ≤ 12 months)

1.30.3 Follow-up (> 12 months)

1.31 Reduction in anxiety symptoms
(child report) at follow-up

1.31.1 Follow-up (≤ 6 months)

1.32 Sensitivity analysis: remission of
primary anxiety diagnosis post-treat-
ment (ITT) (only studies where se-
quence generation is clear)

1.33 Sensitivity analysis: remission of
primary anxiety diagnosis post-treat-
ment (ITT) (only studies where blind
assessors used)

5

3

3

2

5

3

3

2

5

5

20

31

130

166

131

128

161

114

179

1476

2037

Odds Ratio (IV, Random, 95%
CI)

Subtotals only

Odds Ratio (IV, Random, 95%
CI)

8.25 [0.69, 98.10]

Odds Ratio (IV, Random, 95%
CI)

3.75 [0.25, 56.88]

Odds Ratio (IV, Random, 95%
CI)

0.48 [0.17, 1.38]

Odds Ratio (IV, Random, 95%
CI)

Subtotals only

Odds Ratio (IV, Random, 95%
CI)

8.68 [0.72,
104.46]

Odds Ratio (IV, Random, 95%
CI)

5.01 [0.70, 35.87]

Odds Ratio (IV, Random, 95%
CI)

1.25 [0.36, 4.34]

Std. Mean Difference (IV, Ran-
dom, 95% CI)

Subtotals only

Std. Mean Difference (IV, Ran-
dom, 95% CI)

-1.92 [-2.95,
-0.89]

Odds Ratio (IV, Random, 95%
CI)

4.84 [3.03, 7.73]

Odds Ratio (IV, Random, 95%
CI)

5.54 [3.76, 8.18]

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

208

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.1.   Comparison 1: CBT versus waitlist/no treatment, Outcome 1: Remission of primary anxiety diagnosis
post-treatment (ITT)

Study or Subgroup

Events

Total

CBT

Wait list / no treatment
Events

Total

Weight

Odds Ratio
IV, Random, 95% CI

Odds Ratio
IV, Random, 95% CI

1.1.1 Child focused
Dadds 1997
Flannery Schroeder 2000
Flannery Schroeder 2000
Gallagher 2004
Kendall 1994
Kendall 1997
Lau 2010
Masia Warner 2005
Masia Warner 2011
McNally Keehn 2013
Olivares 2005
Olivares 2014
Olivares 2014
Olivares 2019
Olivares 2019
Ollendick 2009
Ost 2001
Perrin 2019
Rosa Alcazar 2009
Sanchez Garcia 2009
Spence 2000
Villabo 2018
Villabo 2018
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.85; Chi² = 43.41, df = 22 (P = 0.004); I² = 49%
Test for overall effect: Z = 7.94 (P < 0.00001)

23
18
13
12
40
69
21
21
20
12
17
39
39
36
36
85
21
20
20
28
19
55
55
719

21
9
6
5
17
32
14
12
9
7
10
11
20
8
13
47
18
16
12
21
11
29
36

28
2
1
0
1
17
0
5
1
0
0
2
2
0
0
1
0
0
0
0
1
4
4

384

69

1.1.2 Child and parent
Arendt 2016
Cornacchio 2019
Hirshfeld Becker 2010
Holmes 2014
Ishikawa 2019
Kidd 2018
McConachie 2014
Melfsen 2011
Ost 2001
Rapee 2006
Santucci 2013
Schneider 2011
Silverman 1999b
Spence 2000
Spence 2006
Spence 2011
Waters 2009
Wergeland 2014
Wergeland 2014
Wood 2015
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.28; Chi² = 29.75, df = 19 (P = 0.06); I² = 36%
Test for overall effect: Z = 6.79 (P < 0.00001)

56
14
34
20
23
26
17
21
20
90
15
21
37
17
22
44
31
67
77
19
671

37
1
22
9
10
18
0
7
12
44
7
16
16
14
13
13
17
24
27
6

6
1
13
3
4
10
1
2
0
17
1
4
5
1
3
4
1
3
3
6

313

88

33
7
7
11
20
49
17
21
20
10
17
19
20
18
18
41
10
20
20
25
7
27
28
465

53
15
30
22
24
23
15
23
9
87
14
22
19
8
23
27
5
19
19
14
471

2.1%
1.9%
1.4%
1.0%
1.6%
3.8%
1.0%
2.7%
1.6%
1.0%
1.0%
2.2%
2.3%
1.0%
1.0%
1.7%
1.0%
1.0%
1.0%
1.0%
1.5%
3.0%
2.9%
38.7%

3.3%
1.1%
3.3%
2.4%
2.7%
3.0%
0.9%
2.1%
1.0%
4.0%
1.5%
2.5%
2.9%
1.3%
2.5%
2.9%
1.5%
2.7%
2.7%
2.5%
46.6%

1.88 [0.33 , 10.63]
2.50 [0.38 , 16.42]
5.14 [0.48 , 55.64]
16.87 [0.81 , 351.79]
14.04 [1.71 , 115.41]
1.63 [0.77 , 3.46]
67.67 [3.56 , 1287.81]
4.27 [1.13 , 16.05]
15.55 [1.73 , 139.65]
28.64 [1.37 , 600.41]
49.00 [2.53 , 948.62]
3.34 [0.66 , 16.92]
9.47 [1.93 , 46.46]
11.04 [0.60 , 202.89]
21.26 [1.18 , 381.56]
49.47 [6.50 , 376.64]
111.00 [5.21 , 2363.64]
150.33 [7.54 , 2997.83]
60.29 [3.20 , 1137.79]
146.20 [7.89 , 2709.82]
8.25 [0.82 , 82.67]
6.41 [1.96 , 21.01]
11.37 [3.44 , 37.58]
10.42 [5.84 , 18.58]

15.25 [5.53 , 42.05]
1.08 [0.06 , 19.05]
2.40 [0.87 , 6.57]
5.18 [1.15 , 23.29]
3.85 [0.99 , 14.89]
2.92 [0.91 , 9.44]
0.28 [0.01 , 7.31]
5.25 [0.95 , 29.05]
27.94 [1.43 , 546.98]
3.94 [2.01 , 7.71]
11.38 [1.17 , 110.42]
14.40 [3.29 , 63.08]
2.13 [0.64 , 7.16]
32.67 [2.85 , 374.13]
9.63 [2.19 , 42.37]
2.41 [0.70 , 8.36]
4.86 [0.49 , 48.57]
2.98 [0.79 , 11.26]
2.88 [0.77 , 10.77]
0.62 [0.15 , 2.58]
4.08 [2.72 , 6.11]

1.1.3 Parent only
Cartwright Hatton 2011
Cobham 2017

21
20

37
33

5
6

33
30

3.0%
3.1%

7.35 [2.32 , 23.27]
6.15 [1.98 , 19.14]

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

209

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Analysis 1.1.   (Continued)

21
20
18
25
21

Cartwright Hatton 2011
Cobham 2017
Thirlwall 2013
Thirlwall 2013
Waters 2009
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.74; Chi² = 13.17, df = 4 (P = 0.01); I² = 70%
Test for overall effect: Z = 2.20 (P = 0.03)

37
33
61
64
38
233

5
6
11
11
1

105

34

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.61; Chi² = 97.73, df = 47 (P < 0.0001); I² = 52%
Test for overall effect: Z = 9.96 (P < 0.00001)
Test for subgroup differences: Chi² = 8.57, df = 2 (P = 0.01), I² = 76.7%

1623

802

191

Cochrane Database of Systematic Reviews

33
30
34
35
6
138

3.0%
3.1%
3.5%
3.6%
1.5%
14.7%

7.35 [2.32 , 23.27]
6.15 [1.98 , 19.14]
0.88 [0.35 , 2.16]
1.40 [0.58 , 3.35]
6.18 [0.66 , 58.03]
2.83 [1.12 , 7.16]

1074

100.0%

5.45 [3.90 , 7.60]

0.1
0.001
Favours Wait list / no treatment

1

10

1000

Favours CBT

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

210

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.2.   Comparison 1: CBT versus waitlist/no treatment, Outcome 2: Subgroup analysis: remission of primary
anxiety diagnosis post-treatment (ITT) (individual vs group)

Study or Subgroup

Events

Total

CBT

Wait list / no treatment
Events

Total

Weight

Odds Ratio
IV, Random, 95% CI

Odds Ratio
IV, Random, 95% CI

1.2.1 Individual focused
Flannery Schroeder 2000
Hirshfeld Becker 2010
Ishikawa 2019
Kendall 1994
Kendall 1997
Masia Warner 2011
McNally Keehn 2013
Melfsen 2011
Ollendick 2009
Ost 2001
Ost 2001
Perrin 2019
Schneider 2011
Spence 2011
Thirlwall 2013
Thirlwall 2013
Villabo 2018
Wergeland 2014
Wood 2015
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.92; Chi² = 51.71, df = 18 (P < 0.0001); I² = 65%
Test for overall effect: Z = 5.16 (P < 0.00001)

18
34
23
40
69
20
12
21
85
20
21
20
21
44
64
61
55
77
19
724

2
13
4
1
17
1
0
2
1
0
0
0
4
4
11
11
4
3
6

9
22
10
17
32
9
7
7
47
12
18
16
16
13
25
18
29
27
6

340

84

1.2.2 Group focused
Arendt 2016
Cartwright Hatton 2011
Cobham 2017
Cornacchio 2019
Dadds 1997
Flannery Schroeder 2000
Gallagher 2004
Holmes 2014
Kidd 2018
Lau 2010
Masia Warner 2005
McConachie 2014
Olivares 2005
Olivares 2014
Olivares 2014
Olivares 2019
Olivares 2019
Rapee 2006
Rosa Alcazar 2009
Sanchez Garcia 2009
Santucci 2013
Silverman 1999b
Spence 2000
Spence 2000
Spence 2006
Villabo 2018
Waters 2009
Waters 2009
Wergeland 2014
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.15; Chi² = 34.41, df = 28 (P = 0.19); I² = 19%

56
37
33
14
23
13
12
20
26
21
21
17
17
39
39
36
36
90
20
28
15
37
17
19
22
55
38
31
67
899

37
21
20
1
21
6
5
9
18
14
12
0
10
20
11
13
8
44
12
21
7
16
14
11
13
36
21
17
24

6
5
6
1
28
1
0
3
10
0
5
1
0
2
2
0
0
17
0
0
1
5
1
1
3
4
1
1
3

462

107

7
30
24
20
49
20
10
23
41
9
10
20
22
27
35
34
27
19
14
441

53
33
30
15
33
7
11
22
23
17
21
15
17
20
19
18
18
87
20
25
14
19
8
7
23
28
6
5
19
633

4.6%
7.2%
6.1%
4.1%
8.0%
3.9%
2.6%
5.1%
4.3%
2.7%
2.6%
2.6%
5.7%
6.5%
7.6%
7.5%
6.6%
6.2%
5.9%
100.0%

7.3%
6.1%
6.2%
1.3%
3.2%
1.9%
1.2%
4.1%
6.0%
1.3%
5.0%
1.0%
1.2%
3.7%
3.6%
1.3%
1.3%
11.3%
1.3%
1.3%
2.0%
5.7%
1.8%
2.0%
4.2%
5.8%
2.1%
2.0%
5.0%
100.0%

2.50 [0.38 , 16.42]
2.40 [0.87 , 6.57]
3.85 [0.99 , 14.89]
14.04 [1.71 , 115.41]
1.63 [0.77 , 3.46]
15.55 [1.73 , 139.65]
28.64 [1.37 , 600.41]
5.25 [0.95 , 29.05]
49.47 [6.50 , 376.64]
27.94 [1.43 , 546.98]
111.00 [5.21 , 2363.64]
150.33 [7.54 , 2997.83]
14.40 [3.29 , 63.08]
2.41 [0.70 , 8.36]
1.40 [0.58 , 3.35]
0.88 [0.35 , 2.16]
6.41 [1.96 , 21.01]
2.88 [0.77 , 10.77]
0.62 [0.15 , 2.58]
4.53 [2.55 , 8.03]

15.25 [5.53 , 42.05]
7.35 [2.32 , 23.27]
6.15 [1.98 , 19.14]
1.08 [0.06 , 19.05]
1.88 [0.33 , 10.63]
5.14 [0.48 , 55.64]
16.87 [0.81 , 351.79]
5.18 [1.15 , 23.29]
2.92 [0.91 , 9.44]
67.67 [3.56 , 1287.81]
4.27 [1.13 , 16.05]
0.28 [0.01 , 7.31]
49.00 [2.53 , 948.62]
9.47 [1.93 , 46.46]
3.34 [0.66 , 16.92]
21.26 [1.18 , 381.56]
11.04 [0.60 , 202.89]
3.94 [2.01 , 7.71]
60.29 [3.20 , 1137.79]
146.20 [7.89 , 2709.82]
11.38 [1.17 , 110.42]
2.13 [0.64 , 7.16]
32.67 [2.85 , 374.13]
8.25 [0.82 , 82.67]
9.63 [2.19 , 42.37]
11.37 [3.44 , 37.58]
6.18 [0.66 , 58.03]
4.86 [0.49 , 48.57]
2.98 [0.79 , 11.26]
6.25 [4.45 , 8.78]

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

211

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Analysis 1.2.   (Continued)

Cochrane Database of Systematic Reviews

Total events:
Heterogeneity: Tau² = 0.15; Chi² = 34.41, df = 28 (P = 0.19); I² = 19%
Test for overall effect: Z = 10.55 (P < 0.00001)

462

107

Test for subgroup differences: Chi² = 0.90, df = 1 (P = 0.34), I² = 0%

0.1
0.001
Favours Wait list / no treatment

1

10

1000

Favours CBT

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

212

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.3.   Comparison 1: CBT versus waitlist/no treatment, Outcome 3: Subgroup analysis: remission of primary
anxiety diagnosis post-treatment (ITT) (amount of therapist contact time)

Study or Subgroup

Events

Total

CBT

Wait list / no treatment
Events

Total

Weight

Odds Ratio
IV, Random, 95% CI

Odds Ratio
IV, Random, 95% CI

1.3.1 Therapist contact (< 10 hours)
Cobham 2017
Gallagher 2004
Ishikawa 2019
Ollendick 2009
Ost 2001
Ost 2001
Thirlwall 2013
Thirlwall 2013
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 1.55; Chi² = 27.73, df = 7 (P = 0.0002); I² = 75%
Test for overall effect: Z = 3.29 (P = 0.0010)

33
12
23
85
20
21
61
64
319

20
5
10
47
12
18
18
25

6
0
4
1
0
0
11
11

155

33

1.3.2 Therapist contact (≥10 and < 20 hours)
Dadds 1997
Flannery Schroeder 2000
Holmes 2014
Kendall 1994
Kendall 1997
Lau 2010
Masia Warner 2005
Masia Warner 2011
Olivares 2005
Olivares 2014
Olivares 2014
Olivares 2019
Olivares 2019
Perrin 2019
Rapee 2006
Rosa Alcazar 2009
Sanchez Garcia 2009
Schneider 2011
Silverman 1999b
Spence 2000
Spence 2006
Spence 2011
Villabo 2018
Villabo 2018
Waters 2009
Wergeland 2014
Wergeland 2014
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.36; Chi² = 42.26, df = 26 (P = 0.02); I² = 38%
Test for overall effect: Z = 8.85 (P < 0.00001)

23
18
20
40
69
21
21
20
17
39
39
36
36
20
90
20
28
21
37
19
22
44
55
55
38
67
77
992

21
9
9
17
32
14
12
9
10
20
11
13
8
16
44
12
21
16
16
11
13
13
36
29
21
24
27

28
2
3
1
17
0
5
1
0
2
2
0
0
0
17
0
0
4
5
1
3
4
4
4
1
3
3

484

110

1.3.3 Therapist contact (≥ 20 hours)
Arendt 2016
Cartwright Hatton 2011
Cornacchio 2019
Flannery Schroeder 2000
Hirshfeld Becker 2010
Kidd 2018
McConachie 2014
McNally Keehn 2013
Melfsen 2011
Santucci 2013

37
21
1
6
22
18
0
7
7
7

56
37
14
13
34
26
17
12
21
15

6
5
1
1
13
10
1
0
2
1

30
11
24
41
9
10
34
35
194

33
7
22
20
49
17
21
20
17
20
19
18
18
20
87
20
25
22
19
7
23
27
28
27
6
19
19
630

53
33
15
7
30
23
15
10
23
14

16.0%
7.7%
14.9%
11.5%
7.8%
7.6%
17.1%
17.3%
100.0%

6.15 [1.98 , 19.14]
16.87 [0.81 , 351.79]
3.85 [0.99 , 14.89]
49.47 [6.50 , 376.64]
27.94 [1.43 , 546.98]
111.00 [5.21 , 2363.64]
0.88 [0.35 , 2.16]
1.40 [0.58 , 3.35]
6.12 [2.08 , 18.00]

3.5%
3.1%
4.2%
2.6%
7.9%
1.5%
4.9%
2.5%
1.5%
3.9%
3.8%
1.6%
1.6%
1.5%
8.4%
1.5%
1.5%
4.3%
5.4%
2.3%
4.3%
5.2%
5.5%
5.5%
2.4%
4.9%
4.9%
100.0%

12.5%
11.6%
4.2%
5.5%
12.6%
11.4%
3.4%
3.8%
8.2%
5.9%

1.88 [0.33 , 10.63]
2.50 [0.38 , 16.42]
5.18 [1.15 , 23.29]
14.04 [1.71 , 115.41]
1.63 [0.77 , 3.46]
67.67 [3.56 , 1287.81]
4.27 [1.13 , 16.05]
15.55 [1.73 , 139.65]
49.00 [2.53 , 948.62]
9.47 [1.93 , 46.46]
3.34 [0.66 , 16.92]
21.26 [1.18 , 381.56]
11.04 [0.60 , 202.89]
150.33 [7.54 , 2997.83]
3.94 [2.01 , 7.71]
60.29 [3.20 , 1137.79]
146.20 [7.89 , 2709.82]
14.40 [3.29 , 63.08]
2.13 [0.64 , 7.16]
8.25 [0.82 , 82.67]
9.63 [2.19 , 42.37]
2.41 [0.70 , 8.36]
11.37 [3.44 , 37.58]
6.41 [1.96 , 21.01]
6.18 [0.66 , 58.03]
2.98 [0.79 , 11.26]
2.88 [0.77 , 10.77]
5.85 [3.95 , 8.64]

15.25 [5.53 , 42.05]
7.35 [2.32 , 23.27]
1.08 [0.06 , 19.05]
5.14 [0.48 , 55.64]
2.40 [0.87 , 6.57]
2.92 [0.91 , 9.44]
0.28 [0.01 , 7.31]
28.64 [1.37 , 600.41]
5.25 [0.95 , 29.05]
11.38 [1.17 , 110.42]

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

213

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Analysis 1.3.   (Continued)

Cochrane Database of Systematic Reviews

7
7
14
17
6

Melfsen 2011
Santucci 2013
Spence 2000
Waters 2009
Wood 2015
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.68; Chi² = 24.07, df = 12 (P = 0.02); I² = 50%
Test for overall effect: Z = 4.34 (P < 0.0001)

21
15
17
31
19
312

2
1
1
1
6

163

48

23
14
8
5
14
250

8.2%
5.9%
5.3%
5.8%
9.8%
100.0%

5.25 [0.95 , 29.05]
11.38 [1.17 , 110.42]
32.67 [2.85 , 374.13]
4.86 [0.49 , 48.57]
0.62 [0.15 , 2.58]
4.44 [2.26 , 8.72]

Test for subgroup differences: Chi² = 0.52, df = 2 (P = 0.77), I² = 0%

0.1
0.001
Favours Wait list / no treatment

1

10

1000

Favours CBT

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

214

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.4.   Comparison 1: CBT versus waitlist/no treatment, Outcome 4: Subgroup analysis: remission of primary
anxiety diagnosis post-treatment (ITT) (age)

Study or Subgroup

Events

Total

CBT

Wait list / no treatment
Events

Total

Weight

Odds Ratio
IV, Random, 95% CI

Odds Ratio
IV, Random, 95% CI

1.4.1 ≤ 12 years
Cartwright Hatton 2011
Cornacchio 2019
Gallagher 2004
Hirshfeld Becker 2010
Holmes 2014
Lau 2010
Rapee 2006
Santucci 2013
Schneider 2011
Thirlwall 2013
Thirlwall 2013
Waters 2009
Waters 2009
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.51; Chi² = 25.87, df = 12 (P = 0.01); I² = 54%
Test for overall effect: Z = 4.62 (P < 0.00001)

37
14
12
34
20
21
90
15
21
61
64
38
31
458

5
1
0
13
3
0
17
1
4
11
11
1
1

21
1
5
22
9
14
44
7
16
18
25
21
17

220

68

1.4.2 Mixed age range (< 12 and ≥ 12 years)
Arendt 2016
Cobham 2017
Dadds 1997
Flannery Schroeder 2000
Flannery Schroeder 2000
Ishikawa 2019
Kendall 1994
Kendall 1997
Masia Warner 2011
McConachie 2014
McNally Keehn 2013
Melfsen 2011
Ollendick 2009
Ost 2001
Ost 2001
Perrin 2019
Sanchez Garcia 2009
Silverman 1999b
Spence 2000
Spence 2000
Spence 2006
Villabo 2018
Villabo 2018
Wergeland 2014
Wergeland 2014
Wood 2015
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.84; Chi² = 58.15, df = 25 (P = 0.0002); I² = 57%
Test for overall effect: Z = 7.31 (P < 0.00001)

56
33
23
18
13
23
40
69
20
17
12
21
85
21
20
20
28
37
19
17
22
55
55
77
67
19
887

37
20
21
9
6
10
17
32
9
0
7
7
47
18
12
16
21
16
11
14
13
29
36
27
24
6

6
6
28
2
1
4
1
17
1
1
0
2
1
0
0
0
0
5
1
1
3
4
4
3
3
6

100

465

33
15
11
30
22
17
87
14
22
34
35
6
5
331

53
30
33
7
7
24
20
49
20
15
10
23
41
10
9
20
25
19
7
8
23
27
28
19
19
14
560

10.3%
3.3%
3.0%
11.3%
8.0%
3.2%
14.0%
4.7%
8.1%
12.1%
12.4%
4.8%
4.6%
100.0%

5.9%
5.5%
4.0%
3.7%
2.8%
4.9%
3.2%
6.6%
3.1%
1.8%
2.0%
4.0%
3.4%
2.0%
2.1%
2.0%
2.1%
5.3%
2.9%
2.7%
4.6%
5.4%
5.3%
5.0%
5.0%
4.7%
100.0%

7.35 [2.32 , 23.27]
1.08 [0.06 , 19.05]
16.87 [0.81 , 351.79]
2.40 [0.87 , 6.57]
5.18 [1.15 , 23.29]
67.67 [3.56 , 1287.81]
3.94 [2.01 , 7.71]
11.38 [1.17 , 110.42]
14.40 [3.29 , 63.08]
0.88 [0.35 , 2.16]
1.40 [0.58 , 3.35]
6.18 [0.66 , 58.03]
4.86 [0.49 , 48.57]
3.93 [2.20 , 7.02]

15.25 [5.53 , 42.05]
6.15 [1.98 , 19.14]
1.88 [0.33 , 10.63]
2.50 [0.38 , 16.42]
5.14 [0.48 , 55.64]
3.85 [0.99 , 14.89]
14.04 [1.71 , 115.41]
1.63 [0.77 , 3.46]
15.55 [1.73 , 139.65]
0.28 [0.01 , 7.31]
28.64 [1.37 , 600.41]
5.25 [0.95 , 29.05]
49.47 [6.50 , 376.64]
111.00 [5.21 , 2363.64]
27.94 [1.43 , 546.98]
150.33 [7.54 , 2997.83]
146.20 [7.89 , 2709.82]
2.13 [0.64 , 7.16]
8.25 [0.82 , 82.67]
32.67 [2.85 , 374.13]
9.63 [2.19 , 42.37]
6.41 [1.96 , 21.01]
11.37 [3.44 , 37.58]
2.88 [0.77 , 10.77]
2.98 [0.79 , 11.26]
0.62 [0.15 , 2.58]
6.43 [3.90 , 10.58]

1.4.3 ≥ 12 years
Kidd 2018
Masia Warner 2005
Olivares 2005
Olivares 2014
Olivares 2014
Olivares 2019

18
12
10
11
20
8

26
21
17
39
39
36

10
5
0
2
2
0

23
21
17
19
20
18

20.9%
17.3%
4.2%
12.5%
12.9%
4.4%

2.92 [0.91 , 9.44]
4.27 [1.13 , 16.05]
49.00 [2.53 , 948.62]
3.34 [0.66 , 16.92]
9.47 [1.93 , 46.46]
11.04 [0.60 , 202.89]

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

215

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Analysis 1.4.   (Continued)

Cochrane Database of Systematic Reviews

20
8
13
12
13

Olivares 2014
Olivares 2019
Olivares 2019
Rosa Alcazar 2009
Spence 2011
Subtotal (95% CI)
23
Total events:
Heterogeneity: Tau² = 0.13; Chi² = 9.32, df = 8 (P = 0.32); I² = 14%
Test for overall effect: Z = 5.22 (P < 0.00001)

39
36
36
20
44
278

2
0
0
0
4

117

20
18
18
20
27
183

12.9%
4.4%
4.4%
4.3%
19.1%
100.0%

9.47 [1.93 , 46.46]
11.04 [0.60 , 202.89]
21.26 [1.18 , 381.56]
60.29 [3.20 , 1137.79]
2.41 [0.70 , 8.36]
5.28 [2.83 , 9.86]

Test for subgroup differences: Chi² = 1.59, df = 2 (P = 0.45), I² = 0%

0.1
0.001
Favours Wait list / no treatment

1

10

1000

Favours CBT

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

216

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.5.   Comparison 1: CBT versus waitlist/no treatment, Outcome 5: Subgroup analysis: remission of primary
anxiety diagnosis post-treatment (ITT) (ASD vs non-ASD)

Study or Subgroup

Events

Total

CBT

Wait list / no treatment
Events

Total

Weight

Odds Ratio
IV, Random, 95% CI

Odds Ratio
IV, Random, 95% CI

1.5.1 Sample with ASD
Kidd 2018
McConachie 2014
McNally Keehn 2013
Wood 2015
Subtotal (95% CI)
17
Total events:
Heterogeneity: Tau² = 1.28; Chi² = 7.24, df = 3 (P = 0.06); I² = 59%
Test for overall effect: Z = 0.76 (P = 0.45)

26
17
12
19
74

18
0
7
6

10
1
0
6

31

1.5.2 Not sample with ASD
Arendt 2016
Cartwright Hatton 2011
Cobham 2017
Cornacchio 2019
Dadds 1997
Flannery Schroeder 2000
Flannery Schroeder 2000
Gallagher 2004
Hirshfeld Becker 2010
Holmes 2014
Ishikawa 2019
Kendall 1994
Kendall 1997
Lau 2010
Masia Warner 2005
Masia Warner 2011
Melfsen 2011
Olivares 2005
Olivares 2014
Olivares 2014
Olivares 2019
Olivares 2019
Ollendick 2009
Ost 2001
Ost 2001
Perrin 2019
Rapee 2006
Rosa Alcazar 2009
Sanchez Garcia 2009
Santucci 2013
Schneider 2011
Silverman 1999b
Spence 2000
Spence 2000
Spence 2006
Spence 2011
Thirlwall 2013
Thirlwall 2013
Villabo 2018
Villabo 2018
Waters 2009
Waters 2009
Wergeland 2014
Wergeland 2014
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.55; Chi² = 85.92, df = 43 (P = 0.0001); I² = 50%

56
37
33
14
23
18
13
12
34
20
23
40
69
21
21
20
21
17
39
39
36
36
85
20
21
20
90
20
28
15
21
37
17
19
22
44
64
61
55
55
31
38
77
67
1549

37
21
20
1
21
9
6
5
22
9
10
17
32
14
12
9
7
10
11
20
8
13
47
12
18
16
44
12
21
7
16
16
14
11
13
13
25
18
36
29
17
21
27
24

6
5
6
1
28
2
1
0
13
3
4
1
17
0
5
1
2
0
2
2
0
0
1
0
0
0
17
0
0
1
4
5
1
1
3
4
11
11
4
4
1
1
3
3

771

174

23
15
10
14
62

36.4%
14.6%
16.2%
32.8%
100.0%

2.92 [0.91 , 9.44]
0.28 [0.01 , 7.31]
28.64 [1.37 , 600.41]
0.62 [0.15 , 2.58]
1.79 [0.39 , 8.16]

53
33
30
15
33
7
7
11
30
22
24
20
49
17
21
20
23
17
19
20
18
18
41
9
10
20
87
20
25
14
22
19
8
7
23
27
35
34
28
27
5
6
19
19
1012

3.6%
3.3%
3.3%
1.1%
2.2%
2.0%
1.5%
1.0%
3.6%
2.6%
2.9%
1.7%
4.2%
1.1%
2.9%
1.6%
2.3%
1.0%
2.4%
2.5%
1.1%
1.1%
1.8%
1.0%
1.0%
1.0%
4.4%
1.1%
1.1%
1.6%
2.7%
3.2%
1.4%
1.5%
2.6%
3.1%
4.0%
3.9%
3.2%
3.2%
1.5%
1.6%
3.0%
2.9%
100.0%

15.25 [5.53 , 42.05]
7.35 [2.32 , 23.27]
6.15 [1.98 , 19.14]
1.08 [0.06 , 19.05]
1.88 [0.33 , 10.63]
2.50 [0.38 , 16.42]
5.14 [0.48 , 55.64]
16.87 [0.81 , 351.79]
2.40 [0.87 , 6.57]
5.18 [1.15 , 23.29]
3.85 [0.99 , 14.89]
14.04 [1.71 , 115.41]
1.63 [0.77 , 3.46]
67.67 [3.56 , 1287.81]
4.27 [1.13 , 16.05]
15.55 [1.73 , 139.65]
5.25 [0.95 , 29.05]
49.00 [2.53 , 948.62]
3.34 [0.66 , 16.92]
9.47 [1.93 , 46.46]
11.04 [0.60 , 202.89]
21.26 [1.18 , 381.56]
49.47 [6.50 , 376.64]
27.94 [1.43 , 546.98]
111.00 [5.21 , 2363.64]
150.33 [7.54 , 2997.83]
3.94 [2.01 , 7.71]
60.29 [3.20 , 1137.79]
146.20 [7.89 , 2709.82]
11.38 [1.17 , 110.42]
14.40 [3.29 , 63.08]
2.13 [0.64 , 7.16]
32.67 [2.85 , 374.13]
8.25 [0.82 , 82.67]
9.63 [2.19 , 42.37]
2.41 [0.70 , 8.36]
1.40 [0.58 , 3.35]
0.88 [0.35 , 2.16]
11.37 [3.44 , 37.58]
6.41 [1.96 , 21.01]
4.86 [0.49 , 48.57]
6.18 [0.66 , 58.03]
2.88 [0.77 , 10.77]
2.98 [0.79 , 11.26]
5.88 [4.19 , 8.24]

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

217

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Analysis 1.5.   (Continued)

Cochrane Database of Systematic Reviews

Total events:
Heterogeneity: Tau² = 0.55; Chi² = 85.92, df = 43 (P = 0.0001); I² = 50%
Test for overall effect: Z = 10.28 (P < 0.00001)

771

174

Test for subgroup differences: Chi² = 2.25, df = 1 (P = 0.13), I² = 55.5%

0.1
0.001
Favours Wait list / no treatment

1

10

1000

Favours CBT

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

218

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.6.   Comparison 1: CBT versus waitlist/no treatment, Outcome
6: Remission of primary anxiety diagnosis post-treatment (completers)

Study or Subgroup

Events

Total

CBT

Wait list / no treatment
Events

Total

Weight

Odds Ratio
IV, Random, 95% CI

Odds Ratio
IV, Random, 95% CI

Arendt 2016
Cartwright Hatton 2011
Cobham 2017
Cornacchio 2019
Dadds 1997
Flannery Schroeder 2000
Flannery Schroeder 2000
Gallagher 2004
Hirshfeld Becker 2010
Holmes 2014
Ishikawa 2019
Kendall 1994
Kendall 1997
Kidd 2018
Lau 2010
Masia Warner 2005
Masia Warner 2011
McNally Keehn 2013
Melfsen 2011
Olivares 2005
Olivares 2014
Olivares 2014
Olivares 2019
Olivares 2019
Ollendick 2009
Ost 2001
Ost 2001
Perrin 2019
Rapee 2006
Rosa Alcazar 2009
Sanchez Garcia 2009
Santucci 2013
Schneider 2011
Silverman 1999b
Spence 2000
Spence 2000
Spence 2006
Spence 2011
Thirlwall 2013
Thirlwall 2013
Villabo 2018
Villabo 2018
Waters 2009
Waters 2009
Wergeland 2014
Wergeland 2014
Wood 2015

37
21
20
1
21
6
9
5
22
9
10
17
32
18
14
12
9
7
7
10
11
20
13
8
47
12
18
16
44
12
21
7
16
16
11
14
13
13
18
25
36
29
21
17
27
24
6

56
37
31
14
22
12
13
12
29
17
22
27
60
25
21
18
20
12
15
17
37
38
34
24
85
20
21
18
72
20
28
14
18
25
19
16
20
40
46
50
55
55
25
23
64
59
16

4
5
5
0
27
0
1
0
11
0
3
1
2
6
0
1
0
0
0
0
0
0
0
0
1
0
0
0
5
0
0
0
3
2
1
0
3
1
8
8
4
4
1
1
2
2
3

51
33
29
14
32
6
6
11
28
19
23
20
34
19
17
17
19
10
21
17
17
18
18
18
41
9
10
20
75
20
25
13
21
16
7
7
23
24
31
32
28
27
6
5
18
18
11

4.2%
4.2%
4.0%
0.8%
1.7%
1.0%
1.4%
1.0%
4.3%
1.0%
3.1%
1.8%
3.0%
3.6%
1.0%
1.6%
1.0%
1.0%
1.0%
1.0%
1.1%
1.1%
1.1%
1.0%
1.9%
1.0%
1.0%
0.9%
4.8%
1.0%
1.0%
1.0%
2.1%
2.6%
1.6%
0.9%
3.0%
1.8%
4.9%
5.0%
4.0%
4.1%
1.5%
1.5%
2.9%
2.9%
2.6%

22.88 [7.17 , 73.07]
7.35 [2.32 , 23.27]
8.73 [2.60 , 29.33]
3.22 [0.12 , 86.09]
3.89 [0.42 , 35.86]
13.00 [0.60 , 281.46]
11.25 [0.97 , 130.22]
16.87 [0.81 , 351.79]
4.86 [1.55 , 15.18]
43.59 [2.27 , 837.56]
5.56 [1.27 , 24.29]
32.30 [3.74 , 279.31]
18.29 [4.02 , 83.27]
5.57 [1.51 , 20.51]
67.67 [3.56 , 1287.81]
32.00 [3.39 , 302.22]
32.22 [1.71 , 606.80]
28.64 [1.37 , 600.41]
37.94 [1.94 , 740.15]
49.00 [2.53 , 948.62]
15.19 [0.84 , 274.68]
41.00 [2.31 , 729.27]
23.23 [1.29 , 418.15]
19.06 [1.02 , 356.38]
49.47 [6.50 , 376.64]
27.94 [1.43 , 546.98]
111.00 [5.21 , 2363.64]
270.60 [12.13 , 6035.59]
22.00 [7.90 , 61.23]
60.29 [3.20 , 1137.79]
146.20 [7.89 , 2709.82]
27.00 [1.35 , 541.57]
48.00 [7.10 , 324.71]
12.44 [2.29 , 67.56]
8.25 [0.82 , 82.67]
87.00 [3.68 , 2054.22]
12.38 [2.70 , 56.73]
11.07 [1.34 , 91.22]
1.85 [0.68 , 5.02]
3.00 [1.13 , 7.94]
11.37 [3.44 , 37.58]
6.41 [1.96 , 21.01]
26.25 [2.38 , 288.94]
11.33 [1.05 , 122.55]
5.84 [1.24 , 27.54]
5.49 [1.15 , 26.08]
1.60 [0.30 , 8.49]

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.28; Chi² = 61.53, df = 46 (P = 0.06); I² = 25%
Test for overall effect: Z = 15.11 (P < 0.00001)
Test for subgroup differences: Not applicable

1422

802

115

984

100.0%

11.55 [8.41 , 15.86]

0.1
0.001
Favours Wait list / no treatment

1

10

1000

Favours CBT

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

219

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.7.   Comparison 1: CBT versus waitlist/no treatment, Outcome 7: Acceptability (number of participants
lost to post-treatment assessment)

Study or Subgroup

Events

Total

CBT

Wait list / no treatment
Events

Total

Odds Ratio
IV, Random, 95% CI

Weight

Odds Ratio
IV, Random, 95% CI

Afshari 2014
Afshari 2014
Arendt 2016
Barrett 1996
Barrett 1996
Barrett 1998
Barrett 1998
Berge 2017
Chalfant 2007
Cheung 2016
Chiu 2013
Cobham 2017
Cornacchio 2019
Flannery Schroeder 2000
Flannery Schroeder 2000
Hancock 2018
Hancock 2018
Hirshfeld Becker 2010
Holmes 2014
Ishikawa 2019
Kendall 1994
Kendall 1997
Kennedy 2009
Kidd 2018
Lau 2017
Masia Warner 2005
Masia Warner 2011
McConachie 2014
Melfsen 2011
Olivares 2014
Olivares 2014
Olivares 2019
Olivares 2019
Perrin 2019
Rapee 2006
Salari 2018
Santucci 2013
Schneider 2011
Shortt 2001
Silverman 1999b
Simon 2011
Simon 2011
Smith 2014
Spence 2000
Spence 2006
Spence 2011
Thirlwall 2013
Thirlwall 2013
Villabo 2018
Villabo 2018
Waters 2009
Waters 2009
Wergeland 2014
Wergeland 2014
White 2013
Wood 2009
Wood 2015

2
2
0
2
3
2
4
4
4
4
1
2
0
5
1
6
14
5
3
1
13
9
3
1
1
3
0
0
6
1
2
2
12
2
14
5
1
3
6
12
2
2
1
0
2
4
14
15
11
2
13
7
11
8
2
2
3

12
12
56
27
31
17
23
34
32
22
22
33
14
18
13
63
68
34
20
26
40
69
35
26
39
21
20
17
21
39
39
36
36
20
90
20
15
21
54
37
27
18
18
19
22
44
64
61
55
55
38
31
77
67
15
17
19

0
0
3
2
2
2
2
5
0
1
0
1
1
1
1
8
8
2
3
1
0
15
5
4
0
4
1
1
2
2
2
0
0
0
12
3
1
1
1
3
3
2
0
1
0
3
3
3
3
2
0
0
1
1
3
1
3

5
5
53
13
14
10
10
33
19
19
18
30
15
7
7
31
31
30
22
25
20
49
36
23
33
21
20
15
23
19
20
18
18
20
87
22
14
22
17
19
15
15
13
8
23
27
35
34
28
27
6
5
19
19
15
23
14

0.6%
0.6%
0.7%
1.5%
1.7%
1.4%
1.8%
3.1%
0.7%
1.2%
0.6%
1.1%
0.6%
1.2%
0.7%
4.4%
5.8%
2.1%
2.1%
0.8%
0.8%
6.6%
2.7%
1.2%
0.6%
2.3%
0.6%
0.6%
2.1%
1.1%
1.5%
0.7%
0.8%
0.7%
7.9%
2.5%
0.8%
1.2%
1.3%
3.1%
1.7%
1.5%
0.6%
0.6%
0.7%
2.5%
3.5%
3.5%
3.3%
1.6%
0.7%
0.7%
1.4%
1.4%
1.7%
1.0%
2.0%

2.62 [0.11 , 64.69]
2.62 [0.11 , 64.69]
0.13 [0.01 , 2.53]
0.44 [0.05 , 3.54]
0.64 [0.09 , 4.35]
0.53 [0.06 , 4.53]
0.84 [0.13 , 5.56]
0.75 [0.18 , 3.06]
6.16 [0.31 , 120.99]
4.00 [0.41 , 39.37]
2.58 [0.10 , 67.27]
1.87 [0.16 , 21.75]
0.33 [0.01 , 8.88]
2.31 [0.22 , 24.32]
0.50 [0.03 , 9.46]
0.30 [0.09 , 0.97]
0.75 [0.28 , 2.02]
2.41 [0.43 , 13.48]
1.12 [0.20 , 6.30]
0.96 [0.06 , 16.23]
20.13 [1.13 , 358.56]
0.34 [0.13 , 0.86]
0.58 [0.13 , 2.64]
0.19 [0.02 , 1.84]
2.61 [0.10 , 66.25]
0.71 [0.14 , 3.64]
0.32 [0.01 , 8.26]
0.28 [0.01 , 7.31]
4.20 [0.74 , 23.74]
0.22 [0.02 , 2.64]
0.49 [0.06 , 3.74]
2.68 [0.12 , 58.83]
18.88 [1.05 , 339.82]
5.54 [0.25 , 123.08]
1.15 [0.50 , 2.65]
2.11 [0.43 , 10.28]
0.93 [0.05 , 16.42]
3.50 [0.33 , 36.67]
2.00 [0.22 , 17.89]
2.56 [0.62 , 10.51]
0.32 [0.05 , 2.18]
0.81 [0.10 , 6.58]
2.31 [0.09 , 61.41]
0.13 [0.00 , 3.51]
5.73 [0.26 , 126.42]
0.80 [0.16 , 3.88]
2.99 [0.80 , 11.22]
3.37 [0.90 , 12.62]
2.08 [0.53 , 8.18]
0.47 [0.06 , 3.54]
6.88 [0.36 , 131.64]
3.37 [0.17 , 68.20]
3.00 [0.36 , 24.80]
2.44 [0.29 , 20.84]
0.62 [0.09 , 4.34]
2.93 [0.24 , 35.33]
0.69 [0.12 , 4.06]

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.04; Chi² = 58.16, df = 56 (P = 0.40); I² = 4%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable

1919

129

260

1239

100.0%

1.09 [0.85 , 1.41]

0.01

0.1
Favours CBT

1

10

100
Favours Wait list / no treatment

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

220

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Analysis 1.7.   (Continued)

Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable

Cochrane Database of Systematic Reviews

Favours CBT

Favours Wait list / no treatment

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

221

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.8.   Comparison 1: CBT versus waitlist/no treatment, Outcome 8: Remission of all anxiety diagnoses post-
treatment (ITT)

Study or Subgroup

Events

Total

CBT

Wait list / no treatment
Events

Total

Weight

Odds Ratio
IV, Random, 95% CI

Odds Ratio
IV, Random, 95% CI

1.8.1 Child focused
Barrett 1996
Barrett 1998
Chiu 2013
Dadds 1997
Olivares 2005
Perrin 2019
Rosa Alcazar 2009
Sanchez Garcia 2009
Simon 2011
Spence 2000
Villabo 2018
Villabo 2018
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 2.27; Chi² = 37.22, df = 11 (P = 0.0001); I² = 70%
Test for overall effect: Z = 3.99 (P < 0.0001)

31
23
22
23
17
20
20
28
18
19
55
55
331

16
13
21
19
8
16
9
17
13
11
21
31

5
5
3
24
0
0
0
0
13
1
1
2

195

54

1.8.2 Child and parent
Arendt 2016
Barrett 1996
Barrett 1998
Chalfant 2007
Hirshfeld Becker 2010
Ishikawa 2019
Lau 2017
McConachie 2014
Melfsen 2011
Rapee 2006
Shortt 2001
Spence 2000
Spence 2006
Spence 2011
Waters 2009
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.20; Chi² = 18.86, df = 14 (P = 0.17); I² = 26%
Test for overall effect: Z = 6.93 (P < 0.00001)

56
27
17
32
34
26
39
17
21
90
54
17
22
44
31
527

27
21
12
20
17
4
13
0
6
44
33
14
11
9
14

5
5
4
0
7
2
0
1
2
17
2
1
2
4
0

245

52

1.8.3 Parent only
Cartwright Hatton 2011
Cobham 2017
Kennedy 2009
Rapee 2005
Simon 2011
Thirlwall 2013
Thirlwall 2013
Waters 2009
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.43; Chi² = 14.42, df = 7 (P = 0.04); I² = 51%
Test for overall effect: Z = 1.91 (P = 0.06)

37
33
35
60
27
64
61
38
355

12
12
15
30
20
17
7
15

2
2
8
19
14
7
6
1

128

59

Total (95% CI)
568
Total events:
Heterogeneity: Tau² = 0.85; Chi² = 84.49, df = 34 (P < 0.00001); I² = 60%
Test for overall effect: Z = 6.85 (P < 0.00001)
Test for subgroup differences: Chi² = 8.14, df = 2 (P = 0.02), I² = 75.4%

1213

165

13
10
18
33
17
20
20
25
15
7
27
28
233

53
14
10
19
30
25
33
15
23
87
17
8
23
27
5
389

33
30
36
51
15
35
34
6
240

3.6%
3.3%
2.1%
3.6%
1.5%
1.5%
1.5%
1.6%
2.8%
2.1%
2.4%
3.2%
29.2%

4.1%
3.4%
3.0%
1.6%
4.1%
2.8%
1.6%
1.3%
2.9%
4.9%
3.2%
2.0%
3.0%
3.7%
1.5%
43.0%

3.1%
3.1%
4.2%
4.7%
2.2%
4.3%
3.9%
2.2%
27.8%

1.71 [0.46 , 6.39]
1.30 [0.29 , 5.76]
105.00 [9.93 , 1110.02]
1.78 [0.47 , 6.69]
31.32 [1.62 , 604.04]
150.33 [7.54 , 2997.83]
33.87 [1.80 , 636.88]
77.61 [4.29 , 1404.91]
0.40 [0.07 , 2.45]
8.25 [0.82 , 82.67]
16.06 [2.03 , 127.27]
16.79 [3.62 , 77.84]
8.52 [2.97 , 24.39]

8.94 [3.10 , 25.79]
6.30 [1.52 , 26.08]
3.60 [0.70 , 18.56]
63.96 [3.54 , 1155.34]
3.29 [1.12 , 9.68]
2.09 [0.35 , 12.59]
34.13 [1.94 , 600.96]
0.28 [0.01 , 7.31]
4.20 [0.74 , 23.74]
3.94 [2.01 , 7.71]
11.79 [2.44 , 56.85]
32.67 [2.85 , 374.13]
10.50 [1.97 , 56.00]
1.48 [0.41 , 5.37]
9.11 [0.46 , 179.00]
5.19 [3.26 , 8.27]

7.44 [1.52 , 36.37]
8.00 [1.61 , 39.64]
2.63 [0.94 , 7.37]
1.68 [0.79 , 3.60]
0.20 [0.02 , 1.85]
1.45 [0.53 , 3.92]
0.60 [0.19 , 1.97]
3.26 [0.35 , 30.73]
1.89 [0.98 , 3.65]

862

100.0%

4.43 [2.89 , 6.78]

0.1
0.001
Favours Wait list / no treatment

1

10

1000

Favours CBT

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

222

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.8.   (Continued)

Heterogeneity: Tau² = 0.85; Chi² = 84.49, df = 34 (P < 0.00001); I² = 60%
Test for overall effect: Z = 6.85 (P < 0.00001)
Test for subgroup differences: Chi² = 8.14, df = 2 (P = 0.02), I² = 75.4%

0.1
0.001
Favours Wait list / no treatment

1

10

1000

Favours CBT

Analysis 1.9.   Comparison 1: CBT versus waitlist/no treatment, Outcome 9: Subgroup
analysis: remission of all anxiety diagnoses post-treatment (ITT) (individual vs group)

Study or Subgroup

Events

Total

CBT

Wait list / no treatment
Events

Total

Weight

Odds Ratio
IV, Random, 95% CI

Odds Ratio
IV, Random, 95% CI

1.9.1 Individual focused
Barrett 1996
Barrett 1996
Chiu 2013
Hirshfeld Becker 2010
Ishikawa 2019
Melfsen 2011
Perrin 2019
Spence 2011
Thirlwall 2013
Thirlwall 2013
Villabo 2018
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 1.08; Chi² = 29.80, df = 10 (P = 0.0009); I² = 66%
Test for overall effect: Z = 3.29 (P = 0.0010)

31
27
22
34
26
21
20
44
64
61
55
405

16
21
21
17
4
6
16
9
17
7
21

5
5
3
7
2
2
0
4
7
6
1

155

42

1.9.2 Group focused
Arendt 2016
Barrett 1998
Barrett 1998
Cartwright Hatton 2011
Chalfant 2007
Cobham 2017
Dadds 1997
Kennedy 2009
Lau 2017
McConachie 2014
Olivares 2005
Rapee 2005
Rapee 2006
Rosa Alcazar 2009
Sanchez Garcia 2009
Shortt 2001
Simon 2011
Simon 2011
Spence 2000
Spence 2000
Spence 2006
Villabo 2018
Waters 2009
Waters 2009
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.76; Chi² = 52.14, df = 23 (P = 0.0005); I² = 56%
Test for overall effect: Z = 6.11 (P < 0.00001)

56
23
17
37
32
33
23
35
39
17
17
60
90
20
28
54
18
27
19
17
22
55
38
31
808

27
13
12
12
20
12
19
15
13
0
8
30
44
9
17
33
13
20
11
14
11
31
15
14

5
5
4
2
0
2
24
8
0
1
0
19
17
0
0
2
13
14
1
1
2
2
1
0

123

413

13
14
18
30
25
23
20
27
35
34
27
266

53
10
10
33
19
30
33
36
33
15
17
51
87
20
25
17
15
15
7
8
23
28
6
5
596

10.3%
9.9%
6.3%
11.5%
8.3%
8.5%
4.7%
10.5%
11.9%
11.0%
7.2%
100.0%

6.5%
5.1%
4.7%
4.8%
2.3%
4.8%
5.6%
6.5%
2.3%
1.9%
2.2%
7.5%
7.7%
2.3%
2.3%
4.8%
4.2%
3.4%
3.2%
2.9%
4.6%
5.0%
3.3%
2.2%
100.0%

1.71 [0.46 , 6.39]
6.30 [1.52 , 26.08]
105.00 [9.93 , 1110.02]
3.29 [1.12 , 9.68]
2.09 [0.35 , 12.59]
4.20 [0.74 , 23.74]
150.33 [7.54 , 2997.83]
1.48 [0.41 , 5.37]
1.45 [0.53 , 3.92]
0.60 [0.19 , 1.97]
16.06 [2.03 , 127.27]
3.72 [1.70 , 8.12]

8.94 [3.10 , 25.79]
1.30 [0.29 , 5.76]
3.60 [0.70 , 18.56]
7.44 [1.52 , 36.37]
63.96 [3.54 , 1155.34]
8.00 [1.61 , 39.64]
1.78 [0.47 , 6.69]
2.63 [0.94 , 7.37]
34.13 [1.94 , 600.96]
0.28 [0.01 , 7.31]
31.32 [1.62 , 604.04]
1.68 [0.79 , 3.60]
3.94 [2.01 , 7.71]
33.87 [1.80 , 636.88]
77.61 [4.29 , 1404.91]
11.79 [2.44 , 56.85]
0.40 [0.07 , 2.45]
0.20 [0.02 , 1.85]
8.25 [0.82 , 82.67]
32.67 [2.85 , 374.13]
10.50 [1.97 , 56.00]
16.79 [3.62 , 77.84]
3.26 [0.35 , 30.73]
9.11 [0.46 , 179.00]
4.92 [2.95 , 8.20]

Test for subgroup differences: Chi² = 0.35, df = 1 (P = 0.56), I² = 0%

0.1
0.001
Favours Wait list / no treatment

1

10

1000

Favours CBT

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

223

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.10.   Comparison 1: CBT versus waitlist/no treatment, Outcome 10: Subgroup analysis:
remission of all anxiety diagnoses post-treatment (ITT) (amount of therapist contact time)

Study or Subgroup

Events

Total

CBT

Wait list / no treatment
Events

Total

Weight

Odds Ratio
IV, Random, 95% CI

Odds Ratio
IV, Random, 95% CI

1.10.1 Therapist contact (< 10 hours)
12
Cobham 2017
4
Ishikawa 2019
30
Rapee 2005
20
Simon 2011
17
Thirlwall 2013
7
Thirlwall 2013
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.39; Chi² = 9.83, df = 5 (P = 0.08); I² = 49%
Test for overall effect: Z = 0.93 (P = 0.35)

33
26
60
27
64
61
271

2
2
19
14
7
6

50

90

1.10.2 Therapist contact (≥ 10 and < 20 hours)
Barrett 1996
Barrett 1996
Chiu 2013
Dadds 1997
Kennedy 2009
Lau 2017
Olivares 2005
Perrin 2019
Rapee 2006
Rosa Alcazar 2009
Sanchez Garcia 2009
Shortt 2001
Simon 2011
Spence 2000
Spence 2006
Spence 2011
Villabo 2018
Villabo 2018
Waters 2009
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.90; Chi² = 43.27, df = 18 (P = 0.0007); I² = 58%
Test for overall effect: Z = 6.16 (P < 0.00001)

27
31
22
23
35
39
17
20
90
20
28
54
18
19
22
44
55
55
38
657

21
16
21
19
15
13
8
16
44
9
17
33
13
11
11
9
21
31
15

5
5
3
24
8
0
0
0
17
0
0
2
13
1
2
4
1
2
1

343

88

1.10.3 Therapist contact (≥ 20 hours)
27
Arendt 2016
12
Barrett 1998
13
Barrett 1998
12
Cartwright Hatton 2011
20
Chalfant 2007
17
Hirshfeld Becker 2010
0
McConachie 2014
6
Melfsen 2011
14
Spence 2000
14
Waters 2009
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.38; Chi² = 13.73, df = 9 (P = 0.13); I² = 34%
Test for overall effect: Z = 4.66 (P < 0.00001)

56
17
23
37
32
34
17
21
17
31
285

5
4
5
2
0
7
1
2
1
0

135

27

30
25
51
15
35
34
190

13.3%
11.5%
26.2%
8.5%
21.8%
18.7%
100.0%

8.00 [1.61 , 39.64]
2.09 [0.35 , 12.59]
1.68 [0.79 , 3.60]
0.20 [0.02 , 1.85]
1.45 [0.53 , 3.92]
0.60 [0.19 , 1.97]
1.42 [0.68 , 2.96]

14
13
18
33
36
33
17
20
87
20
25
17
15
7
23
27
27
28
6
466

53
10
10
33
19
30
15
23
8
5
206

6.6%
6.9%
4.0%
6.9%
8.0%
3.1%
2.9%
2.9%
9.2%
3.0%
3.0%
6.1%
5.3%
4.1%
5.8%
7.0%
4.7%
6.2%
4.2%
100.0%

17.8%
11.1%
12.5%
11.6%
4.7%
17.5%
3.8%
10.3%
6.2%
4.5%
100.0%

6.30 [1.52 , 26.08]
1.71 [0.46 , 6.39]
105.00 [9.93 , 1110.02]
1.78 [0.47 , 6.69]
2.63 [0.94 , 7.37]
34.13 [1.94 , 600.96]
31.32 [1.62 , 604.04]
150.33 [7.54 , 2997.83]
3.94 [2.01 , 7.71]
33.87 [1.80 , 636.88]
77.61 [4.29 , 1404.91]
11.79 [2.44 , 56.85]
0.40 [0.07 , 2.45]
8.25 [0.82 , 82.67]
10.50 [1.97 , 56.00]
1.48 [0.41 , 5.37]
16.06 [2.03 , 127.27]
16.79 [3.62 , 77.84]
3.26 [0.35 , 30.73]
6.59 [3.62 , 12.01]

8.94 [3.10 , 25.79]
3.60 [0.70 , 18.56]
1.30 [0.29 , 5.76]
7.44 [1.52 , 36.37]
63.96 [3.54 , 1155.34]
3.29 [1.12 , 9.68]
0.28 [0.01 , 7.31]
4.20 [0.74 , 23.74]
32.67 [2.85 , 374.13]
9.11 [0.46 , 179.00]
5.03 [2.55 , 9.93]

Test for subgroup differences: Chi² = 10.75, df = 2 (P = 0.005), I² = 81.4%

0.1
0.001
Favours Wait list / no treatment

1

10

1000

Favours CBT

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

224

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.11.   Comparison 1: CBT versus waitlist/no treatment, Outcome 11:
Subgroup analysis: remission of all anxiety diagnoses post-treatment (ITT) (age)

Study or Subgroup

Events

Total

CBT

Wait list / no treatment
Events

Total

Weight

Odds Ratio
IV, Random, 95% CI

Odds Ratio
IV, Random, 95% CI

1.11.1 ≤ 12 years
Cartwright Hatton 2011
Chiu 2013
Hirshfeld Becker 2010
Kennedy 2009
Lau 2017
Rapee 2005
Rapee 2006
Shortt 2001
Thirlwall 2013
Thirlwall 2013
Waters 2009
Waters 2009
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.59; Chi² = 28.19, df = 11 (P = 0.003); I² = 61%
Test for overall effect: Z = 4.17 (P < 0.0001)

37
22
34
35
39
60
90
54
61
64
31
38
565

2
3
7
8
0
19
17
2
6
7
0
1

12
21
17
15
13
30
44
33
7
17
14
15

238

72

1.11.2 Mixed age range (< 12 years and ≥ 12 years)
Arendt 2016
Barrett 1996
Barrett 1996
Barrett 1998
Barrett 1998
Chalfant 2007
Cobham 2017
Dadds 1997
Ishikawa 2019
McConachie 2014
Melfsen 2011
Perrin 2019
Sanchez Garcia 2009
Simon 2011
Simon 2011
Spence 2000
Spence 2000
Spence 2006
Villabo 2018
Villabo 2018
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 1.17; Chi² = 47.24, df = 19 (P = 0.0003); I² = 60%
Test for overall effect: Z = 4.87 (P < 0.00001)

56
31
27
17
23
32
33
23
26
17
21
20
28
18
27
19
17
22
55
55
567

27
16
21
12
13
20
12
19
4
0
6
16
17
13
20
11
14
11
31
21

5
5
5
4
5
0
2
24
2
1
2
0
0
13
14
1
1
2
2
1

304

89

1.11.3 ≥ 12 years
Olivares 2005
Rosa Alcazar 2009
Spence 2011
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 2.94; Chi² = 6.12, df = 2 (P = 0.05); I² = 67%
Test for overall effect: Z = 1.76 (P = 0.08)

17
20
44
81

0
0
4

8
9
9

26

4

33
18
30
36
33
51
87
17
34
35
5
6
385

53
13
14
10
10
19
30
33
25
15
23
20
25
15
15
7
8
23
28
27
413

7.6%
4.6%
10.5%
10.9%
3.5%
12.7%
13.3%
7.6%
9.9%
11.1%
3.3%
5.0%
100.0%

7.2%
6.5%
6.2%
5.6%
6.0%
3.1%
5.7%
6.5%
5.2%
2.7%
5.4%
3.0%
3.1%
5.2%
4.3%
4.1%
3.9%
5.5%
5.9%
4.6%
100.0%

7.44 [1.52 , 36.37]
105.00 [9.93 , 1110.02]
3.29 [1.12 , 9.68]
2.63 [0.94 , 7.37]
34.13 [1.94 , 600.96]
1.68 [0.79 , 3.60]
3.94 [2.01 , 7.71]
11.79 [2.44 , 56.85]
0.60 [0.19 , 1.97]
1.45 [0.53 , 3.92]
9.11 [0.46 , 179.00]
3.26 [0.35 , 30.73]
3.59 [1.97 , 6.56]

8.94 [3.10 , 25.79]
1.71 [0.46 , 6.39]
6.30 [1.52 , 26.08]
3.60 [0.70 , 18.56]
1.30 [0.29 , 5.76]
63.96 [3.54 , 1155.34]
8.00 [1.61 , 39.64]
1.78 [0.47 , 6.69]
2.09 [0.35 , 12.59]
0.28 [0.01 , 7.31]
4.20 [0.74 , 23.74]
150.33 [7.54 , 2997.83]
77.61 [4.29 , 1404.91]
0.40 [0.07 , 2.45]
0.20 [0.02 , 1.85]
8.25 [0.82 , 82.67]
32.67 [2.85 , 374.13]
10.50 [1.97 , 56.00]
16.79 [3.62 , 77.84]
16.06 [2.03 , 127.27]
4.87 [2.58 , 9.21]

17
20
27
64

28.1%
28.3%
43.5%
100.0%

31.32 [1.62 , 604.04]
33.87 [1.80 , 636.88]
1.48 [0.41 , 5.37]
8.48 [0.79 , 91.08]

Test for subgroup differences: Chi² = 0.80, df = 2 (P = 0.67), I² = 0%

0.1
0.001
Favours Wait list / no treatment

1

10

1000

Favours CBT

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

225

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.12.   Comparison 1: CBT versus waitlist/no treatment, Outcome
12: Remission of all anxiety diagnoses post-treatment (completers)

Study or Subgroup

Events

Total

CBT

Wait list / no treatment
Events

Total

Weight

Odds Ratio
IV, Random, 95% CI

Odds Ratio
IV, Random, 95% CI

Arendt 2016
Barrett 1996
Barrett 1996
Barrett 1998
Barrett 1998
Cartwright Hatton 2011
Chalfant 2007
Chiu 2013
Cobham 2017
Dadds 1997
Hirshfeld Becker 2010
Ishikawa 2019
Kennedy 2009
Lau 2017
Melfsen 2011
Olivares 2005
Perrin 2019
Rapee 2005
Rapee 2006
Rosa Alcazar 2009
Sanchez Garcia 2009
Shortt 2001
Simon 2011
Simon 2011
Spence 2000
Spence 2000
Spence 2006
Spence 2011
Thirlwall 2013
Thirlwall 2013
Villabo 2018
Villabo 2018
Waters 2009
Waters 2009

27
16
21
12
13
12
20
21
12
19
17
4
15
13
6
8
16
30
44
9
17
33
20
13
11
14
11
9
17
7
31
21
14
15

56
28
25
15
19
37
28
21
31
22
29
25
32
38
15
17
18
60
72
20
28
48
25
16
19
16
20
40
50
46
55
55
23
25

3
3
3
2
3
2
0
3
1
23
5
1
2
0
0
0
0
19
5
0
0
1
11
11
1
0
2
1
4
3
2
1
0
1

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.85; Chi² = 68.75, df = 33 (P = 0.0003); I² = 52%
Test for overall effect: Z = 9.49 (P < 0.00001)
Test for subgroup differences: Not applicable

1074

568

113

51
11
12
8
8
33
19
18
29
33
28
24
30
33
21
17
20
51
75
20
25
16
13
12
7
7
23
24
32
31
28
27
5
6

4.3%
3.7%
3.4%
2.8%
3.4%
3.6%
1.8%
1.7%
2.7%
4.0%
4.4%
2.5%
3.6%
1.8%
1.7%
1.7%
1.6%
5.5%
4.9%
1.8%
1.8%
2.7%
3.2%
2.3%
2.4%
1.6%
3.4%
2.7%
4.5%
3.9%
3.7%
2.8%
1.7%
2.5%

14.90 [4.15 , 53.51]
3.56 [0.77 , 16.31]
15.75 [2.91 , 85.22]
12.00 [1.56 , 92.29]
3.61 [0.64 , 20.32]
7.44 [1.52 , 36.37]
94.06 [5.08 , 1741.83]
190.43 [9.16 , 3958.33]
17.68 [2.12 , 147.56]
2.75 [0.66 , 11.46]
6.52 [1.93 , 22.01]
4.38 [0.45 , 42.39]
12.35 [2.51 , 60.80]
35.47 [2.01 , 625.15]
29.42 [1.50 , 576.96]
31.32 [1.62 , 604.04]
270.60 [12.13 , 6035.59]
1.68 [0.79 , 3.60]
22.00 [7.90 , 61.23]
33.87 [1.80 , 636.88]
77.61 [4.29 , 1404.91]
33.00 [3.98 , 273.35]
0.73 [0.12 , 4.39]
0.39 [0.04 , 4.35]
8.25 [0.82 , 82.67]
87.00 [3.68 , 2054.22]
12.83 [2.35 , 70.04]
6.68 [0.79 , 56.48]
3.61 [1.09 , 11.97]
1.68 [0.40 , 7.05]
16.79 [3.62 , 77.84]
16.06 [2.03 , 127.27]
16.79 [0.83 , 340.08]
7.50 [0.76 , 74.16]

797

100.0%

9.13 [5.78 , 14.41]

0.1
0.001
Favours Wait list / no treatment

1

10

1000

Favours CBT

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

226

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.13.   Comparison 1: CBT versus waitlist/no treatment, Outcome
13: Reduction in anxiety symptoms (child report) post-treatment

Study or Subgroup

Mean

CBT
SD

Total

Mean

Wait list / no treatment
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.13.1 Child focused
Afshari 2014
Afshari 2014
Barrett 1996
Berge 2017
Cheung 2016
Chiu 2013
Dadds 1997
Flannery Schroeder 2000
Flannery Schroeder 2000
Gallagher 2004
Kendall 1994
Kendall 1997
Lau 2010
Leutgeb 2012
Masia Warner 2005
McNally Keehn 2013
Olivares 2005
Olivares 2014
Olivares 2014
Ollendick 2009
Ollendick 2009
Ost 2001
Perrin 2019
Rosa Alcazar 2009
Sanchez Garcia 2009
Simon 2011
Spence 2000
Villabo 2018
Villabo 2018
Subtotal (95% CI)
Heterogeneity: Tau² = 0.89; Chi² = 231.01, df = 28 (P < 0.00001); I² = 88%
Test for overall effect: Z = 5.48 (P < 0.00001)

4.6
7.8
6.8
5.1
19.39
17.91
7.36
11.24
5.71
5.8
10.9
11.89
9.26
6.7
6.3
20.79
28.7
7.53
8.13
11.34
9.57
6
12.5
23.38
7.77
23.86
4.68
12.236727503707838
10.975973760901576

31.5
36.7
9
18.6
54.82
47.83
11.44
38.4
43.8
9.75
41.43
43.05
24.86
32.1
16.3
26.75
64.29
41.63
44.54
44.43
48.78
7
15.2
67.99
15.45
26.59
10.31
48.8
48.61

1.13.2 Child and parent
Arendt 2016
Barrett 1996
Chalfant 2007
Hancock 2018
Hancock 2018
Holmes 2014
Ishikawa 2019
Kidd 2018
McConachie 2014
Melfsen 2011
Ost 2001
Rapee 2006
Santucci 2013
Schneider 2011
Shortt 2001
Silverman 1999b
Spence 2000
Spence 2006
Spence 2011
Wergeland 2014
Wergeland 2014
Wood 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.18; Chi² = 67.99, df = 21 (P < 0.00001); I² = 69%
Test for overall effect: Z = 3.99 (P < 0.0001)

14.42
4.6
10.96
13.33
11.56
20.25
17.75
19
18.1
9.13
4.5
16.7
16.67
0.2
0.97
6.19
5.78
11.72
16.649456447584107
13.37
16.27
14.76

21.57
6.6
13.79
54.56
49.46
34.88
28.28
27.2
31.47
12.3
5.65
25.6
29.67
0.23
8.62
8.87
10.06
22.25
31.54
27.49
26.12
49.93

1.13.3 Parent only
Cobham 2017
Salari 2018
Simon 2011
Smith 2014
Thirlwall 2013
Thirlwall 2013
Subtotal (95% CI)
Heterogeneity: Tau² = 0.18; Chi² = 15.59, df = 5 (P = 0.008); I² = 68%
Test for overall effect: Z = 0.19 (P = 0.85)

13.9
4.4
17.68
20.48
20
12.6

34.4
16.3
29.08
52.21
28.47
30

51.8
51.8
11.6
38.7
51.65
52.5
12.65
53.83
53.83
14.73
51.94
49.67
41.12
35
21.5
36.11
126
68.29
68.29
41.86
46.3
6.74
46.3
125.93
30.8
31.59
13.36
51.95
51.95

32.55
11.6
41.37
61.23
61.23
40.84
35.95
29.85
32.33
18.41
6.74
25.5
34.41
0.29
9.82
12.79
13.36
25.83
26.52
29.61
29.61
46.5

42.1
11.23
31.59
51.11
29.4
29.4

10
10
28
29
18
22
23
12
13
12
27
60
21
16
18
12
17
38
37
44
41
21
20
20
28
17
19
55
55
743

56
25
28
68
63
17
25
25
17
21
20
90
14
13
53
25
17
20
44
56
57
14
768

31
20
25
14
47
40
177

13.8
13.8
6
9.3
27.99
15.29
7.71
16.52
16.52
7.66
13.5
10.16
11.77
8.2
10.6
16.46
18.3
5.36
5.36
12.89
8.9
4.4
15.9
17.05
5.75
16.67
8.69
11.865917579353056
11.865917579353056

15.64
6
9.09
11.67
11.67
19.93
19.44894855769845
3.24
27.05
8.53
4.4
15.9
13.15
0.22
2
7.53
8.69
14.02
16.523764704207082
16.23
16.23
15.83

11.5
4.9
16.67
23.63
16.28
16.28

5
5
12
27
18
18
33
6
6
11
20
34
17
14
17
10
17
18
17
21
20
10
20
20
25
13
7
27
28
496

53
11
19
31
31
19
24
19
15
23
9
87
14
21
12
16
7
23
27
17
17
22
517

29
22
14
8
28
29
130

1.1%
1.2%
1.8%
1.7%
1.8%
1.8%
1.9%
1.4%
1.4%
1.6%
1.8%
2.0%
1.7%
1.7%
1.8%
1.6%
1.5%
1.5%
1.6%
1.9%
1.9%
1.7%
1.7%
1.6%
1.8%
1.7%
1.6%
2.0%
2.0%
48.8%

2.0%
1.7%
1.6%
2.0%
2.0%
1.8%
1.9%
1.8%
1.8%
1.8%
1.7%
2.1%
1.7%
1.8%
1.8%
1.8%
1.6%
1.8%
2.0%
1.9%
1.9%
1.8%
40.2%

1.9%
1.8%
1.8%
1.6%
2.0%
2.0%
11.0%

-2.23 [-3.65 , -0.81]
-1.42 [-2.64 , -0.19]
-0.39 [-1.07 , 0.29]
-2.67 [-3.40 , -1.94]
0.13 [-0.53 , 0.78]
-0.27 [-0.90 , 0.35]
-0.16 [-0.69 , 0.38]
-1.12 [-2.18 , -0.06]
-0.94 [-1.97 , 0.08]
-0.71 [-1.56 , 0.14]
-0.86 [-1.46 , -0.25]
-0.58 [-1.01 , -0.15]
-1.52 [-2.26 , -0.79]
-0.38 [-1.10 , 0.35]
-0.59 [-1.27 , 0.09]
-0.47 [-1.33 , 0.38]
-2.50 [-3.43 , -1.58]
-3.80 [-4.72 , -2.88]
-3.17 [-4.01 , -2.32]
0.21 [-0.31 , 0.74]
0.26 [-0.28 , 0.80]
0.05 [-0.71 , 0.80]
-2.13 [-2.92 , -1.34]
-2.78 [-3.67 , -1.88]
-2.19 [-2.89 , -1.50]
-0.23 [-0.96 , 0.49]
-0.50 [-1.38 , 0.38]
-0.26 [-0.72 , 0.20]
-0.29 [-0.75 , 0.16]
-1.04 [-1.41 , -0.67]

-0.73 [-1.11 , -0.34]
-0.97 [-1.72 , -0.22]
-2.64 [-3.45 , -1.84]
-0.52 [-0.95 , -0.08]
-1.01 [-1.46 , -0.55]
-0.29 [-0.95 , 0.37]
-0.41 [-0.97 , 0.16]
-0.18 [-0.78 , 0.42]
-0.04 [-0.73 , 0.66]
-0.68 [-1.29 , -0.07]
-0.24 [-1.03 , 0.55]
0.01 [-0.29 , 0.30]
-0.31 [-1.05 , 0.44]
-0.28 [-0.97 , 0.42]
-0.98 [-1.63 , -0.33]
-0.57 [-1.21 , 0.07]
-0.48 [-1.37 , 0.42]
-0.27 [-0.87 , 0.33]
0.30 [-0.18 , 0.78]
-0.15 [-0.69 , 0.39]
-0.21 [-0.76 , 0.33]
0.22 [-0.45 , 0.89]
-0.45 [-0.67 , -0.23]

-0.59 [-1.11 , -0.08]
1.07 [0.41 , 1.72]
-0.14 [-0.80 , 0.51]
0.05 [-0.82 , 0.92]
-0.05 [-0.52 , 0.42]
0.04 [-0.44 , 0.52]
0.04 [-0.38 , 0.46]

Total (95% CI)
Heterogeneity: Tau² = 0.52; Chi² = 352.54, df = 56 (P < 0.00001); I² = 84%
Test for overall effect: Z = 6.36 (P < 0.00001)
Test for subgroup differences: Chi² = 14.67, df = 2 (P = 0.0007), I² = 86.4%

1688

1143

100.0%

-0.67 [-0.88 , -0.47]

-4

-2
Favours CBT

0

2

4
Favours Wait list / no treatment

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

227

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.14.   Comparison 1: CBT versus waitlist/no treatment, Outcome 14: Sensitivity
analysis: reduction in anxiety symptoms (child report) post-treatment (broad anxiety measures)

Study or Subgroup

Mean

CBT
SD

Total

Mean

Wait list / no treatment
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Afshari 2014
Afshari 2014
Arendt 2016
Barrett 1996
Barrett 1996
Chalfant 2007
Cheung 2016
Chiu 2013
Cobham 2017
Dadds 1997
Flannery Schroeder 2000
Flannery Schroeder 2000
Gallagher 2004
Hancock 2018
Hancock 2018
Holmes 2014
Ishikawa 2019
Kendall 1994
Kendall 1997
Kidd 2018
Lau 2010
Leutgeb 2012
McConachie 2014
McNally Keehn 2013
Ollendick 2009
Ollendick 2009
Ost 2001
Ost 2001
Perrin 2019
Rapee 2006
Salari 2018
Santucci 2013
Schneider 2011
Shortt 2001
Silverman 1999b
Simon 2011
Simon 2011
Smith 2014
Spence 2000
Spence 2000
Spence 2006
Spence 2011
Thirlwall 2013
Thirlwall 2013
Villabo 2018
Villabo 2018
Wergeland 2014
Wergeland 2014
Wood 2009

36.7
31.5
21.57
9
6.6
13.79
54.82
47.83
34.4
11.44
43.8
38.4
9.75
49.46
54.56
34.88
28.28
41.43
43.05
27.2
24.86
32.1
31.47
26.75
44.43
48.78
5.65
7
15.2
25.6
16.3
29.67
0.23
8.62
8.87
26.59
29.08
52.21
10.31
10.06
22.25
31.54
28.47
30
48.8
48.61
27.49
26.12
49.93

7.8
4.6
14.42
6.8
4.6
10.96
19.39
17.91
13.9
7.36
5.71
11.24
5.8
11.56
13.33
20.25
17.75
10.9
11.89
19
9.26
6.7
18.1
20.79
11.34
9.57
4.5
6
12.5
16.7
4.4
16.67
0.2
0.97
6.19
23.86
17.68
20.48
4.68
5.78
11.72
16.649456447584107
20
12.6
12.236727503707838
10.975973760901576
13.37
16.27
14.76

10
10
56
28
25
28
18
22
31
23
13
12
12
63
68
17
25
27
60
25
21
16
17
12
44
41
20
21
20
90
20
14
13
53
25
17
25
14
19
17
20
44
47
40
55
55
56
57
14

51.8
51.8
32.55
11.6
11.6
41.37
51.65
52.5
42.1
12.65
53.83
53.83
14.73
61.23
61.23
40.84
35.95
51.94
49.67
29.85
41.12
35
32.33
36.11
41.86
46.3
6.74
6.74
46.3
25.5
11.23
34.41
0.29
9.82
12.79
31.59
31.59
51.11
13.36
13.36
25.83
26.52
29.4
29.4
51.95
51.95
29.61
29.61
46.5

13.8
13.8
15.64
6
6
9.09
27.99
15.29
11.5
7.71
16.52
16.52
7.66
11.67
11.67
19.93
19.44894855769845
13.5
10.16
3.24
11.77
8.2
27.05
16.46
12.89
8.9
4.4
4.4
15.9
15.9
4.9
13.15
0.22
2
7.53
16.67
16.67
23.63
8.69
8.69
14.02
16.523764704207082
16.28
16.28
11.865917579353056
11.865917579353056
16.23
16.23
15.83

5
5
53
12
11
19
18
18
29
33
6
6
11
31
31
19
24
20
34
19
17
14
15
10
21
20
9
10
20
87
22
14
21
12
16
13
14
8
7
7
23
27
28
29
27
28
17
17
22

1.1%
0.9%
2.7%
2.0%
1.9%
1.7%
2.1%
2.1%
2.4%
2.3%
1.4%
1.3%
1.7%
2.5%
2.6%
2.0%
2.3%
2.2%
2.6%
2.2%
1.9%
1.9%
2.0%
1.6%
2.4%
2.3%
1.8%
1.8%
1.8%
2.9%
2.1%
1.9%
2.0%
2.1%
2.1%
1.9%
2.1%
1.6%
1.6%
1.6%
2.2%
2.5%
2.5%
2.5%
2.5%
2.5%
2.3%
2.3%
2.0%

-1.42 [-2.64 , -0.19]
-2.23 [-3.65 , -0.81]
-0.73 [-1.11 , -0.34]
-0.39 [-1.07 , 0.29]
-0.97 [-1.72 , -0.22]
-2.64 [-3.45 , -1.84]
0.13 [-0.53 , 0.78]
-0.27 [-0.90 , 0.35]
-0.59 [-1.11 , -0.08]
-0.16 [-0.69 , 0.38]
-0.94 [-1.97 , 0.08]
-1.12 [-2.18 , -0.06]
-0.71 [-1.56 , 0.14]
-1.01 [-1.46 , -0.55]
-0.52 [-0.95 , -0.08]
-0.29 [-0.95 , 0.37]
-0.41 [-0.97 , 0.16]
-0.86 [-1.46 , -0.25]
-0.58 [-1.01 , -0.15]
-0.18 [-0.78 , 0.42]
-1.52 [-2.26 , -0.79]
-0.38 [-1.10 , 0.35]
-0.04 [-0.73 , 0.66]
-0.47 [-1.33 , 0.38]
0.21 [-0.31 , 0.74]
0.26 [-0.28 , 0.80]
-0.24 [-1.03 , 0.55]
0.05 [-0.71 , 0.80]
-2.13 [-2.92 , -1.34]
0.01 [-0.29 , 0.30]
1.07 [0.41 , 1.72]
-0.31 [-1.05 , 0.44]
-0.28 [-0.97 , 0.42]
-0.98 [-1.63 , -0.33]
-0.57 [-1.21 , 0.07]
-0.23 [-0.96 , 0.49]
-0.14 [-0.80 , 0.51]
0.05 [-0.82 , 0.92]
-0.50 [-1.38 , 0.38]
-0.48 [-1.37 , 0.42]
-0.27 [-0.87 , 0.33]
0.30 [-0.18 , 0.78]
-0.05 [-0.52 , 0.42]
0.04 [-0.44 , 0.52]
-0.26 [-0.72 , 0.20]
-0.29 [-0.75 , 0.16]
-0.15 [-0.69 , 0.39]
-0.21 [-0.76 , 0.33]
0.22 [-0.45 , 0.89]

Total (95% CI)
Heterogeneity: Tau² = 0.20; Chi² = 152.18, df = 48 (P < 0.00001); I² = 68%
Test for overall effect: Z = 5.13 (P < 0.00001)
Test for subgroup differences: Not applicable

1480

979

100.0%

-0.41 [-0.57 , -0.25]

-4

-2
Favours CBT

0

2

4
Favours Wait list / no treatment

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

228

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.15.   Comparison 1: CBT versus waitlist/no treatment, Outcome 15: Subgroup
analysis: reduction in anxiety symptoms (child report) post-treatment (individual vs group)

Study or Subgroup

Mean

CBT
SD

Total

Mean

Wait list / no treatment
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.15.1 Individual focused
Barrett 1996
Barrett 1996
Berge 2017
Cheung 2016
Chiu 2013
Flannery Schroeder 2000
Ishikawa 2019
Kendall 1994
Kendall 1997
Leutgeb 2012
McNally Keehn 2013
Melfsen 2011
Ollendick 2009
Ollendick 2009
Ost 2001
Ost 2001
Perrin 2019
Schneider 2011
Smith 2014
Spence 2011
Thirlwall 2013
Thirlwall 2013
Villabo 2018
Wergeland 2014
Wood 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.28; Chi² = 94.40, df = 24 (P < 0.00001); I² = 75%
Test for overall effect: Z = 3.13 (P = 0.002)

6.8
4.6
5.1
19.39
17.91
5.71
17.75
10.9
11.89
6.7
20.79
9.13
11.34
9.57
4.5
6
12.5
0.2
20.48
16.649456447584107
20
12.6
10.975973760901576
16.27
14.76

9
6.6
18.6
54.82
47.83
43.8
28.28
41.43
43.05
32.1
26.75
12.3
44.43
48.78
5.65
7
15.2
0.23
52.21
31.54
28.47
30
48.61
26.12
49.93

1.15.2 Group focused
Afshari 2014
Afshari 2014
Arendt 2016
Chalfant 2007
Cobham 2017
Dadds 1997
Flannery Schroeder 2000
Gallagher 2004
Hancock 2018
Hancock 2018
Holmes 2014
Kidd 2018
Lau 2010
Masia Warner 2005
McConachie 2014
Olivares 2005
Olivares 2014
Olivares 2014
Rapee 2006
Rosa Alcazar 2009
Salari 2018
Sanchez Garcia 2009
Santucci 2013
Shortt 2001
Silverman 1999b
Simon 2011
Simon 2011
Spence 2000
Spence 2000
Spence 2006
Villabo 2018
Wergeland 2014
Subtotal (95% CI)
Heterogeneity: Tau² = 0.68; Chi² = 243.09, df = 31 (P < 0.00001); I² = 87%
Test for overall effect: Z = 5.68 (P < 0.00001)

4.6
7.8
14.42
10.96
13.9
7.36
11.24
5.8
11.56
13.33
20.25
19
9.26
6.3
18.1
28.7
7.53
8.13
16.7
23.38
4.4
7.77
16.67
0.97
6.19
23.86
17.68
5.78
4.68
11.72
12.236727503707838
13.37

31.5
36.7
21.57
13.79
34.4
11.44
38.4
9.75
49.46
54.56
34.88
27.2
24.86
16.3
31.47
64.29
41.63
44.54
25.6
67.99
16.3
15.45
29.67
8.62
8.87
26.59
29.08
10.06
10.31
22.25
48.8
27.49

11.6
11.6
38.7
51.65
52.5
53.83
35.95
51.94
49.67
35
36.11
18.41
41.86
46.3
6.74
6.74
46.3
0.29
51.11
26.52
29.4
29.4
51.95
29.61
46.5

51.8
51.8
32.55
41.37
42.1
12.65
53.83
14.73
61.23
61.23
40.84
29.85
41.12
21.5
32.33
126
68.29
68.29
25.5
125.93
11.23
30.8
34.41
9.82
12.79
31.59
31.59
13.36
13.36
25.83
51.95
29.61

28
25
29
18
22
13
25
27
60
16
12
21
44
41
20
21
20
13
14
44
47
40
55
57
14
726

10
10
56
28
31
23
12
12
63
68
17
25
21
18
17
17
38
37
90
20
20
28
14
53
25
17
25
17
19
20
55
56
962

6
6
9.3
27.99
15.29
16.52
19.44894855769845
13.5
10.16
8.2
16.46
8.53
12.89
8.9
4.4
4.4
15.9
0.22
23.63
16.523764704207082
16.28
16.28
11.865917579353056
16.23
15.83

13.8
13.8
15.64
9.09
11.5
7.71
16.52
7.66
11.67
11.67
19.93
3.24
11.77
10.6
27.05
18.3
5.36
5.36
15.9
17.05
4.9
5.75
13.15
2
7.53
16.67
16.67
8.69
8.69
14.02
11.865917579353056
16.23

12
11
27
18
18
6
24
20
34
14
10
23
21
20
9
10
20
21
8
27
28
29
28
17
22
477

5
5
53
19
29
33
6
11
31
31
19
19
17
17
15
17
18
17
87
20
22
25
14
12
16
13
14
7
7
23
27
17
666

3.9%
3.7%
3.7%
4.0%
4.1%
2.8%
4.3%
4.2%
4.8%
3.7%
3.3%
4.1%
4.4%
4.4%
3.5%
3.7%
3.5%
3.8%
3.3%
4.6%
4.6%
4.6%
4.7%
4.4%
3.9%
100.0%

2.1%
2.4%
3.6%
3.0%
3.4%
3.4%
2.6%
3.0%
3.5%
3.5%
3.2%
3.3%
3.1%
3.2%
3.2%
2.8%
2.8%
3.0%
3.6%
2.9%
3.2%
3.2%
3.1%
3.2%
3.3%
3.1%
3.2%
2.9%
2.9%
3.3%
3.5%
3.4%
100.0%

-0.39 [-1.07 , 0.29]
-0.97 [-1.72 , -0.22]
-2.67 [-3.40 , -1.94]
0.13 [-0.53 , 0.78]
-0.27 [-0.90 , 0.35]
-0.94 [-1.97 , 0.08]
-0.41 [-0.97 , 0.16]
-0.86 [-1.46 , -0.25]
-0.58 [-1.01 , -0.15]
-0.38 [-1.10 , 0.35]
-0.47 [-1.33 , 0.38]
-0.68 [-1.29 , -0.07]
0.21 [-0.31 , 0.74]
0.26 [-0.28 , 0.80]
-0.24 [-1.03 , 0.55]
0.05 [-0.71 , 0.80]
-2.13 [-2.92 , -1.34]
-0.28 [-0.97 , 0.42]
0.05 [-0.82 , 0.92]
0.30 [-0.18 , 0.78]
-0.05 [-0.52 , 0.42]
0.04 [-0.44 , 0.52]
-0.29 [-0.75 , 0.16]
-0.21 [-0.76 , 0.33]
0.22 [-0.45 , 0.89]
-0.39 [-0.64 , -0.15]

-2.23 [-3.65 , -0.81]
-1.42 [-2.64 , -0.19]
-0.73 [-1.11 , -0.34]
-2.64 [-3.45 , -1.84]
-0.59 [-1.11 , -0.08]
-0.16 [-0.69 , 0.38]
-1.12 [-2.18 , -0.06]
-0.71 [-1.56 , 0.14]
-1.01 [-1.46 , -0.55]
-0.52 [-0.95 , -0.08]
-0.29 [-0.95 , 0.37]
-0.18 [-0.78 , 0.42]
-1.52 [-2.26 , -0.79]
-0.59 [-1.27 , 0.09]
-0.04 [-0.73 , 0.66]
-2.50 [-3.43 , -1.58]
-3.80 [-4.72 , -2.88]
-3.17 [-4.01 , -2.32]
0.01 [-0.29 , 0.30]
-2.78 [-3.67 , -1.88]
1.07 [0.41 , 1.72]
-2.19 [-2.89 , -1.50]
-0.31 [-1.05 , 0.44]
-0.98 [-1.63 , -0.33]
-0.57 [-1.21 , 0.07]
-0.23 [-0.96 , 0.49]
-0.14 [-0.80 , 0.51]
-0.48 [-1.37 , 0.42]
-0.50 [-1.38 , 0.38]
-0.27 [-0.87 , 0.33]
-0.26 [-0.72 , 0.20]
-0.15 [-0.69 , 0.39]
-0.91 [-1.22 , -0.60]

Test for subgroup differences: Chi² = 6.47, df = 1 (P = 0.01), I² = 84.5%

-4

-2
Favours CBT

0

2

4
Favours Wait list / no treatment

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

229

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.16.   Comparison 1: CBT versus waitlist/no treatment, Outcome 16: Subgroup analysis:
reduction in anxiety symptoms (child report) post-treatment (amount of therapist contact time)

Study or Subgroup

Mean

CBT
SD

Total

Mean

Wait list / no treatment
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.16.1 Therapist contact (< 10 hours)
Berge 2017
Cobham 2017
Gallagher 2004
Ishikawa 2019
Leutgeb 2012
Ollendick 2009
Ollendick 2009
Ost 2001
Ost 2001
Simon 2011
Thirlwall 2013
Thirlwall 2013
Subtotal (95% CI)
Heterogeneity: Tau² = 0.37; Chi² = 54.38, df = 11 (P < 0.00001); I² = 80%
Test for overall effect: Z = 1.81 (P = 0.07)

5.1
13.9
5.8
17.75
6.7
11.34
9.57
6
4.5
17.68
12.6
20

18.6
34.4
9.75
28.28
32.1
44.43
48.78
7
5.65
29.08
30
28.47

29
31
12
25
16
44
41
21
20
25
40
47
351

1.16.2 Therapist contact (≥ 10 and < 20 hours)
Afshari 2014
Afshari 2014
Barrett 1996
Barrett 1996
Cheung 2016
Chiu 2013
Dadds 1997
Flannery Schroeder 2000
Hancock 2018
Hancock 2018
Holmes 2014
Kendall 1994
Kendall 1997
Lau 2010
Masia Warner 2005
Olivares 2005
Olivares 2014
Olivares 2014
Perrin 2019
Rapee 2006
Rosa Alcazar 2009
Salari 2018
Sanchez Garcia 2009
Schneider 2011
Shortt 2001
Silverman 1999b
Simon 2011
Smith 2014
Spence 2000
Spence 2006
Spence 2011
Villabo 2018
Villabo 2018
Wergeland 2014
Wergeland 2014
Subtotal (95% CI)
Heterogeneity: Tau² = 0.62; Chi² = 252.59, df = 34 (P < 0.00001); I² = 87%
Test for overall effect: Z = 5.53 (P < 0.00001)

7.8
4.6
6.8
4.6
19.39
17.91
7.36
5.71
13.33
11.56
20.25
10.9
11.89
9.26
6.3
28.7
8.13
7.53
12.5
16.7
23.38
4.4
7.77
0.2
0.97
6.19
23.86
20.48
4.68
11.72
16.649456447584107
12.236727503707838
10.975973760901576
13.37
16.27

36.7
31.5
9
6.6
54.82
47.83
11.44
43.8
54.56
49.46
34.88
41.43
43.05
24.86
16.3
64.29
44.54
41.63
15.2
25.6
67.99
16.3
15.45
0.23
8.62
8.87
26.59
52.21
10.31
22.25
31.54
48.8
48.61
27.49
26.12

10
10
28
25
18
22
23
13
68
63
17
27
60
21
18
17
37
38
20
90
20
20
28
13
53
25
17
14
19
20
44
55
55
56
57
1121

1.16.3 Therapist contact (≥ 20 hours)
Arendt 2016
Chalfant 2007
Flannery Schroeder 2000
Kidd 2018
McConachie 2014
McNally Keehn 2013
Melfsen 2011
Santucci 2013
Spence 2000
Wood 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.36; Chi² = 36.89, df = 9 (P < 0.0001); I² = 76%
Test for overall effect: Z = 2.74 (P = 0.006)

14.42
10.96
11.24
19
18.1
20.79
9.13
16.67
5.78
14.76

21.57
13.79
38.4
27.2
31.47
26.75
12.3
29.67
10.06
49.93

56
28
12
25
17
12
21
14
17
14
216

38.7
42.1
14.73
35.95
35
41.86
46.3
6.74
6.74
31.59
29.4
29.4

51.8
51.8
11.6
11.6
51.65
52.5
12.65
53.83
61.23
61.23
40.84
51.94
49.67
41.12
21.5
126
68.29
68.29
46.3
25.5
125.93
11.23
30.8
0.29
9.82
12.79
31.59
51.11
13.36
25.83
26.52
51.95
51.95
29.61
29.61

32.55
41.37
53.83
29.85
32.33
36.11
18.41
34.41
13.36
46.5

9.3
11.5
7.66
19.44894855769845
8.2
12.89
8.9
4.4
4.4
16.67
16.28
16.28

13.8
13.8
6
6
27.99
15.29
7.71
16.52
11.67
11.67
19.93
13.5
10.16
11.77
10.6
18.3
5.36
5.36
15.9
15.9
17.05
4.9
5.75
0.22
2
7.53
16.67
23.63
8.69
14.02
16.523764704207082
11.865917579353056
11.865917579353056
16.23
16.23

15.64
9.09
16.52
3.24
27.05
16.46
8.53
13.15
8.69
15.83

27
29
11
24
14
21
20
10
9
14
29
28
236

5
5
12
11
18
18
33
6
31
31
19
20
34
17
17
17
17
18
20
87
20
22
25
21
12
16
13
8
7
23
27
27
28
17
17
719

53
19
6
19
15
10
23
14
7
22
188

7.8%
9.0%
7.1%
8.7%
7.8%
9.0%
8.9%
7.6%
7.4%
8.2%
9.2%
9.3%
100.0%

2.1%
1.9%
2.9%
2.8%
2.9%
3.0%
3.1%
2.4%
3.2%
3.2%
2.9%
3.0%
3.2%
2.8%
2.9%
2.5%
2.7%
2.5%
2.7%
3.3%
2.6%
2.9%
2.9%
2.9%
2.9%
2.9%
2.8%
2.6%
2.6%
3.0%
3.2%
3.2%
3.2%
3.1%
3.1%
100.0%

12.5%
9.4%
7.6%
11.0%
10.3%
9.1%
10.9%
9.9%
8.8%
10.4%
100.0%

-2.67 [-3.40 , -1.94]
-0.59 [-1.11 , -0.08]
-0.71 [-1.56 , 0.14]
-0.41 [-0.97 , 0.16]
-0.38 [-1.10 , 0.35]
0.21 [-0.31 , 0.74]
0.26 [-0.28 , 0.80]
0.05 [-0.71 , 0.80]
-0.24 [-1.03 , 0.55]
-0.14 [-0.80 , 0.51]
0.04 [-0.44 , 0.52]
-0.05 [-0.52 , 0.42]
-0.36 [-0.75 , 0.03]

-1.42 [-2.64 , -0.19]
-2.23 [-3.65 , -0.81]
-0.39 [-1.07 , 0.29]
-0.97 [-1.72 , -0.22]
0.13 [-0.53 , 0.78]
-0.27 [-0.90 , 0.35]
-0.16 [-0.69 , 0.38]
-0.94 [-1.97 , 0.08]
-0.52 [-0.95 , -0.08]
-1.01 [-1.46 , -0.55]
-0.29 [-0.95 , 0.37]
-0.86 [-1.46 , -0.25]
-0.58 [-1.01 , -0.15]
-1.52 [-2.26 , -0.79]
-0.59 [-1.27 , 0.09]
-2.50 [-3.43 , -1.58]
-3.17 [-4.01 , -2.32]
-3.80 [-4.72 , -2.88]
-2.13 [-2.92 , -1.34]
0.01 [-0.29 , 0.30]
-2.78 [-3.67 , -1.88]
1.07 [0.41 , 1.72]
-2.19 [-2.89 , -1.50]
-0.28 [-0.97 , 0.42]
-0.98 [-1.63 , -0.33]
-0.57 [-1.21 , 0.07]
-0.23 [-0.96 , 0.49]
0.05 [-0.82 , 0.92]
-0.50 [-1.38 , 0.38]
-0.27 [-0.87 , 0.33]
0.30 [-0.18 , 0.78]
-0.26 [-0.72 , 0.20]
-0.29 [-0.75 , 0.16]
-0.15 [-0.69 , 0.39]
-0.21 [-0.76 , 0.33]
-0.81 [-1.09 , -0.52]

-0.73 [-1.11 , -0.34]
-2.64 [-3.45 , -1.84]
-1.12 [-2.18 , -0.06]
-0.18 [-0.78 , 0.42]
-0.04 [-0.73 , 0.66]
-0.47 [-1.33 , 0.38]
-0.68 [-1.29 , -0.07]
-0.31 [-1.05 , 0.44]
-0.48 [-1.37 , 0.42]
0.22 [-0.45 , 0.89]
-0.62 [-1.06 , -0.18]

Test for subgroup differences: Chi² = 3.33, df = 2 (P = 0.19), I² = 39.9%

-4

-2
Favours CBT

0

2

4
Favours Wait list / no treatment

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

230

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.17.   Comparison 1: CBT versus waitlist/no treatment, Outcome 17:
Subgroup analysis: reduction in anxiety symptoms (child report) post-treatment (age)

Study or Subgroup

Mean

CBT
SD

Total

Mean

Wait list / no treatment
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.17.1 ≤ 12 years
Cheung 2016
Chiu 2013
Gallagher 2004
Holmes 2014
Lau 2010
Rapee 2006
Salari 2018
Santucci 2013
Schneider 2011
Shortt 2001
Thirlwall 2013
Thirlwall 2013
Subtotal (95% CI)
Heterogeneity: Tau² = 0.21; Chi² = 37.88, df = 11 (P < 0.0001); I² = 71%
Test for overall effect: Z = 1.44 (P = 0.15)

19.39
17.91
5.8
20.25
9.26
16.7
4.4
16.67
0.2
0.97
20
12.6

54.82
47.83
9.75
34.88
24.86
25.6
16.3
29.67
0.23
8.62
28.47
30

18
22
12
17
21
90
20
14
13
53
47
40
367

1.17.2 Mixed age range (< 12 years and ≥ 12 years)
Afshari 2014
Afshari 2014
Arendt 2016
Barrett 1996
Barrett 1996
Berge 2017
Chalfant 2007
Cobham 2017
Dadds 1997
Flannery Schroeder 2000
Flannery Schroeder 2000
Hancock 2018
Hancock 2018
Ishikawa 2019
Kendall 1994
Kendall 1997
Leutgeb 2012
McConachie 2014
McNally Keehn 2013
Melfsen 2011
Ollendick 2009
Ollendick 2009
Ost 2001
Ost 2001
Perrin 2019
Sanchez Garcia 2009
Silverman 1999b
Simon 2011
Simon 2011
Smith 2014
Spence 2000
Spence 2000
Spence 2006
Villabo 2018
Villabo 2018
Wergeland 2014
Wergeland 2014
Wood 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.31; Chi² = 152.25, df = 37 (P < 0.00001); I² = 76%
Test for overall effect: Z = 5.82 (P < 0.00001)

4.6
7.8
14.42
4.6
6.8
5.1
10.96
13.9
7.36
5.71
11.24
13.33
11.56
17.75
10.9
11.89
6.7
18.1
20.79
9.13
11.34
9.57
4.5
6
12.5
7.77
6.19
23.86
17.68
20.48
5.78
4.68
11.72
12.236727503707838
10.975973760901576
16.27
13.37
14.76

31.5
36.7
21.57
6.6
9
18.6
13.79
34.4
11.44
43.8
38.4
54.56
49.46
28.28
41.43
43.05
32.1
31.47
26.75
12.3
44.43
48.78
5.65
7
15.2
15.45
8.87
26.59
29.08
52.21
10.06
10.31
22.25
48.8
48.61
26.12
27.49
49.93

10
10
56
25
28
29
28
31
23
13
12
68
63
25
27
60
16
17
12
21
44
41
20
21
20
28
25
17
25
14
17
19
20
55
55
57
56
14
1122

51.65
52.5
14.73
40.84
41.12
25.5
11.23
34.41
0.29
9.82
29.4
29.4

51.8
51.8
32.55
11.6
11.6
38.7
41.37
42.1
12.65
53.83
53.83
61.23
61.23
35.95
51.94
49.67
35
32.33
36.11
18.41
41.86
46.3
6.74
6.74
46.3
30.8
12.79
31.59
31.59
51.11
13.36
13.36
25.83
51.95
51.95
29.61
29.61
46.5

27.99
15.29
7.66
19.93
11.77
15.9
4.9
13.15
0.22
2
16.28
16.28

13.8
13.8
15.64
6
6
9.3
9.09
11.5
7.71
16.52
16.52
11.67
11.67
19.44894855769845
13.5
10.16
8.2
27.05
16.46
8.53
12.89
8.9
4.4
4.4
15.9
5.75
7.53
16.67
16.67
23.63
8.69
8.69
14.02
11.865917579353056
11.865917579353056
16.23
16.23
15.83

1.17.3 ≥ 12 years
Kidd 2018
Masia Warner 2005
Olivares 2005
Olivares 2014
Olivares 2014
Rosa Alcazar 2009
Spence 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 2.59; Chi² = 122.15, df = 6 (P < 0.00001); I² = 95%
Test for overall effect: Z = 2.85 (P = 0.004)

19
6.3
28.7
8.13
7.53
23.38
16.649456447584107

27.2
16.3
64.29
44.54
41.63
67.99
31.54

29.85
21.5
126
68.29
68.29
125.93
26.52

3.24
10.6
18.3
5.36
5.36
17.05
16.523764704207082

25
18
17
37
38
20
44
199

18
18
11
19
17
87
22
14
21
12
28
29
296

5
5
53
11
12
27
19
29
33
6
6
31
31
24
20
34
14
15
10
23
21
20
9
10
20
25
16
13
14
8
7
7
23
27
28
17
17
22
712

19
17
17
17
18
20
27
135

8.1%
8.3%
6.5%
8.0%
7.4%
11.2%
8.1%
7.3%
7.7%
8.1%
9.7%
9.6%
100.0%

1.4%
1.6%
3.3%
2.5%
2.7%
2.5%
2.4%
3.0%
3.0%
2.0%
1.9%
3.2%
3.1%
2.9%
2.8%
3.2%
2.6%
2.6%
2.3%
2.8%
3.0%
3.0%
2.4%
2.5%
2.4%
2.6%
2.7%
2.6%
2.7%
2.3%
2.2%
2.2%
2.8%
3.1%
3.1%
3.0%
3.0%
2.7%
100.0%

14.6%
14.5%
14.0%
14.1%
14.0%
14.0%
14.8%
100.0%

0.13 [-0.53 , 0.78]
-0.27 [-0.90 , 0.35]
-0.71 [-1.56 , 0.14]
-0.29 [-0.95 , 0.37]
-1.52 [-2.26 , -0.79]
0.01 [-0.29 , 0.30]
1.07 [0.41 , 1.72]
-0.31 [-1.05 , 0.44]
-0.28 [-0.97 , 0.42]
-0.98 [-1.63 , -0.33]
-0.05 [-0.52 , 0.42]
0.04 [-0.44 , 0.52]
-0.23 [-0.54 , 0.08]

-2.23 [-3.65 , -0.81]
-1.42 [-2.64 , -0.19]
-0.73 [-1.11 , -0.34]
-0.97 [-1.72 , -0.22]
-0.39 [-1.07 , 0.29]
-2.67 [-3.40 , -1.94]
-2.64 [-3.45 , -1.84]
-0.59 [-1.11 , -0.08]
-0.16 [-0.69 , 0.38]
-0.94 [-1.97 , 0.08]
-1.12 [-2.18 , -0.06]
-0.52 [-0.95 , -0.08]
-1.01 [-1.46 , -0.55]
-0.41 [-0.97 , 0.16]
-0.86 [-1.46 , -0.25]
-0.58 [-1.01 , -0.15]
-0.38 [-1.10 , 0.35]
-0.04 [-0.73 , 0.66]
-0.47 [-1.33 , 0.38]
-0.68 [-1.29 , -0.07]
0.21 [-0.31 , 0.74]
0.26 [-0.28 , 0.80]
-0.24 [-1.03 , 0.55]
0.05 [-0.71 , 0.80]
-2.13 [-2.92 , -1.34]
-2.19 [-2.89 , -1.50]
-0.57 [-1.21 , 0.07]
-0.23 [-0.96 , 0.49]
-0.14 [-0.80 , 0.51]
0.05 [-0.82 , 0.92]
-0.48 [-1.37 , 0.42]
-0.50 [-1.38 , 0.38]
-0.27 [-0.87 , 0.33]
-0.26 [-0.72 , 0.20]
-0.29 [-0.75 , 0.16]
-0.21 [-0.76 , 0.33]
-0.15 [-0.69 , 0.39]
0.22 [-0.45 , 0.89]
-0.62 [-0.83 , -0.41]

-0.18 [-0.78 , 0.42]
-0.59 [-1.27 , 0.09]
-2.50 [-3.43 , -1.58]
-3.17 [-4.01 , -2.32]
-3.80 [-4.72 , -2.88]
-2.78 [-3.67 , -1.88]
0.30 [-0.18 , 0.78]
-1.78 [-3.01 , -0.56]

Test for subgroup differences: Chi² = 8.27, df = 2 (P = 0.02), I² = 75.8%

-4

-2
Favours CBT

0

2

4
Favours Wait list / no treatment

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

231

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.18.   Comparison 1: CBT versus waitlist/no treatment, Outcome 18: Subgroup
analysis: reduction in anxiety symptoms (child report) post-treatment (ASD vs non-ASD)

Study or Subgroup

Mean

CBT
SD

Total

Mean

Wait list / no treatment
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.18.1 Sample with ASD
Chalfant 2007
Kidd 2018
McConachie 2014
McNally Keehn 2013
Wood 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 1.00; Chi² = 34.31, df = 4 (P < 0.00001); I² = 88%
Test for overall effect: Z = 1.27 (P = 0.20)

10.96
19
18.1
20.79
14.76

13.79
27.2
31.47
26.75
49.93

41.37
29.85
32.33
36.11
46.5

28
25
17
12
14
96

9.09
3.24
27.05
16.46
15.83

19
19
15
10
22
85

19.5%
20.8%
20.2%
19.1%
20.4%
100.0%

-2.64 [-3.45 , -1.84]
-0.18 [-0.78 , 0.42]
-0.04 [-0.73 , 0.66]
-0.47 [-1.33 , 0.38]
0.22 [-0.45 , 0.89]
-0.61 [-1.54 , 0.33]

1.18.2 Not sample with ASD
Afshari 2014
Afshari 2014
Arendt 2016
Barrett 1996
Barrett 1996
Berge 2017
Cheung 2016
Chiu 2013
Cobham 2017
Dadds 1997
Flannery Schroeder 2000
Flannery Schroeder 2000
Gallagher 2004
Hancock 2018
Hancock 2018
Holmes 2014
Ishikawa 2019
Kendall 1994
Kendall 1997
Lau 2010
Leutgeb 2012
Masia Warner 2005
Melfsen 2011
Olivares 2005
Olivares 2014
Olivares 2014
Ollendick 2009
Ollendick 2009
Ost 2001
Ost 2001
Perrin 2019
Rapee 2006
Rosa Alcazar 2009
Salari 2018
Sanchez Garcia 2009
Santucci 2013
Schneider 2011
Shortt 2001
Silverman 1999b
Simon 2011
Simon 2011
Smith 2014
Spence 2000
Spence 2000
Spence 2006
Spence 2011
Thirlwall 2013
Thirlwall 2013
Villabo 2018
Villabo 2018
Wergeland 2014
Wergeland 2014
Subtotal (95% CI)
Heterogeneity: Tau² = 0.50; Chi² = 318.22, df = 51 (P < 0.00001); I² = 84%
Test for overall effect: Z = 6.22 (P < 0.00001)

7.8
4.6
14.42
6.8
4.6
5.1
19.39
17.91
13.9
7.36
11.24
5.71
5.8
13.33
11.56
20.25
17.75
10.9
11.89
9.26
6.7
6.3
9.13
28.7
8.13
7.53
11.34
9.57
6
4.5
12.5
16.7
23.38
4.4
7.77
16.67
0.2
0.97
6.19
23.86
17.68
20.48
5.78
4.68
11.72
16.649456447584107
12.6
20
12.236727503707838
10.975973760901576
16.27
13.37

36.7
31.5
21.57
9
6.6
18.6
54.82
47.83
34.4
11.44
38.4
43.8
9.75
54.56
49.46
34.88
28.28
41.43
43.05
24.86
32.1
16.3
12.3
64.29
44.54
41.63
44.43
48.78
7
5.65
15.2
25.6
67.99
16.3
15.45
29.67
0.23
8.62
8.87
26.59
29.08
52.21
10.06
10.31
22.25
31.54
30
28.47
48.8
48.61
26.12
27.49

10
10
56
28
25
29
18
22
31
23
12
13
12
68
63
17
25
27
60
21
16
18
21
17
37
38
44
41
21
20
20
90
20
20
28
14
13
53
25
17
25
14
17
19
20
44
40
47
55
55
57
56
1592

51.8
51.8
32.55
11.6
11.6
38.7
51.65
52.5
42.1
12.65
53.83
53.83
14.73
61.23
61.23
40.84
35.95
51.94
49.67
41.12
35
21.5
18.41
126
68.29
68.29
41.86
46.3
6.74
6.74
46.3
25.5
125.93
11.23
30.8
34.41
0.29
9.82
12.79
31.59
31.59
51.11
13.36
13.36
25.83
26.52
29.4
29.4
51.95
51.95
29.61
29.61

13.8
13.8
15.64
6
6
9.3
27.99
15.29
11.5
7.71
16.52
16.52
7.66
11.67
11.67
19.93
19.44894855769845
13.5
10.16
11.77
8.2
10.6
8.53
18.3
5.36
5.36
12.89
8.9
4.4
4.4
15.9
15.9
17.05
4.9
5.75
13.15
0.22
2
7.53
16.67
16.67
23.63
8.69
8.69
14.02
16.523764704207082
16.28
16.28
11.865917579353056
11.865917579353056
16.23
16.23

5
5
53
12
11
27
18
18
29
33
6
6
11
31
31
19
24
20
34
17
14
17
23
17
17
18
21
20
10
9
20
87
20
22
25
14
21
12
16
13
14
8
7
7
23
27
29
28
27
28
17
17
1058

1.3%
1.2%
2.2%
1.9%
1.9%
1.9%
2.0%
2.0%
2.1%
2.1%
1.5%
1.6%
1.7%
2.2%
2.2%
2.0%
2.1%
2.0%
2.2%
1.9%
1.9%
1.9%
2.0%
1.7%
1.8%
1.7%
2.1%
2.1%
1.9%
1.8%
1.8%
2.3%
1.7%
2.0%
1.9%
1.9%
1.9%
2.0%
2.0%
1.9%
2.0%
1.7%
1.7%
1.7%
2.0%
2.1%
2.1%
2.2%
2.2%
2.2%
2.1%
2.1%
100.0%

-1.42 [-2.64 , -0.19]
-2.23 [-3.65 , -0.81]
-0.73 [-1.11 , -0.34]
-0.39 [-1.07 , 0.29]
-0.97 [-1.72 , -0.22]
-2.67 [-3.40 , -1.94]
0.13 [-0.53 , 0.78]
-0.27 [-0.90 , 0.35]
-0.59 [-1.11 , -0.08]
-0.16 [-0.69 , 0.38]
-1.12 [-2.18 , -0.06]
-0.94 [-1.97 , 0.08]
-0.71 [-1.56 , 0.14]
-0.52 [-0.95 , -0.08]
-1.01 [-1.46 , -0.55]
-0.29 [-0.95 , 0.37]
-0.41 [-0.97 , 0.16]
-0.86 [-1.46 , -0.25]
-0.58 [-1.01 , -0.15]
-1.52 [-2.26 , -0.79]
-0.38 [-1.10 , 0.35]
-0.59 [-1.27 , 0.09]
-0.68 [-1.29 , -0.07]
-2.50 [-3.43 , -1.58]
-3.17 [-4.01 , -2.32]
-3.80 [-4.72 , -2.88]
0.21 [-0.31 , 0.74]
0.26 [-0.28 , 0.80]
0.05 [-0.71 , 0.80]
-0.24 [-1.03 , 0.55]
-2.13 [-2.92 , -1.34]
0.01 [-0.29 , 0.30]
-2.78 [-3.67 , -1.88]
1.07 [0.41 , 1.72]
-2.19 [-2.89 , -1.50]
-0.31 [-1.05 , 0.44]
-0.28 [-0.97 , 0.42]
-0.98 [-1.63 , -0.33]
-0.57 [-1.21 , 0.07]
-0.23 [-0.96 , 0.49]
-0.14 [-0.80 , 0.51]
0.05 [-0.82 , 0.92]
-0.48 [-1.37 , 0.42]
-0.50 [-1.38 , 0.38]
-0.27 [-0.87 , 0.33]
0.30 [-0.18 , 0.78]
0.04 [-0.44 , 0.52]
-0.05 [-0.52 , 0.42]
-0.26 [-0.72 , 0.20]
-0.29 [-0.75 , 0.16]
-0.21 [-0.76 , 0.33]
-0.15 [-0.69 , 0.39]
-0.68 [-0.90 , -0.47]

Test for subgroup differences: Chi² = 0.02, df = 1 (P = 0.88), I² = 0%

-4

-2
Favours CBT

0

2

4
Favours Wait list / no treatment

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

232

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.19.   Comparison 1: CBT versus waitlist/no treatment, Outcome
19: Reduction in anxiety symptoms (parent report) post-treatment

Study or Subgroup

Mean

CBT
SD

Total

Mean

Wait list / no treatment
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.19.1 Child focused
Afshari 2014
Afshari 2014
Cheung 2016
Chiu 2013
Flannery Schroeder 2000
Flannery Schroeder 2000
Kendall 1994
Kendall 1997
Lau 2010
Masia Warner 2005
McNally Keehn 2013
Olivares 2014
Olivares 2014
Perrin 2019
Rosa Alcazar 2009
Villabo 2018
Villabo 2018
Subtotal (95% CI)
Heterogeneity: Tau² = 0.37; Chi² = 67.98, df = 16 (P < 0.00001); I² = 76%
Test for overall effect: Z = 4.98 (P < 0.00001)

11.7
10.9
18.93
12.64
10.37
10.31
9.55
4.66
10.49
2.6
11.34
10.93
8.27
12.4
17.42
19.133792096706802
18.243848278255324

26.8
29.5
62.71
43.38
38.46
41.08
59
8.21
29.71
9.4
20.08
47.95
51.63
18.9
45.9
47.25
49.72

1.19.2 Child and parent
Arendt 2016
Chalfant 2007
Holmes 2014
Ishikawa 2019
Kidd 2018
Lau 2017
McConachie 2014
Rapee 2006
Santucci 2013
Schneider 2011
Silverman 1999b
Spence 2006
Spence 2011
Wergeland 2014
Wergeland 2014
White 2013
Wood 2009
Wood 2015
Subtotal (95% CI)
Heterogeneity: Tau² = 0.30; Chi² = 78.59, df = 17 (P < 0.00001); I² = 78%
Test for overall effect: Z = 4.57 (P < 0.00001)

12.59
5.11
12.7
12.85
7.7
16.74
16.23
13.6
9.56
0.19
4.61
7.91
11.873516749472332
10.76
15.01
5.67
14.72
12.71

22.25
13.96
29.94
25.42
24.64
44.74
38.35
23.7
28.93
0.23
12.96
19.53
26.78
26.32
28.76
13.6
58.48
50.21

1.19.3 Parent only
Cobham 2017
Kennedy 2009
Rapee 2005
Smith 2014
Thirlwall 2013
Thirlwall 2013
Subtotal (95% CI)
Heterogeneity: Tau² = 0.18; Chi² = 17.42, df = 5 (P = 0.004); I² = 71%
Test for overall effect: Z = 1.77 (P = 0.08)

4.9
18.39
15.09
17.14
12.93
11.52

20.1
50.6
31.24
54.32
24.16
20.45

37.9
37.9
54.59
52.37
52.58
52.58
63.55
10.91
39.29
11.5
31.7
66.37
66.37
38.2
81
50.86
50.86

37.04
44.16
31.47
27.57
29.92
63.28
42
27.7
35.39
0.46
16.94
26.04
25.22
30.53
30.53
16.4
76.57
58.44

32.3
61.04
31.81
52.98
24.15
24.15

11.5
11.5
22.7
18.01
11.07
11.07
12.61
3.99
10.07
3.1
13.36
8.74
8.74
14.9
5.98
18.169686293384366
18.169686293384366

16.95
9.04
8.79
12.835326252183863
8.98
20.85
19.53
13.8
8.21
0.21
5.31
7.69
11.79526599954405
12.36
12.36
8.87
14.65
9.01

11.9
20.79
15.08
14.08
11.36
11.36

10
10
18
22
13
12
27
60
21
18
12
37
38
20
20
55
55
448

56
28
17
25
25
39
17
90
14
14
25
20
44
57
60
15
14
19
579

31
32
59
14
38
42
216

5
5
18
18
6
6
20
34
17
17
10
18
17
20
20
28
27
286

53
19
19
24
19
33
15
87
14
19
16
23
27
16
17
15
22
14
452

29
31
42
8
23
23
156

1.6%
1.6%
2.4%
2.5%
1.7%
1.7%
2.6%
2.9%
2.4%
2.4%
2.0%
2.4%
2.4%
2.4%
2.0%
2.9%
2.9%
38.9%

3.0%
1.7%
2.5%
2.7%
2.5%
2.8%
2.4%
3.1%
2.2%
2.3%
2.5%
2.5%
2.8%
2.7%
2.7%
2.3%
2.3%
2.3%
45.2%

2.6%
2.8%
3.0%
2.0%
2.7%
2.8%
15.9%

-0.90 [-2.03 , 0.24]
-0.71 [-1.83 , 0.40]
0.38 [-0.28 , 1.04]
-0.58 [-1.21 , 0.06]
-1.27 [-2.34 , -0.21]
-1.04 [-2.09 , 0.01]
-0.41 [-0.99 , 0.18]
-0.60 [-1.03 , -0.17]
-0.91 [-1.59 , -0.24]
-0.72 [-1.41 , -0.03]
-0.91 [-1.80 , -0.02]
-1.77 [-2.43 , -1.11]
-1.73 [-2.39 , -1.06]
-1.38 [-2.08 , -0.68]
-2.64 [-3.51 , -1.77]
-0.19 [-0.65 , 0.27]
-0.06 [-0.52 , 0.40]
-0.87 [-1.21 , -0.53]

-0.99 [-1.39 , -0.59]
-4.27 [-5.34 , -3.20]
-0.14 [-0.79 , 0.52]
-0.16 [-0.73 , 0.40]
-0.63 [-1.24 , -0.01]
-0.98 [-1.47 , -0.49]
-0.20 [-0.90 , 0.50]
-0.29 [-0.59 , 0.01]
-0.70 [-1.47 , 0.06]
-1.11 [-1.86 , -0.36]
-0.80 [-1.45 , -0.14]
-0.82 [-1.45 , -0.19]
0.13 [-0.35 , 0.61]
-0.37 [-0.93 , 0.18]
-0.12 [-0.66 , 0.42]
-0.37 [-1.09 , 0.36]
-1.21 [-1.94 , -0.47]
-0.71 [-1.42 , 0.00]
-0.69 [-0.98 , -0.39]

-1.34 [-1.90 , -0.78]
-0.53 [-1.03 , -0.02]
-0.04 [-0.43 , 0.36]
0.08 [-0.79 , 0.95]
0.00 [-0.52 , 0.52]
-0.32 [-0.83 , 0.19]
-0.37 [-0.77 , 0.04]

Total (95% CI)
Heterogeneity: Tau² = 0.30; Chi² = 171.97, df = 40 (P < 0.00001); I² = 77%
Test for overall effect: Z = 7.01 (P < 0.00001)
Test for subgroup differences: Chi² = 3.43, df = 2 (P = 0.18), I² = 41.8%

1243

894

100.0%

-0.70 [-0.90 , -0.51]

-4

-2
Favours CBT

0

2

4
Favours Wait list / no treatment

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

233

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.20.   Comparison 1: CBT versus waitlist/no treatment, Outcome 20: Sensitivity analysis:
reduction in anxiety symptoms (parent report) post-treatment (broad anxiety measures only)

Study or Subgroup

Mean

CBT
SD

Total

Mean

Wait list / no treatment
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Afshari 2014
Afshari 2014
Arendt 2016
Chalfant 2007
Cheung 2016
Chiu 2013
Cobham 2017
Flannery Schroeder 2000
Flannery Schroeder 2000
Holmes 2014
Ishikawa 2019
Kendall 1994
Kendall 1997
Kennedy 2009
Kidd 2018
Lau 2010
Lau 2017
McConachie 2014
McNally Keehn 2013
Perrin 2019
Rapee 2005
Rapee 2006
Santucci 2013
Schneider 2011
Silverman 1999b
Smith 2014
Spence 2006
Spence 2011
Thirlwall 2013
Thirlwall 2013
Villabo 2018
Villabo 2018
Wergeland 2014
Wergeland 2014
White 2013
Wood 2009
Wood 2015

29.5
26.8
22.25
13.96
62.71
43.38
20.1
38.46
41.08
29.94
25.42
59
8.21
50.6
24.64
29.71
44.74
38.35
20.08
18.9
31.24
23.7
28.93
0.23
12.96
54.32
19.53
26.78
20.45
24.16
47.25
49.72
26.32
28.76
13.6
58.48
50.21

10.9
11.7
12.59
5.11
18.93
12.64
4.9
10.37
10.31
12.7
12.85
9.55
4.66
18.39
7.7
10.49
16.74
16.23
11.34
12.4
15.09
13.6
9.56
0.19
4.61
17.14
7.91
11.873516749472332
11.52
12.93
19.133792096706802
18.243848278255324
10.76
15.01
5.67
14.72
12.71

10
10
56
28
18
22
31
13
12
17
25
27
60
32
25
21
39
17
12
20
59
90
14
14
25
14
20
44
42
38
55
55
57
60
15
14
19

37.9
37.9
37.04
44.16
54.59
52.37
32.3
52.58
52.58
31.47
27.57
63.55
10.91
61.04
29.92
39.29
63.28
42
31.7
38.2
31.81
27.7
35.39
0.46
16.94
52.98
26.04
25.22
24.15
24.15
50.86
50.86
30.53
30.53
16.4
76.57
58.44

11.5
11.5
16.95
9.04
22.7
18.01
11.9
11.07
11.07
8.79
12.835326252183863
12.61
3.99
20.79
8.98
10.07
20.85
19.53
13.36
14.9
15.08
13.8
8.21
0.21
5.31
14.08
7.69
11.79526599954405
11.36
11.36
18.169686293384366
18.169686293384366
12.36
12.36
8.87
14.65
9.01

Total (95% CI)
Heterogeneity: Tau² = 0.21; Chi² = 123.51, df = 36 (P < 0.00001); I² = 71%
Test for overall effect: Z = 6.33 (P < 0.00001)
Test for subgroup differences: Not applicable

1130

5
5
53
19
18
18
29
6
6
19
24
20
34
31
19
17
33
15
10
20
42
87
14
19
16
8
23
27
23
23
28
27
16
17
15
22
14

1.6%
1.6%
3.4%
1.7%
2.7%
2.7%
3.0%
1.7%
1.7%
2.7%
3.0%
2.9%
3.3%
3.1%
2.8%
2.6%
3.2%
2.6%
2.1%
2.6%
3.4%
3.7%
2.4%
2.4%
2.7%
2.1%
2.8%
3.2%
3.1%
3.1%
3.3%
3.3%
3.0%
3.0%
2.5%
2.5%
2.5%

-0.71 [-1.83 , 0.40]
-0.90 [-2.03 , 0.24]
-0.99 [-1.39 , -0.59]
-4.27 [-5.34 , -3.20]
0.38 [-0.28 , 1.04]
-0.58 [-1.21 , 0.06]
-1.34 [-1.90 , -0.78]
-1.27 [-2.34 , -0.21]
-1.04 [-2.09 , 0.01]
-0.14 [-0.79 , 0.52]
-0.16 [-0.73 , 0.40]
-0.41 [-0.99 , 0.18]
-0.60 [-1.03 , -0.17]
-0.53 [-1.03 , -0.02]
-0.63 [-1.24 , -0.01]
-0.91 [-1.59 , -0.24]
-0.98 [-1.47 , -0.49]
-0.20 [-0.90 , 0.50]
-0.91 [-1.80 , -0.02]
-1.38 [-2.08 , -0.68]
-0.04 [-0.43 , 0.36]
-0.29 [-0.59 , 0.01]
-0.70 [-1.47 , 0.06]
-1.11 [-1.86 , -0.36]
-0.80 [-1.45 , -0.14]
0.08 [-0.79 , 0.95]
-0.82 [-1.45 , -0.19]
0.13 [-0.35 , 0.61]
-0.32 [-0.83 , 0.19]
0.00 [-0.52 , 0.52]
-0.19 [-0.65 , 0.27]
-0.06 [-0.52 , 0.40]
-0.37 [-0.93 , 0.18]
-0.12 [-0.66 , 0.42]
-0.37 [-1.09 , 0.36]
-1.21 [-1.94 , -0.47]
-0.71 [-1.42 , 0.00]

822

100.0%

-0.59 [-0.77 , -0.41]

-4

-2
Favours CBT

0

2

4
Favours Wait list / no treatment

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

234

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.21.   Comparison 1: CBT versus waitlist/no treatment, Outcome 21: Subgroup
analysis: reduction in anxiety symptoms (parent report) post-treatment (individual vs group)

Study or Subgroup

Mean

CBT
SD

Total

Mean

Wait list / no treatment
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.21.1 Individual focused
Cheung 2016
Chiu 2013
Flannery Schroeder 2000
Ishikawa 2019
Kendall 1994
Kendall 1997
McNally Keehn 2013
Perrin 2019
Schneider 2011
Smith 2014
Spence 2011
Thirlwall 2013
Thirlwall 2013
Villabo 2018
Wergeland 2014
White 2013
Wood 2009
Wood 2015
Subtotal (95% CI)
Heterogeneity: Tau² = 0.12; Chi² = 37.54, df = 17 (P = 0.003); I² = 55%
Test for overall effect: Z = 3.87 (P = 0.0001)

18.93
12.64
10.37
12.85
9.55
4.66
11.34
12.4
0.19
17.14
11.873516749472332
11.52
12.93
19.133792096706802
15.01
5.67
14.72
12.71

62.71
43.38
38.46
25.42
59
8.21
20.08
18.9
0.23
54.32
26.78
20.45
24.16
47.25
28.76
13.6
58.48
50.21

1.21.2 Group focused
Afshari 2014
Afshari 2014
Arendt 2016
Chalfant 2007
Cobham 2017
Flannery Schroeder 2000
Holmes 2014
Kennedy 2009
Kidd 2018
Lau 2010
Lau 2017
Masia Warner 2005
McConachie 2014
Olivares 2014
Olivares 2014
Rapee 2005
Rapee 2006
Rosa Alcazar 2009
Santucci 2013
Silverman 1999b
Spence 2006
Villabo 2018
Wergeland 2014
Subtotal (95% CI)
Heterogeneity: Tau² = 0.40; Chi² = 122.27, df = 22 (P < 0.00001); I² = 82%
Test for overall effect: Z = 6.10 (P < 0.00001)

10.9
11.7
12.59
5.11
4.9
10.31
12.7
18.39
7.7
10.49
16.74
2.6
16.23
8.27
10.93
15.09
13.6
17.42
9.56
4.61
7.91
18.243848278255324
10.76

29.5
26.8
22.25
13.96
20.1
41.08
29.94
50.6
24.64
29.71
44.74
9.4
38.35
51.63
47.95
31.24
23.7
45.9
28.93
12.96
19.53
49.72
26.32

54.59
52.37
52.58
27.57
63.55
10.91
31.7
38.2
0.46
52.98
25.22
24.15
24.15
50.86
30.53
16.4
76.57
58.44

37.9
37.9
37.04
44.16
32.3
52.58
31.47
61.04
29.92
39.29
63.28
11.5
42
66.37
66.37
31.81
27.7
81
35.39
16.94
26.04
50.86
30.53

22.7
18.01
11.07
12.835326252183863
12.61
3.99
13.36
14.9
0.21
14.08
11.79526599954405
11.36
11.36
18.169686293384366
12.36
8.87
14.65
9.01

11.5
11.5
16.95
9.04
11.9
11.07
8.79
20.79
8.98
10.07
20.85
3.1
19.53
8.74
8.74
15.08
13.8
5.98
8.21
5.31
7.69
18.169686293384366
12.36

18
22
13
25
27
60
12
20
14
14
44
42
38
55
60
15
14
19
512

10
10
56
28
31
12
17
32
25
21
39
18
17
38
37
59
90
20
14
25
20
55
57
731

18
18
6
24
20
34
10
20
19
8
27
23
23
28
17
15
22
14
346

5
5
53
19
29
6
19
31
19
17
33
17
15
17
18
42
87
20
14
16
23
27
16
548

5.4%
5.6%
3.0%
6.2%
6.0%
7.5%
3.8%
5.1%
4.7%
3.9%
7.0%
6.7%
6.6%
7.3%
6.4%
4.9%
4.8%
5.0%
100.0%

3.1%
3.1%
5.1%
3.2%
4.7%
3.3%
4.4%
4.9%
4.5%
4.4%
4.9%
4.3%
4.3%
4.4%
4.4%
5.1%
5.4%
3.8%
4.1%
4.4%
4.5%
5.0%
4.7%
100.0%

0.38 [-0.28 , 1.04]
-0.58 [-1.21 , 0.06]
-1.27 [-2.34 , -0.21]
-0.16 [-0.73 , 0.40]
-0.41 [-0.99 , 0.18]
-0.60 [-1.03 , -0.17]
-0.91 [-1.80 , -0.02]
-1.38 [-2.08 , -0.68]
-1.11 [-1.86 , -0.36]
0.08 [-0.79 , 0.95]
0.13 [-0.35 , 0.61]
-0.32 [-0.83 , 0.19]
0.00 [-0.52 , 0.52]
-0.19 [-0.65 , 0.27]
-0.12 [-0.66 , 0.42]
-0.37 [-1.09 , 0.36]
-1.21 [-1.94 , -0.47]
-0.71 [-1.42 , 0.00]
-0.43 [-0.65 , -0.21]

-0.71 [-1.83 , 0.40]
-0.90 [-2.03 , 0.24]
-0.99 [-1.39 , -0.59]
-4.27 [-5.34 , -3.20]
-1.34 [-1.90 , -0.78]
-1.04 [-2.09 , 0.01]
-0.14 [-0.79 , 0.52]
-0.53 [-1.03 , -0.02]
-0.63 [-1.24 , -0.01]
-0.91 [-1.59 , -0.24]
-0.98 [-1.47 , -0.49]
-0.72 [-1.41 , -0.03]
-0.20 [-0.90 , 0.50]
-1.73 [-2.39 , -1.06]
-1.77 [-2.43 , -1.11]
-0.04 [-0.43 , 0.36]
-0.29 [-0.59 , 0.01]
-2.64 [-3.51 , -1.77]
-0.70 [-1.47 , 0.06]
-0.80 [-1.45 , -0.14]
-0.82 [-1.45 , -0.19]
-0.06 [-0.52 , 0.40]
-0.37 [-0.93 , 0.18]
-0.92 [-1.21 , -0.62]

Test for subgroup differences: Chi² = 6.79, df = 1 (P = 0.009), I² = 85.3%

-4

-2
Favours CBT

0

2

4
Favours Wait list / no treatment

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

235

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.22.   Comparison 1: CBT versus waitlist/no treatment, Outcome 22: Subgroup analysis:
reduction in anxiety symptoms (parent report) post-treatment (amount of therapist contact time)

Study or Subgroup

Mean

CBT
SD

Total

Mean

Wait list / no treatment
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.22.1 Therapist contact (< 10 hours)
Cobham 2017
Ishikawa 2019
Rapee 2005
Thirlwall 2013
Thirlwall 2013
Subtotal (95% CI)
Heterogeneity: Tau² = 0.20; Chi² = 16.28, df = 4 (P = 0.003); I² = 75%
Test for overall effect: Z = 1.54 (P = 0.12)

4.9
12.85
15.09
11.52
12.93

20.1
25.42
31.24
20.45
24.16

1.22.2 Therapist contact (≥ 10 and < 20 hours)
Afshari 2014
Afshari 2014
Cheung 2016
Chiu 2013
Flannery Schroeder 2000
Holmes 2014
Kendall 1994
Kendall 1997
Kennedy 2009
Lau 2010
Lau 2017
Masia Warner 2005
Olivares 2014
Olivares 2014
Perrin 2019
Rapee 2006
Rosa Alcazar 2009
Schneider 2011
Silverman 1999b
Smith 2014
Spence 2006
Spence 2011
Villabo 2018
Villabo 2018
Wergeland 2014
Wergeland 2014
Subtotal (95% CI)
Heterogeneity: Tau² = 0.25; Chi² = 94.42, df = 25 (P < 0.00001); I² = 74%
Test for overall effect: Z = 5.67 (P < 0.00001)

11.7
10.9
18.93
12.64
10.37
12.7
9.55
4.66
18.39
10.49
16.74
2.6
10.93
8.27
12.4
13.6
17.42
0.19
4.61
17.14
7.91
11.873516749472332
19.133792096706802
18.243848278255324
15.01
10.76

26.8
29.5
62.71
43.38
38.46
29.94
59
8.21
50.6
29.71
44.74
9.4
47.95
51.63
18.9
23.7
45.9
0.23
12.96
54.32
19.53
26.78
47.25
49.72
28.76
26.32

1.22.3 Therapist contact (≥ 20 hours)
Arendt 2016
Chalfant 2007
Flannery Schroeder 2000
Kidd 2018
McConachie 2014
McNally Keehn 2013
Santucci 2013
White 2013
Wood 2009
Wood 2015
Subtotal (95% CI)
Heterogeneity: Tau² = 0.53; Chi² = 46.03, df = 9 (P < 0.00001); I² = 80%
Test for overall effect: Z = 3.97 (P < 0.0001)

12.59
5.11
10.31
7.7
16.23
11.34
9.56
5.67
14.72
12.71

22.25
13.96
41.08
24.64
38.35
20.08
28.93
13.6
58.48
50.21

31
25
59
42
38
195

10
10
18
22
13
17
27
60
32
21
39
18
37
38
20
90
20
14
25
14
20
44
55
55
60
57
836

56
28
12
25
17
12
14
15
14
19
212

32.3
27.57
31.81
24.15
24.15

11.9
12.835326252183863
15.08
11.36
11.36

29
24
42
23
23
141

18.9%
19.0%
22.2%
20.0%
19.9%
100.0%

-1.34 [-1.90 , -0.78]
-0.16 [-0.73 , 0.40]
-0.04 [-0.43 , 0.36]
-0.32 [-0.83 , 0.19]
0.00 [-0.52 , 0.52]
-0.36 [-0.81 , 0.10]

37.9
37.9
54.59
52.37
52.58
31.47
63.55
10.91
61.04
39.29
63.28
11.5
66.37
66.37
38.2
27.7
81
0.46
16.94
52.98
26.04
25.22
50.86
50.86
30.53
30.53

37.04
44.16
52.58
29.92
42
31.7
35.39
16.4
76.57
58.44

11.5
11.5
22.7
18.01
11.07
8.79
12.61
3.99
20.79
10.07
20.85
3.1
8.74
8.74
14.9
13.8
5.98
0.21
5.31
14.08
7.69
11.79526599954405
18.169686293384366
18.169686293384366
12.36
12.36

16.95
9.04
11.07
8.98
19.53
13.36
8.21
8.87
14.65
9.01

5
5
18
18
6
19
20
34
31
17
33
17
18
17
20
87
20
19
16
8
23
27
28
27
17
16
566

53
19
6
19
15
10
14
15
22
14
187

2.4%
2.4%
3.8%
3.9%
2.5%
3.8%
4.1%
4.7%
4.4%
3.8%
4.4%
3.7%
3.8%
3.8%
3.7%
5.1%
3.1%
3.5%
3.8%
3.1%
3.9%
4.5%
4.6%
4.6%
4.3%
4.2%
100.0%

12.0%
8.2%
8.3%
10.9%
10.4%
9.3%
10.0%
10.3%
10.2%
10.3%
100.0%

-0.90 [-2.03 , 0.24]
-0.71 [-1.83 , 0.40]
0.38 [-0.28 , 1.04]
-0.58 [-1.21 , 0.06]
-1.27 [-2.34 , -0.21]
-0.14 [-0.79 , 0.52]
-0.41 [-0.99 , 0.18]
-0.60 [-1.03 , -0.17]
-0.53 [-1.03 , -0.02]
-0.91 [-1.59 , -0.24]
-0.98 [-1.47 , -0.49]
-0.72 [-1.41 , -0.03]
-1.77 [-2.43 , -1.11]
-1.73 [-2.39 , -1.06]
-1.38 [-2.08 , -0.68]
-0.29 [-0.59 , 0.01]
-2.64 [-3.51 , -1.77]
-1.11 [-1.86 , -0.36]
-0.80 [-1.45 , -0.14]
0.08 [-0.79 , 0.95]
-0.82 [-1.45 , -0.19]
0.13 [-0.35 , 0.61]
-0.19 [-0.65 , 0.27]
-0.06 [-0.52 , 0.40]
-0.12 [-0.66 , 0.42]
-0.37 [-0.93 , 0.18]
-0.66 [-0.89 , -0.43]

-0.99 [-1.39 , -0.59]
-4.27 [-5.34 , -3.20]
-1.04 [-2.09 , 0.01]
-0.63 [-1.24 , -0.01]
-0.20 [-0.90 , 0.50]
-0.91 [-1.80 , -0.02]
-0.70 [-1.47 , 0.06]
-0.37 [-1.09 , 0.36]
-1.21 [-1.94 , -0.47]
-0.71 [-1.42 , 0.00]
-1.03 [-1.55 , -0.52]

Test for subgroup differences: Chi² = 3.77, df = 2 (P = 0.15), I² = 46.9%

-4

-2
Favours CBT

0

2

4
Favours Wait list / no treatment

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

236

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.23.   Comparison 1: CBT versus waitlist/no treatment, Outcome 23: Subgroup
analysis: reduction in anxiety symptoms (parent report) post-treatment (age)

Study or Subgroup

Mean

CBT
SD

Total

Mean

Wait list / no treatment
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.23.1 ≤ 12 years
Cheung 2016
Chiu 2013
Holmes 2014
Kennedy 2009
Lau 2010
Lau 2017
Rapee 2005
Rapee 2006
Santucci 2013
Schneider 2011
Thirlwall 2013
Thirlwall 2013
Subtotal (95% CI)
Heterogeneity: Tau² = 0.08; Chi² = 24.07, df = 11 (P = 0.01); I² = 54%
Test for overall effect: Z = 3.45 (P = 0.0006)

18.93
12.64
12.7
18.39
10.49
16.74
15.09
13.6
9.56
0.19
11.52
12.93

62.71
43.38
29.94
50.6
29.71
44.74
31.24
23.7
28.93
0.23
20.45
24.16

1.23.2 Mixed age range (< 12 years and ≥ 12 years)
Afshari 2014
Afshari 2014
Arendt 2016
Chalfant 2007
Cobham 2017
Flannery Schroeder 2000
Flannery Schroeder 2000
Ishikawa 2019
Kendall 1994
Kendall 1997
McConachie 2014
McNally Keehn 2013
Perrin 2019
Silverman 1999b
Smith 2014
Spence 2006
Villabo 2018
Villabo 2018
Wergeland 2014
Wergeland 2014
Wood 2009
Wood 2015
Subtotal (95% CI)
Heterogeneity: Tau² = 0.31; Chi² = 84.16, df = 21 (P < 0.00001); I² = 75%
Test for overall effect: Z = 5.40 (P < 0.00001)

10.9
11.7
12.59
5.11
4.9
10.31
10.37
12.85
9.55
4.66
16.23
11.34
12.4
4.61
17.14
7.91
19.133792096706802
18.243848278255324
10.76
15.01
14.72
12.71

29.5
26.8
22.25
13.96
20.1
41.08
38.46
25.42
59
8.21
38.35
20.08
18.9
12.96
54.32
19.53
47.25
49.72
26.32
28.76
58.48
50.21

1.23.3 ≥ 12 years
Kidd 2018
Masia Warner 2005
Olivares 2014
Olivares 2014
Rosa Alcazar 2009
Spence 2011
White 2013
Subtotal (95% CI)
Heterogeneity: Tau² = 0.78; Chi² = 48.84, df = 6 (P < 0.00001); I² = 88%
Test for overall effect: Z = 2.99 (P = 0.003)

7.7
2.6
8.27
10.93
17.42
11.873516749472332
5.67

24.64
9.4
51.63
47.95
45.9
26.78
13.6

54.59
52.37
31.47
61.04
39.29
63.28
31.81
27.7
35.39
0.46
24.15
24.15

37.9
37.9
37.04
44.16
32.3
52.58
52.58
27.57
63.55
10.91
42
31.7
38.2
16.94
52.98
26.04
50.86
50.86
30.53
30.53
76.57
58.44

29.92
11.5
66.37
66.37
81
25.22
16.4

18
22
17
32
21
39
59
90
14
14
42
38
406

10
10
56
28
31
12
13
25
27
60
17
12
20
25
14
20
55
55
57
60
14
19
640

25
18
38
37
20
44
15
197

22.7
18.01
8.79
20.79
10.07
20.85
15.08
13.8
8.21
0.21
11.36
11.36

11.5
11.5
16.95
9.04
11.9
11.07
11.07
12.835326252183863
12.61
3.99
19.53
13.36
14.9
5.31
14.08
7.69
18.169686293384366
18.169686293384366
12.36
12.36
14.65
9.01

8.98
3.1
8.74
8.74
5.98
11.79526599954405
8.87

18
18
19
31
17
33
42
87
14
19
23
23
344

5
5
53
19
29
6
6
24
20
34
15
10
20
16
8
23
28
27
16
17
22
14
417

19
17
17
18
20
27
15
133

7.0%
7.2%
7.0%
9.2%
6.8%
9.3%
11.0%
12.8%
5.8%
6.0%
9.0%
8.9%
100.0%

3.2%
3.1%
5.7%
3.3%
5.1%
3.4%
3.3%
5.1%
5.0%
5.6%
4.6%
3.9%
4.6%
4.8%
4.0%
4.9%
5.5%
5.5%
5.1%
5.2%
4.5%
4.5%
100.0%

14.6%
14.2%
14.4%
14.4%
13.1%
15.3%
14.0%
100.0%

0.38 [-0.28 , 1.04]
-0.58 [-1.21 , 0.06]
-0.14 [-0.79 , 0.52]
-0.53 [-1.03 , -0.02]
-0.91 [-1.59 , -0.24]
-0.98 [-1.47 , -0.49]
-0.04 [-0.43 , 0.36]
-0.29 [-0.59 , 0.01]
-0.70 [-1.47 , 0.06]
-1.11 [-1.86 , -0.36]
-0.32 [-0.83 , 0.19]
0.00 [-0.52 , 0.52]
-0.40 [-0.63 , -0.17]

-0.71 [-1.83 , 0.40]
-0.90 [-2.03 , 0.24]
-0.99 [-1.39 , -0.59]
-4.27 [-5.34 , -3.20]
-1.34 [-1.90 , -0.78]
-1.04 [-2.09 , 0.01]
-1.27 [-2.34 , -0.21]
-0.16 [-0.73 , 0.40]
-0.41 [-0.99 , 0.18]
-0.60 [-1.03 , -0.17]
-0.20 [-0.90 , 0.50]
-0.91 [-1.80 , -0.02]
-1.38 [-2.08 , -0.68]
-0.80 [-1.45 , -0.14]
0.08 [-0.79 , 0.95]
-0.82 [-1.45 , -0.19]
-0.19 [-0.65 , 0.27]
-0.06 [-0.52 , 0.40]
-0.37 [-0.93 , 0.18]
-0.12 [-0.66 , 0.42]
-1.21 [-1.94 , -0.47]
-0.71 [-1.42 , 0.00]
-0.76 [-1.04 , -0.49]

-0.63 [-1.24 , -0.01]
-0.72 [-1.41 , -0.03]
-1.73 [-2.39 , -1.06]
-1.77 [-2.43 , -1.11]
-2.64 [-3.51 , -1.77]
0.13 [-0.35 , 0.61]
-0.37 [-1.09 , 0.36]
-1.07 [-1.78 , -0.37]

Test for subgroup differences: Chi² = 5.87, df = 2 (P = 0.05), I² = 65.9%

-4

-2
Favours CBT

0

2

4
Favours Wait list / no treatment

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

237

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.24.   Comparison 1: CBT versus waitlist/no treatment, Outcome 24: Subgroup
analysis: reduction in anxiety symptoms (parent report) post-treatment (ASD vs non-ASD)

Study or Subgroup

Mean

CBT
SD

Total

Mean

Wait list / no treatment
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

1.24.1 Sample with ASD
Chalfant 2007
Kidd 2018
McConachie 2014
McNally Keehn 2013
White 2013
Wood 2009
Wood 2015
Subtotal (95% CI)
Heterogeneity: Tau² = 0.97; Chi² = 45.54, df = 6 (P < 0.00001); I² = 87%
Test for overall effect: Z = 2.80 (P = 0.005)

5.11
7.7
16.23
11.34
5.67
14.72
12.71

13.96
24.64
38.35
20.08
13.6
58.48
50.21

28
25
17
12
15
14
19
130

1.24.2 Not sample with ASD
Afshari 2014
Afshari 2014
Arendt 2016
Cheung 2016
Chiu 2013
Cobham 2017
Flannery Schroeder 2000
Flannery Schroeder 2000
Holmes 2014
Ishikawa 2019
Kendall 1994
Kendall 1997
Kennedy 2009
Lau 2010
Lau 2017
Masia Warner 2005
Olivares 2014
Olivares 2014
Perrin 2019
Rapee 2005
Rapee 2006
Rosa Alcazar 2009
Santucci 2013
Schneider 2011
Silverman 1999b
Smith 2014
Spence 2006
Spence 2011
Thirlwall 2013
Thirlwall 2013
Villabo 2018
Villabo 2018
Wergeland 2014
Wergeland 2014
Subtotal (95% CI)
Heterogeneity: Tau² = 0.22; Chi² = 120.89, df = 33 (P < 0.00001); I² = 73%
Test for overall effect: Z = 6.42 (P < 0.00001)

11.7
10.9
12.59
18.93
12.64
4.9
10.37
10.31
12.7
12.85
9.55
4.66
18.39
10.49
16.74
2.6
10.93
8.27
12.4
15.09
13.6
17.42
9.56
0.19
4.61
17.14
7.91
11.873516749472332
12.93
11.52
19.133792096706802
18.243848278255324
10.76
15.01

26.8
29.5
22.25
62.71
43.38
20.1
38.46
41.08
29.94
25.42
59
8.21
50.6
29.71
44.74
9.4
47.95
51.63
18.9
31.24
23.7
45.9
28.93
0.23
12.96
54.32
19.53
26.78
24.16
20.45
47.25
49.72
26.32
28.76

10
10
56
18
22
31
13
12
17
25
27
60
32
21
39
18
37
38
20
59
90
20
14
14
25
14
20
44
38
42
55
55
57
60
1113

44.16
29.92
42
31.7
16.4
76.57
58.44

37.9
37.9
37.04
54.59
52.37
32.3
52.58
52.58
31.47
27.57
63.55
10.91
61.04
39.29
63.28
11.5
66.37
66.37
38.2
31.81
27.7
81
35.39
0.46
16.94
52.98
26.04
25.22
24.15
24.15
50.86
50.86
30.53
30.53

9.04
8.98
19.53
13.36
8.87
14.65
9.01

11.5
11.5
16.95
22.7
18.01
11.9
11.07
11.07
8.79
12.835326252183863
12.61
3.99
20.79
10.07
20.85
3.1
8.74
8.74
14.9
15.08
13.8
5.98
8.21
0.21
5.31
14.08
7.69
11.79526599954405
11.36
11.36
18.169686293384366
18.169686293384366
12.36
12.36

19
19
15
10
15
22
14
114

5
5
53
18
18
29
6
6
19
24
20
34
31
17
33
17
18
17
20
42
87
20
14
19
16
8
23
27
23
23
28
27
16
17
780

12.7%
15.1%
14.7%
13.7%
14.6%
14.5%
14.6%
100.0%

1.7%
1.8%
3.7%
2.9%
2.9%
3.2%
1.9%
1.9%
2.9%
3.2%
3.1%
3.6%
3.3%
2.8%
3.4%
2.8%
2.9%
2.9%
2.8%
3.7%
3.9%
2.3%
2.6%
2.6%
2.9%
2.3%
3.0%
3.4%
3.3%
3.3%
3.5%
3.5%
3.2%
3.2%
100.0%

-4.27 [-5.34 , -3.20]
-0.63 [-1.24 , -0.01]
-0.20 [-0.90 , 0.50]
-0.91 [-1.80 , -0.02]
-0.37 [-1.09 , 0.36]
-1.21 [-1.94 , -0.47]
-0.71 [-1.42 , 0.00]
-1.12 [-1.91 , -0.34]

-0.90 [-2.03 , 0.24]
-0.71 [-1.83 , 0.40]
-0.99 [-1.39 , -0.59]
0.38 [-0.28 , 1.04]
-0.58 [-1.21 , 0.06]
-1.34 [-1.90 , -0.78]
-1.27 [-2.34 , -0.21]
-1.04 [-2.09 , 0.01]
-0.14 [-0.79 , 0.52]
-0.16 [-0.73 , 0.40]
-0.41 [-0.99 , 0.18]
-0.60 [-1.03 , -0.17]
-0.53 [-1.03 , -0.02]
-0.91 [-1.59 , -0.24]
-0.98 [-1.47 , -0.49]
-0.72 [-1.41 , -0.03]
-1.77 [-2.43 , -1.11]
-1.73 [-2.39 , -1.06]
-1.38 [-2.08 , -0.68]
-0.04 [-0.43 , 0.36]
-0.29 [-0.59 , 0.01]
-2.64 [-3.51 , -1.77]
-0.70 [-1.47 , 0.06]
-1.11 [-1.86 , -0.36]
-0.80 [-1.45 , -0.14]
0.08 [-0.79 , 0.95]
-0.82 [-1.45 , -0.19]
0.13 [-0.35 , 0.61]
0.00 [-0.52 , 0.52]
-0.32 [-0.83 , 0.19]
-0.19 [-0.65 , 0.27]
-0.06 [-0.52 , 0.40]
-0.37 [-0.93 , 0.18]
-0.12 [-0.66 , 0.42]
-0.63 [-0.82 , -0.44]

Test for subgroup differences: Chi² = 1.42, df = 1 (P = 0.23), I² = 29.8%

-4

-2
Favours CBT

0

2

4
Favours Wait list / no treatment

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

238

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.25.   Comparison 1: CBT versus waitlist/no treatment,
Outcome 25: Reduction in depressive symptoms post-treatment

Study or Subgroup

Mean

CBT
SD

Total

Mean

Wait list / no treatment
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Arendt 2016
Barrett 1996
Barrett 1996
Flannery Schroeder 2000
Flannery Schroeder 2000
Gallagher 2004
Ishikawa 2019
Kendall 1994
Kendall 1997
Kidd 2018
Masia Warner 2005
Melfsen 2011
Ollendick 2009
Ollendick 2009
Ost 2001
Ost 2001
Perrin 2019
Salari 2018
Silverman 1999b
Thirlwall 2013
Thirlwall 2013
Wergeland 2014
Wergeland 2014

2.96
4.1
4.5
4.54
4.5
7.33
14.64
5.5
4.95
8.1
8.1
9.71
3.91
4.93
5.35
6.59
6.9
13
5.83
5.57
3.94
6.12
5

3.84
4.8
3.8
5
5.21
5.79
8.75
5.82
6.04
6.3
5
9.06
4.55
3.41
5.6
5.8
9.8
4.6
5.31
5.06
5.04
5.76
4.99

56
25
28
13
12
12
25
27
60
25
18
21
44
41
20
21
20
20
25
42
48
55
55

5.19
6.8
6.8
12.75
12.75
6.91
19.05
9.28
10.56
6.48
8.9
11.22
5.75
4.9
5.42
5.42
25.4
20.54
5.2
4.84
4.84
7.36
7.36

5.32
5.3
5.3
11.44
11.44
6.98
9.112101843153429
7.88
9.73
2.66
5.6
6.8
7.68
3.93
6.2
6.2
14.4
8.9
4.97
5.38
5.38
5.72
5.72

Total (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 39.62, df = 22 (P = 0.01); I² = 44%
Test for overall effect: Z = 3.96 (P < 0.0001)
Test for subgroup differences: Not applicable

713

53
11
12
6
6
11
24
20
34
19
17
23
21
20
9
10
20
22
16
28
29
16
17

6.8%
3.6%
3.8%
2.1%
2.1%
3.0%
4.8%
4.6%
6.1%
4.5%
4.0%
4.5%
5.2%
5.1%
3.2%
3.4%
3.7%
4.1%
4.3%
5.6%
5.8%
4.9%
4.9%

-0.48 [-0.86 , -0.10]
-0.53 [-1.25 , 0.19]
-0.53 [-1.21 , 0.16]
-1.05 [-2.08 , -0.01]
-1.02 [-2.07 , 0.03]
0.06 [-0.75 , 0.88]
-0.49 [-1.05 , 0.08]
-0.55 [-1.14 , 0.04]
-0.73 [-1.17 , -0.30]
0.31 [-0.29 , 0.91]
-0.15 [-0.81 , 0.52]
-0.19 [-0.78 , 0.41]
-0.32 [-0.84 , 0.21]
0.01 [-0.53 , 0.54]
-0.01 [-0.80 , 0.77]
0.19 [-0.56 , 0.95]
-1.47 [-2.18 , -0.77]
-1.03 [-1.68 , -0.38]
0.12 [-0.51 , 0.75]
0.14 [-0.34 , 0.62]
-0.17 [-0.63 , 0.29]
-0.21 [-0.77 , 0.34]
-0.45 [-1.00 , 0.10]

444

100.0%

-0.34 [-0.51 , -0.17]

-4

-2
Favours CBT

0

2

4
Favours Wait list / no treatment

Analysis 1.26.   Comparison 1: CBT versus waitlist/no treatment,
Outcome 26: Improvement in global functioning post-treatment

Study or Subgroup

Mean

CBT
SD

Total

Mean

Wait list / no treatment
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Cornacchio 2019
Holmes 2014
Masia Warner 2005
Masia Warner 2011
Melfsen 2011
Perrin 2019
Salari 2018
Santucci 2013
Spence 2011
Villabo 2018
Villabo 2018
White 2013

53.6
63.82
73.1
67.2
61.19
82.1
60
70.43
60.18
62.81
62.52
62.93

4.6
11.03
10.1
9.39
14.31
8.9
7.3
9.91
10.016206866873308
8.157818335805226
8.676952229901921
9.09

14
17
18
20
21
20
20
14
44
55
55
15

52.5
51.05
51.5
57.1
55.43
59.4
55
58.67
54.04
53.05
53.05
61.47

4.9
7.66
14.2
8.66
5.62
6.7
8.3
4.72
10.132497224277929
8.08365635093427
8.08365635093427
7.77

313
Total (95% CI)
Heterogeneity: Tau² = 0.26; Chi² = 37.41, df = 11 (P < 0.0001); I² = 71%
Test for overall effect: Z = 5.83 (P < 0.00001)
Test for subgroup differences: Not applicable

15
19
17
17
23
20
22
14
27
28
27
15

7.9%
7.9%
7.5%
8.1%
8.9%
6.7%
8.7%
7.0%
9.8%
9.8%
9.8%
8.0%

0.22 [-0.51 , 0.96]
1.33 [0.60 , 2.06]
1.72 [0.93 , 2.51]
1.09 [0.39 , 1.79]
0.53 [-0.07 , 1.13]
2.82 [1.93 , 3.72]
0.63 [0.00 , 1.25]
1.47 [0.62 , 2.32]
0.60 [0.11 , 1.09]
1.19 [0.70 , 1.68]
1.11 [0.61 , 1.60]
0.17 [-0.55 , 0.89]

244

100.0%

1.03 [0.68 , 1.38]

-4
Favours Wait list

-2

0

2
Favours CBT

4

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

239

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.27.   Comparison 1: CBT versus waitlist/no treatment,
Outcome 27: Remission of primary anxiety diagnosis at follow-up (ITT)

Study or Subgroup

Events

Total

CBT

Wait list / no treatment
Events

Total

Odds Ratio
IV, Random, 95% CI

Weight

Odds Ratio
IV, Random, 95% CI

1.27.1 Follow-up (≤ 6 months)
Dadds 1997
Gallagher 2004
Olivares 2005
Rosa Alcazar 2009
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.99; Chi² = 4.97, df = 3 (P = 0.17); I² = 40%
Test for overall effect: Z = 3.03 (P = 0.002)

23
12
17
20
72

21
6
10
11

27
1
0
0

28

48

1.27.2 Follow-up (> 6 and ≤ 12 months)
Cartwright Hatton 2011
Dadds 1997
Rosa Alcazar 2009
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 3.80; Chi² = 11.68, df = 2 (P = 0.003); I² = 83%
Test for overall effect: Z = 0.82 (P = 0.41)

37
23
20
80

20
18
11

8
31
0

39

49

33
11
17
20
81

35.9%
25.8%
19.0%
19.3%
100.0%

2.33 [0.43 , 12.76]
10.00 [0.96 , 104.49]
49.00 [2.53 , 948.62]
49.63 [2.64 , 933.26]
10.94 [2.33 , 51.41]

33
33
20
86

39.0%
34.7%
26.3%
100.0%

3.68 [1.32 , 10.25]
0.23 [0.04 , 1.32]
49.63 [2.64 , 933.26]
2.80 [0.24 , 33.19]

0.1
0.001
Favours Wait list / no treatment

1

10

1000

Favours CBT

Analysis 1.28.   Comparison 1: CBT versus waitlist/no treatment, Outcome
28: Remission of primary anxiety diagnosis at follow-up (completers)

Study or Subgroup

Events

Total

CBT

Wait list / no treatment
Events

Total

Weight

Odds Ratio
IV, Random, 95% CI

Odds Ratio
IV, Random, 95% CI

1.28.1 Follow-up (≤ 6 months)
Dadds 1997
Gallagher 2004
Olivares 2005
Rosa Alcazar 2009
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 1.03; Chi² = 5.06, df = 3 (P = 0.17); I² = 41%
Test for overall effect: Z = 3.06 (P = 0.002)

23
12
16
20
71

21
6
10
11

26
1
0
0

48

27

1.28.2 Follow-up (> 6 and ≤ 12 months)
Cartwright Hatton 2011
Dadds 1997
Rosa Alcazar 2009
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 1.26; Chi² = 4.94, df = 2 (P = 0.08); I² = 60%
Test for overall effect: Z = 1.65 (P = 0.10)

37
20
20
77

20
18
11

8
28
0

49

36

32
11
17
20
80

35.7%
25.8%
19.1%
19.4%
100.0%

2.42 [0.44 , 13.27]
10.00 [0.96 , 104.49]
56.54 [2.88 , 1109.18]
49.63 [2.64 , 933.26]
11.46 [2.40 , 54.67]

33
31
20
84

46.7%
32.8%
20.5%
100.0%

3.68 [1.32 , 10.25]
0.96 [0.15 , 6.35]
49.63 [2.64 , 933.26]
4.04 [0.77 , 21.20]

0.1
0.001
Favours Wait list / no treatment]

1

10

1000

Favours CBT

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

240

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.29.   Comparison 1: CBT versus waitlist/no treatment,
Outcome 29: Remission of all anxiety diagnoses at follow-up (ITT)

Study or Subgroup

Events

Total

CBT

Wait list / no treatment
Events

Total

Odds Ratio
IV, Random, 95% CI

Weight

Odds Ratio
IV, Random, 95% CI

1.29.1 Follow-up (≤ 6 months)
Dadds 1997
Olivares 2005
Rosa Alcazar 2009
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 3.28; Chi² = 6.50, df = 2 (P = 0.04); I² = 69%
Test for overall effect: Z = 1.67 (P = 0.09)

23
17
20
60

26
0
0

19
8
9

36

26

1.29.2 Follow-up (> 6 and ≤ 12 months)
Cartwright Hatton 2011
Dadds 1997
Rosa Alcazar 2009
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 4.81; Chi² = 14.88, df = 2 (P = 0.0006); I² = 87%
Test for overall effect: Z = 0.95 (P = 0.34)

37
23
20
80

3
29
0

17
16
9

42

32

1.29.3 Follow-up (> 12 months)
Dadds 1997
Simon 2011
Simon 2011
Subtotal (95% CI)
56
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.50, df = 2 (P = 0.78); I² = 0%
Test for overall effect: Z = 1.36 (P = 0.17)

23
18
27
68

28
14
14

18
14
23

55

33
17
20
70

42.4%
28.7%
28.9%
100.0%

1.28 [0.33 , 5.00]
31.32 [1.62 , 604.04]
33.87 [1.80 , 636.88]
8.25 [0.69 , 98.10]

33
33
20
86

36.4%
36.3%
27.3%
100.0%

8.50 [2.20 , 32.84]
0.32 [0.08 , 1.24]
33.87 [1.80 , 636.88]
3.75 [0.25 , 56.88]

33
15
15
63

58.4%
20.6%
21.0%
100.0%

0.64 [0.16 , 2.54]
0.25 [0.02 , 2.53]
0.41 [0.04 , 4.06]
0.48 [0.17 , 1.38]

0.1
0.001
Favours Wait list / no treatment

1

10

1000

Favours CBT

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

241

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.30.   Comparison 1: CBT versus waitlist/no treatment, Outcome
30: Remission of all anxiety diagnoses at follow-up (completers)

Study or Subgroup

Events

Total

CBT

Wait list / no treatment
Events

Total

Odds Ratio
IV, Random, 95% CI

Weight

Odds Ratio
IV, Random, 95% CI

1.30.1 Follow-up (≤ 6 months)
Dadds 1997
Olivares 2005
Rosa Alcazar 2009
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 3.32; Chi² = 6.54, df = 2 (P = 0.04); I² = 69%
Test for overall effect: Z = 1.70 (P = 0.09)

23
16
20
59

25
0
0

19
8
9

25

36

1.30.2 Follow-up (> 6 and ≤ 12 months)
Cartwright Hatton 2011
Dadds 1997
Rosa Alcazar 2009
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 2.06; Chi² = 6.81, df = 2 (P = 0.03); I² = 71%
Test for overall effect: Z = 1.61 (P = 0.11)

37
20
20
77

3
27
0

17
17
9

43

30

1.30.3 Follow-up (> 12 months)
Dadds 1997
Simon 2011
Simon 2011
Subtotal (95% CI)
46
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.57, df = 2 (P = 0.75); I² = 0%
Test for overall effect: Z = 0.34 (P = 0.73)

20
16
25
61

23
11
12

18
14
23

55

32
17
20
69

42.3%
28.7%
29.0%
100.0%

1.33 [0.34 , 5.21]
35.00 [1.80 , 680.54]
33.87 [1.80 , 636.88]
8.68 [0.72 , 104.46]

33
31
20
84

39.8%
36.8%
23.4%
100.0%

8.50 [2.20 , 32.84]
0.84 [0.17 , 4.22]
33.87 [1.80 , 636.88]
5.01 [0.70 , 35.87]

28
12
13
53

50.7%
24.4%
24.9%
100.0%

1.96 [0.34 , 11.28]
0.64 [0.05 , 7.96]
0.96 [0.08 , 11.67]
1.25 [0.36 , 4.34]

0.1
0.001
Favours Wait list / no treatment

1

10

1000

Favours CBT

Analysis 1.31.   Comparison 1: CBT versus waitlist/no treatment,
Outcome 31: Reduction in anxiety symptoms (child report) at follow-up

Study or Subgroup

Mean

CBT
SD

Wait list / no treatment
Total
SD

Mean

Weight

Std. Mean Difference
IV, Random, 95% CI

Total

Std. Mean Difference
IV, Random, 95% CI

1.31.1 Follow-up (≤ 6 months)
Afshari 2014
Afshari 2014
Dadds 1997
Gallagher 2004
Olivares 2005
Rosa Alcazar 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 1.36; Chi² = 35.35, df = 5 (P < 0.00001); I² = 86%
Test for overall effect: Z = 3.65 (P = 0.0003)

50.7
50.7
10.68
13.73
127.57
128.21

5.4
8.1
6.5
6.18
33.07
30.94

25.5
22.2
7.76
8
48.84
59.52

10
10
23
12
16
20
91

14
14
7.01
8.13
18.03
18.9

5
5
30
11
17
20
88

14.0%
14.1%
19.2%
17.9%
17.0%
17.8%
100.0%

-2.64 [-4.18 , -1.11]
-2.61 [-4.14 , -1.08]
-0.42 [-0.97 , 0.13]
-0.77 [-1.62 , 0.08]
-2.91 [-3.92 , -1.90]
-2.63 [-3.49 , -1.76]
-1.92 [-2.95 , -0.89]

-4

-2
Favours CBT

0

2

4
Favours Wait list

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

242

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.32.   Comparison 1: CBT versus waitlist/no treatment, Outcome 32: Sensitivity analysis: remission
of primary anxiety diagnosis post-treatment (ITT) (only studies where sequence generation is clear)

Study or Subgroup

Events

Total

CBT

Wait list / no treatment
Events

Total

Weight

Odds Ratio
IV, Random, 95% CI

Odds Ratio
IV, Random, 95% CI

Arendt 2016
Cartwright Hatton 2011
Cobham 2017
Hirshfeld Becker 2010
Holmes 2014
Ishikawa 2019
Kidd 2018
Masia Warner 2011
McConachie 2014
McNally Keehn 2013
Melfsen 2011
Ollendick 2009
Perrin 2019
Rapee 2006
Schneider 2011
Spence 2006
Spence 2011
Thirlwall 2013
Thirlwall 2013
Villabo 2018
Villabo 2018
Wood 2015

37
21
20
22
9
10
18
9
0
7
7
47
16
44
16
13
13
18
25
29
36
6

56
37
33
34
20
23
26
20
17
12
21
85
20
90
21
22
44
61
64
55
55
19

6
5
6
13
3
4
10
1
1
0
2
1
0
17
4
3
4
11
11
4
4
6

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.72; Chi² = 58.30, df = 21 (P < 0.0001); I² = 64%
Test for overall effect: Z = 6.61 (P < 0.00001)
Test for subgroup differences: Not applicable

835

423

116

53
33
30
30
22
24
23
20
15
10
23
41
20
87
22
23
27
34
35
27
28
14

5.8%
5.3%
5.4%
5.8%
4.4%
4.8%
5.3%
2.9%
1.6%
1.8%
3.8%
3.2%
1.9%
6.8%
4.4%
4.4%
5.1%
6.1%
6.2%
5.2%
5.2%
4.5%

15.25 [5.53 , 42.05]
7.35 [2.32 , 23.27]
6.15 [1.98 , 19.14]
2.40 [0.87 , 6.57]
5.18 [1.15 , 23.29]
3.85 [0.99 , 14.89]
2.92 [0.91 , 9.44]
15.55 [1.73 , 139.65]
0.28 [0.01 , 7.31]
28.64 [1.37 , 600.41]
5.25 [0.95 , 29.05]
49.47 [6.50 , 376.64]
150.33 [7.54 , 2997.83]
3.94 [2.01 , 7.71]
14.40 [3.29 , 63.08]
9.63 [2.19 , 42.37]
2.41 [0.70 , 8.36]
0.88 [0.35 , 2.16]
1.40 [0.58 , 3.35]
6.41 [1.96 , 21.01]
11.37 [3.44 , 37.58]
0.62 [0.15 , 2.58]

641

100.0%

4.84 [3.03 , 7.73]

0.1
0.001
Favours Wait list / no treatment

1

10

1000

Favours CBT

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

243

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.33.   Comparison 1: CBT versus waitlist/no treatment, Outcome 33: Sensitivity analysis:
remission of primary anxiety diagnosis post-treatment (ITT) (only studies where blind assessors used)

Study or Subgroup

Events

Total

CBT

Wait list / no treatment
Events

Total

Weight

Odds Ratio
IV, Random, 95% CI

Odds Ratio
IV, Random, 95% CI

Arendt 2016
Cartwright Hatton 2011
Cobham 2017
Cornacchio 2019
Dadds 1997
Gallagher 2004
Hirshfeld Becker 2010
Holmes 2014
Ishikawa 2019
Kidd 2018
Lau 2010
Masia Warner 2005
Masia Warner 2011
McConachie 2014
McNally Keehn 2013
Melfsen 2011
Olivares 2005
Olivares 2019
Olivares 2019
Ollendick 2009
Ost 2001
Ost 2001
Perrin 2019
Rapee 2006
Santucci 2013
Schneider 2011
Silverman 1999b
Spence 2000
Spence 2000
Spence 2011
Thirlwall 2013
Thirlwall 2013
Villabo 2018
Villabo 2018
Waters 2009
Waters 2009
Wood 2015

37
21
20
1
21
5
22
9
10
18
14
12
9
0
7
7
10
8
13
47
18
12
16
44
7
16
16
14
11
13
25
18
29
36
21
17
6

56
37
33
14
23
12
34
20
23
26
21
21
20
17
12
21
17
36
36
85
21
20
20
90
15
21
37
17
19
44
64
61
55
55
38
31
19

6
5
6
1
28
0
13
3
4
10
0
5
1
1
0
2
0
0
0
1
0
0
0
17
1
4
5
1
1
4
11
11
4
4
1
1
6

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.66; Chi² = 78.27, df = 36 (P < 0.0001); I² = 54%
Test for overall effect: Z = 8.63 (P < 0.00001)
Test for subgroup differences: Not applicable

1191

157

610

53
33
30
15
33
11
30
22
24
23
17
21
20
15
10
23
17
18
18
41
10
9
20
87
14
22
19
8
7
27
35
34
27
28
6
5
14

4.2%
3.9%
4.0%
1.4%
2.7%
1.3%
4.3%
3.2%
3.5%
3.9%
1.3%
3.5%
2.1%
1.1%
1.3%
2.8%
1.3%
1.4%
1.4%
2.3%
1.3%
1.3%
1.3%
5.1%
2.0%
3.2%
3.8%
1.8%
1.9%
3.7%
4.6%
4.5%
3.8%
3.8%
2.0%
1.9%
3.3%

15.25 [5.53 , 42.05]
7.35 [2.32 , 23.27]
6.15 [1.98 , 19.14]
1.08 [0.06 , 19.05]
1.88 [0.33 , 10.63]
16.87 [0.81 , 351.79]
2.40 [0.87 , 6.57]
5.18 [1.15 , 23.29]
3.85 [0.99 , 14.89]
2.92 [0.91 , 9.44]
67.67 [3.56 , 1287.81]
4.27 [1.13 , 16.05]
15.55 [1.73 , 139.65]
0.28 [0.01 , 7.31]
28.64 [1.37 , 600.41]
5.25 [0.95 , 29.05]
49.00 [2.53 , 948.62]
11.04 [0.60 , 202.89]
21.26 [1.18 , 381.56]
49.47 [6.50 , 376.64]
111.00 [5.21 , 2363.64]
27.94 [1.43 , 546.98]
150.33 [7.54 , 2997.83]
3.94 [2.01 , 7.71]
11.38 [1.17 , 110.42]
14.40 [3.29 , 63.08]
2.13 [0.64 , 7.16]
32.67 [2.85 , 374.13]
8.25 [0.82 , 82.67]
2.41 [0.70 , 8.36]
1.40 [0.58 , 3.35]
0.88 [0.35 , 2.16]
6.41 [1.96 , 21.01]
11.37 [3.44 , 37.58]
6.18 [0.66 , 58.03]
4.86 [0.49 , 48.57]
0.62 [0.15 , 2.58]

846

100.0%

5.54 [3.76 , 8.18]

0.1
0.001
Favours Wait list / no treatment

1

10

1000

Favours CBT

Comparison 2.   CBT versus treatment as usual

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

2.1 Remission of primary anxiety diagnosis
post-treatment (ITT)

2.1.1 Child focused

8

3

487

315

Odds Ratio (IV, Random,
95% CI)

3.19 [0.90, 11.29]

Odds Ratio (IV, Random,
95% CI)

0.61 [0.18, 2.01]

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

244

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

2.1.2 Child and parent

2.2 Subgroup analysis: remission of prima-
ry anxiety diagnosis post-treatment (ITT)
(ASD vs non-ASD)

2.2.1 Sample with ASD

2.2.2 Not sample with ASD

2.3 Remission of primary anxiety diagnosis
post-treatment (completers)

2.4 Acceptability (number of participants
lost to post-treatment assessment)

2.5 Remission of all anxiety diagnoses post-
treatment (ITT)

2.6 Remission of all anxiety diagnoses post-
treatment (completers)

2.7 Reduction in anxiety symptoms (child
report) post-treatment

2.8 Sensitivity analysis: reduction in anx-
iety symptoms (child report) post-treat-
ment (broad anxiety measures only)

2.9 Reduction in anxiety symptoms (parent
report) post-treatment

2.10 Sensitivity analysis: reduction in anx-
iety symptoms (parent report) post-treat-
ment (broad anxiety measures only)

5

8

4

4

8

8

5

5

6

5

7

6

172

142

345

440

441

203

201

214

187

228

202

Odds Ratio (IV, Random,
95% CI)

8.56 [3.10, 23.66]

Odds Ratio (IV, Random,
95% CI)

Subtotals only

Odds Ratio (IV, Random,
95% CI)

11.25 [3.11,
40.79]

Odds Ratio (IV, Random,
95% CI)

1.14 [0.29, 4.47]

Odds Ratio (IV, Random,
95% CI)

4.87 [1.51, 15.72]

Odds Ratio (IV, Random,
95% CI)

1.37 [0.73, 2.56]

Odds Ratio (IV, Random,
95% CI)

2.74 [1.16, 6.46]

Odds Ratio (IV, Random,
95% CI)

2.78 [1.18, 6.55]

Std. Mean Difference (IV,
Random, 95% CI)

-0.15 [-0.78, 0.48]

Std. Mean Difference (IV,
Random, 95% CI)

0.07 [-0.54, 0.68]

Std. Mean Difference (IV,
Random, 95% CI)

-0.32 [-0.70, 0.06]

Std. Mean Difference (IV,
Random, 95% CI)

-0.16 [-0.44, 0.11]

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

245

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.1.   Comparison 2: CBT versus treatment as usual, Outcome
1: Remission of primary anxiety diagnosis post-treatment (ITT)

Study or Subgroup

Events

Total

Events

Total

Weight

CBT

TAU

Odds Ratio
IV, Random, 95% CI

Odds Ratio
IV, Random, 95% CI

2.1.1 Child focused
Ginsburg 2019a
Sharma 2017
Southam Gerow 2010
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.63; Chi² = 4.93, df = 2 (P = 0.09); I² = 59%
Test for overall effect: Z = 0.82 (P = 0.41)

140
30
24
194

49
30
12

33
27
19

79

91

66
31
24
121

18.3%
9.3%
16.0%
43.7%

0.54 [0.30 , 0.98]
9.98 [0.51 , 193.95]
0.26 [0.07 , 0.94]
0.61 [0.18 , 2.01]

2.1.2 Child and parent
Fujii 2013
Reaven 2012
Shahnavaz 2016
Storch 2013
Storch 2015
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 1.11, df = 4 (P = 0.89); I² = 0%
Test for overall effect: Z = 4.14 (P < 0.0001)

10
24
13
24
16
87

1
0
3
1
0

5
6
7
9
6

33

5

6
26
17
21
15
85

11.0%
9.4%
14.4%
12.2%
9.3%
56.3%

5.00 [0.42 , 59.66]
18.62 [0.99 , 351.22]
5.44 [1.04 , 28.53]
12.00 [1.37 , 105.28]
19.19 [0.97 , 378.28]
8.56 [3.10 , 23.66]

Total (95% CI)
124
Total events:
Heterogeneity: Tau² = 2.17; Chi² = 28.93, df = 7 (P = 0.0001); I² = 76%
Test for overall effect: Z = 1.80 (P = 0.07)
Test for subgroup differences: Chi² = 10.90, df = 1 (P = 0.0010), I² = 90.8%

281

206

84

100.0%

3.19 [0.90 , 11.29]

0.001

0.1
Favours TAU

1

10

1000

Favours CBT

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

246

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.2.   Comparison 2: CBT versus treatment as usual, Outcome 2: Subgroup
analysis: remission of primary anxiety diagnosis post-treatment (ITT) (ASD vs non-ASD)

Study or Subgroup

Events

Total

Events

Total

Weight

CBT

TAU

Odds Ratio
IV, Random, 95% CI

Odds Ratio
IV, Random, 95% CI

2.2.1 Sample with ASD
Fujii 2013
Reaven 2012
Storch 2013
Storch 2015
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 0.65, df = 3 (P = 0.88); I² = 0%
Test for overall effect: Z = 3.68 (P = 0.0002)

10
24
24
16
74

1
0
1
0

5
6
9
6

26

2

6
26
21
15
68

27.0%
19.2%
35.2%
18.7%
100.0%

5.00 [0.42 , 59.66]
18.62 [0.99 , 351.22]
12.00 [1.37 , 105.28]
19.19 [0.97 , 378.28]
11.25 [3.11 , 40.79]

2.2.2 Not sample with ASD
Ginsburg 2019a
Shahnavaz 2016
Sharma 2017
Southam Gerow 2010
Subtotal (95% CI)
Total events:
Heterogeneity: Tau² = 1.32; Chi² = 11.92, df = 3 (P = 0.008); I² = 75%
Test for overall effect: Z = 0.18 (P = 0.85)

66
17
31
24
138

140
13
30
24
207

49
7
30
12

33
3
27
19

98

82

34.5%
24.0%
13.5%
28.0%
100.0%

0.54 [0.30 , 0.98]
5.44 [1.04 , 28.53]
9.98 [0.51 , 193.95]
0.26 [0.07 , 0.94]
1.14 [0.29 , 4.47]

Test for subgroup differences: Chi² = 5.71, df = 1 (P = 0.02), I² = 82.5%

0.001

0.1
Favours TAU

1

10

1000

Favours CBT

Analysis 2.3.   Comparison 2: CBT versus treatment as usual, Outcome
3: Remission of primary anxiety diagnosis post-treatment (completers)

Study or Subgroup

Events

Total

Events

Total

Weight

CBT

TAU

Odds Ratio
IV, Random, 95% CI

Odds Ratio
IV, Random, 95% CI

Fujii 2013
Ginsburg 2019a
Reaven 2012
Shahnavaz 2016
Sharma 2017
Southam Gerow 2010
Storch 2013
Storch 2015

5
50
6
7
30
12
9
6

7
123
21
11
30
18
22
16

0
25
0
3
27
14
1
0

5
58
26
17
31
19
21
15

8.1%
20.6%
9.2%
14.7%
9.1%
16.6%
12.5%
9.1%

24.20 [0.93 , 629.32]
0.90 [0.48 , 1.70]
22.23 [1.17 , 422.07]
8.17 [1.42 , 47.02]
9.98 [0.51 , 193.95]
0.71 [0.17 , 2.94]
13.85 [1.56 , 122.58]
19.19 [0.97 , 378.28]

Total (95% CI)
125
Total events:
Heterogeneity: Tau² = 1.63; Chi² = 21.30, df = 7 (P = 0.003); I² = 67%
Test for overall effect: Z = 2.65 (P = 0.008)
Test for subgroup differences: Not applicable

248

192

70

100.0%

4.87 [1.51 , 15.72]

0.001

0.1
Favours TAU

1

10

1000

Favours CBT

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

247

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.4.   Comparison 2: CBT versus treatment as usual, Outcome 4:
Acceptability (number of participants lost to post-treatment assessment)

Study or Subgroup

Events

Total

Events

Total

Weight

CBT

TAU

Odds Ratio
IV, Random, 95% CI

Odds Ratio
IV, Random, 95% CI

Fujii 2013
Ginsburg 2012
Ginsburg 2019a
O'Brien 2007
Reaven 2012
Shahnavaz 2016
Southam Gerow 2010
Storch 2013

3
1
18
1
3
2
6
2

10
17
140
7
24
13
24
24

1
2
8
1
0
0
5
0

6
15
66
7
26
17
24
21

6.1%
6.2%
49.5%
4.4%
4.3%
4.0%
21.5%
4.1%

2.14 [0.17 , 27.10]
0.41 [0.03 , 5.00]
1.07 [0.44 , 2.60]
1.00 [0.05 , 19.96]
8.63 [0.42 , 176.32]
7.61 [0.33 , 173.38]
1.27 [0.33 , 4.89]
4.78 [0.22 , 105.36]

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 4.58, df = 7 (P = 0.71); I² = 0%
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Not applicable

259

17

36

182

100.0%

1.37 [0.73 , 2.56]

0.01

0.1
Favours CBT

1

10
Favours TAU

100

Analysis 2.5.   Comparison 2: CBT versus treatment as usual,
Outcome 5: Remission of all anxiety diagnoses post-treatment (ITT)

Study or Subgroup

Events

Total

Events

Total

Weight

CBT

TAU

Odds Ratio
IV, Random, 95% CI

Odds Ratio
IV, Random, 95% CI

Barrington 2005
Sciberras 2018
Sharma 2017
Storch 2013
Storch 2015

17
3
30
3
5

28
6
30
24
16

13
0
27
1
0

26
6
31
21
15

63.0%
7.0%
8.4%
13.4%
8.2%

1.55 [0.52 , 4.55]
13.00 [0.51 , 330.48]
9.98 [0.51 , 193.95]
2.86 [0.27 , 29.80]
14.83 [0.74 , 295.97]

104

Total (95% CI)
58
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 3.92, df = 4 (P = 0.42); I² = 0%
Test for overall effect: Z = 2.30 (P = 0.02)
Test for subgroup differences: Not applicable

41

99

100.0%

2.74 [1.16 , 6.46]

0.001

0.1
Favours TAU

1

10

1000

Favours CBT

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

248

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.6.   Comparison 2: CBT versus treatment as usual, Outcome
6: Remission of all anxiety diagnoses post-treatment (completers)

Study or Subgroup

Events

Total

Events

Total

Weight

CBT

TAU

Odds Ratio
IV, Random, 95% CI

Odds Ratio
IV, Random, 95% CI

Barrington 2005
Sciberras 2018
Sharma 2017
Storch 2013
Storch 2015

17
3
30
3
5

28
6
30
22
16

13
0
27
1
0

26
6
31
21
15

63.1%
7.0%
8.4%
13.3%
8.2%

1.55 [0.52 , 4.55]
13.00 [0.51 , 330.48]
9.98 [0.51 , 193.95]
3.16 [0.30 , 33.07]
14.83 [0.74 , 295.97]

102

Total (95% CI)
58
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 3.93, df = 4 (P = 0.42); I² = 0%
Test for overall effect: Z = 2.33 (P = 0.02)
Test for subgroup differences: Not applicable

41

99

100.0%

2.78 [1.18 , 6.55]

0.001

0.1
Favours TAU

1

10

1000

Favours CBT

Analysis 2.7.   Comparison 2: CBT versus treatment as usual, Outcome
7: Reduction in anxiety symptoms (child report) post-treatment

Study or Subgroup

Mean

CBT
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Barrington 2005
Ginsburg 2012
Sciberras 2018
Shahnavaz 2016
Sharma 2017
Southam Gerow 2010

10.4
25.26
25.4
21.1
31.3
36.53

7.1
11.95
14.3
6.5
7.76
9.86

27
17
5
11
30
17

11.1
22.37
17.2
33.3
38.68
29.68

7.4
14.57
12.4
9.7
9.88
6.81

21
15
5
16
31
19

18.7%
17.4%
11.6%
15.6%
19.2%
17.5%

-0.10 [-0.67 , 0.48]
0.21 [-0.48 , 0.91]
0.55 [-0.72 , 1.83]
-1.38 [-2.25 , -0.52]
-0.82 [-1.34 , -0.29]
0.80 [0.12 , 1.48]

Total (95% CI)
Heterogeneity: Tau² = 0.47; Chi² = 23.55, df = 5 (P = 0.0003); I² = 79%
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Not applicable

107

107

100.0%

-0.15 [-0.78 , 0.48]

-4

-2
Favours CBT

0

2
Favours TAU

4

Analysis 2.8.   Comparison 2: CBT versus treatment as usual, Outcome 8: Sensitivity analysis:
reduction in anxiety symptoms (child report) post-treatment (broad anxiety measures only)

Study or Subgroup

Mean

CBT
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Barrington 2005
Ginsburg 2012
Sciberras 2018
Sharma 2017
Southam Gerow 2010

10.4
25.26
25.4
31.3
36.53

7.1
11.95
14.3
7.76
9.86

27
17
5
30
17

11.1
22.37
17.2
38.68
29.68

7.4
14.57
12.4
9.88
6.81

21
15
5
31
19

22.6%
20.6%
12.6%
23.3%
20.8%

-0.10 [-0.67 , 0.48]
0.21 [-0.48 , 0.91]
0.55 [-0.72 , 1.83]
-0.82 [-1.34 , -0.29]
0.80 [0.12 , 1.48]

Total (95% CI)
Heterogeneity: Tau² = 0.34; Chi² = 15.61, df = 4 (P = 0.004); I² = 74%
Test for overall effect: Z = 0.22 (P = 0.83)
Test for subgroup differences: Not applicable

96

91

100.0%

0.07 [-0.54 , 0.68]

-4

-2
Favours CBT

0

2
Favours TAU

4

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

249

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 2.9.   Comparison 2: CBT versus treatment as usual, Outcome
9: Reduction in anxiety symptoms (parent report) post-treatment

Study or Subgroup

Mean

CBT
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Barrington 2005
Ginsburg 2012
Sciberras 2018
Shahnavaz 2016
Southam Gerow 2010
Storch 2013
Storch 2015

27.3
20.07
21.3
21.2
42.75
51.96
56.94

16.7
14.94
17
6.9
8.89
13.44
17.52

27
17
6
11
16
24
16

31.8
18.7
25.4
34.3
41.8
58.43
58.62

17.6
17.58
3.8
8.2
7.88
12.81
17.56

21
15
5
15
19
21
15

18.0%
15.1%
7.6%
11.0%
15.8%
17.5%
14.9%

-0.26 [-0.83 , 0.31]
0.08 [-0.61 , 0.78]
-0.29 [-1.49 , 0.91]
-1.65 [-2.57 , -0.73]
0.11 [-0.55 , 0.78]
-0.48 [-1.08 , 0.11]
-0.09 [-0.80 , 0.61]

Total (95% CI)
Heterogeneity: Tau² = 0.12; Chi² = 11.66, df = 6 (P = 0.07); I² = 49%
Test for overall effect: Z = 1.64 (P = 0.10)
Test for subgroup differences: Not applicable

117

111

100.0%

-0.32 [-0.70 , 0.06]

-4

-2
Favours CBT

0

2
Favours TAU

4

Analysis 2.10.   Comparison 2: CBT versus treatment as usual, Outcome 10: Sensitivity analysis:
reduction in anxiety symptoms (parent report) post-treatment (broad anxiety measures only)

Study or Subgroup

Mean

CBT
SD

Total

Mean

TAU
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Barrington 2005
Ginsburg 2012
Sciberras 2018
Southam Gerow 2010
Storch 2013
Storch 2015

27.3
20.07
21.3
42.75
51.96
56.94

16.7
14.94
17
8.89
13.44
17.52

27
17
6
16
24
16

31.8
18.7
25.4
41.8
58.43
58.62

17.6
17.58
3.8
7.88
12.81
17.56

21
15
5
19
21
15

23.6%
16.0%
5.4%
17.5%
21.9%
15.6%

-0.26 [-0.83 , 0.31]
0.08 [-0.61 , 0.78]
-0.29 [-1.49 , 0.91]
0.11 [-0.55 , 0.78]
-0.48 [-1.08 , 0.11]
-0.09 [-0.80 , 0.61]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.43, df = 5 (P = 0.79); I² = 0%
Test for overall effect: Z = 1.16 (P = 0.25)
Test for subgroup differences: Not applicable

106

96

100.0%

-0.16 [-0.44 , 0.11]

-4

-2
Favours CBT

0

2
Favours TAU

4

Comparison 3.   CBT versus attention control

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

3.1 Remission of primary anxiety diag-
nosis post-treatment (ITT)

3.1.1 Child focused

3.1.2 Child and parent

3.2 Subgroup analysis: remission of pri-
mary anxiety diagnosis post-treatment
(ITT) (individual vs group)

3.2.1 Individual focused

10

7

4

10

5

822

509

313

469

Odds Ratio (IV, Random,
95% CI)

2.28 [1.33, 3.89]

Odds Ratio (IV, Random,
95% CI)

3.58 [1.92, 6.65]

Odds Ratio (IV, Random,
95% CI)

1.12 [0.65, 1.92]

Odds Ratio (IV, Random,
95% CI)

Subtotals only

Odds Ratio (IV, Random,
95% CI)

2.04 [1.06, 3.91]

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

250

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

3.2.2 Group focused

3.3 Remission of primary anxiety diag-
nosis post-treatment (completers)

3.4 Acceptability (number of partici-
pants lost to post-treatment assess-
ment)

3.5 Remission of all anxiety diagnoses
post-treatment (ITT)

3.6 Remission of all anxiety diagnoses
post-treatment (completers)

3.7 Reduction in anxiety symptoms
(child report) post-treatment

3.8 Sensitivity analysis: reduction in anx-
iety symptoms (child report) post-treat-
ment (broad anxiety measures only)

3.9 Reduction in anxiety symptoms (par-
ent report) post-treatment

3.10 Sensitivity analysis: reduction in
anxiety symptoms (parent report) post-
treatment (broad anxiety measures on-
ly)

5

10

12

5

5

15

11

8

4

3.11 Reduction in depressive symptoms
post-treatment

10

3.12 Remission of primary anxiety diag-
nosis at follow-up (ITT)

3.12.1 Follow-up (≤ 6 months)

3.13 Remission of primary anxiety diag-
nosis at follow-up (completers)

3.13.1 Follow-up (≤ 6 months)

3.14 Remission of all anxiety diagnoses
at follow-up (ITT)

3.14.1 Follow-up (≤ 6 months)

3.15 Remission of all anxiety diagnoses
at follow-up (completers)

4

4

4

4

3

3

3

353

752

797

378

359

978

685

638

345

613

341

302

205

Odds Ratio (IV, Random,
95% CI)

3.10 [1.14, 8.45]

Odds Ratio (IV, Random,
95% CI)

3.88 [2.52, 5.97]

Odds Ratio (IV, Random,
95% CI)

1.00 [0.68, 1.49]

Odds Ratio (IV, Random,
95% CI)

2.75 [1.22, 6.17]

Odds Ratio (IV, Random,
95% CI)

3.88 [1.58, 9.51]

Std. Mean Difference (IV,
Random, 95% CI)

-0.31 [-0.51,
-0.11]

Std. Mean Difference (IV,
Random, 95% CI)

-0.18 [-0.34,
-0.02]

Std. Mean Difference (IV,
Random, 95% CI)

-0.25 [-0.61, 0.11]

Std. Mean Difference (IV,
Random, 95% CI)

-0.04 [-0.26, 0.18]

Std. Mean Difference (IV,
Random, 95% CI)

-0.18 [-0.45, 0.09]

Odds Ratio (IV, Random,
95% CI)

Subtotals only

Odds Ratio (IV, Random,
95% CI)

3.06 [1.22, 7.65]

Odds Ratio (IV, Random,
95% CI)

Subtotals only

Odds Ratio (IV, Random,
95% CI)

6.52 [2.58, 16.43]

Odds Ratio (IV, Random,
95% CI)

Subtotals only

Odds Ratio (IV, Random,
95% CI)

5.44 [1.00, 29.60]

Odds Ratio (IV, Random,
95% CI)

Subtotals only

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

251

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

3.15.1 Follow-up (≤ 6 months)

3.16 Reduction in anxiety symptoms
(child report) at follow-up

3.16.1 Follow-up (≤ 6 months)

3.17 Reduction in anxiety symptoms
(parent report) at follow-up

3.17.1 Follow-up (≤ 6 months)

3

6

6

6

6

182

434

434

Odds Ratio (IV, Random,
95% CI)

11.19 [1.94,
64.51]

Std. Mean Difference (IV,
Random, 95% CI)

Subtotals only

Std. Mean Difference (IV,
Random, 95% CI)

-0.44 [-0.79,
-0.08]

Std. Mean Difference (IV,
Random, 95% CI)

Subtotals only

Std. Mean Difference (IV,
Random, 95% CI)

-0.63 [-1.33, 0.08]

Analysis 3.1.   Comparison 3: CBT versus attention control, Outcome
1: Remission of primary anxiety diagnosis post-treatment (ITT)

Study or Subgroup

Events

Total

CBT

Attention control
Total
Events

Weight

Odds Ratio
IV, Random, 95% CI

Odds Ratio
IV, Random, 95% CI

3.1.1 Child focused
Ginsburg 2002
Kendall 2008
Khanna 2010
Masia Warner 2007
Masia Warner 2016
Masia Warner 2016
Ollendick 2009
Rosa Alcazar 2009
Rosa Alcazar 2009
Subtotal (95% CI)
138
Total events:
Heterogeneity: Tau² = 0.32; Chi² = 13.26, df = 8 (P = 0.10); I² = 40%
Test for overall effect: Z = 4.03 (P < 0.0001)

6
55
17
19
46
47
85
10
10
295

6
25
16
17
21
22
70
19
18
214

3
32
12
11
9
12
47
6
6

2
8
6
2
4
4
16
0
0

42

3.1.2 Child and parent
Hudson 2009
Kendall 2008
Last 1998
Silverman 1999a
Subtotal (95% CI)
96
Total events:
Heterogeneity: Tau² = 0.07; Chi² = 3.85, df = 3 (P = 0.28); I² = 22%
Test for overall effect: Z = 0.40 (P = 0.69)

60
56
32
41
189

23
32
13
28

19
9
13
16

57

52
25
24
23
124

3.9%
9.9%
7.1%
5.8%
7.9%
8.2%
11.9%
2.6%
2.6%
59.9%

11.5%
10.0%
9.4%
9.2%
40.1%

484

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.50; Chi² = 28.77, df = 12 (P = 0.004); I² = 58%
Test for overall effect: Z = 3.00 (P = 0.003)
Test for subgroup differences: Chi² = 7.65, df = 1 (P = 0.006), I² = 86.9%

338

234

99

100.0%

2.00 [0.19 , 20.61]
2.96 [1.09 , 8.01]
4.00 [0.93 , 17.11]
10.31 [1.82 , 58.39]
1.03 [0.28 , 3.83]
1.54 [0.43 , 5.47]
4.17 [2.07 , 8.43]
56.33 [2.66 , 1193.81]
53.44 [2.52 , 1134.56]
3.58 [1.92 , 6.65]

1.08 [0.50 , 2.33]
2.37 [0.90 , 6.27]
0.58 [0.20 , 1.69]
0.94 [0.31 , 2.85]
1.12 [0.65 , 1.92]

2.28 [1.33 , 3.89]

0.01

0.1

1

Favours Attention control

10
Favours CBT

100

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

252

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.2.   Comparison 3: CBT versus attention control, Outcome 2: Subgroup analysis:
remission of primary anxiety diagnosis post-treatment (ITT) (individual vs group)

Study or Subgroup

Events

Total

CBT

Attention control
Total
Events

Weight

Odds Ratio
IV, Random, 95% CI

Odds Ratio
IV, Random, 95% CI

3.2.1 Individual focused
Kendall 2008
Kendall 2008
Khanna 2010
Last 1998
Ollendick 2009
Silverman 1999a
Subtotal (95% CI)
164
Total events:
Heterogeneity: Tau² = 0.39; Chi² = 12.45, df = 5 (P = 0.03); I² = 60%
Test for overall effect: Z = 2.13 (P = 0.03)

56
55
17
32
85
41
286

25
25
16
24
70
23
183

9
8
6
13
16
16

32
32
12
13
47
28

68

3.2.2 Group focused
Ginsburg 2002
Hudson 2009
Masia Warner 2007
Masia Warner 2016
Masia Warner 2016
Rosa Alcazar 2009
Rosa Alcazar 2009
Subtotal (95% CI)
70
Total events:
Heterogeneity: Tau² = 1.00; Chi² = 15.96, df = 6 (P = 0.01); I² = 62%
Test for overall effect: Z = 2.21 (P = 0.03)

6
60
19
47
46
10
10
198

6
52
17
22
21
19
18
155

3
23
11
12
9
6
6

2
19
2
4
4
0
0

31

17.5%
17.2%
11.8%
16.2%
21.5%
15.7%
100.0%

2.37 [0.90 , 6.27]
2.96 [1.09 , 8.01]
4.00 [0.93 , 17.11]
0.58 [0.20 , 1.69]
4.17 [2.07 , 8.43]
0.94 [0.31 , 2.85]
2.04 [1.06 , 3.91]

10.8%
22.7%
14.7%
18.5%
18.1%
7.6%
7.6%
100.0%

2.00 [0.19 , 20.61]
1.08 [0.50 , 2.33]
10.31 [1.82 , 58.39]
1.54 [0.43 , 5.47]
1.03 [0.28 , 3.83]
56.33 [2.66 , 1193.81]
53.44 [2.52 , 1134.56]
3.10 [1.14 , 8.45]

Test for subgroup differences: Chi² = 0.48, df = 1 (P = 0.49), I² = 0%

0.01

0.1

1

Favours Attention control

10
Favours CBT

100

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

253

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.3.   Comparison 3: CBT versus attention control, Outcome 3:
Remission of primary anxiety diagnosis post-treatment (completers)

Study or Subgroup

Events

Total

CBT

Attention control
Total
Events

Weight

Odds Ratio
IV, Random, 95% CI

Odds Ratio
IV, Random, 95% CI

Ginsburg 2002
Hudson 2009
Kendall 2008
Kendall 2008
Khanna 2010
Last 1998
Masia Warner 2007
Masia Warner 2016
Masia Warner 2016
Ollendick 2009
Rosa Alcazar 2009
Rosa Alcazar 2009
Silverman 1999a

3
23
32
32
12
13
11
9
12
47
6
6
28

4
53
55
56
16
20
18
43
39
85
10
10
32

1
13
8
9
3
10
0
1
2
16
0
0
9

5
46
25
25
13
21
15
19
19
70
19
18
16

1.8%
15.8%
12.7%
13.1%
5.4%
9.1%
2.0%
3.7%
6.0%
19.3%
1.9%
1.9%
7.3%

12.00 [0.51 , 280.09]
1.95 [0.84 , 4.51]
2.96 [1.09 , 8.01]
2.37 [0.90 , 6.27]
10.00 [1.80 , 55.63]
2.04 [0.58 , 7.17]
47.53 [2.46 , 919.68]
4.76 [0.56 , 40.64]
3.78 [0.75 , 19.00]
4.17 [2.07 , 8.43]
56.33 [2.66 , 1193.81]
53.44 [2.52 , 1134.56]
5.44 [1.29 , 22.98]

441

Total (95% CI)
Total events:
Heterogeneity: Tau² = 0.12; Chi² = 15.20, df = 12 (P = 0.23); I² = 21%
Test for overall effect: Z = 6.17 (P < 0.00001)
Test for subgroup differences: Not applicable

234

311

72

100.0%

3.88 [2.52 , 5.97]

0.01

0.1

1

Favours Attention control

10
Favours CBT

100

Analysis 3.4.   Comparison 3: CBT versus attention control, Outcome 4:
Acceptability (number of participants lost to post-treatment assessment)

Study or Subgroup

Events

Total

CBT

Attention control
Total
Events

Odds Ratio
IV, Random, 95% CI

Weight

Odds Ratio
IV, Random, 95% CI

Ginsburg 2002
Herbert 2009
Herbert 2009
Hudson 2009
Ingul 2013
Ingul 2013
Kendall 2008
Khanna 2010
Last 1998
Masia Warner 2007
Masia Warner 2016
Masia Warner 2016
Pincus 2010
Salum 2018
Silverman 1999a

2
7
7
7
15
38
1
1
12
2
8
3
0
4
9

6
24
23
60
36
58
55
17
32
19
47
46
13
21
41

1
4
3
6
9
9
0
3
3
2
3
2
1
7
7

6
13
13
52
17
17
25
16
24
17
22
21
13
20
23

2.1%
7.2%
6.3%
11.5%
11.5%
12.9%
1.5%
2.7%
7.9%
3.6%
7.5%
4.4%
1.4%
7.6%
11.6%

2.50 [0.16 , 38.60]
0.93 [0.21 , 4.03]
1.46 [0.30 , 6.98]
1.01 [0.32 , 3.23]
0.63 [0.20 , 2.03]
1.69 [0.56 , 5.05]
1.40 [0.06 , 35.66]
0.27 [0.03 , 2.92]
4.20 [1.03 , 17.13]
0.88 [0.11 , 7.06]
1.30 [0.31 , 5.46]
0.66 [0.10 , 4.30]
0.31 [0.01 , 8.30]
0.44 [0.11 , 1.82]
0.64 [0.20 , 2.04]

498

Total (95% CI)
116
Total events:
Heterogeneity: Tau² = 0.00; Chi² = 10.01, df = 14 (P = 0.76); I² = 0%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Not applicable

60

299

100.0%

1.00 [0.68 , 1.49]

0.01

0.1
Favours CBT

1

10

100

Favours Attention control

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

254

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.5.   Comparison 3: CBT versus attention control,
Outcome 5: Remission of all anxiety diagnoses post-treatment (ITT)

Study or Subgroup

Events

Total

CBT

Attention control
Total
Events

Odds Ratio
IV, Random, 95% CI

Weight

Odds Ratio
IV, Random, 95% CI

Ginsburg 2002
Hudson 2009
Kendall 2008
Kendall 2008
Masia Warner 2007
Rosa Alcazar 2009
Rosa Alcazar 2009

2
17
19
23
11
5
4

6
60
55
56
19
10
10

1
13
7
7
2
0
0

6
52
25
25
17
19
18

6.9%
24.6%
21.7%
21.9%
13.2%
5.8%
5.8%

2.50 [0.16 , 38.60]
1.19 [0.51 , 2.75]
1.36 [0.48 , 3.82]
1.79 [0.64 , 4.98]
10.31 [1.82 , 58.39]
39.00 [1.85 , 820.04]
25.62 [1.21 , 543.78]

216

Total (95% CI)
81
Total events:
Heterogeneity: Tau² = 0.51; Chi² = 11.85, df = 6 (P = 0.07); I² = 49%
Test for overall effect: Z = 2.45 (P = 0.01)
Test for subgroup differences: Not applicable

30

162

100.0%

2.75 [1.22 , 6.17]

0.01

0.1

1

Favours Attention control

10
Favours CBT

100

Analysis 3.6.   Comparison 3: CBT versus attention control, Outcome
6: Remission of all anxiety diagnoses post-treatment (completers)

Study or Subgroup

Events

Total

CBT

Attention control
Total
Events

Odds Ratio
IV, Random, 95% CI

Weight

Odds Ratio
IV, Random, 95% CI

Ginsburg 2002
Hudson 2009
Kendall 2008
Kendall 2008
Masia Warner 2007
Rosa Alcazar 2009
Rosa Alcazar 2009

2
17
19
23
11
4
5

4
53
55
56
18
10
10

0
7
7
7
0
0
0

5
46
25
25
15
18
19

5.9%
24.7%
24.0%
24.2%
7.3%
6.9%
7.0%

11.00 [0.37 , 324.52]
2.63 [0.98 , 7.08]
1.36 [0.48 , 3.82]
1.79 [0.64 , 4.98]
47.53 [2.46 , 919.68]
25.62 [1.21 , 543.78]
39.00 [1.85 , 820.04]

206

Total (95% CI)
81
Total events:
Heterogeneity: Tau² = 0.59; Chi² = 11.61, df = 6 (P = 0.07); I² = 48%
Test for overall effect: Z = 2.96 (P = 0.003)
Test for subgroup differences: Not applicable

21

153

100.0%

3.88 [1.58 , 9.51]

0.01

0.1

1

Favours Attention control

10
Favours CBT

100

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

255

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.7.   Comparison 3: CBT versus attention control, Outcome
7: Reduction in anxiety symptoms (child report) post-treatment

Study or Subgroup

Mean

CBT
SD

Total

Attention control
SD

Total

Mean

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Ginsburg 2002
Herbert 2009
Herbert 2009
Hudson 2009
Ingul 2013
Ingul 2013
Kendall 2008
Kendall 2008
Khanna 2010
Last 1998
Masia Warner 2007
Masia Warner 2016
Masia Warner 2016
Muris 2002
Ollendick 2009
Ollendick 2009
Pincus 2010
Rosa Alcazar 2009
Rosa Alcazar 2009
Salum 2018
Silverman 1999a

28.75
32.47
33.4
23.43
14.45
25.16
36.93
36.65
35.8
30.11
13.4
13.76
13.96
23.7
48.78
44.43
45.31
67.99
67.99
39.6
5.77

28.27
19.08
14.72
17.57
8.45
17.1
22.04
19.2
13.1
9.43
7.83
9.58
7.25
14.4
9.57
11.34
22.75
23.38
23.38
17.96
4.1

4
23
22
51
21
20
56
55
17
20
17
47
46
10
41
44
13
10
10
21
32

34.75
34.34
34.34
21.81
22.87
22.87
39.13
39.13
39
32.7
24.6
15.11
15.11
47.5
51.37
43.8
51.25
112.36
78.73
39.79
9.61

17.27
16.26
16.26
17.71
12.84
12.84
19.37
19.37
16.1
7
7.75
9.32
9.32
31.3
8.31
11.21
25.77
11.71
37.17
19.72
7.2

Total (95% CI)
Heterogeneity: Tau² = 0.10; Chi² = 40.95, df = 20 (P = 0.004); I² = 51%
Test for overall effect: Z = 3.09 (P = 0.002)
Test for subgroup differences: Not applicable

580

5
12
11
44
8
8
25
25
16
21
15
22
21
10
40
30
12
19
18
20
16

1.8%
4.5%
4.3%
7.1%
3.5%
3.7%
6.4%
6.4%
4.6%
5.1%
3.9%
6.0%
6.0%
3.1%
6.7%
6.5%
3.9%
2.6%
3.9%
5.1%
5.1%

-0.24 [-1.56 , 1.09]
-0.10 [-0.80 , 0.60]
-0.06 [-0.78 , 0.66]
0.09 [-0.31 , 0.49]
-0.84 [-1.68 , 0.01]
0.14 [-0.68 , 0.96]
-0.10 [-0.57 , 0.37]
-0.13 [-0.60 , 0.35]
-0.21 [-0.90 , 0.47]
-0.31 [-0.92 , 0.31]
-1.40 [-2.19 , -0.62]
-0.14 [-0.65 , 0.37]
-0.14 [-0.66 , 0.37]
-0.94 [-1.87 , -0.00]
-0.29 [-0.72 , 0.15]
0.06 [-0.41 , 0.52]
-0.24 [-1.02 , 0.55]
-2.61 [-3.66 , -1.55]
-0.32 [-1.09 , 0.46]
-0.01 [-0.62 , 0.60]
-0.71 [-1.33 , -0.09]

398

100.0%

-0.31 [-0.51 , -0.11]

-4

-2
Favours CBT

0

2

4

Favours Attention control

Analysis 3.8.   Comparison 3: CBT versus attention control, Outcome 8: Sensitivity analysis:
reduction in anxiety symptoms (child report) post-treatment (broad anxiety measures only)

Study or Subgroup

Mean

CBT
SD

Total

Attention control
SD

Total

Mean

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Ginsburg 2002
Hudson 2009
Ingul 2013
Ingul 2013
Kendall 2008
Kendall 2008
Khanna 2010
Last 1998
Muris 2002
Ollendick 2009
Ollendick 2009
Pincus 2010
Salum 2018
Silverman 1999a

28.75
23.43
25.16
14.45
36.65
36.93
35.8
30.11
23.7
44.43
48.78
45.31
39.6
5.77

28.27
17.57
17.1
8.45
19.2
22.04
13.1
9.43
14.4
11.34
9.57
22.75
17.96
4.1

4
51
20
21
55
56
17
20
10
44
41
13
21
32

34.75
21.81
22.87
22.87
39.13
39.13
39
32.7
47.5
43.8
51.37
51.25
39.79
9.61

17.27
17.71
12.84
12.84
19.37
19.37
16.1
7
31.3
11.21
8.31
25.77
19.72
7.2

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 11.83, df = 13 (P = 0.54); I² = 0%
Test for overall effect: Z = 2.26 (P = 0.02)
Test for subgroup differences: Not applicable

405

5
44
8
8
25
25
16
21
10
30
40
12
20
16

1.4%
14.9%
3.6%
3.4%
10.8%
10.9%
5.2%
6.4%
2.8%
11.3%
12.7%
3.9%
6.5%
6.3%

-0.24 [-1.56 , 1.09]
0.09 [-0.31 , 0.49]
0.14 [-0.68 , 0.96]
-0.84 [-1.68 , 0.01]
-0.13 [-0.60 , 0.35]
-0.10 [-0.57 , 0.37]
-0.21 [-0.90 , 0.47]
-0.31 [-0.92 , 0.31]
-0.94 [-1.87 , -0.00]
0.06 [-0.41 , 0.52]
-0.29 [-0.72 , 0.15]
-0.24 [-1.02 , 0.55]
-0.01 [-0.62 , 0.60]
-0.71 [-1.33 , -0.09]

280

100.0%

-0.18 [-0.34 , -0.02]

-4

-2
Favours CBT

0

2

4

Favours Attention control

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

256

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.9.   Comparison 3: CBT versus attention control, Outcome
9: Reduction in anxiety symptoms (parent report) post-treatment

Study or Subgroup

Mean

CBT
SD

Total

Attention control
SD

Total

Mean

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Herbert 2009
Herbert 2009
Hudson 2009
Kendall 2008
Kendall 2008
Masia Warner 2007
Masia Warner 2016
Masia Warner 2016
Rosa Alcazar 2009
Rosa Alcazar 2009
Salum 2018
Silverman 1999a

62.87
58.73
21.52
11.35
9.23
10.4
20.44
17.22
45.9
45.9
40.79
9.03

16.15
14.25
13.28
5.96
5.25
2.47
10.18
8.74
17.42
17.42
17.32
5.9

23
22
51
55
56
17
47
46
10
10
21
32

55.53
55.53
22.94
10.11
10.11
11.2
17.66
17.66
80.61
72.31
39.16
10.3

15.55
15.55
13.53
5.18
5.18
2.71
6.73
6.73
6.16
9.96
18.56
4.3

Total (95% CI)
Heterogeneity: Tau² = 0.30; Chi² = 47.61, df = 11 (P < 0.00001); I² = 77%
Test for overall effect: Z = 1.37 (P = 0.17)
Test for subgroup differences: Not applicable

390

12
11
44
25
25
15
22
21
18
19
20
16

7.9%
7.8%
10.0%
9.5%
9.5%
8.0%
9.3%
9.2%
5.3%
6.4%
8.6%
8.6%

0.45 [-0.26 , 1.16]
0.21 [-0.51 , 0.94]
-0.11 [-0.51 , 0.30]
0.21 [-0.26 , 0.69]
-0.17 [-0.64 , 0.31]
-0.30 [-1.00 , 0.40]
0.30 [-0.21 , 0.81]
-0.05 [-0.57 , 0.46]
-2.96 [-4.10 , -1.82]
-1.98 [-2.93 , -1.04]
0.09 [-0.52 , 0.70]
-0.23 [-0.83 , 0.37]

248

100.0%

-0.25 [-0.61 , 0.11]

-4

-2
Favours CBT

0

2

4

Favours Attention control

Analysis 3.10.   Comparison 3: CBT versus attention control, Outcome 10: Sensitivity analysis:
reduction in anxiety symptoms (parent report) post-treatment (broad anxiety measures only)

Study or Subgroup

Mean

CBT
SD

Total

Attention control
SD

Total

Mean

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Hudson 2009
Kendall 2008
Kendall 2008
Salum 2018
Silverman 1999a

21.52
11.35
9.23
40.79
9.03

13.28
5.96
5.25
17.32
5.9

51
55
56
21
32

22.94
10.11
10.11
39.16
10.3

13.53
5.18
5.18
18.56
4.3

44
25
25
20
16

30.0%
21.7%
21.9%
13.0%
13.5%

-0.11 [-0.51 , 0.30]
0.21 [-0.26 , 0.69]
-0.17 [-0.64 , 0.31]
0.09 [-0.52 , 0.70]
-0.23 [-0.83 , 0.37]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.04, df = 4 (P = 0.73); I² = 0%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable

215

130

100.0%

-0.04 [-0.26 , 0.18]

-4

-2
Favours CBT

0

2

4

Favours Attention control

Analysis 3.11.   Comparison 3: CBT versus attention control,
Outcome 11: Reduction in depressive symptoms post-treatment

Study or Subgroup

Mean

CBT
SD

Total

Mean

Attention control
SD

Total

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Ingul 2013
Ingul 2013
Kendall 2008
Kendall 2008
Khanna 2010
Last 1998
Masia Warner 2007
Muris 2002
Ollendick 2009
Ollendick 2009
Pincus 2010
Salum 2018
Silverman 1999a

10.24
16.35
7.27
7.98
22.7
5
5.1
4.7
3.91
4.93
8.77
6.35
4.08

9.7
11.48
7.712846426579486
7.857480512225274
9.1
7.52
6.18
3.5
4.55
3.41
8.01
6.09
4.2

21
20
55
56
17
20
17
10
44
41
13
21
32

7.04
7.04
6.95
6.95
21.8
9.53
13
10.5
5.1
5.5
10.8
4.65
8.41

4.62
4.62
8.555992052357231
8.555992052357231
9.2
6.19
6.2
6.3
7.34
3.56
8.18
6.48
7.6

367
Total (95% CI)
Heterogeneity: Tau² = 0.14; Chi² = 29.19, df = 12 (P = 0.004); I² = 59%
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Not applicable

8
8
25
25
16
21
15
10
30
40
12
20
16

6.0%
5.7%
9.7%
9.7%
7.3%
7.9%
6.5%
5.1%
9.8%
10.1%
6.3%
8.0%
7.9%

0.36 [-0.46 , 1.18]
0.89 [0.04 , 1.75]
0.04 [-0.43 , 0.51]
0.13 [-0.35 , 0.60]
0.10 [-0.59 , 0.78]
-0.65 [-1.28 , -0.02]
-1.24 [-2.01 , -0.48]
-1.09 [-2.04 , -0.14]
-0.20 [-0.67 , 0.26]
-0.16 [-0.60 , 0.27]
-0.24 [-1.03 , 0.55]
0.27 [-0.35 , 0.88]
-0.77 [-1.39 , -0.15]

246

100.0%

-0.18 [-0.45 , 0.09]

-4

-2
Favours CBT

0

2

4

Favours Attention control

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

257

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.12.   Comparison 3: CBT versus attention control, Outcome
12: Remission of primary anxiety diagnosis at follow-up (ITT)

Study or Subgroup

Events

Total

CBT

Attention control
Total
Events

Odds Ratio
IV, Random, 95% CI

Weight

Odds Ratio
IV, Random, 95% CI

3.12.1 Follow-up (≤ 6 months)
Hudson 2009
Masia Warner 2007
Masia Warner 2016
Masia Warner 2016
Rosa Alcazar 2009
Rosa Alcazar 2009
Subtotal (95% CI)
87
Total events:
Heterogeneity: Tau² = 0.71; Chi² = 12.62, df = 5 (P = 0.03); I² = 60%
Test for overall effect: Z = 2.39 (P = 0.02)

60
19
47
46
10
10
192

52
17
22
21
19
18
149

35
11
13
17
6
5

28
3
5
5
1
0

42

25.6%
16.5%
20.4%
20.6%
10.0%
7.0%
100.0%

1.20 [0.57 , 2.54]
6.42 [1.37 , 30.05]
1.30 [0.40 , 4.25]
1.88 [0.58 , 6.04]
27.00 [2.50 , 291.19]
37.00 [1.76 , 779.34]
3.06 [1.22 , 7.65]

0.01

0.1

1

Favours Attention control

10
Favours CBT

100

Analysis 3.13.   Comparison 3: CBT versus attention control, Outcome
13: Remission of primary anxiety diagnosis at follow-up (completers)

Study or Subgroup

Events

Total

CBT

Attention control
Total
Events

Odds Ratio
IV, Random, 95% CI

Weight

Odds Ratio
IV, Random, 95% CI

3.13.1 Follow-up (≤ 6 months)
Hudson 2009
Masia Warner 2007
Masia Warner 2016
Masia Warner 2016
Rosa Alcazar 2009
Rosa Alcazar 2009
Subtotal (95% CI)
87
Total events:
Heterogeneity: Tau² = 0.55; Chi² = 9.01, df = 5 (P = 0.11); I² = 44%
Test for overall effect: Z = 3.97 (P < 0.0001)

51
15
43
39
10
10
168

35
11
17
13
6
5

20
1
3
2
1
0

44
15
19
19
19
18
134

27

30.5%
11.4%
21.4%
18.2%
11.0%
7.5%
100.0%

2.63 [1.14 , 6.07]
38.50 [3.75 , 395.41]
3.49 [0.88 , 13.81]
4.25 [0.85 , 21.25]
27.00 [2.50 , 291.19]
37.00 [1.76 , 779.34]
6.52 [2.58 , 16.43]

0.01

0.1

1

Favours Attention control

10
Favours CBT

100

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

258

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.14.   Comparison 3: CBT versus attention control,
Outcome 14: Remission of all anxiety diagnoses at follow-up (ITT)

Study or Subgroup

Events

Total

CBT

Attention control
Total
Events

Odds Ratio
IV, Random, 95% CI

Weight

Odds Ratio
IV, Random, 95% CI

3.14.1 Follow-up (≤ 6 months)
Hudson 2009
Masia Warner 2007
Rosa Alcazar 2009
Rosa Alcazar 2009
Subtotal (95% CI)
44
Total events:
Heterogeneity: Tau² = 1.92; Chi² = 10.54, df = 3 (P = 0.01); I² = 72%
Test for overall effect: Z = 1.96 (P = 0.05)

52
17
18
19
106

60
19
10
10
99

25
10
4
5

21
3
0
0

24

36.1%
29.5%
17.2%
17.2%
100.0%

1.05 [0.50 , 2.24]
5.19 [1.11 , 24.14]
25.62 [1.21 , 543.78]
39.00 [1.85 , 820.04]
5.44 [1.00 , 29.60]

0.01

0.1

1

Favours Attention control

10
Favours CBT

100

Analysis 3.15.   Comparison 3: CBT versus attention control, Outcome
15: Remission of all anxiety diagnoses at follow-up (completers)

Study or Subgroup

Events

Total

CBT

Attention control
Total
Events

Odds Ratio
IV, Random, 95% CI

Weight

Odds Ratio
IV, Random, 95% CI

3.15.1 Follow-up (≤ 6 months)
Hudson 2009
Masia Warner 2007
Rosa Alcazar 2009
Rosa Alcazar 2009
Subtotal (95% CI)
44
Total events:
Heterogeneity: Tau² = 1.89; Chi² = 7.97, df = 3 (P = 0.05); I² = 62%
Test for overall effect: Z = 2.70 (P = 0.007)

51
15
10
10
86

13
1
0
0

25
10
4
5

14

44
15
18
19
96

38.5%
24.5%
18.5%
18.6%
100.0%

2.29 [0.98 , 5.36]
28.00 [2.82 , 277.96]
25.62 [1.21 , 543.78]
39.00 [1.85 , 820.04]
11.19 [1.94 , 64.51]

Test for subgroup differences: Not applicable

0.01

0.1

1

Favours Attention control

10
Favours CBT

100

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

259

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 3.16.   Comparison 3: CBT versus attention control, Outcome
16: Reduction in anxiety symptoms (child report) at follow-up

Study or Subgroup

Mean

CBT
SD

Total

Attention control
SD

Total

Mean

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

3.16.1 Follow-up (≤ 6 months)
Herbert 2009
Herbert 2009
Hudson 2009
Masia Warner 2007
Masia Warner 2016
Masia Warner 2016
Rosa Alcazar 2009
Rosa Alcazar 2009
Silverman 1999a
Subtotal (95% CI)
Heterogeneity: Tau² = 0.19; Chi² = 23.08, df = 8 (P = 0.003); I² = 65%
Test for overall effect: Z = 2.40 (P = 0.02)

29.78
29.78
19.48
23.2
13.03
13.03
113.73
76.35
5

20.77
17.47
17.57
11.62
8.24
7.26
30.94
30.94
5.2

32.21
24.23
17.54
13.1
10.58
10.77
59.52
59.52
4.35

23
22
51
15
47
46
10
10
32
256

13.89
13.89
18.31
11.62
9.4
9.4
12
34.75
4.8

12
11
44
15
22
21
19
18
16
178

10.6%
10.2%
14.6%
10.0%
13.1%
13.0%
7.0%
9.6%
11.9%
100.0%

0.13 [-0.57 , 0.83]
-0.33 [-1.06 , 0.40]
-0.11 [-0.51 , 0.30]
-0.85 [-1.60 , -0.09]
-0.28 [-0.79 , 0.23]
-0.28 [-0.80 , 0.24]
-2.59 [-3.63 , -1.54]
-0.49 [-1.27 , 0.30]
-0.13 [-0.73 , 0.47]
-0.44 [-0.79 , -0.08]

-4

-2
Favours CBT

0

2

4

Favours Attention control

Analysis 3.17.   Comparison 3: CBT versus attention control, Outcome
17: Reduction in anxiety symptoms (parent report) at follow-up

Study or Subgroup

Mean

CBT
SD

Total

Attention control
SD

Total

Mean

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

3.17.1 Follow-up (≤ 6 months)
Herbert 2009
Herbert 2009
Hudson 2009
Masia Warner 2007
Masia Warner 2016
Masia Warner 2016
Rosa Alcazar 2009
Rosa Alcazar 2009
Silverman 1999a
Subtotal (95% CI)
Heterogeneity: Tau² = 0.99; Chi² = 81.78, df = 8 (P < 0.00001); I² = 90%
Test for overall effect: Z = 1.74 (P = 0.08)

18.32
12.88
13.43
1.94
10.48
8.45
11.48
11.48
5.4

57.4
61.08
18.85
8.9
17.62
15.57
31.75
31.75
6.95

47
47
22.24
10.6
16.43
16.43
79.66
72.89
6.01

23
22
51
15
47
46
10
10
32
256

14.21
14.21
13.73
2.32
7.87
7.87
8.37
10.88
4

12
11
44
15
22
21
18
19
16
178

11.5%
11.3%
12.5%
11.4%
12.2%
12.2%
7.9%
9.2%
11.9%
100.0%

0.60 [-0.12 , 1.31]
1.03 [0.26 , 1.80]
-0.25 [-0.65 , 0.16]
-0.77 [-1.52 , -0.03]
0.12 [-0.39 , 0.63]
-0.10 [-0.62 , 0.41]
-4.86 [-6.44 , -3.29]
-3.61 [-4.87 , -2.35]
0.19 [-0.42 , 0.79]
-0.63 [-1.33 , 0.08]

-4

-2
Favours CBT

0

2

4

Favours Attention control

Comparison 4.   CBT versus alternative treatment

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

4.1 Acceptability (number of participants
lost to post-treatment assessment)

4.2 Remission of all anxiety diagnoses post-
treatment (ITT)

4.3 Remission of all anxiety diagnoses post-
treatment (completers)

4.4 Reduction in anxiety symptoms (child
report) post-treatment

7

4

4

6

515

401

348

399

Odds Ratio (IV, Random,
95% CI)

1.58 [0.61, 4.13]

Odds Ratio (IV, Random,
95% CI)

0.89 [0.35, 2.23]

Odds Ratio (IV, Random,
95% CI)

1.52 [0.70, 3.27]

Std. Mean Difference (IV,
Random, 95% CI)

-0.09 [-0.40, 0.21]

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

260

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

4.5 Sensitivity analysis: reduction in anx-
iety symptoms (child report) post-treat-
ment (broad anxiety measures only)

4.6 Reduction in anxiety symptoms (parent
report) post-treatment

5

6

378

423

Std. Mean Difference (IV,
Random, 95% CI)

-0.00 [-0.21, 0.20]

Std. Mean Difference (IV,
Random, 95% CI)

-0.13 [-0.33, 0.06]

Analysis 4.1.   Comparison 4: CBT versus alternative treatment, Outcome 1:
Acceptability (number of participants lost to post-treatment assessment)

Study or Subgroup

Events

Total

CBT

Alternative treatment
Events

Total

Odds Ratio
IV, Random, 95% CI

Weight

Odds Ratio
IV, Random, 95% CI

Cheung 2016
Creswell 2017
Lebowitz 2019
Murphy 2017
Reigada 2015
Salum 2018
Silk 2018

1
11
11
0
2
10
5

20
62
60
17
11
21
90

0
3
16
2
0
2
4

281

Total (95% CI)
40
Total events:
Heterogeneity: Tau² = 0.77; Chi² = 12.66, df = 6 (P = 0.05); I² = 53%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable

27

20
60
64
19
11
17
43

6.8%
19.4%
24.8%
7.3%
7.1%
15.6%
19.0%

3.15 [0.12 , 82.16]
4.10 [1.08 , 15.52]
0.67 [0.28 , 1.60]
0.20 [0.01 , 4.47]
6.05 [0.26 , 142.04]
6.82 [1.24 , 37.54]
0.57 [0.15 , 2.25]

234

100.0%

1.58 [0.61 , 4.13]

0.01

0.1
Favours CBT

1

10

100
Favours Alternative treatment

Analysis 4.2.   Comparison 4: CBT versus alternative treatment,
Outcome 2: Remission of all anxiety diagnoses post-treatment (ITT)

Study or Subgroup

Events

Total

CBT

Alternative treatment
Events

Total

Odds Ratio
IV, Random, 95% CI

Weight

Odds Ratio
IV, Random, 95% CI

Creswell 2017
Lebowitz 2019
Reigada 2015
Silk 2018

20
31
5
74

62
60
11
90

26
49
2
31

60
64
11
43

29.5%
29.0%
13.9%
27.6%

0.62 [0.30 , 1.30]
0.33 [0.15 , 0.71]
3.75 [0.54 , 26.04]
1.79 [0.76 , 4.22]

223

Total (95% CI)
130
Total events:
Heterogeneity: Tau² = 0.61; Chi² = 11.30, df = 3 (P = 0.01); I² = 73%
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Not applicable

108

178

100.0%

0.89 [0.35 , 2.23]

0.01
Favours Alternative treatment

0.1

1

10
Favours CBT

100

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

261

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.3.   Comparison 4: CBT versus alternative treatment, Outcome
3: Remission of all anxiety diagnoses post-treatment (completers)

Study or Subgroup

Events

Total

CBT

Alternative treatment
Events

Total

Odds Ratio
IV, Random, 95% CI

Weight

Odds Ratio
IV, Random, 95% CI

Creswell 2017
Lebowitz 2019
Reigada 2015
Silk 2018

20
31
5
74

50
49
9
85

23
33
2
27

57
48
11
39

31.5%
29.8%
11.1%
27.6%

0.99 [0.45 , 2.14]
0.78 [0.34 , 1.82]
5.63 [0.75 , 42.36]
2.99 [1.18 , 7.57]

193

Total (95% CI)
130
Total events:
Heterogeneity: Tau² = 0.33; Chi² = 6.97, df = 3 (P = 0.07); I² = 57%
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Not applicable

85

155

100.0%

1.52 [0.70 , 3.27]

0.01
Favours Alternative treatment

0.1

1

10
Favours CBT

100

Analysis 4.4.   Comparison 4: CBT versus alternative treatment, Outcome
4: Reduction in anxiety symptoms (child report) post-treatment

Study or Subgroup

Mean

CBT
SD

Total

Alternative treatment
SD

Total

Mean

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Cheung 2016
Creswell 2017
Lebowitz 2019
Reigada 2015
Salum 2018
Silk 2018

50.63
31.49
19.63
5.55
36.58
17

29.32
24.02
14.05
12.57
23.6
15.38

19
39
49
10
21
79

45.4
25.1
22.12
31.04
37.21
19.65

25.46
19
13.9
23.95
18.68
14.48

20
52
48
11
17
34

14.0%
21.0%
21.8%
7.9%
13.7%
21.6%

0.19 [-0.44 , 0.82]
0.30 [-0.12 , 0.72]
-0.18 [-0.58 , 0.22]
-1.26 [-2.22 , -0.31]
-0.03 [-0.67 , 0.61]
-0.17 [-0.58 , 0.23]

Total (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 10.13, df = 5 (P = 0.07); I² = 51%
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Not applicable

217

182

100.0%

-0.09 [-0.40 , 0.21]

-4

-2
Favours CBT

0

2

4
Favours Alternative treatment

Analysis 4.5.   Comparison 4: CBT versus alternative treatment, Outcome 5: Sensitivity analysis:
reduction in anxiety symptoms (child report) post-treatment (broad anxiety measures only)

Study or Subgroup

Mean

CBT
SD

Total

Alternative treatment
SD

Total

Mean

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Cheung 2016
Creswell 2017
Lebowitz 2019
Salum 2018
Silk 2018

50.63
31.49
19.63
36.58
17

29.32
24.02
14.05
23.6
15.38

19
39
49
21
79

45.4
25.1
22.12
37.21
19.65

25.46
19
13.9
18.68
14.48

20
52
48
17
34

10.9%
24.8%
27.1%
10.6%
26.6%

0.19 [-0.44 , 0.82]
0.30 [-0.12 , 0.72]
-0.18 [-0.58 , 0.22]
-0.03 [-0.67 , 0.61]
-0.17 [-0.58 , 0.23]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 3.77, df = 4 (P = 0.44); I² = 0%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable

207

171

100.0%

-0.00 [-0.21 , 0.20]

-4

-2
Favours CBT

0

2

4
Favours Alternative treatment

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

262

 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 4.6.   Comparison 4: CBT versus alternative treatment, Outcome
6: Reduction in anxiety symptoms (parent report) post-treatment

Study or Subgroup

Mean

CBT
SD

Total

Alternative treatment
SD

Total

Mean

Weight

Std. Mean Difference
IV, Random, 95% CI

Std. Mean Difference
IV, Random, 95% CI

Cheung 2016
Creswell 2017
Lebowitz 2019
Murphy 2017
Salum 2018
Silk 2018

47.79
24.87
17.29
27.93
27.81
21.52

23.07
12.96
12.43
14.72
19.98
12.81

19
45
49
17
21
79

50.45
25.82
22.04
22.26
32.17
23.37

24.75
13.33
13.72
10.48
16.62
13.41

20
54
48
19
17
35

9.7%
24.4%
23.8%
8.7%
9.3%
24.1%

-0.11 [-0.74 , 0.52]
-0.07 [-0.47 , 0.32]
-0.36 [-0.76 , 0.04]
0.44 [-0.22 , 1.10]
-0.23 [-0.87 , 0.41]
-0.14 [-0.54 , 0.26]

Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 4.27, df = 5 (P = 0.51); I² = 0%
Test for overall effect: Z = 1.31 (P = 0.19)
Test for subgroup differences: Not applicable

230

193

100.0%

-0.13 [-0.33 , 0.06]

-4

-2
Favours CBT

0

2

4
Favours Alternative treatment

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

263

 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
2
0
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

C
o
g
n
i
t
i
v
e
b
e
h
a
v
i
o
u
r
a
l

t
h
e
r
a
p
y
f
o
r
a
n
x
i
e
t
y
d
i
s
o
r
d
e
r
s
i

n
c
h
i
l

d
r
e
n
a
n
d
a
d
o
l
e
s
c
e
n
t
s
(
R
e
v
i
e
w

)

A D D I T I O N A L   T A B L E S
Table 1.   Summary of characteristics of included studies 

Study

Comparison 1

Compar-
ison 2

Compar-
ison 3

CBT vs
Wait
list / no
treat-
ment

CBT vs
Wait
list / no
treat-
ment

CBT vs
Wait
list / no
treat-
ment

Afshari
2014

CBT vs Wait list / no
treatment

Arendt
2016

Barrett
1996

CBT vs Wait list / no
treatment

CBT vs Wait list / no
treatment

Barrett
1998

CBT vs Wait list / no
treatment

Barrington
2005

CBT vs TAU

Berge
2017

CBT vs Wait list / no
treatment

Cartwright
Hatton
2011

CBT vs Wait list / no
treatment

Chalfant
2007

CBT vs Wait list / no
treatment

Delivery
mode

Delivery
mode

ASD vs
not ASD

Broad vs
specific
anxiety
measure

Ther-
apist
contact
time
(hours)

Age

Setting

Disor-
der-spe-
cific

Other
comor-
bid con-
ditions
(re-
quired)

Broad

Child fo-
cused

Group

Not ASD

10 to 20

mix

clinic

Broad

Broad

Child+par-
ent

Child fo-
cused and
child+par-
ent

Child fo-
cused and
child+par-
ent

Group

Not ASD

20+

mix

Individ-
ual

Not ASD

10 to 20

mix

Group

Not ASD

20+

mix

clinic (uni-
versity)

clinic (uni-
versity)

clinic (uni-
versity)

Broad

Child+par-
ent

Individ-
ual

Not ASD

10 to 20

mix

clinic
(CAMHS)

Specific

Child fo-
cused

Individ-
ual

Not ASD

less than
10

mix

clinic -
dental

Specific
Phobia

Parent on-
ly

Child+par-
ent

Group

Not ASD

20+

≤ 12

clinic-uni-
versity
hospital

Group

ASD

20+

mix

clinic

Child fo-
cused

Individ-
ual

Not ASD

10 to 20

≤ 12

clin-
ic-CAMHS

Broad

Broad

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

Cheung
2016

CBT vs Wait list / no
treatment

CBT vs
Alter-

2
6
4

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
2
0
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

C
o
g
n
i
t
i
v
e
b
e
h
a
v
i
o
u
r
a
l

t
h
e
r
a
p
y
f
o
r
a
n
x
i
e
t
y
d
i
s
o
r
d
e
r
s
i

n
c
h
i
l

d
r
e
n
a
n
d
a
d
o
l
e
s
c
e
n
t
s
(
R
e
v
i
e
w

)

Table 1.   Summary of characteristics of included studies  (Continued)

Chiu 2013

CBT vs Wait list / no
treatment

Cobham
2017

CBT vs Wait list / no
treatment

Cornac-
chio 2019

CBT vs Wait list / no
treatment

Creswell
2017

CBT vs Alertnative
treatment

Dadds
1997

CBT vs Wait list / no
treatment

Flannery
Schroeder
2000

CBT vs Wait list / no
treatment

native
treat-
ment

CBT vs
Wait
list / no
treat-
ment

Broad

Broad

Broad

Broad

Broad

Child fo-
cused

Individ-
ual

Not ASD

10 to 20

≤ 12

school

Parent on-
ly

Child+par-
ent

Group

Not ASD

less than
10

mix

clinic (uni-
versity)

Group

Not ASD

20+

≤ 12

clinic

Parent on-
ly

Individ-
ual

Not ASD

less than
10

≤ 12

clinic
(CAMHS)

Child fo-
cused

Child fo-
cused

Group

Not ASD

10 to 20

mix

school

Individ-
ual and
group

Not ASD

10 to 20
and 20+

mix

clinic (uni-
versity)

Selective
mutism

Fujii 2013

CBT vs TAU

Child+
parent

Individ-
ual

ASD

20+

≤ 12

clinic

Gallagher
2004

CBT vs Wait list / no
treatment

Broad

Child fo-
cused

Group

Not ASD

Ginsburg
2002

CBT vs Attention
control

Ginsburg
2012

Ginsburg
2019

CBT vs TAU

CBT vs TAU

Hancock
2018

CBT vs Wait list / no
treatment

CBT vs
Wait
list / no

2
6
5

Broad

Broad

Broad

Child fo-
cused

Child fo-
cused

Child fo-
cused

Child
+parent

less than
10

less than
10

less than
10

less than
10

≤ 12

clinic

Social
anxiety
disorder

≥ 12

school

mix

school

mix

school

Group

Not ASD

Individ-
ual

Individ-
ual

Not ASD

Not ASD

Group

Not ASD

10 to 20

mix

clinic (uni-
versity)

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 1.   Summary of characteristics of included studies  (Continued)

treat-
ment

CBT vs
Atten-
tion con-
trol

CBT vs
Atten-
tion con-
trol

CBT vs
Atten-
tion con-
trol

Herbert
2009

CBT vs Attention
control

Hirshfeld
Becker
2010

Holmes
2014

Hudson
2009

CBT vs Wait list / no
treatment

CBT vs Wait list / no
treatment

CBT vs Attention
control

Ingul 2003

CBT vs Attention
control

Ishikawa
2019

CBT vs Wait list / no
treatment

Kendall
1994

Kendall
1997

Kendall
2008

CBT vs Wait list / no
treatment

CBT vs Wait list / no
treatment

CBT vs Attention
control

Kennedy
2009

CBT vs Wait list / no
treatment

Khanna
2010

CBT vs Attention
control

C
o
p
y
r
i
g
h
t

©
2
0
2
0
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

C
o
g
n
i
t
i
v
e
b
e
h
a
v
i
o
u
r
a
l

t
h
e
r
a
p
y
f
o
r
a
n
x
i
e
t
y
d
i
s
o
r
d
e
r
s
i

n
c
h
i
l

d
r
e
n
a
n
d
a
d
o
l
e
s
c
e
n
t
s
(
R
e
v
i
e
w

)

2
6
6

Specific

Child fo-
cused

Group
and Indi-
vidual

Not ASD

20+ and
10 to 20

≥ 12

clinic (uni-
versity)

Social
anxiety
disorder

Child +
parent

Individ-
ual

Not ASD

20+

≤ 12

clinic (uni-
versity)

Group

Not ASD

10 to 20

≤ 12

Group

Not ASD

20+

mix

clinic (uni-
versity)

GAD

clinic (uni-
versity)

Not ASD

10 to 20

≥ 12

schools

Social
anxiety
disorder

Not ASD

less than
10

mix

clinic

Not ASD

10 to 20

mix

Not ASD

10 to 20

mix

Not ASD

10 to 20

mix

Child +
parent

Child
+parent

Child fo-
cused

Child
+parent

Child fo-
cused

Child fo-
cused

Child fo-
cused and
child+par-
ent

Parent on-
ly

Individ-
ual and
Group

Individ-
ual

Individ-
ual

Individ-
ual

Individ-
ual

Broad

Broad

Broad

Broad

Broad

Broad

Broad

Broad

Broad

Group

Not ASD

10 to 20

≤ 12

Child fo-
cused

Individ-
ual

Not ASD

10 to 20

mix

clinic (uni-
versity)

clinic (uni-
versity)

clinic (uni-
versity)

clinic (uni-
versity)

clinic (uni-
versity)

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 1.   Summary of characteristics of included studies  (Continued)

Kidd 2018

CBT vs Wait list / no
treatment

Last 1998

CBT vs Attention
control

Lau 2010

CBT vs Wait list / no
treatment

Lau 2017

CBT vs Wait list / no
treatment

Lebowitz
2019

CBT vs Alternative
treatment

Leutgeb
2012

CBT vs Wait list / no
treatment

Broad

Broad

Broad

Broad

Broad

Broad

Child +
parent

Group

ASD

20+

≥ 12

Child and
parent

Individ-
ual

Not ASD

10 to 20

mix

clinic (uni-
versity)

clinic (uni-
versity)

School
refusal

Child fo-
cused

Child
+parent

Child fo-
cused

Child fo-
cused

Group

Not ASD

10 to 20

≤ 12

clinic

Group

Not ASD

10 to 20

≤ 12

child cen-
tres and
preschools

Individ-
ual

Individ-
ual

Not ASD

10 to 20

≤ 12

clinic

Not ASD

less than
10

mix

university

Masia
Warner
2005

Masia
Warner
2007

Masia
Warner
2011

Masia
Warner
2016

CBT vs Wait list / no
treatment

CBT vs Attention
control

CBT vs Wait list / no
treatment

Specific

Child fo-
cused

Group
focused

Not ASD

10 to 20

≥ 12

School

Specific

Child fo-
cused

Group
focused

Not ASD

10 to 20

≥ 12

School

Child fo-
cused

Individ-
ual

Not ASD

10 to 20

mix

primary
care/spe-
cial clinic

CBT vs Attention
control

CBT vs
Atten-
tion con-
trol

Specific

Child fo-
cused

Group
focused

Not ASD

10 to 20

≥ 12

School

Mc-
Conachie
2014

CBT vs Wait list / no
treatment

Broad

Child +
parent

Group

ASD

20+

mix

clinic (uni-
versity)

Specific
Phobia

Social
anxiety
disorder

Social
anxiety
disorder

Social
anxiety
disorder

function-
al physi-
cal com-
plaints

C
o
p
y
r
i
g
h
t

©
2
0
2
0
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

C
o
g
n
i
t
i
v
e
b
e
h
a
v
i
o
u
r
a
l

t
h
e
r
a
p
y
f
o
r
a
n
x
i
e
t
y
d
i
s
o
r
d
e
r
s
i

n
c
h
i
l

d
r
e
n
a
n
d
a
d
o
l
e
s
c
e
n
t
s
(
R
e
v
i
e
w

)

2
6
7

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 1.   Summary of characteristics of included studies  (Continued)

McNal-
ly Keehn
2013

CBT vs Wait list / no
treatment

Melfsen
2011

CBT vs Wait list / no
treatment

Muris 2002

CBT vs Attention
control

Murphy
2017

CBT vs Alternative
treatment

O'Brien
2007

CBT vs TAU

Olivares
2005

CBT vs Wait list / no
treatment

Olivares
2014

CBT vs Wait list / no
treatment

Olivares
2019

CBT vs Wait list / no
treatment

Ollendick
2009

CBT vs Wait list / no
treatment

Ost 2001

CBT vs Wait list / no
treatment

CBT vs
Wait
list / no
treat-
ment

CBT vs
Wait
list / no
treat-
ment

CBT vs
Atten-
tion con-
trol

CBT vs
Wait
list / no

Broad

Child fo-
cused

Individ-
ual

ASD

20+

mix

clinic (uni-
versity)

Specific

Child and
parent

Individ-
ual

Not ASD

20+

mix

clinic

Broad

Broad

Specific

Child fo-
cused

Child fo-
cused

Child and
parent

Child fo-
cused

Specific

Child fo-
cused

Group

Not ASD

less than
10

≤ 12

school

ASD

10 to 20

≥ 12

CAMHS

Individ-
ual fo-
cused

Group

Not ASD

10 to 20

mix

clinic

Group

Not ASD

10 to 20

≥ 12

school

Group

Not ASD

10 to 20

≥ 12

school

Child fo-
cused

Group

Not ASD

10 to 20

≥ 12

school

Social
anxiety
disorder

Social
anxiety
disorder

Social
anxiety
disorder

Social
anxiety
disorder

Broad

Child fo-
cused

Individ-
ual

Not ASD

less than
10

mix

clinic

Specific
Phobia

Broad

Child fo-
cused and
child+par-
ent

Individ-
ual

Not ASD

less than
10

mix

Specific
Phobia

referrals
from clin-
ic and
schools

C
o
p
y
r
i
g
h
t

©
2
0
2
0
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

C
o
g
n
i
t
i
v
e
b
e
h
a
v
i
o
u
r
a
l

t
h
e
r
a
p
y
f
o
r
a
n
x
i
e
t
y
d
i
s
o
r
d
e
r
s
i

n
c
h
i
l

d
r
e
n
a
n
d
a
d
o
l
e
s
c
e
n
t
s
(
R
e
v
i
e
w

)

2
6
8

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
2
0
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

C
o
g
n
i
t
i
v
e
b
e
h
a
v
i
o
u
r
a
l

t
h
e
r
a
p
y
f
o
r
a
n
x
i
e
t
y
d
i
s
o
r
d
e
r
s
i

n
c
h
i
l

d
r
e
n
a
n
d
a
d
o
l
e
s
c
e
n
t
s
(
R
e
v
i
e
w

)

2
6
9

Table 1.   Summary of characteristics of included studies  (Continued)

treat-
ment

Perrin
2019

Pincus
2010

Rapee
2005

Rapee
2006

Reaven
2012

CBT vs Wait list / no
treatment

CBT vs Attention
control

CBt vs Wait list / no
treatment

CBT vs Wait list / no
treatment

CBT vs TAU

Reigada
2015

CBT vs Alternative
treatment

Rosa-Al-
cazar 2009

Cbt vs Attention
control

Broad

Broad

Broad

Broad

Child fo-
cused

Child fo-
cused

Parent on-
ly

Child+par-
ent

Child+par-
ent

Individ-
ual

Individ-
ual

Not ASD

10 to 20

mix

CAMHS

GAD

Not ASD

less than
10

≥ 12

clinic (uni-
versity)

Panic
Disorder

Group

Not ASD

less than
10

≤ 12

preschools

Group

Not ASD

10 to 20

≤ 12

Group

ASD

10 to 20

mix

clinic (uni-
versity)

clinic (uni-
versity)

clinic (uni-
versity)

IBD

Social
anxiety
disorder

Specific

Child fo-
cused

Individ-
ual

Not ASD

10 to 20

mix

Specific

Child fo-
cused

Group

Not ASD

10 to 20

≥ 12

School

CBT vs
Atten-
tion con-
trol

CBT vs
Wait
list / no
treat-
ment

Salari
2018

Salum
2018

CBT vs Wait list / no
treatment

CBT vs Attention
control

Sanchez
Garcia
2009

CBT vs Wait list / no
treatment

Santucci
2013

CBT vs Wait list / no
treatment

CBT vs
Alter-
native
treat-
ment

Broad

Broad

Parent on-
ly

Child+par-
ent

Group

Not ASD

10 to 20

≤ 12

clinic (uni-
versity)

Group

Not ASD

10 to 20

≤ 12

clinic

Specific

Child fo-
cused

Broad

Child
+parent

Group

Not ASD

10 to 20

mix

School

Group

Not ASD

20+

≤ 12

clinic (uni-
versity)

Social
anxiety
disorder

Separa-
tion anx-
iety dis-
order

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 1.   Summary of characteristics of included studies  (Continued)

Schneider
2011

CBT vs Wait list / no
treatment

Broad

Child
+parent

Individ-
ual

Not ASD

10 to 20

≤ 12

clinic (uni-
versity)

Separa-
tion anx-
iety dis-
order

Sciberras
2018

CBT vs TAU

Broad

Child+par-
ent

Individ-
ual

Not ASD

10 to 20

≤ 12

clinic AD-
HD

ADHD

C
o
p
y
r
i
g
h
t

©
2
0
2
0
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

C
o
g
n
i
t
i
v
e
b
e
h
a
v
i
o
u
r
a
l

t
h
e
r
a
p
y
f
o
r
a
n
x
i
e
t
y
d
i
s
o
r
d
e
r
s
i

n
c
h
i
l

d
r
e
n
a
n
d
a
d
o
l
e
s
c
e
n
t
s
(
R
e
v
i
e
w

)

Shah-
navaz
2016

Sharma
2017

Shortt
2001

CBT vs TAU

CBT vs TAU

CBT vs Wait list / no
treatment

Silk 2018

CBT vs Alternative
treatment

Silverman
1999a

CBT vs Attention
control

Silverman
1999b

CBT vs Wait list / no
treatment

Simon
2011

CBt vsWait list / no
treatment

Smith
2014

CBT vs Wait list / no
treatment

CBT vs TAU

Southam
Gerow
2010

CBT vs
Wait
list / no
treat-
ment

Spence
2000

CBT vs Wait list / no
treatment

CBT vs
Wait
list / no

2
7
0

Specific

Child+par-
ent

Individ-
ual

Not ASD

10 to 20

mix

dental
clinics

Specific
Phobia

Broad

Broad

Broad

Broad

Broad

Broad

Broad

Broad

Broad

Child fo-
cused

Child+par-
ent

Group

Not ASD

20+

mix

Group

Not ASD

10 to 20

≤ 12

Child fo-
cused

Individ-
ual

Child+par-
ent

Individ-
ual

Not ASD

10 to 20

mix

Not ASD

10 to 20

mix

Group

Not ASD

10 to 20

mix

Headaches

clinic (uni-
versity)

clinic (uni-
versity)

clinic (uni-
versity)

clinic (uni-
versity)

Child +
parent

Child fo-
cused and
parent on-
ly

Group

Not ASD

mix

School

less than
10 and
10 to 20

Parent on-
ly

Individ-
ual

Child fo-
cused

Individ-
ual

Not ASD

10 to 20

mix

clinic (uni-
versity)

Not ASD

10 to 20

mix

clinics

Child fo-
cused and
child+par-
ent

Group

Not ASD

20+ and
10 to 20

mix

clinic (uni-
versity)

Social
anxiety
disorder

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C
o
p
y
r
i
g
h
t

©
2
0
2
0
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

C
o
g
n
i
t
i
v
e
b
e
h
a
v
i
o
u
r
a
l

t
h
e
r
a
p
y
f
o
r
a
n
x
i
e
t
y
d
i
s
o
r
d
e
r
s
i

n
c
h
i
l

d
r
e
n
a
n
d
a
d
o
l
e
s
c
e
n
t
s
(
R
e
v
i
e
w

)

Table 1.   Summary of characteristics of included studies  (Continued)

Spence
2006

Spence
2011

Storch
2013

Storch
2015

CBT vs Wait list / no
treatment

CBT vs Wait list / no
treatment

CBT vs TAU

CBT vs TAU

Thirlwall
2013

CBT vs Wait list / no
treatment

Villabo
2018

CBT vs Wait list / no
treatment

Waters
2009

CBT vs Wait list / no
treatment

Wergele-
nad 2014

CBT vs Wait list / no
treatment

treat-
ment

CBT vs
Wait
list / no
treat-
ment

CBT vs
Wait
list / no
treat-
ment

CBT vs
Wait
list / no
treat-
ment

CBT vs
Wait
list / no
treat-
ment

Broad

Broad

Broad

Broad

Broad

Child+par-
ent

Group

Not ASD

10 to 20

mix

Child+par-
ent

Individ-
ual

Child+par-
ent

Individ-
ual

Child+par-
ent

Individ-
ual

Not ASD

10 to 20

≥ 12

ASD

20+

≤ 12

ASD

20+

≥ 12

clinic (uni-
versity)

clinic (uni-
versity)

clinic (uni-
versity)

clinic (uni-
versity)

Parent on-
ly

Individ-
ual

Not ASD

less than
10

≤ 12

clinic

Broad

Child fo-
cused

Individ-
ual and
Group

Not ASD

10 to 20

mix

clinic

Group

Not ASD

10 to 20
and 20 +

≤ 12

clinic (uni-
versity)

Child+Par-
ent and
parent on-
ly

Broad

Child+par-
ent

Individ-
ual and
group

Not ASD

10 to 20

mix

clin-
ics-CAMHS

White
2013

Wood
2009

CBT vs Wait list / no
treatment

CBT vs Wait list / no
treatment

2
7
1

Broad

Broad

Child+par-
ent

Individ-
ual

Child+par-
ent

Individ-
ual

ASD

20+

≥ 12

ASD

20+

mix

clinic (uni-
versity)

clinic (uni-
versity)

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 1.   Summary of characteristics of included studies  (Continued)

Wood
2015

CBT vs Wait list / no
treatment

Broad

Child+par-
ent

Individ-
ual

ASD

20+

mix

clinic (uni-
versity)

ASD: autism spectrum disorders
CBT: cognitive behavioural therapy
GAD: generalised anxiety disorder
TAU: treatment as usual

C
o
p
y
r
i
g
h
t

©
2
0
2
0
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

C
o
g
n
i
t
i
v
e
b
e
h
a
v
i
o
u
r
a
l

t
h
e
r
a
p
y
f
o
r
a
n
x
i
e
t
y
d
i
s
o
r
d
e
r
s
i

n
c
h
i
l

d
r
e
n
a
n
d
a
d
o
l
e
s
c
e
n
t
s
(
R
e
v
i
e
w

)

2
7
2

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

A P P E N D I C E S

Appendix 1. Hierarchy of anxiety symptoms measures

Broad-based anxiety measures

1. Spence Children’s Anxiety Scale (SCAS) (child-/parent-report versions) or derivatives of the SCAS, including Revised Children’s Anx-
iety and Depression Scale (RCADS) (child- and parent-report versions) Anxiety Scale and the Preschool Anxiety Scale (parent-report)

2. Multidimensional Anxiety Scale for Children (MASC) (child- and parent-report versions)

3. Screen for Child Anxiety Related Disorders (SCARED) (child- and parent-report versions)

4. Revised Children’s Manifest Anxiety Scale (RCMAS)

5. State-Trait Anxiety Inventory for Children (STAIC) - Trait Scale

6. Child and Adolescent Symptom Inventory-4 ASD Anxiety Scale

Social anxiety (disorder-specific) measures

7. Social Phobia and Anxiety Inventory for Children (SPAI-C)

8. Social Anxiety Scale for Adolescents (SAS-A)/Social Anxiety Scale for Children-Revised (SASC-R)

Appendix 2. Cochrane Common Mental Disorders Controlled Trials Register (CCMDCTR)

Cochrane Common Mental Disorders Controlled Trials Register (CCMDCTR)

Cochrane Common Mental Disorders (CCMD) maintains two archived clinical trials registers at its editorial base in York, UK: a references
register and a studies-based register. The CCMDCTR-References Register contains over 40,000 reports of RCTs in depression, anxiety and
neurosis. Approximately 50% of these references have been tagged to individual, coded trials. The coded trials are held in the CCMDCTR-
Studies Register and records are linked between the two registers through the use of unique Study ID tags. Coding of trials is based on
the EU-Psi coding manual, using a controlled vocabulary; (please contact the CCMD Information Specialists for further details). Reports of
trials for inclusion in the Group's registers are collated from routine (weekly), generic searches of MEDLINE (1950 to 2016), Embase (1974 to
2016) and PsycINFO (1967 to 2016); quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL) and review-specific
searches of additional databases. Reports of trials are also sourced from international trial registers via the World Health Organization's
trials portal (the International Clinical Trials Registry Platform (ICTRP)), pharmaceutical companies, the handsearching of key journals,
conference proceedings and other (non-Cochrane) systematic reviews and meta-analyses.

Details of CCMD's generic search strategies (used to identify RCTs) can be found on the Group's website, (cmd.cochrane.org/specialised-
register), with an example of the core MEDLINE search (used to inform the register) listed below. The Group’s Specialised Register has fallen
out of date with the Editorial Group’s move from Bristol to York in the summer of 2016.

Core search strategy used to inform the Cochrane Common Mental Disorders Group's Specialised Register: OVID MEDLINE (to June
2016)

A weekly search alert based on condition + RCT filter only
1.  [MeSH  Headings]:  eating  disorders/  or  anorexia  nervosa/  or  binge-eating  disorder/  or  bulimia  nervosa/  or  female  athlete  triad
syndrome/ or pica/ or hyperphagia/ or bulimia/ or self-injurious behavior/ or self mutilation/ or suicide/ or suicidal ideation/ or suicide,
attempted/ or mood disorders/ or affective disorders, psychotic/ or bipolar disorder/ or cyclothymic disorder/ or depressive disorder/ or
depression, postpartum/ or depressive disorder, major/ or depressive disorder, treatment-resistant/ or dysthymic disorder/ or seasonal
affective  disorder/  or  neurotic  disorders/  or  depression/  or  adjustment  disorders/  or  exp  antidepressive  agents/  or  anxiety  disorders/
or  agoraphobia/  or  neurocirculatory  asthenia/  or  obsessive-compulsive  disorder/  or  obsessive  hoarding/  or  panic  disorder/  or  phobic
disorders/ or stress disorders, traumatic/ or combat disorders/ or stress disorders, post-traumatic/ or stress disorders, traumatic, acute/
or anxiety/ or anxiety, castration/ or koro/ or anxiety, separation/ or panic/ or exp anti-anxiety agents/ or somatoform disorders/ or body
dysmorphic disorders/ or conversion disorder/ or hypochondriasis/ or neurasthenia/ or hysteria/ or munchausen syndrome by proxy/ or

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

273

 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

munchausen syndrome/ or fatigue syndrome, chronic/ or obsessive behavior/ or compulsive behavior/ or behavior, addictive/ or impulse
control disorders/ or firesetting behavior/ or gambling/ or trichotillomania/ or stress, psychological/ or burnout, professional/ or sexual
dysfunctions, psychological/ or vaginismus/ or Anhedonia/ or Affective Symptoms/ or *Mental Disorders/
2. [Title/ Author Keywords]: (eating disorder* or anorexia nervosa or bulimi* or binge eat* or (self adj (injur* or mutilat*)) or suicide* or
suicidal or parasuicid* or mood disorder* or affective disorder* or bipolar i or bipolar ii or (bipolar and (affective or disorder*)) or mania or
manic or cyclothymic* or depression or depressive or dysthymi* or neurotic or neurosis or adjustment disorder* or antidepress* or anxiety
disorder* or agoraphobia or obsess* or compulsi* or panic or phobi* or ptsd or posttrauma* or post trauma* or combat or somatoform
or somati#ation or medical* unexplained or body dysmorphi* or conversion disorder or hypochondria* or neurastheni* or hysteria or
munchausen or chronic fatigue* or gambling or trichotillomania or vaginismus or anhedoni* or affective symptoms or mental disorder*
or mental health).ti,kf.
3. [RCT filter]: (controlled clinical trial.pt. or randomized controlled trial.pt. or (randomi#ed or randomi#ation).ab,ti. or randomly.ab. or
(random* adj3 (administ* or allocat* or assign* or class* or control* or determine* or divide* or distribut* or expose* or fashion or number*
or place* or recruit* or subsitut* or treat*)).ab. or placebo*.ab,ti. or drug therapy.fs. or trial.ab,ti. or groups.ab. or (control* adj3 (trial*
or  study  or  studies)).ab,ti.  or  ((singl*  or  doubl*  or  tripl*  or  trebl*)  adj3  (blind*  or  mask*  or  dummy*)).mp.  or  clinical  trial,  phase  ii/  or
clinical trial, phase iii/ or clinical trial, phase iv/ or randomized controlled trial/ or pragmatic clinical trial/ or (quasi adj (experimental or
random*)).ti,ab. or ((waitlist* or wait* list* or treatment as usual or TAU) adj3 (control or group)).ab.)
4. (1 and 2 and 3)
Records are screened for reports of RCTs within the scope of the Cochrane Common Mental Disorders Group. Secondary reports of RCTs
are tagged to the appropriate study record.
Similar weekly search alerts are also conducted on OVID Embase and PsycINFO, using relevant subject headings (controlled vocabularies)
and search syntax, appropriate to each resource.

Search strategy for this review

The CCMDCTR was searched for this review using the following terms:

CCMDCTR-Studies (all years up to June 2016)
#1 (anxiety or anxious or phobi* or agoraphobi* or panic or mutism or "school refusal") and STUDY:CRSTYPE and INSEGMENT
#2 behavio* or cognitive or counsel* or train* or therap* or psychotherap* and STUDY:CRSTYPE and INSEGMENT
#3 (child* or adolescent*) and STUDY:CRSTYPE and INSEGMENT
#4 (#1 or #2 or #3)

CCMDCTR-References (all years up to June 2016)
[Outcomes]
#1 (ADIS-C* or ADIS-P* or DISCAP or SCARED or SCAS or RCADS or RCMAS or MASC or CBCL or STAI-C or SPAI-C or SAS-A) AND INSEGMENT
[Condition]
#2 (“anxiety disorder*” or agoraphobi* or “generalized anxiety” or “generalised anxiety” or GAD or (separation near2 anxiety) or (social
near2 anxi*) or (social near2 phobi*) or phobi* or panic or mute* or mutism or (school near2 refus*)) AND INSEGMENT
#3  ((infant*  or  child*  or  adolesc*  or  pediatric*  or  paediatric*  or  teen*  or  young*  or  youth  or  school*  or  preschool*)  near2  anxi*)  AND
INSEGMENT
#4 (anxiety. and (autism or autistic or “child development disorder*”)) AND INSEGMENT
#5 (anxiety or panic or phobi* or agoraphobi*):ti AND INSEGMENT
[Intervention]
#6  ((ACCEPTANCE  and  COMMITMENT)  or  “ANXIETY  MANAGEMENT”  or  “BEHAVIOUR  MODIFICATION”  or  “BEHAVIOR  MODIFICATION”  or
“BEHAVIOURAL MODIFICATION” or “BEHAVIORAL MODIFICATION” or BIBLIOTHERAPY or “COGNITIVE BEHAVIOUR THERAPY“ or “COGNITIVE
BEHAVIOR  THERAPY“  or  “COGNITIVE  BEHAVIOURAL  THERAPY“  or  “COGNITIVE  BEHAVIORAL  THERAPY“  or  “COGNITIVE  THERAPY“  or
“COGNITIVE TECHNIQUES” or “COGNITIVE RESTRUCTURING” or COUNSELING or (PSYCHOTHERAPY near2 GROUP) or “FAMILY THERAPY”
or “GROUP THERAPY” or MINDFULNESS or “PLAY THERAPY” or PSYCHODRAMA or PSYCHOTHERAPY or “RATIONAL EMOTIVE THERAPY” or
RELAXATION or “ROLE PLAYING” or “SENSITIVITY TRAINING” or BIBLIOTHERAPY or “SELF CONTROL”):emt,mh,kw,ky AND INSEGMENT
#7 (CBT or CBGT* or bCBT or b-CBT or GPDCBT or GPD-CBT) AND INSEGMENT
#8 ((cogniti* or behavio*) near3 (counsel* or intervention or therap* or psychotherap* or training or treatment or technique* or restructur*
or defusion)):ti,ab AND INSEGMENT
#9  (“rational  emoti*”  or  (problem*  near2  (focus*  or  sol*))  or  psychoeducat*  or  “role  play*”  or  schema*  or  “self-control*”  or  “self
control*”):ti,ab AND INSEGMENT
#10 (((psychotherap* or therap*) near3 (commitment or acceptance)) or ((self* or stress*) near3 (control or analysis or direct* or esteem
or help or instruct* or manage*))):ti,ab AND INSEGMENT
#11 ((attribution* or reattribution*) near3 (therap* or psychotherap*)):ti,ab AND INSEGMENT
#12  (mindfulness*  or  “third  wave”  or  experiential  or  (behavio*  near3  (activation  or  modification))  or  (thought*  near3  suppress*)  or
rumination):ti,ab AND INSEGMENT
#13 (“anxiety manag*” or “confidence building” or “coping skills” or “exposure therapy” or “exposure task*” or psychoeducat* or psycho-
educat* or relaxation or “sensitivity training” or “self talk” or (social near2 (coach* or skill* or effectiveness))):ti,ab AND INSEGMENT
#14 ((controlling or overcoming) near2 (anxiety or panic or phobi* or agoraphobi* or shyness)):ti,ab AND INSEGMENT

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

274

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

#15  (child*  near2  (cent*  or  deliver*  or  focus*)  adj2  (counsel*  or  intervention*  or  program*  or  psychotherap*  or  therap*  or  train*  or
treat*)):ti,ab AND INSEGMENT
#16 ((parent* or guardian*) near2 (cent* or deliver* or focus*) adj2 (counsel* or intervention* or program* or psychotherap* or therap* or
train* or treat*)):ti,ab AND INSEGMENT
#17 ((individually or group or conjoint or family) near2 (counsel* or intervention* or program* or psychotherap* or therap* or train* or
treat*)):ti,ab AND INSEGMENT
[Age Group]
#18 (infant* or child* or adolesc* or paediatr* or pediatr*):emt,mh,kw,ky,so AND INSEGMENT
#19 (infant* or child* or boy* or girl* or kids or juvenil* or minors or paediatric* or pediatric* or adolesc* or preadolesc* or pre-adolesc*
or pubert* or pubescen* or prepube* or pre-pube* or teen* or (young next (survivor* or offender* or minorit*)) or youth* or school* or
preschool* or nurser* or kindergarten):ti,emt,mh,kw,ky AND INSEGMENT
#20 (#2 OR #3 OR #4 OR #5) [Condition]
#21 (#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17) [Intervention]
#22 (#18 OR #19) [Age Group]
#23 (#20 AND #21 AND #22)
#24 ((anxi* or phobi* or agoraphobi* or panic) and (effectiveness or efficacy or evaluat* or intervention or program* or train* or treat* or
prevent* or therapy or psychotherapy or trial or study) and (infant* or child* or adolesc* or paediatric* or pediatric* or teen* or young* or
youth or school* or preschool*)):ti AND INSEGMENT
#25 (#24 AND #21)
#26 (#1 OR #23 OR #25)
#27 ((OCD or obsessive compulsive or PTSD or posttraumatic stress disorder* or post-traumatic stress disorder*) not (anxi* or phobi* or
agoraphobi* or panic)):ti AND INSEGMENT
#28 (#26 not #27)
#29 ((pregnan* or "post natal" or postnatal* "post partum" or postpartum) not (adolesc* or teen* or young* or youth*)):ti AND INSEGMENT
#30 (#28 not #29)
#31 (“Coping Cat” or “Cool Kids” or “Coping Koala” or “Face your Fear” or “Face your Fears” or “Facing your Fear” or “Facing your Fears”
or (“Multimodal Anxiety” and “Social Skills”) or (Academic and Skills and ”Social Success”) or (Intervention near adolesc* near “Social
Phobia”) or BIACA or IAFS or MASSI or SASS or TAPS) AND INSEGMENT
#32 (#30 OR #31)

Appendix 3. Database search strategies

In addition to searching the CCMDCTR we ran searches on CENTRAL, Ovid MEDLINE, Embase, and PsycINFO as listed below.

Dates of searches: 21 November 2018 and 10 October 2019.

Cochrane Central Register of Controlled Trials (CENTRAL; issue 10 of 12, 2019) in the Cochrane Library
#1 ((infant or infants or child* or adolesc* or pediatric* or paediatric* or teen* or young* or youth or school* or preschool*) and (anxi* or
phobi* or panic)):ti

#2 ((infant or infants or child* or adolesc* or pediatric* or paediatric* or teen* or young* or youth or school* or preschool*) near/2 (anxi*
or phobi* or panic)):ab

#3 MeSH descriptor: [Anxiety Disorders] this term only
#4 MeSH descriptor: [Anxiety] this term only and with qualifier(s): [diagnosis - DI, prevention & control - PC, psychology - PX, therapy - TH]

#5 MeSH descriptor: [Agoraphobia] this term only

#6 MeSH descriptor: [Panic Disorder] this term only

#7 MeSH descriptor: [Anxiety, Separation] this term only

#8 MeSH descriptor: [Phobic Disorders] explode all trees

#9 MeSH descriptor: [Phobia, Social] this term only

#10 (agoraphobi* or "generalized anxiety" or "generalised anxiety" or GAD or "separation anxiety" or (social* NEAR/2 (anxi* or fear*)) or
phobi* or mute or mutes or mutism or "school refusal”):ti,ab,kw

#11 panic:ti,ab,kw

#12 (anxiety near (autism or autistic)):ti,ab,kw
#13 MeSH descriptor: [Child Development Disorders, Pervasive] explode all trees

#14 anxiety:ti,ab,kw

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

275

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

#15 (#13 and #14)

#16 (#3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #15)
#17 MeSH descriptor: [Cognitive Therapy] explode all trees

#18 MeSH descriptor: [Psychotherapy, Group] explode all trees

#19 MeSH descriptor: [Bibliotherapy] this term only

#20 MeSH descriptor: [Early Intervention (Education)] this term only

#21 (CBT or CBGT* or bCBT or b-CBT or GPDCBT or GPD-CBT):ab

#22  ((cogniti*  or  behavio*)  NEAR/3  (counsel*  or  intervention  or  therap*  or  psychotherap*  or  training  or  treatment  or  technique*  or
restructur* or defusion)):Ti,AB

#23  ("rational  emotive"  or  (problem*  NEAR/2  (focus*  or  sol*))  or  psychoeducat*  or  psycho-educat*  or  "role  play"  or  "role  playing"  or
schema* or self-control* or "self control" or "self controlling”):ti,ab

#24 (((psychotherap* or therap*) near/3 (commitment or acceptance)) or ((self* or stress*) near/3 (control or analysis or direct* or esteem
or help or instruct* or manage*))):ti,ab

#25 ((attribution* or reattribution*) near/3 (therap* or psychotherap*)):ti,ab 20

#26  (mindfulness*  or  "third  wave"  or  experiential  or  (behavio*  near/3  (activation  or  modification))  or  (thought*  near/3  suppress*)  or
rumination):ti,ab

#27  ((anxiety  near/2  manag*)  or  "confidence  building"  or  "coping  skills"  or  "exposure  therapy"  or  "exposure  task"  or  "exposure
tasks"  or  psychoeducat*  or  psycho-educat*  or  relaxation  or  "sensitivity  training"  or  "self  talk"  or  (social  near/2  (coach*  or  skill*  or
effectiveness))):ti,ab

#28 ((controlling or overcoming) near/2 (anxiety or panic or phobi* or agoraphobi* or shyness)):ti,ab

#29 (child* near/2 (deliver* or focus*) near/2 (counsel* or intervention* or program* or psychotherap* or therap* or train* or treat*)):ti,ab

#30 ((parent* or guardian*) near/2 (deliver* or focus*) near/2 (counsel* or intervention* or program* or psychotherap* or therap* or train*
or treat*)):ti,ab

#31  ((individual*  or  group  or  conjoint  or  family)  next  (counsel*  or  intervention*  or  program*  or  psychotherap*  or  therap*  or  train*  or
treat*)):ti,ab,kw

#32 ("Coping Cat" or "Cool Kids" or "Coping Koala" or "Facing your Fears" or (Skills near Academic near "Social Success") or (Intervention
near Adolescents near "Social Phobia") or ("Multimodal Anxiety" near "Social Skills") or BIACA or IAFS or MASSI or SASS or TAPS):ti,ab

#33 MeSH descriptor: [Psychotherapy] this term only and with qualifier(s): [methods - MT, standards - ST, statistics & numerical data - SN]

#34 (#17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33)

#35 MeSH descriptor: [Adolescent] this term only 97662

#36 MeSH descriptor: [Child] explode all trees 1394

#37 MeSH descriptor: [Infant] this term only

#38 (infant* or child* or adolesc* or paediatr* or pediatr*):kw,so

#39 (infant* or child* or boy* or girl* or kids or juvenil* or minors or paediatric* or pediatric* or adolesc* or preadolesc* or pre-adolesc*
or pubert* or pubescen* or prepube* or pre-pube* or teen* or (young next (survivor* or offender* or minorit*)) or youth* or schoo* or
preschool* or nurser* or kindergarten):ti,kw

#40 (#36 or #37 or #38 or #39 or #40)
#41 (#17 and #35)
#41 (#16 and #34 and #40)
#42 (#1 or #2) and #34

#43 (#41 or #42)

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

276

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

#44 ((OCD or "obsessive compulsive" or PTSD or "posttraumatic stress" or "post-traumatic stress") not (anxi* or phobi* or agoraphobi*
or panic)):ti

#45 (#43 not #44)
#46 (ADIS-C* or ADIS-P* or DISCAP or SCARED or SCAS or RCADS or RCMAS or MASC or CBCL or STAI-C or SPAI-C or SAS-A):ab
#47 (#46 and #34)
#48 (#47 not #43)
#49 (#48 not #44)

Ovid PsycINFO (all years to October Week 40 2019)
1 clinical trials.sh.
2 (randomi#ed or randomi#ation or randomi#ing).ti,ab,id.
3 (RCT or at random or (random* adj3 (administ* or allocat* or assign* or class* or control* or determine* or divide* or division or distribut*
or expose* or fashion or number* or place* or recruit* or split or subsitut* or treat*))).ti,ab,id.
4 (control* and (trial or study or group) and (placebo or waitlist* or wait* list* or ((treatment or care) adj2 usual))).ti,ab,id,hw.
5 ((single or double or triple or treble) adj2 (blind* or mask* or dummy)).ti,ab,id.
6 trial.ti.
7 placebo.ti,ab,id,hw.
8 treatment outcome.md.
9 treatment effectiveness evaluation.sh.
10 mental health program evaluation.sh.
11 or/1-10
12 *anxiety/
13 anxiety disorders/ or generalized anxiety disorder/ or panic disorder/ or exp phobias/ or separation anxiety disorder/
14 social anxiety/
15 school refusal/ or school phobia/
16 exp separation anxiety/
17 panic/ or panic attack/ or panic disorder/
18 mutism/ or elective mutism/
19 (agoraphobi* or generali#ed anxiety or GAD or separation anxiety or (social* adj2 (anxi* or fear*)) or phobi* or mute? or mutism or school
refusal).ti,ab,id.
20 ((infant? or child* or adolesc* or p?ediatric* or teen* or young* or youth or school? or preschool*) adj2 anxi*).ti,ab,id.
21 over anxious.ti,ab,id.
22 anxiety.ab. /freq=3
23 panic.ti,ab,id,hw.
24 (anxiety adj5 (autism or autistic)).ti,ab,id.
25 anxiety.ti,ab,id,tm. and (autism spectrum disorders/ or autistic thinking/ or exp developmental disabilities/)
26 or/12-25
27 ((anxi* or phobi* or panic) and (effectiveness or efficacy or evaluat* or intervention or program* or train* or treat* or prevent* or therapy
or psychotherapy or trial or study) and (infant? or child* or adolesc* or paediatric* or pediatric* or teen* or young* or youth or school?
or preschool*)).ti.
28 anxiety management/
29 exp cognitive behavior therapy/
30 cognitive techniques/ or cognitive restructuring/ or cognitive therapy/
31 behavior modification/
32 exp relaxation therapy/
33 exp family therapy/
34 exp group psychotherapy/ or psychodrama/ or role playing/ or role playing games/
35 bibliotherapy/
36 counseling/ or group counseling/ or exp psychotherapeutic counseling/ or school counseling/
37 psychotherapy/
38 psychotherapeutic techniques/ or mindfulness/
39 (CBT or CBGT* or bCBT or b-CBT or GPDCBT or GPD-CBT).ab.
40 ((cogniti* or behavio*) adj3 (counsel* or intervention or therap* or psychotherap* or training or treatment or technique* or restructur*
or defusion)).ti,ab,id.
41 (rational emoti* or (problem* adj2 (focus* or sol*)) or psychoeducat* or role play* or schema* or self-control* or self control*).ti,ab,id,hw.
42 (((psychotherap* or therap*) adj3 (commitment or acceptance)) or ((self* or stress*) adj3 (control or analysis or direct* or esteem or help
or instruct* or manage*))).ti,ab,id.
43 ((attribution* or reattribution*) adj3 (therap* or psychotherap*)).ti,ab,id.
44  (mindfulness*  or  third  wave  or  experiential  or  (behavio*  adj3  (activation  or  modification))  or  (thought*  adj3  suppress*)  or
rumination).ti,ab,id.

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

277

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

45  ((anxiety  adj1  manag*)  or  confidence  building  or  coping  skills  or  exposure  therapy  or  exposure  task*  or  psychoeducat*  or  psycho-
educat* or relaxation or sensitivity training or self talk or (social adj2 (coach* or skill* or effectiveness))).ti,ab,id,hw.
46 ((controlling or overcoming) adj2 (anxiety or panic or phobi* or agoraphobi* or shyness)).ti,ab,id.
47 (child* adj2 (centred or centered or deliver* or focus*) adj2 (counsel* or intervention* or program* or psychotherap* or therap* or train*
or treat*)).ti,ab,id.
48 ((parent* or guardian*) adj2 (centred or centered or deliver* or focus*) adj2 (counsel* or intervention* or program* or psychotherap*
or therap* or train* or treat*)).ti,ab,id.
49  ((individually  or  group  or  conjoint  or  family)  adj2  (counsel*  or  intervention*  or  program*  or  psychotherap*  or  therap*  or  train*  or
treat*)).ti,ab,id.
50 (Coping Cat or Cool Kids or Coping Koala or Fac* your Fear? or (Multimodal Anxiety adj Social Skills) or (Skills adj Academic adj Social
Success) or (Intervention adj Adolescents adj Social Phobia) or BIACA or IAFS or MASSI or SASS or TAPS).ti,ab,id.
51 or/28-50
52 pediatrics/
53 child psychiatry/ or child psychopathology/ or child psychology/
54 adolescent psychiatry/ or adolescent psychopathology/ or adolescent psychology/
55 (infant? or child* or adolesc* or paediatr* or pediatr*).hw,jx.
56 (infant* or child* or boy* or girl* or kids or juvenil* or minors or paediatric* or pediatric* or adolesc* or preadolesc* or pre-adolesc*
or pubert* or pubescen* or prepube* or pre-pube* or teen* or (young adj (survivor* or offender* or minorit*)) or youth* or school? or
preschool* or nurser* or kindergarten).ti,id.
57 or/52-56
58 (ADIS-C* or ADIS-P* or DISCAP or SCARED or SCAS or RCADS or RCMAS or MASC or CBCL or STAI-C or SPAI-C or SAS-A).ab,id,tm.
59 11 and 26 and 51 and 57
60 11 and 27 and 51
61 11 and 51 and 58
62 11 and 50
63 59 or 60 or 61 or 62
64 ((OCD or obsessive compulsive or PTSD or posttraumatic stress disorder* or post-traumatic stress disorder*) not (anxi* or phobi* or
agoraphobi* or panic)).ti.
65 63 not 64

Ovid MEDLINE Databases (2016 to 10 Oct 2019)
Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily
1 controlled clinical trial.pt.
2 randomized controlled trial.pt.

3 (randomi#ed or randomi#ation or randomi#ing).ti,ab,kf.
4 (RCT or "at random" or (random* adj3 (administ* or allocat* or assign* or class* or cluster or control* or determine* or divide* or division
or distribut* or expose* or fashion or number* or place* or pragmatic or quasi or recruit* or split or subsitut* or treat*))).ti,ab,kf.
5 (placebo or ((attention or active) adj control*)).ti,ab,kf.
6 trial.ab,ti,kf.
7 ((control* or group* or compar*) adj5 (((care or treatment*) adj2 (usual or standard or routine)) or TAU or CAU)).ab.
8 ((control* or group* or compar*) adj5 (waitlist* or wait* list* or waiting or WLC)).ab.
9 or/1-8
10 ANXIETY DISORDERS/
11 *ANXIETY/di, pc, px, th
12 AGORAPHOBIA/ or PANIC DISORDER/ or ANXIETY, SEPARATION/
13 PHOBIC DISORDERS/ or PHOBIA, SOCIAL/
14 (agoraphobi* or generali#ed anxiety or GAD or separation anxiety or (social* adj2 (anxi* or fear*)) or phobi* or mute? or mutism or school
refusal).ti,ab,kf.
15 ((infant? or child* or adolesc* or p?ediatric* or teen* or young* or youth or school? or preschool*) adj2 anxi*).ti,ab,kf.
16 anxiety.ab. /freq=3
17 panic.mp.
18 (anxiety adj5 (autism or autistic)).ti,ab,kf.
19 anxiety.mp. and (child development disorders, pervasive/px or autism spectrum disorder/px or autistic disorder/px)
20 or/10-19
21 ((anxi* or phobi* or panic) and (effectiveness or efficacy or evaluat* or intervention or program* or train* or treat* or prevent* or therapy
or psychotherapy or trial or study) and (infant? or child* or adolesc* or paediatric* or pediatric* or teen* or young* or youth or school?
or preschool*)).ti.
22 exp COGNITIVE THERAPY/
23 PSYCHOTHERAPY, GROUP/
24 FAMILY THERAPY/ or PSYCHODRAMA/ or ROLE PLAYING/ or SENSITIVITY TRAINING GROUPS/
25 BIBLIOTHERAPY/

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

278

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

26 "EARLY INTERVENTION (Education)"/
27 (CBT or CBGT* or bCBT or b-CBT or GPDCBT or GPD-CBT).ab.
28 ((cogniti* or behavio*) adj3 (counsel* or intervention or therap* or psychotherap* or training or treatment or technique* or restructur*
or defusion)).ti,ab,kf.
29 (rational emoti* or (problem* adj2 (focus* or sol*)) or psychoeducat* or role play* or schema* or self-control* or self control*).ti,ab,kf.
30 (((psychotherap* or therap*) adj3 (commitment or acceptance)) or ((self* or stress*) adj3 (control or analysis or direct* or esteem or help
or instruct* or manage*))).ti,ab,kf.
31 ((attribution* or reattribution*) adj3 (therap* or psychotherap*)).ti,ab,kf.
32  (mindfulness*  or  third  wave  or  experiential  or  (behavio*  adj3  (activation  or  modification))  or  (thought*  adj3  suppress*)  or
rumination).ti,ab,kf.
33  ((anxiety  adj1  manag*)  or  confidence  building  or  coping  skills  or  exposure  therapy  or  exposure  task*  or  psychoeducat*  or  psycho-
educat* or relaxation or sensitivity training or self talk or (social adj2 (coach* or skill* or effectiveness))).ti,ab,kf,hw.
34 ((controlling or overcoming) adj2 (anxiety or panic or phobi* or agoraphobi* or shyness)).ti,ab,kf.
35 (child* adj2 (deliver* or focus*) adj2 (counsel* or intervention* or program* or psychotherap* or therap* or train* or treat*)).ti,ab,kf.
36 ((parent* or guardian*) adj2 (deliver* or focus*) adj2 (counsel* or intervention* or program* or psychotherap* or therap* or train* or
treat*)).ti,ab,kf.
37  ((individually  or  group  or  conjoint  or  family)  adj2  (counsel*  or  intervention*  or  program*  or  psychotherap*  or  therap*  or  train*  or
treat*)).ti,ab,kf.
38 (Coping Cat or Cool Kids or Coping Koala or Fac* your Fear? or (Multimodal Anxiety adj Social Skills) or (Skills adj Academic adj Social
Success) or (Intervention adj Adolescents adj Social Phobia) or BIACA or IAFS or MASSI or SASS or TAPS).ti,ab,kf.
39 *PSYCHOTHERAPY/mt, st, sn, tu
40 or/22-39
41 ADOLESCENT/ or CHILD/ or CHILD, PRESCHOOL/
42 (infant? or child* or adolesc* or paediatr* or pediatr*).hw,jn.
43 (infant* or child* or boy* or girl* or kids or juvenil* or minors or paediatric* or pediatric* or adolesc* or preadolesc* or pre-adolesc*
or pubert* or pubescen* or prepube* or pre-pube* or teen* or (young adj (survivor* or offender* or minorit*)) or youth* or school? or
preschool* or nurser* or kindergarten).ti,kf.
44 (infant? or child* or adolesc* or paediatr* or pediatr*).ab. /freq=3
45 or/41-44
46 9 and 20 and 40 and 45
47 9 and 21 and 40
48 46 or 47
49 (ADIS-C* or ADIS-P* or DISCAP or SCARED or SCAS or RCADS or RCMAS or MASC or CBCL or STAI-C or SPAI-C or SAS-A).ab.
50 9 and 40 and 49
51 48 or 50
52 ((OCD or obsessive compulsive or PTSD or posttraumatic stress disorder* or post-traumatic stress disorder*) not (anxi* or phobi* or
agoraphobi* or panic)).ti.
53 (2016* or 2017* or 2018*).yr,dp,dt,ep,ez.
54 51 not 52
55 53 and 54

Ovid Embase (2016 to 2019 Week 40)
1 randomized controlled trial/
2 randomization.de.
3 controlled clinical trial/ and (Disease Management or Drug Therapy or Prevention or Rehabilitation or Therapy).fs.
4 *clinical trial/
5 placebo.de.
6 placebo.ti,ab.
7 trial.ti.
8 (randomi#ed or randomi#ation or randomi#ing).ti,ab,kw.
9  (RCT  or  "at  random"  or  (random*  adj3  (administ*  or  allocat*  or  assign*  or  class*  or  control*  or  determine*  or  divide*  or  division  or
distribut* or expose* or fashion or number* or place* or recruit* or split or subsitut* or treat*))).ti,ab,kw.
10 ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$ or dummy)).mp.
11 (control* and (trial or study or group) and (placebo or waitlist* or wait* list* or ((treatment or care) adj2 usual))).ti,ab,kw,hw.
12 or/1-11
13 ((animal or nonhuman) not (human and (animal or nonhuman))).de.
14 12 not 13
15 anxiety disorder/ or anxiety neurosis/ or generalized anxiety disorder/ or "mixed anxiety and depression"/ or panic/ or exp phobia/ or
separation anxiety/
16 *anxiety/
17 (agoraphobi* or generali#ed anxiety or GAD or separation anxiety or (social* adj2 (anxi* or fear*)) or phobi* or mute? or mutism or school
refusal).ti,ab,kw.

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

279

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

18 ((infant? or child* or adolesc* or p?ediatric* or teen* or young* or youth or school? or preschool*) adj2 anxi*).ti,ab,kw.
19 anxiety.ab. /freq=3
20 panic.mp.
21 (anxiety adj5 (autism or autistic)).ti,ab,kw.
22 anxiety.mp. and (autism/ or asperger syndrome/ or "pervasive developmental disorder not otherwise specified"/)
23 school refusal/
24 mutism/ or selective mutism/
25 or/15-24
26 cognitive behavioral therapy/ or cognitive behavioral stress management/
27 exp cognitive therapy/
28 psychotherapy/ or bibliotherapy/ or family therapy/ or group therapy/ or mindfulness/ or play therapy/ or psychodrama/ or relaxation
training/ or role playing/
29 (CBT or CBGT* or bCBT or b-CBT or GPDCBT or GPD-CBT).ab.
30 ((cogniti* or behavio*) adj3 (counsel* or intervention or therap* or psychotherap* or training or treatment or technique* or restructur*
or defusion)).ti,ab,kw.
31 (rational emoti* or (problem* adj2 (focus* or sol*)) or psychoeducat* or role play* or schema* or self-control* or self control*).ti,ab,kw.
32 *self control/
33 (((psychotherap* or therap*) adj3 (commitment or acceptance)) or ((self* or stress*) adj3 (control or analysis or direct* or esteem or help
or instruct* or manage*))).ti,ab,kw.
34 ((attribution* or reattribution*) adj3 (therap* or psychotherap*)).ti,ab,kw.
35  (mindfulness*  or  third  wave  or  experiential  or  (behavio*  adj3  (activation  or  modification))  or  (thought*  adj3  suppress*)  or
rumination).ti,ab,kw.
36  ((anxiety  adj1  manag*)  or  confidence  building  or  coping  skills  or  exposure  therapy  or  exposure  task*  or  psychoeducat*  or  psycho-
educat* or relaxation or sensitivity training or self talk or (social adj2 (coach* or skill* or effectiveness))).ti,ab,kw,hw.
37 ((controlling or overcoming) adj2 (anxiety or panic or phobi* or agoraphobi* or shyness)).ti,ab,kw.
38 (child* adj2 (centred or centered or deliver* or focus*) adj2 (counsel* or intervention* or program* or psychotherap* or therap* or train*
or treat*)).ti,ab,kw.
39 ((parent* or guardian*) adj2 (centred or centered or deliver* or focus*) adj2 (counsel* or intervention* or program* or psychotherap*
or therap* or train* or treat*)).ti,ab,kw.
40  ((individually  or  group  or  conjoint  or  family)  adj2  (counsel*  or  intervention*  or  program*  or  psychotherap*  or  therap*  or  train*  or
treat*)).ti,ab,kw.
41 (Coping Cat or Cool Kids or Coping Koala or Fac* your Fear? or (Multimodal Anxiety adj Social Skills) or (Skills adj Academic adj Social
Success) or (Intervention adj Adolescents adj Social Phobia) or BIACA or IAFS or MASSI or SASS or TAPS).ti,ab,kw.
42 or/26-41
43 juvenile/ or exp adolescent/ or exp child/
44 (infant? or child* or adolesc* or paediatr* or pediatr*).hw,jx.
45 (infant* or child* or boy* or girl* or kids or juvenil* or minors or paediatric* or pediatric* or adolesc* or preadolesc* or pre-adolesc*
or pubert* or pubescen* or prepube* or pre-pube* or teen* or (young adj (survivor* or offender* or minorit*)) or youth* or school? or
preschool* or nurser* or kindergarten).ti,kw.
46 or/43-45
47 14 and 25 and 42 and 46
48 ((anxi* or phobi* or panic) and (effectiveness or efficacy or evaluat* or intervention or program* or train* or treat* or prevent* or therapy
or psychotherapy or trial or study) and (infant? or child* or adolesc* or paediatric* or pediatric* or teen* or young* or youth or school?
or preschool*)).ti.
49 14 and 42 and 48
50 (ADIS-C* or ADIS-P* or DISCAP or SCARED or SCAS or RCADS or RCMAS or MASC or CBCL or STAI-C or SPAI-C or SAS-A).ab.
51 14 and 42 and 50
52 47 or 49 or 51
53 ((OCD or obsessive compulsive or PTSD or posttraumatic stress disorder* or post-traumatic stress disorder*) not (anxi* or phobi* or
agoraphobi* or panic)).ti.
54 52 not 53
55 (2016* or 2017* or 2018*).yr,dp,dc.
56 54 and 55

Appendix 4. Grey literature search strategies

We ran the searches listed below on Proquest Dissertations & Theses Global, PQDT Open, Open Access Theses and Dissertations, DART
and NDLTD.

Dates of searches: All years to 14 Oct 2019

Proquest Dissertations & Theses Global search.proquest.com/pqdtglobal/dissertations/

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

280

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

ti(adolescent OR adolescents OR teenager OR teenagers OR teen OR teens OR child OR children OR childhood OR kids OR kiddies OR
youth OR youths OR young OR pediatric OR paediatric OR school OR schools) AND ti(anxiety OR anxious OR fear OR panic OR phobia OR
phobias OR phobic) AND ti(effect OR effects OR effective OR effectiveness OR evaluation OR evaluations OR evaluating OR evaluated OR
findings OR intervention OR interventions OR outcome OR outcomes OR prevent OR preventing OR prevention OR program OR programs
OR programme OR programmes OR psychotherapy OR psychotherapies OR psychotherapeutic OR results OR study OR studies OR therapy
OR therapies OR therapeutic OR treat OR treated OR treating OR treatment OR treatments OR trial OR trials) AND noft(CBT OR cognitive
OR behaviour OR behavioural OR behavior OR behavioral) AND noft(RCT OR randomized OR randomised OR randomly OR assignment OR
allocation)

PQDT Open - open access dissertations and theses pqdtopen.proquest.com/search.html

ti(anxiety OR anxious OR fear OR panic OR phobia OR phobias OR phobic) AND (RCT OR randomized OR randomised OR randomly)

Open Access Theses and Dissertations oatd.org

title:(anxiety  OR  anxious  OR  fear  OR  panic  OR  phobia  OR  phobias  OR  phobic)  AND  title:(adolescent  OR  adolescents  OR  teenager  OR
teenagers OR teen OR teens OR child OR children OR childhood OR kids OR kiddies OR youth OR youths OR young OR pediatric OR paediatric
OR school OR schools) AND (RCT OR randomized OR randomised OR randomly)

DART - Europe e-theses Portal www.dart-europe.eu/basic-search.php

(anxiety OR anxious OR fear OR panic OR phobia OR phobias OR phobic) AND (RCT OR randomized OR randomised OR randomly) AND
(CBT OR cognitive OR behaviour OR behavioural OR behavior OR behavioral) AND (adolescent OR adolescents OR teenager OR teenagers
OR teen OR teens OR child OR children OR childhood OR kids OR kiddies OR youth OR youths OR young OR pediatric OR paediatric OR
school OR schools)

Networked Digital Library of Theses and Dissertations (NDLTD) search.ndltd.org/

title:(anxiety  OR  anxious  OR  fear  OR  panic  OR  phobia  OR  phobias  OR  phobic)  AND  title:(adolescent  OR  adolescents  OR  teenager  OR
teenagers OR teen OR teens OR child OR children OR childhood OR kids OR kiddies OR youth OR youths OR young OR pediatric OR paediatric
OR school OR schools) AND (RCT OR randomized OR randomised OR randomly)

Electronic Theses Online Service (EThOS) - British Library ethos.bl.uk/Home.do

Recommend searching EThOS via Proquest Dissertations and Theses Global (as listed above).

W H A T ' S   N E W

Date

Event

Description

13 November 2020

New search has been performed

This Cochrane Review supersedes the Cochrane Review 'Cogni-
tive behavioural therapy for anxiety disorders in children and
adolescents' published in 2015 (James 2015).

H I S T O R Y

Protocol first published: Issue 10, 2018
Review first published: Issue 11, 2020

C O N T R I B U T I O N S   O F   A U T H O R S

Anthony James and Tessa Reardon reviewed all papers; Angela Soler reviewed papers in Spanish; and Georgina James and Cathy Creswell
reviewed papers where there was any disagreement. Anthony James and Tessa Reardon extracted study data, contacted study authors,
and assessed risk of bias, and were responsible for statistical analyses. Anthony James, Tessa Reardon, and Cathy Creswell were jointly
responsible for interpreting the data and analyses and drafting the text of the review. All authors contributed to revising and finalising
the text.

D E C L A R A T I O N S   O F   I N T E R E S T

Anthony James: nothing to declare

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

281

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Tessa Reardon was funded by a National Institute for Health Research (NIHR) Research Professorship to Cathy Creswell. This study presents
independent research partly funded by the NIHR.
Angela Soler: nothing to declare
Georgina James: nothing to declare
Cathy Creswell was funded by an NIHR Research Professorship. This study presents independent research partly funded by the NIHR.

S O U R C E S   O F   S U P P O R T

Internal sources

• Oxford Healthcare NHS Foundation Trust, UK
• Oxford University Department of Psychiatry, Warneford Hospital, Oxford, UK

External sources

• National Institute for Health Research (NIHR) Research Professorship, UK

Cathy Creswell and Tessa Reardon are funded by an NIHR Research Professorship to Cathy Creswell (NIHR-RP-2014-04-018). This study
presents independent research partly funded by the NIHR.

D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W

• The criteria used to assess the eligibility of studies for inclusion in this review differed from previous versions of this review (e.g. this

review included parent-delivered CBT). We therefore used updated search strategies (see Appendix 2; Appendix 3).

• We removed the 'active control' comparison, dividing this into two separate comparisons: attention controls and alternative treatments.
• As there were a large number of eligible studies (> 80), we only included studies that met the defined eligibility criteria and reported (or

the author provided) data on at least one of the specified primary or secondary outcomes.

• We removed the requirement for therapists to receive regular supervision. Supervision arrangements varied widely across studies and
were not always specified, even where it was suspected to be in place. Rather than specifying supervision as a requirement, we assessed
therapy integrity (including therapist competence and adherence) as part of the 'Risk of bias' assessment in all included studies.

• In the protocol, we specified that participants meet diagnostic criteria for an anxiety disorder. In the review, we clarified that these
baseline diagnoses were made by reliable and valid structured interviews for Diagnostic and Statistical Manual of Mental Disorders (DSM)
or International Classification of Diseases (ICD) child and adolescent anxiety disorders (to be consistent with measures required for
diagnostic outcomes).

• Where  broad  anxiety  symptom  measures  and  disorder-specific  symptom  measures  were  reported,  we  prioritised  broad  anxiety
symptom  measures.  We  also  conducted  sensitivity  analyses  for  child-  and  parent-reported  anxiety  symptom  measures,  removing
studies that only reported disorder-specific symptom measures.

• Child Behaviour Checklist - Internalising Scale was not included as an anxiety symptom measure, as it is not designed to assess only

anxiety symptoms.
• Subgroup analyses.

We  undertook  subgroup  analyses  for  the  primary  outcome  (remission  of  primary  anxiety  disorder)  across  comparisons.  For  the  main
comparison with the largest number of studies (CBT versus waitlist/no treatment), we also undertook subgroup analyses for the most
frequently reported secondary anxiety symptom outcomes (remission of all anxiety diagnoses post-treatment, and reduction in child- and
parent-reported anxiety symptoms post-treatment).

CBT interventions were delivered either individually or in a group format, and also varied in terms of the amount of parental involvement
(child-focused, child and parent, parent-only). We therefore undertook separate subgroup analyses to examine the differences between
individual  versus  group  formats,  and  child-focused,  child-and-parent,  and  parent-only  formats.  We  also  provided  a  more  detailed
description of 'child-focused' and 'child-and-parent' interventions than was given in the protocol.

In  order  to  examine  the  differences  between  interventions  with  varying  amount  of  therapist  contact  time,  we  planned  to  use  four
subgroups; however, we collapsed two of these subgroups due to the small number of studies with < 10 hours therapist contact time. We
therefore examined differences between < 10 hours, ≥ 10 hours and < 20 hours, and ≥ 20 hours.

In order to evaluate differences between different ages, we undertook subgroup analyses to examine differences between studies with
participants ≤ 12 years, ≥ 12 years, and mixed age range including participants < 12 and participants ≥ 12 years.

As the above subgroup analyses were conducted, meta-regression analyses were not required.

In order to ensure that subgroup analyses were meaningful, we only undertook these analyses where data were available from at least
three studies for each subgroup.

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

282

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

• We  made  minor  changes  to  the  Background  to  reflect  up-to-date  evidence  and  to  ensure  that  the  order  in  which  relevant  issues/

objectives/results were presented was as consistent as possible throughout the review.

I N D E X   T E R M S

Medical Subject Headings (MeSH)

Anxiety Disorders  [*therapy];  Bias;  *Cognitive Behavioral Therapy;  Confidence Intervals;  Depression  [therapy];  Lost to Follow-Up; 
Parents;  Randomized Controlled Trials as Topic;  Remission Induction;  Time Factors;  *Waiting Lists

MeSH check words

Adolescent; Child; Child, Preschool; Humans

Cognitive behavioural therapy for anxiety disorders in children and adolescents (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

283
